autophagi
physiolog
process
help
maintain
cellular
homeostasi
degrad
dysfunct
cellular
compon
misfold
protein
foreign
pathogen
convert
use
build
block
amino
acid
nucleic
acid
lipid
cf
mutat
defect
cftr
previous
shown
induc
upregul
transglutaminas
activ
enzym
turn
drive
crosslink
subsequ
disabl
key
protein
need
autophagi
activ
autophagi
impair
correspond
increas
sinc
shown
regul
aggresom
format
accumul
effect
trap
er
prevent
traffick
cell
surfac
effect
autophagi
activ
theori
revers
sequenc
event
allow
misfold
cftr
reach
cell
surfac
direct
restor
autophagi
fatti
acid
cysteamin
conjug
cftr
structur
determin
cryoelectron
microscopi
ford
b
collin
rf
meng
x
life
scienc
univers
manchest
manchest
unit
kingdom
introduct
member
atpbind
cassett
abc
famili
protein
unusu
famili
cftr
oper
ion
channel
rather
transport
abc
transport
thought
oper
pump
undergo
major
structur
chang
move
transport
allocrit
inwardlyexpos
outwardlyexpos
locat
within
transmembran
domain
tmd
altern
accesstyp
mechan
coupl
bind
atp
trigger
dimeris
nucleotidebind
domain
nbd
follow
atp
secondsit
substitut
rescu
fold
also
thermal
stabil
wildtyp
human
cftr
domain
combin
singl
substitut
act
addit
yield
construct
highli
increas
thermost
domain
result
present
anoth
poster
yang
et
al
present
studi
effect
substitut
fold
traffick
fulllength
wildtyp
cftr
mammalian
express
system
effect
monodispers
thermost
detergentpurifi
cftr
investig
recombin
cftr
protein
contain
differ
combin
secondsit
substitut
overexpress
stabl
mammalian
cell
system
develop
lab
hildebrandt
e
et
al
mol
biotechnol
cftr
protein
contain
hisaffin
purif
tag
extracellular
flag
epitop
enhanc
green
fluoresc
protein
egfp
tag
facilit
fluorescenceactiv
cell
sort
fac
fac
analys
antiflag
antibodi
bind
extracellular
flag
tag
indic
significantli
increas
level
cell
surfac
express
wildtyp
cftr
cftr
protein
purifi
use
protocol
optim
lab
hildebrandt
e
et
al
biochim
biophi
acta
fluoresc
size
exclus
chromatographi
fsec
purifi
protein
indic
improv
monodispers
cftr
protein
thermal
stabil
construct
deterg
solut
indic
unfold
temperatur
determin
directli
monitor
protein
intrins
fluoresc
fluoresc
extrins
dye
syproorang
function
temperatur
unfold
occur
broad
temperatur
rang
c
consist
sequenti
unfold
sever
cftr
domain
substitut
also
increas
fulllength
cftr
posit
correl
observ
respect
unfold
temperatur
still
lowtemperatur
transit
fluoresc
signal
c
appar
data
repres
unfold
event
protein
may
suggest
addit
domain
besid
need
stabil
optim
cftr
stabil
introduct
cystic
fibrosi
cf
research
made
advanc
develop
therapeut
modul
cftr
protein
therebi
correct
cftr
defect
molecular
level
western
blot
analys
chlorid
secret
studi
use
primari
human
bronchial
epitheli
cultur
consid
gold
standard
measur
cftr
rescu
howev
observ
discrep
compar
biochem
format
matur
cftr
measur
chlorid
bicarbon
secret
cultur
rescu
mutant
cftr
object
appli
advanc
spheric
cultur
model
mimic
ion
fluid
movement
airway
epithelia
measur
cftr
respons
pharmaceut
agent
compar
result
biochem
function
data
planar
cultur
method
cultur
cf
patient
variou
rare
cftr
mutat
treat
pharmaceut
cftr
rescu
assess
western
blot
analys
examin
cftr
express
matur
uss
chamber
measur
kbr
chloridefre
condit
analyz
secret
chlorid
bicarbon
swell
airway
spheroid
cultur
reflect
cftrmediat
ion
fluid
transport
result
rare
cftr
mutat
vari
respons
cftr
modul
comparison
biochem
function
assay
indic
augment
level
matur
cftr
necessarili
correspond
increas
cftr
function
cultur
cf
patient
express
mutat
maxim
level
cftr
function
uss
chamber
obtain
treat
plu
low
dose
level
matur
cftr
protein
vari
mutant
although
function
assay
measur
chlorid
secret
cftr
also
secret
bicarbon
rescu
bicarbon
secret
strongli
enhanc
combin
maximum
bicarbon
secret
mutant
obtain
use
combin
high
concentr
thu
certain
mutat
cftr
modul
display
differ
effect
chlorid
versu
bicarbon
secret
determin
result
physiolog
relev
use
airway
spheroid
conduct
fluid
cystic
fibrosi
confer
transport
assay
airway
spheroid
cf
patient
express
show
increas
swell
due
cftr
activ
respons
airway
spheroid
cf
patient
homozyg
significantli
rescu
treatment
result
accur
correspond
outcom
cf
patient
receiv
therapi
clinic
thu
demonstr
airway
spheroid
use
precis
preclin
model
identifi
therapeut
specif
tailor
cf
patient
conclus
data
clearli
indic
neither
amount
matur
protein
chlorid
secret
accur
predict
rescu
rare
cftr
mutat
pharmaceut
treatment
spheroid
swell
assay
offer
superior
outcom
measur
precis
pharmacolog
rescu
cftr
cf
patient
bhatt
p
bailey
v
dasgupta
chin
j
w
bresilla
c
kwok
cole
bm
fitzpatrick
r
krous
flatley
discoveri
lab
charlestown
usa
background
cftr
mutat
identifi
mani
mutat
result
loss
cltransport
loss
due
reduct
quantiti
function
cftr
channel
therapeut
intervent
small
molecul
modul
includ
corrector
potenti
restor
cltransport
activ
cftr
potenti
mani
mutat
method
fdliniti
test
distinct
set
modul
classifi
possibl
mechan
action
variou
cfcaus
mutat
express
frt
cell
includ
three
corrector
set
one
potenti
set
set
increas
clcurrent
singl
agent
combin
measur
uss
chamber
equival
current
assay
cfhbe
cell
far
compar
effect
modul
class
class
mutat
electrophysiolog
western
blot
assay
stabl
cell
line
kindli
provid
uab
cff
mrna
level
nonstop
mutat
equival
corrector
ad
hour
prior
experi
respons
measur
increas
clcurrent
stimul
forskolin
potenti
fold
x
increas
baselin
ie
dmsotreat
uncorrect
cell
report
result
rang
effect
test
mutat
largest
effect
almost
increas
clcurrent
also
increas
clcurrent
increas
produc
increas
cell
alon
produc
addit
increas
effect
mutat
test
except
howev
use
combin
show
increas
respons
alon
respons
percent
increas
produc
acut
addit
compar
forskolin
steadi
state
rang
also
measur
uncorrect
cftr
protein
express
use
western
blot
assay
mutat
visibl
band
b
lightest
band
darkest
band
b
band
c
visibl
mutat
except
light
band
c
agreement
electrophysiolog
data
gave
largest
forskolin
respons
uncorrect
cell
summari
modul
set
increas
clcurrent
cfhbe
cell
modul
larger
rel
effect
smallest
uncorrect
clcurrent
increas
increas
modul
set
alon
combin
inhibitor
respons
seen
suggest
matur
cftr
present
modul
increas
clcurrent
howev
uncorrect
clcurrent
low
correct
less
uncorrect
current
conclus
result
show
vitro
effect
differ
cftr
modul
cftr
correl
poorli
effect
mutat
includ
class
mutat
cystic
fibrosi
transmembran
conduct
regul
cftr
tightli
regul
anion
channel
mediat
campstimul
salt
fluid
secret
enabl
effici
mucociliari
clearanc
airway
cf
caus
delet
phenylalanin
posit
disrupt
fold
traffick
gate
surfac
stabil
mutant
cftr
interact
protein
studi
extens
thought
form
protein
complex
local
stabil
cell
surfac
membran
lipid
may
also
play
role
process
receiv
much
less
attent
recent
show
wtcftr
form
subresolut
cluster
homogen
distribut
plasma
membran
primari
human
airway
epitheli
cell
studi
cftr
protein
dynam
reveal
two
dynam
distinct
popul
one
popul
exhibit
small
spatial
scale
transport
dynam
confin
depend
membran
cholesterol
suggest
local
lipid
raft
second
popul
cftr
molecul
larger
spatial
scale
dynam
indic
cftr
later
mobil
outsid
raft
better
understand
import
cftr
cluster
membran
express
stabil
possibl
role
cf
compar
aggreg
state
later
mobil
wtcftr
rescu
treat
cell
distribut
wtand
studi
primari
human
bronchial
epitheli
cell
use
spatial
imag
correl
spectroscopi
ic
cftr
dynam
studi
use
modifi
version
kspace
imag
correl
spectroscopi
kic
quantifi
fraction
wtcftr
within
cholesterolrich
membran
microdomain
mobil
transport
partit
dynam
popul
compar
control
condit
follow
chronic
treatment
combin
potenti
ic
analysi
show
aggreg
state
wtcftr
much
higher
despit
treatment
corrector
combin
potenti
kic
analysi
reveal
partit
lipid
raft
control
condit
confin
significantli
weaker
smaller
fraction
popul
display
confin
compar
wtcftr
correct
restor
normal
confin
fraction
confin
dynam
neither
addit
potenti
confirm
treatment
correct
membran
behavior
result
show
clear
depend
cftr
distribut
dynam
cholesterol
suggest
reduct
confin
could
due
alter
interact
cholesterol
restor
cftr
modul
support
cystic
fibrosi
foundat
pellegrini
swiateckaurban
geisel
school
medicinedartmouth
colleg
hanov
nh
usa
dept
cell
biolog
u
pittsburgh
pittsburgh
pa
usa
numer
cftr
mutat
affect
biosynthet
process
gate
stabil
plasma
membran
preval
among
patient
cystic
fibrosi
cf
exhibit
combin
three
defect
fda
recent
approv
combin
therapi
orkambi
benefit
cf
patient
homozyg
howev
yield
signific
improv
heterozyg
patient
corrector
address
fold
defect
potenti
increas
net
ionchannel
activ
laboratori
focus
develop
stabil
class
modul
increas
halflif
cftr
block
intern
degrad
number
endocyt
adaptor
shown
modul
cftr
intern
includ
sirnamedi
knockdown
increas
plasma
membran
abund
cftr
highlight
potenti
therapeut
target
dab
homolog
dh
domain
necessari
suffici
coassembl
complex
cftr
furthermor
peptid
sequenc
deriv
endogen
partner
domain
amyloid
precursor
protein
app
increas
abund
wtcftr
plasma
membran
human
bronchial
epitheli
cell
confirm
dh
domain
molecular
target
stabilizerbas
therapi
howev
affin
app
decam
low
k
peptid
bioavail
limit
identifi
smallmolecul
inhibitor
use
array
screen
engin
peptid
higher
affin
dh
domain
k
nm
screen
compound
librari
inhibitor
peptidebind
pocket
identifi
multipl
hit
singl
micromolar
affin
hit
valid
use
pulldown
inhibit
test
cytotox
demonstr
biocompat
concentr
high
mm
suggest
potenti
therapeut
window
measur
shortcircuit
current
isc
across
polar
monolay
cf
bronchial
epitheli
cell
treat
alon
combin
inhibitor
threeway
combin
inhibitor
yield
isc
increas
nearli
doubl
seen
data
demonstr
potenti
cftr
stabil
increas
function
rescu
cftr
assay
revalid
format
suitabl
largescal
highthroughput
screen
campaign
final
crystallograph
nmr
structur
analys
ligand
complex
show
site
inhibitor
bind
provid
basi
ration
design
potent
inhibitor
refer
synthes
first
coval
link
cysteamin
fatti
acid
dha
sulfhydryl
group
convert
function
disulfid
moieti
order
enhanc
cellular
penetr
plasma
stabil
oral
bioavail
link
methodolog
take
advantag
intracellular
enzym
enabl
releas
two
biolog
activ
compon
ie
cysteamin
dha
insid
cell
time
equimolar
concentr
process
allow
simultan
inhibit
transglutaminas
upregul
ampk
take
place
enabl
effect
restor
autophagi
cultur
primari
homozyg
hbe
cell
fatti
acid
cysteamin
conjug
synergist
activ
autophagi
concentr
low
level
activ
observ
coval
conjug
could
replic
administ
individu
compon
either
individu
combin
even
much
higher
concentr
autophagi
restor
primari
cf
hbe
cell
increas
traffick
observ
note
increas
cftr
band
c
use
combin
corrector
potenti
show
addit
effect
measur
increas
chlorid
conduct
function
assay
use
cultur
primari
homozyg
hbe
cell
oral
bioavail
mous
rat
dog
druglik
attribut
repres
potenti
new
therapeut
treatment
cf
mutat
current
therapeut
strategi
repair
cystic
fibrosiscaus
defect
chlorid
channel
cftr
develop
novel
better
corrector
improv
fold
potenti
improv
function
galapago
identifi
novel
potenti
potent
improv
channel
activ
temperaturerescu
well
compar
ivacaftor
compromis
drugcorrect
peter
f
et
al
pediatr
pulmonol
current
phase
studi
evalu
safeti
toler
efficaci
cf
patient
use
radiolabel
pulsechas
approach
combin
proteas
suscept
track
fold
assembl
cftr
domain
time
determin
corrector
potenti
work
newli
synthes
protein
use
newli
develop
antibodi
membranespan
domain
cftr
tmd
investig
mode
action
clinic
drug
ivacaftor
found
potenti
chang
proteas
resist
late
stage
cftr
fold
ivacaftor
mimic
conform
effect
nucleotidebind
domain
second
intracellular
loop
cftr
fold
effect
occur
alreadi
cftr
fold
earli
secretori
pathway
appar
contrast
ivacaftor
modul
cftr
function
cell
surfac
sinc
efficaci
dysfunct
channel
greater
compar
ivacaftor
expect
observ
largest
differ
ivacaftor
mutant
therefor
pulselabel
wildtyp
absenc
presenc
chase
h
h
determin
proteas
suscept
cftr
domain
potenti
effect
late
fold
event
chang
ivacaftor
demonstr
novel
potenti
modul
cftr
differ
mode
action
test
addit
proteas
cftr
domain
identifi
possibl
mild
effect
cftr
conform
result
provid
new
import
insight
impact
potenti
cftr
structur
function
bose
sj
liu
j
cai
z
bot
ag
bijveld
mj
de
jong
h
sheppard
dn
school
physiolog
pharmacolog
neurosci
univers
bristol
bristol
unit
kingdom
depart
gastroenterolog
hepatolog
erasmu
univers
medic
center
rotterdam
netherland
speci
differ
cftr
activ
implic
develop
anim
model
cystic
fibrosi
cf
understand
mechan
action
cftr
modul
present
studi
singlechannel
patchclamp
record
use
identifi
differ
respons
human
mous
wildtyp
wt
ivacaftor
kalydeco
excis
insideout
membran
patch
cell
express
recombin
cftr
clamp
mv
use
record
singlechannel
current
amplitud
open
probabl
p
clconcentr
gradient
intracellular
cl
mm
extracellular
cl
mm
process
defect
first
correct
incub
cell
use
lumacaftor
hour
prior
experi
record
made
follow
activ
cftr
mm
atp
nm
pka
effect
ivacaftor
test
concentr
nm
data
shown
mean
sem
analys
use
student
ttest
oneway
anova
construct
test
exhibit
atpand
pkadepend
clcurrent
characterist
cftr
human
wtcftr
pa
p
n
human
show
decreas
pa
p
compar
wt
n
p
previous
report
mous
wtcftr
exhibit
highli
activ
subconduct
brief
open
fulli
open
state
pa
p
n
howev
unlik
human
activ
mous
differ
mous
wtcftr
pa
p
n
p
vs
wt
furthermor
activ
low
temperaturecorrect
human
deactiv
within
minut
follow
increas
temperatur
mous
thermal
stabl
remain
fulli
activ
beyond
minut
ivacaftor
potenti
human
correct
either
low
temperatur
lumacaftor
eg
ivacaftor
increas
p
temperaturecorrect
n
p
howev
effect
p
mous
wt
n
observ
respons
ivacaftor
follow
either
low
temperatur
lumacaftor
correct
n
result
demonstr
produc
function
chang
mous
cftr
observ
human
cftr
disrupt
interact
data
suggest
structur
differ
mous
cftr
compar
human
cftr
might
stabilis
interfac
prevent
thermal
instabl
data
also
show
singlechannel
activ
mous
cftr
potenti
ivacaftor
rang
concentr
provid
rational
use
humanmous
cftr
chimera
investig
bind
site
ivacaftor
support
cf
trust
sjb
recipi
studentship
uk
medic
research
council
hydrolysi
dissoci
two
nbd
return
transport
start
statu
tmd
inwardfac
conform
cftr
atp
bind
appear
requir
open
channel
prior
phosphoryl
event
whilst
atp
hydrolysi
associ
channel
closur
diseasecaus
missens
mutat
appear
greatli
reduc
open
probabl
channel
result
structur
purifi
mutant
version
cftr
determin
cryoelectron
microscopi
singl
particl
deterg
micel
data
collect
krio
microscop
equip
direct
detector
camera
phase
plate
structur
absenc
atp
present
biophys
data
also
present
show
purifi
protein
deterg
micel
spatial
distribut
cystein
residu
consist
current
homolog
model
data
also
impli
stabl
wildtyp
protein
structur
compar
abc
protein
highresolut
structur
avail
also
densiti
map
cftr
obtain
previous
twodimension
crystal
rosenberg
mf
et
al
j
biol
chem
absenc
atp
transmembran
domain
show
outwardfac
configur
deep
wide
central
channel
close
cytoplasm
side
tmd
intracytoplasm
loop
nbd
close
dimer
configur
densiti
atp
observ
densiti
extracellular
loop
weak
impli
region
protein
rel
mobil
disord
outwardfac
conform
region
densiti
around
nbd
account
homolog
abc
transport
probabl
due
regulatori
region
rregion
must
phosphoryl
channel
open
happen
new
structur
cftr
may
provid
new
insight
allow
structuredirect
design
therapeut
target
treatment
cfcaus
mutat
studi
evalu
cftr
mutat
associ
pancreat
suffici
present
compar
small
cystic
fibrosi
patient
popul
curat
histor
design
class
iv
conduct
abnorm
ie
malform
ion
pore
contrast
studi
demonstr
disrupt
cftr
protein
matur
prompt
misfold
caus
gate
defect
exhibit
conduct
similar
wildtyp
also
show
cftr
robustli
rescu
lumacaftor
ivacaftor
cell
line
primari
airway
epithelia
although
unrespons
lowtemperatur
correct
elucid
impact
mutat
protein
biogenesi
secondsit
suppressor
introduc
concert
experi
togeth
pronounc
lumacaftor
correct
absenc
c
rescu
suggest
model
necessari
proper
format
loop
interfac
stabil
find
other
therefor
suggest
import
clinic
studi
test
pharmacolog
correct
cf
subject
carri
defect
note
lumacaftor
rescu
cftr
might
anticip
base
previou
cftr
class
iv
assign
rare
ultraorphan
cftr
mutat
access
novel
therapeut
often
constrain
difficulti
arrang
phase
iii
clinic
trial
restrict
offlabel
use
drug
cost
prohibit
analysi
low
preval
cystic
fibrosi
allel
offer
mean
assess
barrier
person
medicin
engag
best
avail
mechanist
knowledg
toward
treat
patient
rare
form
diseas
fund
cff
nih
chin
yang
molinski
ramjeesingh
eckford
p
bear
ce
molecular
function
structur
hospit
sick
children
toronto
canada
biochemistri
univers
toronto
toronto
canada
physiolog
univers
toronto
toronto
canada
cystic
fibrosi
transmembran
conduct
regul
cftr
uniqu
anion
channel
atpbind
cassett
abc
superfamili
cftr
consist
two
nucleotidebind
domain
nbd
two
membranespan
domain
msd
regulatori
r
domain
cftr
also
alphahel
extens
intracellular
loop
icl
coupl
nbd
msd
via
coupl
helic
regul
cftr
channel
activ
involv
protein
kinas
pka
phosphoryl
r
domain
howev
littl
known
effect
phosphoryl
intramolecular
interact
relat
cftr
channel
activ
previou
studi
similar
abc
transport
btucd
shown
intrins
tryptophan
fluoresc
detect
ureasensit
chang
coupl
msd
nbd
fulllength
btucd
interestingli
found
ureasensit
chang
cftr
similar
studi
btucd
modifi
upon
pka
phosphoryl
tryptophan
quench
cftr
also
modifi
pka
phosphoryl
suggest
modifi
electrostat
environ
cftr
base
cftr
homolog
model
icl
nbd
interfac
mani
tryptophan
phosphoryl
site
may
provid
electrostat
environ
biophys
studi
led
us
propos
phosphoryl
may
modifi
coupl
icl
may
essenti
cftr
channel
activ
order
specif
studi
interfac
cystein
crosslink
studi
cell
employ
use
short
membraneperm
cystein
crosslink
cftr
mutant
lack
nativ
cystein
residu
cysless
two
cystein
engin
interfac
interest
detect
cystein
crosslink
interfac
either
cysless
wt
cftr
howev
detect
shift
sdspage
gel
migrat
singleand
doublecystein
mutant
suggest
cystein
may
access
crosslink
modif
abl
detect
specif
intramolecular
interact
interfac
cysless
wt
cftr
howev
unabl
detect
chang
interfac
upon
pka
phosphoryl
result
similar
previou
studi
l
et
al
j
biol
chem
suggest
either
coupl
helic
stabli
interact
regardless
phosphoryl
statu
subtl
chang
affin
interact
detect
chemic
crosslink
consist
latter
suggest
initi
studi
diseasecaus
mutat
coupl
helic
show
exhibit
defect
phosphorylationdepend
channel
activ
togeth
biophys
studi
reconstitut
fulllength
cftr
protein
cellbas
studi
coupl
mutant
support
hypothesi
coupl
interfac
play
key
role
intramolecular
signal
requir
cftr
channel
regul
author
acknowledg
support
cf
canada
cihr
nserc
major
defect
caus
common
cfcaus
mutat
decreas
thermal
stabil
locat
consequ
fulllength
cftr
secondsit
mutat
thermal
stabil
promot
matur
thermal
stabil
cftr
also
wildtyp
cftr
strategi
use
increas
express
matur
level
cftr
purif
structur
studi
although
progress
made
purif
thermal
stabl
cftr
improv
still
requir
enabl
high
resolut
structur
analys
current
method
monitor
cftr
thermal
stabil
use
inform
biophys
method
differenti
scan
calorimetri
requir
rel
larg
amount
purifi
protein
high
concentr
studi
use
engin
cysless
cftr
develop
maleimid
fluorophor
bind
assay
monitor
chang
temperatur
singl
introduc
cystein
use
membran
cftrexpress
cell
use
method
found
secondsit
mutat
atp
bind
increas
peak
label
temperatur
also
found
nanobodi
specif
alter
temperaturedepend
label
cysless
cftr
correspond
effect
thermal
stabil
isol
thu
rapid
screen
construct
enabl
prior
purif
follow
thermal
unfold
improv
construct
biophys
assay
intrins
tryptophan
fluoresc
small
amount
protein
purifi
scan
nanodifferenti
scan
fluorimetri
nanodsf
use
prometheu
nanotemp
technolog
use
instrument
abl
determin
melt
temperatur
tm
fulllength
cftr
isol
concentr
low
mgml
protein
sampl
size
secondsit
mutat
increas
tm
fulllength
cftr
well
isol
previous
determin
use
techniqu
addit
nanobodi
bind
thermal
stabil
increas
tm
fulllength
cftr
knowledg
gain
studi
enabl
us
develop
strategi
thermal
stabil
cftr
support
nih
cff
gene
therapi
hold
promis
cystic
fibrosi
use
approach
includ
gene
addit
gene
edit
gene
edit
tool
offer
possibl
modifi
cftr
locu
correct
could
persist
progenitor
cell
modifi
dna
doublestrand
break
introduc
use
either
modifi
specif
locu
introduc
insert
delet
indel
repair
nonhomolog
end
join
nhej
enhanc
homologydirect
repair
hdr
obtain
precis
gene
correct
homolog
recombin
investig
strategi
evalu
repair
repres
class
cftr
mutat
intron
mutat
cftr
c
creat
novel
splice
donor
site
kb
intron
mutat
therefor
candid
disrupt
nhej
contrast
delet
mutat
exon
cftr
need
repair
templat
addit
edit
make
precis
replac
mutat
correct
wildtyp
sequenc
util
singl
dual
staphylococcu
pyogen
sp
staphylococcu
aureu
sa
singl
guid
rna
introduc
nonvir
viral
deliveri
remov
replac
deleteri
mutat
effect
repair
nhej
hdr
screen
pair
singl
guid
rna
sgrna
target
indel
singl
sgrna
target
exon
identifi
effici
introduc
doublestrand
break
region
gene
next
test
efficaci
differ
deliveri
vector
assess
natur
indel
indel
effici
express
vector
genom
copi
number
vector
persist
hdr
effici
cell
line
primari
airway
epitheli
cell
result
demonstr
genom
edit
disrupt
mutat
andor
induc
correct
hdr
differ
region
cftr
locu
cheng
singh
ak
tse
c
bridg
rj
physiolog
biophys
rosalind
franklin
univers
medicin
scienc
north
chicago
il
usa
abbvi
north
chicago
il
usa
present
address
cystic
fibrosi
foundat
therapeut
lexington
usa
splice
site
mutat
account
cftr
gene
mutat
identifi
cystic
fibrosi
cf
patient
splice
site
mutat
one
common
cftr
mutat
worldwid
global
databas
patient
cf
least
one
allel
howev
structur
function
defect
cftr
caus
splice
site
mutat
donor
site
intron
remain
unclear
addit
effect
cftr
modul
cftr
splice
site
mutant
still
unknown
character
cftr
explor
potenti
therapeut
strategi
studi
heterolog
primari
hbe
cell
cftr
mutat
patient
code
rtpcr
analysi
indic
splice
site
mutat
caus
cftr
skip
result
delet
amino
acid
cftr
miss
segment
locat
domain
contain
walker
b
motif
atp
bind
site
result
consist
earli
report
strong
tv
et
al
hum
mutat
moreov
cftr
gene
heterozyg
donor
encod
respect
equival
tecc
current
studi
indic
effect
forskolin
potenti
heterozyg
primari
hbe
cell
absenc
corrector
compar
homozyg
primari
hbe
patient
code
combin
corrector
potenti
lower
efficaci
suggest
cftr
impair
chlorid
channel
function
investig
splice
site
mutant
cftr
clone
express
vector
transfect
immort
hbe
cfbe
frt
cell
stabl
cell
line
express
establish
western
blot
analys
reveal
weak
band
b
three
stabl
cell
line
compar
wtcftr
express
cell
suggest
splice
site
mutant
caus
impair
biogenesi
matur
defect
common
cftr
corrector
seri
abbvi
compound
significantli
increas
band
b
produc
band
c
individu
howev
combin
two
compound
result
product
band
c
cfbe
suggest
compound
work
togeth
promot
cftr
matur
rescu
band
c
protein
could
activ
forskolin
forskolin
plu
sever
differ
potenti
includ
genistein
impli
channel
function
also
defect
conclus
cftr
splice
site
mutat
result
multipl
defect
includ
protein
biogenesi
matur
channel
function
illek
b
zlock
l
boeck
c
green
b
lefebvr
e
bate
mcgarri
nielson
dw
finkbein
research
institut
ucsf
benioff
children
hospit
oakland
oakland
ca
usa
patholog
ucsf
san
francisco
ca
usa
pediatr
ucsf
san
francisco
ca
usa
relev
cell
cultur
model
recapitul
function
properti
patientspecif
cftr
mutat
critic
person
medicin
approach
cystic
fibrosi
cf
particularli
valuabl
function
cell
model
propag
conserv
abil
grow
welldifferenti
airway
epithelia
person
chlorid
transport
measur
thirteen
cf
subject
common
rare
cftr
mutat
provid
airway
cell
sampl
nasal
tracheobronchi
tissu
three
cf
individu
genotyp
character
carri
common
mutat
allel
four
cf
individu
rare
cftr
mutat
allel
six
cf
individu
two
rare
cftr
mutat
allel
c
primari
cf
cell
cultur
presenc
rho
kinas
inhibitor
irradi
murin
fibroblast
induc
prolif
state
cfcrc
cell
number
expand
serial
passag
seed
cellscm
onto
snapwel
insert
grown
airliquid
interfac
induc
differenti
activ
mutant
cftr
clcurrent
small
molecul
potenti
corrector
studi
measur
acut
respons
forskolin
follow
cftr
inhibitor
cfcrc
three
cf
patient
homozyg
respond
acut
passag
show
trend
declin
passag
prior
treatment
h
enhanc
current
respons
detect
cfcrc
three
patient
carri
mutat
one
allel
includ
wherea
respons
found
one
patient
carri
genotyp
even
treatment
respons
detect
two
cf
patient
carri
rare
cf
mutat
allel
includ
stop
mutat
splice
mutat
c
c
enhanc
also
observ
contrast
respons
found
splice
mutat
two
cf
patient
carri
similarli
respons
found
patient
genotyp
patient
homozyg
stop
mutat
limit
number
cf
patientderiv
cell
expand
condit
reprogram
use
assess
efficaci
cftrtarget
compound
data
suggest
util
crc
person
ion
transport
measur
uss
chamber
demonstr
respons
smallmolecul
potenti
corrector
select
number
rare
cf
genotyp
support
cystic
fibrosi
foundat
bi
mm
dn
wf
niddk
dn
wf
nigm
mm
elizabeth
nash
foundat
overcom
preval
defect
lead
cystic
fibrosi
two
biomolecular
activ
requir
name
corrector
increas
cftr
level
cell
surfac
potenti
allow
effect
open
cftr
channel
combin
activ
allow
chlorid
ion
transport
yield
improv
hydrat
lung
surfac
develop
seri
compound
capabl
perform
role
alreadi
describ
character
deriv
previous
disclos
potenti
seri
progress
phase
clinic
trial
determin
safeti
toler
activ
patient
harbour
cftr
mutat
character
potenti
shown
use
patientderiv
organoid
focu
patient
organoid
rectal
biopsi
assay
develop
use
organoid
present
well
data
gener
use
potenti
organoid
residu
cftr
activ
complet
absent
organoid
forskolin
titrat
done
organoid
contain
differ
mutat
determin
optim
concentr
assess
potenti
activ
data
show
good
correl
data
obtain
yfp
halid
assay
organoid
case
good
correl
also
seen
use
patientderiv
primari
bronchial
epitheli
cell
organoid
heterozyg
patient
summari
present
develop
assay
use
patientderiv
organoid
data
obtain
use
across
assay
andrew
van
der
pla
gee
vandeveld
musch
verdonck
k
foolen
n
christoph
singh
ak
tse
c
nell
l
conrath
k
galapago
mechelen
belgium
abbvi
chicago
il
usa
address
preval
defect
lead
cystic
fibrosi
molecul
two
biomolecular
activ
requir
corrector
increas
cftr
level
cell
surfac
potenti
allow
effect
open
cftr
channel
combin
activ
allow
chlorid
ion
transport
yield
improv
hydrat
lung
surfac
report
character
novel
seri
potenti
combin
corrector
repres
potenti
new
seri
distinct
improv
potenc
yfp
assay
match
improv
adm
pk
profil
good
exposur
vivo
found
sever
compound
within
seri
compound
test
abl
open
channel
differ
mutant
effici
manner
determin
yfp
halid
assay
use
class
iii
iv
cftr
mutant
perform
transient
transfect
cftr
mutant
cell
iodid
influx
measur
addit
forskolin
potenti
sever
class
iii
mutant
maxim
open
mutant
channel
exceed
use
compar
assay
similar
iodid
influx
level
observ
current
phase
clinic
studi
multipl
compound
seri
exhibit
strong
dosedepend
activ
transepitheli
clamp
circuit
measur
tecc
primari
epitheli
cell
deriv
homozyg
patient
first
correct
either
alon
plu
nextgener
corrector
order
increas
level
cftr
plasma
membran
predict
yfp
halid
assay
result
rescu
cftr
open
dosedepend
manner
compound
seri
summari
describ
identif
secondgener
potenti
seri
good
channel
open
activ
seri
identifi
current
enter
clinic
trial
snitrosoglutathion
gsno
snitrosothiol
endogen
cell
signal
compound
potenti
relev
cystic
fibrosi
cf
human
lung
diseas
snitrosyl
signal
metabol
regul
often
disord
pulmonari
diseas
includ
cf
gsno
level
low
cf
airway
part
increas
express
gsno
reductas
zaman
k
et
al
j
physiol
lung
cell
mol
physiol
cochaperon
cterminu
interact
protein
chip
ubiquitin
ligas
help
target
improperlyfold
cftr
degrad
younger
et
al
j
cell
biol
chip
particular
interest
research
coloc
cftr
interact
chaperon
cochaperon
hop
chip
eight
cystein
residu
potenti
act
snitrosyl
motif
previous
shown
activ
site
cystein
anoth
ubiquitin
ligas
protein
von
hippel
lindau
inhibit
snitrosyl
palmer
l
et
al
jci
therefor
hypothes
chip
could
modifi
gsno
prevent
cftr
degrad
furthermor
inhibit
express
function
chip
hop
snitrosothiol
could
improv
cftr
express
matur
also
may
affect
cell
surfac
stabil
oklyoneda
et
al
scienc
found
chip
express
express
wildtyp
cftr
studi
show
gsno
significantli
decreas
chip
express
hour
respect
p
character
interact
chip
cftr
knock
endogen
chip
nm
chip
sirna
duplex
h
transfect
level
chip
decreas
p
produc
increas
level
immatur
matur
form
cftr
howev
presenc
gsno
increas
cftr
matur
signific
p
addit
demonstr
gsno
snitrosyl
chip
concentrationdepend
manner
confirm
cftr
express
cell
surfac
follow
knockdown
sirna
chip
perform
cellsurfac
label
chip
knockdown
level
full
cftr
matur
cell
surfac
increas
p
howev
presenc
gsno
ensur
increas
cftr
matur
pronounc
p
note
proteosom
inhibitor
prevent
deplet
cellular
chip
level
gsno
treatment
p
gsnotreat
cell
lessubiquitin
cftr
p
gsnountreat
cell
suggest
snitrosyl
chip
inhibit
cftr
ubiquitin
target
chip
degrad
andor
inhibit
chip
function
believ
observ
offer
novel
approach
identifi
key
mechan
snitrosothiol
snitrosyl
chip
increas
cftr
matur
prolong
cftr
cellsurfac
express
support
nih
cleavag
order
activ
nmd
express
minigen
includ
portion
intron
flank
exon
nonsens
mutat
construct
collabor
cystic
fibrosi
foundat
therapeut
minigen
includ
report
system
stabl
cell
line
express
minigen
highthroughput
luminesc
assay
serv
readout
chang
cftr
express
aso
effect
increas
luminesc
qpcr
intracellular
plasmamembran
local
protein
express
channel
conduct
measur
evalu
effect
cftr
screen
aso
relev
four
cftr
nonsens
mutat
vitro
determin
upregul
express
function
cftr
eventu
top
aso
test
cftr
upregul
mous
model
cf
data
proof
concept
data
show
upregul
ptccontain
betaglobin
transcript
report
aso
treatment
target
nmd
factor
sirna
treatment
target
nmd
translat
termin
factor
show
enhanc
readthrough
nmcftr
report
system
vitro
show
synerg
treatment
consid
posit
preliminari
data
aso
synthes
describ
strategi
upregul
nonsens
mutat
cftr
conclus
aso
modul
ptc
readthrough
nmd
pathway
may
abl
upregul
function
protein
product
cftr
nonsens
mutat
work
support
cystic
fibrosi
foundat
ioni
pharmaceut
inc
conrath
k
swensen
gee
verdonck
k
van
der
pla
andrew
hwang
medic
pharmacolog
physiolog
univers
missouri
columbia
mo
usa
galapago
mechelen
belgium
abbvi
chicago
il
usa
use
yfpbase
highthroughput
screen
assay
identifi
novel
compound
potenti
campdepend
activ
low
temperaturerescu
cftr
seri
reagent
develop
improv
potenc
compound
number
new
analogu
compound
profil
addit
yfp
halid
assay
use
class
iii
iv
cftr
mutant
assay
perform
transient
transfect
cftr
mutant
cell
iodid
influx
measur
addit
forskolin
potenti
compound
test
abl
open
channel
differ
mutant
effici
manner
sever
class
iii
mutant
maxim
activ
mutant
channel
exceed
channel
use
compar
assay
iodid
influx
maximum
obtain
furthermor
compound
show
higher
potenc
compar
assay
broad
set
compound
evalu
parallel
low
temperaturerescu
cftr
cftr
good
correl
potenc
two
assay
observ
one
compound
character
detail
patchclamp
techniqu
insideout
patch
excis
cho
cell
transient
express
wt
cftr
applic
compound
result
revers
potenti
activ
channel
preactiv
protein
kinas
atp
wt
cftr
p
presenc
mm
n
open
time
close
time
c
constant
ms
ms
respect
result
compat
seen
jih
ky
hwang
tc
proc
natl
acad
sci
usa
howev
fold
increas
macroscop
cftr
current
observ
fold
jih
hwang
p
dramat
increas
n
ms
c
ms
summari
character
recent
identifi
novel
potenti
perform
confirm
increas
channel
open
observ
primari
cell
use
patch
clamp
hwang
zhang
j
medic
pharmacolog
physiolog
univers
missouri
columbia
mo
usa
depart
biolog
engin
univers
missouri
columbia
mo
usa
coupl
atp
hydrolysi
cftr
nucleotid
bind
domain
nbd
gate
transit
transmembran
domain
tmd
oper
hallmark
transporterturn
ion
channel
whose
defect
function
respons
cystic
fibrosi
exactli
coupl
occur
remain
debat
previou
report
chargeneutr
mutat
cftr
transmembran
segment
q
enabl
direct
visual
atp
hydrolysisdriven
gate
transit
due
exist
two
distinct
openchannel
conduct
level
smaller
larger
prefer
pattern
c
c
transit
c
c
indic
violat
microscop
revers
henc
demand
input
free
energi
like
atp
hydrolysi
cystein
scan
cftr
tm
neg
charg
methanethiosulfon
mtse
also
found
two
openchannel
conduct
level
mtse
modif
prefer
gate
topolog
pattern
c
c
similar
phenotyp
observ
suggest
introduc
neg
charg
posit
confer
uniqu
behavior
wherea
mutat
net
subtract
posit
charg
intern
vestibul
cftr
pore
even
net
charg
unalt
alter
posit
endogen
posit
charg
side
chain
along
respect
could
observ
similar
state
asymmetr
gate
transit
indic
posit
charg
inner
vestibul
also
affect
subconduct
understand
structuralbiochem
mechan
underpin
hydrolysisdriven
transit
examin
effect
channelperm
blocker
scnand
channelimperm
blocker
mopson
state
two
state
show
indistinguish
sensit
scnblock
mopsblock
state
state
net
charg
inner
vestibul
unchang
increas
unexpectedli
howev
net
charg
intern
vestibul
cftr
pore
decreas
differenti
sensit
mopsblock
longer
exist
twostep
block
mechan
propos
explain
differenti
respons
prehydrolyt
posthydrolyt
open
state
mopsblock
mopsfirst
dock
inner
vestibul
pore
sojourn
deeper
pore
furthermor
propos
base
know
gate
conform
chang
cftr
intern
vestibul
expand
transit
mutationinduc
charg
perturb
caus
diminish
electrostat
attract
repuls
mopsfrom
intern
vestibul
state
expans
intern
vestibul
atp
hydrolysi
also
explain
singlechannel
conduct
state
higher
state
collect
current
studi
affirm
perhap
gener
phenotyp
also
provid
larg
toolbox
futur
mechanist
studi
cftr
gate
atp
hydrolysi
membran
partial
restor
chlorid
transport
unfortun
small
molecul
specif
target
lumacaftor
partial
restor
cftr
fold
traffick
must
present
synthesi
maxim
effect
suggest
act
facilit
proper
fold
one
transient
biosynthet
intermedi
understand
manipul
cotransl
fold
pathway
therefor
provid
potenti
approach
cftr
correct
address
challeng
isol
ribosom
nascent
chain
complex
rnc
measur
fret
donor
acceptor
fluorophor
incorpor
synthesi
defin
cotransl
fold
pathway
khushoo
et
al
mol
cell
kim
sj
et
al
scienc
studi
reveal
highli
orchestr
sequenti
fold
pathway
depend
biosynthet
machineri
translat
rate
primari
sequenc
overcom
low
concentr
rnc
obtain
vitro
translat
system
nm
rnc
immobil
nickelntaida
bead
increas
effect
local
concentr
enabl
quantit
fluoresc
measur
via
highcont
microscop
imag
system
allow
rapid
assess
nascent
polypeptid
fold
scalabl
highthroughput
screen
format
bead
imag
provid
except
sensit
allow
detect
attomol
quantiti
protein
x
moleculesbead
high
degre
reproduc
z
score
quantit
imag
immobil
rnc
allow
interrog
lengthdepend
structur
chang
cotransl
fold
intermedi
virtual
stage
synthesi
ii
nascent
protein
fold
ribosom
attach
releas
state
iii
structur
effect
diseaseassoci
mutat
iv
correct
defect
complementari
genet
manipul
moreov
rnc
isol
cellfre
translat
reaction
stabl
room
temperatur
amen
cryopreserv
enabl
scale
effort
need
screen
consist
result
therefor
provid
novel
platform
identifi
small
molecul
interact
de
novo
fold
intermedi
well
fulllength
protein
avoid
problem
associ
largescal
purif
unstabl
lowyield
substrat
support
cff
nih
ala
cui
g
khazanov
n
imhoff
b
senderowitz
h
mccarti
na
emori
univers
atlanta
ga
usa
depart
chemistri
barilan
univers
ramatgan
israel
cystic
fibrosi
cf
caus
lossoffunct
mutat
cystic
fibrosi
transmembran
conduct
regul
cftr
clchannel
increas
evid
suggest
cftr
dysfunct
also
signific
contributor
chronic
obstruct
pulmonari
diseas
copd
cftr
potenti
increas
cftr
activ
might
potenti
therapeut
strategi
copd
patient
addit
cf
patient
report
approv
cftr
potenti
ivacaftor
reduc
cellular
stabil
multipl
offtarget
function
necessit
discoveri
novel
potenti
recent
found
function
blocker
potenti
human
cftr
hcftr
report
identif
nearli
candid
zinc
databas
discov
use
pharmacophor
model
analysi
remov
poreblock
moieti
moreov
screen
candid
compound
two
electrod
voltag
clamp
tevc
found
multipl
compound
potenti
without
detect
block
wthcftr
express
xenopu
oocyt
potent
compound
test
insideout
macropatch
record
compound
potenti
wthcftr
intracellular
side
channel
activ
low
concentr
protein
kinas
pka
u
ml
presenc
mm
mgatp
compound
also
potenti
similar
experiment
condit
studi
test
effect
compound
hcftr
express
human
airway
epithelia
uss
chamber
futur
work
reiter
pharmacophor
analysi
updat
pharmacophor
model
identifi
high
effici
potenti
cff
nih
block
rescu
via
cihil
km
winschel
j
ranganathan
green
cm
mckiernan
pj
swiateckaurban
univ
pittsburgh
school
med
children
hospit
pittsburgh
pittsburgh
pa
usa
royal
colleg
surgeon
ireland
dublin
ireland
transform
growth
factor
tgf
modifi
associ
acceler
lung
diseas
patient
publish
data
demonstr
repress
cftr
mrna
prevent
correctormedi
rescu
repress
may
explain
part
limit
efficaci
corrector
potenti
recent
clinic
trial
studi
conduct
elucid
effector
respons
cftr
repress
order
develop
strategi
precis
elimin
pathogen
activ
control
express
sever
microrna
mirna
includ
inhibit
cftr
posttranscript
act
target
site
cftr
studi
primari
differenti
human
bronchial
epitheli
cfhbe
cell
conduct
examin
whether
upregul
first
examin
express
cfhbe
cell
treatment
qrtpcr
significantli
increas
express
function
time
triplic
differ
cfhbe
cell
p
observ
reciproc
decreas
cftr
mrna
differ
tissu
triplic
p
express
complet
block
inhibitor
publish
studi
demonstr
level
increas
cfhbe
cell
compar
nondiseas
control
gene
polymorph
associ
high
level
hypothes
express
cfhbe
cell
regul
level
differ
cf
patient
thu
examin
express
cf
bronchial
tissu
obtain
lung
transplant
irbapprov
protocol
situ
hybrid
compar
tissu
known
diseas
neg
control
emphysema
posit
control
blind
review
assign
score
base
express
bronchial
epithelium
express
neg
control
compar
posit
control
variabl
cf
sampl
triplic
group
ongo
studi
examin
express
cf
bronchial
epithelium
level
bronchoalveolar
lavag
fluid
gene
polymorph
next
examin
whether
inhibitor
attenu
repress
cftr
differenti
cfhbe
monolay
treat
either
lock
nucleic
acid
lna
tm
conjug
inhibitor
control
exiqon
inc
inhibitor
block
express
compar
partial
attenu
repress
cftr
next
demonstr
lna
tm
conjug
mimic
reduc
cftr
mrna
nondiseas
hbe
monolay
absenc
stimul
taken
togeth
data
provid
strong
evid
effector
repress
cftr
cf
bronchial
epithelium
strategi
block
cftr
repress
may
promot
efficaci
corrector
restor
function
cf
patient
wildtyp
cftr
primari
hbe
cell
treat
resveratrol
vehicl
control
ctrl
lower
concentr
resveratrol
affect
forskolinstimul
short
circuit
current
isc
howev
higher
concentr
resveratorol
inhibit
forskolinstimul
isc
p
differ
donor
resveratrol
also
inhibit
isc
cfhbe
cell
p
differ
donor
control
resveratrol
affect
amiloridesensit
isc
irrespect
concentr
high
concentr
resveratrol
inhibit
cftr
protein
abund
vs
ctrl
vs
ctrl
per
group
differ
donor
howev
effect
cftr
mrna
level
determin
effect
resveratrol
cftr
protein
stabil
inhibit
new
protein
synthesi
cyclohexamid
resveratrol
alter
cftr
protein
stabil
indic
stimul
cftr
protein
degrad
taken
togeth
data
indic
resveratrol
inhibit
cftr
clchannel
function
interf
cftr
posttranscript
biosynthet
pathway
resveratrol
work
via
sever
contextdepend
mechan
includ
activ
class
iii
histon
deacetylas
sirtuin
deacetyl
reaction
catalyz
coupl
cleavag
cofactor
nicotinamid
adenin
dinucleotid
nad
activ
critic
depend
avail
cellular
nad
resveratrol
increas
nad
gener
indic
activ
specif
inhibitor
domin
neg
dn
partial
rescu
resveratrol
inhibit
cftr
protein
level
exert
metabol
effect
via
inhibit
potent
induc
protein
synthesi
mammalian
target
rapamycin
mtor
block
mtor
activ
rapamycin
decreas
cftr
protein
level
similar
resveratrol
suggest
mtor
play
role
resveratroland
inhibit
cftr
current
studi
focu
confirm
role
mtor
cftr
biosynthesi
taken
togeth
studi
demonstr
novel
cftr
biosynthet
pathway
determin
common
nutrit
supplement
resveratrol
may
compromis
correctormedi
rescu
mutant
cftr
cystic
fibrosi
cf
common
lethal
genet
diseas
caus
mutat
cystic
fibrosi
transmembran
conduct
regul
cftr
gene
cf
character
massiv
proinflammatori
phenotyp
lung
aris
profound
express
inflammatori
gene
includ
long
noncod
rna
lncrna
emerg
novel
regul
gene
express
includ
inflammatori
gene
variou
diseas
associ
aberr
express
lncrna
report
role
lncrna
pathogenesi
cf
lung
diseas
find
lncrna
nuclear
enrich
abund
transcript
aberrantli
upregul
cf
cell
includ
cfbe
cf
cell
compar
respect
control
cell
moreov
observ
signific
vivo
upregul
cf
bronchial
brush
compar
normal
human
bronchial
epitheli
cell
shown
regul
express
proinflammatori
cytokin
diseas
consist
find
suppress
cf
lung
epitheli
cell
lead
reduc
express
express
addit
induc
signal
pathway
activ
cf
result
indic
pharmacolog
inhibit
pathway
suppress
well
shown
prevent
bind
repressor
protein
sfpq
splice
factor
prolineglutaminerich
promot
therebi
induc
increas
express
interestingli
data
indic
sfpq
downregul
cf
cell
compar
control
cell
overexpress
sfpq
cf
cell
suppress
also
induc
increas
express
protein
consist
knockdown
sfpq
cftrrepair
control
cell
lead
enhanc
mrna
express
reduct
cftr
protein
level
summari
elev
express
reduc
express
sfpq
cf
epitheli
cell
lead
transcript
activ
hyperexpress
moreov
sfpq
rescu
express
cf
cell
mechan
novel
potenti
target
cf
therapi
contribut
pm
cftr
stabil
includ
compartment
sphingolipid
sl
enrich
lipid
raft
format
multiprotein
complex
involv
ezrin
addit
mani
data
provid
literatur
show
phosphoryl
state
ezrin
turn
regul
plasma
membran
ceramid
level
base
find
investig
effect
potenti
corrector
cftr
pm
microenviron
analys
sl
composit
phosphoryl
state
ezrin
express
cf
noncf
bronchial
epitheli
cell
line
treat
corrector
addit
cell
line
evalu
sl
pattern
lipid
raft
cell
line
treat
observ
import
reduct
phosphoryl
ezrin
reduct
express
modest
differ
sl
pattern
interestingli
lipid
raft
treat
cell
found
mark
increas
sl
speci
particular
ceramid
glucosylceramid
gangliosid
could
respons
ezrin
dephosphoryl
reduct
express
preliminari
result
indic
combin
treatment
correctorpotenti
induc
modif
lipid
raft
organ
term
protein
lipid
could
respons
limit
stabil
mutat
rescu
cftr
pm
level
result
studi
could
permit
develop
new
therapeut
strategi
cf
treatment
use
sl
modul
support
italian
cystic
fibrosi
research
foundat
grant
ffc
synthesi
select
molecular
chaperon
retain
endoplasm
reticulum
er
ubiquitin
target
erassoci
degrad
erad
cytoplasm
proteasom
fail
achiev
transportcompet
conform
exist
small
molecul
corrector
modestli
improv
matur
mutant
protein
though
effect
cftr
ubiquitin
measur
vitro
therefor
hypothes
combin
cftr
corrector
inhibitor
protein
ubiquitin
would
increas
pool
protein
avail
correct
lead
synergist
improv
traffick
function
proofofprincipl
discov
pyrazon
compound
inhibit
ubiquitin
activ
enzym
decreas
ubiquitin
led
small
signific
increas
band
c
chlorid
current
ad
combin
compar
treatment
alon
target
screen
structur
analog
known
inhibitor
ubiquitin
machineri
identifi
addit
compound
decreas
ubiquitin
cftr
well
select
model
substrat
major
compound
fall
two
class
inhibitor
ubiquitin
activ
enzym
inhibitor
ubiquitin
ligas
chip
combin
newli
identifi
inhibitor
promot
increas
traffick
protein
function
beyond
observ
combin
continu
screen
potenti
inhibitor
effort
guid
evolv
structureact
relationship
assist
structur
model
enzym
exist
inhibitor
support
cff
nih
bikard
litvak
jeger
j
suaud
l
rubenstein
rc
pulmonari
children
hospit
philadelphia
philadelphia
pa
usa
pediatr
perelman
school
medicin
univers
pennsylvania
philadelphia
pa
usa
kda
thioredoxinhomolog
protein
endoplasm
reticulum
er
display
chaperonelik
properti
interestingli
singl
cystein
instead
usual
cxxc
thioredoxin
motif
addit
display
chaperonelik
properti
biophys
cellular
level
also
demonstr
role
cortic
neuron
protect
suppress
tumorigenesi
regul
connexin
hemichannel
biogenesi
assembl
previous
demonstr
promot
cftr
biogenesi
suaud
et
al
j
biol
chem
biogenesi
cftr
enac
share
number
featur
subsequ
demonstr
also
regul
enac
biogenesi
function
express
grumbach
et
al
j
physiol
cell
physiol
particular
studi
demonstr
overexpress
wt
increas
enac
function
express
like
due
increas
cleavag
cell
surfac
enac
wherea
overexpress
mutant
lack
singl
cystein
decreas
enac
function
express
due
decreas
enac
cleavag
surfac
overexpress
also
promot
interact
enac
cftr
coat
complex
ii
cop
ii
er
exit
machineri
wherea
overexpress
decreas
interact
data
suggest
model
may
promot
enac
cleavag
biogenesi
direct
enac
golgi
would
subject
cleavag
furin
thu
hypothes
subcellular
local
would
key
determin
regul
enac
cftr
biogenesi
ctermin
er
retent
motif
keel
kdel
variant
associ
less
robust
er
retent
assess
retent
releas
er
critic
regul
enac
cftr
biogenesi
design
mutant
contain
either
kdel
retent
motif
kdel
better
return
er
proxim
golgi
kdel
receptor
mutant
retent
motif
delet
would
interact
less
well
kdel
receptor
therefor
potenti
better
escap
er
interestingli
enac
function
express
decreas
overexpress
kdel
elicit
signific
effect
alreadi
observ
wt
overexpress
express
apic
surfac
chang
overexpress
kdel
contrast
kdel
overexpress
decreas
cftr
function
express
inhibit
enac
cftr
function
express
suggest
role
kdel
receptor
enac
cftr
biogenesi
support
hypothesi
preliminari
data
suggest
sirnamedi
deplet
decreas
process
cleavag
enac
golgi
biogenesi
well
cftr
function
express
togeth
find
suggest
key
regulatori
role
associ
kdel
receptor
biogenesi
enac
cftr
support
grant
cff
tradit
method
primari
cultur
human
airway
epitheli
cell
rare
allow
passag
signific
loss
epitheli
function
recent
develop
approach
includ
irradi
fibroblast
feeder
layer
inclus
rhoassoci
protein
kinas
inhibitor
enabl
passag
fold
expans
cell
number
good
retent
epitheli
function
gold
standard
vitro
test
cftr
corrector
potenti
welldifferenti
primari
human
bronchial
epitheli
cell
obtain
lung
transplant
cf
patient
number
differ
patient
sampl
obtain
manner
small
rang
cftr
mutat
avail
studi
limit
goal
work
establish
method
collect
cultur
expans
primari
human
nasal
epitheli
cell
deriv
noncf
volunt
examin
intersubject
variat
cftr
express
function
nasal
brush
obtain
healthi
noncf
volunt
nasal
cell
collect
second
time
month
later
subject
twenti
sampl
expand
passag
cryopreserv
analysi
cftr
function
express
cell
multipl
passag
seed
onto
filter
support
establish
airliquid
interfac
cultur
epitheli
monolay
transfer
uss
chamber
day
seed
bath
symmetr
kreb
bicarbon
ringer
solut
maintain
shortcircuit
condit
amilorid
forskolin
ad
sequenti
inhibit
sodium
absorpt
stimul
cftrdepend
clsecret
inhibit
cftrdepend
clsecret
respect
viabl
epitheli
cell
cultur
establish
subject
sampl
cultur
seed
onto
filter
support
airliquid
interfac
cultur
develop
high
transepitheli
resist
mean
amiloridesensit
sodium
current
subject
rang
forskokinstimul
current
readili
observ
noncf
monolay
mean
clsecretori
respons
sensit
current
individu
subject
rang
ion
transport
properti
cell
obtain
multipl
brush
subject
qualit
quantit
similar
cftr
mrna
express
across
subject
vari
correl
cftr
clcurrent
epitheli
cell
obtain
nasal
brush
noncf
volunt
readili
isol
cultur
expand
cryopreserv
isol
nasal
epitheli
cell
expand
rapidli
produc
billion
cell
filter
within
week
previous
shown
primari
cultur
cf
patientderiv
nasal
epitheli
cell
sensit
system
test
cftr
function
evalu
small
molecul
cftrdirect
therapeut
current
data
identifi
target
level
cftr
function
noncf
subject
demonstr
wide
rang
normal
cftr
express
function
might
also
contribut
individu
patient
drug
respons
variat
among
cf
subject
support
cf
foundat
aleksandrov
l
cui
l
jensen
l
aleksandrov
riordan
jr
biochemistri
biophys
unc
chapel
hill
nc
usa
cftr
highli
dynam
multidomain
membran
protein
cotransl
fold
culmin
correct
domain
assembl
function
unit
swap
nbd
msd
opposit
halv
molecul
cftr
function
unit
must
maintain
correctli
fold
state
protein
purif
structur
analysi
purpos
alreadi
gener
cftr
construct
stabil
nbd
demonstr
remain
function
two
week
purif
reconstitut
nbd
stabil
msd
may
remain
dynam
part
protein
deterg
disrupt
lipid
bilay
present
improv
protein
stabil
correctli
fold
state
spontan
ss
bond
format
engin
cystein
near
extern
end
format
ss
bond
occur
correctli
fold
protein
revers
restrict
set
msd
structur
configur
ion
pore
close
state
mainten
correct
msd
assembl
purifi
protein
storag
c
evalu
determin
degre
disulfid
bond
reform
remov
reduc
agent
dtt
use
broken
much
shorter
life
time
observ
storag
purifi
protein
condit
disulfid
bond
disrupt
state
nbd
manipul
monitor
atp
bind
limit
proteolysi
also
use
appris
overal
assembl
purifi
protein
distinct
condit
cftr
construct
stabil
nbd
msd
abl
maintain
fold
state
solubil
form
month
purif
refer
aleksandrov
la
et
al
protein
expr
purif
support
nih
cff
increas
greater
seen
lumacaftor
pti
corrector
lumacaftor
also
addit
consist
distinct
mechan
action
two
corrector
lastli
tripl
combin
pti
amplifi
pti
corrector
chronic
ivacaftormedi
destabil
prevent
uss
chamber
assay
pti
potenti
show
compar
efficaci
ivacaftor
hbe
electrophysiolog
measur
amplifi
pti
corrector
pti
potenti
tripl
combin
restor
activ
mutant
protein
nearnorm
cftr
activ
addit
amplifierbas
tripl
combin
provid
potenti
advantag
abil
modul
cftr
overcom
substrat
limit
corrector
potenti
base
data
gener
hbe
cell
combin
use
three
molecul
potenti
restor
mutant
cftr
function
cf
patient
homozyg
mutat
clinic
benefici
level
fund
part
therapeut
develop
award
cystic
fibrosi
foundat
therapeut
inc
turner
abbottbann
k
randel
sh
hanrahan
jw
physiolog
mcgill
univers
montreal
qc
canada
cf
translat
research
centr
mcgill
univers
montreal
qc
canada
verona
pharma
plc
london
unit
kingdom
univers
north
carolina
chapel
hill
nc
usa
human
cyclic
nucleotid
phosphodiesteras
pde
famili
enzym
encod
gene
famili
contain
sever
gene
eg
multipl
splice
variant
degrad
cyclic
nucleotid
shown
inhibit
certain
pde
elev
intracellular
camp
level
camp
stimul
cftrdepend
anion
secret
human
airway
epithelia
suggest
pde
inhibitor
potenti
treatment
option
cystic
fibrosi
cf
patient
previou
studi
focuss
role
regul
cftr
activ
littl
known
regard
import
pde
isoform
recent
demonstr
primari
human
bronchial
epithelia
phbe
express
mrna
level
similar
mrna
therefor
examin
whether
involv
campdepend
stimul
cftr
use
recentlydescrib
inhibitor
pfizer
cfbe
cell
overexpress
wild
type
cftr
cfbewt
phbe
cell
healthi
subject
phbe
wt
grown
polar
monolay
allow
differenti
airliquid
interfac
ali
prior
studi
although
ad
inhibitor
alon
elev
camp
measur
use
elisa
signific
effect
inhibitor
camp
observ
inhibit
submaxim
forskolin
stimul
indic
contribut
camp
metabol
phbe
wt
cfbewt
cell
furthermor
measur
shortcircuit
current
sc
cfbewt
cell
mount
uss
chamber
reveal
inhibit
increas
cftrdepend
sc
cm
p
vs
dmso
small
respons
compar
produc
inhibitor
rolipram
cm
dual
inhibitor
cm
nevertheless
pf
increas
sc
cm
p
vs
dmso
phbe
wt
cell
compar
stimul
rolipram
cm
cm
primari
cell
greater
observ
use
inhibitor
milrinon
inhibitor
sildenafil
moreov
inhibit
enhanc
sc
respons
rolipram
fold
inhibit
increas
respons
pf
fold
indic
inhibitor
act
synergist
cftrdepend
secret
final
assess
effect
inhibit
phbe
cell
cf
patient
genotyp
inhibitor
stimul
sc
ad
alon
howev
enhanc
sc
cf
primari
cell
pretreat
submaxim
concentr
forskolin
summari
data
suggest
novel
regul
cftr
wildtyp
cf
human
airway
epithelia
promin
role
inhibitor
act
synergist
thu
may
repres
novel
therapeut
target
cf
ran
crum
cm
yosipof
kaspi
senderowitz
h
thibodeau
ph
microbiolog
molecular
genet
univers
pittsburgh
pittsburgh
pa
usa
chemistri
bar
ilan
univers
israel
major
cystic
fibrosi
patient
least
one
copi
allel
signific
number
cf
patient
compound
heterozygot
andor
harbour
two
allel
affect
protein
fold
traffick
function
sequenc
variant
identifi
cftr
date
rigor
evalut
effect
protein
structur
function
use
avail
cfcftr
human
abctransport
mutat
databas
identifi
profil
seri
variant
cytosol
domain
cftr
effect
cftr
protein
fold
structur
evalu
mutat
set
within
nbd
studi
design
inform
understand
cftr
biosynthesi
identifi
impact
report
sequenc
variat
provid
experiment
dataset
develop
predict
model
cftr
mutat
respons
treatment
start
mutat
databas
perform
compar
analysi
report
mutat
across
multipl
abctransport
protein
priorit
provid
confid
rare
cfassoci
allel
score
system
rank
mutat
base
conserv
nativ
abctransport
sequenc
report
variant
provid
addit
confid
identif
rare
diseaseassoci
allel
optim
method
priorit
cfcaus
allel
highest
confid
appli
comput
strategi
mutat
databas
identifi
roughli
missens
mutat
interest
subsequ
studi
expand
nbd
mutat
set
roughli
allow
comprehens
mutationdriven
analysi
nbd
fold
structur
cftr
biogenesi
use
dataset
gener
mutat
librari
systemat
studi
fold
stabil
nbd
vitro
effect
mutat
structur
fold
traffick
fulllength
cftr
cell
cultur
use
combin
purifi
nbd
protein
novel
incel
assay
assess
stabil
wildtyp
mutant
nbd
protein
effect
mutat
fold
structur
nbd
isol
parallel
cell
cultur
studi
evalu
effect
mutat
fulllength
cftr
fold
traffick
mutat
within
provid
comprehens
support
hierarch
fold
assembl
cftr
domain
mutat
may
influenc
either
fold
structur
nbd
local
assembl
within
global
quaternari
complex
cftr
correct
defect
either
known
novel
secondsit
suppressor
small
molecul
stratifi
dataset
use
data
develop
comput
approach
explor
relationship
mutat
effect
cftr
structur
function
use
cluster
network
analys
studi
provid
addit
insight
biosynthet
pathway
wildtyp
cftr
inform
understand
molecular
patholog
larg
number
rare
cf
mutat
cftr
class
ii
mutat
compris
cohort
diseaseassoci
allel
proven
difficult
address
current
therapeut
strategi
previous
describ
novel
approach
genomewid
yeast
phenom
identifi
modifi
rescu
class
ii
abnorm
highthroughput
analysi
reveal
ribosom
protein
primari
target
purpos
bind
rrna
form
p
stalk
base
subunit
gtpaseassoci
center
stalk
interact
mani
eukaryot
elong
factor
eef
translat
includ
find
demonstr
sirnamedi
knockdown
partial
correct
function
express
cftr
addit
synergist
lumacaftor
tm
multipl
cell
model
includ
primari
hbe
code
homozyg
next
investig
mechan
underli
cftr
rescu
set
test
secondsit
suppressor
studi
hrptag
cftr
stabli
express
fischer
rat
thyroid
frt
cell
inhibit
display
addit
mutat
improv
stabil
nucleotid
bind
domain
contrast
restor
loop
interfac
confer
signific
increas
plasma
membraneloc
follow
knockdown
find
suggest
stabil
insideout
patch
clamp
analys
util
investig
fold
integr
rescu
protein
preliminari
result
show
inhibit
produc
thermost
channel
compat
profold
effect
mutant
cftr
base
observ
test
whether
addit
class
ii
defect
might
also
rescu
includ
knockdown
result
fold
increas
matur
fullyglycosyl
cftr
cband
improv
vector
ion
transport
three
cftr
mutant
quantifi
western
analysi
short
circuit
current
respect
suggest
previous
suppress
inhibit
interact
slow
translat
allow
ribosom
auxiliari
protein
achiev
nativ
cftr
conform
p
stalk
compon
known
assembl
onto
interact
factor
respons
enzymat
deliveri
aminoacyl
trna
ribosom
investig
whether
knockdown
might
induc
incorpor
noncogn
amino
acid
show
inhibit
promot
increas
fulllength
protein
express
taken
togeth
work
provid
first
evid
repres
novel
therapeut
strategi
rescu
numer
cftr
class
ii
defect
refin
approach
establish
import
ribosom
protein
cftr
fold
furnish
new
molecular
target
experiment
treatment
diseas
support
cff
nih
cystic
fibrosi
cf
delet
phenylalanin
posit
mutat
lead
retent
degrad
cftr
cf
transmembran
conduct
regul
protein
endoplasm
reticulum
qualiti
control
erqc
mechan
compos
seri
enzym
chaperon
edem
endoplasm
reticulum
degrad
enhanc
lectin
variant
name
propos
lectin
ensur
retrotransloc
cytosol
misfold
glycoprotein
releas
er
ermani
proteasom
degrad
mast
sw
moremen
kw
method
enzymol
studi
object
determin
whether
lectin
involv
traffick
defect
design
synthes
multival
iminosugar
rescu
traffick
defect
method
result
first
demonstr
use
westernblot
techniqu
cell
model
stabli
transfect
hela
cell
express
variant
moreov
use
duolink
assay
observ
lectin
interact
next
transfect
cell
specif
sirna
observ
decreas
express
correl
decreas
interact
interestingli
show
use
iodid
efflux
techniqu
restor
cftr
activ
cell
transfect
sirna
sirna
transfect
cell
result
investig
effect
inhibitor
ermani
interact
activ
reveal
corrector
effect
kifunensin
swainsonin
deoxymannojirimycin
dmj
nbutyl
analogu
nbu
dmj
therefor
adapt
click
chemistri
methodolog
synthes
effici
corrector
base
dmj
cluster
screen
observ
trivalentdmj
present
best
effici
ec
next
demonstr
trivalentdmj
decreas
interact
effect
observ
interact
calnexin
suggest
edemdepend
mechan
action
parallel
result
confirm
corrector
effect
corrector
human
polar
bronchial
epitheli
cell
cfbe
use
uss
chamber
techniqu
restor
isc
current
interestingli
confirm
corrector
effect
human
respiratori
epitheli
cell
freshli
isol
cf
patient
use
fluoresc
probe
oxonol
conclus
work
reveal
first
time
interact
isoform
edem
suggest
involv
retent
identifi
inhibit
ermani
correct
traffick
defect
edemdepend
mechan
action
propos
new
seri
watersolubl
nontox
corrector
cystic
fibrosi
cf
lethal
autosom
recess
inherit
diseas
caus
mutat
gene
encod
cystic
fibrosi
transmembran
conduct
regul
cftr
critic
issu
cf
inabl
common
cftr
mutat
delet
phenylalanin
residu
posit
cftr
achiev
nativ
fold
state
requir
export
endoplasm
reticulum
er
traffic
epitheli
cell
apic
membran
instead
cftr
protein
exclus
retain
er
degrad
ubiquitinproteasom
system
process
refer
erassoci
protein
degrad
erad
howev
cftr
mobil
plasma
membran
retain
substanti
cftr
clchannel
function
therefor
understand
molecular
mechan
regul
cftr
degrad
earli
biogenesi
critic
step
achiev
effect
select
mobil
mutant
cftr
er
previous
lab
demonstr
promot
effici
degrad
cftr
fold
mutant
includ
cftr
report
vcpinteract
membran
protein
vimp
erad
compon
play
import
role
degrad
misfold
cftr
overexpress
vimp
reduc
steadyst
level
wt
cftr
respect
cycloheximid
chase
experi
vimp
express
result
shorter
half
life
cftr
min
min
convers
silenc
endogen
vimp
increas
cftr
express
human
airway
epitheli
cell
coimmunoprecipit
immunostain
reveal
vimp
interact
cftr
coloc
mutant
protein
er
region
airway
epitheli
cell
sinc
report
key
regul
cftr
degrad
ask
whether
vimp
play
role
mediat
cftr
degrad
doubl
silenc
experi
perform
compar
silenc
doubl
silenc
vimp
lead
increas
cftr
express
suggest
vimp
util
pathway
cftr
degrad
shown
ubiquitin
ligas
chip
degrad
investig
vimp
associ
specif
ubiquitin
ligas
perform
coimmunoprecipit
found
vimp
interact
chip
cell
overexpress
vimp
virtual
elimin
cftr
express
vimpmedi
mutant
cftr
degrad
abolish
domin
neg
indic
vimp
recruit
degrad
mutant
protein
cell
silenc
vimp
express
increas
matur
function
taken
togeth
data
demonstr
vimp
recruit
degrad
misfold
cftr
downregul
vimp
enhanc
abil
rescu
provid
novel
therapeut
strategi
synergist
restor
mutant
protein
function
fund
support
cff
nhlbinih
reduc
cftr
activ
observ
primari
cf
cell
upon
prolong
treatment
lumacaftor
ivacaftor
may
decreas
clinic
benefit
flatley
discoveri
lab
develop
novel
cftr
corrector
potenti
combin
show
greater
invitro
activ
follow
chronic
treatment
compar
lumacaftor
ivacaftor
combin
method
result
cell
surfac
express
function
activ
determin
cell
treat
lumacaftor
ivacaftor
transfect
overexpress
cftr
plasmid
use
western
blot
experi
cell
hrptag
cftr
plasmid
use
hrp
cell
surfac
assay
homozyg
cf
human
bronchial
cell
hbe
lung
transplant
use
determin
function
activ
electrophysiolog
assay
western
blot
experi
western
blot
experi
hrp
assay
increas
cftr
matur
cell
surfac
express
homozyg
cell
equival
current
function
assay
homozyg
hbe
cell
correct
acut
expos
similar
maximum
chlorid
current
respons
cell
treat
lumacaftor
acut
ivacaftor
hrp
assay
reduct
cftr
surfac
express
observ
follow
hour
exposur
cfbe
cell
lumacaftor
ivacaftor
wherea
reduct
seen
cfbe
cell
expos
see
figur
chronic
exposur
hour
reduc
chlorid
current
compar
exposur
compound
acut
condit
exposur
cell
lumacaftor
ivacaftor
decreas
chlorid
current
conclus
promot
cftr
matur
cell
surfac
express
equival
potenc
efficaci
lumacaftor
upon
chronic
treatment
primari
hbe
cell
combin
cftr
corrector
cftr
potenti
greater
vitro
efficaci
lumacaftor
ivacaftor
combin
substrat
endoplasm
reticulumassoci
degrad
erad
mechan
misfold
dispos
cystic
fibrosi
transmembran
conduct
regul
cftr
remain
incomplet
understood
step
erad
usual
includ
recognit
ubiquitin
modif
proteasom
proteolysi
misfold
protein
due
complex
protract
fold
domain
assembl
requir
much
wt
cftr
common
fold
mutant
cftr
degrad
express
system
protein
ubiquityl
control
oppos
activ
ubiquitin
ligas
deubiquityl
enzym
balanc
ubiquityl
deubiquityl
influenc
varieti
cellular
process
previous
shown
oppos
wt
cftr
cftr
preferenti
modifi
small
ubiquitinlik
modifi
sumo
protein
small
heat
shock
protein
shsp
select
facilit
cftr
degrad
form
conjug
polysumo
chain
follow
ubiquityl
sumotarget
ubiquitin
ligas
stubl
use
proteinbind
array
screen
protein
interact
chain
identifi
target
sumomedi
regul
cftr
biogenesisdegrad
proteinbind
array
sever
deubiquityl
enzym
identifi
exampl
anoth
ubiquitinspecif
proteas
recent
report
capabl
deubiquityl
ubiquityl
sumochain
target
ubiquitin
ligas
thu
counteract
action
dna
damag
respons
understand
role
regul
cftr
biogenesi
degrad
determin
whether
protein
function
similarli
stabil
sumomodifi
cftr
via
deubiquityl
inde
overexpress
either
elev
level
cftr
express
cfbe
cell
cell
addit
also
markedli
reduc
ubiquityl
cftr
wherea
catalyt
inact
mutant
elimin
abil
augment
cftr
express
result
also
reveal
cftr
express
increas
occur
reduct
modif
cftr
reduc
target
cftr
substrat
level
result
suggest
member
ubiquitinspecif
proteas
famili
rescu
modifi
mutant
cftr
degrad
via
deubiquityl
may
via
differ
mechan
refer
ahner
et
al
mol
biol
cell
hendrik
ia
et
al
j
biol
chem
support
grant
niddk
cf
foundat
therapeut
introduct
restor
cftr
function
modul
treatment
demonstr
clinic
efficaci
cf
patient
homozyg
cftr
though
less
ivacaftor
cf
patient
gate
mutat
identifi
factor
limit
respons
cftr
modul
press
need
report
potenti
neg
interact
cftr
vitro
veit
g
et
al
sci
transl
med
traffictransport
trial
minor
patient
receiv
demonstr
increas
effect
orkambi
fev
wainright
ce
et
al
nejm
demonstr
chronic
exposur
wtand
cftr
human
lower
airway
epitheli
cell
laec
shortact
saba
albuterol
suffici
reduc
subsequ
cftr
activ
shown
sabainduc
cftr
dysfunct
link
reduc
cellular
camp
product
hypothes
chronic
saba
longact
laba
use
impair
adenylyl
cyclas
activ
reduc
cftr
function
airway
epithelia
method
stabli
transduc
wtor
grown
permeabl
support
confluenc
studi
uss
chamber
cftr
function
quantifi
shortcircuit
current
isc
cfbe
pretreat
h
prior
studi
result
previous
demonstr
h
continu
exposur
wtcftr
cfbe
saba
albuterol
reduc
cftrdepend
isc
control
vs
saba
stimul
forskolinibmx
stimul
cellperm
howev
saba
pretreat
impair
cftr
activ
control
vs
saba
similarli
h
continu
saba
exposur
cfbe
reduc
cftrdepend
isc
control
vs
saba
stimul
forskolinibmx
stimul
overcam
sabainduc
cftr
dysfunct
control
vs
saba
cm
preliminari
data
cfbe
h
intermitt
saba
exposur
twice
daili
reduc
cftrdepend
isc
control
vs
isaba
chronic
intermitt
laba
exposur
formoterol
twice
daili
howev
reduc
cftrdepend
isc
control
vs
ilaba
conclus
chronic
airway
epitheli
stimul
albuterol
lead
impair
cftr
function
due
reduc
camp
gener
respons
direct
adenylyl
cyclas
stimul
forskolin
impair
overcom
applic
exogen
camp
directli
implic
downregul
adenylyl
cyclas
function
chronic
saba
use
earli
data
suggest
twicedaili
saba
dose
insuffici
replic
effect
intermitt
dose
laba
similarli
impair
cftr
activ
ongo
work
evalu
intermitt
saba
laba
exposur
process
includ
transcriptom
evalu
effect
chronic
exposur
given
nearubiquit
use
patient
cf
potenti
neg
interact
essenti
issu
studi
support
cfft
discoveri
small
molecul
correct
fold
defect
caus
cftr
enhanc
cell
surfac
function
becom
prioriti
cystic
fibrosi
translat
research
increas
endoplasm
reticulum
er
local
pool
mutant
cftr
avail
pharmacolog
correct
could
offer
substanti
benefit
compoundheterozyg
individu
carri
one
copi
misfold
cftr
undergo
prematur
degrad
initi
ubiquitin
follow
target
erassoci
degrad
erad
machineri
proteasom
ubiquitin
ligas
play
import
role
rout
cftr
degrad
novel
compound
block
cftr
ubiquitin
could
augment
mutant
protein
pool
act
upon
small
molecul
corrector
use
ubipro
tm
discoveri
platform
conduct
primari
fretbas
screen
librari
contain
small
molecul
isol
compound
attenu
ubiquitin
catalyz
total
specif
inhibitor
select
verifi
blockad
recombin
human
cftr
ubiquitin
priorit
abil
promot
surfac
express
cftrhrp
epitheli
cell
model
nineteen
compound
next
evalu
effect
cftr
band
b
accumul
rescu
lumacaftor
two
term
increas
cftr
frt
cell
synergist
enhanc
chlorid
transport
combin
lumacaftor
also
increas
steadyst
level
mutant
cftr
class
defect
class
ii
synergist
rescu
observ
follow
lumacaftor
result
indic
inhibit
specif
ubiquitin
ligas
augment
repar
pool
cftr
point
novel
drugdevelop
strategi
addit
demonstr
modul
improv
stabil
indic
share
degrad
pathway
could
target
enhanc
correct
among
patient
carri
allel
compound
describ
current
evalu
primari
airway
epitheli
cell
experiment
therapeut
broad
spectrum
individu
cystic
fibrosi
fund
nih
cff
shift
chang
upon
bind
provid
evid
alloster
coupl
direct
bind
site
interfac
tightli
link
nbd
dimer
surfac
previou
studi
shown
import
role
modul
conform
ren
hy
et
al
mol
biol
cell
addit
mode
bind
provid
insight
conform
dynam
allosteri
within
cftr
interpret
data
propos
action
subsequ
destabil
helic
contribut
mechan
action
alloster
stabil
interact
releas
rer
region
core
therebi
promot
nbd
dimer
stabil
fulllength
cftr
work
fund
grant
cystic
fibrosi
foundat
therapeut
cystic
fibrosi
canada
nonsens
mutat
repres
cystic
fibrosi
cf
caus
allel
mutat
result
prematur
degrad
cystic
fibrosi
transmembran
conduct
regul
cftr
mrna
would
code
translat
truncat
protein
current
therapeut
strategi
focus
suppress
nonsensemedi
mrna
decay
nmd
pathway
andor
induc
readthrough
prematur
termin
codon
ptc
alter
translat
machineri
allow
misincorpor
amino
acid
site
nonsens
codon
investig
toler
missens
amino
acid
assess
cftr
matur
function
variant
matur
test
function
use
transepitheli
resist
singlechannel
activ
assay
data
indic
amino
acid
substitut
toler
posit
highli
evolutionarili
conserv
posit
requir
specif
amino
acid
correct
fold
andor
function
thu
readthrough
agent
may
clinic
benefit
appli
cftr
contain
nonsens
codon
posit
highli
conserv
overcom
obstacl
util
modifi
trna
recogn
ptc
mediat
incorpor
desir
amino
acid
demonstr
improv
cftr
function
cell
harbor
mutat
formul
deliveri
modifi
trna
nanoparticl
develop
screen
small
librari
nanoparticl
uniqu
function
group
capabl
rna
deliveri
use
cell
line
contain
endogen
nonsens
mutat
offtarget
effect
modifi
trna
natur
stop
codon
experiment
assess
posit
formul
assess
primari
hbe
deriv
cf
patient
explant
harbor
nonsens
mutat
cftr
data
suggest
nanoparticl
deliveri
modifi
trna
improv
cftr
function
primari
hbe
may
offer
altern
therapeut
approach
treatment
cf
caus
nonsens
mutat
despit
critic
role
cftr
process
gate
direct
detect
nucleotid
bind
domain
nbd
heterodimer
remain
elus
channel
gate
studi
indic
channel
rapidli
cycl
open
close
conform
suggest
nbd
dimer
form
modest
affin
dimer
isol
nbd
like
compromis
disrupt
critic
interact
intracellular
loop
icl
qloop
nbd
previous
shown
qloop
isol
domain
exchang
dimerfavor
dimerunfavor
posit
delet
push
qloop
dimerincompat
posit
chong
pa
et
al
j
biol
chem
similarli
isol
sidechain
eponym
qloop
glutamin
flip
roughli
degre
hydrogen
bond
zhao
x
et
al
ped
pulmonol
rotat
alphahel
subdomain
dimercompat
posit
mutat
disrupt
hydrogen
bond
allow
alphahel
subdomain
move
partway
back
dimercompat
posit
qloop
problem
may
mitig
interact
icl
nonetheless
probabl
contribut
energet
modest
affin
nbd
dimer
fulllength
cftr
use
comput
bioinformat
tool
predict
mutat
stabil
nbd
dimer
dual
goal
understand
impedi
nbd
heterodimer
wt
cftr
obtain
stabl
nbd
dimer
biophys
studi
success
stabil
biophys
studi
includ
cd
nmr
studi
nbd
heterodimer
assay
use
thermal
melt
assay
nmr
chemic
shift
perturb
experi
nmr
paramagnet
relax
enhanc
pre
techniqu
success
use
confirm
homodimer
probe
effect
diseasecaus
mutat
ctermin
tail
cftr
regulatori
insert
r
region
phosphoryl
nonphosphoryl
nbd
heterodim
provid
progress
updat
experi
work
also
enabl
studi
small
molecul
modul
target
nbd
dimer
interfac
support
grant
cystic
fibrosi
foundat
therapeut
cystic
fibrosi
canada
express
cftr
expos
cse
hydrogen
peroxid
shown
previous
stimul
cftr
function
cigarett
smoke
contain
oxid
therefor
explor
role
reactiv
oxygen
speci
pretreat
cell
nacetylcystein
nac
stimul
cse
strongli
attenu
mm
nac
consist
involv
reactiv
oxygen
speci
acut
secretori
respons
cse
may
host
defens
mechan
clear
noxiou
stimuli
epitheli
surfac
support
canadian
institut
health
research
effort
understand
sodium
correct
traffick
cystic
fibrosi
cf
epithelia
recent
demonstr
transient
increas
express
cf
epitheli
cell
treat
occur
process
mediat
elong
protein
scaffold
protein
requir
activ
also
compon
elong
complex
appear
regul
number
cellular
process
includ
rna
polymeras
ii
activ
data
suggest
increas
express
promot
traffick
hypothes
increas
express
promot
traffick
plasma
membran
test
hypothesi
perform
uss
chamber
experi
cell
overexpress
cftr
cell
transfect
specif
sirna
overexpress
increas
cftrmediat
current
cell
wherea
deplet
sirna
cftr
cell
decreas
cftrmediat
current
previous
shown
increas
express
promot
interact
epitheli
sodium
channel
enac
cargo
recognit
compon
coat
complex
ii
cop
ii
machineri
carri
protein
cargo
endoplasm
reticulum
golgi
coimmunoprecipit
experi
cf
bronchiolar
epitheli
cell
overexpress
increas
express
promot
interact
data
provid
mechanist
link
increas
express
lead
increas
express
result
improv
traffick
also
interrog
mechan
usual
found
cytoplasm
abl
transloc
nucleu
regul
express
nuclear
local
signal
nl
therefor
like
need
carrier
move
nucleu
initi
hypothes
specif
activ
serv
carrier
previous
demonstr
transloc
nucleu
treatment
test
hypothesi
use
luciferas
report
assay
cell
luciferas
express
control
human
promot
howev
overexpress
mutant
construct
includ
constitut
activ
tyrosin
serin
phosphorylationdefici
mutant
suggest
phosphoryl
state
regul
transloc
nucleu
express
respons
instead
overexpress
elong
complex
protein
name
similar
lucifereas
report
assay
suggest
contain
nl
may
carri
nucleu
respons
togeth
data
suggest
mechan
improv
traffick
potenti
identifi
new
target
intervent
refer
suaud
l
et
al
j
biol
chem
chookang
lr
zeitlin
pl
ajp
lung
cell
mol
physiol
support
cystic
fibrosi
cf
chronic
lethal
genet
diseas
caus
mutat
gene
encod
cystic
fibrosi
transmembran
conduct
regul
cftr
previous
construct
variant
nucleotidebind
domain
human
cftr
maintain
nativelik
stabil
visibl
fluorophor
coval
bound
singl
label
site
fluoresc
selfquench
fsq
label
domain
upon
unfoldingaggreg
provid
robust
accur
highthroughput
assay
compound
offset
temperaturedepend
fold
defect
isol
fulllength
human
use
fsq
assay
demonstr
bind
sever
common
nucleotid
analog
tighter
atp
physiolog
ligand
demonstr
analog
preserv
gate
function
channel
even
c
atp
extend
approach
establish
equival
fsq
assay
compound
stabil
interfac
human
cftr
assay
exploit
recent
breakthrough
produc
monodispers
stabl
construct
nucleotidebind
domain
human
cftr
coval
link
construct
construct
use
fsq
assay
via
internbd
linker
etta
energydepend
translat
throttl
bacteri
protein
two
tandem
nbd
biophys
structur
studi
shown
linker
motif
etta
compat
function
atpmedi
heterodimer
tandem
nbd
homolog
cftr
differenti
scan
calorimetri
dsc
show
unfold
independ
result
ettalink
fusion
protein
construct
monodispers
high
concentr
purif
use
fsq
assay
construct
screen
compound
promot
tight
nucleotidedepend
thermodynam
interact
compound
would
facilit
highresolut
structur
studi
function
interfac
human
cftr
stabil
open
state
activ
cftr
channel
base
result
describ
nucleotid
analog
stabil
isol
compound
stabil
interfac
could
also
potenti
repres
lead
compound
drug
correct
temperaturesensit
fold
defect
fulllength
human
refer
g
et
al
nat
struct
mol
biol
chen
b
et
al
nat
struct
mol
biol
di
provid
evid
particip
chaperoneassist
degrad
cftr
autophagi
initi
set
experi
demonstr
increas
cftr
band
b
upon
sirnamedi
knockdown
cell
suggest
block
mutant
cftr
autophag
degrad
experi
allow
us
investig
role
small
heat
shock
protein
play
misfold
cftr
degrad
establish
interact
small
heat
shock
protein
shsp
occur
though
ipv
motif
present
hydrophob
groov
strand
protein
fuch
et
al
biochem
j
present
studi
examin
interact
sinc
possibl
interact
similarli
shsp
previous
show
initi
degrad
cftr
promot
modif
mutant
ahner
et
al
mol
biol
cell
show
overexpress
also
reduc
cftr
band
b
view
recogn
interact
degrad
pathway
interest
evalu
similaritiesdiffer
pathway
shspmediat
degrad
demonstr
select
recognit
cftr
band
b
direct
proteinprotein
interact
studi
point
mutat
block
interact
also
abolish
interact
immatur
cftr
find
suggest
recognit
cftr
requir
cooper
involv
aggresom
marker
pathway
provid
evid
select
target
toward
aggresom
structur
aggreg
cftr
found
coloc
posit
compart
cell
also
coprecipit
cftr
immunoprecipit
assay
altogeth
data
suggest
select
dispos
misfold
cftr
mediat
aggresomelysosom
degrad
assist
chaperonemedi
autophagi
cftr
identifi
role
shsp
cooper
process
support
grant
niddk
cfft
preval
cfcaus
mutat
impair
first
nucleotidebind
domain
fold
also
interdomain
assembl
cftr
result
defect
traffick
protein
plasma
membran
cell
residu
lie
interfac
intracellular
cytoplasm
loop
transmembran
domain
recent
nmr
studi
indic
interact
induc
alloster
coupl
conform
chang
region
ctermin
region
includ
betastand
helic
interestingli
locat
distal
structur
critic
cftr
process
channel
activ
histidin
residu
well
conserv
across
speci
human
cftr
amino
acid
substitut
report
four
missens
variant
exogen
express
cell
three
disrupt
cftr
matur
contrast
cftr
properli
process
similar
level
matur
wildtyp
cftr
four
variant
ci
fail
matur
thu
neither
process
defect
mutat
secondsit
suppressor
contrast
block
abil
smallmolecul
corrector
analog
rescu
cftr
mutat
perturb
contact
without
direct
alter
fold
examin
effect
cftr
biogenesi
ci
cftr
decreas
level
matur
respons
compar
cftr
result
impli
exert
mild
fold
defect
aggrav
biosynthet
defect
cftr
enhanc
fold
delet
ri
ridel
restor
contact
introduct
secondsit
suppressor
partial
rescu
cftr
still
lower
level
compar
cftr
result
indic
alloster
fold
effect
ctermin
region
play
role
correct
cftr
respons
alloster
fold
defect
cftr
partial
restor
combin
two
separ
fold
mechan
improv
fold
facilit
interdomain
assembl
support
nih
cff
delet
phenylalanin
cftr
class
ii
fold
matur
mutant
common
mutat
associ
cf
result
mutat
vast
major
cftr
protein
degrad
proteasom
result
defici
function
cftr
protein
plasma
membran
ultim
defici
chlorid
ion
flux
even
pharmacolog
rescu
corrector
treatment
cftr
protein
cell
surfac
still
show
defect
channel
open
defici
overcom
addit
potenti
molecul
build
proteostasi
therapeut
inc
cftr
amplifi
high
throughput
phenotyp
screen
perform
search
novel
modul
effici
synerg
amplifi
class
modul
due
report
vitro
destabil
cftr
protein
chronic
exposur
certain
potenti
chronic
dose
condit
employ
phenotyp
screen
discov
potentiatorlik
molecul
lack
destabil
effect
enrich
compound
confer
potenti
activ
forskolinmedi
activ
perform
without
acut
addit
potenti
molecul
paradigm
sever
distinct
chemic
seri
novel
cftr
modul
discov
modul
select
lack
destabil
activ
chronic
exposur
one
new
class
compound
also
demonstr
activ
hbe
acut
exposur
seri
exhibit
amplifi
activ
increas
level
immatur
cftr
protein
compound
increas
level
matur
cftr
protein
consist
lack
corrector
activ
investig
modul
show
work
cooper
known
corrector
amplifi
synerg
known
potenti
lastli
cftrmediat
chlorid
transport
assay
compound
demonstr
mutationdepend
efficaci
distinct
known
cftr
potenti
summari
report
new
class
cftr
modul
characterist
distinct
known
potenti
corrector
amplifi
may
repres
novel
mechan
improv
mutant
cftr
function
object
gener
recogn
wildtyp
cftr
protein
undergo
posttransl
modif
ubiquitin
sumoyl
multipl
lysin
protein
one
subcellular
locat
previous
group
show
ubiquitin
lysin
residu
wildtyp
cftr
regul
stabil
subcellular
local
hypothes
compar
wildtyp
cftr
lysin
residu
cftr
differenti
modifi
posttransl
modif
interfer
posttransl
modif
lysin
residu
cftr
stabil
protein
regul
subcellular
local
method
cell
transfect
cftr
cdna
sitedirect
mutat
lysin
arginin
perform
prevent
posttransl
modif
whole
cell
plasma
membran
express
level
cftr
ktor
mutant
cftr
measur
posttransl
modif
ubiquitin
sumoyl
analyz
immunoblot
assay
previous
show
posttransl
modif
specif
lysin
residu
regul
stabil
subcellular
local
wildtyp
cftr
howev
lysin
residu
cftr
play
similar
role
except
ntail
lysin
residu
instead
found
differ
lysin
residu
cftr
involv
stabil
protein
express
use
combin
steadyst
immunoblot
analysi
surfac
biotinyl
demonstr
lysinetoarginin
mutat
ntail
r
domain
led
matur
cftr
product
along
increas
sumoyl
conclus
ntail
r
domain
lysin
resid
cftr
critic
degrad
cftr
protein
interfer
posttransl
modif
lysinetoarginin
mutat
allow
matur
cftr
product
ubiquitin
andor
sumoyl
like
involv
biosynthesi
process
understand
posttransl
modif
cftr
stabil
product
may
lead
improv
proteinspar
therapeut
strategi
yang
z
j
zhou
q
khazanov
n
hildebrandt
e
dai
q
ding
h
macon
kj
l
riordan
jr
deluca
lj
kapp
jc
urbatsch
il
senderowitz
h
brouillett
c
univers
alabama
birmingham
birmingham
al
usa
israel
texa
tech
univ
health
scienc
ctr
lubbock
tx
usa
unc
chapel
hill
chapel
hill
nc
usa
sever
secondsit
mutat
alon
combin
thermal
stabil
isol
promot
matur
traffick
fulllength
fl
et
al
j
mol
biol
importantli
correct
effect
also
shown
posit
correl
extent
thermal
stabil
latter
observ
enabl
stabil
predict
correct
subset
mutat
also
shown
increas
exogen
express
level
wt
cftr
well
purif
yield
thermost
reconstitut
channel
activ
aleksandrov
et
al
protein
expr
purif
immedi
goal
present
studi
extend
previou
work
identifi
addit
mutat
maxim
stabil
isol
domain
combin
like
newli
report
stabil
use
differenti
scan
calorimetri
dsc
unfold
temperatur
singl
stabil
mutant
aa
determin
variou
combin
two
three
also
introduc
determin
mutant
studi
found
stabil
effect
gener
addit
except
note
present
largest
stabil
effect
observ
combin
toprank
singl
mutat
increas
close
c
wt
aa
smaller
subset
also
introduc
differ
extent
stabil
found
correl
shift
structur
paramet
ultim
predict
shift
new
mutat
singl
mutat
model
exist
structur
pdb
id
construct
studi
chang
solventaccess
surfac
area
calcul
free
energi
stabil
comput
use
sever
differ
predict
algorithm
favor
qualit
quantit
correl
predict
actual
shift
found
set
basi
predict
effect
futur
mutat
stabil
predict
could
potenti
extend
fulllength
cftr
select
combomut
introduc
human
wt
fl
cftr
express
mammalian
cell
purifi
unfold
temperatur
determin
posit
correl
cftr
observ
result
shown
detail
analysi
thermal
unfold
present
anoth
poster
urbatsch
et
al
work
support
cystic
fibrosi
foundat
therapeut
mutat
caus
stargardt
macular
degener
result
failur
recycl
alltran
retin
invari
end
legal
blind
known
cure
test
hypothesi
use
cell
stabli
express
common
diseasecaus
mutant
previous
publish
corrector
rescu
also
rescu
mutat
high
degre
homolog
nbd
appli
stabli
express
mutant
express
less
protein
wt
larg
increas
mutant
protein
level
occur
cell
grown
c
demonstr
mutant
like
mani
cftr
traffick
mutant
temperatur
sensit
translat
inhibit
mutant
protein
rapidli
disappear
wherea
remain
stabl
data
indic
mutant
protein
unstabl
rapidli
degrad
similar
corrector
increas
total
protein
cell
surfac
express
fold
respect
contrast
effect
greater
increas
steadyst
protein
level
fold
greatest
respons
note
follow
treatment
mutant
observ
plasma
membran
assess
surfac
biotinyl
suggest
traffick
plasma
membran
restor
interestingli
consid
class
corrector
effect
increas
steadyst
protein
level
mutant
wherea
combin
class
addit
compar
alon
contrast
combin
class
corrector
effect
studi
show
hsp
import
rescu
mutant
may
rescu
mutant
protein
direct
effect
fold
conclus
corrector
rescu
mutant
select
within
region
greatest
similar
result
suggest
may
even
effect
increas
traffick
mutant
alreadi
clinic
trial
cf
consider
given
possibl
affect
abc
transport
protein
motif
common
cftr
boinot
c
sabirzhanova
guggino
wb
cebotaru
l
depart
medicin
john
hopkin
u
baltimor
md
usa
depart
physiolog
john
hopkin
u
baltimor
md
usa
cf
approxim
patient
least
one
copi
mutat
homozyg
mutat
sever
cf
also
caus
class
mutat
includ
prematur
stop
codon
mutat
found
cf
chromosom
thu
achiev
goal
treat
everyon
therapi
develop
restor
function
patient
earli
stop
codon
sever
studi
perform
system
administr
gentamicin
show
aminoglycosid
partial
rescu
cftr
activ
cf
subject
class
mutat
purpos
present
work
investig
two
common
diseaseassoci
stop
mutat
stop
codon
mutat
rescu
treat
cell
small
molecul
corrector
use
polar
airway
epitheli
cell
express
either
cdna
creat
lab
use
flipin
technolog
cell
line
display
small
steadyst
amount
truncat
protein
surprisingli
treat
proteasom
inhibitor
steadyst
level
increas
respect
smaller
signific
increas
note
inhibit
tubacin
applic
combin
small
molecul
corrector
increas
steadyst
level
truncat
protein
fold
data
indic
truncat
protein
produc
rapidli
degrad
combin
plu
gentamicin
produc
increas
cftr
protein
respect
determin
whether
chlorid
transport
function
cftr
restor
perform
short
circuit
current
experi
cftrdepend
chlorid
current
increas
approxim
mutant
treat
combin
current
also
increas
mutant
treat
gentamicin
treat
cell
plu
gentamicin
increas
cftrgener
current
cell
contain
mutat
compar
treatment
alon
contrast
plu
gentamicin
treatment
increas
cftrdepend
current
cell
contain
mutant
compar
treatment
appli
individu
conclus
provid
evid
gener
truncat
protein
rapidli
degrad
combin
corrector
increas
level
mutant
protein
function
studi
show
gentamicin
plu
corrector
may
prefer
treatment
particularli
mutant
although
stop
mutat
rescu
extent
combin
corrector
plu
readthrough
agent
better
option
may
achiev
use
aav
vector
contain
cftr
gener
chlorid
current
hazlett
hf
czum
j
nymon
dorman
griffin
ashar
geisel
school
medicin
dartmouth
lebanon
nh
usa
dartmouth
hitchcock
medic
center
lebanon
nh
usa
background
lung
function
declin
cf
larg
attribut
irrevers
destruct
muscl
elast
tissu
airway
process
refer
bronchiectasi
report
clearli
demonstr
bronchiectasi
develop
local
region
lung
specif
region
bronchiectasi
worsen
time
recent
report
demonstr
bronchiectasi
develop
preferenti
upper
lobe
lung
despit
mucu
plug
occur
diffus
previous
shown
stabil
microbiom
differ
region
lung
despit
clear
differ
region
lung
damag
find
suggest
local
host
factor
promot
lung
damag
actual
mechan
underli
region
heterogen
diseas
remain
unclear
method
fifteen
cf
subject
underw
ct
scan
bronchoscopi
ct
scan
obtain
calcul
lobar
brodi
score
local
anesthesia
bronchoscop
insert
transor
pass
vocal
cord
region
bronchoalveolar
lavag
bal
sampl
obtain
lobe
highest
lowest
median
brodi
score
primari
alveolar
macrophag
am
isol
region
region
inflammatori
cytokin
measur
elisa
result
found
major
patient
highest
brodi
score
rul
inflammatori
cytokin
level
correl
significantli
brodi
score
region
differ
brodi
score
due
larg
part
region
differ
bronchiectasi
peribronchi
wall
thicken
am
region
highest
brodi
score
demonstr
robust
inflammatori
respons
hypoxia
compar
am
region
lowest
brodi
score
region
differ
inflammatori
respons
am
pseudomona
rnaseq
analys
region
am
demonstr
upregul
gene
regul
glycolysi
am
isol
region
highest
brodi
score
use
seahors
xf
confirm
am
region
higher
brodi
score
glycolyt
compar
am
region
lower
brodi
score
addit
treat
am
high
brodi
score
region
glycolysi
blocker
result
decreas
inflamm
follow
hypoxia
conclus
studi
first
demonstr
metabol
differ
am
isol
differ
region
cf
lung
data
suggest
glycolysisox
pho
balanc
may
import
regul
hypoxiainduc
inflamm
am
balanc
alter
pool
reduc
equival
directli
affect
epigenet
landscap
cell
therebi
alter
potenti
metabol
respons
fund
work
fund
nih
cff
aa
saavedra
mt
rysavi
n
cacer
nick
ja
nation
jewish
health
denver
co
usa
univers
colorado
aurora
co
usa
background
treatment
outcom
acut
pulmonari
exacerb
ape
cystic
fibrosi
cf
suboptim
treat
subject
return
baselin
pulmonari
function
follow
therapi
grow
appreci
dysregul
cell
respons
specif
cytokin
profil
may
contribut
pathogen
cf
inflamm
role
time
ape
incomplet
understood
effector
memori
cell
use
model
system
cf
immun
signatur
abund
lung
tissu
traffic
peripher
circul
manifest
recal
program
respons
stimul
allow
host
effici
clear
pathogen
hypothes
time
pulmonari
exacerb
differ
memori
cell
effector
function
includ
cytokin
product
prolifer
would
stratifi
subject
exacerb
frequent
versu
requir
intraven
antibiot
infrequ
method
cf
subject
diagnos
acut
exacerb
faculti
member
colorado
adult
cf
program
underw
phlebotomi
diagnosi
end
ape
treatment
irbapprov
protocol
patient
design
frequent
versu
infrequ
exacerb
categori
memori
cell
isol
phenotyp
determin
flow
cytometri
ex
vivo
stimul
isol
memori
cell
via
cell
receptor
agonist
antibodi
allow
global
activ
previous
program
effector
function
compar
memori
cell
respons
normal
healthi
cf
subject
result
abil
memori
cell
cf
subject
baselin
exacerb
express
lfng
maxim
activ
cell
receptor
tcr
fall
short
normal
healthi
control
n
cf
normal
frequent
exacerb
memori
cell
manifest
phenotyp
character
low
prolifer
lfngexpress
memori
cell
increas
rather
decreas
express
ape
end
frequent
dual
express
p
memori
cell
drawn
exacerb
treatment
demonstr
mark
express
cell
exhaust
marker
compar
normal
control
p
conclus
memori
cell
subset
measur
peripher
blood
distinct
signatur
time
ape
link
diseas
cours
character
effector
memori
cell
cf
host
pulmonari
exacerb
demonstr
immunosuppress
phenotyp
evid
cell
exhaust
reduc
prolifer
reduc
interferon
gamma
suggest
defect
bacteri
kill
sinc
immunolog
signatur
directli
measur
peripher
blood
repres
potenti
use
tool
stratifi
patient
respons
time
exacerb
treatment
serv
biomark
host
defens
also
target
futur
immun
modul
stanton
ba
barnabi
r
berwin
b
ashar
microbiolog
immunolog
geisel
school
medicin
dartmouth
hanov
nh
usa
depart
medicin
geisel
school
medicin
dartmouth
hanov
nh
usa
macrophag
play
key
role
clear
p
aeruginosa
lung
infect
respons
bacteri
infect
macrophag
migrat
lung
phagocytos
kill
bacteria
releas
sever
cytokin
includ
howev
cf
macrophag
exhibit
reduc
abil
kill
p
aeruginosa
manifest
increas
cytokin
secret
compar
noncf
macrophag
sever
report
demonstr
cftr
express
macrophag
bactericid
activ
macrophag
defect
cf
moreov
inhibit
wtcftr
reduc
phagocytosi
macrophag
contrast
increas
export
endoplasm
reticulum
plasma
membran
clcurrent
cf
monocyt
shown
increas
abund
immun
cell
phagolysosom
play
import
role
bactericid
activ
recent
clinic
trial
orkambi
cf
patient
homozyg
mutat
demonstr
small
increas
decreas
rate
exacerb
howev
studi
effect
abil
macrophag
phagocytos
kill
p
aeruginosa
thu
goal
studi
examin
abil
stimul
cf
macrophag
phagocytos
kill
p
aeruginosa
reduc
cytokin
secret
stabl
subject
cf
n
donat
blood
isol
monocyt
differenti
macrophag
monocytederiv
macrophag
mdm
incub
mcsf
ngml
day
increas
phagocyt
uptak
p
aeruginosa
compar
vehicletr
mdm
although
combin
also
increas
phagocyt
uptak
p
aeruginosa
compar
vehicletr
mdm
increas
valu
significantli
less
alon
alon
increas
abil
mdm
kill
phagocytos
p
aeruginosa
compar
vehicletr
mdm
also
increas
abil
mdm
kill
p
aeruginosa
compar
vehicletr
mdm
valu
less
increas
alon
preliminari
studi
also
reveal
decreas
p
aeruginosastimul
secret
mdm
respect
moreov
combin
effect
decreas
p
aeruginosastimul
cytokin
secret
mdm
alon
reduc
p
aeruginosastimul
secret
respect
conclus
increas
abil
cf
mdm
phagocytos
kill
p
aeruginosa
reduc
efficaci
stimul
abil
cf
mdm
phagocytos
kill
p
aeruginosa
contrast
increas
abil
reduc
p
aeruginosastimul
cytokin
secret
cf
mdm
support
nih
cff
ba
aa
brown
n
white
pohl
k
gargoum
fs
hawkin
p
qayyum
reev
e
mcelvaney
ng
medicin
royal
colleg
surgeon
ireland
dublin
beaumont
ireland
beaumont
hospit
dublin
ireland
introduct
cystic
fibrosi
cf
inherit
genet
condit
result
higher
frequenc
airway
infect
caus
irrevers
damag
lung
eventu
respiratori
failur
increas
evid
suggest
cf
neutrophil
possess
intrins
patholog
inflammatori
defect
hydrogen
voltageg
channel
transmembran
proton
channel
regul
ph
chang
across
cell
membran
neutrophil
central
sustain
activ
nadph
oxidas
upon
uptak
pathogen
murin
knockout
studi
demonstr
increas
phagosom
ph
significantli
higher
primari
granul
degranul
reduc
kill
neutrophil
cf
neutrophil
demonstr
increas
primari
granul
degranul
hypothesis
cf
cell
may
reduc
abund
aim
work
investig
whether
alter
surfac
cf
neutrophil
result
alter
ph
phagosom
kill
method
ethic
approv
obtain
beaumont
hospit
patient
cf
homozyg
mutat
heterozyg
mutat
receiv
ivacaftor
recruit
studi
neutrophil
phagosom
isol
postphagocytosi
iggopsonis
latex
particl
follow
nitrogen
cavit
subsequ
sucros
gradient
ultracentrifug
western
blot
fac
analysi
perform
isol
cf
noncf
bronchiectasi
ncfb
healthi
control
hc
neutrophil
alter
phagosom
ph
assess
postphagocytosi
staphylococcu
aureu
label
phsensit
fluoresc
probe
bcecf
statist
analysi
carri
use
graphpad
prism
result
protein
abund
significantli
reduc
whole
cell
lysat
cf
neutrophil
compar
hc
p
ncfb
p
abund
neutrophil
membran
significantli
decreas
cf
neutrophil
rest
poststimul
compar
hc
p
ncfb
p
ph
cf
cytosol
lower
hc
neutrophil
cytosol
p
inhibit
zncl
reduc
cytosol
ph
compar
nontreat
hc
cell
p
cf
phagosom
demonstr
significantli
higher
ph
compar
hc
phagosom
p
significantli
higher
level
primari
granul
marker
myeloperoxidas
mpo
p
observ
cf
phagosom
compar
hc
inhibit
hc
neutrophil
zncl
increas
primari
granul
degranul
compar
untreat
cell
abund
protein
intracellularli
p
neutrophil
membran
p
restor
hc
level
patient
receiv
ivacaftor
similarli
intraphagosom
primari
degranul
significantli
reduc
patient
receiv
ivacaftor
therapi
conclus
reduc
abund
cf
neutrophil
gener
alkalin
phagosom
ph
unphysiolog
low
adequ
ro
product
ultim
lead
impair
bacteri
kill
cf
day
bj
min
e
nichol
chandler
jd
medicin
nation
jewish
health
denver
co
usa
pediatr
nation
jewish
health
denver
co
usa
div
pulmonari
allergi
critic
care
medicin
emori
univers
atlanta
ga
usa
introduct
chronic
bacteri
lung
infect
hallmark
cystic
fibrosi
cf
lung
diseas
difficult
erad
chronic
lung
infect
result
chronic
lung
inflamm
creat
paradox
antiinflammatori
therapi
suppress
alreadi
inadequ
lung
immun
respons
recent
report
lung
innat
immun
respons
gener
hypothiocyanit
select
metabol
host
thioredoxin
reductas
metazoan
type
pathogen
thioredoxin
reductas
nonmetazoan
type
fact
bacteri
thioredoxin
reductas
readili
inhibit
hypothiocyanit
thioredoxin
reductas
critic
enzym
suppli
essenti
cofactor
thioredoxin
ribonucleotid
reductas
convert
rna
dna
potenti
import
pathway
cf
lung
thiocyan
substrat
hypothiocyan
format
small
anion
transport
cftr
dysfunct
cf
method
investig
abil
hypothiocyan
inactiv
bacteri
thioredoxin
reductas
purifi
e
coli
thioredoxin
reductas
incub
increas
concentr
hypothiocyanit
assay
abil
inhibit
thioredoxin
reduct
addit
look
hypothiocyanit
abil
oxid
cystein
residu
bacteri
thioredoxin
reductas
compar
anoth
common
oxid
hydrogen
peroxid
studi
perform
use
dimedon
label
western
blot
analysi
thioredoxin
reductas
activ
measur
spectrophotometr
follow
nadph
util
bacteri
viabil
assess
use
standard
dilut
methodolog
determin
coloni
form
unit
cfu
bacteri
lysat
assess
abil
metabol
hypothiocyanit
measur
loss
hypothiocyanit
time
use
spectrophotometri
hplc
electrochem
detect
assay
result
hypothiocyanit
readili
inactiv
bacteri
thioredoxin
reductas
much
potent
oxid
cystein
residu
bacteri
thioredoxin
reductas
hydrogen
peroxid
next
look
number
cf
pathogen
abil
lysat
metabol
hypothiocyan
versu
resist
kill
number
multidrugresist
pathogen
isol
includ
pseudomona
aeruginosa
burkholderia
cepacia
methicillinresist
staphylococcu
aureu
unabl
metabol
hypothiocyanit
readili
erad
mic
rang
conclus
report
hypothiocyanit
oxid
inactiv
bacteri
thioredoxin
reductas
critic
enzym
suppli
essenti
cofactor
thioredoxin
ribonucleotid
reductas
convert
rna
dna
hypothiocyanit
inactiv
bacteri
thioredoxin
reductas
may
import
mechan
kill
suppress
bacteria
cf
lung
therapeut
util
hypothiocyan
pathway
versu
hypochlorit
pathway
could
result
less
lung
inflamm
improv
bacteri
clearanc
cf
lung
support
cff
research
grant
birket
tuggl
kl
oden
fernandez
cm
chu
kk
tearney
gj
fanucchi
mv
sorscher
ej
row
sm
medicin
univers
alabama
birmingham
birmingham
al
usa
cystic
fibrosi
foundat
bethesda
md
usa
massachusett
gener
hospit
boston
usa
background
cystic
fibrosi
cf
lung
character
delay
mucociliari
clearanc
mcc
although
mechan
well
understood
recent
center
develop
first
cftr
rat
recapitul
featur
highli
relev
cf
lung
diseas
importantli
rat
airway
express
submucos
gland
develop
time
featur
distinct
murin
model
accur
repres
human
physiolog
delay
mucociliari
transport
develop
rat
age
allow
detail
investig
mechan
underli
abnorm
mucu
transport
method
trachea
cf
wt
rat
variou
age
stage
airway
develop
imag
use
microopt
coher
tomographi
evalu
paramet
includ
airway
surfac
liquid
asl
periciliari
layer
pcl
depth
mucociliari
transport
mct
viscos
simultan
situ
physiolog
condit
mucu
viscos
measur
situ
particl
track
microrheolog
solut
nahco
tri
hepe
ph
increment
ad
apic
surfac
mct
measur
taken
minut
addit
result
cf
rat
week
old
prior
develop
submucos
gland
exhibit
reduc
asl
cf
vs
control
p
pcl
cf
vs
control
p
depth
well
hyperacid
airway
surfac
ph
cf
vs
wt
p
surprisingli
demonstr
normal
mct
rate
month
age
cf
rat
express
matur
airway
submucos
gland
exhibit
spontan
mucu
plug
enlarg
airway
submucos
gland
larg
airway
accompani
delay
mct
rate
mmmin
cf
vs
mmmin
control
p
hypervisc
mucu
cp
cf
vs
cp
wt
reduc
ph
mct
rate
older
rat
secondari
defici
bicarbon
transport
could
recapitul
wt
trachea
bicarbonatefre
buffer
abnorm
mct
correct
cf
rat
trachea
addit
bicarbon
increas
concentr
directli
airway
surfac
peak
effect
mmmin
nahco
vs
mmmin
baselin
p
restor
mct
achiev
bicarbon
ph
addit
tri
correct
mct
rate
ph
hepe
addit
effect
ph
like
due
zwitterion
versu
ionic
natur
conclus
mucu
transport
defect
present
progress
cf
rat
associ
gland
develop
hypervisc
mucu
effect
depend
bicarbon
recapitul
remov
deplet
asl
hyperacid
ph
present
prior
develop
mct
defect
suggest
may
necessari
suffici
delay
mucu
transport
mct
rate
cf
trachea
correct
addit
bicarbon
ph
rang
nahco
effect
lack
effect
ph
correct
zwitterion
buffer
suggest
mucu
transport
defect
depend
normal
ion
exchang
fischer
aj
shanrock
cr
yahr
tl
welsh
pediatr
univers
iowa
iowa
citi
ia
usa
microbiolog
univers
iowa
iowa
citi
ia
usa
intern
medicin
univers
iowa
iowa
citi
ia
usa
object
cystic
fibrosi
cf
initi
respiratori
infect
associ
subsequ
develop
bronchiectasi
mucu
releas
submucos
gland
smg
defect
cf
pig
bacteri
attach
smg
mucu
could
facilit
airway
infect
aim
visual
cf
pathogen
bind
newborn
pig
trachea
determin
whether
site
bind
influenc
subsequ
clearanc
mucociliari
transport
hypothes
staphylococcu
aureu
pseudomona
aeruginosa
preferenti
bind
smgderiv
mucu
strand
bacteri
clearanc
worsen
cf
stimul
smg
secret
methacholin
mch
mucu
integr
depend
disulfid
bond
strand
may
target
reduc
agent
method
trachea
obtain
newborn
cf
noncf
pig
submerg
hepe
buffer
salin
ph
aureu
strain
p
aeruginosa
strain
pak
express
gfp
ad
cfu
ml
visual
gfplabel
bacteria
confoc
microscopi
use
red
fluoresc
nanospher
identifi
mucu
strand
imari
softwar
use
track
instantan
speed
individu
bacteria
test
suscept
mucu
strand
mucolyt
agent
count
mucu
strand
ad
mm
dithiothreitol
dtt
mgml
dnase
result
first
hour
infect
gfp
signal
aureu
p
aeruginosa
enrich
smgderiv
mucu
strand
p
aeruginosa
aureu
also
visual
less
frequent
aggreg
bound
mucos
surfac
mucu
strand
heterogen
strand
select
bound
nanospher
other
select
bound
gfpp
aeruginosa
observ
differ
cf
noncf
trachea
bind
transport
bacteria
absenc
mch
follow
vivo
mch
cf
trachea
transport
gfp
aureu
less
effect
noncf
litterm
control
fraction
time
motion
cf
noncf
p
aureu
alon
alter
mucociliari
transport
tantalum
microdisk
cf
noncf
pig
mucu
strand
bind
aureu
p
aeruginosa
suscept
mm
dtt
aureu
strand
per
cm
treatment
strand
per
cm
p
dtt
concentr
show
bactericid
effect
dnase
effect
number
bacterialaden
mucu
strand
mucos
surfac
aggreg
p
aeruginosa
resist
dtt
dnase
conclus
aureu
p
aeruginosa
adher
primarili
smgderiv
mucu
initi
infect
releas
mucu
strand
defect
cf
clearanc
bacteria
may
also
impair
mucu
strand
heterogen
bind
specif
uniformli
suscept
reduc
agent
dtt
reduc
agent
may
help
releas
mucu
strand
facilit
clearanc
bacteria
follow
initi
infect
howev
p
aeruginosa
adher
mucos
surfac
resist
clearanc
even
treatment
dtt
suggest
bind
receptor
releas
reduc
agent
abraham
wm
sabat
jr
mcclain
ball
rw
cohen
milla
c
research
mount
sinai
med
center
miami
beach
fl
usa
silurian
pharmaceut
oakland
ca
usa
pediatr
stanford
univ
stanford
ca
usa
introduct
key
pathophysiolog
endpoint
cftr
dysfunct
airway
mucu
stasi
slow
mucu
clearanc
becom
problemat
cf
exacerb
addit
effect
increas
airway
load
free
neutrophil
elastas
model
event
use
aerosol
challeng
cftrinh
alon
combin
aerosol
human
neutrophil
elastas
hne
studi
effect
challeng
whole
lung
mucociliari
clearanc
mcc
surrog
marker
tracheal
mucu
veloc
tmv
sheep
show
cftrinh
cftrinhhn
slow
tmv
show
clinic
use
agent
eg
hyperton
salin
albuterol
fail
revers
dysfunct
pediatr
pulmonol
attempt
revers
tmv
impair
produc
aerosol
challeng
cftrinh
cftrinhhn
aerosol
ivacaftor
compar
result
obtain
aerosol
breven
natur
product
produc
k
brevi
method
studi
conduct
approv
mount
sinai
medic
center
anim
research
committe
method
measur
tmv
aerosol
nebul
publish
chest
j
physiol
lung
cell
mol
physiol
therapeut
efficaci
ivacaftor
breven
breath
assess
treat
sheep
agent
cftrinh
challeng
without
addit
hne
recoveri
tmv
treatment
determin
result
data
report
mean
percent
baselin
challeng
cftrinh
slow
tmv
tmv
remain
low
challeng
hne
cftrinh
reduc
fall
tmv
increas
time
cours
respons
ivacaftor
given
revers
cftrinhinduc
slow
tmv
mg
return
tmv
baselin
breven
given
gave
similar
result
hne
ad
cftrinh
challeng
mg
ivacaftor
revers
tmv
maximum
respect
mg
dose
fail
correct
mucociliari
dysfunct
tmv
remain
breven
howev
correct
tmv
baselin
tmv
remain
level
conclus
data
may
first
show
aerosol
ivacaftor
effect
revers
cftrinh
cftrinhhn
induc
slow
mucu
transport
vivo
consist
report
ovin
cftr
respond
ivacaftor
vitro
aerosol
breven
also
correct
dysfunct
cftrinhhn
challeng
model
lower
dose
sinc
inflamm
imped
cftr
restor
therapi
increas
potenc
breven
may
function
antiinflammatori
properti
ajrccm
result
suggest
breven
alon
adjunct
current
therapi
may
benefici
treatment
airway
diseas
character
cftr
dysfunct
background
loss
cftrmediat
airway
hydrat
hypothes
initi
defect
cf
airway
diseas
recent
anim
studi
suggest
reduc
bacteri
kill
subsequ
airway
infect
may
preced
chang
mucu
hydrat
assess
factor
associ
earliest
stage
airway
diseas
human
measur
mucin
metabolom
profil
bronchoalveolar
lavag
fluid
balf
rel
measur
infect
inflamm
structur
lung
diseas
preschool
subject
enrol
arest
cf
method
separ
aliquot
balf
obtain
right
middl
lobe
lingula
preschool
subject
cf
lobe
enrol
arest
cf
age
year
noncf
diseas
control
lobe
age
year
mucin
concentr
measur
refractometri
stain
intens
immunohistochemistri
rheolog
characterist
microbead
rheolog
find
analyz
rel
balf
inflammatori
marker
cultur
metabolom
profil
subject
lobe
well
lobespecif
ct
score
bronchial
wall
thicken
bronchiectasi
marker
structur
lung
diseas
result
airway
mucu
concentr
higher
preschool
subject
cf
rel
noncf
diseas
control
vs
cf
p
even
subset
without
airway
infect
vs
p
mucu
concentr
correl
inflammatori
marker
includ
p
neutrophil
p
well
metabolom
biomark
airway
hypoxia
lactat
p
oxid
stress
oxid
glutathion
p
stain
intens
vs
p
vs
p
elev
cf
suggest
mucin
aros
airway
epithelia
gland
mucu
concentr
highli
elev
lobe
bronchial
wall
thicken
earli
marker
diseas
p
anova
chang
structur
lung
diseas
score
associ
alter
mucu
rheolog
conclus
airway
mucu
elev
preschool
children
cf
associ
inflammatori
marker
chang
airway
milieu
earli
structur
lung
diseas
find
appear
independ
airway
infect
consist
airway
mucu
dehydr
initi
defect
human
cf
airway
diseas
thu
airway
dehydr
remain
high
valu
target
therapeut
intervent
youngest
children
cf
sever
member
famili
anion
transport
associ
cftr
form
complex
cftr
function
reciproc
regul
regul
involv
interact
sta
domain
member
r
domain
cftr
eukaryot
sta
domain
compos
two
highli
conserv
region
bracket
uniqu
interven
sequenc
iv
specif
region
involv
interact
cftr
identifi
found
sever
epithelia
includ
airway
function
constitut
activ
chlorid
channel
coexpress
wt
cftr
result
synergist
increas
respons
camp
stimul
synerg
indic
reciproc
regul
abil
coimmunoprecipit
wt
cftr
suggest
physic
interact
j
gen
physiol
use
eukaryot
linear
motif
resourc
nucleic
acid
re
scan
sta
domain
potenti
regulatori
motif
found
motifrich
region
iv
search
ncbi
singlenucleotid
polymorph
snp
databas
identifi
sever
snp
within
iv
one
snp
locat
predict
phosphoryl
site
also
predict
part
bind
motif
led
strike
chang
express
alon
cell
produc
wholecel
constitut
chlorid
current
pa
similar
nativ
coexpress
wt
cftr
howev
constitut
chlorid
current
increas
pa
significantli
greater
observ
coexpress
nativ
wt
cftr
pa
cell
surfac
biotinyl
show
increas
protein
plasma
membran
rel
wt
suggest
increas
activ
result
interact
variant
cftr
predict
phosphoryl
site
also
test
alanin
aspart
acid
substitut
interestingli
produc
opposit
pattern
seen
high
constitut
activ
express
alon
substanti
diminish
coexpress
wt
cftr
alter
constitut
activ
confirm
sourc
constitut
chlorid
current
observ
coexpress
cftr
construct
contain
sta
domain
alon
aa
sta
test
sta
nonconduct
still
interact
wt
cftr
facilit
synergist
respons
camp
stimul
comparison
wholecel
chlorid
current
measur
coexpress
wt
cftr
sta
current
measur
coexpress
full
length
wt
cftr
confirm
sourc
constitut
chlorid
current
thu
amino
acid
substitut
iv
led
modif
constitut
activ
enhanc
suppress
coexpress
wt
cftr
result
suggest
motifrich
region
iv
may
involv
reciproc
regul
cftr
support
cff
nih
dong
q
shah
vs
tang
x
welsh
randak
co
stead
famili
depart
pediatr
univers
iowa
iowa
citi
ia
usa
depart
molecular
physiolog
biophys
univers
iowa
iowa
citi
ia
usa
medic
scientist
train
program
univers
iowa
iowa
citi
ia
usa
depart
intern
medicin
univers
iowa
iowa
citi
ia
usa
howard
hugh
medic
institut
iowa
citi
ia
usa
cystic
fibrosi
transmembran
conduct
regul
cftr
cland
hco
channel
cf
lung
diseas
develop
defect
cftr
hco
channel
activ
result
airway
surfac
liquid
asl
acidif
lower
asl
ph
caus
host
defens
defect
reduc
abil
asl
kill
bacteria
increas
asl
viscos
therebi
impair
mucociliari
clearanc
cftr
function
coupl
either
atpas
p
adenyl
kinas
atp
adp
activ
role
adenyl
kinasedepend
channel
activ
vivo
known
show
mutat
cftr
amino
acid
disrupt
adenyl
kinasebut
atpasedepend
channel
activ
gave
us
unpreced
opportun
test
hypothesi
normal
cftr
function
airway
epithelia
reli
adenyl
kinas
activ
found
wildtyp
adenyl
kinasedefici
mutant
cftr
local
apic
membran
airway
epithelia
express
similar
amount
cftrdepend
cland
hco
short
circuit
current
transepitheli
conduct
significantli
lower
epithelia
express
cftr
obtain
similar
find
cftr
carri
cfassoci
mutat
airway
epithelia
cf
donor
lower
asl
ph
compar
noncf
express
wildtyp
cftr
correct
asl
ph
express
cftr
likewis
wildtyp
cftr
cftr
express
increas
abil
epithelia
kill
bacteria
reduc
asl
viscos
experi
perform
ref
thu
result
indic
physiolog
role
cftr
airway
epithelia
reli
adenyl
kinas
activ
refer
shah
vs
et
al
airway
acidif
initi
host
defens
abnorm
cystic
fibrosi
mice
scienc
pezzulo
aa
et
al
reduc
airway
surfac
ph
impair
bacteri
kill
porcin
cystic
fibrosi
lung
natur
tang
xx
et
al
j
clin
invest
randak
c
welsh
mj
intrins
adenyl
kinas
activ
regul
gate
abc
transport
cftr
cell
randak
co
welsh
mj
adenyl
kinas
activ
abc
transport
j
biol
chem
dong
q
et
al
mutat
conserv
qloop
glutamin
select
disrupt
adenyl
kinasedepend
channel
gate
atpbind
cassett
abc
adenyl
kinas
cystic
fibrosi
transmembran
conduct
regul
cftr
reduc
channel
function
primari
human
airway
epithelia
j
biol
chem
jone
ct
et
al
hum
mol
genet
import
part
airway
innat
defens
system
reduc
cf
subject
cf
anim
model
ex
vivo
ferret
trachea
mcc
veloc
mccv
enhanc
enac
inhibit
synergist
increas
combin
low
dose
carbachol
carb
ca
agonist
forskolin
fsk
camp
agonist
joo
et
al
submit
airway
submucos
gland
smg
secret
also
reduc
subject
cf
anim
cf
model
also
synergist
increas
combin
low
dose
carb
fsk
better
understand
mechan
synergist
mccv
increas
compar
measur
mccv
smg
secret
shortcircuit
current
isc
ex
vivo
ferret
pig
trachea
methodolog
mccv
measur
via
particl
track
jeong
jh
et
al
j
physiol
lung
cell
mol
physiol
mucu
secret
rate
individu
tracheal
gland
measur
via
timelaps
optic
imag
mucu
bubbl
form
oil
layer
joo
ns
et
al
j
physiol
lung
cell
mol
physiol
transtrach
epitheli
isc
measur
cm
expos
surfac
made
via
voltag
clamp
uss
chamber
situat
stimul
min
carb
fsk
follow
min
combin
treatment
compound
ad
basolater
result
mccv
smg
secret
rate
induc
combin
treatment
significantli
faster
either
drug
alon
sum
valu
mccv
averag
period
mmmin
carb
n
ferret
trachea
fsk
n
combin
n
arithmet
sum
vs
combin
p
smg
secret
rate
averag
carb
fsk
nlmin
gland
carb
n
fsk
n
combin
combin
vs
arithmet
sum
contrast
isc
increas
induc
combin
treatment
smaller
sum
singl
treatment
valu
averag
carb
n
ferret
fsk
n
ferret
combin
n
ferret
combin
vs
arithmet
sum
p
pig
trachea
also
show
smaller
isc
respons
combin
agonist
averag
fsk
n
pig
carb
n
pig
combin
n
pig
combin
vs
arithmet
sum
p
conclus
forskolin
plu
carbachol
synergist
increas
mccv
smg
secret
rate
contrast
combin
stimul
produc
smaller
isc
increas
sum
agonist
use
alon
isc
reflect
anionmedi
secret
sodium
absorpt
forskolin
stimul
secret
carbachol
transient
increas
secret
produc
longer
term
inhibit
absorpt
joo
ns
et
al
sci
rep
two
process
subtract
regard
isc
mutual
reinforc
respect
mucos
fluid
accumul
coordin
action
acceler
mccv
support
cff
cfft
recent
rehydr
agent
gain
attent
treatment
patient
mucoobstruct
lung
diseas
particularli
cystic
fibrosi
cf
one
agent
inhal
hyperton
salin
hs
purportedli
creat
lumin
osmot
ion
gradient
draw
addit
water
onto
dehyr
concentr
airway
surfac
layer
asl
hs
report
improv
mucu
clearanc
rate
lung
function
reduc
number
acut
exacerb
howev
mechan
durat
action
mucu
hydrat
agent
acceler
clearanc
cf
patient
poorli
understood
mucu
layer
polym
gel
swell
shrink
upon
addit
remov
water
typic
hydrat
mucu
layer
control
ion
transport
across
epithelium
howev
cf
dysregul
cftrmediat
ion
transport
result
airway
fluid
deplet
mucin
hyperconcentr
hypothes
kinet
mucu
swell
ad
fluid
determin
balanc
drive
forc
osmot
pressur
revers
associ
mucin
globular
domain
resist
forc
friction
fluid
ie
solvent
penetr
mesh
mucin
network
elast
stretch
mucin
hypothes
two
stage
mucu
swell
rapid
osmot
gel
swell
phase
mucu
swell
without
signific
rearrang
intermolecular
associ
slow
mucu
dissolut
state
mucin
molecul
continu
rearrang
reduc
overlap
one
test
hypothes
develop
novel
duallabel
imag
techniqu
monitor
swell
kinet
mucu
layer
rang
concent
repons
exposur
isoton
solut
experi
mucusswel
kinet
normal
increas
swell
height
h
initi
height
h
mucu
layer
h
h
h
record
function
time
result
demonstr
kinet
mucu
swell
depend
specif
mucu
properti
eg
increas
initi
mucu
concentr
osmot
pressur
lead
faster
longer
swell
kind
mucu
cf
sputum
sampl
mucu
human
airway
cultur
show
swell
curv
fast
follow
slow
phase
dissolut
behavior
contrast
mucu
obtain
porcin
gland
stimul
acetylcholin
exhibit
fast
swell
phase
reach
equilibrium
swell
plateau
suggest
gland
mucu
biochem
biophys
differ
superfici
mucu
therapeut
perspect
envis
model
system
appli
test
effect
mucu
hydrat
agent
mucolyt
design
reestablish
normal
hydrat
statu
asl
facilit
effici
mucu
clearanc
work
support
cfft
mucu
clearanc
consortium
cystic
fibrosi
cf
loss
cystic
fibrosi
transmembran
conduct
regul
cftr
anion
channel
activ
caus
airway
surfac
liquid
asl
ph
becom
acid
impair
airway
host
defens
one
potenti
therapeut
approach
correct
acid
ph
cf
airway
aerosol
hco
andor
nonbicarbon
ph
buffer
show
rais
asl
ph
inhal
hco
increas
ph
howev
effect
transient
ph
return
baselin
valu
within
minut
tromethamin
tham
buffer
long
serum
halflif
use
intraven
formul
treat
metabol
acidosi
found
tromethamin
aerosol
increas
asl
ph
vivo
least
hour
enhanc
bacteri
kill
inhal
hyperton
salin
nacl
deliv
peopl
cf
attempt
promot
mucu
clearanc
increas
ionic
strength
inhibit
asl
antimicrobi
factor
ad
tromethamin
hyperton
salin
appli
cf
sputum
found
tromethamin
alon
combin
hyperton
salin
increas
ph
enhanc
bacteri
kill
find
suggest
aerosol
hco
independ
buffer
tromethamin
either
alon
combin
hyperton
salin
might
therapeut
benefit
cf
airway
diseas
dickinson
j
hupp
sweeter
j
brodi
sl
unmc
omaha
ne
usa
int
med
washington
univers
st
loui
mo
usa
background
autophagi
cellular
pathway
respons
traffick
intracellular
cargo
within
doublemembran
structur
term
autophagosom
respons
metabol
demand
pathogen
recognit
immun
activ
recent
recogn
paradigm
autophagi
protein
necessari
protein
secret
common
gene
variant
autophagi
regulatori
protein
amino
acid
substitut
associ
defect
epitheli
secret
inflamm
inflammatori
bowel
diseas
risk
gg
vs
nonrisk
aa
recent
report
autophagi
requir
secret
known
whether
autophagi
regul
secret
independ
inflamm
preval
gene
variant
cystic
fibrosi
cf
known
effect
secret
known
object
identifi
preval
gene
variant
adult
cf
singlesit
cf
center
compar
secret
risk
allel
gg
vs
nonrisk
allel
aa
well
airway
epitheli
cell
method
inhibit
autophagi
done
deplet
regulatori
protein
use
rnai
htec
without
variant
gg
knockdown
verifi
gene
express
immunoblot
vitro
role
variant
secret
investig
welldifferenti
primari
human
airway
epitheli
cell
htec
deriv
donor
lung
suitabl
transplant
basal
atpg
activ
secret
measur
htec
gg
vs
aa
ali
condit
autophagi
activ
determin
flux
assay
use
chloroquin
transient
autophagosomelysosom
inhibit
quantifi
level
use
immunoblot
genom
dna
isol
deidentifi
blood
sampl
adult
cf
age
rang
unmc
agegend
match
control
nebraska
biobank
repositori
genotyp
identifi
taqman
probe
confirm
use
sanger
sequenc
result
deplet
htec
reduc
level
consist
reduc
autophagi
basal
atpactiv
secret
significantli
reduc
htec
immunofluoresc
stain
confirm
intracellular
retent
mucou
cell
hypertrophi
htec
despit
differ
secret
chang
total
express
htec
gene
risk
variant
gg
identifi
adult
cf
patient
compar
person
without
cf
preliminari
data
htec
risk
gg
vs
nonrisk
aa
variant
differ
htec
donor
genotyp
indic
risk
variant
reduc
autophagi
activ
lcbii
level
reduc
atpactiv
secret
conclus
autophagi
regul
basal
atpmedi
secret
independ
inflamm
provid
addit
valid
autophagi
activ
broadli
requir
mucin
secret
risk
variant
gg
common
adult
cf
found
lower
frequenc
noncf
individu
vitro
genet
variant
may
convey
reduc
cellular
autophagi
alter
secret
airway
epitheli
cell
affect
individu
luan
x
grishchenko
n
chapman
ianowski
jp
physiolog
univers
saskatchewan
saskatoon
sk
canada
anatomi
cell
biolog
univers
saskatchewan
saskatoon
sk
canada
balanc
fluid
secret
absorpt
crucial
part
maintain
healthi
respiratori
tract
failur
maintain
critic
volum
airway
surfac
fluid
may
caus
blockag
airflow
lead
reduc
mucociliari
clearanc
normal
protect
airway
infect
epitheli
cell
regul
ion
fluid
balanc
therefor
cornerston
keep
fluid
balanc
airway
major
contribut
liquid
secret
upper
airway
airway
submucos
gland
play
major
role
secret
airway
surfac
liquid
larg
airway
hand
distal
airway
submucos
gland
regul
airway
surfac
liquid
layer
depend
balanc
secret
absorpt
ion
fluid
surfac
epithelia
cf
patient
airway
surfac
liquid
volum
regulatori
function
seem
abnorm
result
collaps
innat
immun
defens
research
project
investig
function
airway
submucos
gland
surfac
epithelia
role
cf
airway
diseas
use
cftrswine
use
electrophysiolog
techniqu
show
serou
acini
collect
duct
submucos
gland
transport
na
lumen
gland
stimul
campelev
agent
forskolin
cholinerg
agonist
carbachol
interestingli
found
ciliat
duct
transport
na
opposit
direct
ie
lumen
basolater
side
forskolin
carbachol
stimul
hypothes
ciliat
duct
function
reduc
osmot
pressur
fluid
secret
gland
cftrgland
segment
fail
respond
forskolin
stimul
respond
cholinerg
stimul
suggest
involv
cftr
forskolinstimul
secret
moreov
result
show
distal
airway
epithelia
wildtyp
cftrswine
lung
differ
ion
transport
properti
wildtyp
lung
distal
airway
epithelia
cell
seem
abl
secret
absorb
fluid
ion
howev
cf
distal
airway
epithelia
display
significantli
lower
basal
ion
transport
well
reduc
respons
forskolin
stimul
cf
tissu
averag
reduc
respons
enac
sodium
channel
blocker
amilorid
howev
tissu
site
respons
amilorid
four
time
higher
wildtyp
suggest
epitheli
cell
seem
hyperact
enac
activ
could
indic
airway
surfac
liquid
hyperabsorpt
site
hypothes
hyperabsorpt
site
cf
distal
airway
might
origin
point
cf
small
airway
diseas
start
support
cystic
fibrosi
canada
canadian
institut
health
research
luan
x
chapman
ianowski
jp
physiolog
univers
saskatchewan
saskatoon
sk
canada
anatomi
cell
biolog
univers
saskatchewan
saskatoon
sk
canada
although
chronic
infect
inflamm
major
part
cf
lung
diseas
recent
data
suggest
pathogen
event
cf
airway
diseas
start
abnorm
bacteri
erad
airway
surfac
liquid
asl
play
import
role
airway
defenc
mechan
bacteria
evid
suggest
abnorm
asl
secret
cf
airway
may
involv
cf
airway
pathogenesi
recent
show
inhal
pseudomoa
aeruginosa
trigger
asl
secret
upper
swine
airway
ex
vivo
also
suggest
basal
spontan
asl
secret
may
protect
airway
normal
airway
hypothes
cf
airway
respons
fail
lead
failur
erad
pathogen
howev
whether
asl
secret
inhal
p
aeruginosa
actual
occur
vivo
whether
respons
miss
cf
airway
never
directli
test
creat
novel
noninvas
vivo
imag
method
studi
asl
secret
swine
use
synchrotronbas
phase
contrast
imag
overcom
limit
convent
imag
method
provid
soft
tissu
discrimin
appropri
spatial
tempor
resolut
live
anim
imag
success
studi
asl
secret
chang
respons
inhal
bacteria
object
project
investig
effect
inhal
p
aeruginosa
asl
secret
live
cftr
swine
use
synchrotronbas
phase
contrast
imag
method
cftr
piglet
age
day
old
imag
canadian
light
sourc
biomed
imag
therapi
beamlin
result
show
p
aeruginosa
well
haemophilu
influenza
staphylococcu
aureu
trigger
asl
secret
vivo
cftrpig
fail
respond
p
aeruginosa
interestingli
also
detect
basal
spontan
asl
secret
wildtyp
anim
suppress
cftr
swine
result
indic
asl
secret
inhal
p
aeruginosa
miss
cf
airway
may
contribut
airway
defenc
failur
lead
chronic
infect
inflamm
moreov
result
suggest
basal
asl
secret
lost
cftrpiglet
basal
secret
might
play
major
function
help
airway
defenc
trap
particl
inhal
air
explain
mucu
viscos
chang
cf
airway
support
cystic
fibrosi
canada
canadian
institut
health
research
luan
x
belev
g
chapman
ianowski
jp
physiolog
univers
saskatchewan
saskatoon
sk
canada
anatomi
cell
biolog
univers
saskatchewan
saskatoon
sk
canada
canadian
light
sourc
inc
saskatoon
sk
canada
strong
evid
cf
lung
diseas
start
small
airway
studi
show
cf
children
may
develop
small
airway
structur
damag
earli
life
recent
studi
show
newborn
cf
piglet
show
lesion
airway
appear
region
obstruct
airflow
distal
airway
without
obviou
evid
airway
infect
inflamm
mucu
accumul
howev
still
unclear
cftr
dysfunct
lead
cf
peripher
airway
diseas
evid
suggest
cf
lung
lesion
occur
small
airway
less
mm
diamet
unfortun
current
imag
method
hospit
ct
mri
unabl
visual
small
airway
cross
section
thu
new
imag
method
requir
provid
highresolut
imag
small
airway
perform
longitudin
studi
order
follow
develop
cf
small
airway
diseas
object
develop
new
imag
method
studi
cf
airway
diseas
distal
airway
track
progress
live
swine
propos
use
synchrotronbas
phase
contrast
imag
method
visual
distal
airway
investig
possibl
anatom
physiolog
variat
earli
stage
diseas
substanti
evid
synchrotronbas
phase
contrast
imag
great
potenti
imag
lung
larg
differ
refract
index
air
fluid
soft
tissu
give
strong
refract
signatur
easili
detect
use
phaserel
imag
method
preliminari
data
suggest
synchrotronbas
phase
contrast
imag
ct
scan
allow
us
visual
investig
distal
airway
highenergi
monochromat
xray
kev
select
sinc
higher
xray
energi
lower
radiat
dose
deliv
anim
also
order
provid
better
signaltonois
ratio
sampletodetector
distanc
care
chosen
highlight
distal
airway
avoid
detect
alveolu
data
show
airway
smaller
diamet
detect
ex
vivo
prepar
result
indic
phase
contrast
imag
ct
provid
much
better
imag
qualiti
reason
radiat
dose
futur
want
compar
small
airway
anatomi
wildtyp
cftrswine
ultim
goal
investig
chang
airway
anatomi
understand
caus
air
trap
cf
airway
use
live
cf
swine
follow
progress
diseas
time
cf
anim
develop
chronic
infect
inflamm
pseudomona
aeruginosa
colon
promin
inflamm
massiv
express
neutrophil
chemokin
lumin
infiltr
neutrophil
hallmark
chronic
lung
diseas
cystic
fibrosi
cf
patient
nocicept
transient
receptor
potenti
ankyrin
calcium
channel
recent
found
involv
nonneurogen
inflamm
investig
role
cf
respiratori
inflammatori
model
vitro
express
evalu
cf
lung
tissu
section
cell
immunohistochemistri
immunofluoresc
epitheli
cell
line
primari
cell
cf
patient
util
check
function
modul
calcium
imag
b
downmodul
function
express
pharmacolog
inhibitor
sirna
silenc
c
assess
effect
downmodul
express
releas
cytokin
upon
exposur
proinflammatori
challeng
qrtpcr
bioplex
assay
channel
express
cf
pseudostratifi
columnar
epithelium
face
bronchial
lumina
expos
bacteria
coexpress
inhibit
express
result
relev
reduct
releas
sever
cytokin
includ
proinflammatori
cytokin
cf
primari
bronchial
epitheli
cell
expos
p
aeruginosa
supernat
mucopurul
materi
smm
deriv
chronic
infect
airway
cf
patient
conclus
channel
involv
regul
extent
airway
inflamm
driven
cf
bronchial
epitheli
cell
key
regul
activ
ion
transport
channel
involv
transepitheli
fluid
secret
airway
epithelia
dysregul
intracellular
ca
homeostasi
cf
bronchial
epitheli
cell
claim
potenti
druggabl
target
compens
cftr
cltransport
defect
andor
reduc
excess
cf
lung
inflamm
summari
see
figur
howev
precis
identif
ca
transporterchannel
target
contradictori
requir
understand
pro
con
pharmacolog
modul
intracellular
ca
mobil
present
result
focus
role
intracellular
ca
modul
activ
upon
interact
p
aeruginosa
bronchial
epitheli
cell
induc
classic
intracellular
proinflammatori
signal
lead
upregul
releas
previous
show
direct
interact
p
aeruginosa
tolllik
receptor
strongli
overexpress
gene
phosphoryl
mitogen
activ
protein
kinas
jnk
downstream
kinas
lead
intranuclear
transloc
transcript
factor
nfkb
creb
chop
releas
atp
extracellular
milieu
abl
sustain
purinerg
receptorsand
phospolipas
c
beta
releas
intracellular
ca
potenti
inflammatori
pathway
recent
observ
flagellin
p
aeruginosa
alter
cfspecif
manner
ca
homeostasi
lead
mitochondri
perturb
increas
ca
influx
product
reactiv
oxygen
speci
drive
exagger
inflammasom
activ
releas
open
question
role
differ
intracellular
ca
compart
subcellular
domain
widen
panel
candid
molecular
target
consid
gastrointestin
diseas
one
earliest
manifest
cystic
fibrosi
cf
present
lifelong
condit
dysbiosi
lowgrad
inflamm
increas
risk
gastrointestin
cancer
recent
shown
age
cf
mice
develop
intestin
polyp
alter
signal
pathway
respons
intestin
stem
cell
isc
prolifer
bl
et
al
oncogen
base
previou
evid
intestin
hyperprolifer
cf
mice
investig
two
hypothes
use
sexmatch
wildtyp
wt
cftr
knockout
ko
mice
first
hypothesi
ask
whether
cftr
ko
intestin
hyperprolifer
either
epithelialautonom
effect
cftr
loss
secondari
environment
condit
cf
intestin
studi
comparison
made
freshli
isol
intestin
crypt
ex
vivo
intestin
epitheli
crypt
organoid
enteroid
grown
passag
primari
cultur
rel
wt
ex
vivo
cftr
ko
crypt
cftr
ko
enteroid
devoid
inflamm
microbiom
system
factor
similar
increas
epitheli
prolifer
number
isc
vs
level
activ
wnt
target
gene
previou
studi
shown
bind
signal
mediat
dishevel
dvl
wnt
receptor
frizzl
fz
stabil
phsensit
interact
plasma
membran
facilit
wnt
signal
sinc
shown
cftr
ko
crypt
epithelium
maintain
alkalin
intracellular
ph
liu
j
et
al
j
physiol
cell
physiol
hypothes
dvl
would
close
associ
plasma
membran
cftr
ko
rel
wt
enteroid
use
enteroid
cftr
ko
wt
mice
bred
plasma
membran
dtomato
mice
found
close
associ
plasma
membran
apic
pole
crypt
base
cell
cftr
ko
crypt
reduct
associ
apic
pole
reduc
intracellular
ph
cftr
ko
enteroid
correl
decreas
activ
prolifer
conclud
intestin
hyperprolifer
cftr
ko
intestin
epithelialautonom
consequ
cftr
loss
potenti
mechan
increas
signal
hyperprolifer
cftr
ko
intestin
increas
plasma
membran
associ
result
dysregul
intracellular
ph
crypt
base
cell
fund
nih
cff
background
measur
airway
surfac
liquid
asl
primari
airway
epitheli
cultur
aec
grown
airliquid
interfac
ali
identifi
asl
deplet
characterist
abnorm
cystic
fibrosi
cf
may
use
endpoint
preclin
test
strategi
improv
airway
surfac
hydrat
patient
cf
tradit
asl
height
measur
fluoresc
confoc
microscopi
addit
fluoresc
label
liquid
apic
surfac
epithelium
howev
sever
hour
requir
restor
steadi
state
asl
depth
volum
challeng
object
provid
novel
approach
studi
asl
depth
regul
use
confoc
reflect
microscopi
method
primari
aec
isol
cultur
ali
mice
model
cf
lung
diseas
wildtyp
litterm
control
asl
height
measur
simultan
confoc
reflect
microscopi
fluoresc
microscopi
refer
result
compar
result
directli
fluoresc
dye
addit
asl
height
aec
wildtyp
mice
obtain
reflect
rm
fluoresc
microscopi
fm
differ
rm
vs
fm
volum
challeng
asl
height
reduc
rm
vs
fm
asl
height
recov
normal
level
differ
two
techniqu
rm
vs
fm
aec
mice
asl
height
similar
earli
time
point
remain
reduc
rm
vs
fm
differ
techniqu
conclus
reflect
confoc
microscopi
use
altern
method
fluoresc
microscopi
studi
asl
height
dy
regul
approach
may
facilit
preclin
evalu
novel
drug
design
improv
airway
surfac
hydrat
patient
cf
physiolog
condit
support
bmbf
neutrophil
elastas
ne
destruct
serin
proteas
found
primari
granul
neutrophil
predominantli
inhibit
antitrypsin
aat
ne
play
major
role
pulmonari
inflamm
uncheck
lung
level
releas
activ
ne
cleav
elastin
lead
structur
damag
impair
lung
function
exagger
ne
level
also
compromis
protect
antimicrobi
screen
lung
degrad
import
antiproteas
antimicrobi
peptid
reason
ne
major
drug
target
novel
therapi
inflammatori
lung
diseas
includ
cystic
fibrosi
cf
noncf
bronchiectasi
ncfb
antitrypsin
defici
aatd
studi
evalu
novel
protein
epitop
mimet
pem
ne
inhibitor
therapeut
potenti
cf
ncfb
aatd
compar
ic
valu
prototyp
inhibitor
known
endogen
inhibitor
aat
lung
fluid
whilst
also
evalu
toxic
function
effect
neutrophil
ethic
approv
obtain
beaumont
hospit
bronchoalveolar
lavag
fluid
balf
collect
consent
cf
mean
fev
aatd
patient
mean
fev
sputum
sampl
also
collect
cf
mean
fev
ncfb
mean
fev
patient
ne
activ
quantifi
use
specif
fluoresc
reson
energi
transfer
fret
substrat
rang
inhibitor
concentr
evalu
determin
ic
viabil
neutrophilmedi
bacteri
kill
assay
determin
potenti
cell
toxic
issu
host
defens
capabl
aat
stabil
respiratori
sampl
hour
determin
western
immunoblot
analysi
lcm
respect
oneway
anova
follow
post
hoc
tukey
test
use
determin
signific
aat
ic
valu
significantli
lower
observ
prototyp
inhibitor
cf
p
ncfb
p
aatd
p
note
statist
differ
observ
ic
valu
aat
cf
ncfb
aatd
p
importantli
affect
neutrophil
viabil
abil
effect
kill
pseudomona
aeruginosa
staphylococcu
aureu
vitro
concentr
aat
integr
preserv
cf
balf
sputum
sampl
contrast
partial
degrad
time
cours
therebi
avoid
potenti
drug
accumul
lung
result
indic
compar
ne
inhibitori
action
aat
whilst
impact
upon
neutrophil
function
therefor
repres
novel
potenti
therapeut
avenu
explor
inflammatori
lung
diseas
cf
ncfb
aatd
vivo
effect
novel
ne
pem
inhibitor
determin
model
airway
infect
futur
cf
lung
diseas
addit
level
elev
plasma
lower
airway
cf
patient
relationship
infecti
statu
lung
diseas
sever
harri
w
et
al
pediatr
pulmonol
howev
unclear
neg
impact
cf
lung
diseas
clearer
understand
effect
cf
lung
diseas
may
allow
better
select
patientspecif
treatment
regimen
group
previous
demonstr
exposur
primari
human
airway
epitheli
cell
vitro
downregul
cftr
altern
chlorid
transport
sun
h
et
al
plo
one
previous
also
shown
brief
pulmonari
administr
recombin
mice
suffici
downregul
cftr
well
induc
mucou
cell
hyperplasia
examin
effect
overexpress
via
adenovir
vector
mous
lung
hypothes
pulmonari
exposur
vivo
downregul
chlorid
transport
promot
goblet
cell
hyperplasia
method
transient
pulmonari
overexpress
achiev
use
adenovir
vector
contain
transgen
dose
rang
x
x
pfu
pb
empti
vector
control
intratrach
administ
wildtyp
mice
one
week
mice
sacrif
balf
lung
collect
cytolog
elisa
histolog
western
blot
analysi
result
expect
caus
increas
express
dosedepend
manner
maximum
ngml
bal
highest
dosag
mice
expos
lost
start
weight
day
control
mice
lose
weight
mice
expos
pfu
show
increas
cellular
bal
increas
lymphocyt
neutrophil
compar
control
cftr
protein
level
reduc
control
level
highest
dosag
trichrom
stain
reveal
signific
fibrosi
although
pa
stain
show
dosedepend
increas
goblet
cell
number
anim
expos
conclus
overexpress
administr
pulmonari
suffici
replic
import
featur
cf
dosedepend
manner
includ
weight
loss
pulmonari
inflamm
goblet
cell
hyperplasia
cftr
reduct
futur
studi
defin
molecul
pathway
activ
downstream
respons
effect
investig
potenti
therapeut
target
object
aspergillu
fumigatu
colon
airway
patient
cystic
fibrosi
cf
frequent
caus
allerg
bronchopulmonari
aspergillosi
abpa
character
type
airway
inflamm
associ
sever
cf
lung
diseas
howev
mechan
lead
aspergillu
fumigatusinduc
type
airway
inflamm
cf
airway
remain
poorli
understood
hypothes
reduc
mucociliari
clearanc
characterist
featur
cf
facilit
aspergillu
fumigatusinduc
type
airway
inflamm
method
test
hypothesi
juvenil
mice
cflike
lung
diseas
wildtyp
wt
control
challeng
aspergillu
fumigatu
extract
af
vehicl
alon
key
featur
type
airway
inflamm
airway
eosinophilia
goblet
cell
metaplasia
airway
hyperrespons
compar
cellular
sourc
type
signatur
cytokin
molecular
mechan
lead
express
investig
addit
effect
therapeut
improv
mucu
clearanc
inhibit
epitheli
sodium
channel
enac
topic
administr
amilorid
evalu
result
mucociliari
clearanc
whole
lung
af
clearanc
significantli
reduc
mice
compar
wt
litterm
reduc
clearanc
af
aggrav
secret
airway
eosinophilia
airway
hyperrespons
mice
treat
af
increas
express
detect
airway
epitheli
cell
mice
treat
vehicl
af
vitro
stimul
induc
express
primari
tracheal
epitheli
cell
isol
wt
mice
number
produc
tcell
type
innat
lymphoid
cell
elev
lung
mice
challeng
af
prevent
treatment
enac
blocker
amilorid
improv
airway
surfac
hydrat
mucu
clearanc
abrog
afinduc
airway
eosinophilia
wt
mice
amilorid
treatment
prevent
induct
express
respons
af
challeng
conclus
data
support
impair
clearanc
inhal
af
trigger
product
multipl
cell
type
airway
play
import
role
pathogenesi
type
airway
inflamm
suggest
therapeut
improv
mucociliari
clearanc
may
effect
strategi
prevent
diseas
aggrav
inflammatori
respons
cf
support
dfg
bmbf
cystic
fibrosi
cf
character
progress
chronic
infect
inflamm
airway
repres
major
caus
mortal
cf
patient
sever
studi
indic
sphingolipid
sl
play
regulatori
role
cf
lung
inflamm
fact
downregul
plasma
membran
pm
associ
signific
reduct
p
aeruginosa
infect
well
reduct
intrins
inflammatori
state
cf
human
bronchial
epitheli
cell
howev
nowaday
accept
addit
sever
enzym
involv
sl
catabol
associ
pm
enzym
could
directli
involv
insitu
pm
modif
result
activ
inflammatori
respons
occur
cf
even
possibl
involv
unknown
far
address
issu
measur
activ
main
pmhydrolas
wildtyp
cf
human
bronchial
epitheli
cell
cell
show
doubl
activ
activ
fourfold
higher
respect
cell
investig
effect
p
aeruginosa
strain
hydrolyt
enzym
found
similar
activ
notinfect
infect
cell
known
sl
form
special
region
call
lipid
raft
abl
recruit
mediat
signal
transduct
order
examin
whether
p
aeruginosa
infect
induc
modif
level
isol
deterg
resist
membran
fraction
drm
infect
infect
cell
cell
infect
caus
increas
glucosylceramid
ceramid
reduct
also
observ
increas
activ
convers
chang
found
sl
composit
drm
cell
taken
togeth
data
suggest
cf
cell
p
aeruginosa
infect
caus
recruit
pm
glycohydrolas
lipid
raft
concomit
presenc
enzym
substrat
allow
chang
sl
composit
ceramid
respons
activ
inflammatori
respons
introduct
defect
cftr
function
affect
mucinproduc
organ
specif
cf
pathogenesi
character
buildup
viscou
mucu
organ
lung
sinus
intestin
pancrea
reproduct
tract
reason
cf
also
known
mucoviscidosi
suggest
polymer
gelform
mucin
larg
olink
glycoprotein
respons
viscoelast
properti
mucu
play
critic
role
diseas
cftr
malfunct
caus
reduc
transepitheli
clsecret
na
hyperabsorpt
mucin
hyperconcentr
result
slow
mucociliari
clearanc
mcc
goal
understand
factor
regul
mucu
viscoelast
restor
normal
mucu
properti
cf
ivacaftor
cftr
potenti
eg
target
mutat
shown
yield
larg
improv
lung
function
ivacaftor
also
shown
dramat
increas
rate
mcc
significantli
improv
ventil
defect
suggest
effect
mucu
biophys
properti
howev
direct
effect
cftr
rescu
mucin
concentr
mucu
transport
establish
method
investig
molecular
mechan
link
cftr
rescu
improv
mucu
properti
use
immort
hbe
cell
carri
mutat
ie
cell
measur
effect
ivacaftor
mucin
product
mucu
properti
also
use
cftr
cf
mous
model
studi
impact
cftr
function
gastrointestin
mucu
use
intestin
organoid
identifi
modul
effect
mice
result
cell
show
enhanc
transepitheli
shortcircuit
current
treat
ivacaftor
treatment
effect
mucin
mrna
express
mucin
secret
ciliari
beat
frequenc
cbf
howev
cilia
beat
amplitud
cba
greater
ivacaftortr
cell
suggest
effect
surround
milieu
ie
mucu
layer
perhap
due
improv
hydrat
current
work
collect
undilut
mucu
cell
measur
percent
solid
passiv
bead
diffus
ie
microrheolog
use
two
approach
show
gut
mucu
concentr
cf
mice
vs
wt
mice
bead
subdiffus
reduc
cf
mucu
confirm
robust
gutmucu
phenotyp
model
test
cftr
modul
murin
enteroid
uncov
potenti
compound
would
rescu
murin
cftr
activ
identifi
correctorpotenti
combin
wherein
cf
organoid
swell
wt
similar
ivacaftor
model
use
studi
molecularorganiz
chang
within
mucin
polymer
network
follow
cftr
rescu
conclus
demonstr
cftr
rescu
direct
effect
mucin
product
andor
cbf
improv
mucu
viscoelast
properti
use
murin
intestin
organoid
identifi
two
compound
restor
cftr
function
mice
modul
compound
use
vivo
studi
effect
cftr
rescu
mucu
concentr
ph
viscoelast
properti
bacteri
burden
gi
transit
chronic
inflamm
remain
challeng
cystic
fibrosi
cf
patient
left
untreat
inflamm
contribut
larg
pulmonari
lung
function
declin
highdos
ibuprofen
current
antiinflammatori
approv
cf
foundat
benefit
includ
decreas
lung
diseas
progress
reduc
neutrophil
migrat
decreas
propens
nasal
polyp
growth
howev
mechan
action
unclear
patient
prescrib
highdos
ibuprofen
due
potenti
side
effect
includ
gastrointestin
bleed
renal
injuri
clear
need
understand
mechan
ibuprofen
efficaci
order
develop
effect
safer
replac
previous
lab
report
microtubul
acetyl
express
polymer
rate
decreas
cf
epitheli
cell
decreas
microtubul
format
rate
contribut
decreas
intracellular
transport
thu
inflammatori
signal
hypothes
highdos
ibuprofen
improv
inflamm
via
improv
microtubul
structur
dynam
microtubul
polymer
rate
analyz
initi
microtubul
format
percent
cell
alphatubulin
aster
variou
time
point
determin
highdos
ibuprofen
hour
increas
cf
cell
aster
minut
repolymer
normal
wildtyp
cell
function
less
cf
cell
accumul
cholesterol
treat
highdos
ibuprofen
indic
reinstat
intracellular
transport
compar
microtubul
polymer
rate
analges
cyclooxygenas
inhibitor
ie
aspirin
acetaminophen
celecoxib
reform
microtubul
specif
highdos
ibuprofen
drug
significantli
increas
cf
microtubul
format
rate
enhanc
microtubul
polymer
confirm
primari
human
nasal
epitheli
hne
cell
obtain
cf
patient
ibuprofen
treatment
mechanist
effect
ibuprofen
mimick
stimul
ampk
aicar
increas
cf
cell
aster
minut
repolymer
reduct
cf
cell
accumul
cholesterol
effect
ibuprofen
block
ampk
inhibitor
compound
c
conclud
highdos
ibuprofen
treatment
enhanc
microtubul
format
cf
cell
like
ampkrel
pathway
implic
microtubul
structur
dynam
import
facet
link
cftr
inflamm
support
cff
nih
introduct
cystic
fibrosi
cf
primordi
character
loss
anion
secret
apic
side
epithelium
due
mutat
cftr
gene
cftr
dysfunct
affect
multipl
complex
interact
element
airway
electrophysiolog
network
ultim
lead
organ
level
diseas
exist
sever
experiment
techniqu
allow
character
interact
govern
mechan
howev
gener
lack
abil
provid
simultan
inform
individu
dynam
multipl
network
element
without
need
significantli
perturb
natur
monolay
describ
develop
silico
compartmentbas
model
allow
explor
interact
element
captur
volum
regul
ion
transport
condit
uss
chamber
uc
experi
method
model
center
cellular
compart
interfac
two
semiinfinit
sourcesink
repres
apic
basolater
fluid
volum
uc
gener
system
differenti
algebra
equat
relat
chang
intracellular
electrolyt
concentr
membran
potenti
ion
movement
function
time
uc
experi
fulli
differenti
primari
human
bronchial
epithelia
hbe
cultur
use
inform
model
paramet
cellular
volum
regul
ionic
flux
permeabl
estim
use
nonlinear
regress
unperturb
uc
shortcircuit
current
data
obtain
isoton
condit
remain
model
paramet
obtain
previou
literatur
model
human
airway
electrophysiolog
guilherm
jm
et
al
biophi
j
cibel
v
et
al
biophi
j
novotni
ja
jakobsson
e
j
physiol
result
model
valid
perform
simul
silico
respons
model
common
challeng
use
uc
experi
eg
amilorid
forskolin
simul
result
compar
actual
valu
obtain
analog
uc
experi
model
predict
noncf
cf
hbe
respons
amilorid
within
ucmeasur
amiloridesensit
current
predict
experiment
forskolininduc
current
within
actual
ucmeasur
forskolin
respons
conclus
model
recapitul
experiment
result
provid
strong
support
novel
mathemat
stabl
uc
model
incorpor
electron
chemic
cellular
respons
result
silico
model
tandem
uc
experi
highlight
abil
model
provid
insight
interindividu
differ
observ
differ
hbe
cultur
differ
challeng
therapeut
support
nih
approxim
suffer
million
carrier
cystic
fibrosi
cf
one
common
lethal
genet
diseas
worldwid
mutat
within
cystic
fibrosi
transmembran
regul
cftr
gene
result
alter
anion
cland
hco
secret
across
airway
epithelia
combin
hyperabsorpt
na
via
epitheli
sodium
channel
enac
lead
reduc
airway
surfac
liquid
asl
volum
impair
mucociliari
clearanc
chronic
inflamm
bacteri
colon
cystic
fibrosi
cf
airway
excess
volum
mucopurul
materi
mm
present
within
cf
airway
result
airway
obstruct
turn
airway
obstruct
diseas
report
account
death
cf
patient
addit
mm
present
within
cf
lung
contain
numer
proteas
may
abnorm
regul
enac
activ
degrad
asl
protein
requir
innat
defens
previous
report
secret
protein
regul
enac
activ
asl
hydrat
level
regul
enac
defect
cf
airway
furthermor
past
studi
shown
proteas
cleav
hypothes
proteas
present
within
cf
mucopurul
materi
cleav
may
alter
abil
regul
enac
postmortem
mm
harvest
pseudomona
aeruginosaand
staphyloccocu
aureusposit
cf
lung
level
determin
western
blot
follow
incub
mm
presenc
absenc
proteas
inhibitor
signific
breakdown
observ
incub
mm
dilut
pb
hour
n
mm
preincub
proteas
inhibitor
includ
aprotinin
edta
leupeptinin
determin
enzym
respons
cleavag
compound
fail
inhibit
cleavag
n
sivelestat
neutrophil
elastas
ne
inhibitor
significantli
prevent
cleavag
p
n
given
regul
enac
activ
cleav
mm
effect
mm
alon
combin
enac
protein
level
normal
human
bronchial
epitheli
cell
hbec
investig
proteolyt
cleavag
indic
preliminari
data
n
increas
level
cleav
subunit
express
observ
compar
control
convers
decreas
protein
level
consist
enac
degrad
reduc
enac
activ
evid
normal
hbec
incub
alon
mm
combin
effect
mm
cf
hbec
remain
determin
conclus
shown
mm
readili
cleav
cleavag
prevent
neutrophil
elastas
inhibitor
sivelestat
abnorm
cleavag
cf
mm
may
impair
abil
regul
innat
defens
cf
airway
fund
nih
background
cystic
fibrosi
cf
devast
congenit
diseas
afflict
peopl
worldwid
result
lossoffunct
mutat
epitheli
chlorid
channel
cystic
fibrosi
transmembran
conduct
regul
cftr
cf
patient
commonli
present
persist
pulmonari
bacteri
infect
correspond
worsen
clinic
prognosi
sphingomyelinas
smase
enzym
cleav
membran
lipid
sphingomyelin
phosphocholin
ceramid
secret
bacteri
virul
factor
shown
inhibit
cftr
chlorid
channel
function
may
contribut
observ
exacerb
diseas
dehydr
airway
facilit
bronchial
plug
goal
studi
determin
mechan
smase
inhibit
cftr
channel
activ
result
data
indic
isol
aureu
collect
airway
cf
patient
avidli
secret
smase
vitro
found
aureu
isol
caus
hotcold
hemolysi
grown
blood
agar
plate
condit
mediat
liquid
cultur
isol
show
signific
smase
activ
fluorometr
smasespecif
assay
addit
found
evid
inhibit
cftr
channel
activ
aureu
smase
occur
via
novel
statedepend
process
inhibit
occur
plasma
membran
reli
regulatori
r
domain
patchclamp
experi
also
indic
inhibit
membran
delimit
suggest
effect
reli
intracellular
factor
experi
perform
mutant
channel
show
channel
increas
activ
decreas
sensit
inhibit
smase
convers
mutat
decreas
channel
activ
increas
sensit
inhibit
suggest
inhibit
repres
cftr
lock
close
state
final
found
kalydeco
pretreat
protect
cftr
inhibitori
effect
smase
support
conclus
smase
target
close
state
cftr
conclus
taken
togeth
data
suggest
aureu
isol
cf
patient
avidli
secret
smase
inhibit
cftr
vitro
occur
via
novel
statedepend
mechan
smase
secret
cf
lung
could
limit
cftrmediat
chlorid
secret
fund
project
provid
nih
grant
rational
mani
infant
cystic
fibrosi
cf
structur
airway
injuri
airway
obstruct
howev
abnorm
often
clinic
silent
develop
sensit
tool
detect
earli
silent
diseas
imper
comput
fluid
dynam
cfd
techniqu
use
comput
model
measur
airflow
airway
resist
cfd
model
newborn
cf
pig
demonstr
airflow
abnorm
awadalla
et
al
ann
biom
eng
appli
infant
studi
use
preliminari
data
larg
prospect
studi
estim
airflow
infant
cf
use
cfd
techniqu
hypothes
increas
airway
resist
would
correl
inflamm
bronchoalveolar
lavag
fluid
balf
airway
obstruct
measur
infant
pulmonari
function
test
ipft
method
newbornscreen
infant
diagnos
cf
ipft
rais
volum
techniqu
balf
obtain
month
cytolog
measur
balf
chest
ct
scan
obtain
month
threedimension
conduct
airway
reconstruct
creat
ct
scan
crosssect
area
airway
estim
cfd
simul
laminar
steadyst
inspiratori
airflow
lmin
estim
airway
resist
pressur
drop
pa
flow
rate
ml
trachea
distal
bronchi
lobar
airflow
result
nine
infant
mean
age
month
time
ct
scan
averag
distal
airway
segment
model
use
cfd
techniqu
mean
airway
resist
paml
sd
airway
resist
significantli
correl
height
weight
resist
moder
correl
neutrophil
percentag
balf
r
balf
measur
resist
mildli
correl
balf
r
resist
significantli
correl
ipft
indic
resist
strongli
correl
proport
airflow
went
left
right
lung
r
airflow
correl
distal
airway
crosssect
area
r
lobar
crosssect
area
conclus
inflamm
balf
month
age
correl
airway
resist
month
age
airway
resist
correl
alter
airflow
airway
size
provid
evid
power
earli
relationship
inflamm
airway
injuri
lack
associ
inflamm
month
suggest
remodel
airway
might
occur
earli
life
associ
inflamm
comparison
variabl
addit
subject
need
cfd
method
complex
replac
ipft
may
provid
supplementari
clinic
inform
otherwis
silent
window
support
nhlbi
content
sole
respons
author
repres
offici
view
nih
studi
evalu
pulmonari
pathophysiolog
transgen
gutcorrect
cystic
fibrosi
cf
pig
four
sow
produc
piglet
stillborn
anim
surviv
beyond
week
failur
surviv
beyond
neonat
period
piglet
judg
result
metabol
dysfunct
like
relat
genet
manipul
cftr
gut
express
due
clone
artifact
plasma
analysi
neonat
anim
show
low
plasma
protein
highli
elev
liver
enzym
sever
acidosi
surviv
offspr
receiv
furosemid
system
edema
one
piglet
surviv
week
intens
care
human
euthan
due
respiratori
distress
gener
sever
edema
necropsi
find
suggest
clinic
featur
observ
unrel
cf
phenotyp
consist
observ
neonat
anim
physiolog
evalu
perform
lung
tissu
pig
surviv
month
age
acetylcholineand
forskolininduc
mucou
liquid
secret
significantli
lower
cf
bronchi
noncf
bronchi
percent
nonvolatil
solid
mucu
secret
cf
bronchi
elev
follow
acetylcholin
forskolin
compar
mucu
secret
noncf
bronchi
mucociliari
transport
excis
trachea
reduc
cf
trachea
rel
noncf
trachea
diamet
cf
trachea
less
noncf
pig
spite
greater
bodi
weight
despit
exhibit
sever
metabol
dysfunct
high
mortal
neonat
period
cf
anim
model
appear
express
import
characterist
human
cf
pulmonari
diseas
chronic
infect
cystic
fibrosi
cf
lung
pseudomona
aeruginosa
pa
associ
acceler
declin
lung
function
pa
bacteria
cultur
cf
sputum
secret
algin
major
compon
biofilm
biofilm
protect
bacteria
kill
antibiot
host
defens
novel
algin
oligom
oligog
low
molecular
weight
oligosaccharid
enrich
sodium
algin
polysaccharid
oligom
compos
acid
g
acid
oligog
current
phase
clinic
trial
cf
patient
previou
vitro
studi
shown
abil
oligog
disrupt
biofilm
format
potenti
effect
certain
antibiot
moreov
grich
oligom
also
shown
disrupt
interact
complex
mucu
reduc
crosslink
within
mucu
g
subunit
preferenti
bind
calcium
dival
cation
crosslink
pa
algin
polym
increas
pa
biofilm
gelat
hypothesi
hypothes
oligog
disrupt
algin
crosslink
induc
calcium
increas
neutrophil
capac
kill
pa
bacteria
grown
biofilm
overnight
cultur
dilut
od
trypticas
soy
broth
tsb
divid
two
separ
group
one
one
without
oligog
biofilm
format
induc
ad
cultur
filter
diamet
place
trypticas
soy
agar
tsa
static
condit
equal
volum
use
plankton
condit
h
tsa
agit
bacteria
opson
autolog
serum
min
gentl
agit
ad
neutrophil
cell
incub
gentl
agit
incub
reactant
dilut
water
rt
cell
lysi
vortex
sec
serial
dilut
plate
tsa
incub
overnight
determin
effect
oligog
neutrophilmedi
bacteri
kill
colonyform
unit
cfu
count
standard
platecount
procedur
result
oligog
concentr
complet
revers
calciuminduc
gelat
sodium
algin
chang
biofilm
coloni
greenbrown
turquois
color
suggest
oligog
markedli
alter
biofilm
expect
neutrophil
readili
kill
bacteria
grown
plankton
condit
within
h
kill
index
n
p
compar
neutrophil
index
decreas
addit
oligog
kill
index
n
p
contrast
neutrophil
kill
grown
biofilm
decreas
respect
observ
plankton
bacteria
addit
oligog
pa
grown
biofilm
significantli
increas
neutrophil
kill
bacteria
kill
index
n
p
conclus
conclud
oligog
affect
bacteri
biofilm
markedli
disrupt
calciumdepend
algin
gelat
increas
efficaci
neutrophilmedi
kill
pa
bacteria
grown
biofilm
support
grant
aid
research
cystic
fibrosi
foundat
cfft
award
flagellin
flg
key
protein
compon
bacteri
flagella
express
number
organ
includ
pseudomona
aeruginosa
proinflammatori
activ
bacteri
flg
well
document
leukocyt
although
effect
airway
epitheli
function
less
clear
acut
addit
flg
murin
trachea
exvivo
demonstr
inhibit
na
transport
kunzelmann
k
et
al
faseb
j
although
effect
human
tissu
examin
aim
present
studi
test
hypothesi
prolong
exposur
primari
cultur
human
bronchial
epitheli
cell
hbec
airliquid
interfac
flg
would
modifi
structur
function
tissu
condit
might
reason
expect
model
aspect
environ
chronic
colonis
human
lung
particular
region
adjac
infect
mucu
plug
concentrationrespons
studi
cf
noncf
hbec
donor
demonstr
flginduc
reduct
transepitheli
resist
r
concentr
flg
low
ngml
significantli
attenu
r
cultur
treat
initi
day
airliquid
interfac
associ
reduct
r
concentrationdepend
increas
goblet
cell
donor
studi
ion
transport
properti
flgtreat
hbec
studi
noncf
hbec
increas
amiloridesensit
short
circuit
current
isc
increas
forskolinstimul
isc
utpstimul
anionsecretori
isc
respons
also
increas
approxim
cfhbec
effect
flg
pretreat
amiloridesensit
isc
variabl
enhanc
small
respons
forskolin
howev
enhanc
respons
utp
still
observ
cfhbec
togeth
data
would
support
model
wherebi
healthi
airway
epithelium
flg
drive
increas
mucin
load
parallel
increas
capac
secret
fluid
noncf
epithelium
mediat
camp
cftr
ca
regul
anion
conduct
homeostat
mechan
like
develop
ensur
appropri
hydrat
mucu
gel
therefor
enabl
mucu
pathogen
clearanc
similar
flgdriven
goblet
cell
phenotyp
cf
airway
may
imbal
mucinfluid
load
absenc
cftr
function
predispos
mucu
plug
failur
clear
plug
contribut
chronic
colonis
lung
rational
cystic
fibrosi
cf
autosom
recess
inherit
disord
characteris
sustain
neutrophil
recruit
neutrophildomin
infiltr
plasma
membran
metalloproteinas
involv
cleavag
proinflammatori
membran
bound
cytokin
receptor
augment
inflamm
cholesterol
major
structur
compon
membran
influenc
membran
stabil
activ
protein
resid
previous
demonstr
neutrophil
plasma
membran
cholesterol
reduc
cf
therefor
aim
studi
investig
effect
reduc
neutrophil
plasma
membran
cholesterol
content
activ
adult
cf
specif
object
investig
circul
level
solubl
receptor
determin
whether
ivacaftor
therapi
mediat
reduct
activ
indirectli
reduc
inflamm
method
peripher
blood
neutrophil
plasma
isol
healthi
control
hc
donor
patient
cf
pwcf
either
homozyg
mutat
heterozyg
mutat
preand
postivacaftor
therapi
elisa
employ
quantifi
plasma
level
proinflammatori
mediat
activ
determin
fluorometr
flow
cytometri
investig
level
membranebound
ethic
approv
obtain
beaumont
hospit
ethic
committe
student
test
use
determin
signific
result
hc
neutrophil
expos
cholesteroldeplet
drug
methyl
beta
cyclodextrin
demonstr
increas
activ
result
reduc
membran
bound
increas
furthermor
neutrophil
isol
pwcf
reduc
plasma
membran
cholesterol
result
increas
activ
decreas
membranebound
elev
circul
level
complex
bound
found
plasma
pwcf
neutrophil
isol
patient
receiv
ivacaftor
therapi
increas
plasma
membran
cholesterol
reduc
activ
result
increas
membranebound
furthermor
ivacaftor
therapi
decreas
circul
plasma
level
conclus
novel
find
indic
blood
neutrophil
provid
sourc
proinflammatori
mediat
increas
circul
level
addit
demonstr
ivacaftor
therapi
indirectli
reduc
activ
therebi
reduc
inflammatori
burden
conclus
studi
emphasis
role
neutrophil
augment
inflammatori
environ
pwcf
identifi
new
antiinflammatori
role
ivacaftor
therapi
treatment
cf
studi
fund
sfi
grant
number
howev
function
role
phenotyp
airway
macrophag
cflike
lung
diseas
need
investig
object
aim
studi
character
phenotyp
airway
macrophag
isol
lung
mice
wildtyp
wt
control
compar
respons
stimul
lipopolysaccharid
lp
pseudomona
aeruginosa
ex
vivo
method
achiev
goal
primari
airway
macrophag
mice
wt
control
isol
bronchoalveolar
lavag
bal
macrophag
cultur
expos
lipopolysaccharid
lp
ngml
medium
alon
supernat
cell
collect
hour
posttreat
express
macrophag
signatur
proinflammatori
mediat
determin
result
isol
airway
macrophag
mice
show
significantli
increas
baselin
express
gene
associ
altern
activ
arginas
p
wt
vs
chemokin
p
p
compar
wildtyp
control
upon
treatment
airway
macrophag
lp
key
gene
involv
proinflammatori
antibacteri
respons
upregul
wt
macrophag
howev
express
level
lpsinduc
proinflammatori
mediat
like
p
p
p
p
p
significantli
enhanc
airway
macrophag
isol
mice
compar
wt
control
conclus
find
indic
mucostat
airway
environ
trigger
polar
airway
macrophag
toward
altern
activ
baselin
prime
augment
cytokin
respons
challeng
bacterialderiv
lp
result
suggest
activ
airway
macrophag
may
play
import
role
vivo
pathogenesi
chronic
airway
inflamm
better
understand
mechan
underli
macrophag
activ
may
lead
novel
antiinflammatori
therapi
cf
support
bmbf
human
nasal
potenti
differ
assay
wide
accept
method
measur
cftr
activ
vivo
nasal
epithelium
may
reflect
cftr
activ
within
sinus
develop
endoscop
direct
sinu
potenti
differ
edspd
assay
direct
target
patholog
epithelium
use
endoscop
edspd
suggest
techniqu
may
superior
nasal
pd
assay
provid
improv
capabl
measur
vivo
chlorid
cl
activ
site
diseas
object
studi
evalu
edspd
assay
novel
instrument
detect
diminish
chlorid
cl
transport
site
inflamm
human
sinus
method
patient
undergo
sinu
surgeri
prospect
enrol
potenti
differ
cathet
insert
endoscop
visual
maxillari
ethmoid
frontal
sinus
abbrevi
protocol
detect
cftrmediat
cltransport
follow
ringer
solut
baselin
potenti
differ
amilorid
blockad
epitheli
sodium
na
channel
low
cl
isoproterenol
activ
cltransport
result
correl
mucos
grade
cathet
site
use
visual
analog
scale
va
result
twelv
patient
includ
studi
edspd
assay
reveal
significantli
diminish
respons
amilorid
clfree
ringersisoproterenol
cr
compar
control
amilorid
mv
control
vs
cr
p
cl
freeisoproterenol
mv
control
vs
cr
p
robust
baselin
potenti
differ
indic
presenc
epitheli
integr
preserv
tight
junction
moder
signific
neg
correl
amilorid
respons
sinu
mucosa
grade
system
r
ci
p
indic
higher
va
mucos
grade
correl
diminish
na
channel
function
transport
sinu
mucosa
grade
also
demonstr
strong
signific
posit
correl
maxim
stimul
cltransport
clfree
isoproterenol
r
p
posit
correl
indic
higher
mucos
grade
endoscop
find
wors
associ
decreas
abil
secret
clthrough
epithelium
conclus
markedli
diminish
clsecret
na
absorpt
across
vivo
sinu
epithelium
human
subject
cr
signific
inflamm
measur
edspd
assay
suggest
acquir
cftr
enac
dysfunct
mucos
site
inflamm
cr
compar
nasal
caviti
sinus
provid
attract
model
pd
measur
line
epithelium
continu
qualit
similar
lower
respiratori
epithelium
includ
similar
ion
transport
mechan
microbiolog
patient
may
deriv
therapeut
benefit
clsecretagogu
object
chronic
rhinosinus
cr
affect
nearli
us
popul
year
estim
million
yearli
physician
visit
enorm
impact
qualiti
life
sinus
heterogen
diseas
univers
hallmark
involv
dysfunct
mucociliari
clearanc
mcc
reminisc
cystic
fibrosi
cf
object
current
studi
investig
influenc
mucu
stasi
transepitheli
chlorid
transport
use
preclin
rabbit
model
rhinosinus
rabbit
chosen
small
rodent
reproduc
key
aspect
human
upper
airway
physiolog
previou
experi
show
rabbit
human
nasal
epithelium
similar
physiolog
featur
vitro
creat
rabbit
model
sinus
without
administr
bacteria
pathogen
steril
synthet
spong
place
middl
meatu
natur
outflow
tract
maxillari
sinu
new
zealand
white
rabbit
block
mucociliari
flow
sinu
two
week
method
transnas
endoscop
approach
caus
damag
sinu
mucosa
revers
remov
merocel
transnas
allow
assess
recoveri
two
week
merocel
placement
remov
synthet
spong
half
rabbit
assess
develop
acut
rhinosinus
ar
rest
rabbit
observ
anoth
week
see
whether
rabbit
develop
cr
histolog
section
ct
imag
microbiom
analysi
nasal
potenti
differ
npd
assay
microopt
coher
tomographi
perform
character
preclin
model
rhinosinus
result
ct
demonstr
opacif
left
sinus
placement
steril
pack
rabbit
n
seen
week
rabbit
follow
n
histolog
rabbit
section
week
show
find
acut
inflamm
mostli
neutrophil
superfici
ulcer
week
signific
infiltr
plasma
cell
lymphocyt
note
osteiti
hyperplast
chang
control
rabbit
significantli
greater
mean
npd
polar
rabbit
sinu
inflamm
mv
vs
mv
p
microenviron
markedli
differ
two
group
shannon
divers
index
significantli
elev
sinus
rabbit
compar
control
vs
p
sampl
week
domin
anaerob
bacteria
maxillari
sinu
epithelia
sinus
rabbit
demonstr
significantli
lower
pcl
depth
compar
control
sinus
vs
control
p
conclus
block
mcc
two
week
rabbit
exhibit
featur
ar
week
cr
week
shift
sinu
bacteri
colon
observ
decreas
transepitheli
chlorid
transport
sinus
rabbit
compar
control
lower
pcl
depth
may
repres
cftr
dysfunct
rhinosinus
mucu
stasi
via
blockag
sinu
ostia
may
lead
hypoxia
result
substanti
chang
sinu
microbiom
cftr
dysfunct
rhinosinus
beati
tc
brown
mr
forrest
oa
ingersol
stecenko
tirouvanziam
r
pediatr
emori
univers
atlanta
ga
usa
background
cf
airway
diseas
domin
intens
neutrophil
inflamm
inflamm
result
high
level
enzym
neutrophil
elastas
ne
myeloperoxidas
damag
airway
perpetu
inflamm
inhal
corticosteroid
ic
frequent
use
attempt
reduc
inflamm
howev
evid
clinic
benefit
withdraw
ic
shown
safe
balfourlynn
im
et
al
cochran
databas
syst
rev
furthermor
studi
suggest
ic
detriment
effect
cf
increas
preval
infect
pseudomona
previou
work
lab
demonstr
system
steroid
increas
activ
primari
granul
exocytosi
subsequ
releas
ne
laval
j
et
al
j
immunol
base
prior
studi
hypothes
ic
withdraw
would
result
improv
lung
function
decreas
inflammatori
marker
method
cf
patient
year
age
older
treat
ic
consecut
month
elig
enrol
subject
requir
baselin
health
predict
subject
exclud
evid
asthma
previou
failur
ic
withdraw
oral
corticosteroid
reason
lung
function
measur
blood
sampl
induc
sputum
obtain
prior
minimum
day
cessat
ic
flow
cytometri
use
identifi
live
sputum
neutrophil
quantifi
surfac
marker
primari
granul
exocytosi
ne
activ
measur
sputum
spectrophotometri
result
six
patient
enrol
studi
four
complet
sampl
collect
plan
continu
enrol
complet
data
initi
six
patient
august
present
octob
four
patient
complet
studi
far
predict
increas
averag
sinc
ic
withdraw
averag
acut
pulmonari
exacerb
incid
decreas
per
year
complet
clinic
data
experiment
result
airway
neutrophil
function
ne
activ
report
six
patient
complet
august
discuss
prospect
trial
ic
withdraw
cf
help
better
understand
relationship
airway
neutrophil
function
ne
activ
lung
function
cf
baselin
influenc
steroid
antiinflammatori
may
provid
inform
target
better
specif
antiinflammatori
treatment
cf
airway
diseas
fund
studi
provid
cystic
fibrosi
foundat
tb
children
healthcar
atlanta
friend
fund
tb
rt
emorychildren
center
cf
research
startup
fund
rt
chandler
jd
horati
h
scholt
bj
jone
dp
chang
metabol
compon
fluid
infanc
may
key
prevent
adult
diseas
method
employ
target
biocrat
idkit
untarget
qexact
lcm
thermo
metabolom
bronchoalveolar
lavag
fluid
balf
cf
infant
age
month
copi
homozyg
well
acut
respiratori
distress
syndrom
ard
patient
healthi
control
hc
chest
comput
tomographi
ct
scan
cf
infant
also
score
accord
pragma
method
sensit
measur
earli
lung
diseas
discrimin
bronchiectasi
air
trap
mucu
plug
result
cf
metabol
profil
markedli
differ
hc
ard
clear
differ
ard
hc
also
observ
cfinfant
balf
target
metabolom
reveal
increas
hydroxyprolin
putrescin
spermidin
compar
control
p
like
reflect
increas
proteolysi
hydroxyprolin
arginas
activ
putrescin
spermidin
neutrophil
activ
earli
cf
lung
diseas
use
untarget
metabolom
also
identifi
uniqu
mz
featur
cf
balf
significantli
differ
hc
falsediscoveri
rate
threshold
match
known
metabolit
includ
hydroxyprolin
untarget
analysi
quantif
hydroxyprolin
significantli
associ
target
data
quantif
r
p
suggest
good
agreement
method
final
test
associ
metabolom
data
pragma
ct
score
cf
infant
use
partial
least
squar
method
identifi
biomark
make
mechanist
infer
regard
earli
cf
lung
diseas
develop
total
target
metabolit
untarget
mz
featur
associ
pragma
ct
score
high
model
import
ie
variabl
import
project
among
known
match
metabolit
associ
glutathion
oxid
glutathion
sulfonamid
cysteinyl
glutathion
phospholipid
metabol
present
conclus
metabolom
readili
discrimin
infant
cf
noncf
control
identifi
novel
factor
associ
lung
diseas
sever
newli
identifi
candid
may
valid
biomark
lead
mechanist
target
intervent
strategi
arrest
diseas
progress
chronic
pulmonari
infect
continu
predomin
caus
morbid
patient
cystic
fibrosi
cf
emerg
multidrug
total
drugresist
strain
p
aeruginosa
increas
threat
patient
henc
urgent
need
develop
new
strategi
combat
p
aeruginosa
infect
pathogen
profil
p
aeruginosa
relat
abil
secret
varieti
virul
factor
promot
biofilm
format
strategi
strengthen
abil
host
inhibit
virul
factor
would
allow
enhanc
bacteri
clearanc
could
employ
treatment
resist
infect
recent
shown
laboratori
strain
p
aeruginosa
inhibit
express
macrophag
investig
effect
cf
isol
p
aeruginosa
mucoid
nonmucoid
depend
gene
macrophag
epitheli
cell
human
moncocytederiv
macrophag
epitheli
cell
treat
cfbr
nonmucoid
cfbr
mucoid
p
aeruginosa
moi
show
significantli
reduc
express
messag
protein
timedepend
manner
furthermor
gene
scaveng
receptor
enzym
possess
lactonas
activ
enhanc
hydrolysi
quorumsens
molecul
also
inhibit
isol
pioglitazon
ligand
enhanc
clearanc
p
aeruginosa
macrophag
infect
p
aeruginosa
mechanist
show
agonist
induc
paraoxonas
enhanc
bacteri
clearanc
togeth
data
show
cf
isol
p
aeruginosa
inhibit
express
host
cell
suggest
mechan
bacteria
evad
host
defens
downregul
depend
gene
pathogen
compromis
phagocytosi
enhanc
virul
studi
suggest
role
immunotherapi
p
aeruginosa
infect
patient
cf
epidemiolog
studi
suggest
antivir
host
defens
may
compromis
peopl
cystic
fibrosi
cf
patient
exhibit
prolong
recoveri
time
frequent
hospit
associ
viral
respiratori
infect
vitro
studi
implic
impair
antivir
respons
airway
epithelia
featur
phenotyp
airway
home
multilay
antivir
host
defens
may
cellbas
extracellular
compar
noncf
cell
cf
airway
epithelia
support
greater
level
viral
infect
replic
infect
sever
class
respiratori
virus
exhibit
dysregul
express
sever
gene
product
involv
host
defens
studi
hypothes
airway
surfac
liquid
exhibit
direct
antivir
activ
antivir
activ
respiratori
secret
reduc
cf
test
hypothes
develop
vitro
assay
measur
innat
antivir
activ
present
nativ
airway
secret
cf
noncf
pig
found
cellfre
tracheal
nasal
secret
newborn
noncf
pig
exhibit
dosedepend
inhibitori
activ
sever
envelop
encapsid
virus
includ
sendai
viru
sev
respiratori
syncyti
viru
rsv
influenza
adenoviru
activ
heat
labil
also
detect
human
nasal
secret
importantli
found
antisev
activ
nasal
secret
newborn
cf
pig
significantli
diminish
rel
noncf
litterm
control
mix
cf
noncf
secret
vari
ratio
observ
correl
amount
noncf
secret
antisev
activ
suggest
possibl
reduc
abund
function
antivir
factor
cf
secret
base
previou
report
cathepsin
activ
elev
cf
airway
fluid
human
subject
measur
cystein
proteas
activ
newborn
cf
noncf
pig
secret
found
increas
cathepsin
b
l
slike
activ
bal
newborn
cf
pig
rel
noncf
litterm
similarli
observ
trend
toward
increas
cathepsin
b
activ
newborn
cf
nasal
secret
observ
antisev
activ
pig
antimicrobi
peptid
abolish
pretreat
cathepsin
b
suggest
increas
cathepsin
activ
may
neg
influenc
activ
secret
antivir
factor
data
indic
nativ
airway
secret
exhibit
inhibitori
activ
virus
birth
antivir
capac
cf
airway
secret
diminish
rel
noncf
futur
studi
investig
possibl
contribut
secret
proteas
phenomenon
well
overal
impact
loss
cftr
function
cellular
extracellular
antivir
defens
onset
progress
cf
lung
diseas
levi
ej
baron
c
bruscia
em
egan
pediatr
yale
school
medicin
new
ct
usa
background
recent
suggest
innat
immun
respons
dysregul
cf
innat
immun
system
respons
activ
host
defens
well
initi
tissu
repair
thu
essenti
maintain
tissu
homeostasi
macrophag
key
player
innat
immun
system
continu
survey
extracellular
environ
adopt
distinct
characterist
via
activ
specif
immun
signal
polar
process
activ
allow
macrophag
respond
function
appropri
preserv
tissu
homeostasi
vitro
macrophag
differenti
two
major
phenotyp
lpsinfgamma
essenti
proinflammatori
respons
essenti
tissu
repair
hypothesi
hypothes
intrins
defect
cf
macrophag
affect
abil
adequ
respond
extracellular
stimuli
affect
phenotyp
respons
contribut
state
hyperinflamm
method
peripher
bloodderiv
monocyt
healthi
donor
hd
well
cf
subject
differenti
macrophag
use
rpmi
media
ngml
mcsf
day
cell
treat
hour
ngml
lp
plu
ngml
infgamma
activ
phenotyp
ngml
activ
phenotyp
rna
isol
revers
transcrib
cdna
qrtpcr
perform
use
tnfalpha
primer
marker
mrc
ppargamma
marker
total
seven
experi
perform
use
differ
set
hd
cf
subject
util
x
x
cell
per
well
result
expect
hd
macrophag
experi
demonstr
appropri
plastic
polar
increas
express
marker
decreas
express
marker
respons
lp
infgamma
furthermor
demonstr
modestli
increas
express
marker
decreas
express
marker
respons
mark
contrast
stimul
lpsinfgamma
cf
macrophag
experi
demonstr
hyperinflamm
dramat
increas
express
level
marker
well
aberr
polar
evidenc
increas
express
level
maker
aberr
polar
character
increas
express
marker
presenc
addit
increas
express
marker
conclus
data
suggest
lack
function
cftr
macrophag
lead
inabl
macrophag
adequ
respond
environment
cue
activ
appropri
phenotyp
suggest
intrins
cellular
defect
moreov
mechan
underli
aberr
respons
like
involv
alter
intracellular
signal
transduct
current
investig
futur
consider
interrog
pathway
well
role
insulinlik
growth
factor
macrophag
activ
support
nih
cff
seri
eleg
studi
yankaska
knowl
boucher
colleagu
use
nasal
cell
deriv
nasal
polyp
establish
util
nasal
airway
cell
studi
electrolyt
transport
noncf
cf
donor
result
pioneer
studi
establish
high
rate
sodium
transport
lack
chlorid
secret
camp
agonist
cfderiv
nasal
cell
compar
noncf
cell
studi
report
design
establish
vitro
diagnost
method
determin
respons
cf
nasal
epitheli
cell
deriv
nasal
brush
biopsi
nasal
epithelium
express
abund
amount
cftr
protein
compar
potenti
tissu
sourc
minim
invas
procedur
use
procur
nasal
epitheli
cell
sampl
patient
method
work
collabor
physician
acquir
nasal
epitheli
cell
brush
biopsi
noncf
cf
donor
nasal
cell
x
expand
x
vitro
use
recent
publish
method
growth
expans
primari
cell
primari
nasal
epitheli
cell
differenti
permeabl
support
electrophysiolog
studi
use
method
alreadi
establish
routin
use
bridg
lab
efficaci
kalydeco
experiment
drug
known
efficaci
cftr
evalu
result
date
donor
enrol
studi
noncf
cf
donor
nasal
cell
noncf
cf
donor
success
expand
grown
permeabl
support
noncf
cf
cell
well
differenti
evidenc
abund
ciliat
cell
mucu
secret
goblet
cell
baselin
electrolyt
transport
phenotyp
expect
noncf
cell
display
low
sodium
transport
chlorid
secretori
respons
camp
agonist
cf
cell
display
high
sodium
transport
secretori
respons
camp
agonist
chlorid
secret
unalt
cftr
corrector
potenti
kalydeco
noncf
cell
contrast
chlorid
secret
improv
overnight
treatment
potenti
kalydeco
cf
cell
conclus
preliminari
result
document
feasibl
harvest
nasal
epitheli
cell
expand
cell
grow
cell
electrophysiolog
pharmacolog
studi
baselin
electrolyt
transport
phenotyp
well
respons
known
cftr
modul
demonstr
util
nasal
cell
resourc
cf
drug
discoveri
outcom
preliminari
studi
consid
highli
success
method
protocol
develop
allow
test
newli
approv
drug
small
number
patient
rare
mutat
would
otherwis
exclud
clinic
trial
moreov
anticip
nasal
cell
use
assist
stratif
patient
popul
clinic
trial
therebi
acceler
approv
drug
treatment
cf
support
cff
introduct
chronic
airway
inflamm
impair
inflammatori
respons
infect
among
main
manifest
cf
although
sever
mechan
link
abnorm
ion
secret
inflammatori
dysregul
suggest
link
cftr
function
alter
inflammatori
respons
need
better
understood
lipid
raft
microdomain
lrm
special
region
plasma
membran
particular
lipid
protein
composit
other
shown
cftr
lrm
critic
modul
inflammatori
immun
respons
present
work
investig
cftr
mutant
modifi
proteom
lrm
proinflammatori
condit
method
hela
cell
stabli
transfect
either
wildtyp
grown
dmem
incub
cell
lyse
triton
cell
lysat
equal
amount
protein
centrifug
sucros
densiti
gradient
purifi
lrm
lrm
trypsindigest
peptid
analyz
nanorslc
ltqorbitrap
velo
ms
gradient
protein
quantifi
silac
approach
use
maxquant
statist
analysi
perform
perseu
immunocytochemistri
confoc
microscopi
perform
hela
cell
bronchial
epitheli
cfbe
cell
issu
homozyg
patient
immort
gruenert
cftr
immunodetect
perform
iggclon
dilut
immunoloc
igg
dilut
cholera
toxin
subunit
b
cell
stain
concentr
preliminari
data
order
discrimin
chang
recruit
lipid
raft
chang
global
express
protein
analyz
total
proteom
unveil
protein
constitut
differenti
express
wt
cell
total
cell
protein
identifi
quantifi
parallel
analyz
lrm
fraction
identifi
protein
differenti
recruit
lipid
raft
lrm
fraction
could
identifi
quantifi
protein
could
identifi
lrm
among
protein
protein
show
signific
ratio
variat
stimul
protein
differenti
recruit
lrm
inflammatori
exposur
increas
cell
respect
wildtyp
includ
gprotein
coupl
receptor
anion
transport
one
cellsurfac
mucin
hela
cfbe
cell
confirm
one
gprotein
coupl
receptor
reloc
lrm
along
min
treatment
result
could
enlighten
crosstalk
cftr
impact
cell
respons
inflammatori
challeng
support
extend
recent
find
bitam
et
al
novel
aspect
work
address
first
time
impact
cftr
mutat
stimul
lrm
proteom
support
french
associ
vaincr
la
mucoviscidos
cystic
fibrosi
cf
airway
diseas
character
thicken
mucu
increas
viscoelast
properti
result
poor
clearanc
lung
increas
infect
airway
inflamm
current
debat
cf
commun
caus
patholog
thicken
mucu
one
hypothesi
defect
chlorid
transport
absent
misfold
cystic
fibrosi
transmembran
conduct
regul
cftr
result
sodium
hyperabsorpt
maintain
intracellular
ionic
balanc
hypothesi
water
move
sodium
airway
lumen
underli
cellular
epithelium
therebi
dehydr
airway
surfac
layer
asl
creat
high
concentr
mucu
increas
viscoelast
properti
compet
hypothesi
defect
cftr
inhibit
bicarbon
secret
asl
result
acidif
asl
therebi
increas
rheolog
properti
mucu
layer
imped
clearanc
seek
defin
rel
contribut
compet
hypothesi
mucu
ph
concentr
increas
viscoelast
properti
cf
mucu
perform
assay
mucu
harvest
human
bronchial
epitheli
cell
cultur
model
system
allow
control
mucu
concentr
defin
solid
dri
weight
well
ph
result
show
alter
ph
result
doubl
viscos
mucu
solid
mucu
howev
result
also
show
doubl
concentr
mucu
solid
solid
result
increas
viscos
mucu
increas
mucu
concentr
result
increas
buffer
capac
mucu
make
resist
chang
ph
taken
togeth
result
show
ph
alter
viscos
low
concentr
mucu
effect
diminish
high
mucu
solid
data
show
solid
ultim
domin
factor
creat
highli
viscou
mucu
hallmark
cf
airway
diseas
hill
db
forest
seim
ramsey
ka
esther
cr
muhlebach
ms
stick
sm
boucher
rc
cystic
fibrosi
center
univers
north
carolina
chapel
hill
chapel
hill
nc
usa
center
interdisciplinari
appli
mathemat
univers
north
carolina
chapel
hill
chapel
hill
nc
usa
mathemat
univers
north
carolina
chapel
hill
chapel
hill
nc
usa
pediatr
pumonolog
univers
north
carolina
chapel
hill
chapel
hill
nc
usa
pediatr
univers
north
carolina
chapel
hill
chapel
hill
ny
usa
respiratori
medicin
princess
margaret
hospit
children
perth
wa
australia
arest
cf
project
repres
uniqu
opportun
document
earli
onset
airway
diseas
cystic
fibrosi
ongo
studi
bronchoalveolar
lavag
bal
sampl
collect
pediatr
patient
regular
interv
first
year
life
goal
analysi
investig
chang
rheolog
properti
mucu
brought
cf
airway
diseas
previous
shown
cf
sputum
character
significantli
increas
mucin
concentr
result
modifi
biophys
properti
viscoelast
osmot
pressur
due
dilut
natur
bal
sampl
determin
nativ
concentr
mucu
along
airway
bal
sampl
proven
imposs
small
fleck
concentr
viscoelast
mucu
present
pediatr
cf
bal
sampl
also
contain
highli
dilut
mucu
rheolog
ident
salin
combin
sophist
microbead
rheolog
measur
bal
sampl
advanc
data
analyt
abl
determin
divers
rheolog
microenviron
tracer
particl
sampl
specif
emb
micron
diamet
tracer
particl
sampl
volum
analyz
diffus
fluctuat
analyt
firstli
determin
particl
track
path
consist
normal
salin
exclud
analysi
nonexclud
particl
anomal
subdiffus
paramet
particl
path
calcul
reflect
motil
rang
dilut
pure
mucu
sampl
compar
result
adult
cf
normal
bal
find
sampl
collect
pediatr
arest
particip
display
rheolog
lie
healthi
adult
adult
cf
patient
addit
compar
result
particl
track
patient
noncf
pediatr
diseas
patient
tradit
clinic
biomark
ct
scan
score
cell
count
mechan
loss
cftr
lead
blunt
akt
signal
respons
activ
remain
investig
test
whether
ezrin
member
ezrinradixinmoesin
protein
bridg
cytoskeleton
cell
membran
protein
link
cftr
signal
method
gener
cultur
bone
marrow
cell
wt
litterm
mice
day
mcsf
human
differenti
peripher
blood
healthi
donor
hd
cf
patient
day
human
mcsf
murin
cell
line
stabli
infect
retrovir
vector
express
shrna
ezrin
shrnaezr
scrambl
control
shrnactr
celecoxib
studi
murin
human
treat
overnight
celecoxib
vehicl
dmso
challeng
lp
result
use
confoc
transmiss
electron
microscopi
show
respons
lp
form
plasma
membran
ruffl
high
level
ezrin
contrast
loss
cftr
caus
profound
reduct
ezrin
protein
level
plasma
membran
ruffl
respons
lp
activ
cf
ezrin
trap
intracellularli
fail
phosphoryl
actinbind
domain
thu
lead
proteasomedepend
degrad
reduc
ezrin
also
observ
human
cf
bear
class
iii
mild
cftr
mutat
studi
reveal
ezrin
requir
induct
respons
lp
low
level
ezrin
also
augment
signal
respons
lp
impair
pseudomona
aeruginosa
phagocytosi
treatment
celecoxib
nonsteroid
antiinflammatori
drug
previous
use
reestablish
signal
cf
challeng
lp
reduc
lung
hyperinflamm
cf
mice
increas
ezrin
level
promot
phosphoryl
cf
cell
thu
specul
benefici
effect
celecoxib
cf
part
due
ezrin
protein
stabil
ensur
effici
signal
respons
lp
conclus
summari
identifi
major
dysfunct
organ
plasma
membran
ruffl
cf
activ
disrupt
key
immun
signal
network
weaken
host
defens
fund
cff
cui
leung
h
chu
k
ford
hyun
c
yin
b
singh
k
birket
solomon
g
row
sm
tearney
gj
mgh
boston
usa
ntu
singapor
singapor
uab
birmingham
al
usa
hm
boston
usa
gregori
fleme
jame
cystic
fibrosi
research
ctr
birmingham
al
usa
background
mucociliari
clearanc
mcc
critic
defens
mechan
human
respiratori
system
cf
impair
mcc
often
lead
sever
morbid
obstruct
airway
increas
suscept
chronic
lung
infect
provid
high
resolut
crosssect
imag
capabl
rapid
imag
speed
frame
per
second
liu
l
et
al
plo
one
technolog
group
pioneer
use
uniqu
tool
capabl
facilit
understand
mechanist
pathway
associ
cf
pathogenesi
method
imag
capabl
perform
comprehens
analysi
variou
aspect
cf
pathophysiolog
function
microanatomi
airway
epithelium
includ
asl
pcl
thick
cilia
beat
frequenc
mucociliari
transport
rate
mct
addit
ex
vivo
work
perform
benchtop
imag
system
also
develop
rigid
mm
probe
vivo
imag
airway
epithelium
breath
swine
improv
clinic
util
cf
studi
report
implement
flexibl
probe
design
compat
standard
clinic
bronchoscop
probe
smaller
diamet
mm
transduc
beam
scan
motion
use
flexibl
polyetheretherketon
tube
new
design
allow
probe
fit
instrument
channel
bronchoscop
proxim
end
piezoelectr
stack
motor
attach
instrument
channel
bronchoscop
via
custom
ergonom
attach
piezo
motor
provid
longitudin
scan
hz
approxim
field
view
result
figur
compar
two
imag
excis
mice
trachea
tissu
one
obtain
benchtop
system
miniatur
flexibl
probe
case
cilia
apic
surfac
clearli
distinguish
indic
flexibl
bronchial
probe
compar
imag
perform
benchtop
system
conclus
success
develop
miniatur
flexibl
probe
suitabl
imag
epitheli
function
microanatomi
vivo
translat
human
subject
greatli
benefit
studi
cf
pathogenesi
assess
efficaci
experiment
therapeut
grate
acknowledg
support
work
nih
cff
fund
figur
comparison
mous
trachea
tissu
imag
obtain
benchtop
system
left
flexibl
bronchial
probe
right
cilia
tip
green
arrow
periciliari
liquid
pcl
layer
red
bar
seen
surfac
epitheli
layer
ep
tracheal
submucos
gland
smg
impact
airway
health
secret
mucu
serou
fluid
contribut
cellular
regener
tissuespecif
stem
cell
sc
nich
shown
cftr
defect
lead
dysregul
smg
sc
nich
like
alter
gland
secret
much
still
unknown
regard
glandular
sc
regul
wnt
signal
requir
lineag
commit
glandular
sc
smg
morphogenesi
surfac
airway
epithelium
sae
whether
similar
wntdepend
process
coordin
sc
expans
adult
smg
follow
airway
injuri
remain
unknown
found
two
wntreport
mice
batgal
tcflef
coexpress
activ
cycl
sc
primordi
glandular
placod
small
subset
adult
smg
progenitor
cell
enter
cell
cycl
hour
follow
airway
injuri
homeostasi
wnt
report
show
nonoverlap
cellular
pattern
express
sae
smg
follow
tracheal
injuri
prolifer
accompani
dynam
chang
wntreport
activ
analysi
wntrelat
signal
gene
reveal
uniqu
tempor
chang
express
within
proxim
glandcontain
distal
glandfre
portion
trachea
exampl
seven
wnt
ligand
six
wnt
receptor
differenti
regul
addit
wnt
modul
bambi
downstream
target
wnt
signal
myc
also
differenti
express
follow
injuri
wnt
stimul
vivo
vitro
promot
epitheli
prolifer
smg
sae
interestingli
slowli
cycl
nucleotid
labelretain
cell
lrc
smg
spatial
posit
near
cluster
batgal
posit
serou
tubul
isol
cultur
tetinduc
lrc
demonstr
smg
lrc
prolif
sae
lrc
cultur
expand
smgderiv
progenitor
cell
outcompet
saederiv
progenitor
regener
tracheal
xenograft
epithelium
use
clonal
analysi
competit
assay
smgderiv
progenitor
also
multipot
cell
type
surfac
airway
epithelium
form
glandlik
structur
xenograft
studi
demonstr
import
wnt
signal
modul
sc
phenotyp
within
tracheal
nich
provid
new
insight
phenotyp
differ
smg
sae
sc
studi
also
provid
foundat
isol
propag
multipot
glandular
progenitor
may
use
sc
therapi
cf
airway
diseas
pseudomona
aeruginosa
opportunist
pathogen
caus
infect
cystic
fibrosi
cf
patient
chronic
cf
airway
also
character
robust
neutrophil
infiltr
neutrophil
fight
p
aeruginosa
multipl
mechan
besid
phagocytosi
also
releas
neutrophil
extracellular
trap
net
trap
pathogen
net
compos
extracellular
dna
decor
histon
granul
compon
net
present
cf
airway
indic
recruit
neutrophil
extrud
net
like
respons
bacteria
includ
p
aeruginosa
although
clinic
potenti
relev
mechan
cf
detail
p
aeruginosainduc
net
format
remain
unclear
previous
shown
laboratori
standard
strain
cf
isol
p
aeruginosa
strong
induc
net
format
human
neutrophil
vitro
identifi
bacteri
compon
crucial
net
induct
cultur
p
aeruginosa
differ
length
time
repres
bacteria
earli
late
exponenti
earli
stationari
growth
phase
interestingli
p
aeruginosa
earli
exponenti
growth
phase
trigger
robust
net
format
bacteria
older
cultur
led
diminish
net
releas
indic
bacteri
componentsvirul
factor
characterist
earli
growth
phase
mainli
respons
trigger
net
format
aflagel
mutant
p
aeruginosa
pak
serious
impair
trigger
net
purifi
flagellum
flagellin
monom
fail
stimul
net
releas
human
neutrophil
antibodi
influenc
abil
p
aeruginosa
trigger
net
releas
similarli
murin
neutrophil
defici
main
flagellinsens
receptor
releas
net
respons
p
aeruginosa
wildtyp
neutrophil
seemingli
paradox
find
p
aeruginosainduc
net
releas
flagellumdepend
could
explain
requir
flagellar
motil
main
function
flagellum
provid
bacterium
abil
swim
test
flagellar
motordefici
p
aeruginosa
pak
mutant
dmotabd
dmotbcd
express
flagellum
unabl
move
abil
induc
net
human
neutrophil
interestingli
found
motordefici
mutant
incap
induc
net
format
summari
identifi
bacteri
flagellum
major
compon
p
aeruginosa
induc
net
flagellum
stimul
net
format
bind
flagellumsens
receptor
provid
swim
motil
specul
mechan
could
also
partial
respons
welldescrib
loss
flagellum
p
aeruginosa
cf
airway
infect
specif
object
use
transcriptom
analysi
connect
map
discov
novel
mechan
identifi
smallmolecul
treatment
gcm
method
result
lincscmap
connect
map
collect
chemicalinduc
transcript
profil
signatur
multipl
cell
line
allow
input
transcript
signatur
interest
databas
retriev
compound
may
replic
revert
input
signatur
gener
transcript
signatur
consist
top
upand
downregul
gene
hae
cultur
expos
week
result
robust
gcm
lincscmap
databas
identifi
multipl
compound
may
revert
transcript
signatur
hypothes
compound
may
block
induc
gcm
expos
hae
cultur
presenc
top
compound
multipl
compound
prevent
gcm
includ
blocker
pathway
known
play
role
gcm
found
inhibitor
dosedepend
block
gcm
multipl
hae
donor
also
revert
gcm
establish
conclus
conclud
robustli
prevent
gcm
hae
specul
play
direct
role
gcm
like
act
downstream
bind
therefor
may
involv
gcm
induc
broad
varieti
mechan
multipl
inhibitor
current
use
clinic
trial
predominantli
cancer
treatment
repurpos
drug
block
gcm
may
allow
control
mucu
hypersecret
cystic
fibrosi
airway
diseas
support
univers
iowa
carver
colleg
medicin
physicianscientist
train
program
introduct
glucos
present
airway
patient
affect
cystic
fibrosisrel
diabet
cfrd
bacteri
airway
infect
sinc
lung
function
patient
diagnos
cfrd
declin
acceler
rate
sinc
insulin
control
glucos
metabol
effect
insulin
normal
cf
airway
epithelia
glucos
clearanc
investig
method
determin
whether
airway
epithelia
function
apic
insulin
receptor
contribut
glucos
clearanc
whether
respons
impair
cf
insulin
respons
human
airway
epitheli
cell
matur
airliquid
interfac
character
pkb
akt
signal
pathway
analysi
util
pharmacolog
immunoblot
assay
result
applic
insulin
stimul
glucos
uptak
normal
primari
human
airway
epitheli
cell
human
airway
cell
express
mutant
cftr
less
respons
insulin
increas
glucos
uptak
much
wildtyp
applic
enhanc
akt
activ
increas
amount
akt
phosphoryl
function
airway
cell
express
mutant
cftr
conclus
insulin
stimul
signal
preferenti
normal
airway
cell
cf
airway
cell
activ
insulin
import
glucos
uptak
normal
human
airway
cell
respons
insulin
cf
patient
airway
epithelia
impair
insulinindepend
approach
may
need
provid
efficaci
treatment
cf
cfrd
strug
lj
behalf
intern
cf
gene
modifi
co
genet
genom
biolog
hospit
sick
children
toronto
canada
inserm
pari
franc
univers
north
carolinacas
western
reserv
chapel
hill
nc
usa
john
hopkin
univers
baltimor
md
usa
introduct
meconium
ileu
mi
intestin
obstruct
birth
herit
previou
genomewid
associ
studi
mi
intern
cf
gene
modifi
consortium
icfgmc
identifi
snp
near
find
sinc
replic
shown
contribut
diseas
sever
cfaffect
organ
lung
report
result
metagwa
mi
expand
cf
popul
icfgmc
goal
identifi
addit
loci
contribut
mi
suscept
addit
insight
diseas
sever
cfaffect
organ
method
analyz
individu
cf
consist
four
patient
collect
recruit
john
hopkin
univers
univers
north
carolinacas
western
reserv
univers
populationbas
patient
cohort
franc
canada
genotyp
varieti
platform
imput
common
set
million
snp
four
cohort
analyz
snp
across
genom
separ
combin
use
random
effect
metaanalysi
john
hopkin
cohort
contain
sibl
gener
estim
equat
compound
symmetri
covari
structur
use
account
related
sibl
pair
group
use
logist
regress
genomewid
signific
find
nearbi
variant
linkag
disequilibrium
ld
assess
context
publicli
avail
data
roadmap
epigenom
encod
project
result
interpret
five
loci
contain
snp
reach
genomewid
signific
threshold
p
loci
includ
previous
report
mi
candid
gene
three
novel
region
contain
anion
transporterexchang
known
interact
cftr
encod
amino
acid
transport
express
intestin
high
ld
top
rank
snp
locu
fall
put
promot
gene
analysi
context
chromatin
state
dnase
hypersensit
transcript
factor
bind
data
enabl
us
narrow
region
associ
snp
close
transcript
start
site
may
influenc
express
level
encod
cation
trypsinogen
proteas
pancrea
elev
serum
level
indic
cf
newborn
given
region
associ
recent
report
luciferas
assay
promot
variant
strong
ld
associ
childhoodonset
pancreat
appear
decreas
level
may
increas
risk
mi
recent
report
contribut
cf
lung
diseas
nongastr
proton
pump
work
togeth
transport
cholesterol
sterol
liver
enterocyt
small
intestin
conclus
associ
variant
suggest
regulatori
effect
gene
express
locat
near
gene
previous
implic
cf
fund
receiv
cff
cf
canada
cihr
genom
canada
inserm
blackman
sm
b
strug
lj
pace
rg
corvol
h
rommen
jm
drumm
ml
knowl
mr
cut
gr
pediatr
endocrinolog
john
hopkin
univers
baltimor
md
usa
genet
john
hopkin
univers
baltimor
md
usa
hospit
sick
children
toronto
canada
univers
toronto
toronto
canada
pediatr
pulmonolog
trousseau
pari
franc
pierr
et
mari
curi
pari
franc
pediatr
case
western
reserv
univers
cleveland
oh
usa
marsico
lung
institut
univ
north
carolina
chapel
hill
nc
usa
background
cfrelat
diabet
cfrd
develop
time
adolesc
adult
cf
caus
wors
lung
function
mortal
previou
studi
demonstr
variat
risk
cfrd
due
gene
cftr
ie
genet
modifi
identifi
cfrd
modifi
variant
loci
see
use
genomewid
candidatebas
associ
studi
blackmansm
et
al
diabet
intern
cf
gene
modifi
consortium
icfgmc
recent
increas
sampl
size
complet
lung
phenotyp
metaanalysi
corvol
h
et
al
nat
commun
object
identifi
new
risk
loci
cfrd
genomewid
associ
metaanalysi
designmethod
cf
studi
particip
recruit
icfgmc
studi
almost
north
america
franc
inclus
exclus
criteria
describ
earlier
gwa
blackman
et
al
includ
requir
cftr
genotyp
known
caus
sever
exocrin
pancreat
insuffici
diabet
defin
insulin
treatment
least
year
genotyp
qualiti
control
imput
perform
describ
corvol
et
al
variant
minor
allel
frequenc
analyz
associ
associ
test
use
cox
proport
hazard
regress
within
studi
cohort
adjust
popul
stratif
cohort
combin
fixedeffect
metaanalysi
result
total
individu
full
genotyp
phenotyp
inform
cfrd
confirm
occur
frequent
femal
hr
previou
gwa
substanti
differ
cfrd
cumul
incid
note
studi
cohort
notabl
previous
associ
variant
cfrd
modifi
loci
show
independ
replic
p
variant
newli
test
sampl
locu
continu
strong
genomewid
support
two
loci
variant
associ
cfrd
p
includ
signific
evid
heterogen
among
cohort
loci
cochran
associ
snp
new
loci
lie
andor
adjac
gene
previous
associ
cfrd
type
diabet
conclus
increas
sampl
size
increas
power
detect
cfrd
genet
modifi
previous
identifi
cfrd
modifi
loci
replic
preliminari
analys
identifi
far
new
cfrd
modifi
loci
result
support
import
role
type
diabet
risk
gene
cfrd
reveal
new
loci
involv
cfrd
pathogenesi
support
cff
nih
gilead
scienc
cf
canada
cihr
genom
canada
singl
nucleotid
polymorph
snp
within
modifi
risk
cfrelat
diabet
cfrd
blackman
sm
et
al
diabet
meconium
ileu
sun
l
et
al
nat
genet
evalu
genet
architectur
sequenc
entir
locu
kb
kb
gene
kb
homozygot
two
linkag
disequilibrium
ld
block
defin
singl
recombin
intron
identifi
haplotyp
test
associ
cfrd
onset
use
continu
trait
sever
reflect
earlier
onset
cfrd
vs
older
age
without
cfrd
diagnosi
blackman
sm
et
al
two
common
haplotyp
frequenc
within
ld
block
contain
variant
identifi
gwa
associ
higher
lower
risk
cfrd
respect
code
snp
ld
either
haplotyp
individu
snp
show
greater
associ
cfrd
two
common
haplotyp
suggest
cfrd
risk
confer
either
singl
snp
high
ld
remaind
haplotyp
combin
noncod
snp
next
analyz
variant
associ
express
eqtl
report
gtex
within
kb
three
tissu
known
express
pancrea
lung
stomach
pancrea
eqtl
cluster
two
group
one
one
gene
group
signific
eqtl
intron
associ
cfrd
ld
cfrdassoci
variant
eqtl
pvalu
group
snp
pvalu
rang
howev
region
contain
cfrdrisk
variant
lung
stomach
tissu
signific
eqtl
region
pvalu
respect
neither
cfrdassoci
annot
human
proteincod
isoform
isoform
code
protein
termin
pdzdomain
bind
motif
facilit
interact
cftr
isoform
code
protein
lack
pdzbind
motif
compar
genom
analysi
predict
isoform
present
speci
beyond
xenopu
wherea
isoform
primatespecif
transcriptom
analysi
reveal
isoform
primari
transcript
lung
pancrea
salivari
gland
skin
stomach
per
tissu
human
protein
atla
isoform
lower
express
found
lung
skin
isoform
respect
isoform
identifi
tissu
rtpcr
rna
transcript
detect
abund
isoform
primari
stomach
lung
pancrea
tissu
wherea
isoform
encod
pdzbind
motif
ie
isoform
found
lung
isoform
also
previous
report
primari
lung
cell
bertrand
ca
et
al
pediatr
pulmonol
togeth
result
support
role
cfrdassoci
variant
influenc
express
isoform
pancrea
fund
cff
aetnau
healthcar
chair
introduct
consider
phenotyp
divers
exist
among
patient
cftr
mutat
addit
genet
modifi
contribut
variabl
previous
estim
lung
function
varianc
attribut
noncftr
genet
factor
previous
associ
lung
function
gener
popul
chronic
lung
diseas
especi
copd
protein
rhogap
domain
suggest
involv
modul
activ
rhogtpas
key
regul
cytoskelet
dynam
studi
assess
involv
cf
patient
fev
variabl
character
biolog
role
method
contribut
modifi
gene
lung
function
test
vega
versatil
genebas
associ
studi
includ
french
cf
patient
cell
cultur
medium
gibco
supplement
fc
antibiot
primari
human
bronchial
epitheli
cell
hbec
control
cf
patient
epithelix
antibodi
sigmaaldrich
sirna
ambion
express
plasmid
origen
knockout
mice
obtain
knockout
mous
project
result
use
vega
show
associ
lung
function
cf
patient
immunohistochemistri
human
mous
lung
show
detect
bronchial
alveolar
type
ii
cell
inflammatori
context
mrna
express
downregul
especi
cell
hbec
cell
order
understand
consequ
downregul
use
sirna
observ
induct
factin
stress
fiber
cell
hbec
increas
rhoa
activ
convers
rhoa
activ
diminish
overexpress
furthermor
inhibit
express
enhanc
reduct
emt
marker
ecadherin
express
increas
vimentin
preliminari
result
use
wildtyp
mice
show
differ
weight
appear
breath
rate
conclus
observ
gene
associ
lung
function
cf
patient
data
suggest
involv
cytoskelet
dynam
confirm
expect
role
rhogap
regul
rhoa
activ
may
contribut
emt
process
futur
vivo
studi
use
physiopatholog
model
result
increas
understand
gene
affect
lung
function
cf
patient
ks
usa
univ
north
carolina
chapel
hill
nc
usa
john
hopkin
hospit
baltimor
md
usa
case
western
reserv
univ
cleveland
oh
usa
univ
toronto
toronto
canada
north
carolina
state
univ
raleigh
nc
usa
background
cf
chronic
pulmonari
infect
p
aeruginosa
associ
lung
function
declin
decreas
surviv
studi
herit
chronic
p
aeruginosa
infect
shown
estim
concord
analysi
adjust
age
onset
infect
green
et
al
j
pediatr
studi
suggest
host
genet
suscept
chronic
p
aeruginosa
infect
hypothes
vivo
human
nasal
epithelia
show
differenti
gene
express
associ
age
onset
chronic
p
aeruginosa
infect
method
enrol
cf
subject
pancreat
insuffici
cftr
mutat
homozyg
obtain
nasal
mucos
epithelia
via
curettag
biopsi
isol
rna
submit
mrnaseq
age
onset
chronic
p
aeruginosa
infect
determin
annual
nasopharyng
sputum
cultur
data
chronic
infect
defin
p
aeruginosa
cultur
consecut
year
year
unless
subject
consecut
year
neg
cultur
meet
posit
criteria
earli
life
subject
age
requir
least
neg
cultur
first
posit
cultur
could
consid
analysi
pittman
je
et
al
pediatr
pulmonol
perform
safe
pathway
analysi
integr
principl
compon
clinic
covari
includ
sex
lung
transplant
nasal
steroid
use
inflamm
index
express
addit
control
lung
diseas
sever
primari
analysi
use
azithromycin
exploratori
covari
secondari
analys
fdr
valu
met
statist
signific
character
age
onset
chronic
p
aeruginosa
infect
subject
subject
neg
p
aeruginosa
final
cultur
analysi
show
signific
pathway
associ
age
onset
chronic
p
aeruginosa
infect
primari
analysi
primari
secondari
analys
combin
includ
mani
gene
relat
cell
surfac
glycoprotein
receptor
cellular
integr
innat
immun
respons
eg
egfr
one
exampl
express
cell
surfac
receptor
significantli
contribut
pathway
signific
wherein
increas
express
associ
later
age
onset
chronic
p
aeruginosa
infect
p
analys
discuss
human
respiratori
epithelia
vital
compon
innat
immun
system
studi
cf
respiratori
epithelia
show
signific
differenti
express
gene
relat
cellular
growth
develop
immun
cellcel
signal
associ
age
onset
chronic
p
aeruginosa
infect
futur
mechanist
studi
identifi
candid
gene
may
elucid
pathophysiolog
cf
host
suscept
p
aeruginosa
infect
fund
gilead
scienc
research
scholar
program
desai
syke
j
stephenson
quon
bs
univers
british
columbia
vancouv
bc
canada
div
resp
st
paul
hospit
vancouv
bc
canada
div
resp
st
michael
hospit
toronto
canada
introduct
approxim
cf
diagnos
made
adulthood
cf
mutat
observ
adultdiagnos
ad
case
differ
childhooddiagnos
cf
often
lead
milder
diseas
phenotyp
proport
ad
patient
specif
mutat
could
benefit
current
avail
cftr
modul
therapi
across
canada
remain
unknown
purpos
studi
describ
frequenc
specif
cf
mutat
ad
cf
patient
current
aliv
canada
estim
proport
could
benefit
current
avail
cftr
modul
therapi
method
populationbas
cohort
studi
ad
cf
patient
year
current
aliv
diagnos
without
prior
lung
transplant
follow
canadian
cf
registri
character
preval
cf
mutat
ad
cohort
specif
focus
mutat
target
homozyg
gate
mutat
mutat
clinic
characterist
includ
sweat
chlorid
pancreat
statu
predict
use
gli
refer
norm
p
aeruginosa
cultur
statu
evalu
within
year
diagnosi
last
report
clinic
visit
result
ad
patient
identifi
current
aliv
without
lung
transplant
mean
age
diagnosi
year
patient
present
pulmonari
symptom
mean
sweat
chlorid
measur
time
diagnosi
meql
thirtynin
percent
classifi
pancreat
insuffici
base
pancreat
enzym
use
mean
bmi
diagnosi
kgm
seven
percent
ad
cf
patient
homozyg
heterozyg
two
mutat
one
identifi
mutat
mutat
identifi
miss
genotyp
data
twenti
percent
mutat
target
current
avail
cftr
modul
therapi
specif
mutat
homozyg
gate
mutat
patient
gate
mutat
identifi
cohort
clinic
characterist
ad
patient
stratifi
mutat
summar
tabl
conclus
twenti
percent
ad
cf
patient
canada
mutat
may
target
current
avail
cftr
modul
therapi
cftr
modul
therapi
target
mutat
observ
commonli
ad
cf
patient
need
rock
mj
makholm
l
pediatr
univers
wisconsin
madison
wi
usa
background
despit
make
genet
diagnosi
cf
unit
state
cystic
fibrosi
foundat
cff
european
cystic
fibrosi
societi
state
sweat
chlorid
test
alway
necessari
farrel
pm
et
al
j
pediatr
castellani
c
et
al
j
cyst
fibro
previou
studi
compar
quantiti
suffici
qn
rate
gibsoncook
collect
versu
collect
yield
conflict
result
hammond
colleagu
hammond
et
al
j
pediatr
found
qn
rate
gibsoncook
collect
qn
defin
mg
sweat
compar
qn
rate
qn
defin
convers
laguna
colleagu
laguna
ta
et
al
pediatr
pulmonol
found
qn
rate
qn
defin
mg
sweat
gibsoncook
collect
compar
qn
rate
sweat
test
method
univers
wisconsinmadison
chang
gibsoncook
collect
collect
septemb
object
describ
histor
qn
rate
sweat
test
via
gibsoncook
collect
sweat
onto
filter
paper
compar
sweat
collect
method
sweat
test
perform
bilater
technician
perform
test
year
experi
sweat
test
qn
data
septemb
sweat
collect
via
gibsoncook
summar
qn
defin
sweat
weight
mg
arm
sweat
collect
method
chang
sept
qn
data
april
also
summar
qn
defin
sweat
arm
result
list
tabl
conclus
sweat
collect
via
result
higher
qn
rate
gibsoncook
collect
higher
rate
appli
patient
month
age
introduct
although
cystic
fibrosi
cf
associ
mutat
cftr
gene
similar
mutat
genotyp
observ
differ
clinic
manifest
phenotyp
one
patient
anoth
chitinas
gene
inflammatori
marker
increas
blood
patient
inflammatori
diseas
includ
cf
hector
et
al
plo
one
kang
mj
et
al
j
respir
cell
mol
biol
studi
also
shown
invers
correl
pulmonari
function
hector
et
al
specif
alter
gene
express
diseas
could
explain
presenc
singl
nucleotid
polymorph
snp
specif
region
gene
thomsen
sb
et
al
plo
one
purpos
studi
determin
presenc
snp
could
chang
gene
express
lead
higher
level
well
specif
clinic
profil
cf
patient
object
determin
associ
genotyp
select
snp
promot
region
serum
concentr
well
clinic
marker
diseas
sever
clinic
cohort
cf
patient
method
develop
prospect
cohort
studi
adult
cf
patient
blood
sampl
collect
analys
dna
snp
circul
level
present
preliminari
data
obtain
patient
snp
circul
level
correl
follow
biolog
clinic
paramet
fev
bodi
mass
index
bmi
glucos
toler
episod
pulmonari
exacerb
statist
analys
test
use
spss
result
subgroup
adult
patient
mean
age
year
mean
bmi
kgm
found
patient
express
genotyp
higher
level
blood
also
express
patient
like
episod
pulmonari
exacerb
also
observ
patient
lowest
valu
fev
tend
express
genotyp
conclus
preliminari
data
suggest
could
suscept
gene
modifi
gene
specif
genotyp
could
lead
increas
circul
level
preliminari
data
need
confirm
larger
cohort
patient
well
larger
independ
confirmatori
cohort
result
could
also
provid
inform
regard
role
cf
pathophysiolog
role
novel
biomark
diseas
evolut
acknowledg
support
cystic
fibrosi
canada
grant
postdoctor
fellowship
splice
variant
number
consequ
protein
synthesi
rang
product
protein
truncat
form
protein
reduc
quantiti
wildtyp
protein
differenti
among
possibl
essenti
design
test
therapeut
strategi
treat
splicesit
variant
splicesit
variant
permit
express
cftr
protein
whether
aberr
reduc
quantiti
normal
may
respond
corrector
andor
potenti
therapi
stratifi
molecular
consequ
splice
variant
creat
seri
express
minigen
emg
bear
put
diseas
associ
splicesit
variant
sourc
cfmd
variant
caus
splice
defect
one
spliceisoform
detect
variant
includ
six
leaki
variant
allow
product
reduc
amount
fulllength
cftr
mrna
g
g
c
legaci
nomenclatur
varieti
splice
defect
observ
exon
skip
n
variant
shorten
exon
variant
cryptic
splicesit
activ
intron
n
variant
complet
abridg
intron
retent
n
variant
effect
splice
variant
cftr
protein
product
process
evalu
western
blot
four
categori
observ
protein
n
variant
eg
ii
core
glycosyl
truncat
protein
variant
eg
iii
complex
glycosyl
truncat
protein
variant
eg
iv
complex
glycosyl
fulllength
protein
leaki
splice
variant
list
among
six
leaki
splice
variant
four
gener
full
length
cftr
band
c
less
wt
level
g
c
milder
phenotyp
associ
variant
except
one
consist
presenc
reduc
full
length
mrna
protein
evalu
feasibl
use
small
molecul
achiev
therapeut
level
chlorid
transport
perform
shortcircuit
current
isc
measur
mdck
flpin
stabl
cell
line
express
g
variant
cell
treat
either
corrector
molecul
potenti
molecul
ad
isc
measur
apic
side
transwel
isc
valu
observ
variant
g
rel
wt
untreat
result
suggest
patient
carri
leaki
splice
site
variant
benefit
combin
corrector
potenti
rather
potenti
alon
treatment
strategi
could
also
benefit
splice
site
variant
gener
core
eg
complex
glycosyl
truncat
protein
eg
work
support
cff
mdbr
nih
sever
amino
acid
residu
found
transmembran
domain
line
cftr
channel
pore
involv
ion
conduct
cftr
bear
diseasecaus
amino
acid
substitut
express
fischer
rat
thyroid
frt
cell
minim
forskolinactiv
chlorid
transport
minim
respons
lack
chlorid
conduct
surpris
variant
associ
milder
phenotyp
due
low
rate
pancreat
insuffici
pi
lack
respons
variant
also
surpris
variant
gener
matur
cftr
protein
cell
cultur
explor
discrep
sought
test
variant
use
airway
epitheli
cell
line
gener
stabl
express
singl
copi
cftr
cdna
contain
variant
western
blot
use
antibodi
unc
use
quantifi
amount
cftr
produc
assess
degre
process
ccb
ratio
uss
chamber
use
measur
short
circuit
current
sc
activ
cftr
chlorid
transport
forskolin
stimul
inhibit
effect
corrector
measur
incub
equal
volum
dmso
express
fulli
process
cftr
indistinguish
wt
show
reduc
protein
level
process
report
frt
hela
cell
contrast
frt
cell
variant
test
gener
forskolinstimul
current
rang
wt
consist
mild
clinic
present
patient
variant
unlik
partial
function
cftr
variant
variant
demonstr
minim
respons
consist
data
frt
cell
notabl
respons
variant
corrector
consist
across
variant
show
chang
protein
fold
process
sc
signific
respons
either
corrector
contrast
use
cell
incub
corrector
increas
protein
level
dmso
wt
increas
ccb
ratio
dmso
forskolinstimul
chlorid
current
increas
dmso
wt
increas
current
result
total
current
wt
case
correct
protein
fold
gener
properli
process
cftr
significantli
improv
conduct
respons
stark
contrast
demonstr
increas
conduct
respons
even
though
abl
gener
properli
process
cftr
inspect
locat
nonrespond
residu
reveal
predict
line
channel
pore
activ
particip
ion
conduct
evid
publish
suggest
hypothes
cftr
variant
residu
directli
involv
ion
conduct
compris
uniqu
theratyp
may
requir
new
class
molecular
therapi
extens
phenotyp
variabl
observ
cf
patient
homozyg
common
cfcaus
variant
determin
whether
variant
cftr
locu
contribut
phenotyp
variabl
also
inform
search
small
molecul
therapi
target
cftr
systemat
investig
genet
variat
present
cf
allel
bear
overarch
goal
identifi
variant
combin
variant
modifi
diseas
sever
associ
mutat
perform
deep
resequenc
intragen
extragen
region
surround
cftr
chromosom
phase
encompass
cftr
extend
kb
kb
gene
sequenc
homozygot
select
extrem
sweat
chlorid
concentr
phase
kb
region
includ
entir
topolog
associ
domain
cftr
sequenc
homozygot
drawn
extrem
lung
function
total
variant
observ
common
variant
maf
test
associ
sweat
chlorid
concentr
lung
function
singl
variant
associ
test
reveal
signific
associ
either
trait
increas
power
detect
rare
variant
associ
cohort
regionbas
burden
assay
use
skato
algorithm
perform
identifi
group
variant
associ
trait
variat
variant
test
associ
sweat
chlorid
lung
function
group
defin
seri
overlap
window
offset
increment
window
gener
test
pvalu
pvalu
bonferroni
correct
multipl
test
base
total
number
uniqu
window
assay
test
common
rare
variant
reveal
seven
region
signific
p
five
overlap
known
regulatori
element
chromatin
interact
notabl
one
region
associ
sweat
chlorid
concentr
lung
function
region
upstream
cftr
shown
interact
cftr
promotor
chromatin
interact
studi
three
addit
region
associ
sweat
chlorid
concentr
two
addit
region
associ
lung
function
collect
find
suggest
combin
rare
common
variat
within
known
suspect
regulatori
region
cftr
locu
may
contribut
phenotyp
heterogen
observ
homozyg
patient
variant
loci
may
modifi
cftr
express
level
andor
time
express
inform
futur
studi
regulatori
architectur
cftr
locu
ration
design
specif
molecular
therapi
support
cff
nih
innogenet
holog
implement
current
holog
panel
infant
state
il
irt
measur
top
specimen
day
screen
variant
variant
origin
describ
mild
mutat
associ
congenit
bilater
absenc
va
deferen
cbavd
men
howev
evalu
introduc
possibl
variant
like
benign
polymorph
diseasecaus
individu
unless
pair
cf
mutat
allel
specif
recent
studi
indic
tripl
complex
allel
includ
variant
may
respons
diseas
phenotyp
method
databas
establish
onset
cf
nb
track
outcom
infant
seen
ann
robert
h
luri
children
hospit
followup
posit
cf
nb
retrospect
chart
review
perform
infant
abnorm
cf
nb
receiv
followup
care
institut
sinc
decemb
use
current
holog
molecular
screen
panel
descript
statist
perform
result
sinc
implement
current
holog
panel
decemb
infant
refer
ann
robert
h
luri
children
hospit
chicago
followup
posit
cf
nb
total
infant
identifi
heterozyg
variant
without
second
mutat
heterozygot
carrier
variant
normal
followup
sweat
test
four
addit
infant
identifi
carri
variant
combin
known
cf
mutat
four
infant
three
normal
followup
sweat
test
one
posit
sweat
test
follow
intermedi
sweat
test
current
diagnosi
cftrrelat
metabol
syndrom
crm
note
infant
subsequ
determin
tripl
complex
allel
addit
known
cf
mutat
full
gene
sequenc
offer
remain
three
famili
despit
normal
sweat
test
two
famili
declin
addit
genet
remain
infant
also
found
carri
tripl
complex
allel
combin
mutat
conclus
overal
find
consist
previou
studi
regard
classif
variant
given
emot
duress
associ
posit
cf
nb
well
establish
literatur
reconsider
given
valu
includ
infant
heterozyg
variant
absenc
known
cf
mutat
posit
cf
newborn
screen
pool
gene
close
structur
function
associ
cftr
gene
increas
express
thought
play
role
diseas
manifest
cystic
fibrosi
cf
inherit
multisystem
diseas
character
progress
deterior
lung
function
pancreat
insuffici
attribut
dysfunct
singl
gene
encod
cystic
fibrosi
transmembran
conduct
regul
cftr
correl
cftr
genotyp
clinic
sever
poor
regard
cf
lung
diseas
variabl
clinic
cours
even
patient
cftr
mutat
suggest
modifi
gene
andor
epigenet
modif
impact
diseas
sever
object
analyz
promot
snp
methyl
statu
among
cf
proband
sibl
parent
differ
cftr
genotyp
correl
sever
lung
diseas
defin
chang
forc
expiratori
volum
second
respons
antibiot
sweat
chlorid
level
time
diagnosi
cftr
genotyp
method
analyz
proband
cf
sibl
parent
follow
children
hospit
wisconsin
luri
children
cf
center
symptom
medic
histori
record
via
questionnair
enter
databas
valid
red
cap
use
cf
foundat
patient
registri
inform
data
variabl
collect
includ
patient
demograph
sweat
chlorid
level
age
diagnosi
growth
lung
function
respiratori
microbiolog
cf
therapi
particip
genotyp
snp
methyl
statu
analyz
sibl
analys
incorpor
gener
estim
equat
account
related
sibl
pair
analys
use
logist
regress
associ
analysi
result
plasmainduc
transcript
profil
cf
patient
cftr
mutat
display
differenti
express
log
ratio
fdr
among
proband
sibl
parent
suggest
genet
environment
factor
influenc
cf
phenotyp
ongo
work
target
deriv
genet
epigenet
data
promot
region
cf
proband
sibl
parent
use
develop
molecularbas
method
conclus
subfamili
c
member
atpfind
cassett
abc
transport
gene
cftr
uniqu
among
abc
subfamili
c
member
transport
due
intrins
abil
conduct
chlorid
ion
much
faster
rate
share
closest
homolog
known
interact
cftr
snp
rs
fall
put
promot
gene
suggest
regulatori
effect
express
correl
lung
diseas
sever
futur
studi
involv
analysi
context
chromatin
state
dnase
hypersensit
transcript
factor
bind
data
enabl
us
associ
potenti
function
snp
influenc
express
level
diseas
sever
spatial
tempor
regul
cystic
fibrosi
transmembran
conduct
regul
gene
cftr
endodermderiv
cell
type
tightli
regul
cell
type
lung
epithelium
show
dynam
differ
rna
level
develop
addit
base
rnaseq
express
valu
read
per
kilobas
per
million
rpkm
adult
epitheli
tissu
cftr
express
broad
rang
level
low
lung
epitheli
rpkm
modest
express
pancreat
epitheli
rpmk
intermedi
level
salivari
gland
colon
tissu
rpmk
low
express
cftr
lung
tissu
lead
fewer
cftr
protein
correct
pharmacolog
exist
futur
therapi
therefor
method
increas
amount
cftr
rna
thu
cftr
protein
would
increas
pool
correct
protein
small
molecul
combin
synthet
dna
bind
protein
crispr
associ
protein
enzym
activ
transcript
target
gene
advantag
synthet
approach
allow
specif
robust
activ
without
reli
endogen
cofactor
util
base
method
synthet
upregul
cftr
express
adult
lung
epithelium
cell
line
lesser
extent
pancreat
cell
line
current
explor
tunabl
synthet
cftr
activ
method
determin
predict
control
amount
cftr
rna
produc
differ
epitheli
cell
type
result
show
altern
method
cftr
modul
well
avenu
better
quantit
understand
cftr
mrna
level
cellular
function
introduct
airliquid
interfac
ali
cultur
mucociliari
differenti
airway
epitheli
cell
wellestablish
model
determin
cftr
function
cftr
modul
respons
nasal
turbin
easi
access
sourc
airway
epitheli
cell
howev
despit
report
use
nasal
airway
epitheli
cell
naec
differenti
cell
alicultur
less
effici
compar
lower
airway
epitheli
cell
therefor
aim
optim
differenti
naec
alicultur
use
small
molecul
ttnpb
studi
part
hitcf
program
method
bronchial
airway
epitheli
cell
baec
obtain
tumorfre
lung
resect
materi
naec
obtain
nasal
brush
airway
epitheli
basal
cell
isol
donor
materi
expand
use
mitot
inactiv
mous
fibroblast
feeder
cell
alicultur
expand
cell
perform
previous
describ
amatngalim
gd
et
al
j
immunol
instead
retino
acid
use
small
molecul
ttnpb
highli
potent
retino
acid
analog
moreov
use
rock
inhibitor
submerg
cultur
phase
explor
effect
tgfbeta
inhibit
use
inhibitor
result
baec
effici
differenti
combin
ttnpb
contrast
naec
reach
full
confluenc
submerg
phase
display
long
stretch
squamou
morpholog
upon
week
ali
cultur
includ
submerg
phase
cultur
drastic
improv
naec
confluenc
monolay
display
similar
cuboid
cell
morpholog
baec
cultur
moreov
includ
combin
ttnpb
aliphas
increas
transepitheli
electr
resist
prevent
occurr
squamou
cell
mucin
deposit
apic
compart
ciliari
beat
observ
week
cultur
conclus
replac
retino
acid
ttnpb
includ
improv
mucociliari
differenti
naec
similar
extent
baec
improv
protocol
use
novel
combin
small
molecul
use
effici
differenti
naec
usag
cell
cftr
function
measur
introduct
novel
cf
therapi
correct
molecular
defect
limit
number
cftr
mutat
expand
drug
patient
rarenovel
mutat
facilit
patientderiv
model
system
quantifi
cftr
restor
model
base
nasal
epitheli
cell
nec
may
provid
noninvas
portabl
option
modul
test
sought
develop
reliabl
necderiv
model
system
quantifi
cftr
function
modul
method
nec
obtain
inferior
turbin
curettag
healthi
volunt
patient
cf
expand
confluenc
condit
reprogram
cultur
condit
previous
describ
liu
x
et
al
j
pathol
passag
cell
suspend
matrigel
fed
daili
ultroserg
airway
differenti
media
matur
day
matur
sphere
imag
incub
chamber
stimul
forskolinibmx
rais
camp
activ
cftr
lumin
area
preand
poststimul
sphere
measur
percent
chang
calcul
sphere
per
condit
result
nec
sphere
form
within
day
plate
reliabl
polar
apic
cell
surfac
toward
sphere
lumen
sphere
demonstr
marker
matur
respiratori
epithelium
includ
lumin
ciliamucu
secret
tight
junction
cftr
across
donorscondit
stimul
function
cftr
led
lumin
ionfluid
secret
sphere
swell
stimul
dysfunct
cftr
led
reduc
swell
shrink
specif
wtcftr
sphere
swell
stimul
shrank
stimul
treatment
cftr
inhibitor
donor
p
untreat
homozyg
sphere
shrank
stimul
revers
swell
pretreat
donor
p
incub
c
donor
trend
recapitul
sphere
deriv
wt
cftr
laec
sphere
partialfunct
mutat
swell
intermedi
noncf
control
sphere
donor
sphere
heterozyg
gate
mutat
show
increas
swell
follow
stimul
treat
vs
without
sphere
two
patient
one
copi
second
process
mutat
respond
robustli
vs
baselin
vs
baselin
conclus
human
nec
spheroid
abl
reliabl
differenti
spectrum
cftr
activ
normal
wtcftr
partial
nearabs
homozygot
function
sphere
patient
homozyg
gate
mutat
respond
appropri
modul
recapitul
clinic
efficaci
ex
vivo
model
system
addit
sphere
select
patient
rare
cftr
mutat
respond
robustli
avail
modul
suggest
potenti
gateway
logic
assess
therapi
patient
model
hold
promis
person
test
cftr
modul
drive
therapeut
evalu
support
cfft
introduct
cystic
fibrosi
cf
caus
mutat
cftr
gene
result
lack
function
cftr
channel
transport
cland
hco
across
apic
membran
epitheli
tissu
cf
airway
character
diminish
hydrat
epitheli
surfac
alter
mucu
viscoelast
impair
mucociliari
clearanc
enhanc
surfac
hydrat
facilit
airway
clearanc
improv
viscoelast
properti
mucu
current
accur
relev
preclin
model
predict
rescu
mucu
properti
cf
therapeut
avail
util
measur
viscoelast
mucu
properti
nasal
bronchial
organoid
predict
outcom
pharmacolog
treatment
thu
offer
advanc
translat
model
preclin
test
aim
research
develop
involv
cftr
modul
compound
rapidli
acceler
addit
cftrtarget
drug
epitheli
na
channel
enac
inhibitor
mucolyt
may
benefit
cf
patient
affect
cf
airway
hydrat
mucu
structur
composit
goal
studi
develop
util
preclin
assay
leverag
nasal
bronchial
organoid
obtain
insight
activ
agent
cf
mucu
viscoelast
transport
cf
furthermor
evalu
properti
organoid
mucu
person
measur
diseas
sever
method
chang
viscoelast
properti
nasal
bronchial
spheroid
mucu
determin
util
particl
track
microrheolog
ptm
fluoresc
passiv
tracer
particl
introduc
lumen
spheroid
video
tracer
particl
motion
obtain
frequencydepend
viscoelast
properti
tracer
particl
local
environ
calcul
describ
recent
particl
track
microrheolog
measur
spheroid
demonstr
fluoresc
microspher
deliv
spheroid
lumen
either
cocultur
inject
track
assess
alter
mucu
viscoelast
properti
upon
activ
cftr
result
clearli
indic
cftr
function
affect
mucu
viscoelast
properti
activ
cftr
function
result
decreas
mucu
viscos
elast
across
broad
rang
biolog
relev
frequenc
compar
vehicl
control
conclus
viscoelast
properti
organoid
mucu
precis
biologicallyrelev
predictor
clinic
efficaci
ion
channeland
mucustarget
pharmacolog
treatment
implement
preclin
organoid
mucu
assay
allow
accur
predict
clinic
outcom
cf
drug
essenti
identifi
success
therapi
individu
tailor
treat
cf
patient
support
nih
cff
rational
cf
mous
model
wide
use
cf
research
recapitul
mani
diseas
manifest
cf
observ
patient
includ
diseas
aspect
gastrointestin
immun
pulmonari
epitheli
endocrin
reproduct
system
sinc
public
first
cf
mous
model
least
cf
mous
model
publish
util
cf
research
commun
provid
new
understand
cf
abil
test
therapeut
strategi
vivo
cf
mous
model
prove
use
convent
gene
target
method
defici
includ
use
select
marker
affect
cftr
express
allow
gene
target
desir
genet
background
lead
lengthi
process
last
year
new
gene
edit
system
crisprca
util
creat
specif
gene
mutat
faster
without
issu
convent
gene
target
aim
studi
util
crisprca
system
make
three
common
mutat
mous
cftr
util
vivo
studi
cf
research
commun
method
creat
three
cftr
mutat
guid
rna
grna
direct
nucleas
specif
dna
sequenc
evalu
util
vitro
transcript
screen
system
optim
grna
oligonucleotid
carri
desir
cftr
mutat
inject
onecel
mous
embryo
background
implant
pseudopregn
mice
cwru
transgen
target
facil
dna
result
pup
three
line
sequenc
use
next
gener
sequenc
miseq
instrument
allow
accur
identif
mutat
present
identifi
mate
founder
creat
line
mutat
result
creation
strain
identifi
mice
cftr
mutat
contain
mutat
creation
strain
identifi
mice
cftr
mutat
contain
mutat
creation
strain
identifi
mice
cftr
mutat
contain
mutat
strain
display
reduc
cftr
function
mild
cf
manifest
similar
cftr
mous
intestin
shortcircuit
current
measur
intestin
section
significantli
reduc
mice
compar
wildtyp
mice
vs
cm
p
weight
mice
reduc
age
compar
wildtyp
p
surviv
similar
cf
manifest
strain
current
assess
creat
three
cftr
mutat
mous
util
crisprca
gene
edit
system
mutat
creat
high
rate
short
time
period
compar
convent
gene
target
method
model
use
vivo
test
cftrdirect
therapi
strategi
develop
bronchiectasi
cf
patient
thought
occur
result
lifelong
cycl
infect
inflamm
symptomat
treatment
antibiot
significantli
prolong
life
cf
patient
howev
emerg
multipl
antibioticresist
strain
still
plagu
cf
clinic
care
cf
ferret
model
provid
opportun
studi
develop
bacteri
antibiot
resist
bronchiectasi
experiment
set
free
preexist
multidrug
resist
bacteri
strain
method
matur
year
old
cohort
cftrko
ferret
agetreatmentmatch
control
maintain
birth
combin
antibiot
twice
daili
piperacillintazobactam
mgkg
enrofloxacin
mgkg
metronidazol
mgkg
underw
longitudin
bronchoscop
collect
bronchoalveolar
lavag
fluid
balf
along
highresolut
ct
imag
imag
quantifi
standard
fashion
incorpor
data
one
scan
anim
balf
assay
cultur
bacteria
cfuml
interrog
rdna
bacteri
genom
mean
qpcr
fungal
pathogen
undergo
investig
use
select
cultur
method
qualit
pcr
balf
sampl
result
ct
imag
cohort
demonstr
develop
sever
structur
lung
diseas
consist
bronchiectasi
cf
ferret
compar
agetreatmentmatch
control
cf
cartilagin
airway
larger
adjac
vessel
ratio
vs
extend
closer
pleura
vs
bronchial
wall
thicker
upper
lobe
vs
imag
untreat
wildtyp
ferret
demonstr
differ
endpoint
treat
noncf
control
balf
cf
control
anim
prolong
period
time
reveal
bacteri
burden
differ
except
one
cf
anim
transient
colon
two
sequenti
balf
collect
infect
spontan
resolv
total
cohort
bacteri
burden
cfuml
rdna
bacteri
genom
quantif
significantli
differ
respect
sever
mucu
plug
lung
one
cf
ferret
occur
twice
treat
novel
mucolyt
paag
synedgen
inc
subsequ
aerosol
paag
treatment
anim
prevent
reoccurr
neutrophil
count
balf
cf
anim
elev
proteom
analysi
balf
demonstr
enhanc
mucu
inflammatori
protein
cf
anim
discuss
result
suggest
cf
bronchiectasi
evolv
absenc
bacteri
colon
hypothes
mucu
impact
secondari
impair
clearanc
enhanc
inflamm
even
absenc
bacteri
infect
process
lead
structur
chang
cf
lung
broaden
diseas
detect
character
earlystag
window
potenti
therapeut
intervent
still
challeng
incomplet
understand
pathophysiolog
earlycf
lung
thu
anim
model
need
effect
recapitul
pulmonari
phenotyp
characterist
earlystag
diseas
method
investig
young
cf
mice
determin
exhibit
pulmonari
phenotyp
consist
earli
cf
lung
diseas
pulmonari
mechan
examin
week
old
congen
cf
mice
use
forc
oscil
techniqu
flexiv
gross
histolog
measur
larg
small
airway
quantifi
via
light
microscopi
alveolar
duct
sac
distal
airspac
calcul
report
mean
linear
intercept
mli
result
signific
differ
resist
measur
lumin
diamet
larg
airway
bronchiol
termin
bronchiol
respiratori
bronchiol
howev
cf
mous
model
promin
differ
mechan
properti
peripher
lung
compart
identifi
static
lung
complianc
decreas
mlcmh
mlcmh
p
compar
wildtyp
wt
control
mlcmh
tissu
elast
increas
cmh
oml
cmh
oml
p
compar
wt
cmh
oml
tissu
damp
also
increas
cf
model
cmh
oml
cmh
oml
compar
wt
cmh
oml
lastli
cf
mice
exhibit
distal
airspac
enlarg
significantli
increas
mean
linear
intercept
mm
p
mm
p
compar
wt
mm
conclus
peripher
lung
young
cf
mice
carri
two
independ
cftr
mutat
demonstr
impair
abil
stretch
expand
reveal
measur
differ
larg
conduct
airway
furthermor
significantli
increas
distanc
ga
exchang
surfac
alveolar
sac
duct
cf
mous
parenchyma
find
consist
earli
develop
diseas
peripher
lung
compart
absenc
infect
inflammatori
symptom
provid
compel
framework
establish
cf
mous
model
repres
earli
lung
phenotyp
cf
patient
test
stimul
sweat
secret
provid
real
time
assay
base
function
cystic
fibrosi
transmembran
conduct
regul
cftr
discrimin
cystic
fibrosi
cf
patient
healthi
control
therefor
sought
determin
feasibl
safeti
efficaci
assay
sweat
children
identifi
newborn
screen
help
determin
prognos
individu
cftrrelat
metabol
syndrom
crm
method
preschool
age
children
posit
newborn
screen
test
cf
particip
crosssect
studi
sweat
rate
measur
evaporimeteri
cyberderm
inc
transepiderm
water
loss
kg
h
om
hr
select
stimul
sweat
gland
either
cholinerg
net
peak
sweat
respons
assay
evapor
rate
compar
cf
crm
cohort
result
pilot
test
adult
children
year
age
evalu
cf
crm
test
protocol
well
toler
electrocardiogram
vital
sign
within
normal
rang
subject
mean
evapor
sweat
rate
group
respons
cholinerg
stimul
similar
cf
crm
p
well
stimul
cf
crm
p
sweat
test
safe
well
toler
young
children
howev
sweat
secret
rate
measur
evaporimeteri
small
discrimin
cf
crm
cohort
introduct
mous
model
human
diseas
power
tool
enabl
studi
complex
mechan
evalu
potenti
novel
therapi
unfortun
cftr
defici
mous
develop
spontan
lung
diseas
two
mous
model
result
cflike
lung
diseas
due
upregul
enac
airway
epitheli
cell
aec
hypothes
enac
hyperact
lead
mucu
dehydr
accumul
cf
patient
increas
enac
level
lung
mall
et
al
nat
med
delet
ubiquitin
ligas
control
level
enac
cell
surfac
airway
epitheli
cell
aec
demonstr
increas
level
enac
express
result
cystic
fibrosislik
diseas
kimura
et
al
pna
aec
specif
knockout
result
asl
deplet
reduc
mucu
transport
goblet
cell
metaplasia
mucu
accumul
massiv
inflamm
fibrosi
death
week
age
evalu
antisens
strategi
establish
adultonset
cystic
fibrosi
mous
model
object
target
aec
antisens
oligonucleotid
aso
deliveri
lung
adult
mice
goal
creat
late
onset
mous
model
cystic
fibrosi
method
identifi
sever
specif
aso
assess
effect
reduc
target
mrna
level
cell
cultur
potent
aso
test
intratrach
instil
lung
adult
mice
lung
fraction
densiti
gradient
mrna
sever
gene
involv
mucu
product
assess
rtpcr
enac
protein
level
determin
western
analysi
lung
process
histopatholog
result
deliv
specif
aso
directli
lung
normal
adult
mice
administr
week
six
week
result
rna
knockdown
increas
enac
protein
began
increas
earli
day
initi
aso
dose
rna
level
mucu
marker
includ
spdef
significantli
increas
aso
treatment
passtain
lung
section
timecours
asotr
mice
demonstr
goblet
cell
number
mucu
accumul
begin
dose
aso
reach
maximum
level
week
dose
inflamm
also
increas
throughout
lung
week
abil
aso
induc
goblet
cell
metaplasia
specif
effect
control
aso
effect
addit
test
abil
aso
induc
airway
hyperrespons
ahr
find
dose
respons
increas
methacholin
compar
vehicletr
mice
mice
treat
aso
week
follow
discontinu
dose
still
exhibit
lung
histopatholog
ahr
week
week
stop
dose
conclus
mani
endpoint
observ
knockout
mice
cf
patient
reproduc
asoinduc
model
therefor
model
may
use
evalu
novel
therapi
adult
onset
cflike
diseas
rational
patientderiv
model
system
need
examin
activ
modul
agent
cf
patient
rare
cftr
mutat
bronchial
epitheli
cell
model
detect
quantifi
cftr
function
pharmacolog
modul
obtain
cell
invas
similar
model
system
brush
nasal
cell
attract
due
simplic
sampl
procur
seek
determin
electrophysiolog
behavior
pair
nasal
bronchial
cell
cf
patient
focus
modul
impact
cftr
function
method
cell
cf
patient
obtain
brush
gener
bronchi
inferior
nasal
turbin
cultur
petri
dish
media
upon
reach
confluenc
cell
passag
onto
collagenco
insert
matur
ultroserg
media
matur
insert
treat
vehicl
hour
studi
voltag
clamp
condit
short
circuit
current
monitor
uss
chamber
baselin
current
symmetr
ringer
buffer
follow
apic
exchang
low
cl
buffer
addit
amilorid
forskolinibmx
cftr
apic
except
apicalbasolater
forskolinibmx
result
nasal
bronchial
pair
brush
provid
eight
donor
three
pair
result
current
avail
report
baselin
resist
control
nasal
cell
monolay
cm
sd
cm
sd
bronchial
monolay
amiloridesensit
current
nasal
monolay
sd
sd
bronchial
monolay
magnitud
current
correct
greater
bronchial
monolay
nasal
monolay
within
subject
pair
correl
well
ident
perform
nasal
cell
monolay
appear
suitabl
proxi
brush
bronchial
cell
monolay
studi
cftr
modul
support
cfft
cough
clearanc
cc
import
airway
defens
mechan
enhanc
remov
accumul
mucu
lung
clinic
studi
reveal
cc
less
effect
clear
mucu
peopl
cf
compar
healthi
individu
howev
current
gap
knowledg
cc
defect
cf
therapeut
use
increas
cc
previou
studi
demonstr
cf
dysregul
ion
transport
ie
defect
cftr
lead
airway
fluid
deplet
mucin
hyperconcentr
impair
mucociliari
clearanc
eg
collaps
periciliari
layer
adhes
mucu
airway
surfac
layer
furthermor
properti
mucu
hypothes
heavili
influenc
two
major
gel
form
mucin
noncf
healthi
mucu
domin
clinic
studi
shown
express
upregul
cf
patient
acut
exacerb
therefor
hypothes
cc
control
larg
mucu
concentr
addit
depend
rel
absolut
amount
studi
effect
cfrelat
concentr
chang
mucu
properti
cough
clearanc
rate
develop
vitro
cough
machin
incorpor
welldifferenti
human
bronchial
epitheli
cultur
within
custom
chamber
use
subject
cultur
coughmimick
airflow
veloc
meter
per
second
studi
compar
effect
endogen
mucu
rang
mucu
concentr
span
healthi
cf
well
exogen
mucu
differ
ratio
cc
mucu
captur
track
movement
particl
embed
mucu
layer
hispe
camera
millisecond
airflow
puls
result
reveal
cc
critic
depend
upon
mucu
concentr
found
healthi
noncf
mucu
cough
produc
substanti
higher
clearanc
rate
transport
cilia
vs
howev
studi
demonstr
like
ciliamedi
mucu
clearanc
abil
clear
mucu
cough
also
significantli
reduc
mucu
becom
concentr
cf
studi
also
show
mucu
effect
clear
cough
support
hypothesi
import
clear
mucu
howev
cc
significantli
reduc
mucu
concentr
final
therapeut
prospect
use
novel
devic
show
cough
clearanc
acceler
combin
mucu
hydrat
hyperton
salin
reduc
agent
dtt
result
demonstr
util
model
system
robustli
assay
paramet
mediat
cc
health
fail
diseas
rel
effect
work
support
cfft
mucu
clearanc
consortium
cf
human
bronchial
epitheli
cf
hbe
cultur
demonstr
characterist
associ
cystic
fibrosi
pathophysiolog
defect
traffick
cftr
absenc
chlorid
transport
welldifferenti
cf
hbe
cell
may
cultur
filter
airliquid
interfac
ali
describ
neuberg
et
al
respons
corrector
compound
measur
use
equival
current
assay
develop
bridg
van
driessch
system
use
heavili
optim
corrector
increasingli
studi
mechan
rescu
evalu
influenc
filter
plate
made
differ
materi
pore
densiti
corrector
respons
differenti
state
cftr
level
ali
cultur
homozygot
cf
hbe
cell
differenti
standard
polyest
membran
support
corn
pore
x
porescm
compar
cell
differenti
polycarbon
membran
support
corn
pore
x
porescm
cultur
evalu
hematoxylin
eosin
h
e
stain
morpholog
pcr
cftr
mrna
level
differenti
marker
western
blot
cftr
protein
matur
equival
current
electrophysiolog
assay
basal
correctorinduc
respons
forskolin
potenti
amilorid
respons
transepitheli
resist
h
e
stain
reveal
cell
grown
polyest
membran
form
cuboid
epithelium
cell
grown
polycarbon
membran
form
pseudostratifi
columnar
epithelium
similar
natur
morpholog
lung
epithelium
cell
polycarbon
support
significantli
greater
cftr
activ
respons
corrector
treatment
polyest
support
increas
corrector
respons
observ
well
sever
corrector
scaffold
distinct
mechan
unexpectedli
biochem
character
cftr
reveal
increas
mrna
protein
level
explain
enhanc
function
activ
polycarbon
support
combin
signific
improv
cellular
differenti
corrector
respons
cf
hbe
cell
grown
polycarbon
filter
appear
offer
robust
physiolog
relev
system
studi
mechan
rescu
optim
corrector
mutat
common
prematur
termin
codon
ptc
cftr
second
common
cfcaus
allel
previous
show
yeast
oligomycin
member
abc
gene
famili
serv
use
model
genomewid
analysi
modifi
govern
biogenesi
work
demonstr
evolutionari
conserv
genegen
interact
yeast
human
result
discoveri
novel
target
improv
misfold
result
mutat
cerevisia
homolog
thu
use
phenom
model
identifi
gene
target
promot
readthrough
introduc
full
genom
collect
cerevisia
knockout
knockdown
ykokd
strain
perform
quantit
high
throughput
cell
array
phenotyp
qhtcp
measur
growth
oligomycin
endpoint
nonsens
codon
suppress
parallel
analysi
mutant
serv
control
effect
ykokd
mutat
oligomycin
sensit
aminoglycosid
readthrough
agent
increas
oligomycin
resist
context
effect
strain
similarli
exhibit
increas
fluoresc
cultur
support
use
genomewid
screen
analysi
across
complet
yeast
delet
strain
librari
concert
reveal
particip
nonsens
mediat
decay
nmd
pathway
known
target
readthrough
overal
discov
candid
gene
target
potent
delet
induc
full
length
gene
interact
test
thu
far
secondari
assay
readthrough
base
fluoresc
valid
primari
phenotyp
result
addit
test
hit
combin
epistasi
analysi
progress
also
ongo
use
technolog
establish
pharmacogenom
approach
determin
gene
respons
effect
readthrough
agent
taken
togeth
studi
describ
power
new
system
applic
cystic
fibrosi
drug
discoveri
diseas
cystic
fibrosi
cf
normal
water
salt
mucu
concentr
abnorm
normal
mucu
layer
becom
dehydr
compress
periciliari
gel
layer
collaps
cilia
prevent
normal
clearanc
properti
flow
mucu
layer
predict
heavili
influenc
two
major
gelform
mucin
data
cell
cultur
induc
secret
anim
model
suggest
form
basi
normal
flow
gel
howev
lung
irrit
allergi
pollut
andor
infect
level
increas
hypothes
ciliadepend
mucu
flow
cough
clearanc
control
differ
biophys
properti
mucu
layer
underli
periciliari
gel
layer
differ
biophys
properti
control
larg
mucu
concentr
biophys
properti
mucu
layer
modifi
rel
absolut
increas
provid
framework
allow
direct
comparison
biophys
properti
compar
develop
cell
defici
one
mucin
studi
util
delet
either
gener
monomucinproduc
cell
normal
produc
mucin
nearli
equal
ratio
result
western
blot
rtpcr
sequenc
mass
spectrometri
clonal
select
cell
confirm
monomucin
product
demonstr
util
genom
edit
gener
cell
model
lack
mucin
protein
mucin
collect
apic
wash
clonal
deriv
cell
line
collect
concentr
harvest
mucu
evalu
varieti
biophys
techniqu
includ
measur
adhes
cohes
strength
cough
clearanc
light
scatter
mucociliari
clearanc
light
scatter
demonstr
approxim
reduct
monomucin
concentr
compar
mucinsuffici
cell
consist
concept
mucu
produc
cell
contain
nearli
equal
proport
preliminari
studi
evalu
mucu
transport
ciliat
airway
cultur
indic
mucin
transport
less
effici
mucu
result
studi
help
elucid
complex
relationship
mucu
properti
mucin
composit
ultim
help
understand
mucu
pathogenesi
cf
birmingham
birmingham
al
usa
cystic
fibrosi
foundat
bethesda
md
usa
cincinnati
children
hospit
medic
center
cincinnati
oh
usa
univers
north
carolina
chapel
hill
chapel
hill
nc
usa
case
western
reserv
univers
cleveland
oh
usa
univers
pittsburgh
pittsburgh
pa
usa
background
human
airway
epitheli
hae
cell
differenti
monolay
form
basi
preclin
studi
mani
cftr
modul
hae
provid
mean
studi
diseas
mutationspecif
question
hae
especi
human
nasal
epitheli
hne
cell
easili
acquir
patient
variou
cftr
mutat
recent
advanc
allow
largescal
expans
cell
without
alter
cellular
genom
allow
establish
hne
biobank
possibl
concept
leverag
multipl
site
collect
hne
cell
observ
trial
tdn
object
studi
aim
demonstr
capac
largescal
collect
ship
expans
bank
hne
cell
divers
patient
popul
test
use
standard
procedur
condit
reprogram
via
fibroblast
cocultur
allow
expans
cell
biorepositori
cell
futur
use
method
site
train
patient
divers
cftr
mutat
normal
subject
hne
cell
collect
via
nasal
brush
curettag
hne
cell
ship
overnight
media
contain
antibiot
ceftazidim
tobramycin
vancomycin
ml
amphotericin
b
two
repositori
lab
process
cell
use
multipl
centrifug
includ
dissolut
mucu
clump
accutas
cell
ad
coat
dish
adher
irradi
fmedia
rhokinas
inhibitor
ad
daili
epitheli
island
form
confluent
dish
thereaft
cell
passag
twice
expand
cell
cryopreserv
freez
media
cellsaliquot
result
part
prospect
studi
normal
cf
sampl
receiv
central
process
lab
site
particip
studi
via
cytolog
brush
sampl
contain
viabl
cell
suitabl
initi
cultur
viabl
cell
pellet
obtain
free
initi
infect
allow
expans
mean
initi
viabl
cell
pellet
contain
cell
cell
expand
split
mean
day
passag
passag
mean
estim
cell
count
cell
test
viabil
freez
frozen
cell
pellet
demonstr
viabl
cell
reexpans
cell
viabl
trypan
blue
stain
defrost
conclus
demonstr
feasibl
acquisit
expans
hne
cell
divers
subject
although
initi
cell
collect
rel
low
number
viabl
cell
demonstr
abil
expand
cell
signific
quantiti
viabl
cell
suitabl
biorepositori
storag
focus
effort
increas
yield
also
focus
optim
protocol
ion
transport
mucociliari
differenti
support
cfft
cff
nih
introduct
determin
effect
put
cf
cell
gene
therapi
improv
cftr
ion
channel
defect
live
intact
cf
mice
use
wellestablish
transepitheli
potenti
differ
pd
techniqu
nasal
airway
mice
orient
vertic
enabl
placement
electrod
tip
nare
onto
ciliat
epithelium
method
use
slow
infus
rate
sequenti
kreb
buffer
flowrat
limit
larg
abil
anim
cope
fluid
volum
deliv
assess
rapid
pd
protocol
use
higher
fluid
rate
mice
nonsurg
intub
elimin
fluid
ingress
lung
method
normal
cf
uncfabp
mice
anaesthetis
nonsurg
intub
cannula
bd
insyt
tm
iv
cathet
permit
normal
breath
perfus
solut
deliveri
first
examin
feasibl
infus
rate
compar
standard
anim
use
normal
basal
b
low
chlorid
lc
kerb
buffer
determin
optim
flow
rate
standard
slow
infus
rate
compar
optim
infus
rate
normal
cf
mice
use
addit
sodium
channel
blocker
amilorid
isoproterenol
iso
sequenc
nasal
perfus
b
ba
lca
lcaiso
buffer
perform
week
apart
allow
complet
recoveri
airway
epithelium
physic
disturb
may
occur
due
previou
placement
recordingperfus
cannula
result
signific
differ
chang
nasal
pd
normal
mice
lc
condit
faster
infus
rate
compar
standard
rate
ns
anova
optim
flow
rate
rapid
consist
stabilis
pd
record
infus
rate
result
typic
reduct
pd
assess
time
min
test
rate
cf
mice
display
signific
differ
nasal
pd
respons
lca
perfus
normal
mice
mean
sem
mv
vs
cf
mice
mv
p
pair
ttest
differ
maintain
irrespect
infus
rate
ns
pair
ttest
addit
iso
lca
perfus
also
demonstr
signific
differ
normal
mice
cf
mice
p
ttest
discuss
rapid
infus
method
conjunct
nonsurg
intub
provid
similar
pd
measur
capabl
much
slower
establish
method
elimin
potenti
advers
effect
due
fluid
inhal
improv
pd
assess
throughput
reduc
anaesthesia
time
fluid
load
requir
allow
inclus
addit
perfus
solut
discrimin
specif
chang
bioelectr
defect
respons
cf
chang
improv
qualiti
speed
nasal
pd
protocol
vivo
assess
new
therapi
correct
basic
defect
cf
airway
acknowledg
support
usa
cf
foundat
foundat
nhmrc
intestin
organoid
use
studi
cftr
function
mean
cftrdepend
forskolininduc
swell
fi
matrigel
cultur
condit
fi
organoid
clearli
differ
organoid
mild
sever
even
ident
cfcaus
mutat
exact
mechan
caus
differ
swell
remain
incomplet
understood
addit
cultur
approach
assay
may
help
studi
mechan
control
differ
organoid
swell
relat
phenotyp
cftr
ion
channel
activ
aim
set
altern
cftr
assay
use
intestin
monolay
gener
rectal
organoid
cultur
hypothes
cftr
genotypespecif
differ
organoid
swell
reflect
forskolininduc
current
monolay
studi
part
hitcf
program
organoid
gener
previous
describ
adapt
monolay
cultur
method
publish
uss
chamber
measur
perform
monolay
six
cftr
genotyp
wildtyp
carrier
monolay
gener
disrupt
trypsin
organoid
seed
singl
cell
onto
precoat
transwel
insert
plu
organoid
cultur
medium
rock
inhibitor
monitor
transepitheli
electr
resist
teer
valu
day
resist
ohmcm
insert
transfer
uss
chamber
monitor
shortcircuit
voltageclamp
transepitheli
ion
transport
addit
amilorid
forskolin
dose
rang
cftr
inh
dose
rang
everi
cftr
genotyp
measur
two
four
independ
experi
two
donor
forskolin
dosedepend
induc
transepitheli
ion
transport
cftrdepend
manner
indic
inhibit
upon
addit
cftr
inh
absenc
current
cftr
class
iclass
monolay
respons
forskolin
monolay
lie
like
fi
howev
sensit
assay
seem
reduc
compar
fi
respons
forskolin
minor
compar
fi
genotyp
respond
compar
also
distinguish
wild
type
base
forskolin
respons
data
suggest
monolay
gener
rectal
organoid
use
studi
function
cftr
uss
chamber
current
preliminari
data
suggest
setup
help
complement
fi
studi
allow
direct
studi
ion
channel
activ
independ
coupl
fluid
secret
via
select
stimul
apic
basolater
compart
jerusalem
israel
cf
center
sheba
medic
center
tel
hashom
israel
cf
center
rambam
medic
center
haifa
israel
cf
center
carmel
medic
center
haifa
israel
cf
center
shaar
zedek
medic
center
jerusalem
israel
cf
center
soroka
medic
center
beersheva
israel
cf
center
schneider
children
hospit
petach
tiqva
israel
cystic
fibrosi
associ
defect
campmedi
cftr
cl
secret
acceler
rate
basal
na
transport
across
epitheli
membran
result
chang
transepitheli
potenti
differ
pd
measur
nasal
epithelium
npd
sweat
chlorid
concentr
still
gold
standard
diagnosi
cf
new
cf
phenotyp
recogn
eg
cystic
fibrosi
transmembran
conduct
regul
cftr
relat
disord
emerg
number
nonclass
atyp
phenotyp
patient
uncertain
diagnos
repres
challeng
aim
studi
compar
diagnost
outcom
cohort
patient
refer
electrophysiolog
test
method
patient
suspect
cf
refer
sweat
test
gibson
cook
macroduct
npd
knowl
one
tertiari
center
sweat
test
defin
normal
borderlin
posit
measur
e
defin
abnorm
npd
e
defin
normal
npd
final
diagnosi
defin
registr
isra
cf
registri
result
patient
underw
npd
sweat
test
sweat
patient
normal
npd
abnorm
cf
registri
diagnos
abnorm
cf
registri
sensit
npd
specif
neg
predict
valu
better
sweat
test
sensit
specif
neg
predict
valu
patient
normal
sweat
test
abnorm
npd
regist
cf
patient
posit
sweat
test
normal
npd
cf
registri
sensit
npd
group
specif
posit
predict
valu
neg
predict
valu
patient
borderlin
sweat
test
normal
npd
registri
patient
abnorm
npd
registri
conclus
patient
question
diagnosi
cf
npd
use
best
rule
diagnosi
presenc
fals
posit
sweat
test
bo
ac
tidden
h
pediatr
pulmonolog
radiolog
erasmu
mcsophia
children
hospit
rotterdam
netherland
background
cystic
fibrosi
cf
progress
small
airway
diseas
sad
mucu
impact
play
major
role
pathophysiolog
cf
lung
diseas
inhal
dornas
alfa
success
improv
sad
howev
residu
sad
persist
progress
age
patient
cf
akita
nebul
allow
effici
target
small
airway
improv
sad
substanti
stabl
patient
cf
mainten
dornas
alfa
therapi
patient
admit
exacerb
comput
fluid
dynam
cfd
show
inhal
antibiot
concentr
invers
relat
sever
structur
chang
seen
chest
ctscan
cfd
allow
us
person
aerosol
deliveri
strategi
dornas
alfa
effect
treatment
sad
take
account
presenc
structur
lung
chang
predict
local
dornas
alfa
concentr
airway
patient
cf
differ
diseas
sever
nebul
akita
target
small
airway
pari
lc
plu
pari
eflow
nebul
method
cfd
appli
patientspecif
airway
model
reconstruct
chest
ctscan
reconstruct
airway
model
simul
perform
fluidda
nv
kontich
belgium
follow
inform
use
simul
nebul
dornas
alfa
mg
akita
mg
pari
lc
plu
pari
eflow
aerosol
diamet
epitheli
line
fluid
thick
concentr
express
rel
effect
dornas
alfa
concentr
result
report
median
rang
result
ctscan
male
select
age
year
cfct
bronchiectasi
subscor
max
pred
akita
result
significantli
higher
dornas
alfa
concentr
small
airway
nebul
p
half
nebul
dose
larg
airway
concentr
akita
time
higher
pari
lc
plu
pari
eflow
respect
small
airway
concentr
time
higher
nebul
akita
pari
lc
plu
pari
eflow
concentr
small
airway
combin
time
akita
time
pari
lc
plu
pari
eflow
look
separ
lung
lobe
sever
lobe
receiv
dornas
alfa
concentr
pari
lc
plu
pari
eflow
conclus
cfd
model
show
airway
receiv
suffici
dornas
alfa
concentr
half
dose
nebul
akita
result
small
airway
dornas
alfa
concentr
time
higher
pari
lc
plu
pari
eflow
nebul
promis
improv
sad
patient
sever
cf
lung
diseas
research
fund
financi
support
provid
roch
pharmaceut
smallmolecul
corrector
cftr
misfold
develop
therapi
cystic
fibrosi
corrector
activ
assay
cell
line
express
recombin
cftr
well
patientderiv
primari
cell
howev
poor
correl
cell
line
assay
primari
cell
assay
necessit
use
patient
bronchial
epitheli
cell
assay
optim
corrector
compound
cultur
welldifferenti
cf
human
bronchial
epitheli
cf
hbe
cell
requir
signific
invest
time
effort
well
use
reagent
cell
limit
avail
high
cost
assay
corrector
activ
perform
semiautom
format
equival
current
assay
use
equip
method
develop
bridg
van
driessch
assay
great
improv
electrophysiolog
assay
uss
chamber
still
remain
laborintens
author
implement
sever
improv
cultur
differenti
protocol
develop
neuberg
et
al
equival
current
assay
method
develop
bridg
van
driessch
industri
set
result
effici
use
limit
avail
cf
patient
cell
reduct
workload
gener
reproduc
corrector
doserespons
data
acceler
optim
corrector
compound
modif
includ
prepar
cryopreserv
cell
bank
passag
use
passag
ceil
gener
welldifferenti
epithelia
increas
yield
assay
plate
per
passag
vial
use
semiand
fullyautom
robot
liquid
handler
substanti
reduc
amount
manual
effort
medium
chang
increas
number
assay
plate
per
equival
current
experi
increas
number
data
point
per
experi
use
autom
dispens
add
dmso
solut
corrector
directli
assay
plate
reduc
workload
improv
data
qualiti
corrector
doserespons
test
combin
protocol
modif
support
increas
assay
throughput
togeth
robust
reproduc
determin
corrector
doserespons
curv
improv
potenti
broad
applic
mani
laboratori
cultur
cf
hbe
cell
studi
mechan
rescu
optim
corrector
cystic
fibrosi
cf
patient
poor
phenotypegenotyp
correl
cf
transmembran
conduct
regul
cftr
mutat
describ
particular
regard
sever
pulmonari
infect
thu
identif
noncftr
genet
variat
contributor
individu
risk
factor
lung
patholog
one
clinic
need
challeng
ahead
cf
date
genet
studi
human
ongo
join
approach
recent
highli
geneticallydivers
mous
resourc
popul
collabor
cross
cc
gener
mimic
genet
divers
human
popul
http
csbiounceduccstatusindexpi
took
advantag
mous
resourc
defin
host
genet
variat
influenc
sever
p
aeruginosa
lung
infect
largescal
screen
p
aeruginosa
infect
carri
cohort
cc
line
cc
mice
infect
cf
clinic
p
aeruginosa
strain
subsequ
monitor
mortal
mean
surviv
time
morbid
chang
bodi
weight
seven
day
postinfect
cc
mice
exhibit
distinct
diseas
phenotyp
p
aeruginosa
infect
rang
complet
resist
lethal
diseas
sever
pneumonia
character
high
bacteri
burden
importantli
differenti
respons
p
aeruginosa
infect
cc
line
found
greater
report
classic
inbr
mice
detail
analysi
cc
mice
show
initi
variabl
includ
bodi
weight
age
gender
influenc
p
aeruginosa
outcom
emphas
role
complex
genet
trait
sever
infect
broadsens
herit
phenotyp
trait
evalu
confirm
influenc
genet
factor
rather
environment
factor
among
cc
line
p
aeruginosa
infect
next
quantit
trait
locu
qtl
map
perform
found
signific
locu
chromosom
name
pseudomona
respiratori
infect
resist
locu
associ
sever
infect
seven
day
postinfect
mortal
refin
qtl
local
exploit
sequenc
variat
eight
founder
murin
strain
cc
geneprotein
public
databas
identifi
gene
new
candid
diseasemodifi
airway
infect
promis
candid
gene
relat
leukocyt
recruit
inflammatori
process
valid
candid
gene
ongo
model
system
conclud
cc
mice
repres
innov
model
reproduc
variabl
respons
relat
diseas
sever
human
affect
p
aeruginosa
pneumonia
ii
host
genet
play
signific
role
modul
lung
defenc
diseas
sever
p
aeruginosa
pneumonia
iii
set
gene
involv
pathogenesi
p
aeruginosa
infect
may
explor
complement
human
studi
support
italian
cf
research
foundat
ffc
ffc
hartmann
layish
pratley
bredberg
u
haseltin
e
beusman
j
lesko
lj
trame
mn
pharmaceut
univers
florida
orlando
fl
usa
central
florida
pulmonari
group
orlando
fl
usa
translat
research
institut
metabol
diabet
orlando
fl
usa
vertex
pharmaceut
boston
usa
introduct
cystic
fibrosi
cf
one
common
lifeshorten
genet
diseas
caus
mutat
cftr
gene
lead
reduc
synthesi
function
stabil
andor
traffick
cftr
protein
cf
diseas
progress
hypothes
greatli
influenc
type
cftr
mutat
well
patient
demograph
bmi
pancreat
statu
onset
diabet
treatment
pancreat
enzym
insulin
aim
analysi
develop
popul
pharmacodynam
poppd
model
order
evalu
contribut
factor
influenc
diseas
progress
measur
chang
cf
subject
method
poppd
model
develop
describ
longitudin
chang
cf
subject
monitor
routin
clinic
practic
averag
period
year
tabl
effect
differ
covari
diseas
progress
examin
estim
fraction
chang
induc
covari
covari
combin
covari
test
mutat
age
gender
bmi
diabet
statu
pancreat
statu
sweatchlorid
level
subject
pancreat
insuffici
pancreat
enzym
replac
therapi
diabet
subject
given
insulin
result
linear
diseas
progress
model
slope
l
year
found
best
describ
observ
data
cf
subject
includ
analysi
addit
model
identifi
key
covari
contribut
declin
estim
fraction
chang
slope
chang
slope
shown
diabet
pancreat
insuffici
femal
gender
effect
older
age
contribut
declin
baselin
base
subject
age
bmi
determin
benefici
lung
function
effect
slope
base
individu
bmi
homozyg
caus
declin
faster
compar
heterozyg
subject
conclus
use
poppd
model
abl
describ
timecours
cf
subject
well
identifi
factor
influenc
cf
diseas
progress
measur
chang
time
develop
model
may
use
tool
clinic
practic
predict
chang
timecours
individu
cf
patient
determin
possibl
risk
factor
worsen
well
factor
improv
lung
function
cystic
fibrosi
cf
common
genet
diseas
caus
defect
cf
transmembran
conduct
regul
cftr
membranebound
anion
channel
permeabl
chlorid
bicarbon
main
featur
cf
lung
diseas
bacteri
colon
chronic
infect
conduct
airway
thought
due
alter
physic
chemic
properti
airway
surfac
liquid
asl
patholog
clinic
data
suggest
diseas
initi
distal
small
airway
diamet
howev
studi
regard
pathogenesi
cf
reli
data
excis
cultur
proxim
larg
airway
tracheal
bronchi
tissu
thu
direct
experiment
data
support
dogma
cf
lung
diseas
initi
distal
small
airway
group
engin
pig
either
delet
mutat
cftr
mimic
human
cf
cf
pig
develop
spontan
airway
infect
airway
becom
obstruct
mucu
inflammatori
cell
model
provid
unpreced
opportun
investig
spatial
origin
cf
lung
diseas
hypothes
select
express
cftr
distal
small
airway
vivo
prevent
develop
lung
diseas
cf
pig
use
direct
evolut
strategi
vitro
vivo
identifi
novel
adenoassoci
viru
vector
high
tropism
larg
small
airway
epitheli
cell
base
previou
studi
indic
small
airway
higher
surfact
protein
spd
express
compar
larg
airway
construct
vector
direct
express
egfp
cftr
small
airway
epithelia
use
spd
promot
fragment
significantli
gfp
cell
small
airway
cultur
infect
egfp
compar
larg
airway
cultur
administr
egfp
trachea
distal
small
airway
live
pig
bronchoscop
confirm
gfp
cell
observ
distal
small
airway
trachea
bronchi
vivo
addit
significantli
campstimul
short
circuit
current
cf
small
airway
cultur
infect
vitro
ultim
tool
allow
us
test
hypothesi
futur
studi
vivo
enhanc
understand
cf
lung
diseas
pathogenesi
congenit
absenc
va
deferen
observ
clinic
manifest
upward
male
cystic
fibrosi
studi
investig
loss
male
reproduct
structur
cf
rat
model
includ
epididymi
region
involut
va
base
analysi
cftr
male
anim
rang
development
abnorm
shown
occur
perinat
time
mate
histomorphometri
use
establish
cf
embryon
wolffian
mullerian
duct
develop
normal
structur
begin
degener
region
atresia
va
deferen
time
birth
immedi
thereaft
observ
indic
lumin
mucu
physic
obstruct
moreov
contrast
parenchym
damag
human
porcin
cf
lung
pancrea
indic
inflammatori
cell
infiltr
increas
myofibroblast
differenti
judg
signal
note
associ
involut
va
interestingli
found
epididym
defect
diminish
smooth
muscl
prolifer
appear
predat
loss
va
deferen
addit
rnaseq
tissu
biopsi
cf
male
rat
reproduct
tract
suggest
gross
alter
signal
development
pathway
includ
homeoboxlik
transcript
factor
loss
function
associ
previous
destruct
mesonephr
duct
deriv
studi
knockout
mice
immunohistochemistri
determin
role
pathway
within
develop
rat
genitourinari
tract
togeth
studi
androgen
receptor
signal
tunel
assay
monitor
epitheli
apoptosi
progress
find
provid
import
test
fundament
mechan
underli
tissu
damag
cystic
fibrosi
reproduct
epithelia
potenti
relev
gener
exocrin
abnorm
diseas
fund
cff
nih
cf
patient
harbor
rare
cftr
mutat
unrespons
current
pharmaceut
intervent
current
therapeut
option
beyond
secondari
therapi
induc
pluripot
stem
ip
cell
repres
patientspecif
renew
resourc
deriv
tissu
affect
cf
serv
valuabl
platform
drug
discoveri
develop
use
ip
line
deriv
patient
cohort
harbor
rare
cfcaus
mutat
gcftr
model
drug
respons
engin
lung
epithelium
mutat
promin
middl
eastern
popul
caus
aberr
splice
delet
six
residu
nucleotidebind
domain
lead
nearli
undetect
protein
chlorid
channel
activ
chronic
acut
exposur
lumacaftor
ivacaftor
respect
condit
mimick
combin
therapeut
orkambi
tm
significantli
rescu
cell
surfac
express
activ
mutant
overexpress
hek
cell
shown
western
blot
fluorescencebas
assay
monitor
membran
potenti
flipr
valid
orkambi
tm
effect
patientderiv
lung
epithelium
studi
requir
innov
given
inaccess
tissu
ip
cell
gener
affect
individu
bear
gcftr
differenti
lung
epithelium
use
publish
protocol
wong
ap
et
al
nat
protoc
correct
potenti
led
modest
signific
chang
apic
cftr
mediat
chlorid
conduct
measur
use
flipr
importantli
multiwel
plate
reader
assay
rank
respons
ipscderiv
lung
tissu
multimodul
point
util
platform
develop
person
treatment
individu
rare
mutat
futur
work
util
edit
isotyp
control
deciph
patientspecif
benchmark
maximum
improv
upon
correct
cftr
locu
work
support
al
qamra
hold
inc
cf
canada
cihr
project
establish
catalog
divers
cftr
mutat
promot
discoveri
novel
precisiontyp
approach
therapi
laboratori
particip
cf
theratyp
initi
develop
epitheli
cell
model
encod
clinic
relev
mutat
fischer
rat
thyroid
frt
flpin
tm
background
date
establish
isogen
frt
cell
line
express
rare
cf
allel
singl
chromosom
insert
sitea
well
mechanist
import
cftr
intend
improv
understand
missens
nonsens
abnorm
frt
line
demonstr
similar
level
cftr
mrna
profil
accord
steadyst
core
fulli
glycosyl
protein
vector
ion
transport
respons
corrector
molecul
potenti
activ
special
assay
tailor
individu
cf
allel
insight
global
analysi
mutant
present
includ
observ
distinct
mutat
eg
cftr
class
ii
iv
significantli
stabil
chronic
treatment
corrector
potenti
molecul
numer
process
mutat
class
ii
show
correct
suggest
share
offpathway
misfold
intermedi
mani
gate
defect
class
iii
potenti
manner
correl
strongli
allel
clinic
approv
treatment
kalydeco
conduct
mutat
class
iv
may
exhibit
minim
respons
potenti
therapi
although
except
exist
eg
major
cftr
mutat
display
molecular
characterist
one
tradit
subcategori
indic
import
new
method
reclassifi
allel
focu
theratyp
find
highlight
signific
cellbas
model
system
understand
cf
diseas
pathogenesi
direct
therapeut
trial
help
advanc
precis
treatment
individu
diseas
fund
cff
nih
even
though
cystic
fibrosi
cf
lung
diseas
character
sever
persist
neutrophil
inflamm
actual
role
phagocyt
diseas
pathogenesi
underappreci
one
major
obstacl
imped
relat
research
neutrophil
isol
cf
patient
shortliv
ex
vivo
nonpermiss
genet
manipul
take
advantag
new
geneedit
technolog
establish
neutrophilprecursor
cell
line
unlimit
cf
neutrophil
differenti
dimethyl
sulfoxid
dmso
induct
specif
sgrna
target
sequenc
exon
human
cftr
gene
cover
site
identifi
synthes
engin
pyogen
plasmid
bb
result
vector
verifi
dna
sequenc
singlestrand
dna
oligo
synthes
templat
homologydirect
repair
hdr
dna
doubl
strand
break
dsb
oligo
complementari
nontarget
strand
cftr
exon
homolog
upstream
homolog
downstream
dsb
site
two
modif
delet
immedi
downstream
dsb
site
creat
mutat
silent
point
mutat
creat
sspi
restrict
enzym
cut
site
upstream
dsb
site
test
principl
cell
transfect
plasmid
hdr
templat
via
calcium
phosphat
precipit
fortyeight
hour
posttransfect
gfpposit
cell
facssort
singlecellclon
limit
dilut
dna
pcramplif
cell
clone
follow
sspi
analyt
digest
dna
sequenc
confirm
clone
doubleallel
hdr
clone
singleallel
hdr
creat
design
neutrophil
precursor
cell
line
cell
transfect
vector
plasmid
along
hdr
templat
oligo
via
electropor
twentyfour
hour
later
gfpposit
cell
facssort
singlecel
clone
cell
clone
current
expans
analyz
similarli
hdr
anticip
neutrophil
precursor
cell
line
establish
cf
research
drug
screen
work
support
cfft
research
grant
mani
cfcaus
mutat
rare
present
within
scope
fdaapprov
popul
cftr
modul
therapi
current
mean
test
avail
cf
modul
ultrarar
popul
either
potenti
corrector
may
benefit
subpopul
patient
costli
nofon
trial
group
variou
cftr
mutat
singl
studi
popul
may
problemat
recent
focu
shift
ex
vivo
approach
address
challeng
chosen
model
cultur
human
sweat
gland
highli
sensit
cftr
modul
therapi
object
isol
cultur
propag
character
sweat
gland
epitheli
cell
human
subject
result
show
enzymat
digest
skin
sampl
remnant
surgic
specimen
punch
biopsi
enabl
isol
sweat
gland
microdissect
separ
duct
coil
sever
coat
protocol
condit
test
enhanc
adher
isol
sweat
gland
cultur
found
irradi
fibroblast
cocultur
provid
superior
background
success
initi
cellular
growth
observ
success
outgrowth
intact
gland
separ
coil
thu
far
outgrowth
duct
challeng
cellular
growth
begin
typic
sever
day
gener
reach
point
passag
begin
day
current
assess
media
condit
enhanc
growth
rate
propag
antibodi
stain
use
cytokeratin
marker
coil
cytokeratin
marker
duct
demonstr
multipl
clear
subpopul
cell
within
cell
outgrowth
antibodi
stain
intact
tissu
demonstr
use
marker
identifi
duct
vs
coil
conjunct
establish
protocol
cultur
sweat
gland
epitheli
cell
perform
patch
clamp
studi
provid
function
character
cellular
cultur
multipl
channel
popul
observ
includ
small
linear
conduct
clchannel
control
subject
respons
ivacaftor
ultim
goal
provid
method
wherebi
sampl
cf
patient
obtain
punch
biopsi
sweat
gland
cultur
establish
ex
vivo
test
efficaci
cf
modul
undertaken
use
electrophysiolog
techniqu
enabl
precis
approach
rare
cftr
variant
support
cfft
introduct
number
therapeut
molecul
investig
necess
develop
person
therapi
cf
requir
physiolog
relev
human
system
test
efficaci
molecul
restor
cftr
function
vitro
reconstitut
epithelium
primari
human
nasal
epitheli
hne
cell
promis
system
predict
drug
activ
patient
sinc
nasal
epithelium
much
easier
sampl
bronchial
epithelium
provid
possibl
repeat
isol
cell
patient
effort
concentr
improv
hne
cultur
gener
aim
studi
develop
physiolog
relev
tool
vitro
predict
efficaci
given
compound
individu
patient
primari
measur
character
comparison
primari
human
nasal
cell
commonli
known
bronchial
epitheli
cell
cultur
condit
test
efficaci
cftr
corrector
cell
model
method
nasal
epitheli
cell
isol
brush
inferior
nasal
turbin
bronchial
cell
issu
bronchial
explant
grown
micropor
insert
airliquid
interfac
week
differenti
incub
combin
short
circuit
current
experi
perform
uss
chamber
system
clconcentr
gradient
immunocytochemistri
confoc
microscopi
done
cftr
immunodetect
iggclon
dilut
accompani
apic
plasma
membran
stain
wheat
germ
agglutinin
result
primari
hne
cell
cultur
recapitul
properti
bronchial
epithelium
term
cftr
express
ion
transport
expect
statist
signific
differ
amilorid
forskolin
observ
wtwt
cell
cultur
nasal
healthi
cf
patient
bronchial
origin
cf
patient
treatment
homozyg
hne
hbe
cultur
correct
cftr
variabl
patientdepend
level
hbe
cultur
homozyg
patient
incub
averag
correct
cftrdepend
clsecret
statist
signific
take
account
interand
intrapati
variabl
twosampl
ttest
power
analysi
estim
patient
requir
achiev
correct
power
provid
control
treat
insert
analyz
patient
also
observ
residu
cftrdepend
clsecret
signific
correct
hne
hbe
cultur
issu
patient
mild
cf
phenotyp
variou
cftrrelat
genotyp
conclus
primari
hne
cultur
previou
cell
amplif
implement
model
test
efficaci
cftr
corrector
patientderiv
differenti
epithelia
constitut
tool
person
therapi
cf
lacerda
kojukhova
discoveri
charl
river
laboratori
inc
cleveland
oh
usa
function
evalu
corrector
potenti
primari
cultur
cystic
fibrosi
patient
deriv
bronchialtrach
epitheli
cell
critic
compon
advanc
develop
compound
gener
highli
differenti
air
liquid
interfac
cultur
cystic
fibrosi
patient
deriv
primari
bronchial
epithelia
cfhbe
cultur
protocol
describ
neuberg
et
al
epithelia
typic
plate
snapwel
polyest
polyethylen
terephthal
insert
evalu
cultur
condit
found
epithelia
plate
polycarbon
snapwel
insert
gener
cftr
short
circuit
current
factor
greater
compar
cell
polyest
insert
enacand
calciumactiv
current
magnitud
also
affect
well
composit
calcium
activ
current
corrector
potenti
respons
maintain
similar
respons
obtain
polyest
insert
similar
chang
insert
type
impact
phenotyp
tracheal
gland
cell
increas
signal
magnitud
use
expand
fidel
rang
current
measur
background
earli
onset
progress
lung
diseas
children
cystic
fibrosi
cf
indic
sensit
noninvas
outcom
measur
need
diagnost
monitor
earli
intervent
clinic
trial
lung
clearanc
index
lci
chest
magnet
reson
imag
mri
shown
detect
earli
lung
diseas
cf
howev
relationship
two
measur
remain
unknown
object
aim
studi
therefor
correl
lci
abnorm
detect
mri
infant
preschool
children
cf
method
multipl
breath
washout
mbw
chest
mri
perform
clinic
stabl
young
children
cf
infant
preschool
children
year
annual
checkup
cf
center
children
cf
agematch
pulmonari
healthi
children
underw
weightadapt
mbw
test
sedat
use
sulphur
hexafluorid
sf
bodi
weight
nitrogen
n
washout
bodi
weight
assess
lci
determin
lci
zscore
mri
scan
also
perform
sedat
evalu
use
dedic
morphofunct
score
result
lci
zscore
significantli
increas
children
cf
compar
pulmonari
healthi
control
p
chest
mri
detect
abnorm
lung
structur
perfus
infant
preschool
children
cf
airway
wall
thickeningbronchiectasi
mucu
plug
constitut
preval
morpholog
abnorm
infant
preschool
children
cf
lci
zscore
correl
strongli
mri
morpholog
score
mridefin
airway
wall
thickeningbronchiectasi
p
p
mri
global
score
measur
integr
abnorm
detect
mri
p
p
howev
correl
lci
zscore
mri
mucu
plug
score
observ
infant
p
preschool
children
cf
lci
correl
mri
perfus
score
either
age
group
conclus
result
indic
lci
mri
may
use
complementari
tool
noninvas
monitor
quantit
endpoint
earli
intervent
trial
young
children
cf
howev
data
also
suggest
mri
sensit
lci
detect
earli
region
mucu
plug
caus
abnorm
lung
perfus
infant
preschool
children
cf
seattl
children
hospit
seattl
wa
usa
vertex
pharmaceut
incorpor
boston
usa
vertex
pharmaceut
europ
limit
london
unit
kingdom
imperi
colleg
london
london
unit
kingdom
royal
brompton
harefield
nh
foundat
trust
london
unit
kingdom
behalf
klimb
studi
group
introduct
openlabel
phase
kiwi
studi
demonstr
pharmacokinet
safeti
ivacaftor
iva
patient
pt
age
cf
cftr
gate
mutat
similar
seen
older
pt
davi
jc
et
al
lancet
respir
med
report
final
result
klimb
longterm
extens
kiwi
method
pt
complet
kiwi
part
b
wk
iva
could
enrol
klimb
openlabel
extens
studi
evalu
addit
wk
treatment
pt
age
receiv
weightbas
dose
mg
bodi
weight
kg
mg
kg
pt
turn
trial
receiv
mg
iva
primari
outcom
safeti
outcom
includ
chang
baselin
start
kiwi
sweat
chlorid
weight
bmi
fecal
immunoreact
trypsinogen
irt
level
result
total
pt
kiwi
part
b
enrol
klimb
mean
age
klimb
baselin
five
discontinu
studi
drug
due
elev
altast
level
switch
commerci
iva
noncompli
common
ae
grade
cough
eleven
pt
seriou
ae
consid
relat
iva
elev
altast
level
ten
pt
elev
altast
level
uln
pt
elev
altast
level
uln
kiwi
iva
maintain
resum
pt
except
discontinu
signific
improv
sweat
chlorid
irt
concentr
bmi
zscore
observ
wk
wk
total
tabl
conclus
iva
demonstr
stabl
safeti
profil
extend
followup
period
pt
cf
age
cftr
gate
mutat
report
advers
event
consist
known
safeti
profil
incid
elev
liver
function
test
per
period
consist
observ
kiwi
improv
seen
kiwi
sweat
chlorid
bmi
zscore
measur
pancreat
function
maintain
klimb
sponsor
vertex
pharmaceut
incorpor
set
function
cftr
assay
use
patientderiv
intestin
stem
cell
cultur
term
organoid
dekker
jf
et
al
nat
med
assay
allow
quantif
individu
respons
cftrmodul
drug
exampl
potenti
ivacaftor
combin
food
supplement
curcumin
genistein
harbor
potenti
activ
show
clear
differ
potenc
efficaci
differ
treatment
modal
object
evalu
correl
vitro
efficaci
cftr
potenti
organoid
correspond
vivo
treatment
effect
individu
patient
cf
studi
part
hitcf
program
method
total
patient
least
one
gate
mutat
sequenti
treat
week
curcumin
genistein
follow
washout
week
ivacaftor
treatment
organoid
cultur
establish
potenti
efficaci
investig
use
forskolininduc
swell
fi
assay
togeth
pure
compound
plasma
patient
collect
treatment
vivo
treatment
effect
evalu
measur
chang
predict
sweat
chlorid
concentr
scc
result
respons
organoid
show
similar
efficaci
much
lower
potenc
food
supplement
curcumin
genistein
comparison
ivacaftor
restor
fi
dekker
jf
et
al
j
cyst
fibro
plasma
patient
collect
treatment
ivacaftor
strongli
potenti
cftr
activ
organoid
absent
use
plasma
subject
receiv
curcumin
genistein
patient
treat
curcumin
genistein
mean
chang
ns
rang
scc
mmoll
rang
patient
treat
ivacaftor
mean
chang
rang
mean
scc
chang
mmoll
rang
conclus
behalf
part
b
investig
group
introduct
prior
publish
clinic
trial
lumacaftorivacaftor
lumiva
gener
well
toler
led
improv
lung
function
efficaci
measur
patient
pt
age
cf
homozyg
mutat
report
find
multicent
openlabel
phase
studi
evalu
lumiva
pediatr
pt
cf
mutat
statu
method
pt
age
receiv
lumiva
mg
h
wk
dosag
determin
part
studi
primari
endpoint
part
b
safeti
toler
lumiva
wk
safeti
measur
includ
advers
event
ae
spirometri
secondari
endpoint
includ
sweat
chlorid
bmi
height
weight
cfqr
lung
clearanc
index
lung
volum
turnov
requir
reach
start
n
concentr
lci
measur
exploratori
endpoint
result
pt
enrol
femal
mean
age
complet
treatment
inelig
withdrew
discontinu
due
ae
rash
elev
ast
alt
level
resolv
follow
drug
withdraw
ae
report
pt
mild
moder
sever
common
ae
cough
headach
infect
pulmonari
exacerb
nasal
congest
seriou
ae
report
pt
possibl
relat
studi
drug
elev
astalt
ae
special
interest
observ
pt
elev
astalt
respiratori
event
dyspnea
respir
abnorm
wheez
signific
improv
observ
cfqr
score
wk
ls
mean
chang
baselin
ci
sweat
chlorid
bmi
lci
tabl
washout
valu
return
near
baselin
sweat
chlorid
ppfev
lci
bmi
tabl
conclus
lumiva
gener
well
toler
pt
cf
age
yr
homozyg
mutat
safeti
profil
consist
observ
older
pt
discontinu
due
ae
infrequ
respiratori
ae
associ
treatment
discontinu
clinic
improv
observ
lung
function
sweat
chlorid
bmi
cfqr
score
support
efficaci
lumiva
popul
sponsor
vertex
pharmaceut
incorpor
method
pt
lumiva
traffictransport
continu
assign
dosag
progress
pt
placebo
pbo
random
lumiva
dosag
primari
endpoint
safeti
progress
wk
primari
efficaci
analysi
wk
sensit
analys
wk
rate
fev
declin
analyz
match
studi
pt
pt
homozyg
us
cff
patient
registri
use
propens
score
base
variabl
associ
fev
declin
result
market
mg
lum
iva
dosag
report
result
includ
traffictransport
pt
receiv
lum
iva
wk
pt
pbo
traffictransport
receiv
lumiva
wk
progress
safeti
profil
consist
traffictransport
common
ae
pex
cough
increas
sputum
hemoptysi
dyspnea
traffic
transport
respiratori
ae
occur
pt
initi
lumiva
progress
mostli
occur
first
wk
blood
pressur
increas
seen
traffictransport
also
observ
progress
previous
report
three
death
occur
progress
consid
unrel
lumiva
mean
ppfev
remain
pretreat
baselin
lumiva
lumiva
group
absolut
ls
mean
chang
percentag
point
progress
wk
start
lumiva
pbo
pt
ls
mean
increas
percentag
point
ppfev
wk
progress
bmi
continu
improv
progress
lumiva
lumiva
group
ls
mean
chang
kgm
wk
kgm
wk
reduct
pex
risk
maintain
annual
event
rate
pt
receiv
wk
lumivasimilar
observ
traffictransport
less
pbo
rate
traffictransport
rate
ppfev
declin
lumiva
pt
match
control
group
well
match
pt
receiv
lum
iva
slower
rate
declin
control
vs
percentag
point
per
year
respect
p
conclus
safeti
profil
extend
lumiva
pt
cf
age
yr
homozyg
wk
consist
pivot
studi
lumiva
maintain
mean
ppfev
pretreat
baselin
show
sustain
benefit
pex
rate
bmi
wk
lumiva
also
result
decreas
annual
rate
ppfev
declin
vs
match
control
effect
similar
reduct
previous
observ
ivatr
pt
sponsor
introduct
pseudomona
aeruginosa
preval
caus
lung
infect
adult
cf
associ
increas
morbid
progress
infect
initi
onset
chronic
diseas
p
aeruginosa
acquir
trait
mucoidi
antibiot
resist
loss
motil
alter
quorum
sens
correl
stage
infect
pulmonari
exacerb
lung
function
declin
mayerhamblett
n
et
al
j
respir
crit
care
med
therefor
phenotyp
may
serv
prognost
indic
patient
outcom
diseas
progress
longterm
goal
identifi
volatil
biomark
use
rapidli
sensit
noninvas
detect
chronic
infectionassoci
p
aeruginosa
phenotyp
directli
lung
specimen
ie
sputum
bronchoalveolar
lavag
bal
breath
object
goal
studi
identifi
p
aeruginosa
volatil
characterist
chronic
infect
adapt
put
biomark
p
aeruginosa
phenotyp
associ
chronic
infect
method
pair
earlyand
lateinfect
p
aeruginosa
isol
patient
phenotyp
antibiot
resist
mucoidi
motil
swim
swarm
twitch
product
proteas
rhamnolipid
pyoverdin
pyocyanin
select
gene
sequenc
confirm
known
mutat
associ
phenotyp
isol
cultur
aerob
rich
media
headspac
volatil
collect
analysi
comprehens
twodimension
ga
chromatographi
timeofflight
mass
spectrometri
multidimension
statist
analys
use
identifi
characterist
chang
volatil
progress
infect
put
biomark
specif
chronicinfect
phenotyp
volatil
analysi
sputum
bal
breath
p
aeruginosainfect
patient
analyz
confirm
presenc
biomark
patient
specimen
result
p
aeruginosa
lateinfect
isol
exhibit
differ
volatil
profil
earlyinfect
isol
evolv
analysi
pair
sampl
expand
set
previouslyidentifi
biomark
mucoidi
identifi
new
put
biomark
quorumregul
phenotyp
subset
volatil
confirm
present
lung
specimen
p
aeruginosainfect
patient
perform
addit
longitudin
analys
volatil
p
aeruginosa
chronic
infect
valid
put
biomark
identifi
introduct
serin
trypsinlik
tl
proteas
excess
activ
cf
airway
promot
activ
epitheli
sodium
channel
enac
airway
dehydr
key
initi
factor
cf
lung
diseas
furthermor
tlproteas
enhanc
mucin
gene
express
mucu
hypersecret
well
inflamm
human
airway
epitheli
cell
relationship
tlproteas
activ
markersoutcom
cf
airway
diseas
howev
report
date
object
primari
object
current
investig
determin
whether
tlproteas
activ
measur
adult
cf
sputum
sol
correl
lung
diseas
patient
outcom
surviv
secondari
object
compar
strength
relationship
observ
neutrophil
elastas
ne
establish
proteas
biomark
method
crosssect
retrospect
studi
analys
cf
sputum
sol
collect
clinic
stabl
adult
cf
patient
proteas
activ
measur
monitor
hydrolysi
peptidebas
substrat
bocqarnh
mec
use
determin
tl
activ
ne
activ
measur
use
nmethoxysuccinylaapvpnitroanilid
biomark
inflamm
measur
elisa
lung
function
assess
spirometri
fev
mortal
data
retrospect
obtain
time
month
death
transplant
use
subsequ
surviv
analysi
result
tllike
proteas
activ
invers
correl
lung
function
fev
howev
relationship
observ
contrast
ne
found
correl
p
p
show
relationship
lung
function
indic
serin
proteas
play
distinct
role
within
diseas
process
kaplanmei
analysi
demonstr
significantli
reduc
surviv
individu
abovemedian
tlproteas
activ
level
ne
activ
show
relationship
patient
surviv
use
multivari
analysi
adjust
age
bmi
significantli
increas
mortal
hazard
hr
ci
also
identifi
find
support
analysi
valid
cohort
consist
sampl
collect
separ
cohort
adult
cf
patient
conclus
tlproteas
activ
invers
correl
reduc
lung
function
patient
surviv
tryptic
activ
may
repres
novel
biomark
moreov
covari
requir
consider
model
cf
outcom
object
subject
cystic
fibrosi
cf
live
netherland
mutat
report
cftr
mutat
respons
caus
cf
subject
remain
rare
noncharacter
mutat
subject
identif
cftrrestor
drug
challeng
develop
function
cftr
assay
use
patientderiv
intestin
stem
cell
term
organoid
cftr
function
responsetotherapi
measur
easili
forskolininduc
swell
fi
assay
assay
ideal
drugscreen
platform
identifi
novel
drug
restor
cftr
function
patientspecif
manner
preclin
set
proofofconcept
studi
part
dutch
hitcf
program
demonstr
abil
repurpos
exist
drug
ivacaftor
andor
lumacaftor
cf
subject
harbor
rare
cftr
mutat
drug
regist
use
mediumtohigh
throughput
screen
ht
format
organoid
gener
cf
subject
harbor
homozyg
c
mutat
respons
ivacaftor
andor
lumacaftor
investig
use
fi
assay
three
cf
subject
clinic
treat
ivacaftor
base
organoid
respons
clinic
outcom
paramet
scc
npd
cfqr
evalu
result
vitro
pharmacolog
restor
cftr
function
ivacaftor
observ
cf
subject
mutat
ii
ivacaftorlumacaftor
mutat
drug
respons
measur
homozyg
c
organoid
three
cf
subject
select
vivo
treatment
ivacaftor
treat
monitor
period
cftrdepend
biomark
evalu
vivo
effect
scc
npd
pulmonari
function
paramet
airway
resist
cfqr
improv
significantli
two
cf
subject
mutat
cf
subject
harbor
mutat
conclus
data
obtain
proofofconcept
studi
indic
feasibl
strength
vitro
ht
organoidswel
assay
identifi
cftrrestor
therapi
extrem
rare
uncharacter
cftr
mutat
importantli
vitro
fi
measur
correl
vivo
drug
respons
next
use
novel
ht
format
screen
publish
clinic
approv
cftrrestor
compound
ii
fdaapprov
drug
librari
iii
regist
ivacaftor
lumacaftor
drug
anticip
identifi
novel
andor
repurpos
old
cftrrestor
compound
andor
drug
cf
patient
extrem
rare
cftr
mutat
preval
dutch
cf
popul
kruisselbrink
e
van
der
ent
ck
beekman
j
pediatr
pulmonolog
univers
medic
center
utrecht
utrecht
netherland
regen
medicin
center
univers
medic
center
utrecht
utrecht
netherland
approxim
report
mutat
cystic
fibrosi
transmembran
conduct
regul
cftr
gene
caus
aberr
premrna
splice
thu
constitut
signific
proport
report
cftr
mutat
major
document
splice
mutat
rare
orphan
mutat
indic
need
develop
therapeut
requir
novel
highli
person
drug
develop
approach
one
straightforward
splice
modul
approach
use
antisens
oligonucleotid
aon
short
complementari
rna
molecul
nucleotid
basepair
target
premrna
therebi
correct
aberr
splice
mask
modul
aberr
splice
site
splice
regulatori
element
forc
spliceosom
machineri
use
authent
splice
site
rapid
standard
preclin
approach
facilit
select
aon
potenti
vivo
benefit
current
import
ratelimit
step
cftr
splice
modul
therapi
last
year
develop
novel
function
cftr
assay
use
organoid
cftr
function
respons
therapi
measur
forskolininduc
swell
fi
assay
importantli
fi
measur
correl
known
cftr
genotypephenotyperesponsetotherapi
relat
indic
organoid
vitro
model
incorpor
import
vivo
diseas
characterist
therapeut
effect
present
approach
part
dutch
hitcf
program
set
novel
therapeut
develop
pipelin
identif
aon
target
cftr
splice
mutat
recent
expand
optim
fi
assay
mediumtohigh
throughputscreen
format
aon
develop
pipelin
consist
three
success
step
identif
develop
candid
aon
sequenc
use
previous
publish
guidelin
bioinformat
tool
potenti
modul
level
correctli
splice
cftr
cf
subject
ii
efficaci
test
aon
restor
cftr
function
organoid
harbor
splice
mutat
use
twostep
aontil
approach
select
effect
aon
iii
character
valid
aoninduc
mechan
splice
modul
organoid
primari
airway
cell
approach
establish
robust
develop
pipelin
use
intestin
organoid
cf
subject
allow
us
quickli
identifi
antisens
oligonucleotid
therapi
address
need
subject
express
cftr
splice
mutat
modul
aon
subjectspecif
manner
preclin
set
antiinflammatori
therapi
need
improv
outcom
individu
cf
biomark
inflamm
oxid
stress
play
critic
role
antiinflammatori
drug
develop
howev
inform
respons
biomark
sputum
andor
blood
need
determin
method
recent
complet
clinic
trial
oral
antioxidantenrich
multivitamin
supplement
cf
subject
year
age
predict
random
week
antioxidantenrich
multivitamin
control
multivitamin
without
antioxid
system
sputum
marker
inflamm
oxid
stress
blood
marker
wbc
count
hscrp
calprotectin
serum
amyloid
myeloperoxidas
mpo
malondialdehyd
protein
carbonyl
total
antioxid
capac
sputum
marker
mpo
free
neutrophil
elastas
activ
slpi
urin
marker
measur
baselin
week
along
clinic
outcom
pulmonari
function
anthropometr
measur
pulmonari
exacerb
result
baselin
biomark
data
avail
subject
male
femal
mean
age
subject
year
year
age
year
year
age
mean
predict
system
sputum
biomark
data
age
gender
underli
lung
function
report
correl
marker
inflamm
oxid
stress
key
clinic
endpoint
includ
determin
addit
longitudin
chang
biomark
week
examin
control
group
conclus
analys
help
determin
biomark
includ
endpoint
antiinflammatori
clinic
trial
target
trial
term
age
pediatr
subject
adult
underli
lung
function
background
cystic
fibrosi
transmembran
conduct
regul
cftr
function
channel
regul
transport
ion
across
epitheli
barrier
mutat
cftr
gene
form
basi
clinic
manifest
cf
affect
epitheli
innat
immun
function
lung
epitheli
dysfunct
result
initi
proinflammatori
cascad
cf
airway
lead
recruit
leukocyt
exosom
nanovesicl
activ
secret
live
cell
contain
protein
involv
celltocel
signal
order
shed
light
cftr
dysfunct
could
potenti
regul
inflammatori
respons
characteris
exosom
releas
cell
mutat
cftr
method
exosom
isol
wtand
cf
patient
sampl
cell
use
ultracentrifug
exosom
fraction
analys
mass
spectrometri
bioinformat
use
ingenu
pathway
analysi
perform
exosom
characteris
nanosit
analysi
biochem
assay
result
observ
higher
number
exosom
releas
cell
compar
wt
cell
use
nanosit
analysi
also
increas
number
protein
identifi
exosom
popul
ingenu
pathway
analysi
show
top
pathway
differ
exosom
wt
vs
exosom
includ
eukaryot
initi
factor
pathway
pathway
associ
nfkb
integrin
signal
acut
inflammatori
respons
fact
exosom
enrich
integrin
report
play
role
leukocyt
transmigr
current
character
role
exosom
modul
neutrophil
transmigr
furthermor
analys
exosom
profil
cf
patient
bal
fluid
serum
identifi
differ
protein
cf
patient
control
cf
fluid
current
examin
exosom
profil
serum
sampl
cf
patient
differ
treatment
conclus
found
evid
exosom
cell
uniqu
protein
profil
rich
inflammatori
modul
may
regul
leukocyt
transmigr
cf
airway
establish
novel
connect
cftr
dysfunct
exosom
biogenesi
cf
inflamm
investig
addit
identifi
potenti
diagnost
role
exosom
cf
patient
fluid
determin
safeti
toler
pharmacokinet
pk
cystic
fibrosi
transmembran
conduct
regul
cftr
amplifi
subject
cystic
fibrosi
cf
healthi
volunt
background
despit
signific
advanc
achiev
current
approv
cftr
modul
substanti
medic
need
remain
cf
patient
either
elig
experi
suboptim
benefit
genotyp
restrict
treatment
option
highthroughput
screen
strategi
enrich
small
molecul
act
translat
sequenc
cftr
mrna
transcript
use
identifi
new
class
cftr
modul
term
cftr
amplifi
data
gener
vitro
cftr
amplifi
demonstr
improv
chlorid
current
across
multipl
cftr
mutat
synergi
cftr
modul
corrector
potenti
amplifi
cftr
mutat
agnost
lead
increas
level
immatur
cftr
protein
along
stabil
cftr
mrna
allow
substrat
cftr
modul
act
upon
amplifi
current
phase
trial
design
determin
safeti
toler
cf
subject
healthi
volunt
method
random
doubleblind
placebocontrol
phase
clinic
studi
conduct
subject
cf
age
forc
expiratori
volum
second
predict
singleascend
dose
sad
studi
cf
subject
consist
three
cohort
random
activ
placebo
oral
dose
start
mg
sad
portion
follow
multipl
ascend
dose
mad
studi
consist
three
cohort
subject
random
activ
placebo
dose
seven
day
oral
daili
dose
start
primari
object
assess
safeti
toler
secondari
object
assess
pk
exploratori
object
includ
chang
sweat
chlorid
measur
well
chang
cftr
mrna
express
nasal
brush
order
valid
use
mrna
express
biomark
predict
patient
respons
investig
drug
concurr
addit
phase
drugdrug
interact
ddi
studi
oral
hormon
contracept
healthi
volunt
conduct
sad
mad
dose
escal
compon
prior
ddi
evalu
safeti
toler
pk
cftr
mrna
express
assess
result
preliminari
data
sad
mad
cohort
includ
safeti
toler
pk
biomark
evalu
phase
trial
expect
advanc
north
american
cystic
fibrosi
confer
nacfc
conclus
repres
new
class
cftr
modul
clinic
develop
target
cf
patient
mutat
one
therapeut
strategi
enhanc
clinic
benefit
patient
cf
one
two
copi
combin
cftr
corrector
act
differ
mechan
increas
cftr
cell
surfac
use
cellbas
assay
cftr
function
identifi
nextgener
cftr
corrector
activ
addit
firstgener
corrector
lumacaftor
extens
medicin
chemistri
optim
pharmacolog
activ
druglik
properti
led
discoveri
nextgener
cftr
corrector
earlystag
clinic
studi
method
pharmacolog
activ
assess
biochem
function
studi
use
cultur
human
bronchial
epitheli
hbe
cell
deriv
five
patient
cf
homozyg
patient
heterozyg
either
produc
fulllength
cftr
protein
function
data
normal
chlorid
transport
hbe
deriv
noncf
donor
normal
result
cftr
corrector
facilit
process
traffick
cftr
increas
amount
cftr
cell
surfac
addit
firstgener
cftr
corrector
combin
facilit
process
traffick
cftr
indic
combin
deliv
cftr
cell
surfac
either
corrector
alon
uss
chamber
studi
use
treatment
alon
enhanc
chlorid
transport
baselin
normal
normal
respect
compar
lumacaftor
plu
ivacaftor
increas
chlorid
transport
normal
tripl
combin
ivacaftor
increas
chlorid
transport
normal
respect
level
higher
level
chlorid
transport
treat
ivacaftor
normal
condit
test
respons
approxim
half
observ
consist
gene
dose
effect
addit
improv
chlorid
transport
tripl
combin
improv
fluid
transport
ciliari
beat
frequenc
lumacaftor
ivacaftor
homozyg
heterozyg
hbe
addit
result
progress
identif
optim
nextgener
corrector
discuss
conclus
vitro
data
support
clinic
evalu
combin
firstgener
cftr
corrector
ivacaftor
evalu
clinic
benefit
patient
cf
one
cftr
allel
sponsor
prematur
termin
codon
ptc
cftr
result
nonfunct
cftr
protein
proxim
caus
cfcaus
allel
aminoglycosid
ag
gentamicin
synthet
ag
eloxx
ataluren
ptc
therapeut
escin
shown
induc
readthrough
rt
ptc
partial
restor
cftr
protein
express
function
achiev
therapeut
level
shown
combin
approach
use
cftr
potenti
ivacaftor
corrector
lumacaftor
benefici
enhanc
rt
prematur
stop
mutat
use
novel
corrector
potenti
galapago
examin
modul
synergist
effect
rt
agent
could
enhanc
cftr
function
achiev
therapeut
level
stabli
transduc
fisher
rat
thyroid
frt
cell
pretreat
escin
induc
rt
corrector
earli
corrector
corrector
late
corrector
complementari
alon
combin
enhanc
process
transepitheli
conduct
gt
record
cftr
stimul
forskolin
follow
investig
potenti
previous
describ
ivacaftor
similar
studi
also
carri
primari
hbe
human
bronchial
epitheli
cell
shortcircuit
current
isc
analysi
cellsurfac
express
assay
horseradish
peroxidas
hrp
tag
cell
use
examin
cell
surfac
express
cftr
follow
treatment
show
dosedepend
increas
cftr
activ
gt
three
frt
cftr
ptc
cell
line
compar
vehicl
control
p
rt
induc
pretreat
frt
cftr
activ
significantli
greater
p
triplecombin
approach
corrector
alon
combin
significantli
enhanc
cftrdepend
gt
compar
alon
indic
synergi
cftr
modul
rt
agent
hrp
assay
cftr
express
level
significantli
higher
combin
compar
vehicl
escin
show
signific
synergi
pretreat
gt
mscm
compar
gt
mscm
contrast
frt
frt
cell
significantli
efficaci
alon
combin
rt
agent
addit
respons
significantli
higher
mutat
compar
mutat
evalu
cftr
activ
primari
cell
progress
conclus
combin
novel
corrector
potenti
show
signific
synergi
rt
agent
combin
corrector
exhibit
signific
benefit
mutat
corrector
therapi
efficaci
without
rt
especi
combin
combin
therapi
cftr
modul
rt
agent
may
use
approach
augment
repair
cftr
nonsens
mutat
cf
patient
prematur
termin
codon
ptc
mutat
nonsens
mutat
found
cftr
gene
least
one
allel
nonsens
mutat
also
refer
class
mutat
caus
prematur
termin
cftr
protein
translat
consequ
function
fulllength
cftr
protein
gener
ptc
mutant
gene
patient
nonsens
mutat
allel
readthroughpromot
therapeut
seriou
unmet
need
small
moleculemedi
readthrough
ptc
hold
promis
potenti
treatment
patient
mutat
class
report
function
rescu
efficaci
natur
modifi
aminoglycosid
ag
gentamicin
nbxx
eloxx
pharmaceut
previous
shown
promot
ptc
readthrough
nonag
small
molecul
readthrough
modul
studi
ataluren
shown
modest
efficaci
cf
patient
current
pivot
clinic
trial
also
test
compound
vitro
readthrough
activ
report
assess
function
rescu
two
common
cftr
nonsens
mutat
well
readthrough
drug
test
alon
combin
nonsens
mediat
decay
nmd
inhibitor
amlexanox
andor
cftr
corrector
conduct
g
studi
perform
isogen
frt
cell
line
stabli
transfect
cftr
ptc
mutant
hbe
equival
current
eq
measur
carri
heterozygot
primari
hbe
cell
genotyp
key
find
hbe
respons
three
two
donor
cell
test
certain
treatment
abovement
agent
eloxx
ag
treatment
yield
increas
cftrmediat
current
two
contain
donor
cell
function
rescu
cftr
eloxx
ag
cell
quit
modest
signific
control
inhibitor
doubl
cftr
activ
combin
confirm
yield
margin
increas
amlexanox
ineffect
frt
efficaci
three
ptc
mutat
gentamicin
compar
ataluren
ineffect
show
margin
rescu
cftr
function
coincub
boost
readthroughmedi
cftr
activ
mscm
ca
increas
cftr
activ
combo
compound
ineffect
cftr
hbe
frt
streptomycinhygromycin
b
ag
media
supplement
measur
effect
compound
activ
data
support
find
well
function
data
best
ptc
hit
compound
librari
screen
present
confer
introduct
cystic
fibrosi
cf
monogen
lethal
disord
caus
mutat
cftr
gene
common
mutat
lead
proteinmisfold
induc
rosmedi
autophagyimpair
lead
cftraccumul
aggresomebodi
moreov
impair
autophagosomemedi
clearanc
pseudomona
aeruginosa
pa
common
cf
pathogen
henc
studi
synthes
evalu
efficaci
cysteamin
autophagi
induc
antibacteri
drug
tag
dendrim
ddn
cy
rescu
protein
aggreg
pa
infect
method
diaminobutan
dab
dendrim
core
amin
surfac
synthes
react
core
amin
dendrim
traut
reagent
form
result
nanoformul
character
use
autophagyreport
assay
pagegel
analysi
transmiss
electron
microscopi
tem
andor
cell
use
determin
therapeut
efficaci
ddn
cy
compar
ddn
rescu
immunofluoresc
microscopi
flow
cytometri
immunoblot
moreov
cell
treat
ddncontrol
ddn
cy
infect
moi
bacteri
count
quantifi
immunofluoresc
microscopi
flow
cytometri
result
first
synthes
character
ddn
cy
briefli
acid
page
use
analyz
cysteamin
conjug
comparison
ladder
use
verifi
presenc
conjug
obtain
synthesi
condit
compar
unreact
show
one
band
b
moreov
observ
evid
crosslink
conjug
via
disulfid
format
next
character
size
dispers
ddn
cy
formul
tem
found
ddnddn
cy
size
around
nm
efficaci
ddnci
inhibit
ubiquitin
protein
accumul
aggresom
bodi
verifi
assay
also
investig
effect
ddn
cy
observ
modest
rescu
cform
immunofluoresc
microscopi
cell
transfect
show
ddn
cy
treatment
rescu
aggresom
bodi
induc
traffick
cell
membran
verifi
result
flow
cytometri
observ
signific
p
ddn
vs
ddn
cy
rescu
ddn
cy
treatment
use
nonpermeabil
cell
immunostain
cftr
final
assess
antibacteri
potenti
ddn
cy
treat
cell
infect
observ
signific
p
ddn
vs
ddn
cy
decreas
intracellular
bacteri
count
immunofluoresc
microscopi
flow
cytometri
conclus
demonstr
therapeut
efficaci
dendrimerbas
select
autophagyinduct
ddn
cy
rescu
aggresom
bodi
promot
traffick
cell
membran
moreov
ddn
cy
treatment
significantli
inhibit
painfect
cf
cell
induc
autophagymedi
bacteri
clearanc
wang
x
tse
c
abbvi
inc
north
chicago
il
usa
galapago
mechelen
belgium
address
preval
defect
lead
cystic
fibrosi
two
biomolecular
activ
requir
name
corrector
increas
properli
fold
level
cell
surfac
potenti
allow
effect
open
channel
combin
activ
allow
chlorid
ion
transport
lead
improv
hydrat
lung
surfac
subsequ
enhanc
mucociliari
clearanc
abbvi
galapago
collabor
develop
seri
compound
capabl
perform
activ
individu
orkambi
vertex
pharmaceut
repres
first
diseasemodifi
therapi
cf
patient
homozyg
mutat
approv
base
margin
statist
signific
improv
lung
function
fev
howev
still
exist
high
unmet
medic
need
cf
patient
robust
therapi
herein
report
identif
vitro
character
novel
potent
oral
bioavail
corrector
current
clinic
trial
exhibit
substanti
improv
exist
corrector
clinic
includ
improv
potenc
drugdruginteract
ddi
compar
lumacaftor
improv
potenc
efficaci
compar
abbv
exhibit
potent
vitro
function
activ
primari
patient
cell
harbor
cftr
ec
sum
repres
second
compon
threecompon
combin
therapi
treat
preval
cftr
mutat
sa
cb
yf
wg
sg
yj
bl
xs
am
tv
cy
xw
ct
employe
abbvi
design
studi
conduct
financi
support
research
conduct
abbvi
provid
abbvi
abbvi
particip
interpret
data
review
approv
public
madden
dr
biochemistri
dartmouth
colleg
hanov
nh
usa
chemistri
dartmouth
colleg
hanov
nh
usa
pharmacolog
toxicolog
dartmouth
colleg
hanov
nh
usa
cf
lethal
autosom
recess
diseas
gene
encod
cf
transmembran
conduct
regul
cftr
mutat
common
mutat
cftr
result
primari
intracellular
defect
ineffici
fold
er
diminish
chlorid
transport
across
apic
membran
increas
lysosom
degrad
fdaapprov
combin
therapi
allevi
defect
assist
proper
cftr
fold
er
enhanc
abil
cftr
efflux
chlorid
apic
membran
combinatori
treatment
howev
demonstr
modest
effect
homozyg
cf
patient
efficaci
heterozyg
patient
current
therapeut
design
stabil
cftr
rapid
lysosom
degrad
matur
cftr
facilit
cftrassoci
ligand
cal
neg
regul
bind
cftr
cterminu
via
pdz
domainmedi
interact
cheng
j
et
al
j
biol
chem
directli
address
cftr
instabl
engin
seri
synthet
peptid
inhibitor
cal
ical
bind
cal
pdz
domain
calp
unpreced
select
vouillem
l
et
al
angew
chem
int
ed
engl
inhibitor
significantli
increas
cftr
abund
conduct
apic
membran
determin
therapeut
lead
amen
nonproteinogen
amino
acid
substitut
substitut
acetyl
lysin
residu
modulatori
site
along
ical
without
ablat
target
affin
crystal
peptid
complex
calp
determin
structur
complex
resolut
amach
jf
et
al
plo
one
data
hypothes
incorpor
complex
unnatur
sidechain
ical
enhanc
affin
select
toward
calp
util
highthroughput
silico
model
identifi
put
modif
coupl
modulatori
lysin
residu
enhanc
affin
ical
peptidomimet
calp
perform
fluoresc
polar
competit
assay
determin
inhibit
constant
k
calp
modifi
peptid
among
peptid
investig
observ
increas
affin
calp
ical
k
rel
unmodifi
peptid
indic
moderatetoweak
interact
furthermor
subject
peptidomimet
crystallograph
analysi
understand
potenti
mechan
modif
enhanc
affin
toward
calp
experi
demonstr
incorpor
synthet
sidechain
modif
modulatori
site
enhanc
bind
affin
calp
ical
extend
experiment
workflow
ical
site
greatli
expand
chemic
divers
avail
explor
order
enhanc
affin
select
therapeut
lead
select
highli
potent
ical
therapeut
administ
conjunct
orkambi
could
attenu
mutant
cftr
defect
augment
treatment
efficaci
broader
spectrum
cf
patient
work
support
part
nih
award
background
rna
edit
enzymat
process
initi
sitedirect
mutagenesi
within
rna
process
catalyz
adenosin
deaminas
act
rna
adar
famili
enzym
convert
adenosin
inosin
variou
rna
structur
similar
guanosin
g
atoi
chang
interpret
atog
chang
ribosom
biolog
process
result
mechan
protein
function
may
alter
particularli
edit
occur
within
mrna
code
region
lab
engin
recombin
adar
guid
edit
reaction
specif
adenosin
choos
within
rna
use
sitedirect
rna
edit
sdre
strategi
attempt
correct
common
prematur
termin
stop
codon
ptc
cftr
transient
transfect
cell
object
longterm
goal
use
sdre
restor
function
cftr
chlorid
current
five
frequent
ptc
mutat
within
cftr
shortterm
aim
maxim
effici
sdre
correct
differ
cftr
ptc
reduc
offtarget
edit
transient
transfect
system
method
first
step
test
edit
effici
sdre
five
cftr
ptc
cell
transient
transfect
differ
cftr
mutat
editas
rna
guid
four
day
posttransfect
measur
correct
level
rna
rtpcr
direct
sequenc
reduc
offtarget
edit
event
ad
larg
tantigen
nuclear
local
signal
nl
recombin
edit
enzym
immunofluoresc
experi
perform
antibodi
determin
nuclear
local
next
test
edit
effici
nuclearloc
enzym
differ
cftr
ptc
result
conclus
use
sdre
detect
effici
edit
target
adenosin
cell
cftr
ptc
test
cftr
ugag
ugaa
ugag
ugag
uaa
howev
variou
degre
offtarget
edit
event
depend
mutat
decreas
offtarget
edit
ad
nl
editas
test
abil
reduc
offtarget
ptc
use
nuclear
editas
abl
decreas
offtarget
event
howev
also
slight
decreas
edit
effici
target
adenosin
futur
experi
focu
test
strategi
fischer
rat
thyroid
frt
epitheli
cell
stabli
express
cftr
ptc
construct
also
assess
function
correct
test
strategi
epitheli
cell
monolay
use
uss
chamber
support
work
fund
part
cff
award
thank
support
also
support
nind
rcmi
grant
rr
respons
drug
therapi
deep
intron
splice
mutat
g
g
c
caus
incorpor
prematur
stop
codon
matur
cftr
transcript
due
creation
cryptic
splice
site
three
mutat
account
entri
cf
databas
cfcaus
mutat
creat
pair
crispr
creat
two
adjac
doublestrand
break
close
mutat
allow
us
delet
short
intron
sequenc
nhej
nonhomolog
end
join
highli
effici
way
design
test
abil
differ
pair
grna
caus
delet
intron
region
three
mutat
found
grna
pair
clone
tandem
bb
vector
capabl
express
grna
show
construct
reagent
abl
caus
desir
delet
effici
human
trachael
epitheli
cell
line
construct
hybrid
minigen
system
allow
heterolog
splice
reaction
plasmid
exon
sequenc
clone
wildtyp
mutant
cftr
region
interest
fulli
character
effect
mutat
splice
process
moreov
select
reagent
cotransfect
minigen
carri
splice
variant
aberr
splice
pattern
success
correct
due
delet
cryptic
signal
show
high
level
normal
splice
transcript
nhej
base
edit
construct
evalu
epitheli
cell
deriv
patient
carri
mutat
determin
level
restor
cftr
function
univers
iowa
iowa
citi
ia
usa
viral
vector
deliv
cystic
fibrosi
transmembran
conduct
regul
cftr
complement
anion
channel
defect
cystic
fibrosi
cf
airway
epithelia
inde
gene
therapi
cur
strategi
regardless
diseasecaus
mutat
import
goal
cf
gene
therapi
achiev
longterm
function
correct
mani
vector
option
evalu
integr
vector
greatest
potenti
maintain
stabl
express
time
without
requir
repeat
administr
studi
function
vivo
cftr
channel
activ
restor
airway
cf
pig
use
two
integr
vector
option
lentivir
vector
hybrid
piggybacaav
vector
freshli
excis
tracheal
bronchu
tissu
cultur
sinu
cell
observ
signific
increas
transepitheli
campstimul
current
evid
function
cftr
addit
observ
increas
tracheal
airway
surfac
liquid
asl
ph
bacteri
kill
cftr
vectortr
anim
cultur
airway
epitheli
cell
treat
pig
observ
increas
asl
ph
decreas
mucu
viscos
third
vector
system
base
integr
hybrid
piggybacadenovir
vector
current
evalu
lentivir
vector
vet
option
cf
gene
therapi
wherea
emerg
technolog
dna
transposonbas
hybrid
vector
provid
new
tool
vivo
gene
transfer
present
excit
opportun
increas
deliveri
effici
therapeut
gene
cftr
result
demonstr
cftr
deliveri
use
integr
viral
vector
partial
correct
anion
channel
defect
larg
anim
cf
model
valid
translat
strategi
treat
prevent
cf
lung
diseas
background
inflamm
infect
begin
earli
infanc
patient
cystic
fibrosi
cf
littl
known
regard
gene
pathway
contribut
pathophysiolog
differ
accord
age
whole
genom
blood
transcriptom
analysi
repres
comprehens
tool
gain
understand
pathogenesi
diseas
studi
evalu
valu
gene
express
profil
identifi
pathway
activ
suppress
infant
young
children
cf
method
seventi
children
year
age
cf
infant
children
agematch
healthi
control
hc
prospect
enrol
blood
obtain
gene
express
profil
analys
transcript
signatur
identifi
valid
independ
set
linear
mix
model
adjust
age
multipl
test
modular
analysi
molecular
distanc
health
mdth
ingenu
pathway
analysi
perform
identifi
specif
immun
pathway
express
accord
age
result
median
age
cf
infant
month
year
children
linear
mix
model
p
benjaminihochberg
chang
identifi
lower
number
transcript
express
cf
infant
vs
hc
differenti
express
genesbiosignatur
compar
older
children
cf
transcript
modular
analysi
demonstr
decreas
express
monocyt
inflamm
apoptosi
cell
death
relat
gene
cf
infant
contrast
transcript
signatur
switch
proinflammatori
hyperinn
decreas
adapt
immun
respons
throughout
child
cohort
figur
conclus
gene
express
profil
promis
tool
aid
discrimin
earli
cf
diseas
especi
infant
young
children
earli
intervent
may
signific
impact
gene
express
profil
provid
insight
pathway
innat
adapt
immun
disrupt
cf
may
futur
prognost
indic
target
novel
therapeut
intervent
introduct
cystic
fibrosi
cf
autosom
recess
disord
caus
differ
mutat
gene
encod
cf
transmembran
conduct
regul
cftr
one
common
mutat
class
prematur
termin
codon
ptc
cftr
result
nonfunct
cftr
protein
caus
cfcaus
allel
previous
screen
clinic
avail
compound
effici
enhanc
translat
readthrough
ptc
improv
cftr
function
among
lead
compound
screen
escin
herbal
extract
consist
shown
enhanc
cftr
activ
nonsensemutationexpress
frt
hbe
cell
current
studi
examin
role
escin
cftr
cell
surfac
express
evalu
bioavail
mice
method
determin
cell
surfac
express
cftr
protein
adapt
reporterbas
horseradish
peroxidas
hrp
assay
stabli
transduc
frt
cell
express
cdna
tag
hrp
second
membran
span
domain
monolay
treat
escin
posit
control
vehicl
control
dmso
hour
follow
measur
chemiluminesc
activ
pharmacokinet
properti
escin
investig
mice
follow
intraperiton
ip
subcutan
sc
administr
escin
mean
plasma
concentr
analyz
use
noncompartment
analysi
result
strong
correl
p
readthrough
detect
dual
luciferas
mrnabas
report
compar
cftr
surfac
express
use
panel
readthrough
agent
escin
significantli
enhanc
cftr
surfac
express
frt
hrp
cell
frt
hrp
frt
hrp
respect
p
result
confirm
western
blot
escin
level
mice
plasma
show
two
peak
correspond
two
known
activ
isom
escin
escin
ia
escin
ib
concentr
escin
ia
escin
ib
total
escin
ia
ib
time
lower
sc
dose
compar
ip
administr
nearli
undetect
oral
administr
uniqu
mice
sinc
shown
human
readili
absorb
escin
mean
peak
concentr
escin
ia
ngml
escin
ib
ngml
total
escin
ngml
observ
hour
sc
dose
auc
last
valu
escin
ia
ml
escin
ib
total
escin
ia
ib
demonstr
stabl
level
maxim
effect
concentr
vitro
suitabl
vivo
studi
conclus
escin
enhanc
cell
surfac
express
sever
common
cftr
nonsens
mutat
correspond
biochem
readthrough
function
activ
escin
bioavail
ip
administr
mice
level
suffici
mimic
desir
human
exposur
achiev
po
efficaci
escin
transgen
mice
current
progress
set
stage
conduct
clinic
trial
cf
patient
nonsens
mutat
cystic
fibrosi
cf
caus
mutat
gene
encod
cystic
fibrosi
transmembran
conduct
regul
cftr
anion
channel
airway
diseas
major
sourc
morbid
mortal
success
implement
geneand
cellbas
therapi
cystic
fibrosi
cf
airway
diseas
requir
knowledg
relationship
percentag
target
cell
level
cftr
express
correct
electrolyt
transport
rescu
host
defens
defect
previou
studi
suggest
airway
epitheli
cell
express
cftr
gener
wildtyp
level
clsecret
overexpress
cftr
offer
advantag
compar
endogen
express
level
howev
recent
discoveri
focus
attent
cftrmediat
hco
secret
airway
surfac
liquid
asl
ph
critic
host
defens
cf
pathogenesi
therefor
gener
porcin
airway
epithelia
vari
ratio
cf
wildtyp
cell
epithelia
mix
secret
hco
half
rate
wildtyp
epithelia
likewis
heterozyg
epithelia
cftr
cftr
express
cftr
secret
hco
wildtyp
valu
asl
ph
antimicrobi
activ
viscos
show
similar
relationship
amount
cftr
overexpress
cftr
increas
hco
secret
rate
greater
wildtyp
asl
ph
exceed
wildtyp
valu
thu
contrast
clsecret
amount
cftr
ratelimit
hco
secret
correct
host
defens
defect
addit
overexpress
cftr
might
produc
greater
benefit
express
cftr
wildtyp
level
target
small
fraction
cell
find
may
also
explain
risk
airway
diseas
cf
carrier
vonk
hagemeij
mc
oppelaar
h
van
der
ent
ck
beekman
j
pediatr
pulmonolog
univers
medic
center
utrecht
utrecht
netherland
regen
medicin
center
univers
medic
center
utrecht
utrecht
netherland
object
approxim
differ
mutat
cystic
fibrosi
transmembran
conduct
regul
cftr
gene
report
caus
cystic
fibrosi
cf
common
lifeshorten
autosom
recess
diseas
worldwid
two
cftrrestor
drug
ivacaftor
lumacaftor
approv
therapi
cf
rel
small
number
cftr
mutat
clear
need
preclin
highthroughput
screen
ht
approach
exist
identifi
new
cftrrestor
drug
compound
cf
subject
independ
preval
particular
mutat
method
year
ago
develop
patientspecif
function
cftr
assay
use
intestin
organoid
term
forskolininduc
swell
fi
assay
fluid
secret
organoid
lumen
forskolin
administr
organoid
cultur
process
complet
depend
presenc
function
cftr
measur
simpl
phenotyp
function
readout
importantli
organoid
fi
assay
rel
simpl
assay
set
readout
ii
speed
iii
robust
iv
accuraci
highli
suitabl
patientspecif
primari
screen
platform
identif
preclin
valid
cftrrestor
drug
compound
result
studi
part
dutch
hitcf
program
expand
optim
fi
assay
mediumtohigh
throughputscreen
format
valid
ht
screen
platform
measur
fi
respons
ivacaftorlumacaftor
treatment
previous
character
organoid
harbor
homozyg
mutat
demonstr
autom
dispens
organoid
compound
feasibl
format
underscor
result
replicateexperi
signal
variabl
zfactor
spatial
uniform
studi
conclus
patientspecif
cftr
function
ht
measur
signific
throughput
allow
us
screen
thousand
condit
per
person
per
week
current
mediumtohigh
throughput
set
use
small
molecul
cftrrestor
approach
alreadi
start
util
ht
screen
platform
among
other
develop
splice
modul
therapi
use
antisens
oligonucleotid
restor
aberr
cftr
splice
identifi
andor
repurpos
old
new
compoundsdrug
restor
cftr
function
patient
rare
uncharacter
cftr
mutat
preval
dutch
cf
popul
rainbow
project
cell
biolog
erasmu
mc
rotterdam
nl
netherland
medicin
human
genet
mcgill
univers
montreal
qc
canada
clinic
immunolog
central
univers
venezuela
caraca
venezuela
bolivarian
republ
lexicon
pharmaceut
inc
woodland
tx
usa
sophia
ped
pulmonol
erasmu
mc
rotterdam
netherland
introduct
aberr
lipid
metabol
might
involv
cf
lung
inflamm
remodel
separ
hitcf
studi
show
bioactiv
lipid
marker
oxid
stress
lung
lavag
fluid
includ
sphingosin
correl
earli
cf
lung
diseas
cf
infant
therefor
studi
mous
model
whether
pharmacolog
correct
sphingosin
metabol
reduc
inflamm
mucu
product
tissu
remodel
cftr
cftr
mice
analyz
total
lung
sphingosin
level
mass
spectrometri
correl
basal
lpsfmlp
induc
lung
inflamm
fac
analysi
myeloid
cell
quantit
histolog
elisa
inflamm
marker
intervent
studi
experiment
antiinflammatori
drug
lyas
inhibitor
lexicon
pharmaceut
inc
result
observ
fourfold
reduct
lung
tissu
adult
unchalleng
cftr
mutant
mice
compar
normal
p
correl
enhanc
infiltr
myeloid
cell
particular
granulocyt
inflammatori
monocyt
band
tcell
p
moreov
mutant
mice
observ
ino
granulocyt
subpopul
absent
normal
mice
importantli
ratio
proinflammatori
macrophagederiv
dendrit
cell
modc
convent
dendrit
cell
cdc
twofold
higher
mutant
mice
p
two
week
acut
intranas
challeng
bacteri
toxin
lpsfmlp
observ
high
level
induc
mucin
proinflammatori
cytokin
includ
kc
elisa
p
mutant
compar
normal
oral
applic
inhibitor
increas
level
mutant
mous
tissu
tenfold
normal
lung
modccdc
ratio
strongli
reduc
band
tcell
count
granulocyt
ino
express
unchalleng
mutant
mice
lpsfmlp
challeng
mutant
mice
treat
observ
reduc
level
proinflammatori
cytokin
near
normal
level
p
conclus
cftr
mutant
mice
present
basal
lung
inflamm
delay
resolut
induc
inflamm
correl
reduc
tissu
level
lung
phenotyp
partial
correct
lyas
inhibitor
suggest
causal
relationship
abnorm
metabol
cf
lung
inflamm
provid
strong
rational
therapeut
target
signal
pathway
cf
patient
acknowledg
fund
dutch
cf
foundat
ncf
hitcf
dutch
lung
fund
disclosur
part
studi
fund
lexicon
pharmaceut
inc
cell
biolog
erasmu
mc
rotterdam
nl
netherland
sophia
ped
pulmonol
erasmu
mc
rotterdam
netherland
lacdr
leiden
netherland
center
cf
airway
diseas
research
emori
univers
atlanta
ga
usa
univers
western
australia
perth
wa
australia
introduct
cf
clinic
erasmu
mc
rotterdam
utrecht
univers
mc
engag
screen
protocol
pioneer
australian
cf
commun
arest
cf
cf
patient
identifi
neonat
screen
follow
annual
ct
scan
bronchoscopi
collect
bronchoalveolar
lavag
fluid
balf
approach
allow
uniqu
studi
earli
cf
lung
diseas
drug
target
find
valid
hitcf
program
abnorm
lung
bioactiv
lipid
metabol
observ
sever
group
cf
patient
cf
mutant
mice
bioactiv
lipid
gener
involv
inflamm
tissu
remodel
report
result
lipidom
studi
arestcf
balf
sampl
method
use
stateoftheart
lcm
platform
lacdr
leiden
establish
method
analys
panel
oxylipid
polar
lipid
fatti
acid
ml
cf
balf
obtain
australian
arestcf
consortium
studi
cohort
includ
cf
infant
yr
nulltomoder
lung
ct
diseas
score
base
pragma
score
method
reflect
bronchiectasi
bronchial
thicken
air
trap
mucu
plug
noncf
infant
recurr
lung
inflamm
result
analysi
yield
matrix
ten
thousand
data
point
cover
rang
bioactiv
lipid
involv
inflamm
oxid
stress
tissu
injuri
data
correl
lung
ct
score
clinic
paramet
includ
neutrophil
count
bacteri
load
cluster
analysi
distinguish
cf
noncf
patient
base
notabl
marker
oxid
stress
even
neutrophil
count
bacteri
load
differ
two
group
suggest
cf
patient
specif
characterist
respect
bioactiv
lipid
profil
irrespect
level
airway
inflamm
use
fisher
correl
test
identifi
lipid
speci
signific
correl
r
p
pragma
ct
score
data
emerg
two
cluster
sphingosin
phospholipas
pathway
correl
high
diseas
score
ongo
studi
erasmu
mc
arestcf
cohort
present
ibal
studi
current
studi
includ
analysi
aberr
neutrophil
function
earli
cf
lung
diseas
relat
lipidom
marker
conclus
arestcf
lipidom
approach
prove
effect
monitor
develop
lung
patholog
cf
infant
year
offer
valuabl
opportun
research
identifi
biomark
sphingosin
phospholipas
pathway
correl
diseas
progress
allow
us
identifi
new
therapeut
target
monitor
effect
therapeut
intervent
better
tailor
treatment
individu
patient
support
ncf
hitcf
zonmw
object
valid
use
nitrogen
washout
determin
lung
clearanc
index
lci
depend
assumpt
nitrogen
back
diffus
blood
tissu
significantli
affect
nitrogen
washout
curv
object
present
studi
determin
whether
back
diffus
distort
n
washout
curv
signific
effect
lci
method
healthi
adult
recruit
age
studi
subject
breath
quietli
bag
contain
sf
air
endtid
concentr
sf
stabl
ga
concentr
analyz
innocor
lci
devic
pulmotrac
inc
atlanta
ga
equip
softwar
version
develop
specif
project
configur
opencircuit
techniqu
washout
perform
subject
breath
n
concentr
less
washout
subject
ask
perform
two
breathhold
maneuv
second
second
washout
rate
back
diffus
estim
compar
chang
sf
n
concentr
follow
breath
hold
measur
repeat
low
level
exercis
cycl
ergomet
result
figur
show
typic
record
n
sf
washout
two
breathhold
maneuv
mean
rel
chang
n
rang
correspond
n
back
diffus
rang
mlsec
mean
rel
chang
n
rang
correspond
n
back
diffus
rang
mlsec
also
observ
slow
declin
n
concentr
even
reach
call
question
whether
true
steadi
state
n
back
diffus
increas
markedli
low
level
exercis
watt
conclus
signific
intrasubject
variat
effect
n
back
diffus
consequ
variabl
effect
lci
cardiac
output
affect
n
back
diffus
may
contribut
variabl
mbw
measur
n
back
diffus
may
import
uncontrol
confound
studi
use
lcin
addit
data
young
adult
collect
includ
prior
nacfc
normal
endtid
concentr
sf
diamond
n
squar
ga
concentr
breathhold
occur
second
circl
shown
inset
meijer
l
heryarnaud
g
le
berr
r
nowak
e
le
roux
l
gueganton
l
mottier
rault
g
manro
therapeut
roscoff
franc
chu
brest
brest
franc
de
brest
brest
franc
centr
de
perharidi
roscoff
franc
object
roscovitin
oral
avail
kinas
inhibitor
drug
undergon
extens
phase
ii
clinic
trial
variou
cancer
clinic
evalu
cush
diseas
rheumatoid
arthriti
roscovitin
display
biolog
properti
suggest
potenti
benefit
cf
treatment
roscocf
clinic
studi
aim
evalu
therapeut
potenti
method
phase
doserang
multicent
doubleblind
placebocontrol
studi
involv
cf
patient
launch
evalu
safeti
effect
r
roscovitin
adult
cf
patient
carri
two
cfcaus
mutat
least
one
mutat
chronic
infect
pseudomona
aeruginosa
result
experiment
result
shown
roscovitin
act
proteostasi
regul
partial
correct
traffick
roscovitin
stimul
bactericid
properti
alveolar
macrophag
lower
abnorm
elev
intraphagolysosom
ph
cf
macrophag
roscovitin
display
antiinflammatori
properti
due
effect
neutrophil
eosinophil
inflammatori
lymphocyt
balanc
conclus
repurpos
roscovitin
cf
therapeut
valid
propos
present
clinic
protocol
design
valid
safeti
potenti
benefici
effect
roscovitin
cf
patient
chronic
lung
p
aeruginosa
infect
hope
first
clinic
result
manag
paranas
sinus
complic
cystic
fibrosi
cf
challeng
otorhinolaryngologist
care
cf
sinus
system
repres
p
aeruginosa
reservoir
affect
lower
airway
system
earli
diagnosi
followup
ent
complic
cf
mucocel
polyposi
import
order
treat
current
maxillofaci
ct
use
radiolog
exam
followup
cf
patient
sinonas
complic
howev
radiat
exposur
patient
well
known
issu
conebeam
ct
scan
cbct
currrent
use
maxillofaci
surgeri
expeci
develop
reconstruct
lower
radiat
exposur
order
reduc
radiat
damag
without
lose
clinic
inform
experiment
protocol
featur
cone
beam
ct
cbct
current
progress
center
ent
followup
cf
patient
may
octob
patient
attend
ent
cf
clinic
evalu
paranas
sinus
complic
cbct
male
femal
mean
age
rang
radiolog
result
describ
qualit
quantit
use
lundmackay
score
figur
cbctguid
lundmackay
score
mean
result
rang
relev
radiolog
find
sinonas
polyposi
medial
maxillari
sinus
wall
mucocel
bone
resorpt
mean
effect
dose
result
confirm
effect
cbct
detect
common
paranas
sinus
complic
cf
compar
standard
maxillofaci
ct
howev
remain
gold
standard
major
complic
suspect
eg
orbit
skull
base
eros
cbct
demonstr
combin
low
irradi
good
imag
resolut
maxillofaci
district
cf
patient
opinion
repres
optimum
techniqu
permit
much
stricter
radiolog
followup
cf
patient
attend
ent
lund
vj
mackay
stage
rhinosinusitu
rhinolog
background
advanc
cystic
fibrosi
cf
drug
develop
includ
adopt
therapi
target
underli
cf
genet
defect
standard
care
soc
cf
transmembran
conduct
regul
cftr
modul
therapi
includ
ivacaftor
iva
lumacaftor
lum
iva
develop
new
second
gener
modul
anticip
work
well
better
exist
modul
present
uniqu
challeng
need
evalu
replac
rather
addon
current
soc
object
assess
feasibl
use
placebo
control
us
evalu
modul
method
physician
patientfamili
survey
independ
administ
decemb
februari
respect
willing
enrol
placebocontrol
trial
vari
durat
candid
superior
sup
noninferior
ni
soc
physician
cohort
compos
center
director
cf
therapeut
develop
network
repres
center
conduct
major
us
cf
trial
patientfamili
cohort
compos
member
cf
foundat
adult
famili
advisor
afa
group
survey
question
cohort
custom
base
genotyp
current
use
iva
lumiva
famili
member
answer
behalf
patient
result
survey
complet
physician
cf
cohort
member
vari
respons
rate
question
tabl
provid
willing
particip
random
placebocontrol
trial
durat
modul
hypothes
sup
ni
iva
lumiva
patient
respons
report
subset
patient
current
take
iva
homozygot
current
versu
current
take
lumiva
gener
willing
particip
placebocontrol
trial
decreas
trial
durat
increas
particip
ni
compar
sup
trial
patient
current
take
lumiva
consist
less
will
take
lumiva
particip
placebocontrol
studi
regardless
durat
notabl
differ
particip
rate
physician
patient
take
lumiva
modul
expect
ni
sup
conclus
data
indic
hesit
cf
commun
toward
particip
placebocontrol
modul
trial
particularli
extend
durat
like
grow
access
modul
increas
result
essenti
develop
feasibl
drug
develop
plan
collabor
regul
continu
enabl
identif
safe
efficaci
modul
introduct
crosssect
studi
show
ventil
distribut
outcom
obtain
multipl
breath
washout
techniqu
mbw
sensit
detect
presenc
extent
structur
lung
damag
infect
inflamm
infant
young
children
cystic
fibrosi
cf
howev
longitudin
data
assess
progress
earli
diseas
need
elucid
mbw
tool
effect
monitor
diseas
object
determin
chang
ventil
distribut
outcom
includ
lung
clearanc
index
lci
moment
ratio
identifi
structur
lung
diseas
progress
chest
comput
tomographi
ct
extent
pulmonari
infect
inflamm
method
twentyeight
children
cf
age
year
underw
serial
mbw
measur
bronchoalveolar
lavag
fluid
bal
chest
ct
period
structur
lung
diseas
assess
use
cfct
score
differenti
cell
count
perform
neutrophil
elastas
ne
interleukin
quantifi
elisa
inflammatori
score
deriv
princip
compon
ne
concentr
total
neutrophil
inflamm
chang
mbw
ct
infect
inflamm
outcom
repeat
visit
assess
use
mix
effect
model
result
increas
lci
significantli
associ
progress
bronchiectasi
coeffici
ci
air
trap
coeffici
ci
bronchial
wall
thicken
coeffici
ci
signific
associ
chang
mbw
outcom
extent
ne
howev
increas
significantli
associ
higher
inflammatori
score
coeffici
ci
increas
neutrophil
coeffici
ci
lci
increas
unit
ci
proinflammatori
pathogen
detect
second
visit
first
visit
conclus
increas
lci
one
year
associ
progress
bronchiectasi
bronchial
wall
thicken
air
trap
ct
ventil
distribut
outcom
also
associ
progress
inflamm
infect
onset
lci
may
sensit
tool
monitor
progress
structur
lung
diseas
develop
lower
respiratori
tract
inflamm
infect
young
children
cf
support
cystic
fibrosi
foundat
chen
k
koll
j
pediatr
univers
pittsburgh
pittsburgh
pa
usa
signific
morbid
cystic
fibrosi
cf
result
chronic
lung
inflamm
commonli
due
pseudomona
aeruginosa
infect
recent
data
suggest
contribut
patholog
inflamm
set
abnorm
mucos
immun
immun
driven
inflammatori
respons
may
repres
novel
target
block
aberr
inflamm
cf
inde
transcriptom
analysi
rnaseq
airway
epithelium
cf
patient
underw
clinic
bronchoscopi
reveal
dramat
upregul
downstream
signatur
gene
implic
signific
contribut
mediat
immun
cf
lung
bromodomain
extratermin
domain
bet
chromatin
modul
regul
cell
respons
specif
mediat
inflamm
mechan
includ
bromodomaindepend
inhibit
acetyl
histon
locu
show
vitro
bet
inhibit
potent
suppress
cell
respons
explant
cf
tissu
inhibit
driven
chemokin
product
human
bronchial
epitheli
cell
hbe
cell
pseudomona
aeruginosa
aspergillu
fumigatu
lung
infect
murin
model
bet
inhibit
decreas
inflamm
without
exacerb
bacteri
fungal
infect
suggest
bet
inhibit
may
effect
safe
therapeut
approach
treat
lung
inflamm
cf
patient
background
purpos
guluron
oligom
oligog
deriv
seawe
algin
demonstr
disrupt
bacteri
biofilm
releas
stagnant
mucin
vitro
ex
vivo
vivo
oligog
current
clinic
develop
cf
purpos
present
studi
demonstr
clinic
efficaci
cf
patient
studi
outlin
trial
randomis
doubleblind
placebocontrol
crossov
phase
ii
trial
adult
cf
patient
stabl
therapeut
regimen
site
across
five
european
countri
subject
histori
pseudomona
aeruginosa
pa
infect
concomit
use
nacetyl
cystein
hyperton
salin
mannitol
permit
studi
trial
primari
efficaci
outcom
chang
inhal
oligog
versu
placebo
secondari
outcom
includ
effect
mucociliari
cough
clearanc
mcc
lung
clearanc
index
lci
sputum
rheolog
microbiolog
qualityoflif
mcc
lci
assess
perform
subset
patient
secondari
object
demonstr
safeti
toler
inhal
oligog
dri
powder
inhal
evalu
patient
complianc
treatment
result
conclus
provid
octob
support
cystic
fibrosi
foundat
eurostar
programm
algipharma
armstrong
da
nymon
ab
hazlett
hf
marsit
cj
ashar
emori
univ
atlanta
ga
usa
pulmonari
dartmouthhitchcock
med
ctr
lebanon
nh
usa
introduct
region
differ
resid
lung
macrophag
respons
hypoxia
may
import
factor
develop
bronchiectat
lung
diseas
cystic
fibrosi
cf
yet
known
region
variat
cfrelat
lung
diseas
due
differ
microbi
pathogen
variat
host
respons
infect
combin
two
increas
understand
region
variat
may
aid
discoveri
intervent
slow
progress
lung
diseas
hogan
da
et
al
plo
one
microrna
ubiquit
regul
human
biolog
much
optim
exist
microrna
biomark
cancer
lung
diseas
vencken
sf
et
al
thorax
recent
clinic
cellbas
studi
reveal
cfspecif
alter
mirna
express
henc
follow
modul
mirna
express
vivo
look
appeal
develop
new
cf
therapi
possibl
mirna
may
act
phenotyp
modifi
could
use
diagnost
prognost
biomark
warrant
investig
noel
leal
cystic
fibrosi
light
new
research
work
seek
identifi
deriv
microrna
distinguish
region
differ
associ
oxygen
stress
compar
altern
lobe
lung
method
studi
perform
use
primari
isol
human
subject
via
bronchoalveolar
lavag
bal
fluid
total
rna
isol
microrna
profil
assay
via
nanostr
ncounter
microrna
assay
result
parallel
profil
vitro
oxygen
stress
induc
via
hypoxia
reveal
static
converg
diverg
express
mirna
examin
phenotyp
complex
lung
macrophag
right
lower
lobe
rll
vs
right
upper
lobe
rul
measur
microrna
express
hour
posthypoxia
treatment
healthi
particip
detect
differ
microrna
top
microrna
express
fourteen
mirna
differenti
express
rll
vs
rul
includ
rll
rul
rll
rul
interestingli
express
five
microrna
elev
rll
respons
hypoxia
demonstr
static
express
rul
upon
oxygen
challeng
mirna
readili
detect
cf
howev
compar
express
function
signific
remain
determin
conclus
data
demonstr
microrna
differenti
express
rll
vs
rul
oxygen
stress
may
import
understand
synthesi
secret
abund
mirna
resid
lung
induc
hypoxia
potenti
shed
new
light
patholog
lead
way
innov
therapi
ongo
studi
explor
role
mirna
allow
us
better
character
cf
lung
region
hypox
inflammatori
respons
identifi
key
molecul
modul
diseas
object
summar
frequenc
treatment
pulmonari
exacerb
pex
multicountri
cohort
patient
cf
homozyg
gene
mutat
medic
record
data
patient
cf
year
age
cftr
modul
collect
retrospect
cf
center
australia
canada
franc
germani
itali
spain
demograph
clinic
characterist
resourc
util
obtain
baselin
period
followup
period
rang
month
frequenc
treatment
pex
defin
mention
record
pex
hospit
outpati
visit
requir
nonroutin
antibiot
treatment
assess
descript
baselin
followup
period
age
year
lung
function
ppfev
overal
result
data
patient
includ
mean
followup
period
month
baselin
mean
sd
age
year
mean
sd
ppfev
frequenc
treatment
pex
baselin
period
summar
tabl
mean
pex
rate
baselin
period
followup
period
proport
pex
requir
hospit
rose
proport
pex
requir
hospit
intraven
antibiot
rose
durat
antibiot
treatment
pex
stabl
baselin
day
followup
day
followup
period
proport
patient
pex
rate
pex
higher
among
adult
adolesc
patient
ppfev
group
ppfev
group
followup
period
mean
sd
rang
length
hospit
stay
pex
day
data
avail
baselin
period
conclus
major
patient
cf
homozyg
gene
mutat
studi
experienc
least
pex
annual
pex
resourc
intens
rate
pex
suggest
increas
time
highest
among
adult
advanc
diseas
base
lung
function
consist
progress
diseas
introduct
intestin
inflamm
recogn
manifest
cystic
fibrosi
cf
major
studi
gut
inflamm
util
stool
calprotectin
biomark
inflamm
numer
studi
report
signific
elev
stool
calprotectin
compar
healthi
control
stool
calprotectin
level
report
correl
growth
qualiti
life
questionnair
score
ivacaftor
cystic
fibrosi
transmembran
conduct
regul
cftr
potenti
shown
improv
lung
function
reduc
pulmonari
exacerb
ivacaftor
also
associ
consider
weight
gain
may
sole
explain
improv
pulmonari
statu
improv
gastrointestin
physiolog
specul
altern
explan
normal
intestin
ph
histopatholog
observ
ivacaftor
effect
intestin
inflamm
fulli
establish
thu
aim
studi
determin
whether
ivacaftor
reduc
intestin
inflamm
patient
cf
method
calprotectin
measur
stool
sampl
prospect
collect
patient
cf
carri
least
one
mutat
toronto
sydney
children
hospit
cf
clinic
canada
australia
respect
baselin
prior
start
ivacaftor
treatment
wilcoxon
signedrank
test
fisher
exact
test
use
compar
continu
categor
calprotectin
data
respect
baselin
start
ivacaftor
result
baselin
posttreat
stool
sampl
obtain
patient
children
adult
male
median
iqr
age
year
stool
posttreat
collect
median
iqr
month
start
ivacaftor
signific
reduct
stool
calprotectin
level
baselin
posttreat
median
vs
mgkg
p
increas
normal
calprotectin
level
baselin
ivacaftor
base
calprotectin
cutoff
mgkg
howev
statist
signific
p
children
signific
increas
posttreat
weight
zscore
median
iqr
vs
p
adult
bmi
increas
significantli
baselin
posttreat
introduct
inhal
antisens
oligonucleotid
aso
distribut
broadli
mani
cell
type
lung
downregul
gene
express
induc
rnase
h
depend
degrad
target
mrna
evalu
antisens
strategi
treatment
cf
inhibit
epitheli
sodium
channel
enac
demonstr
enac
hyperact
lead
mucu
dehydr
accumul
cf
patient
increas
enac
level
lung
result
cystic
fibrosislik
diseas
mice
mous
model
cf
gener
overexpress
enac
mall
et
al
natur
med
delet
ubiquitin
ligas
control
level
enac
cell
surfac
airway
epitheli
cell
aec
demonstr
increas
level
enac
express
kimura
et
al
pna
object
administ
enac
aso
inhal
determin
effect
genet
modifi
mous
model
cf
model
induc
asomedi
knockdown
method
identifi
sever
enac
specif
aso
assess
effect
reduc
target
mrna
level
cell
cultur
mice
potent
aso
test
inhal
cf
mous
model
mrna
enac
sever
gene
involv
mucu
product
assess
rtpcr
result
intranas
administr
two
independ
enac
aso
ko
pup
result
reduc
enac
mrna
mucu
order
studi
cf
endpoint
adult
mice
maintain
phenotyp
knockout
mous
deliv
specif
aso
directli
lung
normal
adult
mice
result
rna
knockdown
increas
goblet
cell
mucu
accumul
inflamm
airway
hyperrespons
ahr
rna
level
mucu
marker
includ
spdef
significantli
increas
aso
treatment
aerosol
deliveri
enac
aso
produc
doserespons
mrna
reduct
enac
aec
pretreat
enac
aso
downregul
mucu
marker
express
prevent
goblet
cell
mucu
accumul
inflamm
ahr
induc
aso
prophylact
activ
establish
aerosol
enac
aso
abil
therapeut
revers
cf
endpoint
asoinduc
model
determin
establish
cf
phenotyp
aerosol
enac
aso
abl
revers
induc
mucu
marker
mucu
overproduct
addit
ahr
establish
group
dose
enac
control
aso
enac
aso
abl
revers
ahr
level
effect
observ
control
aso
effect
enac
aso
model
confirm
transgen
mice
conclus
inhal
treatment
enac
aso
improv
diseas
phenotyp
asoinduc
model
genet
modifi
cf
lung
diseas
mous
model
data
demonstr
antisens
inhibit
enac
aec
could
effect
approach
treatment
cf
introduct
pulmonari
exacerb
pe
import
clinic
event
cystic
fibrosi
cf
patient
associ
decreas
qualiti
life
acceler
lung
diseas
progress
increas
risk
death
ataluren
induc
readthrough
prematur
stop
codon
therebi
promot
cftr
product
cf
patient
cftr
nonsens
mutat
aim
investig
effect
ataluren
exacerb
lung
function
patient
cftr
nonsens
mutat
least
one
allel
method
posthoc
analysi
conduct
effect
ataluren
pe
defin
modifi
fuch
criteria
patient
receiv
chronic
inhal
tobramycin
result
patient
receiv
chronic
inhal
tobramycin
fewer
pe
patient
receiv
ataluren
vs
patient
receiv
placebo
vs
clinic
benefit
ataluren
consist
across
prognost
indic
diseas
sever
eg
femal
gender
p
aeruginosa
infect
predict
pp
fev
pancreat
insuffici
statu
cfrelat
diabet
figur
median
time
first
pe
day
patient
ataluren
vs
day
placebo
mean
durat
hospit
day
ataluren
vs
day
placebo
rel
chang
baselin
ppfev
show
signific
differ
ataluren
placebo
vs
differ
rel
ppfev
patient
year
old
vs
conclus
posthoc
analysi
ataluren
significantli
reduc
pe
patient
cftr
nonsens
mutat
receiv
chronic
inhal
tobramycin
clinic
benefit
support
fev
data
ataluren
show
promis
potenti
therapi
underli
caus
diseas
cf
patient
nonsens
mutat
least
one
allel
cftr
gene
introduct
inhal
mannitol
im
examin
sever
acut
shortand
longterm
studi
shown
benefici
effect
lung
function
mcc
qol
sputum
properti
compar
control
method
multicentr
randomis
crossov
studi
assess
efficaci
week
treatment
im
bd
compar
placebo
nonrespir
mannitol
cf
subject
age
year
primari
endpoint
absolut
chang
baselin
ppfev
secondari
endpoint
includ
fef
posttreat
sputum
weight
prespecifi
subgroup
analys
includ
age
rhdnase
use
annual
rate
declin
ppfev
screen
ppfev
result
total
subject
randomis
receiv
studi
drug
mean
sd
age
year
mean
sd
baselin
percent
predict
pp
fev
take
rhdnase
signific
absolut
improv
ppfev
im
group
treatment
differ
placebo
correspond
rel
differ
fef
treatment
differ
rel
chang
baselin
im
group
acut
posttreat
sputum
weight
significantli
higher
placebo
group
differ
prespecifi
subgroup
treatment
differ
consist
favour
im
point
estim
subgroup
consist
overal
treatment
differ
rhdnase
user
ci
rhdnase
nonus
ci
year
ci
year
ci
declin
ppfev
pa
baselin
ci
declin
ppfev
pa
baselin
ci
screen
ppfev
ci
screen
ppfev
ci
advers
event
ae
number
similar
arm
studi
withdraw
due
ae
low
im
placebo
seriou
ae
less
frequent
im
arm
im
placebo
common
ae
overal
subgroup
cough
pulmonari
exacerb
pulmonari
exacerb
lower
im
group
haemoptysi
uncommon
im
placebo
mild
treatment
emerg
death
studi
studi
confirm
im
addon
therapi
optim
care
provid
immedi
signific
benefit
lung
function
sputum
weight
children
adolesc
irrespect
rhdnase
use
age
diseas
sever
ae
less
common
mannitol
group
im
associ
reduc
incid
pulmonari
exacerb
incid
haemoptysi
low
similar
group
common
mutat
patient
cystic
fibrosi
cf
interfer
transport
cftr
protein
cell
surfac
impair
chlorid
channel
function
lead
disrupt
fluid
balanc
epitheli
tissu
notabl
lung
epitheli
sodium
channel
enac
paradox
overact
cf
one
primari
protein
respons
fluid
balanc
lung
appear
partial
regul
cftr
thu
cftr
dysfunct
may
contribut
excess
intracellular
sodium
transport
via
enac
secondarili
excess
h
absorpt
inhal
enac
inhibitor
activ
studi
preclin
model
earli
phase
trial
design
act
directli
respiratori
epithelium
minim
system
exposur
anim
model
alon
plu
hyperton
salin
hs
produc
larg
sustain
increas
mucociliari
clearanc
confoc
studi
increas
airwaysurfac
liquid
asl
height
observ
plu
hs
plu
lumacaftor
ivacaftor
lumiva
therapi
thelin
w
pediatr
pulmonol
multipl
phase
studi
shown
well
toler
recent
complet
phase
trial
confirm
toler
profil
patient
cf
restrict
mutat
receiv
cftr
modul
therapi
report
addit
preclin
find
support
rational
ad
enac
inhibit
cf
modul
therapi
method
effect
lumiva
evalu
asl
height
ciliari
beat
frequenc
cbf
human
bronchial
epithelia
hbe
homozyg
cell
treat
lum
iva
combin
lumiva
use
experiment
paradigm
design
best
captur
effect
enac
inhibit
asl
cbf
hour
result
augment
effect
combin
lum
iva
asl
cbf
compar
lumiva
alon
exposur
hbe
cell
lumiva
plu
presenc
vasoact
intestin
protein
result
increas
cbf
vs
lumiva
alon
addit
combin
lumiva
significantli
increas
asl
height
hour
compar
vehicl
alon
conclus
success
cftr
potenti
corrector
enabl
research
focus
improv
airway
hydrat
ciliari
motil
restor
balanc
enac
cftr
preclin
studi
hbe
cell
continu
confirm
valu
multifactori
approach
earli
phase
trial
confirm
welltoler
healthi
volunt
patient
cf
studi
design
ongo
phase
clinic
trial
util
enac
inhibit
standard
care
lumiva
therapi
present
sponsor
vertex
pharmaceut
incorpor
one
therapeut
strategi
treat
cf
enhanc
chlorid
transport
increas
amount
function
cftr
cell
surfac
use
combin
small
molecul
cftr
modul
cftr
corrector
potenti
clinicalstag
cftr
corrector
share
structur
featur
lumacaftor
present
nonclin
profil
includ
vitro
pharmacolog
vivo
pharmacokinet
characterist
method
result
biochem
pharmacolog
profil
alon
combin
ivacaftor
investig
human
bronchial
epitheli
hbe
cell
deriv
multipl
homozyg
cf
donor
western
blot
studi
treatment
either
alon
combin
nm
ivacaftor
improv
cellular
process
traffick
determin
increas
matur
glycosyl
cftr
uss
chamber
studi
use
cell
deriv
six
donor
treatment
alon
enhanc
chlorid
transport
baselin
normal
level
halfmaxim
effect
concentr
ec
nm
cotreat
hour
ivacaftor
enhanc
chlorid
transport
noncf
airway
cell
minim
respons
ivacaftor
monotherapi
observ
consist
littletono
cell
surfac
absenc
treatment
cultur
cell
ivacaftor
also
increas
fluid
transport
ciliari
beat
frequenc
level
greater
observ
either
agent
alon
vitro
data
demonstr
combin
ivacaftor
provid
improv
chlorid
transport
fluid
transport
ciliari
beat
frequenc
cell
combin
also
explor
panel
cell
express
differ
mutant
cftr
form
includ
mutant
cftr
form
associ
sever
moder
defect
process
traffick
defect
channel
gate
activ
residu
chlorid
transport
overal
vitro
data
demonstr
combin
ivacaftor
improv
chlorid
transport
either
agent
alon
cell
express
wide
rang
mutant
cftr
form
favor
preclin
pharmacokinet
profil
low
clearanc
high
oral
bioavail
good
distribut
target
tissu
risk
drugdrug
interact
small
sinc
inhibit
induc
major
cytochrom
enzym
vitro
conclus
togeth
data
support
continu
evalu
combin
ivacaftor
clinic
trial
evalu
outcom
rang
cftr
mutat
sponsor
vertex
pharmaceut
incorpor
introduct
inflamm
play
import
role
pathogenesi
cf
assess
effect
combin
therapi
lumacaftor
lum
cftr
corrector
ivacaftor
iva
cftr
potenti
biomark
system
inflamm
relationship
lung
function
patient
cf
age
year
homozyg
method
patient
random
phase
trial
lumiva
traffic
transport
provid
baselin
blood
sampl
either
studi
patient
includ
present
post
hoc
analysi
patient
assign
receiv
lum
mg
qd
mg
plu
iva
mg
placebo
percent
predict
fev
ppfev
white
blood
cell
wbc
count
level
calprotectin
creactiv
protein
crp
immunoglobulin
g
igg
interleukin
il
record
baselin
studi
week
analyz
linear
regress
result
statist
signific
reduct
calprotectin
crp
igg
p
observ
lumiva
vs
placebo
addit
signific
improv
ppfev
signific
invers
correl
exist
baselin
ppfev
crp
p
calprotectin
level
well
chang
baselin
ppfev
biomark
crp
calprotectin
statist
signific
reduct
monocyt
neutrophil
count
observ
wbc
analys
conclus
improv
observ
ppfev
week
lumiva
treatment
associ
reduct
calprotectin
crp
igg
level
data
support
effect
lumiva
amelior
cfrelat
inflamm
sponsor
vertex
pharmaceut
incorpor
introduct
mainten
adequ
airway
surfac
liquid
asl
proper
function
mucociliari
transit
mct
system
pathophysiolog
cf
airway
diseas
well
understood
recent
paramet
imposs
measur
live
anim
goal
noninvas
assess
asl
mct
outcom
measur
develop
genet
pharmaceut
cf
airway
treatment
develop
synchrotron
xray
imag
method
enabl
monitor
measur
airway
surfac
health
method
develop
mice
synchrotron
japan
plan
transit
larger
anim
model
view
futur
use
cf
anim
techniqu
translat
larger
imag
medic
beamlin
imbl
xray
beam
australian
synchrotron
begun
provid
updat
stateoftheart
vivo
asl
depth
mct
measur
method
anaesthetis
nasal
airway
normal
cf
mice
trachea
ventil
normal
mice
imag
mct
track
particl
diamet
insuffl
airway
prior
imag
effect
airwayrehydr
therapi
eg
hyperton
salin
assess
deliveri
use
aeroneb
vibrat
mesh
nebulis
phasegrid
place
immedi
trachea
arrang
cover
half
fieldofview
order
reconstruct
airway
surfac
imag
sampleinduc
distort
grid
observ
metr
downstream
allow
asl
depth
calcul
segment
freshlyexcis
pig
sheep
trachea
imag
imbl
mct
track
particl
insuffl
onto
segment
aeroneb
nebulis
use
deliv
aerosolis
hyperton
isoton
salin
mct
rate
asl
depth
chang
respons
treatment
calcul
postexperi
result
increas
mct
asl
depth
detect
mice
follow
administr
aerosolis
rehydr
therapi
asl
depth
chang
last
minut
posttreat
agre
cell
cultur
studi
assess
optic
microscopi
imbl
mct
visibl
live
sheep
pig
tracheal
segment
bead
move
direct
preferenti
mct
includ
vertic
tracheal
wall
orient
graviti
coher
flux
densiti
imbl
allow
asl
depth
assess
perform
discuss
high
spatial
resolut
synchrotron
phasecontrast
xray
imag
reveal
depth
asl
layer
use
track
mct
live
mous
nasal
tracheal
airway
also
demonstr
wide
beam
imbl
suitabl
imag
mct
ex
vivo
tissu
sampl
expect
live
imag
intact
pig
feasibl
studi
plan
aug
noninvas
imag
mct
cf
pig
model
may
achiev
futur
acknowledg
support
wch
foundat
nhmrc
australian
synchrotron
isap
perfluorin
ga
mri
detect
region
ventil
heterogen
cf
goralski
jl
akinnagb
e
charl
hc
donaldson
sh
lee
marsico
lung
institut
unc
chapel
hill
nc
usa
biomed
engin
unc
chapel
hill
nc
usa
radiolog
duke
univers
medic
center
durham
nc
usa
radiolog
unc
chapel
hill
nc
usa
rational
current
avail
endpoint
test
new
therapi
cf
gener
offer
inform
lung
structur
chest
radiographi
chest
ct
function
spirometri
lung
clearanc
index
addit
current
radiograph
techniqu
employ
imag
lung
requir
use
ioniz
radiat
limit
translat
young
children
hamper
repetit
use
measur
time
use
inhal
ga
contrast
agent
greatli
improv
suitabl
mri
techniqu
pulmonari
imag
enhanc
perfluorin
ga
allow
function
assess
multipl
breath
ga
kinet
healthi
diseas
lung
method
healthi
control
mean
subject
stabl
cf
mean
underw
perfluoropropan
pfp
enhanc
magnet
reson
imag
f
mri
use
pfp
mix
oxygen
ratio
inert
inhal
gaseou
contrast
agent
subject
instruct
seri
breathhold
imag
sequenc
obtain
studi
washin
washout
kinet
region
ventil
safeti
monitor
via
continu
puls
oximetri
endtid
co
measur
spirometri
perform
f
mri
ensur
chang
lung
function
result
studi
ga
inhal
result
signal
satur
color
map
creat
compar
ventil
subject
cf
healthi
control
includ
baselin
timetomaxim
signal
satur
slope
washin
washout
curv
ventil
heterogen
note
subject
cf
pronounc
lower
lung
function
wherea
rel
homogen
ga
diffus
observ
normal
subject
figur
show
colormap
comparison
time
maximum
washin
pfp
healthi
control
subject
panel
predict
cf
patient
panel
b
predict
demonstr
delay
heterogen
contrast
ga
washin
expect
subject
airway
obstruct
region
fail
demonstr
ga
signal
conclus
pair
h
imag
f
mri
offer
simultan
spatial
function
inform
ga
diffus
reflect
heterogen
lung
ventil
cf
lung
diseas
overt
safeti
concern
note
studi
includ
chang
postmri
futur
studi
plan
studi
techniqu
outcom
measur
treatment
cf
pulmonari
exacerb
control
b
cf
delay
ga
washin
slowfil
compart
background
comput
tomographi
studi
infant
cf
reveal
progress
structur
lung
diseas
present
much
earlier
symptom
unfortun
sever
limit
tool
avail
safe
evalu
youngest
patient
hamper
clinic
abil
interven
patient
prevent
irrevers
damag
even
lowdos
ct
limit
util
radiationsensit
popul
digit
chest
tomosynthesi
dct
commerci
avail
imag
techniqu
reconstruct
imag
slice
acquisit
seri
project
imag
imag
inplan
resolut
dct
higher
ct
significantli
lower
radiat
dose
scan
time
unfortun
second
well
beyond
normal
respiratori
cycl
young
patient
develop
stationari
digit
chest
tomosynthesi
system
sdct
util
stationari
gantri
multipl
independ
activ
xray
focal
spot
base
carbon
nanotub
cnt
xray
technolog
key
advantag
system
potenti
perform
gate
xray
imag
project
acquir
synchron
patient
respiratori
cycl
goal
firstinhuman
studi
evalu
sdct
system
convent
radiographi
adult
pediatr
cf
patient
method
cf
patient
undergo
clinic
indic
chest
radiograph
recruit
patient
underw
sdct
imag
cnt
linear
xray
sourc
tube
digit
xray
detector
place
behind
patient
patient
imag
supin
posit
imag
time
second
perform
breath
hold
radiat
dose
approxim
microgray
vs
approxim
milligray
ct
reconstruct
perform
iter
reconstruct
algorithm
imag
review
boardcertifi
radiologist
result
twenti
patient
complet
singleimag
studi
imag
qualiti
rate
radiologist
significantli
higher
convent
radiograph
confid
evalu
bronchiectasi
nodular
architectur
chang
exceed
convent
chest
radiograph
full
comparison
studi
plan
includ
evalu
sdct
versu
cxr
brasfield
score
conclus
stationari
chest
tomosynthesi
potenti
perform
lowdos
highresolut
evalu
thorax
like
abl
extend
techniqu
younger
patient
use
gate
studi
possibl
convent
chest
tomosynthesi
system
technolog
potenti
provid
earli
evalu
lung
field
asymptomat
children
introduct
spyryx
bioscienc
develop
inhal
peptid
optim
synthet
mimet
enacregul
domain
short
palat
lung
nasal
epitheli
clone
peptid
demonstr
signific
airway
surfac
liquid
asl
regul
restor
tracheal
mucu
veloc
sheep
model
cf
compel
toxicolog
profil
hyperkalemia
seen
enacaffect
agent
safeti
profil
present
challeng
manufactur
materi
toxicolog
studi
requir
dose
maximum
feasibl
dose
scale
manufactur
approach
commerci
batch
size
object
object
studi
optim
solut
formul
perform
nebul
perform
character
support
achiev
maximum
feasibl
dose
inhal
exposur
inden
toxicolog
studi
develop
requir
demonstr
stabil
abil
scale
product
scale
liter
method
formul
stabil
optim
studi
conduct
small
scale
compound
mgml
nacl
ph
sampl
place
stabil
long
term
acceler
rh
rh
analyz
rphplc
impur
profil
month
deliveri
rate
determin
solo
nebul
concentr
rang
mgml
optim
formul
determin
l
batch
compound
steril
filter
packag
releas
glp
toxicolog
result
ph
formul
show
good
stabil
longterm
storag
condit
puriti
unchang
month
acceler
condit
puriti
decreas
three
ph
formul
month
ph
formul
select
develop
differ
stabil
observ
ph
would
avoid
ad
acid
load
cf
airway
extrapol
shelf
life
puriti
formul
month
solo
nebul
nebul
rate
drop
mlmin
concentr
salin
alon
mlmin
mgml
due
increas
surfac
action
formul
term
peptid
deliveri
plateau
mg
min
reach
mgml
formul
select
kg
gmpgrade
prepar
yield
l
steril
batch
met
preliminari
drug
product
specif
prepar
util
glp
toxicolog
studi
conclus
data
gener
formul
optim
studi
support
refriger
solut
inhal
mgml
adjust
ph
predict
shelf
life
approach
two
year
nebul
studi
support
conclus
maximum
feasibl
dose
deliv
glp
toxicolog
toxicolog
batch
manufactur
scale
repres
much
dose
potenti
human
dose
cf
patient
lack
proper
function
cftr
caus
chronic
lung
infect
difficult
treat
convent
antibiot
pseudomona
aeruginosa
common
particularli
virul
pathogen
caus
signific
level
morbid
mortal
intracellular
bacteri
colon
p
aeruginosa
macrophag
mast
cell
epitheli
cell
particularli
difficult
erad
antibiot
even
cellperm
autophagi
catabol
process
cell
use
degrad
variou
defect
proteinsforeign
pathogen
convert
use
cellular
build
block
amino
acid
lipid
cf
known
autophagi
impair
compromis
patient
abil
clear
chronic
lung
infect
autophagi
activ
enabl
altern
mechan
clear
bacteri
infect
cell
therefor
could
potenti
use
use
combin
antiinfect
agent
fatti
acid
cysteamin
conjug
new
chemic
entiti
activ
autophagi
cultur
primari
homozyg
human
bronchial
epitheli
hbe
cell
concentr
low
vitro
studi
involv
hbe
cell
infect
p
aeruginosa
signific
reduct
intracellular
bacteri
load
observ
cell
pretreat
reduct
cfu
compar
observ
similarli
infect
hbe
cell
treat
cytochalasin
cellperm
antibiot
bacteri
clearanc
demonstr
first
vivo
studi
use
femal
balbc
mice
dose
oral
day
prior
infect
lethal
challeng
p
aeruginosa
evalu
chronic
p
aeruginosa
infect
model
involv
gutcorrect
cf
mice
vivo
model
cf
lung
infect
inflamm
treatment
result
decreas
bacteri
load
without
drug
drug
n
although
differ
total
white
blood
cell
count
bronchoalveolar
lavag
fluid
shift
away
neutrophil
versu
n
increas
number
macrophag
versu
n
paramet
p
use
analysi
varianc
vehicl
treat
anim
repres
potenti
new
therapeut
treatment
cf
key
exposur
paramet
auc
c
trough
substanti
enhanc
rel
ivacaftor
halflif
approxim
hour
support
develop
oncedaili
treatment
cystic
fibrosi
patient
gate
mutat
part
phase
clinic
develop
program
safeti
toler
steadyst
pk
profil
follow
multipledos
administr
character
method
multipledos
studi
doubleblind
placebocontrol
studi
assess
dose
administ
oncedaili
consecut
day
cohort
enrol
new
subject
subject
receiv
activ
drug
receiv
placebo
random
subject
dose
fed
condit
highfat
breakfast
provid
day
day
approxim
minut
prior
dose
dose
escal
initi
safeti
toler
found
support
proceed
higher
dose
pharmacokinet
blood
sampl
collect
sever
time
point
postdos
day
day
hour
postdos
day
day
plasma
concentr
metabolit
analyz
lcmsm
steadyst
pk
profil
evalu
three
dose
cohort
result
show
doseproport
increas
exposur
repeat
dose
dose
rel
dose
dose
show
higher
doseproport
increas
exposur
follow
day
dose
suggest
satur
metabol
steadyst
plasma
exposur
achiev
day
three
dose
averag
plasma
halflif
across
three
dose
approxim
hour
contrari
report
valu
kalydeco
steadi
state
metabolit
exposur
profil
day
dose
show
greatest
exposur
plasma
parent
drug
averag
parent
metabolit
major
metabolit
auc
ratio
mg
mg
dose
mg
dose
three
dose
welltoler
safeti
profil
similar
report
kalydeco
conclus
repeat
dose
safeti
toler
pharmacokinet
profil
continu
support
develop
oncedaili
cftr
potenti
base
known
pharmacodynamicpharmacokinet
relationship
ivacaftor
repeat
dose
studi
provid
necessari
data
select
potenti
effect
dose
clinic
trial
patient
gate
mutat
recombin
human
dnase
enzymat
cleav
extracellular
dna
sputa
cystic
fibrosi
cf
patient
henc
reduc
sputum
viscoelast
accumul
lung
patient
enabl
better
sputum
expector
actin
potent
inhibitor
dnase
found
high
concentr
cf
patient
sputum
may
decreas
enzym
dna
degrad
activ
therefor
interf
effect
inhal
dnase
lung
cf
patient
order
reduc
actindnas
interact
subsequ
inhibit
dnase
activ
protalix
develop
actininhibitionresist
dnase
airdnas
chemic
modifi
enzym
airdnas
protalix
proprietari
chemicallymodifi
plant
cellexpress
recombin
human
dnase
produc
tobacco
cell
develop
treatment
patient
cystic
fibrosi
administ
inhal
vitro
ex
vivo
studi
shown
airdnas
biolog
activ
exhibit
resist
inhibit
actin
relev
concentr
compar
ex
vivo
efficaci
studi
airdnas
dornas
alfa
commerci
avail
dnase
produc
cho
cell
show
greater
effici
reduc
viscoelast
dna
content
cf
sputa
compar
dornas
alfa
product
thu
airdnas
potenti
recombin
dnase
prepar
superior
activ
treat
cf
patient
base
chemic
modif
design
enhanc
enzym
efficaci
cf
patient
sputa
novel
treatment
may
result
improv
lung
function
decreas
incid
recurr
infect
patient
toxicolog
studi
support
proof
concept
studi
complet
clinic
trial
healthi
volunt
complet
patient
clinic
trial
plan
initi
second
half
background
high
level
inflamm
associ
chronic
inflammatori
immun
mediat
condit
cf
cf
associ
exagger
prolong
inflamm
lung
contribut
lung
injuri
fibrosi
loss
lung
function
pulmonari
infect
appar
cf
airway
adapt
innat
immun
respons
disproportion
dysregul
even
absenc
clinic
appar
infect
often
evid
inflamm
cf
airway
cf
patient
show
elev
level
neutrophil
lung
increas
neutrophil
elastas
myeloperoxidas
activ
cf
macrophag
display
spontan
exagger
pulmonari
infiltr
polar
proinflammatori
phenotyp
lesser
extent
antiinflammatori
phenotyp
cell
adapt
immun
system
lymphocyt
abund
cf
airway
produc
high
level
inflammatori
cytokin
addit
imbal
lymphocyt
subset
may
import
role
cf
inflammatori
respons
therapeut
regimen
cf
gener
involv
manag
symptom
attempt
slow
progress
diseas
howev
repeat
cycl
inflamm
injuri
fibrosi
caus
chronic
lifethreaten
manifest
ultim
lead
respiratori
failur
thu
therapi
target
inflammatori
environ
disrupt
destruct
cycl
infect
inflamm
fibrosi
would
major
impact
prevent
progress
lung
diseas
perinat
stem
cell
antiinflammatori
properti
make
promis
cell
therapeut
approach
treat
cf
hypothesi
hypothes
perinat
stem
cell
capabl
modul
chronic
hyperinflammatori
environ
cf
lung
method
perinat
stem
cell
administ
mous
model
bleomycininduc
lung
injuri
inflamm
fibrosi
hour
injuri
pulmonari
inflamm
evalu
day
post
injuri
pulmonari
fibrosi
day
post
injuri
evalu
antiinflammatori
effect
perinat
stem
cell
human
immun
cell
peripher
blood
collect
human
cystic
fibrosi
noncyst
fibrosi
subject
seri
vitro
immun
function
assay
perform
immun
cell
isol
blood
sampl
use
untouch
magnet
neg
isol
stimul
antigen
mimic
inflamm
vitro
effect
perinat
cell
test
lymphocyt
prolifer
neutrophil
migrat
neutrophil
enzymat
activ
includ
myeloperoxidas
mpo
elastas
ne
result
perinat
stem
cell
significantli
reduc
neutrophil
macrophag
pulmonari
migrat
lung
bleomycininjur
mous
prevent
pulmonari
fibrosi
loss
lung
function
human
sampl
administr
perinat
stem
cell
inhibit
lymphocyt
prolifer
attenu
neutrophil
enzymat
activ
preliminari
data
suggest
perinat
stem
cell
therapi
may
use
immunemodulatori
therapi
cf
ashkenazi
siti
de
boeck
c
efrati
sheba
medic
center
ganey
tikva
israel
univers
leuven
leuven
belgium
introduct
allerg
bronchopulmonari
aspergillosi
abpa
common
condit
patient
cystic
fibrosi
cf
asthma
character
respons
elev
serum
eosinophilia
increas
total
serum
ige
abpa
occur
patient
cf
omalizumab
human
recombin
monoclon
antibodi
target
highaffin
fc
receptor
ige
prevent
bind
ige
immun
effector
cell
mediat
inflamm
hypersensit
respons
aim
studi
explor
effect
omalizumab
treat
abpa
patient
cf
method
retrospect
studi
perform
cf
center
israel
belgium
inclus
criteria
cf
patient
patholog
sweat
test
proven
mutat
diagnosi
abpa
given
accord
establish
criteria
chosen
main
outcom
paramet
fev
bmi
pulmonari
exacerb
pex
steroidspar
effect
measur
taken
last
visit
start
treatment
pretreat
last
visit
treatment
first
visit
stop
treatment
posttreat
result
describ
patient
male
femal
israel
belgium
averag
age
year
patient
mutat
class
ii
cystic
fibrosisrel
diabet
cfrd
confirm
patient
averag
treatment
time
omalizumab
month
compar
preand
posttreat
fev
show
improv
patient
stabl
fev
cfrd
decreas
mean
drop
pred
none
femal
lung
function
deterior
ci
ns
reduct
bmi
record
patient
stabl
improv
treatment
patient
experienc
mean
pex
per
patient
pex
per
month
treatment
femal
experienc
averag
pex
male
per
patient
steroid
dosag
could
reduc
treatment
peroid
patient
posttreat
ige
level
decreas
patient
increas
none
reduc
ige
level
show
improv
outcom
paramet
elev
level
better
outcom
pex
conclus
patient
abpa
treat
omalizumab
seem
deriv
benefit
paramet
evalu
omalizumab
seem
improv
cours
abpa
pex
rate
higher
expect
small
seri
cfrd
male
gender
seem
associ
wors
abpa
diseas
cours
conclud
decreas
serum
ige
omalizumab
treatment
associ
clinic
improv
studi
need
determin
role
omalizumab
abpa
background
multipl
breath
washout
mbw
test
advantag
tradit
lung
function
test
especi
young
children
cystic
fibrosi
cf
mbw
test
requir
activ
cooper
subject
accur
interpret
mbw
outcom
requir
technic
correct
test
perform
facilit
standard
approach
measur
interpret
mbw
outcom
mbw
core
center
develop
mbw
center
provid
standard
train
certif
mbw
oper
support
feedback
well
central
overread
mbw
data
collect
intervent
studi
summar
experi
mbw
center
toronto
method
three
region
mbw
center
align
train
certif
protocol
complement
standard
oper
procedur
exhalyz
ecomed
ag
duernten
switzerland
mbw
devic
jensen
r
et
al
plo
current
prerequisit
becom
certifi
mbw
oper
collect
data
intervent
studi
requir
attend
handson
train
well
success
rate
certif
test
demonstr
compet
test
evalu
success
train
certif
program
respect
intervent
studi
data
proport
accept
test
calcul
aggreg
result
site
intervent
studi
result
date
oper
site
attend
one
twoday
train
session
toronto
particip
site
train
school
age
year
preschool
year
mbw
test
traine
submit
certif
test
success
complet
certif
process
mbw
test
children
year
older
similarli
success
certifi
preschool
test
current
toronto
mbw
center
review
studi
data
intervent
studi
test
occas
analyz
date
overal
review
mbw
test
classifi
technic
accept
signific
improv
success
rate
first
studi
visit
subsequ
studi
visit
p
across
studi
conclus
overal
establish
train
certif
protocol
led
high
mbw
test
success
rate
intervent
studi
mbw
success
rate
compar
publish
feasibl
data
report
experienc
mbw
research
center
continu
feedback
mbw
oper
provid
insight
addit
train
need
object
identifi
oper
challeng
conduct
pabd
trial
designmethod
conduct
onlin
survey
one
pabd
trial
investig
anoth
commun
provid
cp
also
conduct
qualit
interview
parent
children
invit
particip
clinic
research
industri
repres
affili
pabd
trial
lastli
use
aggreg
analysi
clinicaltrialsgov
aact
databas
identifi
number
characterist
pediatr
antibiot
drug
trial
regist
clinicaltrialsgov
result
mani
investig
cp
said
parent
concern
aspect
clinic
research
particularli
number
blood
draw
invas
procedur
potenti
side
effect
use
experiment
drug
logist
among
parent
newborn
concern
express
contact
research
soon
birth
research
staff
unfamiliar
child
care
investig
indic
adequ
research
administr
infrastructur
key
success
trial
implement
pabd
trial
repres
cohort
intervent
observ
pediatr
trial
pabd
trial
focus
primarili
infect
otiti
media
pneumonia
trial
accept
neonat
conclus
develop
recommend
improv
effici
pabd
trial
depend
identifi
challeng
face
stakehold
result
elucid
need
chang
benefit
risk
child
particip
research
better
commun
parent
underscor
import
improv
clinic
trial
infrastructur
draft
consider
trial
design
chang
present
draft
consider
may
includ
need
address
parent
provid
concern
less
burdensom
trial
design
signific
provid
support
clinic
trial
sensit
train
approach
parent
medic
compromis
children
introduct
neutrophil
elastas
implic
patholog
process
multipl
lung
diseas
includ
cystic
fibrosi
neutrophil
elastas
inhibit
genet
defici
lead
impair
airway
function
method
purifi
hne
character
vitro
levelsact
three
protein
compar
lung
tissu
lysat
cf
noncf
patient
cleavag
also
assess
cf
patient
sputa
result
analysi
reveal
effici
proteolyz
vitro
result
proteolyz
incap
inhibit
neutrophil
elastas
monoclon
antibodi
specif
inhibit
block
inactiv
vitro
use
newli
develop
activ
assay
found
neutrophil
elastas
activ
elev
human
lung
tissu
cystic
fibrosi
patient
compar
noncf
control
speci
consist
nativ
form
detect
human
lung
tissu
speci
consist
detect
sputum
cf
patient
small
set
human
lung
tissu
analyz
activ
correl
cleavag
spearman
r
elastas
activ
correl
cleavag
spearman
r
activ
also
correl
elastas
activ
spearman
r
consist
hypothesi
activ
inactiv
conclus
proteas
reportedli
capabl
inactiv
activ
cf
lung
tissu
correl
degre
cleavag
togeth
find
support
hypothesi
may
partial
restor
function
via
inhibit
determin
impact
human
neutrophil
elastas
hne
cystic
fibrosi
cf
patient
sputa
degrad
function
introduct
human
monoclon
antibodi
select
potent
alloster
inhibitor
proand
member
zincdepend
endopeptidas
degrad
extracellular
matrix
ecm
inflamm
wound
heal
increas
level
observ
sputa
cf
subject
consid
import
mediat
pathogenesi
cf
inhibit
activ
thu
potenti
benefici
cf
subject
multipl
proteas
includ
hne
report
elev
cf
sputa
digest
vitro
experi
perform
determin
stabil
function
cf
sputa
proteolyticrich
environ
found
cf
airway
method
incub
hour
sputa
cf
patient
purifi
recombin
hne
vitro
postincub
sampl
test
assess
abil
bind
abil
inhibit
catalysi
use
peptid
proteolysi
assay
result
minim
degrad
presenc
cf
sputum
recombin
hne
digest
result
specif
molecular
weight
fragment
correspond
report
digest
hing
region
possibl
leav
fab
intact
also
lose
abil
bind
inhibit
catalysi
cf
sputum
presenc
endogen
spike
hne
conclus
data
suggest
fulli
function
abil
bind
well
inhibit
presenc
endogen
well
spike
hne
cf
sputa
background
chronic
airway
infect
creat
intens
inflamm
drive
cf
airway
diseas
acut
pulmonari
exacerb
ape
punctuat
diseas
cours
caus
stepwis
decreas
lung
function
biomark
inflamm
may
quantifi
diseas
statu
provid
new
predictor
diseas
outcom
surviv
precis
accur
report
result
investig
therapi
design
studi
identifi
biomark
cf
airway
diseas
patient
repres
nation
popul
studi
design
random
prospect
observ
cohort
studi
patient
cf
produc
sputum
method
irb
approv
randomli
select
recruit
patient
year
age
expector
sputum
accredit
cf
center
arizona
colorado
idaho
montana
nevada
new
mexico
wyom
random
stabl
patient
reduc
season
centerspecif
highacuityspecif
bias
collect
sputum
use
redcap
record
clinic
data
enrol
ape
ape
followup
stabl
followup
visit
report
summari
statist
patient
recruit
enrol
period
result
success
recruit
patient
comparison
patient
cf
foundat
patient
registri
cffpr
produc
sputum
show
count
measur
gender
age
percentpredict
fev
weightforag
zscore
height
pancreat
suffici
diabet
cultur
staphylococcu
aureu
pseudomona
aeruginosa
burkholderia
cepacia
complex
significantli
differ
mountain
west
patient
fewer
infect
methicillinresist
aureu
mrsa
vs
p
ape
vs
per
year
p
receiv
treatment
inhal
aztreonam
azithromycin
hyperton
salin
dornas
alpha
p
inhal
tobramycin
conclus
random
patient
recruit
produc
studi
cohort
repres
us
cf
popul
mountain
west
cf
provid
may
aggress
treatment
confirm
use
recent
cffpr
data
need
current
interpret
associ
clinic
aspect
diseas
futur
conclus
biomark
discoveri
secur
generaliz
cf
patient
produc
sputum
acknowledg
great
thank
mwcfc
research
coordin
n
argel
durham
b
glover
c
kopecki
molina
k
poch
redway
sprandel
varela
r
yoshikawa
fund
cf
foundat
fuch
hj
et
al
n
engl
j
med
consist
intraven
iv
antibiot
administr
presenc
respiratori
sign
symptom
increas
cough
chang
sputum
fev
declin
etc
chang
health
demograph
treatment
threshold
sinc
public
fuch
definit
chang
demograph
patient
volunt
cf
clinic
trial
result
overal
reduct
use
iv
antibiot
treatment
exacerb
clinic
trial
expand
modifi
fuch
exacerb
definit
develop
respons
chang
expand
definit
differ
origin
oral
inhal
andor
iv
antibiot
may
use
respons
presenc
sign
symptom
modifi
fuch
definit
requir
presenc
fuch
sign
symptom
irrespect
treatment
although
three
definit
employ
variou
studi
seldom
ever
compar
within
singl
studi
compar
atalurenassoci
reduct
exacerb
incid
use
three
differ
fuch
exacerb
definit
method
phase
random
doubleblind
placebocontrol
studi
effect
ataluren
predict
fev
exacerb
conduct
among
patient
carri
cftr
nonsens
mutat
post
hoc
comparison
atalurenassoci
chang
exacerb
incid
function
three
fuch
definit
among
patient
concomitantli
receiv
inhal
aminoglycosid
conduct
result
patient
receiv
chronic
inhal
aminoglycosid
reduct
exacerb
rate
observ
patient
receiv
ataluren
vs
receiv
placebo
irrespect
fuch
definit
use
tabl
atalurenassoci
clinic
benefit
found
statist
signific
use
expand
modifi
fuch
definit
origin
fuch
definit
conclus
differ
util
three
fuch
exacerb
definit
clearli
demonstr
analys
point
estim
atalurenassoci
reduct
exacerb
rate
popul
analyz
compar
across
three
exacerb
definit
rate
reduct
rang
statist
signific
shown
expand
modifi
fuch
definit
due
higher
frequenc
event
case
averag
event
per
patient
origin
fuch
definit
much
lower
frequenc
averag
event
per
patient
introduct
neutrophil
elastas
ne
level
frequent
elev
cystic
fibrosi
cf
sputum
correl
inflammatori
marker
measur
lung
impair
decreas
fev
ne
therefor
consid
potenti
biomark
exacerb
howev
tool
avail
monitor
proteas
level
home
clinic
routin
monitoringmeasur
ne
sputum
could
assist
proactiv
manag
cf
patient
identifi
earli
sign
exacerb
could
facilit
preemptiv
medic
intervent
avoid
potenti
seriou
complic
proaxsi
develop
activitybas
immunoassay
abi
ne
quantif
incorpor
molecul
capabl
rapid
select
bind
activ
ne
translat
technolog
point
care
poc
test
form
later
flow
devic
lfd
provid
valuabl
tool
monitor
diseas
activ
aim
develop
valid
prototyp
lfd
rapidli
detect
activ
ne
airway
sampl
method
experi
perform
use
prototyp
lfd
compos
conjug
pad
contain
detector
compon
appropri
test
control
reagent
stripe
onto
nitrocellulos
membran
cf
sol
netagrun
buffer
transfer
sequenti
reaction
tube
total
volum
left
stand
minut
signal
intens
score
close
relat
proteas
ie
cathepsin
g
catg
human
airway
trypsin
hat
also
examin
evalu
assay
specif
result
follow
initi
quantif
use
abi
activ
ne
immunoassay
proaxsi
ltd
subset
cf
sol
sampl
contain
differ
level
activ
ne
select
inclus
studi
lfd
analysi
reveal
excel
correl
two
assay
platform
signal
ne
detect
less
second
assay
also
found
highli
sensit
posit
signal
note
biolog
sampl
contain
ngml
activ
ne
specif
analysi
reveal
neglig
crossreact
upon
test
proteas
catg
hat
conclus
develop
highli
sensit
specif
lfd
rapid
detect
activ
ne
complex
clinic
sampl
could
prove
vital
tool
cf
manag
account
devic
capac
measur
ne
establish
biomark
infect
anticip
posit
test
would
prompt
individu
seek
medic
attent
mitig
risk
exacerb
lead
hospitalis
introduct
neutrophil
elastas
ne
serin
proteas
releas
azurophil
granul
leukocyt
neutrophil
primari
role
assist
proteolyt
breakdown
destruct
phagocytos
foreign
pathogen
part
normal
immun
respons
howev
secret
activ
ne
implic
contribut
rang
inflammatori
disord
includ
rheumatoid
arthriti
chronic
obstruct
pulmonari
diseas
copd
cystic
fibrosi
cf
proaxsi
develop
rang
proteasetag
abl
rapidli
select
bind
activ
proteas
incorpor
proteasetag
within
activitydepend
immunoassay
enabl
quantif
activ
proteas
within
biolog
sampl
result
recent
commercialis
proteasetag
activ
neutrophil
elastas
immunoassay
aim
report
applic
benefit
ne
ultra
novel
biotinyl
proteasetag
target
ne
furthermor
compar
anoth
commerci
avail
irrevers
ne
inhibitor
meosucaapvch
cl
term
select
stabil
method
kinet
evalu
select
profil
ne
ultra
meosucaapvch
cl
ne
proteas
includ
thrombin
cathepsin
g
cathepsin
b
chymotrypsin
determin
fluorogen
steadyst
enzym
assay
stabil
ne
ultra
meosucaapvch
cl
compar
overnight
incub
vv
serum
cf
patient
follow
ne
activ
assay
furthermor
applic
ne
ultra
activitybas
probe
abp
detect
ne
cf
sol
sampl
carri
sdspage
electroblot
techniqu
result
ne
ultra
meosucaapvch
cl
show
excel
irrevers
inhibit
ne
similar
potenc
display
k
k
valu
x
min
x
min
respect
ne
ultra
display
excel
select
ne
effect
activ
proteas
includ
cathepsin
g
thrombin
cathepsin
b
contrast
meosucaapvch
cl
complet
abrog
activ
cathepsin
b
term
stabil
follow
overnight
incub
ne
ultra
meosucaapvch
cl
display
inhibitori
action
ne
howev
meosucaapvch
cl
show
slight
reduct
potenc
suggest
lower
stabil
biolog
sampl
ne
ultra
examin
abp
enabl
streptavidinmedi
detect
ne
cf
sol
sampl
follow
separ
detect
via
sdspage
electroblot
conclus
report
applic
novel
proteasetag
ne
ultra
irrevers
inhibitor
potent
abp
ne
affin
label
number
advantag
commerci
avail
irrevers
ne
inhibitor
meosucaapvch
cl
term
improv
stabil
select
well
abil
visualis
activ
ne
clinic
sampl
use
combin
streptavidinconjug
ne
ultra
therefor
potenti
broad
applic
across
laboratorybas
cf
research
background
cf
caus
mutat
cystic
fibrosi
transmembran
conduct
regul
cftr
ion
channel
regul
airway
surfac
liquid
asl
current
paradigm
absenc
function
cftr
lead
decreas
asl
ph
coakley
rd
et
al
pna
reduc
ciliari
beat
frequenc
clarymeinesz
c
et
al
erj
increas
mucu
viscos
matsui
h
et
al
jci
impair
innat
immun
pezzulo
aa
et
al
natur
hypothes
nebul
nahco
restor
asl
ph
improv
airway
function
cf
object
studi
evalu
safeti
toler
inhal
nahco
assess
pulmonari
function
effect
airway
ph
patient
cf
method
part
safeti
toler
individu
cf
receiv
nebul
nahco
concentr
spirometri
cough
frequenc
measur
prepost
nebul
part
effect
inhal
nahco
random
doubleblind
crossov
studi
conduct
compar
effect
hyperton
nahco
hyperton
salin
individu
cf
receiv
nebul
dose
nahco
salin
separ
hour
spirometri
exhal
breath
condens
ebc
ph
sputum
ph
measur
patient
return
day
later
receiv
altern
solut
studi
protocol
approv
institut
review
board
univers
pittsburgh
result
part
patient
nebul
nahco
one
patient
histori
reactiv
airway
unabl
complet
nahco
inhal
due
dyspnea
chest
tight
reliev
albuterol
mean
fev
significantli
chang
inhal
nahco
mean
rang
previous
report
nonsignific
trend
increas
cough
increas
nahco
concentr
part
patient
toler
inhal
nahco
hyperton
salin
nahco
associ
decreas
fev
one
dose
mean
rang
subject
decreas
fev
fev
statist
chang
salin
mean
rang
fev
decreas
one
patient
group
patient
abl
produc
suffici
sputum
analysi
statist
signific
chang
note
ph
ebc
sputum
dose
nahco
ebc
ph
sputum
ph
salin
ebc
ph
sputum
ph
p
valu
report
pair
ttest
discuss
shown
acut
nebul
nahco
safe
well
toler
individu
cf
patient
discontinu
administr
due
bronchospasm
nahco
inhal
associ
decreas
fev
similar
observ
inhal
hyperton
agent
robinson
et
al
erj
low
sampl
size
limit
abil
definit
assess
chang
ebc
sputum
ph
investig
necessari
assess
whether
longterm
inhal
nahco
improv
lung
function
cf
cystic
fibrosi
cf
caus
mutat
cystic
fibrosi
transmembran
conduct
regul
cftr
gene
frequent
cf
character
hypersecret
proinflammatori
chemokin
airway
lumen
consequ
induc
highli
inflammatori
cellular
phenotyp
typic
cf
subsequ
fibrosi
caus
airway
destruct
lead
morbid
mortal
previous
report
upregul
cystic
fibrosi
lung
epitheli
cell
howev
molecular
mechan
regul
manifest
diseas
phenotyp
cf
well
understood
report
regulatori
associ
protein
mtor
complex
rptor
novel
target
cf
lung
epitheli
cell
suppress
rptor
express
subsequ
activ
signal
result
induct
fibrosi
upregul
connect
tissu
growth
factor
ctgf
cf
lung
epitheli
cell
thu
propos
regul
fibrosi
cf
lung
axi
mechan
potenti
target
cf
therapi
character
small
airway
mucu
obstruct
associ
acceler
loss
lung
function
mortal
cigarett
smoke
caus
reduc
cystic
fibrosi
transmembran
conduct
regul
cftr
activ
enhanc
mucu
express
lead
impair
mucociliari
clearanc
patient
copd
without
cftr
mutat
reduc
cftr
activ
independ
associ
chronic
bronchiti
cftr
potenti
ivacaftor
approv
cf
also
augment
function
wildtyp
cftr
includ
airway
epithelium
acquir
cftr
dysfunct
test
whether
cftr
potenti
might
help
copd
conduct
pilot
studi
determin
safeti
efficaci
pharmacokinet
ivacaftor
copd
patient
chronic
bronchiti
method
twelv
activ
former
smoker
copd
chronic
bronchiti
enrol
doubleblind
random
placebocontrol
pilot
trial
investig
effect
ivacaftor
cftr
function
patientreport
outcom
bronchiti
symptom
ivacaftor
pharmacokinet
day
treatment
prepar
subsequ
studi
result
patient
random
fashion
ivacaftor
placebo
baselin
characterist
wellmatch
arm
although
mean
sweat
chlorid
lower
anticip
ivacaftor
welltoler
seriou
advers
event
attribut
studi
drug
day
treatment
patient
receiv
ivacaftor
exhibit
nonsignific
improv
cftr
function
detect
improv
sweat
chlorid
mmoll
ivacaftor
vs
placebo
compar
baselin
nasal
potenti
differ
mv
ivacaftor
group
vs
mv
placebo
compar
baselin
subject
receiv
ivacaftor
nonsignific
improv
symptom
detect
breathless
cough
sputum
scale
bcss
exceed
mcid
unit
mean
chang
ivacaftor
vs
placebo
compar
baselin
subject
diminish
cftr
function
baselin
robust
respons
meaning
chang
spirometri
pharmacokinet
reveal
stabl
ivacaftor
level
auc
mirror
experi
cf
patient
complet
cftr
sequenc
detect
genet
cftr
defect
largest
respond
ivacaftor
group
heterozygot
synonym
cftr
variant
conclus
ivacaftor
safe
welltoler
patient
copd
exhibit
predict
pharmacokinet
nonsignific
improv
cftr
activ
respiratori
symptom
ivacaftor
treatment
mean
chang
npd
sweat
chlorid
suggest
improv
wildtyp
cftr
activ
result
set
stage
longer
trial
determin
effect
cftr
potenti
clinic
outcom
patient
chronic
bronchiti
appropri
power
studi
enrich
patient
profound
cftr
dysfunct
baselin
support
nih
background
pulmonari
exacerb
pex
common
event
punctuat
clinic
cours
cf
associ
signific
morbid
mortal
present
pauciti
marker
guid
pex
manag
decis
earli
chang
clinic
paramet
symptom
lung
function
inadequ
discrimin
treatment
respond
vs
nonrespond
lead
delay
clinic
recognit
treatment
nonrespons
identifi
bloodbas
biomark
chang
earli
cours
pex
treatment
predict
respons
therapi
method
pex
adult
cf
patient
hospit
intraven
iv
antibiot
includ
bedsid
spirometri
cf
respiratori
symptom
diari
cfrsd
serumplasma
sampl
collect
within
hour
initi
iv
antibiot
therapi
day
day
day
treatment
complet
chronic
respiratori
infect
symptom
score
criss
deriv
cfrsd
three
definit
pex
treatment
nonrespons
employ
definit
rel
improv
begin
end
treatment
criss
definit
criss
score
decreas
less
median
point
begin
end
treatment
composit
definit
defin
one
follow
failur
predict
recov
best
prior
month
end
antibiot
therapi
prolong
antibiot
therapi
day
switch
antibiot
due
poor
clinic
respons
semitarget
proteom
analysi
perform
plasma
multipl
reaction
monitor
mass
spectrometri
mrmm
uniqu
protein
measur
mesoscal
discoveri
carlsbad
ca
use
measur
serum
level
four
addit
protein
tnfalpha
calprotectin
protein
panel
classifi
creat
use
elast
net
classifi
highest
leav
one
cross
valid
auc
present
result
sever
blood
protein
chang
abund
begin
end
exacerb
chang
earli
day
capabl
discrimin
treatment
respond
vs
nonrespond
panel
consist
rel
chang
monocyt
differenti
antigen
heparin
cofactor
level
demonstr
best
perform
predict
treatment
nonrespons
accord
definit
auc
sn
sp
panel
consist
absolut
chang
fibrinogen
beta
gamma
chain
level
demonstr
best
perform
predict
treatment
nonrespons
accord
criss
definit
auc
sn
sp
protein
panel
perform
well
predict
treatment
nonrespons
accord
composit
definit
conclus
use
mrmm
immunoassay
identifi
sever
promis
bloodbas
protein
panel
measur
serial
earli
cours
pex
use
predict
treatment
nonrespons
futur
studi
plan
valid
result
fund
sourc
cf
canada
background
cystic
fibrosi
cf
realiz
promis
person
medicin
recent
advanc
drug
develop
target
cftr
directli
result
lung
function
improv
variabl
respons
demand
better
predict
outcom
improv
manag
decis
genet
modifi
contribut
diseas
sever
cf
pancrea
intestin
birth
assess
relationship
diseas
sever
therapeut
respons
cf
lung
method
associ
lung
diseas
sever
assess
individu
canadian
french
cf
gene
modifi
consortia
gate
mutat
homozyg
variabl
respons
cftrdirect
potenti
therapi
attribut
genotyp
assess
canadian
cf
patient
gate
mutat
final
primari
airway
cell
cultur
use
determin
genotyp
display
differenti
modif
cftr
function
upon
treatment
cftr
corrector
cf
individu
gate
mutat
retain
cellsurfac
local
protein
show
modifi
lung
function
case
individu
homozyg
cell
surfac
express
lack
treatment
respons
ivacaftor
improv
channel
open
probabl
patient
gate
mutat
show
substanti
variabl
respons
explain
notabl
homozyg
primari
bronchial
cell
treat
drug
restor
surfac
cftr
likewis
modifi
treatment
respons
summari
find
indic
airway
modif
requir
cftr
cell
surfac
common
variat
could
predict
respons
cftrdirect
therapeut
introduct
cf
character
oxidantantioxid
imbal
oxid
stress
may
play
signific
role
pathophysiolog
cf
lung
diseas
purpos
studi
evalu
effect
oral
antioxidantenrich
multivitamin
supplement
antioxid
level
marker
inflamm
oxid
stress
clinic
outcom
method
multicent
random
doubleblind
control
trial
pancreat
insuffici
cf
subject
year
age
older
predict
random
week
antioxidantenrich
multivitamin
mean
age
mean
pred
control
multivitamin
without
antioxid
mean
age
mean
pred
safeti
toler
assess
chang
system
antioxid
level
lutein
lycopen
erythrocyt
glutathion
peroxidas
activ
system
sputum
marker
inflamm
oxid
stress
system
marker
wbc
count
hscrp
calprotectin
serum
amyloid
myeloperoxidas
mpo
malondialdehyd
protein
carbonyl
total
antioxid
capac
sputum
marker
mpo
free
neutrophil
elastas
activ
slpi
clinic
outcom
pulmonari
function
anthropometr
measur
pulmonari
exacerb
evalu
result
chang
sputum
mpo
concentr
treatment
period
primari
efficaci
endpoint
significantli
differ
antioxidantsuppl
group
control
group
modelbas
estim
differ
group
chang
sputum
mpo
ngml
ci
system
antioxid
level
lutein
significantli
increas
antioxidanttr
group
p
signific
chang
system
sputum
marker
inflamm
oxid
stress
wherea
lung
function
growth
endpoint
differ
group
week
antioxidanttr
group
lower
risk
time
first
pulmonari
exacerb
requir
antibiot
control
group
hazard
ci
adverseev
incid
toler
similar
group
conclus
antioxid
supplement
safe
well
toler
led
increas
system
antioxid
level
without
significantli
impact
inflamm
oxid
stress
increas
time
first
exacerb
clinic
relev
improv
observ
antioxidanttr
group
cfft
support
acknowledg
tdn
site
cf
patient
famili
prospect
twopart
multicent
prospect
longitudin
studi
cftrdepend
diseas
profil
cf
explor
biomark
clinic
physiolog
characterist
across
variou
degre
cf
sever
biospecimen
clinic
data
collect
better
understand
molecular
mediat
profil
character
specif
level
cftr
activ
gain
import
inform
biomark
track
relationship
cftr
activ
restor
abstract
present
studi
design
characterist
recruit
subject
part
method
healthi
noncf
control
year
age
cohort
compar
two
cf
cohort
defin
cftr
genotyp
one
least
one
partial
function
cftr
variant
cohort
less
sever
diseas
two
mutat
absent
cftr
function
cohort
sever
diseas
cohort
subject
studi
twice
period
cohort
cf
subject
complet
visit
month
assess
includ
histori
spirometri
clinic
laboratori
sweat
chlorid
measur
biomark
measur
sputum
blood
urin
stool
sampl
subject
contribut
biospecimen
cfft
biorepositori
subset
cf
subject
undergo
intestin
ph
measur
nasal
epitheli
cell
procur
result
date
partialfunct
cf
subject
cohort
absentfunct
cf
subject
cohort
healthi
control
enrol
baselin
demograph
clinic
characterist
cohort
display
tabl
cohort
particip
complet
studi
visit
cohort
subject
cohort
subject
complet
studi
visit
mean
sweat
chlorid
concentr
significantli
differ
across
cohort
cohort
mmoll
sd
cohort
mmoll
sd
cohort
mmoll
sd
p
pairwis
comparison
cohort
among
cf
cohort
withinsubject
varianc
less
betweensubject
varianc
cohort
mmoll
vs
cohort
vs
conclus
prospect
success
enrol
healthi
noncf
control
cf
subject
differ
cftr
genet
sever
sweat
chlorid
clearli
distinguish
cohort
reflect
underli
cftr
activ
prospect
data
biospecimen
may
yield
addit
biomark
discrimin
level
cftr
function
differ
organ
prove
use
defin
biolog
phenotyp
facilit
person
therapeut
approach
cf
support
cfft
acknowledg
tdn
site
cf
patient
famili
introduct
recent
describ
lower
muscl
oxygen
extract
ex
exercis
patient
cf
compar
control
may
contribut
reduc
exercis
capac
sildenafil
phosphodiesteras
type
inhibitor
use
improv
exercis
capac
patient
popul
howev
effect
sildenafil
muscl
ex
exercis
cf
unknown
purpos
studi
sought
test
hypothesi
sildenafil
improv
ex
maxim
exercis
patient
cf
method
eleven
patient
cf
male
femal
year
volunt
studi
increment
exercis
test
exhaust
perform
cycl
ergomet
use
godfrey
protocol
determin
exercis
capac
vo
peak
baselin
follow
four
week
sildenafil
treatment
mg
tid
signalmorpholog
imped
cardiolog
physioflow
use
monitor
hemodynam
measur
rest
maxim
exercis
max
treatment
sildenafil
ex
determin
use
deriv
fick
equat
exercis
factor
calcul
ratio
cardiac
output
consumpt
result
signific
differ
rest
maxim
cardiac
output
rest
max
arteri
satur
rest
max
observ
follow
treatment
control
fatfre
mass
differ
rest
ex
observ
preand
posttreat
vs
howev
ex
maxim
exercis
significantli
higher
sildenafil
compar
treatment
signific
correl
identifi
maxim
exercis
ex
vo
peak
diastol
blood
pressur
addit
exercis
factor
significantli
associ
baselin
pulmonari
function
fev
conclus
first
time
document
four
week
sildenafil
treatment
improv
muscl
extract
maxim
exercis
patient
cf
increas
extract
may
contribut
improv
exercis
capac
popul
futur
studi
warrant
investig
long
term
effect
sildenafil
sustain
improv
extract
cf
support
part
nihniddk
rah
object
assess
realworld
diseas
burden
among
patient
canada
cf
year
old
homozyg
cftr
modul
method
demograph
clinic
characterist
resourc
util
obtain
retrospect
medic
record
cf
clinic
baselin
period
followup
period
descript
analys
perform
age
year
averag
baselin
lung
function
ppfev
overal
pulmonari
exacerb
pex
defin
mention
record
hospit
outpati
visit
requir
nonroutin
antibiot
treatment
result
data
patient
includ
tabl
show
baselin
patient
characterist
patient
comorbid
baselin
commonli
pancreat
insuffici
nasal
polyp
followup
period
median
month
patient
newli
emerg
comorbid
includ
newli
diagnos
impair
glucos
toler
cfrelat
diabet
depress
mean
pex
rate
baselin
vs
followup
followup
period
proport
patient
pex
rate
pex
higher
among
adult
adolesc
among
patient
ppfev
group
patientyear
ppfev
group
followup
period
hospit
reason
mean
length
stay
day
patient
mean
outpati
visitsyear
baselin
period
patient
use
antibiot
asthma
medic
mucolyt
percentag
followup
respect
conclus
togeth
result
suggest
patient
canada
cf
homozyg
mutat
consider
progress
burden
ill
lead
increas
resourc
util
patient
age
diseas
progress
sponsor
vertex
pharmaceut
incorpor
lung
function
calcul
use
global
lung
initi
equat
calcul
patient
cystic
fibrosi
character
ion
channel
abnorm
produc
airway
surfac
liquid
asl
volum
deplet
mucu
hyperconcentr
result
thick
adher
airway
mucu
plug
resist
mucociliari
cough
clearanc
experiment
asl
deplet
mucu
hyperconcentr
gener
mice
airwaytarget
overexpress
epitheli
na
channel
subunit
encod
gene
express
transgen
caus
airway
surfac
dehydr
consequ
increas
mucu
concentr
lead
osmot
compress
cilia
mucu
adhes
lung
patholog
mice
character
airway
mucu
obstruct
inflamm
suscept
spontan
bacteri
infect
recapitul
main
featur
cf
lung
diseas
import
hyperconcentr
mucu
pathophysiolog
cf
lung
diseas
led
us
use
mous
vivo
model
test
efficaci
variou
mucusmobil
agent
effort
focus
action
reduc
agent
base
rational
reduc
molecular
weight
mw
mucin
polym
cut
intermolecular
disulphidebond
predict
reduc
viscou
elast
moduli
mucu
gel
increas
abil
mucin
diffus
swell
gel
thu
aid
transport
mucu
plug
lung
preliminari
experi
perform
use
noseonli
aerosol
deliveri
system
adapt
deliv
small
volum
polydispers
particl
analysi
aerosol
deposit
fraction
use
nm
fluoresc
latex
bead
indic
less
total
number
bead
gener
deposit
lung
wildtyp
wt
mice
nonetheless
agaros
western
blot
analysi
bal
harvest
wt
mice
aerosol
singl
dose
proprietari
reduc
agent
rx
indic
signific
decreas
high
mw
polym
compar
mice
aerosol
isoosmot
vehicl
mucu
plug
mice
airway
easili
detect
histolog
effect
rx
treatment
also
assess
morphometr
intralumin
abpa
posit
area
demonstr
feasibl
approach
studi
involv
aerosol
rx
mice
observ
dosedepend
reduct
lung
mucu
content
ie
vehicl
mm
lung
mm
deposit
rx
mm
lung
mm
deposit
rx
mm
lung
mean
sem
notabl
preliminari
experi
test
efficaci
benchmark
mucolyt
nacetylcystein
nac
suggest
compound
dose
concentr
activ
rx
mm
ineffect
promot
mucu
plug
clearanc
mice
mirror
poor
efficaci
nac
clinic
cumul
data
indic
develop
clinic
relev
platform
perform
initi
test
efficacytox
mucusmobil
agent
introduct
progress
lung
diseas
due
mucociliari
dysfunct
remain
problem
cystic
fibrosi
cf
inflamm
usual
associ
cf
airway
diseas
reduc
chlorid
secret
decreas
bk
conduct
otherwis
provid
drive
forc
secret
thu
antiinflammatori
cf
therapi
import
cf
care
angiotensin
receptor
blocker
arb
potent
antiinflammatori
properti
investig
effect
losartan
mucociliari
dysfunct
vitro
vivo
method
cfbe
cell
obtain
homozyg
individu
transplant
lifecent
northwest
irb
approv
cell
redifferenti
airliquid
interfac
inflamm
induc
ngml
h
cytokin
associ
wors
pulmonari
outcom
cf
bk
channel
activ
airway
surfac
liquid
asl
volum
ciliari
beat
frequenc
cbf
measur
publish
vivo
experi
mount
sinai
medic
center
iauac
approv
tracheal
mucu
veloc
tmv
studi
sheep
challeng
either
three
consecut
day
ml
h
later
human
neutrophil
elastas
hne
ml
tmv
measur
h
one
day
h
later
ml
tmv
measur
h
result
cfbe
cell
treatment
losartan
rescu
reduct
bk
activ
downregul
subunit
asl
volum
cbf
assur
vivo
relev
sheep
challeng
aerosol
hne
consecut
day
result
tmv
reduct
persist
day
cessat
challeng
losartan
given
inhal
day
mg
revers
mucociliari
dysfunct
kept
transport
normal
next
day
losartan
also
revers
tmv
reduct
respons
see
figur
conclus
result
show
inflammatori
mediat
reduc
altern
chlorid
transport
cf
cell
result
dysfunct
paramet
govern
mucociliari
clearanc
vitro
tmv
vivo
losartan
overcom
inflammatori
condit
lead
sustain
recoveri
asl
volum
vitro
tmv
vivo
result
set
stage
clinic
trial
use
arb
cf
patient
tracheal
mucu
veolciti
tmv
sheep
introduct
cystic
fibrosi
cf
patient
frequent
colon
nonmucoid
pseudomona
aeruginosa
howev
time
adapt
cf
lung
mutat
mucoid
form
strongli
associ
increas
morbid
colistin
frequent
prescrib
inhal
therapi
patient
acquisit
resist
recent
report
oligog
low
molecular
weight
sodium
algin
oligom
deriv
seawe
previous
shown
disrupt
p
aeruginosa
biofilm
format
powel
lc
et
al
j
respir
cell
mol
biol
disrupt
mucin
crosslink
within
biofilm
network
significantli
reduc
cf
sputum
viscoelast
pritchard
mf
et
al
mol
pharma
method
studi
investig
abil
oligog
potenti
antimicrobi
properti
colistin
establish
pseudomon
biofilm
effect
growth
media
vitro
test
explor
use
synthet
artifici
sputum
medium
standard
mueller
hinton
mh
broth
growth
curv
quantit
analysi
mucoid
pseudomon
biofilm
treat
colistin
andor
oligog
mgml
conduct
media
confoc
laser
scan
microscopi
employ
visual
biofilm
disrupt
quantifi
use
comstat
imag
analysi
scan
electron
microscop
imag
establish
biofilm
taken
compar
nonmucoid
mucoid
strain
treat
colistin
oligog
mgml
interact
oligog
pseudomon
algin
express
quorumsens
qs
molecul
studi
use
circular
dichroism
liquid
chromatographymass
spectrometri
result
biofilm
morpholog
grown
medium
character
dens
spheric
microcoloni
format
colistinoligog
combin
therapi
induc
mark
increas
disrupt
establish
biofilm
follow
treatment
mh
broth
p
medium
spheric
microcoloni
medium
associ
decreas
effici
colistin
revers
potenti
cotreat
oligog
establish
biofilm
model
mechanist
studi
reveal
reduct
qs
signal
treat
oligog
p
whilst
level
remain
unchang
p
conclus
data
demonstr
tight
microcoloni
format
typic
found
within
cf
lung
observ
convent
vitro
growth
condit
confer
resist
antibiot
treatment
data
support
use
oligog
potenti
antibiot
therapi
support
european
social
fund
algipharma
background
lung
clearanc
index
lci
repres
pulmonari
ventil
inhomogen
vi
sensit
spirometri
detect
earli
lung
diseas
cystic
fibrosi
cf
howev
lci
provid
global
measur
vi
provid
insight
region
diseas
pulmonari
magnet
reson
imag
mri
use
hyperpolar
xe
ga
region
quantifi
vi
measur
percentag
unventil
lung
volum
ventil
defect
percent
vdp
aim
studi
compar
spirometri
lci
vdp
pediatr
popul
healthi
particip
particip
cf
method
part
ongo
studi
valid
xemri
outcom
measur
cf
healthi
particip
cf
age
recruit
lci
measur
use
exhalyz
ecomed
ag
pulmonari
xemri
perform
mri
scanner
gehc
vdp
calcul
unventil
lung
volum
divid
total
thorac
caviti
volum
spirometri
perform
accord
american
thorac
societi
guidelin
result
compar
healthi
control
particip
cf
significantli
higher
vdp
lci
signific
differ
forc
expiratori
volum
one
second
fev
two
group
figur
strong
correl
r
measur
lci
vdp
discuss
measur
vdp
use
xemri
feasibl
pediatr
popul
vi
quantif
use
techniqu
correl
close
lci
xemri
lci
could
detect
differ
healthi
cf
particip
convent
spirometri
could
thu
vdp
could
marker
earli
lung
diseas
cf
could
provid
sensit
radiationfre
modal
monitor
progress
respons
treatment
patient
pulmonari
inflamm
cystic
fibrosi
cf
associ
exagger
neutrophil
respons
lead
lung
damag
subsequ
respiratori
failur
effect
treatment
underli
chronic
inflamm
need
activin
key
modul
inflammatori
cascad
level
correl
reduc
respiratori
function
cf
patient
hardi
cl
et
al
immunol
cell
biol
follistatin
natur
occur
glycoprotein
effect
inhibitor
activin
activ
effect
modul
inflamm
cf
assess
use
mice
recapitul
hallmark
cf
lung
diseas
exhibit
elev
activin
level
lung
tissu
recombin
human
follistatin
fst
administ
intranas
everi
second
day
week
mice
significantli
reduc
airway
neutrophil
mucu
product
bronchoalveolar
lavag
bal
fluid
level
activin
inflammatori
cytokin
includ
gcsf
lung
tissu
express
profibrot
gene
pdgfa
pdgfb
gene
code
collagen
reduc
express
level
protect
proteas
inhibitor
includ
ortholog
increas
fst
treatment
collect
data
show
fst
modul
neutrophil
airway
inflamm
potenti
regul
gene
involv
tissu
damag
repair
data
support
therapeut
applic
fst
treat
cf
lung
diseas
new
oral
inhal
therapeut
prepar
recombin
human
follistatin
safeti
toxicolog
studi
rat
cynomolgu
monkey
show
singl
multipl
inhal
daili
dose
day
well
toler
signific
advers
effect
respiratori
paramet
locomotor
activ
cardiovascular
system
addit
advers
chang
clinic
patholog
paramet
tissu
organ
patholog
pharmacokinet
analysi
serum
indic
minim
system
exposur
inhal
firstinhuman
phase
clinic
trial
safeti
pharmacokinet
effect
healthi
male
particip
commenc
result
singl
ascend
dose
studi
show
well
toler
particip
seriou
advers
event
report
advers
event
consid
mild
doselimit
toxic
clinic
signific
chang
laboratori
assess
vital
sign
ecg
pulmonari
function
test
physic
examin
baselin
treatment
group
multipl
ascend
dose
studi
complet
result
expect
juli
second
phase
clinic
studi
assess
pharmacodynam
effect
lung
inflamm
plan
introduct
two
new
version
betasweat
secret
test
focus
defect
cftrdepend
betaadrenerg
pathway
recent
develop
claim
advantag
suffici
sensit
quantifi
half
cftr
function
heterozyg
atyp
cf
measur
efficaci
novel
therapi
rate
water
evapor
kg
waterhrm
volum
sweat
droplet
nlmin
measur
appar
healthi
femal
year
follow
origin
report
protocol
evaporimetri
bubbl
test
result
cholinerg
phase
normal
maxim
evaporimetr
respons
min
intraderm
inject
carbachol
kg
waterhrm
volum
rate
droplet
obtain
min
methacholin
inject
nlmin
howev
betaadrenerg
isoprenalin
plu
aminophyllin
respons
evalu
presenc
atropin
inhibit
prior
cholinerg
stimul
abolish
cholinerg
ratio
evaporimetri
bubbl
test
respect
elicit
diagnosi
cf
result
confirm
repeat
test
least
twice
histori
current
medic
possibl
interf
pharmacolog
agent
use
test
reveal
longterm
year
treatment
wellcontrol
primari
angl
closur
glaucoma
consist
daili
topic
use
betablock
carteol
dropleft
eye
appar
symptom
betablock
intox
heart
rate
beat
per
min
regular
sinu
rhythm
asthma
symptom
sweat
chlorid
concentr
determin
pilocarpin
iontophoresi
use
coulometr
method
mmoll
cl
conclus
two
new
version
betasweat
secret
test
sensit
quantifi
betaadrenerg
contribut
sweat
secret
betablock
treatment
even
topic
use
lead
falseposit
result
much
attent
paid
use
current
medic
may
interfer
pharmacolog
step
test
support
belgian
cf
foundat
cystic
fibrosi
cf
common
lifelimit
autosom
recess
disord
amongst
caucasian
cf
genet
disord
affect
mostli
lung
also
pancrea
liver
kidney
intestin
longterm
issu
includ
difficulti
breath
cough
sputum
result
extracellular
dna
accumul
sputum
frequent
lung
infect
patient
exhibit
lung
diseas
consist
failur
innat
airway
defens
mechan
mucu
repres
main
barrier
airway
epithelium
extern
environ
thu
primari
defens
mechan
airway
airway
mucu
dehydr
seem
paramount
initi
cf
lung
diseas
pulmonari
diseas
major
caus
morbid
mortal
cf
patient
recombin
human
dnase
enzymat
cleav
extracellular
dna
sputa
cystic
fibrosi
cf
patient
henc
reduc
sputum
viscoelast
accumul
lung
patient
thu
enabl
better
sputum
expector
actin
potent
inhibitor
dnase
activ
found
high
concentr
cf
patient
sputum
may
decreas
enzym
dna
degrad
activ
therefor
interf
effect
inhal
dnase
lung
cf
patient
protalix
develop
chemic
modifi
plant
cellexpress
actininhibitionresist
dnase
airdnas
administ
inhal
report
result
phase
random
doubleblind
placebocontrol
singleascendingdos
multipleascendingdos
studi
design
evalu
safeti
toler
pharmacokinet
inhal
air
dnase
healthi
volunt
interim
report
phase
iia
proofofconcept
openlabel
studi
evalu
safeti
toler
pharmacokinet
exploratori
efficaci
paramet
air
patient
cystic
fibrosi
previous
treat
background
novel
cystic
fibrosi
transmembran
conduct
regul
cftr
corrector
clinic
develop
treatment
cystic
fibrosi
cf
cellular
assay
shown
potent
corrector
partial
restor
cftr
cell
surfac
express
use
line
harbour
hrptag
cftr
primari
bronchial
epitheli
cell
deriv
patient
homozyg
combin
cftr
potenti
restor
function
cftr
exhibit
potent
activ
ec
repres
one
compon
futur
potentiatorcorrector
combin
therapi
target
broad
cf
patient
popul
method
object
random
doubleblind
placebocontrol
firstinhuman
studi
design
assess
safeti
toler
pharmacokinet
properti
healthi
volunt
studi
consist
two
part
first
part
assess
singl
ascend
dose
sad
mg
qd
mg
qd
administ
two
altern
cohort
subject
second
part
assess
multipl
ascend
dose
mad
mg
qd
mg
qd
three
sequenti
cohort
subject
wherebi
dose
administ
day
subject
random
ratio
activ
versu
placebo
healthi
subject
includ
safeti
toler
evalu
consist
advers
event
clinic
laboratori
paramet
physic
examin
vital
sign
ecg
plasma
urin
pharmacokinet
determin
result
report
preliminari
result
phase
studi
followup
last
cohort
mad
part
still
ongo
time
submiss
dose
rang
test
associ
seriou
advers
event
sae
prematur
discontinu
due
advers
event
base
upon
blind
data
follow
advers
event
ae
report
least
possibl
relat
headach
flush
asthenia
fatigu
gastroenter
diarrhoea
abdomin
pain
thirst
abdomin
discomfort
pruritu
consid
mild
clinic
laboratori
paramet
physic
examin
vital
sign
ecg
show
clinic
relev
find
given
oral
liquid
formul
fed
state
rapidli
absorb
median
tmax
elimin
mean
appar
exposur
c
max
auc
increas
dose
proport
mg
slightli
dose
proport
mg
steadi
state
reach
within
day
conclus
preliminari
result
firstinhuman
studi
demonstr
safe
well
toler
administ
day
mg
qd
healthi
subject
full
safeti
pk
data
present
confer
find
support
develop
treatment
subject
cf
de
boeck
c
background
novel
cystic
fibrosi
transmembran
conduct
regul
cftr
potenti
clinic
develop
treatment
cystic
fibrosi
shown
safe
well
toler
week
dose
mg
oral
twice
daili
healthi
subject
vitro
assay
cftr
show
open
dysfunct
channel
high
potenc
togeth
result
suggest
could
benefici
cf
patient
harbour
mutat
method
object
phase
iia
openlabel
multicentr
studi
design
evalu
two
dose
two
week
dose
follow
two
week
dose
primari
studi
object
evalu
safeti
toler
secondari
outcom
paramet
includ
sweat
chlorid
concentr
pharmacodynam
biomark
pulmonari
function
addit
explor
correl
biomark
chang
plasma
exposur
main
studi
inclus
criteria
cf
mutat
one
allel
age
year
fev
predict
normal
subject
treat
ivacaftor
washout
prior
start
first
dose
requir
least
subject
includ
studi
result
time
submiss
abstract
studi
still
ongo
subject
screen
subject
enrol
subject
complet
studi
date
unexpect
safeti
signal
detect
studi
continu
plan
current
project
complet
enrol
end
june
consequ
expect
toplin
result
becom
avail
septemb
conclus
pend
result
background
bronchoalveolar
lavag
bal
potenti
use
outcom
measur
clinic
trial
children
cf
use
limit
variat
approach
differ
centr
first
lavag
airway
compon
frequent
use
cultur
mani
institut
subsequ
lavag
distalalveolar
fraction
use
measur
inflamm
pool
bal
offer
opportun
gather
homogen
sampl
greater
volum
greater
represent
proxim
airway
compon
sought
determin
pool
lavag
fraction
advers
affect
relationship
infect
inflamm
bal
compar
standard
approach
use
first
lavag
cultur
subsequ
lavag
inflammatori
marker
result
children
cf
mean
age
year
rang
control
mean
age
year
rang
recruit
cultur
result
sampl
show
concord
first
pool
lavag
term
identif
organ
semiquantit
cultur
result
similar
differ
greater
growth
pool
lavag
greater
first
lavag
instanc
cultur
result
differ
case
repres
known
pathogen
case
grew
first
lavag
alon
pool
lavag
alon
roc
curv
demonstr
similar
efficaci
pool
first
lavag
diagnost
tool
detect
known
pathogen
bland
altman
analysi
demonstr
strong
agreement
two
method
term
detect
inflamm
infect
present
neutrophil
elastas
ne
detect
sampl
undetect
case
ne
detect
pool
lavag
undetect
standard
lavag
mean
level
higher
pool
sampl
compar
standard
lavag
show
greater
spread
valu
better
abl
discrimin
cf
control
without
infect
bal
statist
signific
conclus
pool
bal
allow
collect
larger
volum
sampl
without
advers
affect
relationship
infect
inflamm
may
better
suit
detect
chang
inflamm
result
treatment
intervent
bechetoil
c
jubeau
l
juarezperez
v
stragen
lyon
franc
alaxia
sa
lyon
franc
introduct
cystic
fibrosi
cf
longer
consid
childhood
diseas
develop
countri
median
surviv
rate
year
old
epidemiolog
chang
contribut
emerg
pathogen
difficult
treat
diseas
evolut
fix
combin
two
endogen
compound
innat
immun
system
oscnand
lactoferrin
lf
reduc
cf
patient
oscndisturb
cell
machineri
lf
either
act
iron
chelat
andor
direct
interact
bacteri
membran
combin
effect
oscn
bovin
lf
blf
may
offer
innov
multitarget
strategi
fight
resist
pathogen
materi
method
assay
achromobact
xylosoxidan
ax
burkholderia
cepacia
complex
bcc
burkholderia
spp
bsp
multidrug
resist
mdr
pseudomona
aeruginosa
pamdr
clinic
isol
determin
minim
inhibitori
concentr
mic
perform
broth
microdilut
method
adapt
clsi
guidelin
timekil
experi
perform
speciesgroup
microdilut
method
describ
clsi
guidelin
time
point
h
fix
combin
oscnand
blf
compound
interact
assay
twodimension
checkerboard
test
broth
microdilut
method
fic
index
calcul
efficaci
presenc
complex
matric
test
biofilm
mbec
devic
sputum
wv
timekil
assay
result
abl
inhibit
growth
bacteri
strain
test
suscept
rank
base
median
mic
valu
pamdr
ax
bsp
bcc
oscn
mic
median
valu
mic
rang
whole
seri
despit
gener
accept
bacteriostat
clsi
standard
condit
blf
inhibit
growth
strain
mic
median
valu
mic
rang
howev
checkerboard
analys
show
blf
interact
posit
oscn
presenc
reduc
oscnrequir
inhibit
bacteri
growth
averag
valu
compar
mic
valu
oscnalon
fic
index
isol
posit
interact
blf
oscnkil
properti
confirm
timekil
experi
presenc
blf
hamper
limit
regrowth
bacteria
may
occur
oscnalon
exposur
comparison
mic
valu
plankton
cultur
minim
biofilm
inhibitori
concentr
mic
valu
presenc
sputum
demonstr
minim
variat
activ
fold
biofilm
unchang
activ
combin
presenc
sputum
conclus
taken
togeth
result
confirm
therapeut
potenti
emerg
pathogen
among
cf
popul
broadspectrum
antibacteri
product
preserv
kill
capac
complex
biolog
matric
may
contribut
futur
manag
lung
infect
caus
emerg
multiresist
bacteria
cf
patient
introduct
new
surrog
paramet
requir
assess
effect
cftr
modul
provid
restrict
sensit
assess
inflamm
epitheli
line
fluid
elf
interest
lower
airway
sampl
bal
limit
invas
cf
upper
airway
mucosa
equal
reveal
defect
cftr
channel
frequent
caus
chronic
rhinosinus
cf
aim
present
studi
assess
potenti
discrimin
cftr
modul
effect
elf
noninvas
sampl
upper
airway
nasal
lavag
nl
method
cf
patient
mutat
receiv
new
ivacaftor
iva
therapi
attend
jena
innsbruck
univers
cf
center
includ
prospect
studi
nl
perform
instil
ml
isoton
salin
nostril
reclin
head
close
soft
palat
secret
collect
steril
beaker
anteflect
head
patient
train
perform
nl
sampl
home
everi
second
day
prior
new
iva
therapi
home
secret
immedi
frozen
transfer
ice
center
store
assess
inflammatori
mediat
concentr
elisa
neutrophil
elastas
ne
multiplex
immunoassay
interleukin
il
result
altogeth
nl
sampl
longitudin
collect
includ
patient
treatment
iva
comparison
nl
level
iva
treatment
declin
mean
pgml
pgml
fold
pgml
pgml
fold
respect
wherea
ne
appear
reduc
pgml
respect
ngml
chang
signific
publish
studi
iva
improv
sweat
chlorid
lung
function
bodi
weight
patient
conclus
mediat
serial
homebas
sampl
elf
upper
airway
nl
reveal
signific
decreas
newli
introduc
treatment
iva
includ
patient
novel
approach
appear
suitabl
combin
direct
freez
noninvas
method
promis
assess
therapeut
effect
cftr
modul
airway
inflamm
method
obtain
nasal
lavag
fluid
x
nacl
cystic
fibrosi
loss
cftr
combin
hyperact
enac
lead
mucu
dehydr
decreas
airway
surfac
liquid
asl
height
healthi
lung
short
palat
lung
nasal
epitheli
clone
secret
airway
epithelia
key
neg
regul
enac
effect
attenu
acid
ph
protein
fail
neg
regul
enac
cf
lung
previou
work
identifi
acid
residu
nterminu
demonstr
regul
enac
sinc
unstabl
proteolyt
environ
cf
lung
suitabl
therapeut
cf
provid
basi
gener
optim
therapeut
object
object
work
design
valid
novel
therapeut
base
suitabl
treatment
cystic
fibrosi
desir
compound
would
effect
regul
asl
height
amilorid
sensit
current
vitro
also
regul
mucu
hydrat
vivo
presenc
cftr
inhibit
method
human
bronchial
epitheli
cell
hbec
deriv
healthi
cf
lung
treat
asl
height
amiloridesensit
current
determin
test
vivo
effect
sheep
treat
follow
hour
later
nebul
placebo
presenc
absenc
hyperton
salin
tracheal
mucu
veloc
tmv
measur
hourli
hour
result
sequenc
optim
produc
analog
demonstr
fold
increas
potenc
regul
asl
height
compar
parent
peptid
moreov
significantli
inhibit
amiloridesensit
current
normal
cfderiv
hbec
subnanomolar
rang
test
vivo
effect
sheep
deliv
placebo
via
nebul
treatment
cftrinhibit
anim
show
dosedepend
restor
tmv
observ
increas
tmv
independ
hyperton
salin
suggest
effect
potent
current
therapeut
conclus
potent
regul
enac
capabl
regul
mucu
hydrat
vitro
vivo
introduct
cftr
affect
electrolyt
transport
mani
organ
includ
gastrointestin
gi
system
result
pancreat
insuffici
nutrit
malabsorpt
signific
reduct
gi
motil
alter
fecal
microbiota
caus
mucu
adhes
distal
intestin
obstruct
syndrom
dio
meconium
ileu
mi
due
highli
viscou
adhes
intestin
mucu
affect
mani
cf
patient
caus
substanti
morbid
decreas
qualiti
life
previous
show
novel
uniqu
biopolym
poli
acetyl
arginyl
glucosamin
polycation
polysaccharid
interdigit
human
mucu
interact
purifi
mucin
normal
structur
decreas
viscos
elast
adhes
cf
airway
mucu
substanti
improv
mucociliari
transport
also
shown
relat
polym
prevent
incid
dio
cftr
mice
significantli
improv
surviv
growth
turn
cftr
rat
investig
whether
prevent
develop
dio
also
treat
document
obstruct
rat
allow
us
evalu
endpoint
includ
diagnost
imag
dio
treatment
studi
progress
method
natur
histori
studi
intestin
cftr
rat
euthan
week
collect
gross
patholog
histopatholog
analysi
stool
serum
collect
ongo
evalu
inflamm
prevent
studi
due
earli
onset
dio
cftr
rat
week
age
random
administ
paag
mgkgd
oral
gavag
daili
golyt
vehicl
control
day
regular
diet
bodi
weight
gener
health
monitor
daili
result
evalu
cftr
rat
week
determin
dio
occur
earli
week
age
indic
intervent
need
earlier
age
observ
cftr
mice
studi
earli
treatment
surviv
improv
gross
examin
intestin
display
obviou
obstruct
due
dio
untreat
control
rat
compar
healthyappear
intestin
golytelytr
cftr
rat
histolog
evalu
intestin
control
rat
indic
epitheli
cell
slough
crypt
dilat
adher
mucu
also
appear
increas
bacteri
load
promin
mucos
inflamm
conclus
current
treatment
intend
address
underli
adhes
properti
cf
mucu
caus
impact
mucu
stool
associ
inflamm
repres
signific
unmet
medic
need
cftr
rat
develop
dio
earli
week
age
intervent
novel
biopolym
prevent
develop
dio
cftr
rat
improv
surviv
growth
data
provid
strong
basi
evalu
effect
antiadhes
mucolyt
therapi
cf
intestin
diseas
human
introduct
forskolininduc
swell
fi
use
measur
individu
cftr
residu
function
aim
studi
compar
cftr
residu
function
intestin
organoid
current
diagnost
tool
sweat
chlorid
concentr
scc
intestin
current
measur
icm
valid
predict
capac
model
clinic
outcom
paramet
infant
cf
studi
part
hitcf
program
method
cf
clinic
univers
medic
center
utrecht
erasmu
mc
rotterdam
infant
cf
identifi
newborn
screen
enrol
monitor
protocol
pioneer
australian
cf
research
group
arestcf
protocol
includ
biannual
bronchoscopi
collect
balf
chest
ct
start
age
age
year
patient
also
undergo
rectal
biopsi
icm
perform
icm
organoid
cultur
residu
materi
fi
measur
sever
cf
lung
diseas
score
use
pragma
score
method
reflect
bronchiectasi
bronchial
thicken
air
trap
mucu
plug
result
cftr
measur
clinic
paramet
infant
differ
genotyp
analyz
fi
correl
icm
scc
r
respect
p
children
high
fi
valu
lower
valu
irt
immunoreact
trypsinogen
often
pancreat
suffici
lower
ct
pragma
score
age
year
compar
children
lower
fi
valu
versu
p
versu
p
versu
diseas
p
respect
high
versu
low
scc
signific
relat
fecal
elastas
valu
p
icm
relat
clinic
paramet
conclus
fi
intestin
organoid
correl
well
current
establish
cftrdepend
biomark
scc
icm
stratif
fi
appear
better
identifi
subgroup
differ
pulmonari
gastrointestin
clinic
outcom
paramet
compar
scc
icm
introduct
forskolininduc
swell
fi
intestin
organoid
use
measur
individu
cftr
residu
function
aim
studi
analys
relat
fi
clinic
outcom
paramet
adult
cf
homozyg
mutat
studi
part
hitcf
program
method
multicentr
observ
studi
studi
visit
subject
underw
rectal
biopsi
well
chest
ct
pulmonari
function
test
relev
diagnost
clinic
paramet
collect
outpati
visit
five
year
studi
visit
age
forskolininduc
swell
fi
measur
cultur
intestin
organoid
paramet
cftr
activ
result
data
patient
cf
collect
analys
subject
whose
organoid
demonstr
higher
fi
valu
versu
lower
fi
valu
higher
bmi
versu
kg
p
tend
lower
crispinnorman
score
chest
xray
versu
p
higher
mean
last
year
versu
ltr
p
conclus
preliminari
data
suggest
fi
intestin
organoid
defin
clinic
distinct
subgroup
adult
homozyg
subject
implic
cftr
residu
function
modifi
diseas
subject
ident
cfcaus
mutat
infram
prematur
termin
codon
ptc
compris
diseaseassoci
mutat
translat
ptcharbor
mrna
gener
truncat
protein
unstabl
andor
lack
normal
function
drug
identifi
suppress
translat
termin
ptc
restor
fulllength
protein
also
refer
readthrough
ptc
subset
aminoglycosid
shown
induc
ptc
readthrough
amount
fulllength
protein
gener
drug
suffici
correct
phenotyp
mani
diseas
includ
cystic
fibrosi
cf
furthermor
aminoglycosid
toxic
limit
longterm
clinic
use
addit
ptc
also
frequent
elicit
nonsensemedi
mrna
decay
nmd
nmd
conserv
mrna
surveil
pathway
preferenti
degrad
ptccontain
mrna
therebi
diminish
pool
mrna
avail
translat
ptc
readthrough
current
compound
induc
ptc
suppress
mediat
nmd
inhibit
alon
although
capac
mediat
respons
extent
goal
studi
develop
report
system
allow
us
systemat
identifi
new
compound
abil
simultan
induc
ptc
suppress
reduc
nmd
would
provid
optim
therapeut
potenti
cf
patient
describ
develop
character
nanoluc
luciferasebas
dual
rtnmd
report
well
nmdonli
rtonli
control
report
fischer
rat
thyroid
frt
cell
respons
report
ptc
suppress
nmd
inhibit
test
treatment
cell
varieti
ptc
suppressor
nmd
inhibitor
individu
togeth
result
show
nmd
inhibit
alon
increas
nanoluc
luciferas
activ
mrna
abund
express
dual
rtnmd
report
fold
treatment
varieti
readthrough
drug
increas
nanoluc
activ
fold
importantli
combin
nmd
inhibitor
readthrough
drug
increas
nanoluc
activ
much
depend
ptc
context
cell
line
synergist
effect
combin
nmd
inhibit
readthrough
observ
dual
rtnmd
report
seen
nmdonli
rtonli
control
result
demonstr
new
nanoluc
luciferasebas
rtnmd
report
system
use
simultan
monitor
nmd
inhibit
ptc
suppress
anticip
use
system
allow
identif
new
effect
compound
treatment
cf
patient
harbor
ptc
introduct
lumacaftor
ivacaftor
combin
therapi
expect
debut
netherland
standard
care
patient
year
age
homozyg
mutat
known
drug
respons
therapi
may
vari
significantli
clear
yet
patient
benefit
recent
develop
enabl
us
assess
effect
cftrmodifi
drug
vitro
function
cftr
assay
use
patientderiv
intestin
organoid
dekker
jf
et
al
nat
med
assay
may
facilit
futur
person
medicin
approach
predict
clinic
respons
base
effect
function
cftr
mutant
protein
organoid
object
project
evalu
clinic
respons
treatment
lumacaftorivacaftor
patient
homozyg
mutat
assess
vitroin
vivo
correspond
respons
project
part
hitcf
program
method
aim
measur
treatment
effect
two
time
daili
mg
lumacaftorivacaftor
therapi
six
month
treatment
one
hundr
sixti
patient
evalu
clinic
respons
baselin
measur
perform
includ
qualiti
life
cfqr
lung
function
fev
express
predict
bodi
mass
index
bmi
sweat
chlorid
concentr
scc
rate
pulmonari
exacerb
preced
period
six
month
concurr
intestin
stem
cell
cultur
deriv
rectal
biopsi
test
therapyinduc
activ
cftr
protein
subsequ
vitroin
vivo
correspond
treatment
evalu
result
current
baselin
measur
perform
patient
median
age
year
iqr
patient
male
measur
show
larg
variabl
diseas
sever
median
score
cfqr
respiratori
domain
iqr
fev
predict
iqr
bmi
kgm
iqr
scc
mmoll
iqr
preliminari
data
vitro
organoid
cftr
respons
lumacaftorivacaftor
show
quit
variabl
respons
individu
patient
updat
result
present
confer
conclus
result
project
facilit
person
medicin
approach
lumacaftorivacaftor
combin
therapi
homozyg
patient
cf
valid
predict
capac
drug
test
intestin
organoid
vitro
introduct
cystic
fibrosi
cf
characteris
neutrophildomin
airway
inflamm
part
attribut
potent
chemotact
agent
high
level
neutrophil
elastas
ne
found
bronchoalveolar
lavag
fluid
balf
patient
cf
antitrypsin
aat
acut
phase
protein
possess
immun
regulatori
antiinflammatori
properti
glycosyl
protein
posttransl
modifi
via
addit
nglycosid
link
oligosaccharid
sialic
acid
give
rise
differ
glycoform
aim
studi
investig
abil
aat
versu
aat
increas
sialyl
saat
inhibit
signal
biolog
consequ
aatinduc
inhibit
investig
level
neutrophil
chemotaxi
method
balf
obtain
patient
cf
healthi
control
level
balf
quantifi
via
elisa
activ
level
ne
cf
balf
quantifi
specif
fluoresc
reson
energi
transfer
substrat
fret
aat
purifi
human
plasma
use
resin
aat
glycoform
determin
isoelectr
focus
abil
aat
saat
inhibit
ne
determin
via
fret
abil
saat
aat
bind
determin
slot
blot
neutrophil
chemotaxi
respons
presenc
aat
saat
measur
boyden
chamber
statist
signific
obtain
studentst
test
mannwhitney
test
oneway
anova
follow
post
hoc
bonferroni
test
ethic
approv
grant
beaumont
ethic
committe
result
ex
vivo
analysi
demonstr
significantli
higher
level
balf
patient
cf
compar
healthi
control
activ
level
ne
found
cf
balf
rang
result
fret
analysi
demonstr
signific
differ
antin
capac
aat
compar
saat
ns
slot
blot
analysi
reveal
saat
bound
higher
level
compar
aat
neutrophil
chemotact
index
respons
significantli
reduc
presenc
saat
comparison
aat
p
conclus
conclus
studi
demonstr
alter
bind
capac
saat
saat
bind
greater
extent
aat
bind
cxc
chemokin
saat
modul
neutrophil
migrat
result
studi
indic
saat
inhibit
signal
justifi
use
glycoform
aat
increas
sialic
acid
residu
effect
aerosolis
treatment
cf
studi
fund
sfi
grant
number
sought
determin
rate
advers
event
discontinu
cystic
fibrosi
center
method
observ
analysi
adult
pediatr
n
patient
vanderbilt
univers
medic
center
cystic
fibrosi
clinic
perform
patient
analyz
base
elig
receiv
lumacaftorivacaftor
medic
record
patient
receiv
medic
review
determin
date
medic
initi
well
advers
event
experienc
lastli
record
analyz
determin
medic
discontinu
data
collect
result
lumacaftorivacaftor
initi
adult
children
n
adult
children
experienc
advers
event
n
adult
children
experienc
seriou
advers
event
common
advers
event
infecti
pulmonari
exacerb
patient
requir
oral
iv
antibiot
common
advers
event
includ
chest
tight
patient
diarrhea
abdomin
pain
dyspnea
medic
discontinu
n
adult
children
patient
due
advers
event
discontinu
averag
durat
therapi
day
seriou
advers
event
clinic
popul
respiratori
failur
occur
two
instanc
patient
within
hour
initiatingreiniti
lumacaftorivacaftor
therapi
conclus
report
singlecent
experi
describ
toler
lumacaftorivacaftor
adult
pediatr
patient
outsid
random
control
trial
report
similar
rate
advers
seriou
advers
event
traffic
transport
studi
howev
report
much
higher
discontinu
rate
differ
may
relat
medic
use
patient
center
whose
characterist
deviat
studi
inclusionexclus
criteria
also
possibl
particip
bia
among
studi
subject
toward
continu
well
process
clinic
decisionmak
outsid
research
studi
environ
may
contribut
observ
differ
discontinu
rate
volum
composit
airway
surfac
liquid
asl
thin
layer
fluid
cover
lumin
apic
surfac
airway
epithelium
import
maintain
ciliari
function
mucociliari
clearanc
antimicrobi
properti
airway
cf
homeostat
mechan
impair
lead
dehydr
acid
asl
asl
volum
deplet
cf
secondari
defect
anion
transport
cftr
abnorm
cftrmediat
bicarbon
transport
creat
unfavor
acid
environ
impair
antimicrobi
function
alter
mucu
properti
clearanc
diseas
mechan
creat
disord
airway
milieu
consist
thick
mucopurul
secret
chronic
bacteri
infect
previous
report
aerosol
breven
natur
product
produc
dinoflagel
karenia
brevi
augment
wholelung
mucociliari
clearanc
surrog
marker
tracheal
mucu
veloc
tmv
nebul
sheep
diminish
cftr
activ
due
aerosol
challeng
human
neutrophil
elastas
breven
potent
voltagesensit
sodium
channel
vssc
inhibitor
yet
known
express
epitheli
cell
breven
affect
enac
cftr
suggest
may
alter
function
ion
transport
affect
asl
depth
augment
mucu
clearanc
use
onemicron
resolut
optic
coher
tomographi
examin
effect
breven
asl
depth
cf
primari
human
bronchial
epitheli
hbe
cell
homozyg
hour
brevenaltr
basolater
cell
exhibit
significantli
higher
asl
depth
p
vs
vehicl
control
compar
favor
treatment
posit
control
correctorpotenti
therapi
lumacaftor
ivacaftor
augment
asl
depth
observ
hour
reflect
kinet
pathway
compar
baselin
chang
asl
depth
hour
breven
treatment
p
vs
pn
vehicl
control
p
lumacaftorivacaftor
breven
effect
ciliari
beat
frequenc
hz
hour
analysi
chang
mucociliari
transport
progress
overal
result
indic
breven
augment
asl
depth
without
alter
ciliari
beat
primari
hbe
monolay
activ
even
ad
basolater
compart
partial
explain
breven
augment
mucociliari
transport
sheep
suggest
need
mechanist
studi
determin
molecular
target
confirm
vssc
inhibitor
may
therapeut
target
augment
asl
depth
cf
breven
may
benefici
adjuv
therapi
improv
asl
depth
mucociliari
clearanc
cf
patient
poor
airway
clearanc
associ
abnorm
viscoelast
airway
mucu
import
target
cf
therapi
airway
mucin
unusu
cystein
cy
rich
show
increas
intraand
intermolecular
disulfid
bond
oxid
condit
howev
system
inhal
mucolyt
agent
nacetyl
cy
gener
reduct
exhibit
poor
clinic
efficaci
well
offtarget
toxic
low
toler
replac
potent
disulfidespecif
enzymat
reduct
potenti
creat
pharmacolog
superior
drug
human
txn
highli
select
disulfid
bondreduc
enzym
normal
secret
airway
strong
activ
cf
sputum
viscoelast
micromolar
concentr
optim
txn
inhal
agent
engin
nonsystem
thioltrap
variant
enabl
stabl
coval
linkag
mucin
disulfid
bond
theradux
nativ
txn
unusu
low
cy
thiol
pka
thu
increas
disulfidereduc
activ
sever
vs
classic
thiol
agent
pka
larg
inact
vivo
neutraltoacid
cf
airway
previous
demonstr
theradux
induc
inflamm
rat
aerosol
inhal
vivo
human
cell
vitro
normal
viscoelast
expector
human
cf
sputum
greater
degre
nativ
txn
thiol
agent
therefor
hypothes
theradux
improv
mucu
transport
evalu
use
primari
human
bronchial
epitheli
hbe
monolay
examin
mucu
transport
situ
follow
treatment
theradux
mm
vs
dtt
mm
pb
control
via
onemicron
resolut
optic
coher
tomographi
theraduxtr
cell
exhibit
increas
mucociliari
transport
mmmin
p
vs
pb
mmmin
exceed
effect
dtt
mmmin
ciliari
beat
also
increas
theradux
treatment
hz
observ
dtt
hz
vehicl
control
hz
viscou
elast
moduli
cf
hbe
mucu
reduc
follow
treatment
ex
vivo
mm
theradux
analysi
chang
viscos
situ
progress
result
indic
reduc
disulfid
bond
theradux
increas
mucu
transport
suggest
theradux
may
potenti
cf
treatment
act
efficaci
modifi
excess
mucin
viscoelast
optim
activ
across
broad
airway
ph
microenviron
nonsens
mediat
mrna
decay
nmd
oper
variabl
effici
complet
degrad
transcript
contain
nonsens
mutat
test
hypothesi
nonsens
mutat
vari
effect
mrna
stabil
protein
synthesi
inform
use
inform
treatment
first
determin
mrna
protein
characterist
nonsens
mutat
select
exon
cftr
util
express
minigen
contain
fulllength
abridg
intron
plasmid
contain
cftr
cdna
observ
signific
reduct
cftr
transcript
gener
mutat
protein
process
flpin
cell
reveal
mutant
protein
exon
exon
core
glycosyl
exon
exon
complex
glycosyl
local
studi
polar
mdck
cell
reveal
coreglycosyl
truncat
protein
cytosol
distribut
complexglycosyl
truncat
protein
basolater
apic
distribut
second
residu
cftr
function
retain
truncat
mutat
determin
shortcircuit
current
isc
measur
mdck
flpin
stabl
cell
line
truncat
mutat
fell
three
broad
group
four
mutat
eg
produc
coreglycosyl
protein
gener
current
b
five
mutat
eg
synthes
truncat
glycosyl
protein
gener
current
c
two
mutat
last
exon
eg
gener
current
wt
cftr
next
evalu
whether
cftr
truncat
protein
correct
andor
potenti
isc
valu
rel
wt
combin
treatment
h
show
improv
group
group
b
group
c
lastli
test
role
nmd
inhibit
final
outcom
corrector
potenti
therapi
nt
show
improv
chlorid
transport
h
treatment
either
caffein
mm
azacytidin
interestingli
caffein
azacytidin
combin
result
increas
respect
isc
valu
taken
togeth
nonsens
mutat
permit
translat
stabl
glycosyl
protein
correct
potenti
therapeut
level
respons
small
molecul
corrector
potenti
treatment
augment
nmd
inhibit
work
support
cff
mdbr
nih
great
progress
made
develop
diseas
modifi
therapi
cystic
fibrosi
cf
ivacaftor
lumacaftor
provid
proofofconcept
cftr
therapeut
target
also
deliv
firstinclass
medicin
cf
patient
nonsens
prematur
termin
codon
ptc
mutat
found
least
one
allel
approxim
cf
case
overal
urgent
unmet
need
therapeut
develop
cftr
mutat
class
develop
highthroughput
screen
assay
cftr
nonsens
mutat
readthrough
modul
base
traffick
cftr
report
horseradish
peroxidas
hrp
fuse
extracellular
loop
cftr
construct
allow
robust
readout
cftr
cell
surfac
stabl
cell
line
express
cftrhrp
fusion
protein
gener
frt
cell
three
assay
develop
repres
cftr
ptc
mutant
result
uaa
ochr
stop
codon
mutat
uga
opal
stop
codon
ht
assay
exist
readthrough
modul
geneticin
gentamicin
increas
report
signal
dosedepend
manner
approxim
eighti
thousand
compound
screen
two
ptc
mutant
cftr
hit
rate
cutoff
vehicl
cftr
cftr
respect
overlap
two
hit
set
stringent
hit
threshold
rel
small
hit
screen
hit
also
screen
overlap
increas
compound
includ
second
screen
achiev
least
stringent
hit
criterion
ie
hrp
activ
greater
three
standard
deviat
mean
neg
control
current
effort
aim
identifi
readthrough
agent
efficaci
multipl
ptc
mutat
cftr
hit
confirm
origin
screen
assay
almost
complet
hit
profil
three
assay
repres
mutat
cftr
help
identifi
hit
panptc
efficaci
given
essenti
cellular
process
involv
translat
potenti
impact
readthrough
ptc
mutat
also
test
hit
cytotox
initi
result
demonstr
high
hit
confirm
rate
complex
hit
profil
due
appar
differenti
allel
prefer
fulllength
readthrough
product
cftr
detect
frt
cell
express
cftr
incub
hit
compound
ongo
hit
analysi
mean
analyz
readthrough
protein
product
mrna
level
target
cluster
confirm
hit
cast
light
mechanismofact
therapeut
potenti
hit
studi
intend
character
featur
molecular
pathogenesi
relat
cftr
protein
fold
channel
gate
base
express
protocol
use
isogen
flpin
deriv
fischer
rat
thyroid
frt
cell
truncat
protein
level
markedli
diminish
compar
wildtyp
partial
rescu
chronic
treatment
prolong
incub
accentu
increas
mrna
protein
fashion
unrel
translat
readthrough
addit
protein
could
increas
proteasom
inhibitor
alln
demonstr
import
proteasom
degrad
truncat
mutant
order
determin
amount
cftr
cell
surfac
variou
condit
horseradish
peroxidas
hrp
tag
insert
extern
direct
segment
cftr
cellbas
chemiluminesc
fac
perform
monitor
surfac
express
cftrhrp
follow
exposur
corrector
andor
potenti
chronic
treatment
margin
increas
hrp
signal
howev
combin
treatment
result
mark
enhanc
hrp
presenc
absenc
respect
flow
cytometri
support
find
indic
cftr
traffic
minim
cell
surfac
augment
cftr
modul
given
combin
other
report
previous
cftr
maintain
low
level
residu
function
ion
channel
uss
chamber
studi
demonstr
treatment
either
acut
induc
activ
also
show
cftr
exhibit
signific
channel
gate
defect
activ
membran
patch
substanti
increas
curcumin
taken
togeth
result
suggest
cftr
truncat
posit
lead
protein
poorli
function
specul
absenc
carboxi
termin
pdz
domain
andor
portion
particip
domain
swap
may
confer
defect
overal
stabil
small
molecul
develop
address
mutat
may
therefor
requir
improv
mrna
stabil
enhanc
protein
matur
overcom
abnorm
channel
gate
addit
promot
readthrough
nonsens
codon
summari
evalu
provid
framework
drug
discoveri
relev
prematur
truncat
infram
prematur
termin
codon
ptc
account
diseaseassoci
mutat
ptc
suppress
therapi
util
small
molecul
suppress
translat
termin
ptc
partial
restor
synthesi
fulllength
protein
ptc
suppress
mediat
base
pair
nearcogn
aminoacyltrna
ptc
howev
littl
known
ident
amino
acid
insert
ptc
suppress
mammalian
cell
sequenc
context
surround
ptc
influenc
amino
acid
incorpor
use
report
system
determin
amino
acid
insert
ptc
uga
codon
context
natur
three
upstream
downstream
cftr
codon
suppress
tandem
mass
spectrometri
msm
reveal
leucin
cystein
tryptophan
insert
context
follow
uga
suppress
interestingli
amino
acid
proport
significantli
differ
identifi
follow
suppress
uga
mutat
cystein
tryptophan
arginin
result
demonstr
first
time
local
sequenc
context
play
key
role
determin
amino
acid
insert
ptc
suppress
rel
proport
found
variant
gener
suppress
exhibit
reduc
cftr
matur
activ
compar
wildtyp
cftr
cftr
corrector
potenti
enhanc
activ
mani
variant
induc
suppress
result
suggest
ptc
suppress
combin
cftr
modul
may
benefici
treatment
cf
patient
ptc
process
valid
report
determin
amino
acid
insert
suppress
ptc
effect
cftr
function
addit
also
construct
report
examin
suppress
ptc
identifi
cf
patient
studi
provid
import
mechanist
detail
ptc
suppress
aid
select
effect
drug
tailor
specif
cftr
nonsens
mutat
rational
almost
half
cf
patient
experi
form
intestin
obstruct
lifetim
includ
meconium
ileu
distal
intestin
obstruct
syndrom
less
sever
underdiagnos
constip
current
treatment
vari
degre
effect
patient
patient
new
therapi
necessari
linzess
novel
drug
use
treatment
irrit
bowel
syndrom
chronic
constip
wide
prescrib
cf
patient
treat
intestin
issu
sinc
activ
cftr
thought
main
mechan
action
aim
studi
test
effect
linzess
treat
intestin
obstruct
cf
effect
identifi
cftrdepend
cftrindepend
mechan
action
method
linzess
increas
intestin
lumin
water
content
agonist
guanyl
cyclas
c
receptor
increas
cgmp
activ
cftr
test
activ
mutant
cftr
epitheli
membran
intestin
cf
mice
carri
mutat
util
test
improv
cftr
activ
intestin
motil
intestin
fluid
transport
small
intestin
bacteri
overgrowth
intestin
histolog
intestin
cf
mice
carri
null
cftr
allel
also
util
test
possibl
cftrindepend
mechan
improv
cf
intestin
result
intestin
shortcircuit
current
sc
indic
cftr
function
measur
uss
chamber
util
intestin
section
wildtyp
wt
mice
exposur
linzess
wt
intestin
display
signific
increas
sc
intestin
display
increas
sc
cf
mice
display
significantli
slow
intestin
transit
compar
wt
mice
vs
geometr
center
fluoresc
gcf
p
one
exposur
linzess
null
cf
mice
display
significantli
improv
intestin
transit
gcf
respect
p
compar
untreat
cf
studi
ongo
investig
addit
aspect
intestin
cf
improv
intestin
fluid
transport
small
intestin
bacteri
overgrowth
intestin
histolog
addit
cf
patient
cf
center
receiv
fdaapprov
linzess
report
improv
intestin
symptom
conclus
linzess
effect
improv
cf
intestin
manifest
cftrindepend
mechan
intestin
cf
mice
carri
either
null
cftr
allel
display
improv
intestin
transit
increas
fluid
retent
initi
studi
suggest
linzess
may
block
intestin
sodium
absorpt
cf
intestin
improv
cf
intestin
environ
possibl
decreas
intestin
obstruct
background
progress
cf
lung
diseas
induc
episod
infecti
event
call
acut
pulmonari
exacerb
pex
episod
indic
either
acquisit
new
bacteri
infect
chang
densiti
previous
colon
bacteria
pex
poorli
defin
difficult
diagnos
set
chronic
inflamm
current
biochem
test
diagnos
cf
pulmonari
exacerb
consensu
diagnost
criteria
constitut
exacerb
neutrophil
express
highli
specif
acut
infect
even
background
chronic
inflamm
diagnost
acut
bacteri
infect
subject
sepsi
rheumatoid
arthriti
hypothes
quantit
flow
cytometri
assay
measur
express
directli
circul
cf
neutrophil
could
sensit
predict
acut
exacerb
reflect
neutrophil
phagocyt
activ
time
acut
exacerb
method
cf
patient
baselin
health
diagnos
pex
enrol
irb
approv
protocol
pex
patient
diagnos
base
current
cff
guidelin
faculti
member
colorado
adult
cf
program
blood
sampl
cf
patient
healthi
control
stain
antibodi
express
neutrophil
quantit
util
quantum
mesf
bead
facscanto
ii
capclia
certifi
laboratori
nation
jewish
health
phagocytosi
activ
isol
neutrophil
measur
cytoselect
phagocytosi
assay
cellbiolab
ca
baselin
interferon
stimul
condit
cytochalasin
use
phagocytosisinhibitor
control
superoxid
anion
gener
neutrophil
measur
reduct
cytochrom
c
result
date
measur
patient
baselin
pex
healthi
noncf
subject
demonstr
differ
express
pex
baselin
patient
p
well
pex
patient
healthi
noncf
subject
p
compar
abil
phagocytos
heatinactiv
e
coli
circul
neutrophil
pex
patient
show
signific
differ
compar
cf
patient
baselin
p
pex
neutrophil
also
demonstr
reduc
capac
gener
superoxid
anion
compar
cf
subject
baselin
health
conclus
neutrophil
promis
candid
diagnosi
pulmonari
exacerb
test
run
whole
blood
result
avail
within
hour
cap
clia
certifi
laboratori
circul
cf
neutrophil
time
exacerb
differ
oxid
burst
phagocytosi
activ
directli
assay
peripher
blood
studi
support
colorado
bioscienc
discoveri
evalu
program
abnorm
airway
smooth
muscl
asm
function
thought
contribut
airway
hyperreact
cystic
fibrosi
cf
airway
hyperrespons
frequent
report
suggest
alter
asm
physiolog
may
contribut
cf
airway
diseas
previous
shown
newborn
cftrpig
display
asm
abnorm
prior
onset
inflamm
infect
includ
increas
basal
tone
increas
bronchodil
respons
decreas
calcium
reuptak
goal
studi
identifi
whole
genom
transcript
proteom
chang
porcin
cf
asm
prior
airway
inflamm
infect
investig
whether
specif
pathway
associ
cf
airway
reactiv
determin
cf
pig
asm
transcriptom
use
identifi
potenti
asm
therapeut
cf
airway
narrow
diseas
total
rna
sequenc
newborn
noncf
cf
asm
reveal
differenti
signific
chang
muscl
contract
relat
gene
ontolog
pathway
highthroughput
elisa
protein
comparison
noncf
cf
asm
cell
reveal
complementari
pathway
dysregul
genom
proteom
signatur
use
perform
pathway
analysi
largescal
chang
transcript
protein
abund
phosphoryl
statu
significantli
differ
mapk
control
pathway
cf
sampl
calciumsensit
tyrosin
kinas
known
upstream
regul
mapk
pathway
show
increas
phosphoryl
statu
suggest
increas
activ
use
small
molecul
inhibitor
test
whether
block
activ
could
alter
airway
contractil
wildtyp
precis
cut
lung
slice
pretreat
kinas
inhibitor
demonstr
decreas
airway
narrow
respons
cholinerg
stimul
compar
dmso
control
addit
pretreat
compound
isol
wildtyp
smooth
muscl
strip
diminish
forc
product
decreas
myosin
light
chain
phosphoryl
studi
show
loss
cftr
asm
caus
genomewid
transcript
proteom
chang
includ
expect
alter
muscl
contract
transcript
protein
analysi
transcript
proteom
chang
reveal
signific
dysregul
mapk
pathway
suggest
basi
chang
contractil
machineri
cytoskelet
arrang
transcript
factor
activ
addit
abl
identifi
novel
tyrosin
kinas
inhibitor
modul
asm
function
recogn
newborn
cf
pig
model
asm
hyperreact
absent
inflamm
enhanc
molecular
understand
asm
biolog
pathophysiolog
addit
discov
novel
therapeut
airflow
limit
support
american
asthma
foundat
background
indoleamin
ido
catalyz
convers
tryptophan
kynurenin
k
elev
level
ido
detect
associ
respiratori
diseas
includ
cystic
fibrosi
cf
increas
level
ido
activ
infect
believ
due
host
cell
pathogen
increas
level
ido
modul
immun
respons
microbi
pathogen
chronic
infect
includ
respiratori
diseas
cf
sinc
activ
infect
cf
patient
associ
exacerb
exbn
hypothes
elev
level
ido
would
detect
plasma
cf
patient
exbn
primari
object
studi
examin
level
ido
activ
determin
rel
amount
k
plasma
cf
patient
without
exbn
method
heparin
blood
collect
control
cont
exbn
cf
patient
plasma
collect
treat
trichloroacet
acid
clear
supernat
use
determin
k
level
k
separ
rp
column
mm
x
mm
use
shimadzu
hplc
system
mobil
phase
mm
acet
acidsodium
acet
ph
acetonitril
mlmin
hplc
grade
k
use
extern
intern
standard
k
nm
nm
detect
use
uv
detector
k
level
determin
standard
curv
kt
ratio
repres
rel
activ
ido
calcul
k
level
patient
result
detect
level
k
observ
patient
either
cont
exbn
group
mean
k
level
cont
exbn
patient
rang
rang
respect
similarli
mean
level
cont
exbn
patient
rang
rang
respect
mean
kt
ratio
cont
exbn
patient
rang
rang
respect
comparison
kt
ratio
cont
exbn
patient
show
significantli
higher
exbn
patient
conclus
kt
ratio
repres
rel
activ
ido
significantli
higher
cf
patient
exbn
compar
nonexbn
patient
plasma
level
ido
activ
potenti
use
biomark
onset
exbn
cf
patient
initi
analysi
whole
lung
mcc
gamma
scintigraphi
unabl
determin
whether
mcc
improv
previous
wellventil
region
lung
whether
improv
ventil
follow
treatment
may
also
allow
enhanc
mcc
lung
region
particl
could
previous
deposit
method
recent
appli
new
analyt
method
determin
heterogen
deposit
timedepend
retent
pixelbypixel
basi
two
particip
site
unc
jhu
fiduci
marker
use
accur
align
gamma
scintigraphi
imag
baselin
month
begin
treatment
ivacaftor
cf
patient
mutat
deposit
retent
imag
obtain
immedi
follow
inhal
radiolabel
particl
colloid
mmad
control
breath
condit
minut
particl
clearanc
result
found
improv
homogen
deposit
ie
decreas
region
higher
hot
lower
cold
particl
deposit
lung
bennett
wd
et
al
j
aerosol
med
pulm
drug
deliv
follow
ivacaftor
treatment
mean
number
ratio
nr
hot
pixel
rel
lung
size
decreas
mean
nr
cold
nr
hot
cold
pixel
significantli
correl
pred
subject
preand
postivacaftor
treatment
word
follow
ivacaftor
treatment
fewer
site
obstruct
associ
particl
deposit
impact
ie
decreas
hot
region
recruit
previous
unventil
lung
unit
particl
inhal
ie
decreas
cold
region
whole
lung
clearanc
improv
follow
treatment
mean
clearanc
min
vs
p
pixellevel
analysi
clearanc
show
fraction
noncold
pixel
clear
greater
min
increas
indic
recruit
fastclear
region
ivacaftor
treatment
conclus
ivacaftor
treatment
cf
mutat
improv
homogen
particl
deposit
like
due
improv
region
ventil
clearanc
greater
fraction
whole
lung
find
may
enhanc
understand
mechan
action
ivacaftor
furthermor
imag
analysi
method
use
may
provid
sensit
measur
chang
deposit
mucociliari
clearanc
associ
therapeut
intervent
patient
airway
diseas
support
cf
foundat
nih
introduct
nasal
potenti
differ
npd
measur
believ
reflect
vivo
function
cystic
fibrosi
transmembran
conduct
regul
cftr
protein
npd
show
signific
chang
ivacaftortr
patient
phase
clinic
trial
nasal
cell
cultur
techniqu
use
new
model
system
predict
clinic
respons
cftrmodifi
drug
object
compar
ivacaftorinduc
chang
npd
patient
ivacaftorinduc
chang
cftrmediat
current
nasal
cell
gener
patient
method
npd
perform
baselin
month
follow
start
ivacaftor
treatment
cf
patient
age
rang
year
voltag
respons
perfus
chloridefre
isoproterenol
contain
solut
use
function
cftr
readout
best
respons
nostril
centr
consid
normal
abnorm
intermedi
result
keenan
k
et
al
j
cyst
fibro
nasal
cell
obtain
nasal
brush
cf
patient
baselin
expand
grown
airliquid
interfac
cftrmediat
current
measur
forskolininduc
current
ieqfsk
follow
enac
inhibit
uss
chamber
cf
patient
npd
nasal
cell
function
avail
result
follow
treatment
ivacaftor
respons
chang
mean
confid
interv
ci
pair
ttest
baselin
result
patient
within
cf
diagnost
rang
ivacaftor
treatment
increas
respons
one
patient
healthi
control
rang
patient
anoth
patient
intermedi
rang
associ
cftrrelat
disord
patient
nasal
cell
cultur
addit
ivacaftor
increas
ieqfsk
mean
ci
pair
ttest
ieqfsk
respons
ivacaftor
nasal
cell
correl
ivacaftorinduc
chang
npd
conclus
npd
nasal
epitheli
cell
display
signific
chang
ivacaftor
respons
variabl
individu
cf
patient
absenc
correl
test
may
explain
differ
methodolog
assess
cftr
function
small
sampl
size
well
impact
adher
ivacaftor
therapi
npd
result
studi
partli
fund
vertex
pharmaceut
prevail
hypothesi
explain
pathogenesi
cf
lung
diseas
link
dysregul
ion
transport
eventu
disrupt
mucociliari
clearanc
mcc
accordingli
use
gamma
scintigraphi
follow
control
inhal
radiolabel
particl
character
mcc
cf
donaldson
sh
et
al
proc
thorac
soc
recent
attempt
improv
methodolog
allow
better
assess
mcc
region
lung
affect
earli
cf
lung
diseas
small
airway
apic
lung
region
healthi
subject
shown
larg
particl
inhal
slowli
lp
silp
method
bypass
extrathorac
airway
effici
deposit
bronchial
airway
compar
standard
tidal
breath
lp
particl
tb
method
zeman
kl
et
al
j
aerosol
med
pulm
drug
deliv
final
hypothes
cf
patient
inhal
radioaerosol
supin
posit
remov
gravit
depend
ventil
base
lung
would
enhanc
abil
measur
mcc
lung
apic
method
two
group
adult
cf
patient
inhal
radioaerosol
use
either
silp
tb
method
follow
gamma
camera
imag
period
hour
subgroup
silp
group
studi
twice
baselin
measur
mcc
compar
measur
hyperton
salin
hs
challeng
perform
min
hour
radioaerosol
inhal
major
residu
tracer
expect
small
airway
second
small
group
patient
mcc
region
deposit
measur
follow
silp
inhal
sit
vs
supin
posit
result
baselin
condit
chang
clearabl
fraction
associ
small
airway
clearanc
post
radioaerosol
deposit
greater
silp
vs
tb
method
vs
p
use
silp
method
found
hs
challeng
dramat
enhanc
small
airway
clearanc
clearanc
min
hour
baselin
vs
hs
p
furthermor
hs
challeng
increas
small
airway
clearabl
fraction
p
subgroup
patient
final
found
chang
apexbas
deposit
radioaerosol
inhal
sit
vs
supin
inhal
vs
respect
neither
differ
mcc
two
differ
inhal
posit
conclus
silp
method
provid
greater
signal
measur
small
airway
clearanc
cf
lung
tb
inhal
method
period
defin
domin
small
airway
retent
clearanc
rate
clearabl
fraction
dramat
enhanc
acut
hs
treatment
final
inhal
silp
method
supin
posit
target
radioaerosol
apic
lung
region
allow
better
measur
mcc
region
overal
data
suggest
silp
method
superior
exist
tb
method
test
therapeut
aim
enhanc
mcc
small
airway
cf
support
cf
foundat
despit
multisystem
approach
treat
cystic
fibrosi
cf
recommend
screen
program
specif
address
cf
oral
health
variou
cf
treatment
affect
oral
health
includ
regular
high
calori
snackssuppl
inhal
treatment
antibiot
surgeri
oral
find
dental
cari
enamel
defect
may
result
cf
diseas
andor
treatment
us
studi
report
oral
health
cf
patient
late
aim
report
oral
health
statu
cf
patient
us
cf
center
method
crosssect
sampl
cf
patient
children
hospit
wisconsin
cf
center
enrol
age
year
old
mean
year
dental
cari
enamel
defect
plaqu
gingiv
assess
two
calibr
pediatr
dentist
use
probe
mirror
artifici
light
age
gender
medic
histori
treatmentssurgeri
oral
health
behavior
collect
questionnair
oral
health
assess
includ
dental
plaqu
via
greenevermillion
oral
hygien
index
b
gingiv
via
commun
periodont
index
treatment
need
gi
c
enamel
defect
via
development
defect
enamel
index
dental
cari
via
decayedmissingfil
teeth
index
dmft
intern
cari
detect
assess
system
ii
criteria
result
cf
children
cari
experi
wherea
children
year
old
nation
cari
experi
cf
sampl
dmft
consid
consider
lower
nation
mean
averag
cf
patient
teeth
dental
plaqu
gingiv
also
type
enamel
development
defect
much
higher
gener
report
healthi
children
defect
occur
perman
teeth
commonli
first
perman
molar
upper
central
incisor
form
first
year
life
regard
oral
health
behavior
patient
report
brush
least
day
report
consum
sugari
snack
twice
day
visit
dentist
time
yearli
conclus
result
suggest
cf
patient
lower
dental
cari
preval
regardless
frequent
snack
consumpt
etiolog
may
relat
inhaledor
antibiot
usag
oral
clean
practic
inhal
medic
regular
dental
care
may
select
bia
cohort
seen
dentist
regularli
howev
frequenc
similar
otherwis
report
despit
half
patient
may
present
dental
defect
especi
teeth
develop
first
year
life
defect
may
relat
cf
diseas
treatment
surgeri
defect
lead
aesthet
issu
tooth
sensit
loss
tooth
structur
beget
pain
need
restor
treatment
ie
crown
tooth
loss
next
step
includ
analysi
trend
associ
cf
diseas
treatment
earli
studi
mice
resistin
identifi
adipokin
promot
insulin
resist
inflamm
howev
human
resistin
made
primarili
polymorphonuclear
neutrophil
pmn
consist
dual
role
metabol
inflammatori
mediat
human
resistin
found
abnorm
level
metabol
disord
disord
link
pmndriven
inflamm
cystic
fibrosi
cf
combin
pmndomin
airway
inflamm
profound
metabol
anomali
consist
resistin
elev
plasma
airway
fluid
cf
patient
compar
healthi
control
hc
clinic
sputum
resistin
level
correl
neg
cf
lung
function
probe
resistin
signal
cascad
cf
airway
method
blood
sputum
pmn
adult
cf
patient
analyz
flow
cytometri
surfac
express
resistin
recent
identifi
receptor
adenylylcyclas
associ
protein
addit
hc
blood
pmn
stimul
vitro
latrunculin
b
lb
formyl
peptid
fmlf
induc
primari
granul
exocytosi
analyz
surfac
express
resistin
flow
cytometri
resistin
level
extracellular
fluid
measur
elisa
addit
obtain
bronchoalveolar
lavag
fluid
balf
cf
infant
airway
resistin
level
measur
elisa
earlier
stage
diseas
result
cf
sputum
pmn
express
significantli
higher
resistin
surfac
express
blood
pmn
concomit
previous
observ
high
primari
granul
releas
evidenc
high
surfac
express
vitro
primari
granul
exocytosi
pmn
induc
lb
fmlf
lead
high
surfac
express
also
higher
surfac
express
resistin
consist
vivo
result
lb
fmlf
stimul
pmn
also
led
resistin
accumul
extracellular
fluid
final
measur
signific
resisitin
level
cf
infant
balf
suggest
mediat
present
chronic
stage
diseas
also
earli
process
conclus
result
suggest
live
cf
airway
pmn
express
cell
surfac
resistin
may
mediat
cellcellsign
ii
pmn
like
serv
target
resistin
also
sourc
sinc
induct
primari
granul
exocytosi
lead
resistin
releas
iii
resistin
may
serv
marker
chronic
also
earli
cf
airway
diseas
evidenc
presenc
balf
cf
infant
therapeut
effect
direct
potenti
cftr
ie
function
class
iii
iv
cftr
mutat
previous
demonstr
ivacaftor
find
support
notion
cftr
potenti
yield
clinic
benefit
cf
patient
select
genotyp
defin
inclus
exclus
criteria
base
cftr
genotyp
function
class
clinic
trial
cftr
potenti
reli
part
predict
preclin
electrophysiolog
experi
test
activ
novel
cftr
potenti
function
class
iii
class
iv
cftr
mutat
express
fischer
rat
thyroid
frt
cell
assess
correl
potenc
clinic
efficaci
patient
carri
cftr
mutat
method
vitro
short
circuit
current
isc
measur
carri
frt
cell
stabl
express
cftr
mutat
cell
seed
onto
snapwel
insert
cultur
day
test
insert
mount
vertic
diffus
chamber
bath
apic
basolater
ml
physiolog
salt
solut
insert
voltag
clamp
mv
chang
isc
record
follow
forskolin
subsequ
cftr
potenti
treatment
ec
valu
gener
measur
mean
delta
chang
forskolin
baselin
n
clinic
trial
cf
patient
carri
least
one
gate
residu
function
mutat
random
receiv
mg
bid
mg
bid
placebo
week
interim
analysi
conduct
patient
complet
week
therapi
pharmacodynam
endpoint
sweat
clwere
assess
result
activ
class
iv
mutat
um
um
um
also
activ
test
cell
express
class
ii
mutat
um
um
cf
patient
demonstr
improv
sweat
clin
patient
carri
mutat
respect
conclus
vitro
isc
data
demonstr
potent
cftr
potenti
across
differ
function
class
cftr
mutat
isc
vitro
data
translat
clinic
efficaci
cf
patient
carri
cftr
mutat
find
support
assess
class
iii
iv
mutat
elucid
therapeut
potenti
shown
cf
subject
somewhat
lower
lung
water
densiti
frc
significantli
higher
lung
water
densiti
tlc
compar
normal
control
interpret
find
reflect
presenc
excess
fluid
biofilm
accumul
patholog
lead
increas
densiti
tlc
also
air
trap
lung
peripheri
result
decreas
densiti
frc
preliminari
data
show
ratio
median
lung
water
densiti
frc
tlc
mfld
ratio
significantli
smaller
cf
patient
control
goal
studi
demonstr
lung
abnorm
cf
spatial
identifi
chang
mfld
ratio
compar
region
probabilist
librari
mfld
ratio
control
techniqu
abl
captur
efficaci
therapi
method
mri
spirometr
data
collect
control
age
fev
time
point
femal
age
stabl
cf
diseas
male
age
cf
onset
sever
exacerb
fraction
lung
water
densiti
fld
acquir
duplic
entir
lung
mri
frc
tlc
median
fld
mfld
calcul
region
left
right
lung
total
region
lung
volum
region
design
follow
lung
equal
divid
medial
later
section
section
divid
region
superimpos
grid
onto
lung
section
cf
subject
region
tscore
mfld
ratio
calcul
compar
control
data
use
crawfordhowel
tscore
methodolog
j
clin
exp
tscore
indic
mfld
ratio
one
standard
deviat
control
averag
abnorm
mfld
ratio
region
chang
tscore
time
point
also
calcul
indic
mfld
ratio
specifi
region
increas
eg
improv
control
popul
result
lung
function
remain
stabl
cf
subject
mri
scan
fig
cf
subject
b
fig
b
posit
respons
therapi
indic
improv
fev
second
visit
region
tscore
region
present
cf
subject
cf
subject
chang
mfld
ratio
remain
rel
stabl
time
point
cf
subject
b
mfld
ratio
improv
region
left
lung
sever
region
right
lung
conclus
result
indic
mfld
ratio
may
sensit
region
identifi
monitor
lung
abnorm
cf
marich
c
lord
j
dasenbrook
ec
flume
pa
jouhikainen
savara
inc
austin
tx
usa
cleveland
clinic
cleveland
oh
usa
musc
charleston
sc
usa
background
random
doubleblind
placebocontrol
phase
ii
studi
perform
novel
inhal
drypowd
vancomycin
aerovanc
treatment
persist
mrsa
lung
infect
cf
patient
pharmacokinet
evalu
subgroup
subject
activ
placebo
use
sputum
plasma
vancomycin
concentr
vancomycintr
subject
present
method
aerovanc
administ
day
two
dose
level
mg
mg
bid
use
reload
capsul
inhal
shortact
bronchodil
pretreat
administ
min
prior
studi
drug
sputum
plasma
sampl
taken
follow
predos
h
postdos
day
sampl
analyz
use
valid
lcm
method
lloq
ngml
plasma
sputum
method
respect
result
plasma
vancomycin
concentr
increas
dose
median
max
approxim
h
administr
mean
c
max
valu
dose
group
dose
proport
similar
among
visit
mg
bid
group
mg
bid
group
mean
accumul
ratio
c
max
auc
mg
bid
group
mg
bid
group
indic
notabl
drug
plasma
accumul
time
sputum
vancomycin
concentr
increas
rapidli
dose
median
max
h
administr
dose
group
mean
c
max
auc
increas
progress
visit
mean
accumul
ratio
c
max
auc
mg
bid
group
mg
bid
group
indic
signific
drug
sputum
accumul
singl
mg
dose
aerovanc
mean
sputum
vancomycin
averag
concentr
four
hour
c
increas
day
bid
dose
respect
singl
mg
dose
aerovanc
mean
c
increas
day
bid
dose
respect
c
exceed
mic
vancomycin
mrsa
c
trough
level
day
significantli
greater
mic
c
trough
mic
ratio
valu
mg
bid
group
day
respect
mg
bid
group
day
respect
auc
conserv
estim
multidos
administr
imput
concentr
trough
valu
particular
visit
estim
auc
mic
ratio
unit
h
mg
bid
group
day
respect
mg
bid
group
day
respect
conclus
plasma
sputum
vancomycin
concentr
gener
dose
proport
appar
plasma
vancomycin
accumul
time
signific
sputum
vancomycin
accumul
observ
consist
vancomycin
sputum
concentr
high
mic
observ
dose
level
minim
system
exposur
multidos
administr
support
nihnhlbi
cfft
recent
clinic
trial
use
cystic
fibrosi
cf
patient
studi
combin
cftr
corrector
potenti
improv
cftr
fold
traffick
channel
gate
lead
approv
although
overal
effect
lung
function
eg
fev
statist
signific
modest
suggest
need
addit
therapeut
approach
altern
mechan
action
therefor
measur
enhanc
vitro
effect
snitrosoglutathion
reductas
inhibitor
gsnori
modul
cftr
ad
cftr
corrector
cftr
potenti
measur
cftr
activ
primari
human
cf
airway
epitheli
hae
cell
uss
chamber
analysi
quantifi
plasma
membran
pm
cftr
protein
express
turnov
line
first
although
addit
chronic
cftr
corrector
potenti
result
compar
level
initi
forskolinmedi
cftr
activ
uss
chamber
addit
appear
stabil
level
cftr
activ
time
inhibit
cftr
inh
posit
chang
slope
also
observ
reflect
sustain
cftr
activ
area
curv
auc
measur
total
net
chlorid
secret
cftr
activ
inhibit
also
demonstr
signific
improv
addit
versu
corrector
potenti
alon
moreov
ad
chronic
cftr
corrector
acut
cftr
potenti
increas
potentiatormedi
short
circuit
current
sc
well
increas
total
potenti
cftr
cftrstimul
auc
observ
sc
inhibit
cftr
inh
also
significantli
greater
cf
hae
cell
treat
corrector
versu
corrector
alon
suggest
addit
increas
cftr
activ
second
express
cftr
plasma
membran
pm
measur
oncel
western
analysi
express
tag
extracellular
loop
cftr
observ
signific
increas
pm
cftr
express
ad
alon
well
addit
cftr
corrector
cell
treat
chronic
cftr
corrector
potenti
signific
decreas
pm
cftr
observ
howev
decreas
pm
cftr
express
significantli
revers
back
corrector
treat
level
alon
addit
furthermor
pm
cftr
turnov
cftr
remain
pm
hour
significantli
improv
ad
cftr
corrector
cftr
corrector
potenti
demonstr
increas
pm
cftr
stabil
current
addit
vitro
studi
ongo
explor
effect
gsnori
wildtyp
cftr
express
function
stabil
overal
preclin
data
provid
evid
util
addit
therapi
approach
use
stabil
correct
potenti
cftr
plasma
membran
cf
patient
mechan
respons
ivacaftormedi
lung
function
improv
remain
incomplet
understood
studi
relationship
infect
inflamm
lung
function
irish
cf
subject
mutat
treat
ivacaftor
report
year
data
subject
chronic
p
aeruginosa
pa
infect
seen
other
ivacaftor
rapidli
improv
lung
function
significantli
increas
fev
within
day
notabl
sputum
pa
densiti
also
declin
rapidli
mean
reduct
log
day
p
total
bacteri
densiti
decreas
lesser
extent
sputum
pa
densiti
continu
declin
day
howev
subject
becam
pa
cultureneg
even
low
initi
sputum
pa
densiti
pa
isol
subject
year
clonallyrel
subject
pretreat
isol
indic
persist
rather
reinfect
improv
lung
inflamm
note
week
treatment
decreas
sputum
neutrophil
elastas
reach
statist
signific
p
respect
interestingli
pa
sputum
densiti
began
rebound
day
ivacaftor
treatment
increas
cfu
note
day
p
howev
sputum
inflammatori
biomark
continu
declin
day
p
fev
measur
show
trend
toward
increas
p
sought
correl
chang
lung
function
infect
inflamm
found
reduct
pa
rel
abund
reduct
total
bacteri
densiti
increas
microbi
divers
day
significantli
correl
fev
increas
day
also
identifi
possibl
indic
longterm
benefit
ivacaftor
rate
chang
postivacaftor
trend
toward
correl
reduct
pa
cfu
day
p
correl
significantli
reduct
pa
cfu
day
p
reduct
sputum
day
also
show
correl
trend
increas
fev
year
p
paposit
subject
microbiolog
paramet
correl
increas
lung
function
pa
densiti
pa
rel
abund
total
bacteri
densiti
microbi
divers
interdepend
chang
one
paramet
chang
other
notabl
pa
densiti
chang
total
bacteri
densiti
absolut
abund
measur
nonpa
organ
increas
thu
pa
densiti
like
primari
microbiolog
paramet
chang
ivacaftor
result
demonstr
ivacaftor
reduc
pa
densiti
inflamm
chronic
infect
cf
patient
although
pa
densiti
may
rebound
year
correl
reduc
pa
densiti
improv
fev
rais
possibl
pa
clearanc
contribut
postivacaftor
increas
lung
function
vertex
unrestrict
grant
support
specimen
collect
antiinflammatori
medic
improv
lung
function
decreas
symptom
cf
patient
howev
side
effect
limit
use
improv
medic
need
gallium
nitrat
propos
novel
treatment
cf
patient
chronic
pseudomona
aeruginosa
pa
airway
infect
antimicrobi
antiinflammatori
effect
vitro
phase
clinic
trial
found
intraven
gallium
treatment
improv
lung
function
cf
patient
chronic
pa
infect
gallium
also
decreas
mortal
murin
pa
lung
infect
howev
remain
unclear
whether
therapeut
effect
gallium
due
antimicrobi
antiinflammatori
activ
galliuminduc
reduct
bacteri
densiti
could
decreas
pulmonari
inflamm
use
two
approach
investig
gallium
antiinflammatori
activ
independ
antimicrobi
effect
first
treat
mice
gallium
expos
heatkil
pa
found
galliumtr
mice
develop
less
lung
injuri
untreat
control
also
investig
gallium
effect
human
monocyt
derivedmacrophag
mdm
expos
lp
stimuli
microarray
analysi
demonstr
gallium
attenu
express
larg
subset
proinflammatori
gene
minim
effect
unstimul
mdm
mdm
stimul
cytokin
trigger
macrophag
phenotyp
flow
cytometr
analys
reveal
gallium
also
attenu
express
macrophag
surfac
marker
find
also
suggest
mechan
gallium
may
dampen
lpsinduc
macrophag
inflamm
gallium
treatment
lpsstimul
macrophag
increas
transcript
cytokin
lessen
macrophag
inflamm
autocrin
fashion
gallium
also
induc
lipocalin
also
known
ngal
gene
express
shown
block
lpsinduc
proinflammatori
macrophag
phenotyp
shift
macrophag
repar
antiinflammatori
phenotyp
data
suggest
gallium
may
suppress
inflamm
induc
stimuli
present
cf
airway
improv
cf
patient
lung
function
follow
intraven
gallium
treatment
may
result
part
dampen
airway
inflamm
object
report
singlecent
clinic
experi
initi
therapi
cf
adult
patient
method
retrospect
review
adult
cf
patient
follow
cf
center
januari
april
identifi
patient
homozyg
cftr
mutat
elig
patient
initi
therapi
approv
dose
use
chartbas
data
follow
paramet
measur
initi
therapi
respiratori
symptom
sign
physic
exam
data
vital
sign
pulmonari
function
test
liver
enzym
ast
alt
alkalin
phosphatas
discontinu
therapi
reason
advers
event
ae
seriou
ae
unplan
antibiot
use
chang
pulmonari
function
highest
forc
expiratori
flow
second
highest
month
start
therapi
chang
bmi
highest
bmi
highest
bmi
month
start
therapi
patient
exclud
analysi
continu
initi
therapi
clinic
trial
patient
lung
transplant
prior
approv
patient
result
elig
cf
patient
start
continu
therapi
mean
month
predict
increas
mean
absolut
patient
continu
medic
patient
absolut
rel
increas
predict
decreas
absolut
rel
patient
continu
therapi
bmi
patient
continu
therapi
increas
compar
pretreat
valu
patient
discontinu
therapi
mean
durat
treatment
discontinu
month
reason
discontinu
includ
worsen
respiratori
symptom
headach
rash
fatigu
muscl
ach
transamin
lung
transplant
among
patient
discontinu
due
worsen
respiratori
symptomssign
common
symptom
patient
includ
chest
tight
increas
cough
dyspnea
pulmonari
exacerb
symptom
occur
earli
day
start
therapi
patient
discontinu
therapi
rechalleng
full
half
dose
return
side
effect
serum
level
liver
enzym
differ
initi
patient
patient
transaminas
increas
one
discontinu
therapi
bmi
chang
worsen
patient
posttreat
conclus
data
confirm
result
clinic
research
trial
indic
safe
welltoler
elig
cf
patient
start
medic
importantli
institut
adult
cf
patient
associ
mean
improv
predict
patient
continu
therapi
everi
patient
improv
bmi
futur
direct
ad
cf
center
gain
multicent
clinic
experi
identifi
patient
characterist
comorbid
could
predict
respond
favor
medic
introduct
acut
pulmonari
exacerb
ape
associ
progress
lung
function
declin
increas
mortal
cystic
fibrosi
cf
role
pulmonari
vascular
diseas
ape
unknown
investig
associ
pulmonari
arteri
enlarg
pa
comput
tomograph
ct
marker
pulmonari
vascular
diseas
prospect
ape
method
analyz
clinic
ct
prospect
exacerb
data
deriv
cohort
adult
cf
patient
measur
pa
level
pa
bifurc
axial
ct
imag
replic
find
valid
cohort
adult
cf
patient
patient
separ
group
base
presenc
absenc
pa
follow
year
deriv
cohort
year
valid
cohort
primari
endpoint
develop
ape
followup
linear
logist
regress
model
use
determin
associ
clinic
factor
pa
ratio
ape
use
cox
regress
determin
time
first
exacerb
result
pa
present
deriv
valid
cohort
deriv
cohort
exacerb
year
valid
cohort
event
year
pa
associ
exacerb
deriv
ci
valid
ci
cohort
adjust
covari
time
first
exacerb
shorter
pa
versu
pa
unadjust
analysi
figur
pa
associ
younger
age
cohort
elev
sweat
chlorid
vs
deriv
group
small
number
individu
valid
cohort
sweat
chlorid
avail
vs
conclus
pa
enlarg
preval
adult
cf
patient
associ
cftr
function
acut
pulmonari
exacerb
risk
two
wellcharacter
cohort
rational
cf
lung
diseas
featur
massiv
neutrophil
recruit
airway
respons
staphylococcu
aureu
pseudomona
aeruginosa
increasingli
mycobacterium
abscessu
chronic
infect
establish
cf
neutrophil
larg
ineffect
erad
bacteria
contribut
worsen
inflamm
tissu
injuri
cftr
modul
ivacaftorlumacaftor
orkambi
approv
treatment
peopl
cf
homozyg
result
decreas
frequenc
pulmonari
exacerb
potenti
mutat
ivacaftor
result
normal
neutrophil
kill
howev
effect
orkambi
neutrophil
function
homozyg
patient
known
method
cf
blood
neutrophil
isol
prior
initi
orkambi
one
month
month
treatment
system
marker
inflamm
neutrophil
respons
contribut
success
bacteria
kill
includ
degranul
antimicrobi
protein
assess
flow
cytometri
follow
incub
cf
healthi
control
neutrophil
aureu
p
aeruginosa
abscessu
time
maximum
chemotaxi
amount
chemotact
cell
migrat
bacteri
stimuli
analyz
chang
clinic
paramet
includ
fev
bmi
neutrophil
blood
count
assess
studi
approv
nation
jewish
health
irb
result
fev
bmi
chang
significantli
orkambi
treatment
blood
neutrophil
count
crp
decreas
significantli
respect
within
month
treatment
p
plasma
concentr
decreas
within
treatment
decreas
orkambi
p
neutrophil
degranul
respons
bacteria
test
reduc
healthi
control
level
cf
neutrophil
orkambi
increas
follow
orkambi
chemotaxi
aureu
differ
healthi
control
cf
neutrophil
orkambi
treatment
howev
follow
treatment
chemotaxi
significantli
delay
neutrophil
chemotaxi
toward
cultur
supernat
abscessu
delay
cf
neutrophil
orkambi
compar
healthi
control
unchang
orkambi
treatment
bacteri
stimuli
test
percentag
chemotact
cell
similar
healthi
control
cf
neutrophil
orkambi
reduc
follow
treatment
p
conclus
togeth
find
indic
orkambi
reduc
system
inflamm
cf
patient
improv
neutrophil
degranul
respons
variou
bacteria
could
nonspecif
antiinflammatori
effect
howev
observ
chang
chemotaxi
correl
observ
result
indic
direct
effect
orkambi
neutrophil
function
warrant
investig
especi
neutrophil
respons
differ
bacteri
speci
appear
select
affect
orkambi
treatment
despit
signific
improv
overal
lung
function
bmi
patient
cohort
orkambi
may
enhanc
innat
respons
bacteria
contribut
report
reduct
frequenc
pulmonari
exacerb
support
cff
cctsi
epitheli
sodium
channel
enac
key
regul
airway
surfac
liquid
asl
height
activ
proteas
lung
implic
cystic
fibrosi
patholog
sever
compani
attempt
target
enac
small
molecul
inhibitor
without
success
compound
fail
earli
clinic
develop
due
system
uptak
induc
hyperkalemia
due
inhibit
enac
identifi
novel
peptid
known
demonstr
effect
regul
asl
height
restor
cftrmediat
inhibit
mucu
clearanc
ovin
model
aim
determin
would
better
toler
smallmolecul
enac
inhibitor
would
safe
toxicolog
studi
method
acut
toxicolog
studi
complet
deliv
rat
canin
intraven
inject
nebul
repeat
dose
toxicolog
studi
complet
deliv
nebul
full
analysi
behavior
clinic
chemistri
hematolog
profil
macroand
microscop
histopatholog
safeti
pharmacolog
studi
evalu
effect
cardiovascular
respiratori
function
well
genotox
herg
inhibit
also
perform
use
combin
intraven
inhal
administr
antidrug
antibodi
develop
assess
elisa
result
analog
fold
potent
natur
enac
inhibitori
peptid
restor
asl
height
cfhbec
effect
deliv
lung
nebul
acut
intraven
dose
rat
mgkg
canin
mgkg
show
advers
effect
chang
heart
rate
blood
pressur
ecg
serum
electrolyt
intraven
display
linear
pharmacokinet
min
dose
toxicolog
test
deliv
nebul
rat
dog
show
advers
toxicolog
find
lungdeposit
dose
mgkgday
respect
low
system
exposur
found
hyperkalemia
occur
signific
inhibit
herg
observ
dose
mm
genotox
effect
found
also
free
chang
respir
cardiovascular
paramet
either
intraven
inhal
administr
antibodi
detect
follow
day
treatment
intraperiton
intranas
administr
conclus
data
suggest
novel
enac
inhibitori
peptid
efficaci
model
cf
extrem
low
toxic
suggest
may
viabl
therapeut
treatment
cf
lung
diseas
low
potenti
renal
side
effect
exhibit
previou
small
molecul
enac
inhibitor
second
fda
approv
cftr
modul
avail
unit
state
landmark
traffic
transport
cf
patient
cystic
fibrosi
homozyg
cftr
mutat
predict
receiv
studi
drug
overal
subject
modest
improv
absolut
mean
chang
across
two
dose
group
signific
declin
need
iv
antibiot
across
two
dose
group
drug
well
toler
subject
subject
random
discontinu
drug
due
advers
event
howev
studi
includ
cf
patient
lung
function
less
signific
liver
diseas
object
prospect
evalu
safeti
efficaci
real
world
popul
cf
adult
includ
patient
signific
liver
diseas
method
adult
cf
patient
mutat
adult
center
patient
offer
therapi
agre
adher
therapi
lab
monitor
review
data
avail
patient
provid
inform
consent
point
result
chest
tight
common
sideeffect
experienc
chest
tight
discontinu
therapi
due
chest
tight
patient
experienc
sever
chest
tight
requir
admiss
treat
iv
antibiot
iv
steroid
increas
airway
clearanc
pulmonari
exacerb
patient
remain
longterm
consent
patient
group
less
initi
subject
discontinu
therapi
due
chest
tight
remain
therapi
reduc
dose
patient
cirrhosi
liver
start
patient
monitor
close
liver
function
monitor
week
month
month
initi
therapi
subject
toler
well
trend
toward
improv
liver
function
evid
liver
toxic
patient
one
reduc
dose
due
chest
tight
symptom
consent
adult
cf
patient
initi
remain
therapi
discontinu
due
chest
tight
dose
reduct
util
patient
liver
diseas
patient
experienc
chest
tight
patient
remain
reduc
dose
lung
function
exacerb
frequenc
analyz
patient
group
complet
month
therapi
conclus
initi
real
adult
cf
center
popul
includ
patient
patient
signific
cf
liver
diseas
chest
tight
seen
sideeffect
much
commonli
seen
trial
patient
report
chest
tight
discontinu
drug
due
sideeffect
patient
patient
cirrhosi
abl
toler
drug
least
perceiv
benefit
overal
impact
lung
function
weight
frequenc
exacerb
studi
walker
sd
henri
b
sueblinvong
v
hunt
wr
medicin
emori
univers
atlanta
ga
usa
background
lumacaftorivacaftor
lumiva
approv
use
cf
patient
homozyg
juli
sought
examin
well
adopt
treatment
clinic
well
whether
patient
show
benefit
similar
seen
phase
studi
drug
method
review
center
patient
registri
identifi
patient
homozyg
bmi
data
last
two
year
reason
patient
use
lumiva
obtain
patient
primari
pulmonologist
start
date
lumiva
came
patient
assist
program
data
deliveri
refil
result
total
patient
homozyg
undergon
lung
transplant
includ
analysi
fiftyfour
prescrib
lumiva
prescrib
drug
common
reason
patient
lost
followup
patient
declin
start
patient
undergon
baselin
eye
exam
high
eight
patient
stop
lumiva
due
chest
tight
andor
declin
patient
drug
month
improv
though
overal
improv
absolut
twentytwo
patient
improv
bmi
though
statist
signific
v
appear
trend
decreas
exacerb
rate
though
patient
drug
long
enough
allow
adequ
comparison
discuss
close
half
elig
patient
prescrib
lumiva
clinic
far
medic
indic
uncommon
reason
withhold
prescript
major
aris
patient
choic
poor
patient
followup
five
patient
predict
mild
symptom
prescrib
drug
compar
realworld
use
versu
phase
studi
overal
chang
patient
though
seem
robust
decreas
pulmonari
exacerb
rate
dropout
rate
markedli
higher
studi
patient
withdrew
use
cite
chest
tight
worsen
dyspnea
side
effect
interestingli
major
patient
improv
bmi
month
seen
random
trial
though
statist
signific
yet
specul
may
due
increas
fat
calori
consumpt
due
drug
absorpt
requir
conclus
lumiva
wide
use
elig
popul
mostli
due
patient
behavior
patient
respons
heterogen
note
signific
benefit
high
rate
drug
cessat
due
side
effect
introduct
mortal
cystic
fibrosi
cf
due
respiratori
failur
although
lung
compromis
frequent
associ
chronic
bacteri
infect
eg
pseudomona
aeruginosa
pa
singl
factor
predict
extent
lung
damag
cf
elucid
caus
studi
natur
autoimmun
cf
context
neutrophil
extracellular
trap
net
format
pa
infect
method
autoantibodi
reactiv
bactericid
permeabilityincreas
protein
antibpi
igg
carbamyl
protein
acarpa
citrullin
protein
acpa
cf
patient
compar
sera
rheumatoid
arthriti
ra
patient
given
associ
airway
inflamm
acpa
induct
ra
reactiv
recombin
bpi
cterminu
fragment
also
evalu
cf
sera
antibodi
titer
obtain
elisa
studi
relat
percentag
forc
expiratori
volum
second
bacteri
colon
sputum
cultur
cftr
mutat
statu
autoantigen
net
posttransl
modif
evalu
immunocytochemistri
bpi
cleavag
netosi
studi
immunoblot
follow
treatment
wildtyp
pa
strain
pa
elastas
defici
counterpart
result
even
though
bpi
carbamyl
protein
citrullin
protein
local
net
data
show
cf
patient
antibpi
autoantibodi
less
present
acpa
contrast
acpaposit
ra
patient
exhibit
reactiv
bpi
interestingli
acarpa
found
cf
ra
cohort
correl
antibpi
igg
titer
contrari
acpa
acarpa
autoantibodi
bpi
recogn
cterminu
bpi
absenc
posttransl
modif
ie
citrullin
carbamyl
isoaspartyl
presenc
antibpi
autoantibodi
acarpa
correl
diminish
lung
function
cf
patient
well
presenc
pa
sputum
cultur
interestingli
pa
treatment
neutrophil
result
pa
elastasemedi
bpi
cleavag
netosi
conclus
firstev
studi
autoimmun
adult
unit
state
cf
cohort
demonstr
autoreact
bpi
reflect
diminish
airway
function
context
pa
infect
specif
cftr
genotyp
moreov
studi
identifi
role
pa
elastas
develop
antibpi
autoimmun
provid
link
pa
clearanc
respiratori
failur
context
autoimmun
cf
introduct
aminoglycosid
ag
glycopeptid
antibiot
essenti
treat
lifethreaten
respiratori
infect
patient
cystic
fibrosi
cf
side
effect
medic
link
caus
hear
kidney
issu
goal
studi
examin
effect
cumul
intraven
iv
ag
andor
glycopeptid
dose
hear
statu
patient
recruit
oregon
health
scienc
univers
adult
pediatr
cf
center
method
hear
threshold
measur
khz
particip
age
year
cf
particip
categor
four
group
ie
quartil
base
lifetim
exposur
iv
antibiot
defin
total
number
dose
calcul
bodi
mass
group
rank
lowest
quartil
highest
quartil
number
cumul
lifetim
dose
addit
analysi
conduct
account
frequenc
dose
per
day
result
logist
regress
model
use
obtain
odd
perman
sensorineur
hear
loss
snhl
quartil
cumul
iv
dose
adjust
gender
age
time
studi
particip
particip
normal
hear
group
significantli
younger
snhl
account
age
differ
particip
highest
exposur
quartil
like
perman
snhl
effect
remain
statist
signific
take
account
frequenc
dose
per
day
consider
variabl
hear
loss
among
subject
within
dose
quartil
conclus
signific
age
effect
group
normal
hear
versu
ear
snhl
cumul
iv
antibiot
dose
may
significantli
neg
effect
hear
sensit
particip
cf
independ
gender
age
variabl
hear
loss
within
quartil
may
suggest
genet
predisposit
drug
suscept
hear
dnabas
analys
cystic
fibrosi
cf
airway
microbiota
challeng
idea
etiolog
cf
infect
two
notabl
find
earli
cf
lung
diseas
microbi
dna
within
sampl
typic
deriv
divers
collect
microb
consid
convent
cf
pathogen
establish
diseas
convent
cf
pathogen
domin
nonconvent
pathogen
often
still
identifi
although
lesser
quantiti
howev
find
complic
airway
sampl
transit
oropharynx
nonconvent
pathogen
highli
abund
addit
collect
devic
eg
bronchoscop
analysi
reagent
harbor
microbi
dna
address
problem
collect
cf
bronchoalveolar
lavag
sampl
total
sampl
subject
endotrach
tube
intub
attempt
bypass
oropharyng
organ
also
includ
control
sampl
identifi
contamin
reagent
bronchoscop
oropharynx
final
young
children
mild
cf
lung
diseas
studi
increas
chanc
collect
sampl
convent
pathogen
domin
bronchoalveolar
lavag
sequenti
perform
four
predetermin
lower
airway
site
addit
site
base
clinic
radiograph
evid
diseas
quantit
pcr
measur
total
bacteri
rrna
gene
abund
suggest
lavag
sampl
could
categor
come
area
establish
nascent
infect
base
bacteri
burden
present
establish
infect
site
rrna
gene
sequenc
show
convent
cf
pathogen
domin
rel
small
fraction
microbi
dna
map
nonconvent
pathogen
contrast
lavag
nascent
infect
site
contain
dna
divers
collect
nonconvent
pathogen
consist
emerg
view
earlyinfect
cf
microbiom
notabl
microbi
dna
profil
nascent
infect
site
differ
markedli
oropharyng
sampl
suggest
endotrach
intub
effect
bypass
upper
airway
contamin
howev
nascent
site
contain
similar
microbi
dna
densiti
profil
control
wash
bronchoscop
perform
procedur
find
suggest
microbi
dna
identifi
nascent
infect
site
like
contamin
find
highlight
need
care
sampl
control
specimen
dnabas
method
use
studi
human
infect
use
whole
genom
sequenc
detail
epidemiolog
analysi
cohort
patient
attend
uk
cf
centr
found
strong
evid
transmiss
patient
sought
determin
global
popul
structur
abscessu
infect
cf
patient
method
carri
whole
genom
sequenc
global
collect
clinic
isol
patient
attend
cf
clinic
uk
ireland
denmark
australia
north
america
assess
clinic
consequ
genet
divers
cellbas
vivo
assay
carri
select
strain
clinic
data
collect
avail
result
phylogenet
analysi
reveal
major
infect
dens
cluster
abscessu
genotyp
low
level
divers
indic
high
level
humanassoci
spread
moreov
identifi
three
recent
emerg
domin
circul
clone
global
dissemin
clone
associ
chronic
infect
increas
phagocyt
uptak
increas
intracellular
surviv
macrophag
within
patient
found
evid
signific
genet
divers
evolutionari
adapt
process
converg
evolut
hypermut
demonstr
propens
abscessu
evolv
environment
organ
transmiss
human
pathogen
conclus
transmiss
clone
abscessu
circul
global
amongst
cf
patient
worryingli
found
clone
associ
wors
clinic
outcom
increas
level
virul
staphylococcu
aureu
preval
bacteri
speci
isol
airway
cystic
fibrosi
cf
patient
childhood
pseudomona
aeruginosa
predominantli
isol
adult
cf
recent
character
p
aeruginosa
biofilm
growth
primari
cf
airway
epitheli
cell
aec
observ
enhanc
biofilm
format
coinfect
respiratori
virus
hendrick
mr
et
al
pna
hypothes
infect
respiratori
virus
alter
microbi
commun
dynam
cf
airway
affect
balanc
aureu
p
aeruginosa
popul
goal
work
compar
aureu
biofilm
growth
cf
noncf
aec
studi
dynam
aureu
infect
alon
coinfect
p
aeruginosa
respiratori
virus
initi
studi
show
increas
aureu
immort
cf
bronchial
aec
hour
confoc
microscopi
reveal
biofilmlik
cluster
bacteria
aec
measur
express
biofilm
plankton
marker
gene
use
quantit
realtim
pcr
confirm
aureu
exist
biofilm
state
cf
aec
learn
aureu
biofilm
growth
differ
distinct
site
respiratori
tract
biofilm
assay
perform
welldifferenti
primari
cf
noncf
bronchial
nasal
sinonas
aec
infect
noncf
cell
type
result
decreas
viabl
aureu
time
howev
cf
nasal
sinonas
aec
show
kill
activ
toward
aureu
cf
bronchial
aec
support
aureu
growth
similar
trend
anti
aureu
activ
observ
growth
assay
util
airway
surfac
liquid
collect
primari
aec
current
studi
evalu
airway
surfac
liquid
ph
cf
noncf
bronchial
cell
determin
ph
dysregul
factor
impact
abil
cf
bronchial
aec
kill
aureu
initi
coinfect
experi
aureu
p
aeruginosa
cf
bronchial
aec
aureu
biofilm
grew
coinfect
p
aeruginosa
howev
coinfect
respiratori
syncyti
viru
rsv
p
aeruginosa
growth
increas
dramat
aureu
growth
decreas
livecel
imag
experi
evalu
biofilm
format
cf
bronchial
aec
flow
condit
show
speci
bacteria
close
associ
within
biofilm
aec
presenc
rsv
coinfect
p
aeruginosa
domin
growth
ongo
experi
investig
specif
host
antimicrobi
mechan
util
viralbacteri
coinfect
might
skew
microbi
commun
cf
airway
background
cf
result
chronic
lung
infect
frequent
exacerb
symptom
chang
microbi
commun
dynam
believ
respons
cf
exacerb
preliminari
evid
indic
anaerob
ferment
metabol
associ
exacerb
develop
cf
hypothes
mucu
ph
drive
dynam
test
use
cultur
microcosm
lung
method
use
novel
wincf
microbi
cultur
system
quinn
ra
et
al
ismej
design
mimic
condit
cf
plug
bronchiol
mucu
sampl
cf
noncf
patient
inocul
wincf
mucu
media
buffer
differ
ph
bacteri
rrna
gene
sequenc
metabolom
use
determin
ph
affect
commun
mathemat
model
use
test
observ
microcosm
dynam
result
separ
microbi
commun
driven
ph
effect
lower
ph
anaerob
commun
domin
higher
ph
pseudomona
aeruginosa
thrive
antibiot
pressur
disrupt
phbase
structur
kill
anaerob
p
aeruginosa
metabolit
produc
p
aeruginosa
also
alter
media
ph
mathemat
model
support
phdriven
commun
dynam
also
reveal
radiu
bronchu
signific
impact
wider
lung
bronchi
creat
room
anaerob
ferment
lead
higher
rate
commun
flux
incorpor
period
antibiot
treatment
exacerb
model
result
cyclic
dynam
anaerob
kill
p
aeruginosa
thrive
anaerob
reestablish
antibiot
pressur
subsid
conclus
studi
support
observ
cf
exacerb
associ
bloom
ferment
anaerob
lower
mucu
ph
antibiot
pressur
destroy
anaerob
set
cyclic
dynam
p
aeruginosa
cycl
microbi
system
like
crucial
cf
diseas
progress
clinic
outcom
typic
respons
sputum
cultur
differ
media
ph
background
immun
respons
pseudomona
aeruginosa
infect
cystic
fibrosi
cf
lung
characteris
neutrophildomin
inflamm
incomplet
effect
clear
infect
caus
lung
tissu
damag
ultim
result
respiratori
failur
combat
bacteri
infect
neutrophil
produc
potent
oxid
hypochlor
acid
hocl
bleach
gener
myeloperoxidas
enzym
account
neutrophil
protein
import
hocl
bacteri
kill
cf
lung
way
p
aeruginosa
defend
hocl
poorli
understood
object
identifi
mechan
use
p
aeruginosa
protect
hocl
method
screen
regulatori
gene
mutant
p
aeruginosa
transposon
librari
alter
hocl
suscept
liberati
nt
et
al
pna
usa
growth
presenc
subleth
concentr
hocl
ppm
follow
record
optic
densiti
nm
hour
mutant
result
screen
identifi
hoclresist
hoclsensit
mutant
consist
phenotyp
strain
mutat
gene
encod
regul
role
control
antibiot
resist
catabolit
repress
motil
methionin
biosynthesi
quorum
sens
interestingli
mutant
gene
homolog
e
coli
hoclsens
regul
rclr
hypt
nemr
display
alter
suscept
hocl
mutant
mext
encod
posit
regul
multidrug
efflux
pump
operon
mexefoprn
sensit
hocl
growth
observ
hour
mutant
ampr
encod
global
regul
found
neg
regul
mexefoprn
display
hocl
resist
exit
lag
phase
hour
earlier
wild
type
wt
addit
screen
strain
mutat
mex
mexf
growth
presenc
hocl
identifi
hour
delay
respect
exit
lag
phase
compar
wt
indic
hocl
sensit
p
aeruginosa
clinic
isol
chronic
cf
lung
infect
identifi
mutat
ampr
mext
suggest
potenti
role
regul
adapt
diaz
caballero
j
et
al
mbio
furthermor
mutant
cbra
cbrb
encod
twocompon
system
regul
carbon
nitrogen
utilis
resist
hocl
indic
rapid
onset
growth
compar
wt
cbrab
neg
regul
global
regul
crc
via
small
rna
crcz
mutant
crc
sensit
hocl
growth
observ
hour
addit
investig
hocl
protect
mechan
mutant
identifi
use
assay
test
hypothesi
hocl
crucial
neutrophilmedi
kill
bacteria
context
cf
infect
success
identifi
number
hoclresist
hoclsensit
mutant
strain
data
suggest
p
aeruginosa
use
differ
hocl
protect
mechan
e
coli
mexefoprn
efflux
pump
potenti
import
protect
hocl
rational
underli
defect
cystic
fibrosi
cf
airway
lead
defect
mucociliari
clearanc
impair
bacteri
kill
result
endobronchi
infect
inflamm
contribut
progress
lung
diseas
littl
known
respiratori
microbiota
earli
cf
airway
relationship
inflamm
object
examin
bacteri
microbiota
inflammatori
profil
bronchoalveolar
lavag
fluid
oropharyng
secret
infant
cf
investig
associ
prophylact
antibiot
use
measur
main
result
infant
cf
two
us
two
australian
center
enrol
prospect
observ
studi
examin
bacteri
inflammatori
profil
upper
lower
respiratori
tract
thirtytwo
infant
underw
bronchoalveolar
lavag
oropharyng
sampl
mean
age
month
bacteri
commun
assess
qpcr
amplicon
sequenc
bacteri
densiti
load
divers
measur
lavag
sampl
analyz
inflammatori
marker
unbound
neutrophil
elastas
absolut
neutrophil
count
anc
shannon
divers
strongli
correl
upper
lower
airway
sampl
given
subject
though
commun
composit
differ
microbi
divers
significantli
lower
younger
subject
treat
daili
antstaphylococc
prophylaxi
lavag
sampl
reduc
divers
correl
strongli
lower
anc
conclus
infant
cf
reduc
bacteri
divers
upper
lower
airway
strongli
associ
use
prophylact
antibiot
younger
age
time
sampl
less
divers
lower
airway
correl
lower
inflamm
bronchoalveolar
lavag
find
suggest
modif
respiratori
microbiom
infant
cf
may
reduc
airway
inflamm
though
studi
need
shannon
divers
lavag
l
oropharyng
r
sampl
infant
take
antibiot
prophylaxi
red
vs
blue
object
respiratori
microbi
composit
patient
cystic
fibrosi
cf
differ
healthi
individu
direct
effect
cftr
mutat
lung
defens
frequent
use
antibiot
treatment
cf
patient
prone
becom
carrier
specif
pathogen
pseudomona
aeruginosa
burkholderia
speci
previou
studi
show
cftrmodifi
treatment
ivacaftor
patient
class
iii
cftr
mutat
decreas
burden
pseudomona
aeruginosa
hoen
ag
et
al
j
pediatr
studi
effect
ivacaftor
treatment
composit
respiratori
microbiom
studi
part
hitcf
program
materi
method
patient
gate
mutat
start
treatment
ivacaftor
nasopharyng
oropharyng
sputum
sampl
obtain
start
treatment
eight
week
start
treatment
nine
month
treatment
addit
sampl
taken
sampl
sequenc
use
rrnabas
sequenc
analyz
microbi
composit
result
total
sampl
obtain
studi
mean
age
sd
patient
year
nasopharyng
sampl
staphylococcu
corynebacterium
pseudomona
aeruginosa
abund
eight
week
treatment
pseudomona
aeruginosa
less
abund
howev
differ
statist
signific
oropharyng
sampl
streptococcu
abund
sputum
sampl
pseudomona
aeruginosa
eight
week
treatment
abundantli
present
togeth
streptococcu
veillonella
prevotella
statist
differ
sampl
eight
week
treatment
found
conclus
preliminari
data
observ
signific
chang
respiratori
microbiom
eight
week
treatment
ivacaftor
patient
gate
mutat
data
nine
month
followup
collect
analyz
next
three
month
present
confer
heirali
acosta
n
ab
canada
univ
british
columbia
vancouv
bc
canada
univ
alberta
edmonton
ab
canada
univ
montreal
montreal
qc
canada
mcmaster
univ
hamilton
canada
introduct
azli
inhal
antibiot
abx
cycl
onoff
fashion
use
treat
chronic
pseudomona
aeruginosa
infect
cf
wherea
aztreonam
consid
spectrum
activ
limit
aerob
gramneg
organ
base
level
achiev
parenter
azli
achiev
extrem
high
concentr
potenti
extend
spectrum
activ
hypothes
azli
activ
organ
within
cf
lung
microbiom
therebi
exert
portion
clinic
benefit
accordingli
sought
determin
shift
cf
microbiota
singl
cycl
therapi
method
plan
cohort
adult
cf
patient
four
clinic
patient
receiv
azli
assess
day
inhal
abx
particip
began
cycl
azli
follow
cycleor
day
tobramycin
solut
ti
sputum
collect
day
abx
azli
azli
ti
clinic
data
includ
cfrespiratori
symptom
diari
cfrsd
lung
function
collect
time
point
correl
microbiom
data
dna
extract
sputum
sampl
region
rrna
gene
sequenc
use
illumina
miseq
microbiom
analysi
perform
r
result
cohort
demograph
initi
cohort
follow
homozyg
pancreat
insuffici
median
age
iqr
bmi
kgm
fev
predict
receiv
azli
sole
inhal
abx
although
receiv
ti
cycl
day
patient
significantli
improv
cfrsd
p
median
improv
fev
l
signific
differ
alphaand
betadivers
measur
sampl
collect
day
vs
suggest
limit
communitywid
differ
cf
microbiota
due
cycl
azli
therapi
signific
differ
observ
braycurti
measur
individu
patient
base
site
suggest
sampl
may
cluster
base
patient
geograph
locat
structur
microbiom
treatment
initi
correl
clinic
respons
current
pursu
discuss
patient
exhibit
clinic
improv
azli
signific
chang
microbiom
observ
initi
azli
suggest
cf
microbiota
rel
resili
inhal
abx
addit
studi
analyz
shift
cf
microbiom
complet
patient
cohort
may
provid
inform
whether
azli
treatment
caus
success
chang
microbiom
andor
could
use
optim
therapi
parkin
md
et
al
j
clin
microbiol
fowerakerj
et
al
j
antimicrob
chemoth
inde
result
profoundli
heterogen
popul
pa
isol
differ
markedli
respect
coloni
morpholog
antibiot
resist
virul
potenti
whether
dynam
divers
popul
infect
pa
exist
potenti
influenc
occurr
exacerb
andor
treatment
respons
heretofor
unknown
major
barrier
understand
flux
pa
popul
dynam
relat
find
conveni
method
collect
regular
sampl
serial
home
collect
storag
frozen
sputum
follow
en
mass
thaw
recoveri
isol
offer
potenti
overcom
limit
howev
freez
known
result
rel
reduct
pa
popul
densiti
project
aim
determin
specif
subpopul
pa
disproport
kill
freez
method
sputum
collect
cf
patient
chronic
pa
infect
half
process
immedi
serial
dilut
onto
macconkey
agar
mac
isol
randomli
select
sampl
term
immedi
commun
ic
half
sputum
sampl
frozen
home
freezer
day
thaw
process
fashion
term
frozen
commun
fc
isol
screen
antibiot
aztreonam
ciprofloxacin
virul
factor
rhamnolipid
proteas
siderophor
hemolysi
understand
effect
freez
subpopul
composit
result
patient
pa
screen
ic
fc
freez
result
reduct
pa
densiti
cfuml
patient
coloni
morpholog
growth
freez
mark
phenotyp
divers
note
ic
fc
patient
statist
differ
least
one
four
virul
factor
assess
ic
fc
least
one
four
virul
factor
differ
howev
consist
pattern
observ
sampl
ic
higher
virul
potenti
fc
other
lower
none
patient
observ
statist
differ
proport
resist
isol
fc
ic
howev
consist
pattern
observ
interpati
analysi
compar
proport
resist
isol
amongst
entir
collect
show
statist
differ
fc
ic
aztreonam
p
ciprofloxacin
discuss
virul
factor
product
antibiot
resist
popul
pa
caus
chronic
cf
lung
infect
heterogen
phenotyp
divers
underestim
one
coloni
analyz
variabl
ic
fc
sampl
observ
evid
kill
specif
subpopul
pa
freez
observ
studi
suggest
home
collect
may
pose
viabl
mean
understand
pa
popul
flux
cf
lung
diseas
introduct
cf
affect
mani
system
bodi
characterist
symptom
dramat
reduc
qualiti
life
associ
accumul
mucu
lung
long
term
static
mucoid
environ
get
colon
divers
commun
microb
virus
fungi
therefor
becom
reservoir
infect
requir
chronic
treatment
antibiot
gener
choic
antibiot
target
mani
case
administ
infect
advanc
addit
longterm
side
effect
drug
eventu
antibiot
resist
bacteria
fungi
take
hold
complic
treatment
translat
genom
research
institut
tgen
collabor
univers
arizona
initi
studi
track
chang
microbi
fungal
commun
time
patient
cf
purpos
studi
better
understand
cf
pulmonari
microbiom
time
determin
emerg
pathogen
antibiot
resist
detect
prior
exacerb
primari
goal
studi
develop
evalu
person
target
microbiom
assay
rapid
character
patient
current
pulmonari
commun
prototyp
diagnost
could
potenti
use
advis
treatment
person
time
method
obtain
consent
adult
subject
year
old
enrol
yearlong
observ
studi
studi
involv
monthli
sputa
collect
patient
cours
one
year
sputa
sampl
analyz
rdna
whole
metagenom
sequenc
wmg
commun
analysi
addit
sputa
sampl
evalu
tgen
nextgen
antimicrobi
resist
detect
ngard
assay
profil
person
microbi
commun
sampl
amplicon
sequenc
result
preliminari
analysi
sampl
time
point
patient
reveal
high
rel
abund
mani
common
pathogen
associ
cf
includ
pseudomona
streptococcu
staphylococcu
haemophilu
enterobacteriacea
variat
among
patient
among
timepoint
within
patient
analysi
metagenom
data
gottcha
wgfast
reveal
overlap
pattern
abl
resolv
speci
strain
level
ngard
sequenc
reveal
two
cf
patient
mrsa
sccmec
type
ii
anoth
patient
mssa
speci
target
achromobact
haemophilu
streptococcu
current
develop
analysi
fungal
commun
ongo
discuss
newer
techniqu
analysi
cf
microbiom
potenti
describ
microbiolog
environ
cf
lung
also
distinguish
suscept
person
treatment
therapi
time
fashion
current
diagnost
cf
exacerb
base
clinic
cultur
microbi
isol
sputum
sampl
follow
antibiot
suscept
test
despit
establish
gold
standard
studi
shown
antimicrobi
suscept
profil
frequent
correl
clinic
outcom
instanc
antibiot
treatment
still
result
patient
recoveri
despit
highli
report
resist
underli
incomplet
understand
microbi
basi
cf
exacerb
best
method
treatment
like
caus
discrep
mani
pathogen
cf
lung
identifi
standard
clinic
lab
bacteri
rrna
gene
profil
shown
cf
lung
infect
much
divers
reveal
clinic
cultur
thu
begun
implement
rapid
respons
pipelin
cf
exacerb
employ
multiom
data
includ
transcriptom
metabolom
rrna
gene
sequenc
provid
time
comprehens
assess
clinician
sputum
sampl
collect
dna
rna
metabolit
extract
follow
nucleic
acid
sequenc
mass
spectrometri
final
data
analysi
pipelin
gener
microbi
taxonomi
gene
express
metabolit
product
inform
requir
highpow
comput
resourc
analyz
despit
enorm
scale
data
gener
highli
streamlin
integr
bioinformat
pipelin
allow
analysi
less
hour
use
small
group
peopl
inform
provid
virul
factor
product
host
inflammatori
signal
gene
express
microb
host
taxonom
profil
bacteri
lung
infect
includ
new
pathogen
may
drive
exacerb
event
penetr
drug
site
infect
recent
applic
pipelin
sever
exacerb
event
show
pseudomona
aeruginosa
growth
slow
despit
lung
microbiom
compos
bacterium
express
mostli
algin
iron
chelat
gene
rdna
sequenc
reveal
possibl
bloom
anaerob
metabolit
product
match
transcriptom
profil
detect
product
siderophor
pyochelin
also
reveal
antibiot
given
patient
reach
site
infect
instanc
omic
pipelin
mosli
harmoni
conclus
exacerb
futur
cf
exacerb
diagnost
diseas
involv
complex
infect
employ
multiom
data
effort
one
show
timefram
produc
analyz
translat
rich
data
physician
approach
gold
standard
bacteri
cultur
introduct
cough
patient
cystic
fibrosi
cf
gener
p
aeruginosa
droplet
nuclei
capabl
travel
metr
remain
viabl
minut
knibb
l
et
al
thorax
cf
foundat
cff
recent
updat
infect
control
guidelin
includ
recommend
patient
cf
wear
surgic
face
mask
commun
area
health
facil
reduc
transmiss
pathogen
saiman
l
et
al
ich
howev
outward
protect
face
mask
worn
cf
patient
extens
studi
aim
studi
investig
effect
face
mask
cough
etiquett
techniqu
reduc
viabl
bioaerosol
patient
cf
chronic
p
aeruginosa
infect
talk
cough
method
twentyf
male
adult
subject
cf
mean
sd
age
fev
predict
enrol
subject
posit
valid
particlefre
aerosolsampl
devic
perform
seri
six
order
randomis
activ
minut
talk
talk
surgic
mask
unmask
cough
cough
surgic
mask
cough
mask
cough
hand
cover
mouth
andersen
cascad
impactor
posit
metr
subject
collect
size
viabl
aerosol
quantit
sputum
aerosol
cultur
perform
total
number
coloni
form
unit
cfu
determin
subject
rate
comfort
level
cough
activ
result
subject
produc
viabl
aerosol
p
aeruginosa
unmask
cough
yet
talk
studi
subject
singl
p
aeruginosa
cfu
detect
posit
correl
sputum
p
aeruginosa
load
unmask
cough
aerosol
p
aeruginosa
cfu
compar
unmask
cough
reduct
viabl
cough
aerosol
use
mask
type
hand
cover
mouth
p
differ
cfu
detect
surgic
mask
compar
cough
manoeuvr
though
patient
rate
surgic
mask
comfort
cfu
detect
hand
cover
mouth
greater
surgic
p
mask
studi
conclus
face
mask
worn
patient
cf
reduc
cough
gener
droplet
nuclei
contain
viabl
p
aeruginosa
surgic
mask
provid
enhanc
patient
comfort
cough
etiquett
provid
less
protect
mask
reduc
aerosol
dispers
data
support
current
cff
infect
control
guidelin
recommend
use
surgic
mask
reduc
environment
contamin
potenti
transmiss
pathogen
microorgan
patient
cf
support
cff
therapeut
usa
princ
charl
hospit
foundat
australia
evolutionari
theori
predict
bacteria
mutat
becom
antibiot
resist
becom
less
fit
antibioticsuscept
rel
antibiot
absent
surprisingli
recent
find
suggest
certain
resist
mutat
increas
bacteri
fit
virul
find
intens
antibiot
treatment
use
cf
rais
possibl
treatment
could
elimin
suscept
isol
replac
hypervirul
antibioticresist
sibl
hypothes
mutat
confer
resist
cfrelev
antibiot
could
lead
enhanc
bacteri
virul
test
first
identifi
mutat
confer
resist
aztreonam
determin
effect
mutat
virul
use
vitro
select
grew
p
aeruginosa
increas
concentr
aztreonam
use
whole
genom
sequenc
identifi
put
resist
mutat
parallel
evolv
lineag
found
common
mutat
affect
gene
involv
antibiot
efflux
cell
wall
remodel
total
differ
nonsynonym
mutat
detect
nald
nalc
mexr
gene
normal
repress
express
mexab
antibiot
efflux
system
furthermor
evolv
strain
mutat
exhibit
increas
mexa
express
determin
whether
aztreonamresist
mutat
enhanc
virul
compar
two
evolv
resist
isol
mutat
nald
mexr
aztreonamsuscept
parent
strain
acut
murin
pneumonia
infect
model
resist
isol
lethal
suscept
parent
strain
result
identifi
p
aeruginosa
mutat
simultan
lead
antibiot
resist
enhanc
virul
data
rais
possibl
select
resist
could
also
lead
enhanc
bacteri
virul
phenotyp
could
promot
cf
pulmonari
diseas
progress
introduc
colorado
cf
research
develop
program
nontubercul
mycobacteria
ntm
molecular
core
offer
wg
ntm
isol
affect
us
cf
patient
genom
surveil
ntm
isol
deriv
us
cf
patient
combin
ntm
isol
phenotyp
biobank
provid
biorepositori
core
provid
critic
resourc
microbiolog
genom
epidemiolog
investig
within
us
cf
commun
inquiri
pleas
visit
http
www
nationaljewishorgcoloradocfresearchanddevelopmentprogram
method
first
year
collect
began
wg
cf
ntm
isol
includ
colorado
cf
patienc
predict
clinic
trial
ntm
isol
prepar
genom
sequenc
use
nextera
xt
librari
prepar
protocol
multiplex
sequenc
use
illumina
miseq
gener
bp
pairedend
sequenc
read
isol
sequenc
read
isol
map
appropri
refer
genom
speci
ie
abscessu
subsp
abscessu
atcc
abscessu
isol
intracellular
atcc
intracellular
chimaera
isol
recov
use
singl
nucleotid
polymorph
snp
variant
identifi
use
samtool
custom
comput
script
use
compar
snp
variat
estim
genom
related
among
isol
sequenc
data
made
public
avail
via
ncbi
bioproject
http
result
interrog
genom
relationship
ntm
isol
within
cf
patient
assess
likelihood
cluster
character
predomin
ntm
speci
affect
us
cf
patient
mean
snp
isol
differ
patient
found
evid
cluster
us
cf
patient
analyz
date
howev
see
cluster
genet
relat
isol
appear
compris
genom
subtyp
within
abscessu
avium
chimaera
intracellular
pangenom
analys
reveal
presenc
mobil
genet
element
may
carri
put
virul
factor
popul
ntm
isol
conclus
describ
dynam
platform
analyz
ntm
affect
us
cf
patient
although
genom
comparison
reveal
genet
similar
isol
within
clinic
relev
ntm
speci
clonal
lineag
share
patient
therefor
observ
cluster
ntm
within
us
cf
patient
investig
date
initi
activ
emphas
advantag
need
integr
genom
sequenc
clinic
cf
care
infect
control
support
background
mycobacterium
abscessu
rapidgrow
mycobacterium
increasingli
isol
lung
patient
cystic
fibrosi
cf
recommend
treatment
regimen
includ
multipl
drug
two
phase
intens
phase
continu
lack
compel
evid
clinic
efficaci
guid
mangag
method
perform
retrospect
review
treatment
outcom
cf
patient
singl
center
least
abscessusposit
respiratori
cultur
underw
intens
phase
treatment
defin
treatment
regimen
includ
least
one
intraven
antibiot
patient
underw
lung
transplant
prior
treatment
exclud
data
collect
electron
medic
record
includ
age
time
treatment
antimycobacteri
drug
receiv
rout
administr
start
stop
date
therapi
fev
prior
treatment
day
posttreat
date
cultur
posit
abscessu
data
analyz
use
parametr
method
result
total
patient
underw
intens
phase
abscessu
treatment
averag
age
year
amikacin
commonli
use
drug
patient
though
inhal
follow
cefoxitin
clarithromycin
patient
treat
three
drug
averag
durat
intens
phase
day
patient
least
acidfast
bacillu
cultur
month
follow
treatment
achiev
bacteri
clearanc
lung
function
valu
avail
patient
pretreat
percent
predict
significantli
chang
day
posttreat
howev
exclud
patient
treat
despit
averag
pretreat
lung
function
predict
may
littl
opportun
improv
observ
signific
increas
predict
day
start
treatment
vs
p
trend
toward
continu
improv
day
subset
patient
treat
clarithromycin
signific
lung
function
improv
p
trend
toward
increas
clearanc
abscessu
vs
conclus
treatment
abscessu
result
shortterm
improv
lung
function
subset
patient
belowaverag
pretreat
furthermor
patient
treat
clarithromycin
appear
posit
clinic
respons
though
interpret
limit
small
number
heterogen
treatment
regimen
investig
need
determin
impact
resist
pattern
continu
phase
find
well
multivari
approach
tri
control
heterogen
howev
find
remain
import
light
current
guidelin
favor
azithromycin
clarithromycin
background
preval
mrsa
infect
increas
cf
patient
associ
consist
declin
higher
mortal
although
case
spontan
clearanc
mrsa
earli
erad
treatment
eet
could
increas
percentag
clearanc
germ
provid
clinic
relev
germfre
period
therefor
avoid
neg
prognost
factor
microbiolog
outcom
could
indic
prevent
persist
infect
eet
mrsa
simpl
way
improv
longterm
prognosi
cf
patient
purpos
compar
statist
efficaci
eet
initi
mrsa
infect
lower
respiratori
tract
cf
patient
evalu
mrsa
antibiot
suscept
initi
infect
studi
design
ongo
largescal
openlabel
multicent
rct
involv
cf
patient
italian
centr
firstnew
mrsa
infect
randomli
assign
activ
arm
observationonli
arm
b
patient
random
arm
administ
associ
antibiot
accord
suscept
pattern
oral
cotrimoxazol
rifampin
day
associ
intranas
mupirocin
day
patient
select
criteria
elig
cf
patient
older
year
demonstr
regular
visit
center
infect
b
cepacia
complex
clinic
sign
respiratori
exacerb
primari
outcom
arm
percentag
erad
failur
calcul
success
erad
defin
absenc
germ
follow
antibiot
treatment
least
antibiogram
period
month
secondari
outcom
antibiot
suscept
mrsa
strain
first
isol
evalu
interim
result
sinc
januari
random
patient
twentynin
assign
arm
arm
b
mean
age
moment
patient
complet
followup
erad
success
arm
patient
cultur
result
neg
arm
b
patient
antibiot
suscept
pattern
mrsa
moment
isol
support
treatment
chosen
therapi
octob
followup
enrol
patient
conclud
polymicrobi
natur
pulmonari
infect
patient
cystic
fibrosi
cf
one
caus
lack
efficaci
exist
antibiot
treatment
cocolon
lung
pseudomona
aeruginosa
burkholderia
cepacia
result
sever
pulmonari
diseas
p
aeruginosa
monoinfect
aim
present
studi
evalu
clinic
efficaci
nebul
solut
novel
firstinclass
antimicrobi
drug
candid
polyn
nhexamethyleneguanidin
modifi
hydrazin
murin
model
caus
mix
infect
clinic
isol
paeruginosabcenocepacia
method
studi
potenc
bacteri
isol
patient
cystic
fibrosi
includ
strain
obtain
cff
therapeut
develop
network
resourc
center
microbiolog
seattl
children
hospit
seattl
wa
usa
institut
human
microbiolog
llc
de
usa
mic
antimicrobi
determin
broth
macrodilut
method
accord
clsi
guidelin
vivo
studi
mice
intranas
infect
p
aeruginosa
b
cenocepacia
cfumous
treatment
start
h
infect
tobramycin
aztreonam
cayston
administ
intranas
inhal
mic
result
exhibit
high
level
antimicrobi
activ
mic
mgl
b
cenocepacia
mgl
p
aeruginosa
tobramycin
aztreonam
less
activ
tobramycin
mic
mgl
p
aeruginosa
activ
b
cenocepacia
aztreonam
mic
mgl
p
aeruginosa
mgl
b
cenocepacia
induc
pneumonia
display
total
death
control
anim
without
treatment
within
h
postinfect
group
mix
infect
group
p
aeruginosa
b
cenocepacia
treat
end
observ
period
h
mice
die
wherea
anim
die
group
challeng
sole
p
aeruginosa
b
cenocepacia
anim
treat
tobramycin
display
mortal
p
aeruginosa
b
cenocepacia
group
p
aeruginosa
b
cenocepacia
group
respect
anim
treat
aztreonam
display
mortal
p
aeruginosa
b
cenocepacia
group
p
aeruginosa
b
cenocepacia
group
respect
conclus
studi
demonstr
mix
p
aeruginosa
b
cenocepacia
infect
lead
higher
mortal
anim
model
possess
great
activ
monoinfect
caus
p
aeruginosa
b
cenocepacia
vivo
anim
model
possess
great
activ
mix
infect
caus
p
aeruginosa
b
cenocepacia
vivo
anim
model
background
crosssect
studi
previous
show
associ
higher
stenotrophomona
maltophilia
antibodi
level
decreas
lung
function
patient
cystic
fibrosi
cf
water
v
et
al
j
respir
crit
care
med
purpos
studi
assess
longitudin
relationship
serolog
respons
maltophilia
clinic
outcom
method
chang
maltophilia
antibodi
level
adult
pediatr
patient
cf
assess
patient
alloc
one
follow
infect
group
base
frequenc
posit
respiratori
tract
cultur
maltophilia
never
maltophilia
never
posit
respiratori
cultur
maltophilia
rare
maltophilia
respiratori
cultur
posit
maltophilia
clear
maltophilia
respiratori
cultur
posit
maltophilia
last
cultur
neg
maltophilia
intermitt
maltophilia
respiratori
cultur
posit
maltophilia
chronic
persist
maltophilia
respiratori
cultur
posit
maltophilia
stanojev
et
al
j
cyst
fibro
investig
whether
antibodi
level
could
predict
subsequ
maltophilia
microbiolog
statu
whether
associ
lung
function
subsequ
pulmonari
exacerb
use
gener
estim
equat
model
account
repeat
event
within
patient
result
repeat
maltophilia
antibodi
sampl
cf
patient
show
antibodi
level
rel
stabl
studi
visit
regardless
infect
group
higher
antibodi
level
independ
associ
subsequ
posit
cultur
ci
increas
hazard
ratio
subsequ
pulmonari
exacerb
hr
ci
p
higher
antibodi
level
independ
associ
steeper
rate
fev
predict
declin
conclus
maltophilia
antibodi
level
may
help
identifi
individu
risk
exacerb
may
benefit
earlier
antimicrobi
treatment
classif
patient
chronic
intermitt
free
infect
may
longer
relev
current
era
erad
therapi
studi
use
latent
class
model
investig
pattern
p
aeruginosa
infect
cf
patient
method
retrospect
studi
includ
patient
follow
hospit
sick
children
st
michael
hospit
toronto
canada
patient
least
respiratori
tract
cultur
includ
latent
class
analysi
patient
assign
group
base
frequenc
posit
cultur
number
group
select
base
schwartz
bayesian
criteria
classif
categori
appli
larger
dataset
investig
differ
clinic
characterist
outcom
group
result
total
respiratori
tract
cultur
avail
patient
studi
period
averag
patient
follow
year
latent
class
analysi
identifi
distinct
pattern
infect
figur
overal
patient
grow
p
aeruginosa
studi
period
chronic
infect
addit
identifi
three
new
group
one
patient
rare
grew
p
aeruginosa
one
probabl
posit
cultur
increas
time
anoth
probabl
posit
cultur
decreas
subsequ
cultur
patient
group
decreas
probabl
posit
cultur
rare
group
highest
use
chronic
inhal
therapi
futur
analys
consid
differ
treatment
affect
classif
patient
whether
distinct
pattern
exist
pediatr
adult
patient
conclus
identifi
three
new
pattern
p
aeruginosa
infect
current
investig
group
differ
term
clinic
characterist
outcom
cf
genet
multiorgan
diseas
caus
absent
dysfunct
cftrmediat
anion
secret
lung
lead
mucu
obstruct
chronic
infectioninflamm
burkholderia
cenocepacia
complex
bcc
group
genet
distinct
speci
although
gener
harmless
human
extrem
pathogen
cf
patient
acquisit
bcc
associ
signific
increas
mortal
treatment
bcc
infect
difficult
bacteria
multidrug
resist
abl
surviv
biofilm
mahenthiralingam
e
et
al
clin
infect
di
short
palat
lung
nasal
epitheli
clone
secret
airway
epithilia
multifunct
innat
defens
protein
known
antimicrobi
function
mani
gramneg
bacteria
includ
bcc
cf
airway
surfac
liquid
asl
character
increas
acid
render
inact
unabl
regul
epitheli
na
channel
enac
garland
al
et
al
pna
therefor
test
hypothes
antimicrobi
antibiofilm
activ
bcc
also
phsensit
method
bcc
clinic
isol
cultur
h
ph
rang
coloni
form
unit
determin
antimicrobi
activ
bcc
clinic
isol
cultur
h
biofilm
presenc
ph
rang
biofilm
growth
measur
crystal
violet
cv
stain
recent
elucid
crystal
structur
screen
novel
mutant
base
structur
phsensit
antimicrobi
activ
cultur
h
mutant
ph
bacteri
growth
measur
od
nm
read
cfu
count
result
antimicrobi
activ
impair
acid
condit
restor
ph
howev
maintain
antibiofilm
activ
low
ph
reduc
biofilm
biomass
h
addit
mutant
phindepend
enac
regul
vari
antimicrobi
effect
mutant
reduc
bacteri
growth
low
ph
mutant
effect
ph
reduc
bacteri
growth
ph
conclus
whilst
mechan
action
current
investig
data
suggest
antimicrobi
activ
bcc
clinic
isol
phdepend
antibiofilm
activ
phindepend
addit
mutant
phindepend
enac
regul
also
retain
phindepend
antimicrobi
activ
suggest
phsensit
region
also
play
role
antimicrobi
activ
whilst
impact
cf
antimicrobi
interact
current
investig
data
suggest
understand
interact
may
import
therapeut
applic
cf
lung
diseas
fund
nih
uk
cf
trust
method
search
calgari
cf
biobank
repositori
bacteri
isol
everi
cf
sputum
sampl
collect
clinic
encount
sinc
adult
gb
isol
sputum
least
one
occas
chart
review
demograph
inform
spirometri
sever
manag
pulmonari
exacerb
pex
coinfect
medic
histori
includ
two
year
preced
two
year
follow
first
gb
isol
primari
outcom
pex
occurr
within
week
first
gb
isol
week
week
sputum
cultur
sever
pex
one
requir
intraven
antibiot
hospit
secondari
outcom
includ
pex
frequenc
first
gb
isol
chang
predict
fev
time
incid
gb
versu
last
clinic
visit
complic
gb
infect
develop
chronic
gb
infect
bacteri
strain
type
perform
pulsefield
gel
electrophoresi
pfge
result
thirti
gb
isol
cultur
individu
male
persist
infect
occur
three
individu
two
clear
spontan
less
six
month
third
clear
month
antibiot
pex
treatment
pfge
perform
viabl
isol
demonstr
strain
capabl
chronic
infect
evid
share
lineag
observ
median
predict
fev
iqr
incid
gb
isol
major
never
smoker
time
gb
isol
individu
experienc
pex
half
sever
gb
isol
associ
pex
one
third
sever
risk
pex
index
gb
isol
significantli
differ
preced
visit
ci
time
gb
isol
one
subject
signific
drop
fev
pex
frequenc
two
year
follow
index
gb
isol
similar
two
preced
year
rr
ci
patient
develop
pneumonia
empyema
conclus
adult
cf
gb
transient
colon
appear
increas
pex
risk
time
index
isol
evid
infect
transmiss
advers
effect
lung
function
time
isol
pex
frequenc
pulmonari
complic
observ
studi
larger
sampl
control
necessari
confirm
advers
effect
gb
exist
adult
cf
pseudomona
aeruginosa
pa
archetyp
cf
pathogen
heterogen
propos
account
part
discord
culturedirect
therapi
exacerb
patient
respons
last
year
staphylococcu
aureu
sa
supplant
pa
common
pathogen
cf
howev
compar
littl
known
aim
studi
determin
divers
within
sa
exist
within
cf
lung
method
sputum
sampl
patient
chronic
sa
infect
defin
cultur
prior
year
attend
calgari
adult
cf
clinic
collect
summer
cultur
mannitol
salt
agar
sputum
sampl
macroscop
ident
randomli
select
isol
collect
isol
independ
confirm
sa
use
catalas
coagulas
test
isol
test
suscept
erythromycin
eri
doxycyclin
doxi
ciprofloxacin
cip
trimethoprimsulfamethoxazol
sxt
use
kirbybau
disc
diffus
addit
isol
test
product
hyaluronidas
ha
proteas
pr
result
total
sa
isol
screen
patient
chronic
sa
mssa
male
median
age
contribut
sputum
sampl
total
heterogen
kirbi
bauer
zone
size
observ
result
macroscop
ident
isol
discord
suscept
test
result
cip
eri
doxi
sxt
sputum
sampl
howev
differ
occur
randomli
particular
patient
confin
small
number
isol
sampl
much
greater
divers
respect
product
virul
factor
sampl
observ
sampl
mark
divers
product
ha
pr
divers
product
virul
factor
occur
major
sputum
sampl
similarli
occur
disproport
patient
divers
observ
phenotyp
conclus
observ
heterogen
albeit
limit
amongst
randomli
identifi
macroscop
ident
isol
individu
cf
sputum
sampl
suggest
phenotyp
divers
exist
amongst
chronic
infect
sa
impli
like
pa
antibiogramdirect
therapi
sa
cf
may
confound
popul
divers
howev
proport
sa
isol
mark
divers
popul
median
much
less
common
report
amongst
chronic
infect
pa
popul
suggest
mere
persist
cf
airway
adequ
explain
diversif
popul
heterogen
introduct
achromobact
spp
emerg
cf
pathogen
report
preval
tradit
achromobact
spp
infect
cf
attribut
exclus
xylosoxidan
ax
biochem
test
rdna
pcr
readili
differenti
speci
howev
recent
data
demonstr
much
greater
breadth
speci
infect
cf
lower
airway
take
advantag
longitudin
strain
collect
establish
encompass
everi
isol
recov
cf
patient
sought
determin
speci
level
ident
achromobact
isol
natur
histori
infect
presenc
common
strain
within
cohort
evalu
potenti
patientpati
spread
particular
phenotyp
trait
differ
speci
correl
abil
caus
chronic
infect
common
cf
isol
method
retrospect
analysi
achromobact
spp
isol
adult
cf
biobank
perform
patient
includ
ever
isol
achromobact
spp
avail
incid
isol
repeat
isol
year
interv
patient
persist
infect
includ
isol
genotyp
use
pulsedfield
gel
electrophoresi
pfge
strain
type
nrda
sequenc
speci
identif
proteolyt
activ
assay
use
platebas
assay
biofilm
format
use
crystal
violet
assay
calgari
biofilm
devic
isol
deriv
noncf
bronchiectasi
ncfb
patient
use
control
result
identifi
achromobact
spp
isol
isol
biobank
decemb
total
isol
includ
total
patient
manifest
chronic
infect
month
eight
transient
infect
mo
also
includ
nine
ncfb
isol
strain
type
pfge
reveal
singl
strain
gener
respons
chronic
infect
share
strain
observ
two
cf
patient
suggest
transmiss
patient
commonli
occur
cf
isol
confirm
achromobact
spp
via
rdna
pcr
xylosoxidan
ax
insuavi
ai
three
spaniu
two
dolen
ad
one
ruhlandii
one
undetermin
speci
nine
achromobact
ncfb
isol
eight
ax
one
undetermin
speci
biofilm
product
significantli
higher
ax
isol
comparison
ai
ad
compar
individu
isol
display
proteas
activ
ax
like
caus
chronic
infect
speci
ax
vs
aiasad
ar
p
conclus
broadli
achromobact
spp
infect
appear
increas
frequenc
speci
level
identif
may
aid
effici
treat
patient
phenotyp
featur
biofilm
product
significantli
differ
speci
chronic
infect
almost
alway
caus
individu
strain
bacteria
share
strain
rare
cohort
introduct
rapid
evapor
ioniz
mass
spectrometri
reim
new
techniqu
shown
accur
classifi
yeast
bacteria
thermal
stress
appli
onto
bacteri
coloni
result
evapor
ionis
metabolit
structur
lipid
mass
spectromet
detect
identifi
analyt
spectral
databas
comparison
strittmatt
n
et
al
anal
chem
describ
applic
reim
cystic
fibrosi
cf
relat
pathogen
show
technolog
identifi
p
aeruginosa
accuraci
differ
observ
phospholipid
rhamnolipid
rang
deriv
quorum
sens
molecul
qsm
also
detect
may
provid
use
biomark
noninvas
diagnost
tool
use
ambient
mass
spectrometr
ms
approach
current
develop
method
isol
collect
cf
sampl
routin
process
royal
brompton
hospit
london
uk
includ
p
aeruginosa
isol
isol
genera
includ
achromobact
xylosoxidan
staphylococcu
aureu
stenotrophomona
maltophilia
burkholderia
spp
genera
confirm
use
microflex
lt
maldi
tof
bruker
dalton
reim
analys
perform
neg
ioniz
mode
coloni
grown
plate
appropri
speci
condit
small
amount
biomass
sampl
directli
medium
use
bipolar
forcep
draw
probe
togeth
electr
current
appli
result
aerosol
channel
xevo
qtof
instrument
water
corpor
minimum
three
technic
measur
acquir
averag
sampl
mass
spectra
subject
background
subtract
mass
drift
correct
unsupervis
supervis
multivari
statist
analys
result
princip
compon
analysi
effect
separ
p
aeruginosa
genera
predict
accur
use
linear
discrimin
analysi
analysi
varianc
reveal
separ
mainli
base
upon
differ
mass
charg
rang
compris
phospholipid
intraspeci
divers
within
p
aeruginosa
explor
rhamnolipid
qsm
found
differ
isol
conclus
reim
clearli
distinguish
p
aeruginosa
cf
pathogen
therebi
support
role
diagnost
tool
intraspeci
differ
also
observ
characterist
p
aeruginosa
featur
identifi
part
studi
may
serv
biomark
develop
directfromsampl
diagnost
tool
inde
current
work
noninvas
detect
approach
base
direct
ms
analysi
skin
secret
exhal
breath
nonculturebas
system
would
save
valuabl
time
diagnosi
whole
genom
sequenc
also
undertaken
parallel
result
use
seek
relationship
clinic
outcom
support
pex
treatment
pex
hospit
certain
advantag
howev
hospit
stay
disrupt
school
daili
activ
whole
famili
life
addit
hospit
costli
carri
risk
acquisit
hospit
pathogen
home
intraven
iv
therapi
implement
worldwid
past
decad
commonli
use
treatment
pex
adult
cf
howev
limit
data
exist
efficaci
safeti
home
iv
therapi
children
cf
studi
investig
clinic
outcom
home
iv
preselect
group
children
cf
method
retrospect
singl
cf
center
data
collect
episod
pex
treat
iv
antibiot
home
hospit
perform
pex
record
independ
entri
home
iv
elig
determin
base
center
criteria
age
famili
comfort
avail
home
health
care
known
drug
allergi
sever
comorbid
patient
stabil
adher
complex
treatment
outcom
measur
includ
fev
fvc
fef
p
time
next
pex
weight
bmi
antibioticrel
advers
reaction
treatment
complic
identifi
result
pex
event
occur
subject
includ
event
treat
hospit
hospit
iv
treat
home
home
iv
median
age
iqr
iqr
home
hospit
iv
group
respect
differ
hospit
home
iv
group
regard
cftr
mutat
known
drug
allergi
presenc
gtube
cfrelat
diabei
respiratori
cultur
higher
percentag
home
iv
group
prior
experi
home
iv
vs
p
nonmedicaid
insur
higher
home
iv
group
follow
data
collect
electron
medic
record
assess
clinic
outcom
demograph
inform
pulmonari
function
fev
baselin
begin
end
vanc
therapi
durat
vanc
treatment
vanc
trough
concentr
weight
begin
end
vanc
therapi
organ
present
sputum
altern
antimrsa
agent
use
clinic
outcom
compar
patient
low
etest
mic
high
etest
mic
result
thirti
mrsa
isol
cf
patient
test
use
etest
vitek
vanc
mic
detect
method
etest
vanc
mic
consist
higher
compar
vitek
p
patient
high
etest
mic
similar
baselin
characterist
vanc
durat
treatment
vanc
trough
concentr
improv
fev
weight
gain
vanc
therapi
compar
patient
low
etest
mic
clear
correl
either
vitek
etest
mic
patient
outcom
trend
toward
patient
high
etest
mic
requir
altern
antimrsa
treatment
patient
low
etest
mic
seen
patient
requir
altern
antimrsa
treatment
linezolid
ceftarolin
better
improv
fev
altern
treatment
versu
treatment
vanc
predict
respect
p
conclus
vancomycin
mic
result
significantli
higher
etest
use
compar
vitek
patient
high
vanc
etest
respond
well
vanc
switch
altern
antimrsa
agent
significantli
better
improv
fev
altern
agent
object
determin
acquisit
sm
associ
acceler
lung
function
declin
identifi
clinic
differ
follow
incid
infect
patient
chronic
intermitt
sm
infect
method
longitudin
retrospect
prepost
studi
conduct
patient
cf
age
year
first
posit
respiratori
cultur
sm
januari
decemb
compar
patient
develop
chronic
intermitt
infect
determin
differ
baselin
characterist
use
fisher
exact
test
wilcoxon
rank
sum
test
chronic
sm
infect
defin
posit
cultur
within
month
evalu
rate
declin
prior
follow
incid
sm
acquisit
patient
use
interrupt
time
seri
analysi
result
among
patient
mean
sd
age
year
mean
sd
bmi
mean
sd
time
acquisit
develop
chronic
sm
infect
intermitt
infect
chronic
infect
cf
cultur
obtain
per
year
compar
intermitt
infect
vs
p
trend
toward
younger
age
year
vs
year
lower
bmi
vs
among
chronic
sm
infect
differ
gender
race
mutat
type
cfrelat
diabet
baselin
lung
function
unadjust
regress
analysi
averag
rate
lung
function
chang
includ
patient
percent
predict
ci
per
year
prior
acquisit
decreas
percent
predict
ci
per
year
acquisit
p
conclus
singlecent
cohort
slightli
half
develop
chronic
sm
infect
follow
incid
infect
chronic
infect
cultur
obtain
trend
toward
younger
age
poorer
nutrit
statu
time
incid
infect
sm
acquisit
associ
acceler
lung
function
declin
fund
research
partial
fund
cff
clinic
fellowship
grant
defici
cftr
function
result
alter
epitheli
cell
ion
transport
contribut
defect
mucociliari
clearanc
subsequ
colon
pseudomona
aeruginosa
new
innov
therapeut
gear
toward
improv
cftr
express
activ
also
manag
inflamm
chronic
infect
use
vivo
murin
model
bone
marrow
transplant
cftrdefici
anim
wildtyp
bone
marrow
shown
provid
benefit
decreas
inflamm
aid
infect
resolut
use
bone
marrow
transplant
howev
counterintuit
cf
sinc
immunosuppress
therapi
requir
prevent
transplant
reject
potenti
exacerb
chronic
pulmonari
infect
cf
patient
begun
pursu
concept
autolog
bone
marrow
correct
therapeut
mesenchym
stem
cell
altern
cell
therapi
tradit
transplant
cf
potenti
mean
improv
manag
infect
inflamm
creat
myeloidspecif
knockout
myeloid
cell
defici
cftr
well
myeloidspecif
knockin
cftr
defici
everywher
myeloid
compart
bone
marrowderiv
macrophag
cftr
defici
wildtyp
anim
infus
murin
model
cf
infect
inflamm
investig
therapeut
potenti
treat
cf
autolog
cell
absenc
irradi
immunosuppress
therapi
impact
bone
marrowderiv
cell
cf
lung
infect
inflamm
investig
use
cf
murin
model
chronic
pseudomona
aeruginosa
infect
demonstr
myeloidspecif
knockout
phenotyp
sever
total
knockout
significantli
fragil
abil
manag
infect
compar
wildtyp
anim
infect
time
consist
previou
studi
use
myeloidspecif
knockin
demonstr
although
statist
improv
surviv
murin
model
lung
infect
inflamm
sever
immun
paramet
improv
term
cytokin
regul
bacteri
resolut
cftrdefici
anim
given
wildtyp
bone
marrowderiv
macrophag
without
irradi
infus
statist
improv
inflamm
infect
resolut
studi
consist
bone
marrow
transplant
mesenchym
stem
cell
studi
suggest
wildtyp
hematopoiet
bone
marrow
cell
bone
marrow
macrophag
mesenchym
stem
cell
potenti
support
cf
immun
enhanc
manag
infect
inflamm
next
step
studi
begin
explor
genom
correct
myeloid
cell
potenti
therapeut
applic
cf
work
fund
cystic
fibrosi
foundat
david
virginia
baldwin
fund
nhlbi
meropenem
iv
carbapenem
antibiot
frequent
use
treatment
cystic
fibrosi
pulmonari
exacerb
date
pauciti
data
exist
regard
use
inhal
meropenem
object
aim
retrospect
studi
evalu
safeti
efficaci
inhal
meropenem
method
data
extract
propietari
patient
analysi
track
system
cfpat
identifi
individu
use
inhal
meropenem
center
use
inhal
meropenem
select
individu
sinc
meropenem
vial
dilut
cc
normal
salin
dose
meropenem
administ
twice
day
use
pari
lc
nebul
standard
compressor
durat
treatment
variabl
first
dose
medic
administ
offic
monitor
safeti
toler
lung
function
measur
preand
postdos
efficaci
paramet
includ
chang
fev
posttreat
subject
chang
symptom
safeti
data
includ
initi
toler
side
effect
chang
bacteri
resist
pattern
result
date
subject
rang
year
undergon
treatment
inhal
meropenem
subject
colon
pseudomona
aeruginosa
pa
burkholderia
cepacia
bc
common
indic
failur
therapi
baselin
fev
subject
fev
significantli
vari
follow
first
dose
administr
offic
median
durat
treatment
day
rang
day
gener
inhal
meropenem
well
toler
patient
experienc
vari
degre
cough
treatment
one
subject
experienc
mild
hemoptysi
interfer
continu
treatment
two
subject
termin
treatment
earli
one
due
chest
tight
one
due
anaphylact
reaction
occur
despit
initi
toler
complet
treatment
experienc
subject
improv
symptom
subject
fev
increas
although
chang
statist
signific
howev
subject
bc
exclud
remain
individu
demonstr
signific
improv
fev
p
bacteri
resist
meropenem
sputum
cultur
appear
chang
posttreat
new
emerg
bc
nontuburculosi
mycobacteria
infect
observ
conclus
preliminari
data
retrospect
studi
suggest
inhal
meropenem
appear
well
toler
minim
side
effect
observ
lung
function
selfreport
clinic
improv
data
suggest
efficaci
pa
without
bc
futur
investig
evalu
inhal
meropenem
prospect
fashion
appear
warrant
introduct
primari
caus
morbid
mortal
amongst
cystic
fibrosi
cf
patient
aris
pulmonari
inflamm
secondari
bacteri
infect
well
document
staphylococcu
aureu
sa
common
pathogen
seen
young
children
cf
pseudomona
aeruginosa
pa
transit
becom
predomin
pathogen
young
adulthood
transit
associ
pa
biofilm
format
phenotyp
chang
unclear
bacteri
interact
within
cf
lung
microbiom
affect
transit
impact
treatment
patient
understand
natur
interact
may
improv
manag
result
better
treatment
outcom
cf
patient
object
determin
effect
sa
interact
pa
biofilm
develop
antimicrobi
resist
context
respons
pa
initi
acquisit
erad
therapi
inhal
tobramycin
method
retrospect
crosssect
studi
take
place
hospit
sick
children
sa
clinic
isol
obtain
children
cf
infect
pa
bacteri
sa
filtrat
deriv
plankton
biofilm
growth
separ
secret
materi
bacteri
cell
newli
acquir
pa
isol
select
patient
fail
erad
therapi
persist
isol
success
erad
therapi
erad
isol
effect
sa
filtrat
pa
biofilm
viabil
thick
assess
confoc
microscopi
examin
effect
sa
filtrat
pa
biofilm
grown
slide
chamber
result
presenc
sa
filtrat
lead
increas
microbi
aggreg
persist
pa
isol
establish
pa
biofilm
effect
erad
pa
isol
increas
aggreg
result
coverag
slide
chamber
without
impact
total
viabl
count
bacteria
biomass
present
determin
cfu
count
biofilm
persist
pa
isol
grown
presenc
filtrat
also
resist
antibiot
kill
tobramycin
kill
media
vs
kill
sa
filtrat
untreat
control
treat
persist
strain
presenc
sa
filtrat
affect
plankton
minimum
inhibitori
concentr
tobramycin
pa
isol
test
presenc
filtrat
sa
isol
affect
initi
format
pa
biofilm
grown
slide
chamber
hour
differ
thick
architectur
observ
conclus
secret
product
sa
abl
interact
establish
pa
biofilm
pa
respons
includ
suscept
tobramycin
differ
bacteri
strain
patient
fail
erad
versu
patient
success
erad
investig
delin
mechan
pa
respons
sa
filtrat
ongo
acknowledg
cystic
fibrosi
canada
fellowship
asm
id
award
chronic
lung
infect
pseudomona
aeruginosa
primari
caus
morbid
mortal
cystic
fibrosi
cf
patient
p
aeruginosa
enter
biofilm
mode
growth
chronic
infect
cf
lung
confer
vastli
increas
resist
clearanc
immun
system
antimicrobi
clinic
studi
found
correl
respiratori
viral
infect
pulmonari
colon
p
aeruginosa
though
mechan
underli
phenomenon
unknown
use
uniqu
model
initi
interact
p
aeruginosa
respiratori
epithelium
recent
demonstr
respiratori
viral
infect
airway
epithelium
stimul
rapid
biofilm
biogenesi
p
aeruginosa
apic
ironbound
transferrin
releas
increas
respiratori
viral
infect
increas
iron
level
requir
induct
biofilm
product
hendrick
mr
proc
natl
acad
sci
usa
addit
studi
isol
primari
sourc
biofilm
stimulatori
effect
extracellular
vesicl
releas
airway
epithelium
viral
infect
use
cocultur
system
polar
cf
bronchial
epitheli
cell
p
aeruginosa
investig
mechan
p
aeruginosa
abl
take
advantag
pulmonari
environ
follow
viral
infect
focus
iron
uptak
homeostasi
pathway
preliminari
data
suggest
p
aeruginosa
util
multipl
iron
uptak
pathway
includ
siderophor
scaveng
increas
iron
apic
secret
airway
epitheli
cell
viral
coinfect
iron
suffici
howev
induc
p
aeruginosa
biofilm
biogenesi
supplement
media
transferrin
concentr
similar
found
apic
secret
airway
cell
viral
infect
induc
biofilm
biogenesi
result
suggest
either
addit
factor
nutrient
present
extracellular
vesicl
releas
respiratori
epithelium
viral
infect
transferrin
must
deliv
extracellular
vesicl
stimul
biofilm
biogenesi
rna
sequenc
analysi
p
aeruginosa
transcriptom
viral
coinfect
reveal
decreas
express
ferrou
iron
uptak
pathway
increas
express
uncharacter
put
iron
uptak
system
indic
adapt
respons
increas
level
extracellular
vesicleassoci
transferrin
viral
coinfect
addit
observ
shift
p
aeruginosa
amino
acid
catabol
pathway
viral
coinfect
suggest
metabol
chang
also
play
role
adapt
condit
creat
viral
infect
studi
suggest
nutrit
immun
compromis
lung
viral
infect
p
aeruginosa
alter
iron
homeostasi
metabol
take
advantag
permiss
environ
provid
potenti
mechan
p
aeruginosa
readili
colon
lung
cf
patient
respiratori
viral
infect
support
nation
institut
health
cystic
fibrosi
foundat
test
hypothesi
iron
homeostasi
also
alter
pn
sinus
viral
infect
lead
increas
bacteri
colon
biofilm
growth
perform
prospect
studi
cohort
cf
subject
chronic
rhinosinus
studi
pn
sinu
secret
collect
well
microbiom
viral
swab
associ
clinic
diseas
sever
score
approxim
everi
three
month
start
januari
preliminarili
analyz
iron
level
pn
sinu
secret
subject
baselin
viral
infect
viral
infect
detect
sampl
rhinoviru
account
infect
iron
level
significantli
increas
pn
sinu
secret
viral
infect
use
primari
pn
sinu
epitheli
cell
deriv
cf
patient
observ
increas
p
aeruginosa
biofilm
growth
presenc
rhinoviru
coinfect
preliminari
microbiom
analysi
found
pseudomona
staphylococcu
domin
genera
suggest
shift
microbi
commun
pn
sinus
occur
follow
viral
infect
clinic
diseas
sever
qualiti
life
score
acut
alter
viral
infect
studi
requir
better
defin
shift
microbi
commun
respiratori
viral
infect
upper
respiratori
tract
determin
longterm
impact
diseas
outcom
support
nih
nsf
cff
object
pseudomona
aeruginosa
strain
subtyp
emerg
australia
chronic
infect
airway
peopl
cf
associ
increas
antibiot
resist
tai
et
al
plo
one
whole
genom
sequenc
wg
princip
use
investig
shortterm
withinhost
divers
antibiot
resist
mechan
method
eleven
isol
repres
rang
differ
antibiot
suscept
profil
collect
isol
cultur
month
individu
cf
underw
wg
phylogeni
built
genom
screen
acquir
resist
gene
use
onlin
databas
card
mergem
resfind
chromosom
gene
associ
antibiot
resist
hypermut
pathoadapt
base
literatur
search
well
intergen
region
inspect
small
genet
variant
refer
genom
analys
access
number
result
three
phylogenet
group
identifi
compris
two
mutat
group
show
frameshift
mutat
caus
delet
mutl
one
nonmut
group
acquir
antibiot
resist
mechan
detect
suggest
resist
princip
driven
chromosom
mutat
ninetyseven
nonsynonym
chromosom
mutat
possibl
associ
antibiot
resist
share
isol
includ
prematur
stop
codon
within
oprd
novel
nucleotid
substitut
ampcampr
intergen
region
resid
within
ampc
promot
region
wg
reveal
mutat
gene
acquir
follow
diverg
group
may
also
impact
activ
antibiot
multidrug
efflux
pump
fortyon
gene
previous
associ
pathoadapt
marvig
rl
et
al
nat
genet
acquir
nonsynonym
mutat
conclus
data
highlight
complex
chronic
p
aeruginosa
infect
may
involv
multitud
coexist
genotyp
divers
sublineag
find
may
suggest
heterogen
popul
adapt
nich
cf
airway
acknowledg
support
australian
infecti
diseas
grant
queensland
australia
qimrbuq
seed
grant
an
l
rider
k
pavel
k
enderbi
b
oad
p
wither
n
sheldon
c
intens
care
unit
musgrov
park
hospit
taunton
somerset
unit
kingdom
depart
pediatr
royal
devon
exet
nh
foundat
trust
exet
devon
unit
kingdom
depart
respiratori
medicin
royal
devon
exet
nh
foundat
trust
exet
devon
unit
kingdom
introduct
exophiala
report
lung
colon
cystic
fibrosi
cf
popul
clear
pathogen
innoc
bystand
aim
review
identifi
preval
exophiala
detect
evid
clinic
deterior
follow
colon
chang
microbiota
also
assess
method
retrospect
case
review
adult
pediatr
cf
patient
colon
exophiala
patient
exophiala
sputum
cough
swab
fiveyear
period
identifi
microbiolog
laboratori
colon
defin
two
exophiala
isol
twelvemonth
period
least
three
month
apart
spirometri
bmi
sputum
cultur
blood
test
review
number
inpati
day
day
intraven
iv
antibiot
medic
prescrib
monitor
variabl
compar
two
year
two
year
first
record
exophiala
isol
result
exophiala
isol
cf
patient
exclud
ever
one
isol
six
patient
femal
five
homozygot
remaind
heterozygot
second
mutat
c
unknown
median
age
colon
year
rang
year
one
patient
die
studi
period
show
littl
chang
fev
fvc
bmi
though
one
patient
deterior
markedli
signific
differ
blood
test
patient
prescrib
corticosteroid
inhal
oral
antibiot
nebul
longterm
oral
antifung
two
year
postexophiala
colon
even
exclud
patient
die
day
spent
inpati
iv
antibiot
two
year
postexophiala
colon
proport
isol
pseudomona
aeruginosa
candida
fell
exophiala
isol
proport
staphylococcu
aureu
unchang
aureobasidium
pullulan
scedosporium
apiospermum
rothia
mucilaginosa
haemophilu
paraphrophilu
also
isol
colon
proport
sputum
sampl
isol
exophiala
rang
median
discuss
singlecent
cohort
patient
isol
exophiala
sever
cf
mutat
although
increas
treatment
time
spent
inpati
observ
postcolon
may
repres
cf
diseas
progress
chang
microbiota
observ
follow
exophiala
colon
mechan
signific
requir
evalu
rarer
fungal
pathogen
also
isol
patient
fungal
organ
appear
domin
microbiom
popul
variabl
term
age
colon
frequenc
isol
diseas
progress
rang
patient
chang
clinic
paramet
one
patient
deterior
die
caus
exophiala
found
declin
work
requir
determin
reason
variabl
pathogen
fungu
background
limit
therapeut
option
enhanc
virul
properti
phenotyp
adapt
mucoid
phenotyp
contribut
expand
threat
effect
therapi
burkholderia
cepacia
complex
lung
biofilm
infect
frequent
associ
cystic
fibrosi
cf
thick
mucu
biofilm
format
cf
lung
render
therapeut
less
effect
seri
nontox
derivat
polyglucosamin
shown
broadli
activ
dermal
mucos
interfac
encompass
newli
develop
class
molecul
design
poli
acetyl
arginyl
glucosamin
paag
specif
deriv
nontox
solubl
biopolym
shown
potenti
wide
rang
antibiot
gramneg
gramposit
bacteria
effect
dissolv
biofilm
includ
b
cepacia
complex
threedimension
checkerboard
synergi
minim
biofilm
erad
concentr
mbec
assay
use
examin
antibiot
synergi
plankton
bacteria
remov
biofilm
form
sever
clinic
isol
b
cepacia
complex
associ
cystic
fibrosi
respect
studi
demonstr
abil
potenti
antibiot
activ
remov
biofilm
goal
support
effect
treatment
method
mbec
assay
perform
use
b
cepacia
complex
strain
isol
sputum
cystic
fibrosi
patient
compar
biofilm
reduct
parker
ae
et
al
j
microbi
method
strain
b
cepacia
complex
consist
multidrug
resist
andor
mucoid
phenotyp
clinic
isol
obtain
seattl
children
hospit
cystic
fibrosi
research
center
birmingham
alabama
antibacteri
potenti
determin
use
checkerboard
assay
stein
c
et
al
plo
one
result
concentr
rang
significantli
reduc
b
cepacia
complex
biofilm
follow
daili
treatment
p
treatment
significantli
reduc
preform
b
cepacia
complex
biofilm
dosedepend
manner
treatment
p
treat
biofilm
less
bacteria
untreat
biofilm
potenti
tobramycin
meropenam
observ
combin
fraction
inhibitori
concentr
fic
calcul
show
paag
abl
potenti
antibacteri
synergi
beyond
rang
achiev
antibiot
alon
fic
demonstr
synergi
antibiot
alon
decreas
upon
addit
enhanc
antibacteri
synergi
conclus
effect
antibiofilm
agent
facilit
remov
biofilm
vitro
studi
show
b
cepacia
complex
biofilm
remov
dosedepend
manner
studi
also
show
interfer
antibacteri
activ
tobramycin
meropenam
actual
potenti
antibiot
novel
multifunct
activ
may
result
posit
therapeut
outcom
particularli
cystic
fibrosisrel
infect
object
evalu
cohort
pediatr
cf
patient
role
first
pa
isol
nutrit
statu
year
age
risk
factor
chronic
pa
infect
evalu
chronic
pa
infect
influenc
lung
function
nutrit
statu
age
year
old
method
perform
retrospect
analysi
patient
followup
florenc
cystic
fibrosi
centr
cf
diagnosi
sweat
chlorid
mmoll
two
known
cf
mutat
age
year
spirometr
microbiolog
evalu
least
time
year
patient
evalu
age
first
pa
colon
age
chronic
pa
colon
pancreat
statu
pancreat
insuffici
pi
pancreat
suffici
ps
weightforlength
percentil
wl
pc
year
age
best
percentil
bodi
mass
index
bmipc
forc
expiratori
volum
second
fev
age
year
pa
microbiolog
statu
defin
accord
leed
criteria
patient
pa
infect
receiv
follow
treatment
erad
twicedaili
inhal
mg
tobramycin
solut
iu
colistin
mgkgday
oral
ciprofloxacin
divid
two
dose
day
end
therapi
patient
repeat
cultur
order
evalu
erad
microorgan
result
patient
elig
studi
pa
never
isol
least
one
isol
pa
follow
group
patient
erad
pa
infect
group
pi
ps
erad
therapi
fail
develop
chronic
pa
infect
mean
age
year
group
pi
ps
mean
age
first
pa
infect
differ
two
group
year
vs
year
p
valu
wl
pc
year
age
avail
subject
group
subject
group
case
wl
pc
percentil
mean
wl
pc
valu
differ
two
group
p
valu
patient
chronic
pa
infect
wors
fev
valu
pcbmi
valu
age
year
patient
intermitt
infect
fev
vs
fev
p
valu
bmipc
vs
bmipc
p
valu
conclus
age
first
pa
isol
nutrit
statu
year
age
influenc
develop
chronic
pa
infect
chronic
pa
infect
associ
wors
lung
function
nutrit
statu
year
aim
goal
character
genet
background
mrsa
isol
cf
center
last
three
year
method
mrsa
isol
collect
patient
regular
followup
last
period
includ
least
one
strainyear
patient
analyz
genom
sequenc
coverag
perform
illumina
miseq
platform
result
total
highqual
refer
genom
de
novo
assembl
use
spade
genom
analysi
perform
infer
wholegenom
phylogeni
epidemiolog
pattern
multilocu
sequenc
type
mlst
loci
type
result
seventyf
mrsa
strain
patient
male
median
age
year
rang
year
analyz
mean
mrsa
colon
time
year
sd
fifteen
patient
harbor
mrsa
less
one
year
mean
time
year
sd
sccmec
type
iv
detect
patient
nineteen
patient
harbor
mrsa
one
year
mean
time
year
sd
sccmec
type
iv
detect
patient
fisher
exact
test
p
mlst
sccmec
analysi
indic
differ
clone
present
cohort
belong
known
epidem
lineag
tabl
thirtytwo
patient
infect
singl
mrsa
clone
mrsa
isol
group
lineag
differ
singl
mutat
pta
allel
clone
close
relat
singl
nucleotid
variat
averag
clone
previous
describ
southern
germani
epidem
clone
whole
genom
analysi
also
show
clone
underw
genet
adapt
independ
patient
sever
singl
nucleotid
specif
variant
conclus
confirm
mrsa
isol
patient
infect
longer
period
belong
mainli
hospitalacquir
ha
mrsa
patient
infect
clone
sever
year
evid
patientspecif
strain
adapt
overal
investig
mrsa
genet
background
import
assess
mrsa
epidemiolog
may
lead
improv
clinic
manag
infect
introduct
combin
tobramycin
bacteri
metabolit
potenti
develop
treatment
chronic
p
aeruginosa
infect
cystic
fibrosi
patient
combin
util
antipersist
strategi
aim
reduc
recurr
infect
method
mic
determin
varieti
cf
clinic
isol
select
divers
set
strain
inclus
studi
p
aeruginosa
cultur
plankton
stationari
phase
psp
use
select
bacteri
persist
bacteria
quasidorm
state
psp
experi
rang
tobramycin
concentr
test
rang
metabolit
concentr
determin
potenti
effect
metabolit
varieti
condit
addit
dish
biofilm
bacteri
aggreg
assay
perform
result
enhanc
kill
order
magnitud
p
aeruginosa
persist
rang
strain
observ
psp
experi
see
exampl
mucoid
cf
isol
figur
potenti
also
observ
biofilm
aggreg
assay
conclus
combin
tobramycin
potenti
remain
attract
therapeut
option
elimin
recurr
p
aeruginosa
infect
erad
bacteri
persist
metaboliteen
erad
pseudomona
persist
psp
cultur
cell
enumer
hour
exposur
tobramycinpotenti
combin
pulmonari
aspergillosi
common
infect
result
signific
morbid
mortal
patient
cystic
fibrosi
depend
state
host
infect
result
aspergillu
bronchiti
allerg
bronchopulmonari
aspergillosi
abpa
associ
diminish
lung
function
pulmonari
exacerb
standard
care
gener
call
oral
dose
triazol
inhibit
fungal
cytochrom
inhibit
fungal
growth
itraconazol
itz
triazol
commonli
use
firstlin
therapi
fungal
infect
treatment
gener
poorli
variabl
bioavail
result
number
system
side
effect
limit
therapeut
potenti
addit
itz
triazol
extens
list
drugdrug
interact
requir
drug
monitor
treatment
may
lead
hepatotox
hypothes
inhal
deliveri
itz
dri
powder
would
result
significantli
higher
lung
exposur
lower
system
exposur
rel
oral
dose
profil
may
allow
improv
efficaci
reduc
overal
dose
reduc
drugdrug
interact
repeat
dose
studi
rat
perform
assess
lung
system
exposur
level
itz
follow
inhal
oral
sporanox
exposur
oral
itz
solut
mgml
dose
daili
via
oral
gavag
mgkgday
novel
dri
powder
formul
itz
deliv
noseonli
inhal
averag
achiev
deliv
dose
mgkgday
rodent
dose
approxim
deliv
dose
consid
reach
lung
mg
kgday
remain
filter
nasopharynx
ultim
like
swallow
blood
sampl
collect
day
predos
immedi
dose
hour
dose
lung
tissu
collect
day
immedi
dose
hour
dose
day
hour
dose
measur
itraconazol
activ
metabolit
hydroxyitraconazol
ohitz
system
exposur
auc
c
max
itz
ohitz
lower
follow
inhal
follow
oral
exposur
day
peak
lung
itraconazol
level
immedi
dose
day
approxim
higher
anim
dose
via
inhal
versu
anim
dose
oral
trough
itraconazol
lung
level
day
hour
dose
day
hour
dose
similar
inhal
oral
dose
rout
data
demonstr
potenti
enabl
significantli
higher
pulmonari
level
itraconazol
reach
site
fungal
infect
approach
potenti
improv
diseas
outcom
reduc
side
effect
profil
associ
oral
dose
bacteria
rare
exist
isol
whether
human
tissu
environ
frequent
coinfect
microb
coinfect
staphylococcu
aureu
pseudomona
aeruginosa
occur
commonli
peopl
cystic
fibrosi
cf
associ
higher
lung
diseas
morbid
mortal
previou
studi
demonstr
interact
two
speci
impact
growth
metabol
littl
known
regard
impact
polymicrobi
interact
biofilm
format
bacteri
commun
lifestyl
suggest
predomin
within
cf
lung
result
persist
infect
aureu
secret
numer
exoproduct
known
interact
host
tissu
influenc
inflammatori
respons
abundantli
secret
aureu
protein
spa
bind
rang
human
glycoprotein
immunoglobulin
molecul
divers
effect
host
includ
inhibit
phagocytosi
aureu
cell
howev
potenti
effect
spa
aureu
exoproduct
coinfect
bacteria
explor
show
aureu
secret
product
includ
spa
significantli
alter
two
behavior
associ
persist
infect
found
spa
inhibit
biofilm
format
p
aeruginosa
cf
sputum
isol
also
inhibit
phagocytosi
neutrophil
p
aeruginosa
isol
test
result
indic
effect
mediat
bind
least
two
p
aeruginosa
cell
surfac
structurestyp
iv
pili
exopolysaccharid
pslthat
confer
attach
surfac
bacteri
cell
thu
found
role
wellstudi
aureu
exoproduct
spa
extend
well
beyond
interact
host
immun
system
impact
persistencerel
behavior
anoth
import
common
cf
pathogen
aureu
frequent
preced
p
aeruginosa
colon
cf
patient
lung
find
suggest
new
model
microbi
commun
interact
impact
persist
host
interact
coinfect
pseudomona
aeruginosa
pa
infect
becom
standard
care
children
cystic
fibrosi
cf
limit
data
success
multistep
protocol
aet
aim
evalu
effect
multistep
erad
protocol
newonset
pa
infect
children
cf
method
threestep
protocol
aet
develop
involv
day
tobramycin
inhal
solut
ti
first
newli
acquir
pa
infect
step
second
cours
ti
patient
fail
convert
neg
cultur
first
cycl
step
day
intraven
antibiot
follow
day
ti
patient
fail
second
erad
attempt
step
conduct
retrospect
review
pediatr
cf
patient
newonset
pa
infect
defin
newli
posit
sputum
cultur
januari
decemb
erad
success
defin
neg
cultur
pa
treatment
success
rate
treatment
step
cumul
success
rate
record
result
studi
period
patient
total
newonset
pa
infect
total
case
symptomat
treat
iv
antibiot
follow
day
ti
becam
pa
cultureneg
pa
infect
asymptomat
case
averag
age
time
infect
year
rang
asymptomat
case
becam
cultureneg
pa
first
ti
cycl
addit
clear
second
cycl
cumul
success
rate
intraven
antibiot
follow
day
ti
administ
case
case
success
clear
fifteen
case
fail
step
consid
chronic
infect
pa
overal
cumul
success
rate
multistep
protocol
conclus
first
step
protocol
led
greatest
erad
success
addit
step
improv
overal
erad
success
rate
random
control
trial
warrant
defin
optim
treatment
strategi
patient
fail
initi
erad
protocol
abscessu
allow
strategi
modifi
risk
infect
transmiss
cf
patient
hypothes
particleassoci
growth
abscessu
support
therebi
test
fit
growth
model
abscessu
use
defin
environment
dust
sampl
method
airborn
sampl
perform
clinic
home
environ
dna
isol
filter
pcramplifi
rrna
amplicon
sequenc
sequenc
read
compar
multipl
rrna
sequenc
databas
qiim
analysi
softwar
use
open
refer
oper
taxonom
unit
otu
pick
analysi
pipelin
gener
annot
otu
count
tabl
bacteri
profil
abscessu
cultur
grown
presenc
defin
dustlik
particl
miner
clay
kaolin
silicon
dioxid
steril
sampl
environment
dust
home
offic
associ
abscessu
dust
particl
determin
light
fluoresc
microscopi
growth
dust
sampl
compar
media
alon
day
suscept
abscessu
antibiot
treatment
also
test
abil
abscessu
associ
dust
sampl
includ
clinic
isol
recov
desicc
test
variou
time
result
mycobacteri
speci
detect
airborn
environment
sampl
vitro
direct
associ
abscessu
defin
environment
dust
sampl
observ
growth
abscessu
enhanc
presenc
environment
dust
sampl
compar
growth
media
alon
appreci
differ
dust
sampl
antibiot
suscept
chang
presenc
particl
test
abil
abscessu
surviv
particl
cultur
dustassoci
abscessu
dri
day
reconstitut
growth
medium
determin
viabil
abscessu
includ
cf
clinic
isol
surviv
desicc
day
conclus
detect
mycobacteria
environment
sampl
associ
growth
chemic
defin
environment
particl
indic
capac
particleassoci
abscessu
environment
sourc
infect
importantli
abscessu
surviv
desicc
extend
period
suggest
potenti
dissemin
environment
sourc
data
indic
fit
abscessu
like
environment
state
physic
associ
particl
airborn
potenti
suggest
new
target
infect
control
support
cystic
fibrosi
foundat
hood
k
novak
kj
pharmaci
nationwid
children
hospit
columbu
oh
usa
purpos
cf
patient
moder
sever
lung
diseas
chronic
pseudomona
aeruginosa
infect
current
guidelin
recommend
chronic
inhal
antibiot
given
onoff
cycl
tobramycin
aztreonam
two
agent
current
approv
use
base
annual
cf
foundat
patient
registri
report
clinic
practic
trend
toward
use
continu
rotat
two
inhal
antibiot
oppos
onoff
cycl
use
singl
agent
current
guidelin
address
incorpor
medic
patient
mainten
regimen
clinic
trial
abl
effect
evalu
risk
benefit
therapi
therefor
primari
object
studi
compar
lung
function
number
pulmonari
exacerb
one
year
lead
initi
dual
rotat
inhal
antibiot
therapi
one
year
dual
therapi
secondari
object
determin
whether
cf
care
team
evalu
document
outcom
dual
therapi
assess
benefit
andor
risk
continu
dual
therapi
method
retrospect
review
conduct
pediatr
adult
cf
patient
receiv
dual
rotat
inhal
antibiot
least
one
year
larg
freestand
children
hospit
hous
pediatr
adult
cf
center
januari
decemb
data
collect
includ
patient
demograph
lung
function
valu
annual
best
mean
number
pulmonari
exacerb
one
year
lead
initi
dual
inhal
antipseudomon
antibiot
therapi
one
year
dual
therapi
data
also
collect
specif
inhal
antipseudomon
antibiot
use
concomit
cf
medic
electron
medic
record
document
primari
object
evalu
use
wilcoxon
sign
rank
test
nonparametr
data
secondari
object
evalu
use
descript
statist
result
total
patient
includ
studi
age
year
major
patient
mean
patient
receiv
inhal
tobramycin
monotherapi
receiv
concomit
azithromycin
primari
outcom
statist
signific
decreas
mean
best
p
patient
switch
monotherapi
dual
therapi
howev
decreas
consist
annual
declin
expect
patient
popul
statist
signific
differ
frequenc
pulmonari
exacerb
subgroup
analysi
patient
receiv
inhal
aztreonam
monotherapi
statist
signific
decreas
best
percentag
point
patient
transit
dual
therapi
p
signific
declin
seen
patient
receiv
inhal
tobramycin
monotherapi
transit
dual
therapi
patient
document
within
electron
medic
record
assess
continu
dual
therapi
conclus
overal
dual
rotat
inhal
antipseudomon
antibiot
appear
improv
lung
function
decreas
frequenc
pulmonari
exacerb
patient
cystic
fibrosi
introduct
pseudomona
aeruginosa
import
pathogen
cystic
fibrosi
cf
major
adult
chronic
colonis
organ
pseudomona
colonis
adher
mucin
form
biofilm
within
stagnant
airway
mucu
layer
surviv
remain
elucid
p
aeruginosa
metabol
versatil
abl
surviv
nutrient
poor
environ
current
data
explain
p
aeruginosa
specif
surviv
airway
preferenti
chosen
sourc
nitrogen
carbon
known
come
amino
acid
polyamin
sugar
glucos
elev
cf
airway
less
prefer
substrat
although
effici
metabolis
via
entnerdoudoroff
pathway
prefer
nutrient
offer
mixtur
along
nonfavour
carbon
sourc
catabol
prefer
substrat
regul
orderli
fashion
catabolit
repress
control
mucin
highli
glycosyl
polypeptid
abund
cf
airway
may
offer
altern
nutrient
sourc
glucos
understand
specif
nutrient
sourc
pseudomona
may
allow
identif
novel
therapeut
target
treat
patient
colonis
organ
aim
evalu
whether
airway
mucin
provid
nutrient
sourc
pseudomona
method
sputum
sampl
dialys
order
remov
low
molecular
weight
sugar
lyophilis
dissolv
ultrapur
water
autoclav
presenc
potassium
phosphat
buffer
protect
phinduc
cleavag
monosaccharid
autoclav
strain
grown
sampl
supplement
growth
assess
via
coloni
form
unit
countsml
serial
dilut
cultur
sampl
plate
luria
agar
defin
time
interv
bacteria
incub
overnight
c
specif
growth
rate
calcul
log
growth
phase
sputa
purifi
via
caesium
guanidin
hydrochlorid
densiti
gradient
centrifug
fraction
contain
mucin
identifi
pool
process
growth
studi
previous
describ
growth
mucin
sugar
galactos
fucos
sialic
acid
nacetylglucosamin
nacetylgalactosamin
also
assess
result
p
aeruginosa
laboratori
strain
show
increas
growth
rate
wv
adult
vs
paediatr
cf
sputum
also
increas
growth
rate
grown
wv
adult
vs
paediatr
cf
purifi
mucin
fraction
unabl
grow
wv
mucin
sugar
compar
neg
control
could
grow
glucos
conclus
first
report
differ
growth
rate
p
aeruginosa
adult
paediatr
cf
sputum
mucin
current
reason
better
growth
adult
mucu
remain
explain
sinc
shown
although
pseudomona
use
glucos
appear
unabl
use
sugar
within
mucin
nutrient
sourc
work
need
clarifi
whether
pseudomona
abil
grow
mucin
protein
growth
due
factor
within
cf
airway
favour
growth
adult
mucu
infect
multidrugresist
mdr
p
aeruginosa
main
caus
morbid
mortal
cf
patient
p
aeruginosa
develop
mdr
phenotyp
persist
cf
airway
accumul
pathoadapt
mutat
wholegenom
sequenc
wg
help
identifi
predict
potenti
molecular
mechan
resist
alreadi
prove
abl
predict
antimicrobi
suscept
sever
pathogen
despit
sever
wg
studi
p
aeruginosa
cf
lineag
publish
evolutionari
trajectori
relat
develop
antimicrobi
resist
remain
mostli
unexplor
date
studi
monitor
develop
mdr
p
aeruginosa
microevolut
cf
airway
provid
innov
genomewid
pictur
acquisit
antibiot
resist
identifi
novel
mechan
allow
surviv
persist
cf
patient
antibiot
therapi
sequenc
genom
p
aeruginosa
clinic
strain
obtain
trentino
region
support
cf
centr
itali
isol
sputum
singl
cf
patient
eightyear
period
genotyp
analysi
popul
silico
mlst
reveal
characterist
singl
clonal
popul
domin
five
close
relat
new
st
variant
indic
member
popul
like
belong
clonal
lineag
evolv
common
ancestor
phenotyp
analysi
show
previous
report
characterist
adapt
cf
lung
includ
loss
motil
proteas
secret
pigment
product
well
chang
product
exopolysaccharid
earli
isol
found
suscept
almost
antibiot
resist
phenotyp
dramat
increas
time
persist
popul
phenotyp
genom
analys
popul
indic
correl
evolut
antibiot
resist
profil
phylogenet
relationship
focus
attent
subgroup
five
clonal
isol
belong
one
suscept
antibiot
two
resist
antibiot
two
mdr
share
genet
background
present
phenotyp
trait
play
key
role
p
aeruginosa
adapt
process
may
involv
phenotyp
resist
genom
analys
comprehens
antibiot
resist
databas
detect
presenc
resist
gene
found
differ
five
strain
neither
presenc
absenc
specif
gene
signific
mutat
consist
hypothesi
mdr
phenotyp
aros
yet
uncharacter
genom
determin
current
investig
genom
transcriptom
isol
look
uncharacter
variat
potenti
involv
develop
mdr
phenotyp
work
support
donat
associazion
trentina
fibrosi
cistica
although
known
cf
patient
elev
circul
mmp
impact
mmp
modul
abil
cf
monocyt
respond
bacteri
stimuli
lp
fulli
character
method
experi
perform
use
primari
human
peripher
blood
monocyt
isol
either
healthi
cf
subject
total
rna
isol
cdna
librari
gener
assay
mrna
interest
use
revers
transcript
polymeras
chain
reaction
rtpcr
result
character
phenotyp
alter
induc
mmp
inhibit
cf
healthi
monocyt
subject
lp
stimul
without
mmp
inhibit
inflammatori
respons
paradigm
measur
variou
timepoint
profil
mrna
express
hour
stimul
lp
cf
monocyt
express
higher
mrna
comparison
healthi
control
monocyt
tnfalpha
mrna
express
greater
healthi
mmpinhibit
lpsstimul
monocyt
compar
control
monocyt
stimul
lp
alon
mmpinhibit
lpsstimul
cf
monocyt
found
tempor
downregul
chang
tnfalpha
mrna
express
hour
compar
cf
monocyt
stimul
lp
alon
interestingli
cf
monocyt
exhibit
rapid
upregul
gene
express
hour
stimul
mmp
inhibitor
regardless
lp
stimul
wherea
healthi
monocyt
exhibit
littl
chang
gene
express
condit
conclus
data
show
cf
monocyt
differenti
inflammatori
respons
bacteri
stimuli
compar
healthi
monocyt
trend
toward
antiinflammatori
respons
cf
monocyt
compar
proinflammatori
respons
healthi
monocyt
preliminari
data
suggest
blockad
mmp
activ
attenu
antiinflammatori
phenotyp
howev
investig
need
fulli
understand
mechan
respons
alter
bacteri
respons
cf
monocyt
introduct
ceftobiprol
broadspectrum
cephalosporin
act
sever
organ
includ
p
aeruginosa
pa
ceftozolanetazobactam
novel
combin
cephalosporin
betalactamas
inhibitor
combin
shown
vitro
activ
multidrug
resist
pa
purpos
studi
evalu
vitro
antibacteri
activ
ceftobiprol
ceftolozanetazobactam
pa
clinic
isol
cf
patient
method
vitro
activ
ceftobiprol
ceftolozanetazobactam
test
pa
isol
includ
cf
clinic
isol
patient
attend
northern
ireland
adult
cf
centr
belfast
citi
hospit
total
bacteraem
isol
noncf
popul
compar
refer
strain
also
studi
mic
ceftobiprol
ceftolozanetazobactam
determin
standard
etest
methodolog
ceftazidim
also
test
standard
disk
suscept
assay
result
distribut
ceftobiprol
ceftolozanetazobactam
mic
shown
tabl
median
mic
ceftolozanetazobactam
cf
pa
respect
total
isol
sensit
ceftolozanetazobactam
two
isol
highli
resist
mic
resist
isol
also
resist
ceftazidim
isol
sensit
ceftolozan
tazobactam
intermedi
resist
ceftazidim
noncf
popul
isol
sensit
ceftazidim
ceftolozanetazobactam
median
mic
respect
ceftobiprol
cf
popul
noncf
popul
respect
assum
mic
noncf
p
aeruginosa
clinic
breakpoint
cf
isol
sensit
ceftobiprol
sensit
noncf
isol
discuss
although
ceftobiprol
good
activ
bacterem
pa
noncf
popul
poor
vitro
activ
cf
isol
result
show
ceftolozanetazobactam
potenti
effect
antimicrobi
evalu
altern
commonli
use
betalactam
treatment
p
aeruginosa
chronic
respiratori
infect
cf
patient
acknowledg
author
ag
support
sipir
research
fellowship
grant
introduct
chronic
respiratori
infect
p
aeruginosa
pa
lead
sever
lung
damag
respiratori
complic
patient
cystic
fibrosi
cf
develop
pa
resist
avail
antibiot
common
major
concern
cf
current
practic
purpos
studi
evalu
antibiot
resist
trend
last
twenti
year
use
novel
score
call
rel
resist
index
rri
method
two
collect
pa
isol
obtain
two
differ
period
time
name
studi
collect
includ
pa
isol
cf
patient
attend
northern
ireland
adult
cf
centr
belfast
modifi
microbiolog
rri
score
calcul
isol
assign
valu
sensit
intermedi
resist
follow
four
antibiot
class
agent
betalactam
aminoglycosid
fluoroquinolon
polymyxin
unpair
twotail
ttest
use
comparison
trend
two
period
result
rri
increas
significantli
ciprofloxacin
p
aminoglycosid
amikacin
tobramycin
p
meropenem
p
pa
isol
mean
rri
valu
antibiot
report
tabl
isol
suscept
colistin
period
except
three
isol
discuss
overal
studi
show
markedli
greater
resist
cohort
rri
marker
may
use
quantit
tool
help
track
resist
emerg
long
period
time
may
use
clinic
trial
beyond
well
ad
valu
exist
histor
registri
data
conclus
accord
index
studi
highlight
increas
number
isol
reduc
suscept
carbapenem
fluoroquinolon
aminoglycosid
may
reflect
chronic
exposur
pa
sever
class
antibiot
use
manag
cf
airway
infect
intrigu
vitro
data
suggest
qs
signal
molecul
sens
epitheli
surfac
via
bitter
tast
receptor
express
airway
cilia
lee
rj
et
al
j
clin
invest
activ
receptor
predict
lead
chang
ciliari
beat
frequenc
nitric
oxid
product
may
enhanc
bacteri
clearanc
three
common
polymorph
exist
gene
code
receptor
alter
amino
acid
sequenc
posit
correl
receptor
function
function
allel
prolinealaninevalin
pav
wherea
nonfunct
allel
alaninevalineisoleucin
avi
residu
vitro
respons
qs
molecul
shown
greatest
cell
pavpav
genotyp
hypothesis
receptor
may
import
host
defenc
pa
peopl
cystic
fibrosi
cf
genotyp
may
therefor
modifi
infect
statu
clinic
outcom
method
patient
year
cf
genotyp
polymorph
gene
pa
infect
statu
determin
retrospect
review
respiratori
cultur
assign
accord
leed
criteria
chronic
paposit
intermitt
paposit
pafre
previou
pa
none
month
never
patient
culturesyear
includ
analysi
clinic
lung
function
data
obtain
patient
annual
review
result
receptor
genotyp
obtain
patient
aviavi
pavpav
avipav
avioth
pavoth
aviavi
pavpav
avi
pav
group
signific
differ
median
age
gender
proport
cftr
mutat
genotyp
signific
differ
proport
patient
infect
categori
tabl
among
patient
intermitt
chronic
pa
infect
signific
differ
genotyp
proport
patient
isol
mucoid
pa
patient
intermitt
chronic
pa
signific
differ
genotyp
mean
percent
predict
fev
aviavi
pavpav
avipav
mean
percent
predict
fvc
conclus
genotyp
variat
bitter
tast
receptor
appear
modifi
infect
statu
pa
peopl
cf
modifi
lung
diseas
peopl
cf
intermitt
chronic
pa
infect
davi
jc
nation
heart
lung
institut
imperi
colleg
london
london
unit
kingdom
paediatr
respiratori
medicin
royal
brompton
hospit
london
unit
kingdom
depart
cystic
fibrosi
royal
brompton
hospit
london
unit
kingdom
background
chronic
infect
pseudomona
aeruginosa
pa
gener
consid
ineradic
longterm
inhal
antipseudomon
antibiot
aim
suppress
bacteri
load
limit
airway
damag
standard
care
observ
patient
inhal
antibiot
regularli
neg
airway
cultur
could
reflect
technic
issu
relat
presenc
antibiot
cultur
sampl
hypothesis
altern
explan
patient
compris
clinic
distinct
group
differ
patient
continu
meet
definit
either
intermitt
chronic
infect
whilst
treatment
conduct
retrospect
review
part
audit
clinic
practic
method
airway
cultur
result
examin
paediatr
adult
patient
attend
singl
cf
centr
prescrib
longterm
inhal
antibiot
ia
ie
exclud
receiv
erad
therapi
new
pa
growth
patient
cultur
year
includ
attempt
minimis
misclassif
clinic
data
includ
lung
function
annual
review
treatment
ia
obtain
nation
cf
registri
local
electron
patient
record
result
data
obtain
patient
longterm
ia
culturesyear
paneg
paposit
paneg
group
higher
median
iqr
percent
predict
fev
paneg
paposit
p
howev
also
younger
median
iqr
age
year
vs
year
p
may
confound
result
therefor
compar
patient
group
could
match
age
within
year
gender
cftr
genotyp
otheroth
paneg
group
still
higher
median
iqr
percent
predict
fev
vs
p
median
iqr
percent
predict
fvc
vs
p
conclus
data
highlight
potenti
clinic
differ
patient
pacultur
neg
pacultur
posit
whilst
receiv
longterm
inhal
antipseudomon
antibiot
whether
differ
mean
fitter
patient
like
clear
pa
pa
clearanc
lead
better
statu
determin
evalu
patient
group
includ
measur
pa
antibodi
propos
explor
mechan
underli
differ
identifi
patient
may
suitabl
trial
antibiot
withdraw
pseudomona
aeruginosa
airway
infect
affect
adult
cystic
fibrosi
sodium
nitrit
inhibit
bacteri
respir
thu
may
provid
novel
antimicrobi
approach
howev
p
aeruginosa
highli
branch
respiratori
chain
thu
precis
target
nitros
stress
unclear
transposon
screen
identifi
roxsr
potenti
regul
nitrit
sensit
roxsr
encod
twocompon
sensorkinas
regul
termin
oxidas
express
p
aeruginosa
may
affect
bacteri
adapt
nitros
stress
transcriptom
analysi
done
rna
sequenc
compar
roxsr
strain
parent
presenc
absenc
sodium
nitrit
liquid
aerob
cultur
loss
roxsr
lead
derepress
norcb
well
misregul
coxa
exposur
nitrit
lead
norcb
well
cytochrom
oxidas
contrast
roxsr
strain
upregul
norcb
upregul
unexpos
cultur
misregul
cytochrom
oxidas
data
suggest
roxsr
addit
anr
dnr
may
regul
denitrif
cytochrom
oxidas
princip
gene
regul
roxsr
role
specif
cytochrom
oxidas
nitrit
sensit
examin
nitrit
sensit
strain
delet
combin
cytochrom
oxidas
test
aerob
lb
liquid
cultur
human
bronchial
epitheli
cell
line
pseudomona
biofilm
cocultur
system
previous
describ
moreaumarqui
et
al
airway
epitheli
associ
biofilm
treat
increas
concentr
sodium
nitrit
roxsr
strain
sensit
nitrit
aerob
anaerob
condit
biotic
biofilm
format
unimpair
howev
result
biofilm
suscept
growth
inhibit
nitrit
acut
mous
pneumonia
model
mice
intranas
inocul
roxsr
bacteria
count
lung
hour
later
loss
roxsr
lead
log
decreas
bacteri
burden
hour
conclus
twocompon
system
roxsr
key
regul
p
aeruginosa
respons
nitrit
liquid
cultur
biotic
biofilm
well
requir
adapt
growth
mous
lung
addit
known
regul
termin
cytochrom
oxidas
tc
also
like
regul
denitrif
object
palivizumab
recommend
reduc
hospit
infant
children
highrisk
sever
respiratori
syncyti
viru
rsv
infect
children
cf
potenti
addit
benefit
prevent
earli
rsv
infect
current
american
academi
pediatr
aap
guidelin
recommend
palivizumab
cf
infant
month
age
clinic
evid
chronic
lung
diseas
andor
nutrit
compromis
month
age
hospit
first
year
life
pulmonari
exacerb
pulmonari
radiograph
abnorm
weight
length
th
percentil
effect
palivizumab
longerterm
outcom
children
cf
unknown
use
cf
foundat
patient
registri
cffpr
evalu
potenti
impact
receiv
palivizumab
infanc
clinic
outcom
age
year
method
perform
retrospect
cohort
analysi
use
cffpr
data
elig
children
born
diagnos
cf
age
month
children
categor
accord
whether
receiv
palivizumab
time
first
year
life
exclud
palivizumab
statu
unknown
children
follow
follow
outcom
hospit
pulmonari
indic
time
first
isol
pseudomona
aeruginosa
pa
among
neg
start
first
rsv
season
fev
predict
age
year
propens
model
develop
adjust
confound
treatment
indic
result
cohort
includ
children
receiv
palivizumab
infanc
annual
palivizumab
use
declin
significantli
studi
period
compar
receiv
palivizumab
infant
receiv
palivizumab
sign
symptom
cf
exampl
prior
receipt
palivizumab
lower
weight
percentil
higher
preval
pa
sever
cftr
mutat
pancreat
enzym
use
overal
hospit
rate
compar
receiv
palivizubmab
children
receiv
palivizumab
higher
hazard
first
isol
pa
ci
among
children
lung
function
data
age
year
receiv
palivizumab
conclus
infant
cf
receiv
palivizumab
evid
sever
cf
diseas
receiv
palivizumab
consist
current
aap
recommend
adjust
diseas
sever
detect
improv
longterm
clinic
outcom
base
receipt
palivizumab
howev
data
avail
registri
allow
us
assess
potenti
benefit
palivizumab
specif
among
infant
chronic
lung
diseas
nutrit
compromis
addit
cffpr
collect
data
rsv
infect
plan
explor
altern
dataset
assess
shortand
longterm
benefit
confer
palivizumab
cf
infant
sever
clinic
manifest
first
year
life
method
patient
year
old
fev
predict
paposit
respiratori
cultur
enrol
cffaccredit
center
us
respiratori
sampl
collect
annual
process
central
refer
laboratori
primari
outcom
measur
annual
chang
proport
subject
whose
least
suscept
pa
isol
increas
aztreonam
minimum
inhibitori
concentr
mic
parenter
aztreonam
suscept
breakpoint
ml
outcom
includ
chang
pa
suscept
aztreonam
antibiot
associ
number
azli
cours
pa
resist
aztreonam
relationship
pa
resist
aztreonam
clinic
outcom
obtain
cff
patient
registri
databas
result
subject
enrol
augnov
cf
center
mean
age
enrol
year
rang
year
mean
fev
predict
rang
year
prior
enrol
subject
receiv
azli
cours
receiv
azli
cours
subject
pair
respiratori
sampl
pa
isol
mic
data
compar
annual
mic
chang
baselin
year
evalu
subject
pa
isol
met
primari
outcom
year
year
year
associ
azli
exposur
yesno
number
cours
subject
diddid
meet
primari
outcom
aztreonam
mic
mic
pa
isol
baselin
year
year
year
signific
differ
annual
percent
chang
fev
predict
year
year
subject
met
vs
meet
primari
outcom
pulmonari
exacerb
rate
diddid
meet
year
primari
outcom
vs
respect
hospit
rate
diddid
meet
year
primari
outcom
vs
respect
conclus
similar
proport
subject
pa
isol
met
primari
outcom
year
compar
year
although
fewer
subject
met
primari
outcom
year
azli
use
associ
meet
primari
outcom
year
thu
far
meet
primari
outcom
exhibit
greater
declin
lung
function
exacerb
hospit
associ
antibiot
treatment
support
gilead
scienc
gut
microbiota
play
essenti
role
human
across
life
span
yet
acquisit
develop
microbi
commun
earli
childhood
remain
larg
unexplor
perturb
microbiom
earli
life
includ
colon
specif
microb
link
mani
diseas
includ
cf
cf
intestin
tract
like
popul
host
maldigest
macroand
micronutri
well
metabolit
alter
intestin
milieu
ie
substrat
ph
oxygen
bacteria
growth
howev
larg
studi
cf
systemat
character
earli
life
gut
microbiota
respect
diet
growth
nutrit
lung
diseas
object
character
gut
microbiota
cf
explor
influenc
cesarean
deliveri
infanc
feed
acid
blocker
use
method
studi
popul
includ
children
born
diagnos
newborn
screen
enrol
first
feed
infant
start
multicent
prospect
studi
conduct
cf
center
madison
milwauke
indianapoli
salt
lake
citi
boston
identifi
optim
feed
cf
infant
fecal
specimen
collect
routin
clinic
visit
infanc
annual
afterward
rrna
gene
pyrosequenc
metagenom
data
analysi
use
qiim
pipelin
perform
biotechnolog
center
uwmadison
analyz
sampl
children
result
sampl
collect
mo
includ
st
nd
rd
children
boy
girl
mi
pi
ps
children
use
acid
blocker
infanc
children
born
cesarean
deliveri
fullterm
normal
birth
weight
nonp
children
exclus
breastf
eb
remain
receiv
either
eb
partial
breast
milk
formula
overal
sequenc
compris
oper
taxonom
unit
uniqu
genera
identifi
total
number
read
present
genera
among
bifidobacterium
abund
genu
follow
bacteroid
streptococcu
blautia
veillonella
lactobacillu
clostridium
enterococcu
ruminococcu
collinsella
citrobact
parabacteroid
dorea
coprococcu
klebsiella
haemophilu
alpha
divers
score
increas
age
abund
bacteroid
blautia
collinsella
coprococcu
increas
age
bifidobacterium
veillonella
decreas
age
cesarean
deliveri
associ
decreas
parabacteroid
st
decreas
bifidobacterium
veillonella
klebsiella
haemophilu
nd
decreas
veillonella
klebsiella
rd
higher
abund
haemophilu
nd
lactobacillu
rd
associ
eb
acid
blocker
use
associ
increas
collinsella
nd
conclus
preliminari
analys
suggest
infant
feed
acid
blocker
use
cesarean
deliveri
could
alter
earli
life
gut
microbiota
composit
latent
class
analysi
microbiota
composit
perform
background
cystic
fibrosi
cf
patient
often
receiv
prolong
cours
broad
spectrum
antibiot
treatment
acut
pulmonari
exacerb
ape
cf
patient
commonli
infect
methicillinresist
staphylococcu
aureu
mrsa
pseudomona
aeruginosa
necessit
antibiot
coverag
organ
previou
studi
noncf
pediatr
patient
suggest
increas
incid
acut
kidney
injuri
aki
vancomycin
combin
piperacillintazobactam
object
studi
determin
differ
aki
patient
receiv
piperacillintazobactam
cefepim
combin
vancomycin
tobramycin
method
irbapprov
retrospect
cohort
studi
conduct
singl
cf
center
patient
includ
hospit
ape
receiv
treatment
intraven
vancomycin
tobramycin
piperacillintazobactam
cefepim
hospit
age
day
year
old
admiss
aki
defin
increas
serum
creatinin
scr
least
primari
outcom
differ
aki
incid
patient
receiv
piperacillintazobactam
cefepim
defin
modifi
pediatr
risk
injuri
failur
loss
endstag
renal
diseas
prifl
criteria
result
studi
includ
seventyeight
patient
patient
cefepim
piperacillintazobactam
group
median
interquartil
rang
age
slightli
older
cefepim
group
year
versu
piperacillintazobactam
group
year
weight
height
greater
cefepim
group
weight
cefepim
kg
vs
piperacillintazobactam
kg
height
cefepim
cm
vs
piperacillintazobactam
cm
aki
identifi
patient
piperacillintazobactam
group
patient
cefepim
group
statist
differ
length
antibiot
day
vs
day
maximum
scr
vs
previou
aminoglycosid
vancomycin
cours
patient
experienc
aki
maximum
vancomycin
trough
measur
piperacillintazobactam
vs
cefepim
group
conclus
studi
suggest
piperacillintazobactam
therapi
combin
intraven
vancomycin
tobramycin
pediatr
cf
patient
may
caus
greater
incid
aki
compar
treatment
cefepim
background
home
nebul
patient
cf
becom
colon
microb
despit
standard
clean
practic
rais
possibl
pathogen
exposur
use
contamin
nebul
blau
h
et
al
child
care
health
dev
cf
foundat
recommend
multipl
differ
method
nebul
disinfect
saiman
l
et
al
infect
control
hosp
epidemiol
less
known
regard
newer
disinfect
techniqu
steam
steril
impact
bacteri
recoveri
patient
nebul
hypothesi
recommend
disinfect
techniqu
differ
respect
bacteri
recoveri
patient
nebul
increas
frequenc
nebul
disinfect
result
decreas
bacteri
recoveri
method
inform
consent
obtain
pediatr
cf
famili
children
year
use
nebul
therapi
daili
pilot
studi
famili
fill
studi
questionnair
regard
nebul
clean
disinfect
techniqu
patient
plu
nebul
swab
eswab
copan
insid
mouthpiec
outlet
chamber
swab
sent
bacteri
fungal
mycobacteri
cultur
recov
microb
identifi
malditof
mass
spectrometri
towl
et
al
j
cyst
fibro
chart
review
collat
demograph
respiratori
cultur
surveri
result
regard
nebul
clean
disinfect
practic
along
microbi
recoveri
nebul
data
analyz
fisher
exact
test
linear
linear
associ
result
although
patient
disinfect
home
nebul
nebul
grew
least
one
microb
commonli
viridan
group
streptococcu
nebul
least
one
cf
pathogen
patient
grew
pseudomona
sp
within
last
year
none
recov
nebul
staphylococcu
aureu
sa
grew
patient
cultur
within
last
year
nebul
grew
sa
sa
recov
twice
patient
patient
nebul
patient
grew
mouth
flora
within
last
year
nebul
disinfect
use
less
like
colon
microb
microb
nebul
disinfect
less
frequent
microb
differ
bacteri
recoveri
compar
differ
disinfect
method
eg
boil
steam
steril
alcohol
bleach
conclus
home
nebul
contamin
microb
regardless
disinfect
method
disinfect
use
result
reduc
microb
recoveri
nebul
compar
less
frequent
disinfect
focu
patient
educ
studi
limit
includ
small
sampl
size
bia
associ
selfreport
current
work
examin
contribut
variabl
microb
recoveri
nebul
eg
antibiot
use
optim
method
nebul
disinfect
method
develop
confidenti
anonym
onlin
survey
determin
select
ip
c
practic
implement
pilot
test
content
expert
includ
former
center
director
revis
survey
contain
item
multiplechoic
yesno
respons
email
includ
remind
sent
director
pediatr
adult
affili
care
center
ask
designe
complet
survey
respond
receiv
gift
card
particip
result
date
center
respons
rate
complet
survey
includ
pediatr
adult
affili
center
overal
center
provid
ip
c
educ
clinic
visit
ip
c
educ
includ
checklist
center
half
use
newslett
signag
cff
educ
materi
patientsfamili
local
ip
c
team
help
develop
educ
center
respect
ip
c
team
help
implement
practic
center
educ
ip
c
cf
consist
provid
inpati
staff
pft
lab
staff
social
worker
fewer
half
center
provid
educ
admit
housekeep
radiolog
phlebotomi
staff
feedback
regard
ip
c
provid
staff
center
perform
audit
environment
clean
center
hold
formal
educ
event
inperson
meet
adult
center
like
allow
individu
cf
attend
inperson
meet
pediatr
center
vs
respect
p
center
also
use
videoconfer
videotap
webinar
provid
educ
center
hold
outdoor
event
pediatr
adult
affili
center
equal
like
allow
individu
cf
attend
respect
common
ip
c
strategi
outdoor
event
foot
rule
use
center
hold
outdoor
event
half
center
particip
nation
local
ip
c
qualiti
improv
project
conclus
respond
cf
care
center
implement
recommend
updat
ip
c
guidelin
partner
ip
c
team
provid
educ
clinic
staff
inpati
staff
patientsfamili
earli
find
also
suggest
addit
educ
opportun
ancillari
staff
improv
audit
feedback
environment
clean
cf
clinic
futur
work
project
focu
review
written
ip
c
protocol
respond
center
select
recommend
ultim
assess
impact
ip
c
guidelin
acquisit
select
cf
pathogen
young
children
microbiom
divers
dynam
respons
therapi
role
mucu
obstruct
inflamm
microbi
interact
unclear
aim
examin
microbiom
young
children
bronchoalveolar
lavag
bal
identifi
chang
relat
age
mucu
concentr
inflamm
method
infant
children
undergo
yearli
bal
part
australian
respiratori
earli
surveil
team
arest
cf
program
includ
subject
one
bal
sampl
right
middl
lobe
rml
one
lingula
subgroup
bronchoscop
wash
bw
ie
flush
bronchoscop
prior
bal
obtain
microbi
character
done
rrna
gene
sequenc
mucu
concentr
measur
refractometri
inflamm
measur
percent
neutrophil
pmn
result
mean
sem
age
children
year
microbiom
data
avail
rml
lingula
bw
sampl
weight
princip
compon
analys
show
clear
separ
bw
bal
sampl
figur
overlap
bacteri
composit
rmllingula
sampl
alpha
divers
shannon
index
tend
decreas
age
especi
first
two
year
shannon
correl
pmn
show
weak
neg
correl
mucin
concentr
r
contrast
mucin
concentr
correl
posit
pmn
discuss
microbiom
character
bal
fluid
young
children
detect
bacteri
taxa
differ
present
reagent
use
perform
bronchoscopi
interestingli
shannon
divers
decreas
increas
mucin
concentr
turn
correl
lower
airway
inflamm
may
impli
import
mucu
obstruct
cf
diseas
taxaspecif
analys
regard
region
divers
age
inflamm
mucu
present
background
bacteri
pathogen
associ
pulmonari
declin
patient
cf
cocolon
multipl
microorgan
common
cf
airway
even
infanc
novel
statist
analysi
simultan
examin
multipl
microorgan
cf
airway
lack
understand
heterogen
joint
profil
respiratori
infect
associ
breastfeed
lead
critic
scientif
insight
optim
earli
life
diseas
manag
object
delin
joint
microorgan
profil
identifi
meaning
cocolon
pattern
examin
associ
breastformula
feed
infant
cf
method
studi
cohort
includ
cf
infant
enrol
first
feed
infant
start
prospect
observ
studi
initi
cf
center
madison
milwauke
boston
indianapoli
salt
lake
citi
identifi
optim
feed
data
respiratori
infect
oropharyng
cultur
collect
routin
cf
center
visit
first
year
life
analyz
appli
latent
class
analysi
lca
jointli
examin
respiratori
infect
statu
intens
defin
infect
coloni
moder
number
coloni
mani
coloni
seven
major
microorgan
mo
age
result
lca
differenti
cohort
cf
infant
three
group
demonstr
distinct
longitudin
cocolon
pattern
microorgan
figur
cf
infant
class
infect
consid
microorgan
four
age
point
cf
infant
class
show
markedli
elev
intens
staphylococcu
aureu
sa
infect
accompani
low
intens
coinfect
nonmucoid
pseudomona
aeruginosa
pa
klebsiella
cf
infant
class
manifest
high
infect
risk
sa
well
multipl
bacteri
pathogen
compar
exclus
formula
feed
exclus
breastfeed
mo
show
signific
protect
effect
infect
acinetobact
ci
throughout
first
year
life
breastfeed
partial
exclus
mo
also
lower
risk
haemophilu
influenza
infect
infanc
ci
conclus
latent
classif
microorgan
profil
provid
new
insight
heterogen
microbi
phenotyp
identifi
cocolon
sa
bacteria
breastfeed
lower
risk
haemophilu
influenza
acinetobact
infect
infanc
fund
background
earli
diagnosi
treatment
respiratori
infect
cornerston
manag
lung
diseas
cystic
fibrosi
cf
introduc
routin
induc
sputum
sampl
part
annual
review
cf
center
children
microbiolog
surveil
mani
children
normal
sputum
produc
whilst
procedur
safe
well
toler
time
consum
requir
special
train
staff
studi
aim
examin
valu
routin
sampl
children
cf
annual
review
method
prospect
observ
studi
involv
children
cf
attend
univers
hospit
leicest
uk
annual
review
januari
decemb
children
abl
perform
lung
function
test
includ
sputum
induct
involv
patient
inhal
increas
concentr
hyperton
salin
minut
provid
drop
fev
accept
end
cycl
sputum
sampl
process
standard
method
look
bacteria
includ
mycobacteria
fungi
result
children
male
mean
age
mean
fev
predict
particip
studi
sampl
analys
studi
period
sampl
result
posit
isol
posit
bacteri
yield
note
sputum
sampl
first
time
isol
includ
atyp
mycobacteria
imag
detail
microbi
isol
note
intraven
antibiot
use
treat
children
new
bacteri
isol
children
isol
mycobacteria
conclus
welltoler
safe
noninvas
method
sampl
lower
airway
children
cf
identifi
new
isol
import
organ
annual
review
sampl
suggest
annual
review
surveil
induc
sputum
use
identifi
import
pathogen
children
often
asymptomat
result
earlier
initi
erad
treatment
cohort
children
pathogen
eg
abscessu
b
cepacia
potenti
infect
children
clinic
airway
patient
cf
harbour
rich
commun
microb
microbiota
role
unclear
studi
adult
demonstr
decreas
commun
divers
may
marker
endstag
diseas
littl
chang
seen
exacerb
zhao
j
et
al
pna
greater
longitudin
studi
microbiota
infanc
need
identifi
earli
chang
could
target
therapeut
prevent
onset
advanc
diseas
hypothesis
chang
airway
microbiota
would
seen
evolv
clinic
statu
infant
cf
method
thirti
infant
cf
diagnos
newborn
screen
recruit
median
age
day
throat
swab
collect
routin
clinic
appoint
year
median
day
visit
quantit
pcr
sequenc
rrna
bacteri
gene
perform
use
illumina
miseq
data
analys
perform
qiim
phyloseq
r
result
streptococcu
common
genu
first
year
life
read
common
genera
includ
haemophilu
veillonella
staphylococcu
pseudomona
low
rel
abund
respect
weak
posit
correl
seen
age
bacteri
load
r
p
alpha
divers
within
sampl
variat
measur
rich
number
differ
speci
even
spread
speci
r
respect
p
signific
influenc
age
beta
divers
sampl
variat
also
demonstr
bray
curti
r
p
preliminari
examin
trend
common
genera
found
streptococcu
haemophilu
begin
similar
rel
abund
diverg
thereaft
streptococcu
increas
month
age
decreas
haemophilu
show
opposit
trend
seven
children
experienc
exacerb
requir
intraven
antibiot
within
first
year
life
signific
differ
found
bacteri
load
alpha
beta
divers
exacerb
treatment
p
genera
level
rel
abund
streptococcu
increas
start
exacerb
declin
sharpli
thereaft
veillonella
granulicatella
show
similar
less
pronounc
trend
wherea
haemophilu
show
opposit
trend
signific
trend
chang
less
common
genera
current
assess
conclus
whilst
small
chang
bacteri
load
alpha
divers
signific
relationship
age
beta
divers
first
year
life
suggest
chang
genera
level
may
greater
influenc
clinic
featur
overal
divers
commun
chang
rel
abund
streptococcu
haemophilu
veillonella
granulicatella
observ
exacerb
albeit
small
number
patient
larger
longitudin
studi
need
determin
clinic
signific
chang
introduct
nontubercul
mycobacteria
ntm
particular
affin
patient
cystic
fibrosi
cf
lead
signific
worsen
diseas
well
known
ntm
live
natur
biofilm
water
soil
recent
studi
shown
rate
infect
correl
directli
atmospher
water
content
object
determin
associ
household
proxim
water
acquisit
ntm
children
cf
method
irbapprov
retrospect
chart
review
complet
cf
patient
cystic
fibrosi
foundationaccredit
center
nemour
children
clinic
pensacola
orlando
florida
inclus
criteria
requir
regular
followup
least
two
acidfast
base
sputum
bronchioalveolar
lavag
cultur
consist
home
address
studi
period
juli
juli
demograph
certain
clinic
inform
obtain
compar
two
group
ntmposit
ntmneg
patient
assess
possibl
confound
distanc
patient
home
nearest
bodi
water
measur
use
geograph
inform
system
mean
closest
distanc
water
ntmposit
ntmneg
group
calcul
compar
nonparametr
mann
whitney
u
test
result
patient
met
inclus
criteria
test
posit
ntm
ntmposit
patient
grew
mycobacterium
avium
complex
grew
mycobacterium
abscessu
complex
grew
organ
signific
differ
ntmposit
ntmneg
patient
relationship
sex
insur
statu
cf
genotyp
mean
percent
predict
fev
though
patient
ntmposit
group
significantli
older
mean
age
year
versu
year
mean
distanc
water
ntmposit
patient
sd
significantli
less
compar
ntmneg
sd
pvalu
live
within
meter
water
sourc
significantli
associ
ntmposit
mean
distanc
water
group
display
bar
graph
error
bar
repres
standard
error
mean
conclus
region
studi
children
cf
live
closer
water
like
acquir
nontubercul
mycobacteria
futur
studi
geograph
area
need
determin
result
generaliz
stenotrophomona
maltophilia
multidrugresist
organ
whose
preval
increas
cf
chronic
infect
stenotrophomona
increas
risk
pulmonari
exacerb
pex
lung
transplant
death
improv
life
expect
led
emerg
new
comorbid
common
one
cfrelat
diabet
blood
glucos
mmoll
glucos
detect
airway
creat
favour
environ
bacteri
growth
lung
cf
patient
object
character
associ
posit
cultur
stenotrophomona
glucos
excurs
larg
adult
popul
cf
method
crosssect
observ
analysi
cf
patient
without
known
cfrd
montreal
cf
cohort
patient
underw
oral
glucos
toler
test
ogtt
glucos
measur
min
measur
refer
blood
glucos
curv
creat
refer
glycemia
curv
repres
threshold
elev
airway
glucos
concentr
creat
select
patient
normal
glucos
level
min
ogtt
mmoll
blood
glucos
level
near
mmoll
mmoll
minut
ogtt
area
curv
auc
time
min
ogtt
auc
measur
use
refer
blood
glucos
patient
higher
glucos
auc
valu
categoris
risk
elev
airway
glucos
pulmonari
bacteri
colonis
airway
mucu
forc
expiratori
volum
sec
fev
age
gender
nutrit
statu
number
pex
requir
intraven
antibiot
collect
statist
analysi
use
mannwhitney
utest
chi
nonparametr
ttest
done
result
patient
year
old
mean
bodi
mass
index
kgm
fev
stenotrophomonasposit
patient
significantli
lower
fev
p
underw
higher
number
pex
p
compar
patient
stenotrophomona
colonis
proport
stenotrophomonasposit
patient
high
glucos
auc
significantli
higher
proport
stenotrophomonasneg
patient
high
glucos
auc
vs
p
conclus
patient
posit
stenotrophomona
cultur
lower
fev
underw
pex
compar
negativestenotrophomona
patient
preval
higher
glucos
auc
valu
higher
stenotrophomonasposit
patient
suggest
presenc
stenotrophomona
associ
deleteri
clinic
outcom
abnorm
glucos
metabol
could
one
contribut
factor
mechanist
studi
necessari
understand
link
stenotrophomona
glucos
homeostasi
refer
method
patient
provid
sputum
sampl
within
three
year
birthday
minimum
followup
five
year
clinic
microbiolog
includ
sputum
sampl
obtain
cacfc
biobank
establish
sinc
tenand
fifteenyear
assess
done
patient
avail
sampl
time
point
duplic
sampl
assess
time
point
abl
sampl
collect
within
day
new
system
antibiot
filter
microbi
composit
determin
via
illumina
miseq
sequenc
rrna
patient
categor
base
rate
lung
function
declin
measur
fev
predict
ie
stabl
year
mild
year
sever
year
result
fifti
adult
male
includ
assess
follow
interv
cohort
compos
homozyg
heterozygot
median
fev
fvc
predict
total
sputum
sampl
assess
patient
categor
year
experienc
stabl
mild
sever
lung
function
declin
group
differ
respect
proport
cultur
pathogen
pa
stabl
mild
sever
p
haemophilu
influenza
hi
stabl
mild
sever
p
except
staphylococcu
aureu
sa
stabl
mild
sever
p
reduct
measur
observ
estim
alpha
divers
time
period
year
sever
group
p
howev
differ
found
stabl
mild
lung
diseas
group
base
rel
abund
genera
drive
reduct
sever
group
includ
pa
hi
prevotella
sa
streptococcu
p
adjust
interestingli
rate
declin
calcul
base
time
year
longer
differ
alpha
divers
sever
group
comparison
rel
abund
among
lung
diseas
group
show
pa
rothia
dialist
hi
prevotella
sa
fusobacterium
streptococcu
neisseria
drive
differ
among
group
p
adjust
determin
cf
microbiom
cluster
base
fev
declin
group
p
permanova
conclus
longitudin
cohort
cf
adolesc
found
relationship
bacteri
divers
rate
lung
function
declin
predomin
constitu
found
microbi
commun
sputum
sampl
introduct
great
effort
made
understand
cf
airway
infect
influenc
clinic
outcom
cf
howev
two
find
dramat
chang
percept
infect
recognit
p
aeruginosa
pa
strain
differ
clinic
prognosi
divers
commun
organ
popul
airway
cf
microbiom
epidem
strain
pa
epa
describ
multidrug
resist
within
clinic
epa
recent
describ
prairi
epidem
strain
pe
whose
infect
associ
increas
risk
exacerb
rate
lung
function
declin
progress
endstag
lung
diseas
compar
uniqu
infect
wherea
earlier
studi
propos
epa
exagger
virul
capac
hypothes
epa
may
select
virul
lower
airway
commun
method
previou
work
group
use
pulsedfield
gel
electrophoresi
multilocu
sequenc
type
determin
pa
infect
strain
type
entir
cohort
last
thirti
year
match
patient
chronic
pe
infect
birth
cohort
year
sex
control
patient
infect
uniqu
nonepidem
strain
pa
upa
examin
longitudin
sputum
biobank
establish
identifi
sputum
sampl
collect
similar
time
period
two
patient
group
three
time
point
analysi
sampl
exclud
collect
within
two
week
system
antibacteri
perform
illumina
miseq
sequenc
region
rrna
gene
result
identifi
sputum
sampl
match
pair
male
femal
pe
upa
infect
patient
analysi
demograph
match
patient
similar
respect
pancreat
insuffici
genotyp
distribut
patient
pe
advanc
airway
diseas
defin
fev
p
sputum
sampl
collect
median
day
apart
pair
pool
analysi
demonstr
sampl
patient
epa
lower
alpha
divers
p
observ
p
proport
commun
abund
pa
pe
group
greater
upa
vs
p
permanova
analysi
microbi
commun
structur
cluster
base
gender
fev
fvc
epa
statu
genera
found
differ
pe
infect
patient
upa
signific
level
includ
streptococcu
fusobacterium
haemophilu
dialist
mycoplasma
eikenella
prevotella
acinetobact
acidovorax
p
adjust
conclus
herein
observ
patient
infect
pe
epa
associ
wors
clinic
outcom
differ
lower
airway
commun
structur
infect
upa
although
epa
may
disproport
virul
pa
strain
may
also
function
modifi
cf
microbiom
one
harm
host
patient
infect
epa
experi
wors
clinic
outcom
collin
orourk
drapeau
g
feinn
r
murray
ts
curti
r
med
sci
frank
h
netter
md
sch
med
quinnipiac
univ
hamden
ct
usa
pulm
ct
child
med
center
hartford
ct
usa
introduct
infect
control
practic
import
optim
health
children
cf
timeconsum
challeng
famili
follow
saiman
l
et
al
infect
control
hosp
epidemiol
awar
cf
foundat
cff
guidelin
adher
cff
infect
control
guidelin
practic
highli
variabl
amongst
patient
center
mirob
et
al
pediatr
pulmunol
wealth
inform
avail
famili
cf
regard
aspect
patient
care
includ
newer
correct
therapi
want
learn
famili
current
knowledg
attitud
regard
infect
control
impact
actual
practic
knowledg
new
advanc
cf
therapi
compar
knowledg
infect
control
guidelin
hypothesi
famili
know
less
routin
infect
control
practic
compar
inform
regard
new
cf
corrector
medic
infect
prevent
import
famili
difficulti
perform
recommend
routin
procedur
nebul
clean
disinfect
method
obtain
inform
consent
children
famili
survey
routin
visit
regard
awar
access
infect
control
guidelin
awar
access
inform
corrector
therapi
attitud
toward
infect
prevent
inform
regard
frequenc
method
home
nebul
clean
disinfect
ccmc
irb
result
compar
use
fisher
exact
test
linear
linear
associ
result
germ
avoid
verysomewhat
import
famili
howev
disinfect
nebul
daili
tabl
dailydisinfect
famili
like
feel
disinfect
import
disinfect
less
often
tabl
famili
felt
nebul
clean
verysomewhat
import
clean
nebul
last
hour
famili
refer
cff
infect
control
guidelin
awar
ivacaftor
inform
reach
statist
signific
abil
find
inform
cff
websit
regard
ivacaftor
associ
increas
likelihood
read
infect
control
guidelin
suggest
gener
knowledg
cf
inform
conclus
posit
relationship
exist
patient
feel
import
disinfect
frequenc
nebul
disinfect
howev
even
though
famili
place
import
germ
avoid
less
half
disinfect
nebul
daili
suggest
educ
regard
import
infect
control
practic
disinfect
may
lead
better
adher
work
underway
understand
challeng
implement
infect
control
practic
famili
acknowledg
import
bustamant
ae
jaimeperez
j
corderoperez
p
villarrealvillarr
c
mercadolongoria
r
clinica
de
fibrosi
neumologia
hospit
universitario
monterrey
nuevo
leon
mexico
hematologia
hospit
universitario
monterrey
nuevo
leon
mexico
laboratorio
unidad
de
hospit
universitario
monterrey
nuevo
leon
mexico
background
cystic
fibrosi
cf
diseas
character
progress
lung
inflamm
larg
trigger
infect
platelet
particip
significantli
inflamm
activ
bacteri
toxin
lipopolysaccharid
pseudomona
aeruginosa
p
aeruginosa
lead
pathogen
infect
cf
patient
repres
determin
factor
deterior
lung
function
shorten
surviv
earli
detect
presenc
pathogen
cf
airway
essenti
establish
earli
treatment
achiev
elimin
main
problem
young
patient
abl
expector
therefor
identif
bacteria
alway
possibl
biomark
peripher
blood
reflect
presenc
pathogen
could
use
object
evalu
platelet
activ
measur
relationship
presenc
p
aeruginosa
cf
airway
method
studi
evalu
stabl
patient
diagnos
cf
follow
cf
clinic
hospit
universitario
monterrey
analyz
data
includ
demograph
inform
cftr
genotyp
spirometr
measur
radiograph
tomograph
evalu
platelet
vegf
peripher
blood
airway
colon
statu
expector
andor
throat
swab
cultur
p
aeruginosa
serolog
patient
accord
leed
classif
divid
three
group
patient
p
aeruginosa
never
detect
patient
intermitt
colon
patient
chronic
colon
result
tabl
cytokin
measur
show
statist
signific
differ
group
cutoff
valu
pgml
associ
area
curv
ci
reflect
presenc
p
aeruginosa
cf
airway
sensit
specif
lung
damag
express
brasfield
score
bhalla
score
spirometri
fvc
statist
signific
differ
group
p
conclus
platelet
activ
measur
may
repres
predict
biomark
presenc
p
aeruginosa
airway
cf
patient
recent
studi
suggest
polymicrobi
natur
infect
play
key
role
drive
cf
lung
diseas
turn
significantli
impact
clinic
outcom
patient
children
aureu
colonizationinfect
usual
preced
chronic
colon
respiratori
tract
p
aeruginosa
continu
adulthood
coisol
p
aeruginosa
cf
respiratori
cultur
date
unclear
whether
aureu
independ
contributor
cf
lung
diseas
pathogenesi
impact
progress
p
aeruginosa
chronic
lung
infect
explor
causal
associ
human
complic
confound
variabl
control
individu
recent
develop
character
murin
model
p
aeruginosa
infect
reliabl
mimick
cours
human
infect
cigana
c
et
al
sci
rep
take
advantag
murin
model
studi
role
aureu
pathogenesi
progress
p
aeruginosa
lung
diseas
mice
infect
aureu
newman
strain
cfu
embed
agar
bead
mimic
chronic
infect
analyz
time
cours
incid
chronic
infect
day
remain
stabl
day
howev
bacteri
load
leukocyt
recruit
cytokineschemokin
level
peak
day
decreas
day
histopatholog
analysi
day
postinfect
show
initi
format
abscess
similar
observ
human
lung
infect
aureu
increas
day
day
aureusinfect
mice
superinfect
p
aeruginosa
strain
embed
agar
bead
day
preinfect
aureu
decreas
acut
mortal
induc
highli
virul
refer
p
aeruginosa
strain
earli
cf
clinic
isol
increas
number
mice
progress
p
aeruginosa
chronic
diseas
addit
aureu
preinfect
increas
incid
chronic
infect
establish
cfadapt
isol
notabl
inflammatori
respons
term
leukocyt
recruit
cytokineschemokin
product
similar
mice
infect
p
aeruginosa
regardless
aureu
preinfect
abscess
format
immunofluoresc
stain
show
aureu
local
mainli
abscess
parenchyma
wherea
p
aeruginosa
mainli
present
agar
bead
bronchial
level
studi
indic
aureu
shape
host
respons
favor
p
aeruginosa
persist
within
lung
notabl
mous
model
refin
studi
invalu
tool
studi
pathogenesi
progress
infect
cf
object
chronic
pseudomona
aeruginosa
lung
infect
sever
complic
cystic
fibrosi
patient
character
antibiotictoler
biofilm
endobronchi
mucu
zone
oxygen
deplet
mainli
due
polymorphonuclear
leukocyt
pmn
activ
exact
mechan
affect
antibiot
effect
biofilm
remain
unclear
accumul
evid
suggest
effici
sever
bactericid
antibiot
ciprofloxacin
enhanc
stimul
aerob
respir
pathogen
lack
increas
toler
fact
bactericid
effect
sever
antibiot
requir
bacteri
metabol
activ
depend
format
reactiv
radic
ro
reoxygen
deplet
biofilm
may
thu
improv
suscept
ciprofloxacin
possibl
restor
aerob
respir
aim
sensit
anox
biofilm
wildtyp
p
aeruginosa
catalasedefici
mutant
creat
toler
ciprofloxacin
hyperbar
oxygen
treatment
hbot
test
strategi
use
reoxygen
deplet
p
aeruginosa
strain
agaros
embed
biofilm
hbot
enhanc
diffus
suppli
aerob
respir
ciprofloxacin
treatment
anox
biofilm
treat
mgl
ciprofloxacin
biofilm
incub
min
hbot
bar
result
demonstr
enhanc
bactericid
activ
ciprofloxacin
p
aeruginosa
agarosebiofilm
min
hbot
p
fact
maximum
enhanc
kill
hbot
exceed
log
use
mgl
ciprofloxacin
preliminari
data
biofilm
supplement
hbo
suggest
ro
contribut
enhanc
activ
ciprofloxacin
conclus
studi
demonstr
biofilm
reoxygen
hbot
significantli
enhanc
bactericid
activ
ciprofloxacin
p
aeruginosa
min
incub
combin
ciprofloxacin
treatment
hbot
thu
clearli
potenti
improv
treatment
p
aeruginosa
biofilm
infect
suggest
consid
hbot
cf
patient
lung
infect
yet
advanc
creat
exacerb
zone
trap
air
furthermor
intend
demonstr
supplement
normobar
may
enhanc
activ
antibiot
cystic
fibrosi
cf
recess
genet
diseas
caus
defect
cftr
lead
impair
chlorid
bicarbon
ion
transport
defect
lead
accumul
dens
intract
mucu
make
patient
suscept
chronic
lung
infect
oligog
refin
low
molecular
weight
oligosaccharid
oligom
deriv
brown
alga
algin
compris
mainli
guluron
inher
calcium
chelat
properti
previou
studi
shown
oligog
disrupt
bacteri
biofilm
vitro
potenti
antibiot
reduc
elev
mucu
viscos
ex
vivo
cf
sputum
oligog
current
phase
iib
trial
cystic
fibrosi
demonstr
excel
safeti
toler
healthi
volunt
cf
patient
studi
random
doubleblind
placebocontrol
crossov
studi
phase
iib
inhal
algin
oligosaccharid
oligog
dpi
day
subject
cystic
fibrosi
use
aztreonam
due
chronic
colon
burkholderia
spp
primari
endpoint
demonstr
efficaci
inhal
oligog
reduc
microbi
burden
burkholderia
spp
measur
expector
sputum
sampl
time
point
studi
secondari
endpoint
includ
evalu
effect
inhal
oligog
variou
efficaci
variabl
eg
lung
function
qol
sputum
rheolog
microbiolog
outcom
measur
microbiolog
object
studi
focus
determin
rel
quantiti
target
pathogen
bacteri
divers
use
cultureindepend
molecular
techniqu
standard
molecular
microbiolog
oper
procedur
develop
quantit
analysi
burkholderia
base
dna
microbiom
analysi
perform
ribosom
intergen
spacer
analysi
risa
use
rapid
qualit
measur
microbiota
follow
deep
sequenc
analysi
rrna
gene
quantif
identif
burkholderia
cepacia
complex
speci
present
sampl
carri
realtim
pcr
rpod
gene
sequenc
reca
gyrb
gene
respect
sequenc
compar
b
cepacia
complex
multilocu
sequenc
type
databas
accur
identif
sputum
sampl
examin
identifi
whether
infect
b
cepacia
complex
strain
remain
studi
bacteri
divers
present
burkholderia
studi
sampl
oligog
therapi
includ
statist
analysi
divers
chang
investig
result
background
recent
studi
demonstr
hypox
epitheli
necrosi
mucusobstruct
airway
trigger
spontan
neutrophil
inflamm
mice
via
releas
inhibit
pathway
antagonist
anakinra
reduc
airway
neutrophilia
structur
lung
damag
model
cf
lung
diseas
fritzsch
b
et
al
j
respir
crit
care
med
howev
effect
anakinra
airway
inflamm
antibacteri
host
defens
context
pseudomona
infect
remain
unknown
object
aim
studi
determin
vivo
effect
anakinra
neutrophil
inflamm
pseudomona
infect
wildtyp
mice
mice
cflike
lung
diseas
method
wildtyp
mice
treat
anakinra
bodi
weight
vehicl
nacl
alon
subcutan
bid
subsequ
challeng
p
aeruginosa
strain
cfumous
vehicl
pb
alon
intratrach
instil
h
pseudomona
infect
bronchoalveolar
lavag
bal
perform
analyz
use
differenti
cell
count
measur
proinflammatori
cytokin
cytometr
bead
assay
quantit
microbiolog
result
acut
infect
induc
robust
neutrophil
inflamm
wildtyp
mice
treatment
anakinra
reduc
neutrophil
wildtyp
mice
p
despit
reduct
airway
neutrophil
anakinra
treatment
neither
aggrav
acut
infect
wildtyp
mice
cfuml
untreat
vs
cfuml
treat
p
conclus
result
support
treatment
antagonist
anakinra
reduc
neutrophil
inflamm
without
exacerb
bacteri
infect
cflike
lung
diseas
mice
data
suggest
anakinra
may
use
novel
antiinflammatori
approach
control
overwhelm
neutrophil
airway
inflamm
without
aggrav
bacteri
infect
cf
howev
clinic
studi
warrant
test
safeti
efficaci
antiinflammatori
strategi
patient
cf
support
grant
european
commiss
framework
program
project
cfmatter
aim
determin
treatment
sputum
cf
patient
result
signific
decreas
total
sputum
microbi
load
microbi
load
key
cf
pathogen
p
aeruginosa
burkholderia
cepacia
complex
bcc
method
sputum
sampl
excess
clinic
requir
collect
cf
patient
chronic
colon
p
aeruginosa
bcc
sputum
plug
select
homogenis
repeat
passag
syring
tobramycin
tobramycin
phosphat
buffer
salin
pb
control
ad
total
viabl
count
measur
hour
total
viabl
count
perform
use
select
agar
plate
p
aeruginosa
bcc
count
nonselect
blood
agar
plate
use
determin
total
sputum
bacteri
load
result
demonstr
bactericid
activ
p
aeruginosa
sampl
test
reduc
total
viabl
count
detect
limit
hour
sampl
p
aeruginosa
sputum
load
approxim
cfug
sputum
figur
remain
sampl
p
aeruginosa
present
higher
load
approxim
cfug
sputum
initi
decreas
p
aeruginosa
viabl
count
howev
hour
signific
regrowth
p
aeruginosa
demonstr
activ
bcc
sputum
decreas
bcc
load
follow
treatment
less
appar
p
aeruginosa
total
sputum
bacteri
load
similar
treat
control
sputum
sampl
p
aeruginosa
bcc
sampl
also
evid
synergist
activ
tobramycin
p
aeruginosa
bcc
discuss
studi
demonstr
treatment
sputum
cf
patient
result
signific
decreas
microbi
load
key
respiratori
pathogen
moreov
signific
chang
total
load
bacteria
present
respiratori
microbiota
fund
depart
educ
learn
studentship
joanna
payn
alaxia
introduct
staphylococcu
aureu
highli
preval
pathogen
cystic
fibrosi
cf
patient
classic
identifi
earli
infanc
incid
aureu
infect
cf
patient
contribut
lung
diseas
increas
mortal
direct
rapid
identif
aureu
respiratori
specimen
cf
patient
challeng
clinic
laboratori
aim
studi
evalu
perform
new
chromogen
medium
intend
isol
aureu
variou
pulmonari
clinic
specimen
cf
patient
method
respiratori
sampl
cf
patient
test
chromid
tm
aureu
elit
said
biomerieux
chromid
tm
aureu
said
biomerieux
bbl
tm
chromagar
tm
aureu
bbl
becton
dickinson
columbia
blood
agar
cna
cna
biomerieux
three
read
perform
identif
chromogen
coloni
confirm
use
malditof
first
sensit
specif
select
evalu
independ
medium
signific
differ
bbl
said
cna
versu
said
test
accord
clsi
ie
perform
consid
significantli
differ
risk
includ
ci
differ
result
sensit
aureu
detect
cf
patient
said
consist
higher
compar
media
whatev
read
time
interestingli
differ
signific
said
compar
bbl
specif
chromogen
media
high
especi
said
bbl
whatev
read
time
select
said
significantli
higher
compar
media
base
number
nonchromogen
coloni
detect
medium
conclus
real
life
condit
chromid
tm
aureu
elit
demonstr
better
earlier
easier
detect
aureu
use
clinic
sampl
cf
patient
compar
classic
media
use
popul
implement
new
chromogen
medium
promis
improv
manag
cf
introduct
chronic
lung
colonis
pseudomona
aeruginosa
occur
cystic
fibrosi
patient
colonis
predomin
biofilm
correl
increas
morbid
mortal
well
increas
resist
antimicrobi
novel
therapi
effect
p
aeruginosa
therefor
urgent
requir
algin
oligog
shown
inhibit
pseudomon
motil
biofilm
assembi
motil
p
aeruginosa
regul
signal
pathway
la
rhl
pathway
environment
tempor
regul
hypothesis
oligog
affect
signal
pathway
p
aeruginosa
method
effect
oligog
acyl
homoserin
lacton
ahl
nbutyryllahl
n
lahl
studi
use
induct
inhibit
respect
chromobacterium
violaceum
biosensor
strain
time
cours
h
oligog
treat
p
aeruginosa
cultur
muellerhinton
mh
use
studi
virul
factor
pyocyanin
rhamnolipid
elastas
proteas
product
use
spectrophotometr
assay
ahl
quantifi
use
liquid
chromatographymass
spectrometri
lcm
express
qs
gene
lasir
rhlir
pile
pqsr
pvdq
studi
use
sybrgreen
realtim
rtpcr
qpcr
biofilm
h
extracellular
dna
edna
grown
mh
extract
quantifi
use
uvvi
spectrophotometri
normalis
cultur
biomass
dryweight
circular
dichroism
spectroscopi
cd
use
studi
interact
acetonitril
acet
acid
oligog
mm
nacl
mm
trishcl
ph
follow
maximum
molar
ratio
respect
result
signific
reduct
ahl
product
observ
follow
oligog
treatment
regul
la
rhl
respect
lcm
show
pronounc
decreas
product
time
whilst
chang
much
lower
level
less
obviou
reduct
ahl
time
cours
sampl
signific
oligog
although
everi
time
point
test
greatest
reduct
oligog
p
effect
oligog
virul
factor
express
appar
pyocyanin
signific
reduct
seen
h
oligog
limit
effect
virul
factor
sampl
h
p
qpcr
show
gene
express
significantli
affect
oligog
effect
virtual
h
predominantli
lasir
signific
differ
edna
seen
h
biofilm
cd
confirm
direct
interact
ahl
oligog
occur
conclus
oligog
affect
signal
pathway
p
aeruginosa
timedepend
manner
show
antibiofilm
effect
reflect
chang
pseudomon
pathogen
background
azithromycin
wide
use
macrolid
antibiot
cystic
fibrosi
cf
littl
known
safeti
longterm
use
report
side
effect
appli
shortterm
use
aim
studi
investig
possibl
azithromycininduc
toxic
kidney
liver
heart
chronic
azithromycin
therapi
whether
longterm
use
consid
safe
regard
condit
organ
method
cf
patient
two
medic
center
netherland
includ
cohort
studi
data
retrospect
extract
januari
decemb
hospit
electron
patient
file
anonym
transfer
databas
index
group
particip
use
azithromycin
least
three
uninterrupt
year
wherea
control
group
particip
use
azithromycin
least
three
uninterrupt
year
reflect
renal
function
estim
glomerular
filtrat
rate
egfr
use
calcul
mdrd
equat
monitor
hepat
function
liver
function
paramet
alanin
aminotransferas
alat
aspart
aminotransferas
asat
gammaglutamyl
transferas
ggt
alkalin
phosphatas
alp
total
bilirubin
tb
use
qtcinterv
use
determin
condit
heart
paramet
reflect
renal
hepat
function
analys
linear
mix
model
analysi
qtcinterv
determin
whether
popul
mean
index
control
group
equal
result
total
adult
patient
index
patient
patient
control
group
includ
studi
health
statu
index
patient
wors
condit
patient
control
group
sinc
presenc
cfrelat
diabet
cfrd
popul
mean
fev
bmi
differ
group
cfrd
fev
bmi
declin
egfr
time
index
group
differ
control
group
whole
studi
period
egfr
higher
index
group
liver
function
paramet
differ
cours
time
index
control
group
alat
asat
ggt
alp
tb
whole
studi
period
ggt
higher
index
group
differ
popul
mean
regard
qtcinterv
influenc
gender
male
femal
conclus
chronic
azithromycin
therapi
consid
safe
regard
risk
kidney
liver
heart
howev
rule
elev
ggt
index
group
due
azithromycininduc
toxic
use
studi
period
research
focu
possibl
azithromycininduc
liver
toxic
introduct
scedosporium
speci
second
common
filament
fungi
found
respiratori
tract
individu
cystic
fibrosi
cf
preval
greater
adult
cf
popul
although
isol
scedosporium
cf
sputum
thought
clinic
associ
pulmonari
morbid
systemat
research
topic
date
object
evalu
associ
scedosporium
poor
clinic
outcom
includ
decrement
lung
function
number
pulmonari
exacerb
adult
cf
popul
method
threeyear
cohort
studi
adult
cystic
fibrosi
foundat
patient
registri
conduct
januari
decemb
exclus
criteria
includ
age
younger
older
year
organ
transplant
baselin
insuffici
clinic
encount
defin
less
scedosporium
infect
defin
presenc
scedosporium
speci
respiratori
cultur
time
chang
lung
function
defin
absolut
chang
fev
percent
predict
baselin
lung
function
lung
function
end
studi
period
pulmonari
exacerb
defin
averag
number
care
episod
exacerb
requir
intraven
antibiot
per
year
multivari
linear
regress
perform
determin
relationship
scedosporium
decreas
fev
percent
predict
multivari
logist
regress
use
evalu
associ
scedosporium
pulmonari
exacerb
follow
independ
variabl
adjust
model
baselin
age
baselin
fev
percent
predict
pancreat
insuffici
genotyp
pseudomona
aeruginosa
colon
result
studi
period
januari
decemb
adult
individu
met
elig
criteria
studi
baselin
characterist
includ
mean
age
year
femal
homozyg
mean
bodi
mass
index
baselin
fev
percent
predict
pancreat
insuffici
cfrelat
diabet
pseudomona
aeruginosa
threeyear
preval
scedosporium
adult
popul
associ
scedosporium
chang
fev
percent
predict
baselin
end
studi
period
confid
interv
pvalu
howev
scedosporium
associ
increas
odd
averag
one
pulmonari
exacerb
per
year
studi
odd
ratio
ci
p
although
attenu
statist
signific
associ
remain
presenc
antifung
therapi
ci
pvalu
also
presenc
scedosporium
associ
greater
number
averag
care
episod
per
year
ci
pvalu
subgroup
least
year
followup
conclus
cf
adult
scedosporium
isol
airway
like
pulmonari
exacerb
without
infect
prospect
studi
need
examin
relationship
scedosporium
pulmonari
exacerb
introduct
chronic
p
aeruginosa
infect
associ
increas
morbid
mortal
cf
patient
initi
acquisit
p
aeruginosa
may
occur
via
transmiss
colonis
individu
contact
contamin
water
sourc
current
understand
risk
factor
acquisit
limit
aim
studi
examin
larg
sampl
environment
water
divers
sourc
method
environment
water
sampl
n
jacuzzi
hydrant
swim
pool
hot
tub
plung
pool
bottl
natur
miner
water
nmw
tap
spring
ice
machin
water
cooler
bore
shower
process
june
april
use
standard
bacteriolog
cultur
method
isol
identif
characteris
p
aeruginosa
parallel
p
aeruginosa
isol
obtain
health
servic
estat
water
underw
suscept
test
antipseudomon
antibiot
tobramycin
amikacin
ceftazadim
pipercillin
tazobactam
meropenem
ciproxin
colistin
aztreonam
accord
clsi
antibiot
suscept
methodolog
isol
also
examin
phenotyp
presenc
mucoidi
pigment
result
hot
tub
jacuzzi
like
environ
p
aeruginosa
isol
p
aeruginosa
isol
sampl
docksid
water
hydrant
bottl
nmw
sampl
sampl
swim
pool
rel
remain
sourc
yield
signific
number
posit
isol
antimicrobi
suscept
studi
health
estat
water
p
aeruginosa
isol
demonstr
pansensit
lack
mucoidi
isol
pigment
signific
differ
season
distribut
posit
isol
discuss
studi
highlight
ubiquit
natur
p
aeruginosa
given
cf
patient
frequent
counsel
make
lifestyl
chang
minim
p
aeruginosa
exposur
result
import
implic
may
mani
impos
lifestyl
chang
less
impact
acquisit
previous
believ
risk
factor
acquisit
remain
unclear
adher
nutrit
statu
genet
may
play
role
loss
cftr
function
associ
earlier
age
acquisit
rosenfeld
et
al
j
cyst
fibro
ireland
cf
popul
remain
infrequ
earli
isol
nonmucoid
pansensit
similar
isol
examin
studi
suggest
isol
health
servic
estat
water
sampl
origin
environment
sourc
conclus
p
aeruginosa
ubiquit
environ
recommend
cf
patient
make
lifestyl
chang
minimis
contact
may
ineffectu
work
need
identifi
highest
risk
acquisit
acknowledg
background
cf
lung
diseas
begin
earli
often
infanc
lower
airway
inflamm
obstruct
recent
investig
highlight
signific
role
virus
cf
pulmonari
exacerb
worldwid
acut
respiratori
ill
common
even
healthi
children
due
viral
infect
infant
cf
acquir
viral
infect
frequent
healthi
counterpart
higher
risk
lower
respiratori
tract
infect
declin
pulmonari
function
hospit
gap
exist
track
earli
respiratori
viral
infect
relat
lower
airway
inflamm
lung
function
abnorm
cf
infant
first
year
life
understand
contribut
respiratori
virus
earli
cf
lung
diseas
could
help
guid
manag
highlight
area
intervent
object
examin
frequenc
respiratori
virus
explor
associ
infect
respiratori
symptom
airway
inflamm
infant
lung
function
cf
infant
first
month
life
method
part
multicent
prospect
studi
infant
cf
diagnos
nb
enrol
evalu
clinic
everi
month
nasopharyng
np
swab
process
use
viral
pcr
obtain
visit
home
parent
time
respiratori
symptom
infant
pulmonari
function
test
use
rais
volum
techniqu
flexibl
bronchoscopi
bal
perform
site
bal
fluid
analyz
cell
count
differenti
inflammatori
marker
ttest
use
compar
outcom
respiratori
viru
vs
without
first
month
life
result
sixtynin
particip
enrol
mean
age
enrol
month
sd
particip
male
caucasian
homozyg
np
swab
test
posit
respiratori
viru
human
rhinoviru
common
follow
human
coronaviru
infant
symptomat
encount
common
symptom
cough
follow
nasal
congest
wheez
odd
viral
detect
increas
number
symptom
ci
signific
associ
respiratori
viru
pulmonari
function
fev
zscore
vs
lower
airway
inflammatori
marker
includ
vs
pgml
ne
vs
conclus
presenc
respiratori
viru
first
month
life
significantli
impact
lower
airway
inflamm
pulmonari
function
cf
infant
hrv
common
viru
line
data
healthi
infant
collect
viral
symptom
data
first
year
along
repeat
pulmonari
function
test
bronchoscopi
month
age
allow
assess
longitudin
chang
potenti
cumul
impact
repeat
viral
infect
also
futur
work
examin
use
antibiot
viral
infect
determin
current
practic
effect
pulmonari
outcom
method
date
subject
enrol
obtain
longitudin
sampl
includ
blood
oral
wash
sputum
fecal
sampl
sampl
obtain
baselin
month
period
stabil
two
subject
inhal
antibiot
sampl
obtain
initi
end
inhal
antibiot
cycl
rrna
gene
sequenc
miseq
illumina
use
assess
microbiom
composit
data
process
qiim
divers
withinsampl
divers
base
shannon
index
divers
betweensampl
divers
base
weight
unifrac
distanc
calcul
mont
carlo
simul
util
compar
differ
sampl
lefs
analysi
evalu
taxonom
differ
lda
result
suffici
sequenc
depth
achiev
sampl
median
iqr
read
per
sampl
divers
significantli
higher
fecal
sampl
p
lower
sputum
sampl
p
divers
plot
show
signific
differ
three
type
sampl
base
unifrac
procrust
analysi
mont
carlo
simul
show
similar
differ
sampl
oral
wash
sputum
fecal
subject
p
comparison
support
microbiota
ident
subject
differ
mucosa
comparison
baselin
time
point
show
signific
similar
two
time
point
sputum
sampl
mont
carlo
p
reach
statist
signific
oral
fecal
sampl
trend
toward
higher
divers
chang
sputum
subject
inhal
antibiot
compar
subject
therapi
vs
case
bronchoscopi
perform
show
achromobact
domin
bal
sampl
rel
abund
genu
much
lower
represent
sputum
oral
wash
respect
conclus
preliminari
data
support
prior
work
show
microbi
similar
crosspollin
differ
mucosa
site
stabil
microbiom
assess
initi
inhal
antibiot
therapi
bronchoscop
assess
lower
airway
microbiom
may
illustr
discrep
lower
airway
microbiota
sputum
pseudomona
aeruginosa
pathogen
observ
live
multicellular
aggreg
cf
airway
key
infect
characterist
includ
noninvas
behaviour
treatment
resist
attribut
aggreg
growth
bacteri
aggreg
typic
thought
result
activ
selfassembl
mechan
akin
observ
vitro
biofilm
howev
mani
cf
clinic
isol
unabl
form
biofilm
vitro
biofilm
format
gene
frequent
target
inactiv
mutat
inhost
evolut
furthermor
bacteria
cf
airway
may
surfac
attach
key
biofilminiti
signal
may
absent
observ
rais
possibl
vivo
aggreg
may
occur
mechan
independ
biofilm
format
investig
whether
environment
condit
cf
airway
could
spontan
promot
bacteri
aggreg
cf
airway
rich
host
polym
mucin
dna
polym
caus
particl
aggreg
via
crowd
mechan
call
deplet
aggreg
particl
aggreg
volum
avail
polym
maxim
entropi
system
incub
p
aeruginosa
synthet
peg
diseas
relev
mucindna
polym
found
bacteria
spontan
aggreg
relationship
bacteri
number
polym
concentr
aggreg
later
arrang
bacteria
within
aggreg
indic
peg
host
polym
caus
aggreg
deplet
mechan
also
found
deplet
aggreg
promot
toler
multipl
antibiot
within
minut
aggreg
format
control
experi
indic
polym
inactiv
antibiot
aggreg
respons
toler
phenotyp
furthermor
deplet
aggreg
promot
toler
strain
biofilm
format
disabl
indic
activ
biofilm
assembl
function
requir
aggreg
dispers
toler
retain
dispers
bacteria
minut
howev
dispers
bacteria
becam
sensit
antibiot
minut
dispers
fact
toler
multipl
antibiot
class
develop
rapidli
persist
time
aggreg
dispers
rais
possibl
deplet
aggreg
may
induc
tolerancepromot
stress
respons
role
produc
antibiot
toler
initi
focus
so
respons
induc
varieti
environment
stress
studi
fluoresc
gene
express
report
indic
so
respons
induc
within
aggreg
furthermor
inactiv
so
respons
sosregul
gene
induc
growth
arrest
markedli
reduc
aggregatemedi
toler
togeth
result
suggest
polymerrich
environ
cf
airway
secret
may
promot
bacteri
aggreg
via
deplet
mechan
result
stressinduc
growth
arrest
antibiot
toler
previous
shown
macrocycl
peptid
exhibit
antibacteri
activ
mice
chronic
pseudomona
aeruginosa
lung
infect
also
immun
modul
activ
yet
antiinflammatori
mechan
action
moa
poorli
understood
current
studi
aim
elucid
antiinflammatori
moa
vivo
use
gene
express
profil
method
chronic
airway
infect
establish
mice
via
intratrach
inject
p
aeruginosaembed
agaros
bead
aerosol
deliv
daili
day
lung
inflamm
assess
cell
count
bronchoalveolar
lavag
bal
fluid
microarray
analysi
identifi
differenti
express
gene
deg
bal
cell
lung
tissu
confirm
clinic
relev
anim
model
data
test
activ
ex
vivo
sputum
cell
cultur
spontan
expector
cf
sputum
sampl
obtain
inpati
outpati
sputum
immun
cell
cultur
ml
hour
antiinflammatori
effect
assess
measur
cytokin
concentr
elisa
result
treatment
mice
chronic
p
aeruginosa
airway
infect
induc
signific
reduct
neutrophil
lung
infiltr
versu
salin
treat
control
day
mean
day
mean
microarray
analysi
reveal
highli
downregul
gene
bal
lung
tissu
ipa
analysi
reveal
potenti
target
known
regul
express
shown
downregul
hour
sputum
cell
cultur
h
h
discuss
data
demonstr
potenti
therapeut
cf
lung
diseas
allevi
pulmonari
neutrophil
inflamm
furthermor
data
begin
indic
confirm
key
cellular
target
moa
name
data
help
direct
develop
futur
translat
moa
studi
acknowledg
fund
provid
cfri
webb
foundat
lead
caus
death
cystic
fibrosi
cf
patient
respiratori
failur
due
chronic
respiratori
infect
increas
cf
patient
exhibit
chronic
mrsa
infect
associ
increas
rate
lung
function
declin
failur
recov
acut
pulmonari
exacerb
increas
mortal
dasenbrook
ec
et
al
jama
mrsa
infect
young
cf
patient
often
grow
biofilm
resist
wildtyp
counterpart
antimicrobi
therapi
clearanc
immun
system
even
though
mrsa
infect
devast
clinic
fundament
gap
understand
dysfunct
immun
cf
lung
hamper
bacteri
clearanc
object
studi
perform
longitudin
sampl
cf
patient
measur
chang
correl
abil
mrsa
isol
form
biofilm
determin
effect
cftr
mutat
abil
macrophag
phagocytos
kill
mrsa
method
serial
sputum
sampl
obtain
patient
chronic
mrsa
infect
mrsapseudomona
aeruginosa
coinfect
quarterli
lab
visit
mrsa
isol
sputum
identifi
standard
morpholog
biochem
characterist
biofilm
format
quantifi
use
establish
polystyren
microtit
plate
assay
measur
phagocytosi
kill
mrsa
murin
macrophag
treat
cftr
inhibitor
vehicl
control
hour
follow
challeng
mrsa
variou
moi
follow
incub
bacteria
allow
phagocytosi
cell
wash
remov
extracellular
bacteria
incub
addit
hour
phagocytosi
assess
enumer
viabl
intracellular
staphylococci
bacteri
kill
measur
enumer
viabl
bacteria
use
standard
microbiolog
plate
result
conclus
result
suggest
macrophag
treat
exhibit
reduc
phagocytosi
mrsa
compar
untreat
macrophag
decreas
amount
viabl
mrsa
recov
treat
macrophag
compar
untreat
macrophag
compar
mrsa
recoveri
approxim
reduct
viabl
mrsa
recov
untreat
macrophag
suggest
kill
intracellular
bacteria
untreat
macrophag
howev
amount
mrsa
recov
treat
macrophag
differ
suggest
treatment
inhibit
bacteri
kill
result
suggest
defici
cftr
activ
macrophag
may
inhibit
phagocytosi
kill
mrsa
may
contribut
develop
chronic
mrsa
infect
cf
patient
introduct
burkholderia
cepacia
complex
bcc
repres
classif
genet
relat
bacteria
found
infect
cystic
fibrosi
cf
patient
infect
bcc
lead
spectrum
clinic
relev
diseas
rang
asymptomat
colon
unclear
signific
necrot
pneumonia
rapid
loss
lung
function
death
howev
presenc
portend
worsen
prognosi
pseudomona
aeruginosa
psa
similar
characterist
regard
success
erad
use
protocolbas
approach
detect
earli
date
standard
antibiot
erad
protocol
treatment
bcc
infect
describ
develop
empir
erad
protocol
center
treatment
protocol
consist
initi
day
therapi
term
induct
phase
includ
intraven
tobramycin
daili
kg
intraven
ceftazidim
gram
three
time
daili
trimethoprimsulfamethoxazol
two
tablet
twice
daili
inhal
tobramycin
mg
twice
daili
azithromycin
mg
daili
follow
complet
induct
phase
patient
receiv
addit
two
month
inhal
tobramycin
mg
twice
daili
trimethoprimsulfamethoxazol
tablet
twice
daili
azithromycin
mg
daili
term
consolid
phase
treatment
conduct
retrospect
chart
review
subject
treat
bcc
center
sputum
sampl
obtain
everi
three
month
follow
initi
protocol
pulmonari
function
test
bodi
mass
index
bmi
patient
defin
success
erad
one
year
neg
cultur
least
three
neg
cultur
result
patient
found
infect
bcc
sputum
cultur
six
patient
identifi
new
infect
place
erad
protocol
seven
patient
identifi
chronic
colonizationinfect
treat
intent
erad
sputum
sampl
obtain
week
initi
demonstr
clearanc
bcc
patient
place
erad
protocol
neg
bcc
cultur
maintain
patient
one
year
followup
signific
differ
seen
fev
predict
bmi
month
posterad
compar
preinfect
baselin
conclus
clearanc
bcc
use
standard
protocol
base
antibiot
sensit
success
one
year
result
clinic
stabil
select
patient
longterm
clinic
effect
bcc
erad
cf
patient
unclear
signific
requir
evalu
multicent
studi
util
protocol
bcc
erad
consid
patient
cystic
fibrosi
cf
detect
respiratori
pathogen
primari
clinic
microbiolog
concern
cultureindepend
rrna
gene
microbiom
sequenc
demonstr
improv
comprehens
sensit
compar
routin
cultur
cf
sputum
sampl
systemat
compar
cultur
detect
pathogen
furthermor
posit
molecular
test
cultureneg
sampl
unclear
signific
object
systemat
compar
rrna
gene
sequenc
cultur
pediatr
cf
patient
six
pathogen
staphylococcu
aureu
haemophilu
influenza
pseudomona
aeruginosa
burkholderia
cepacia
complex
stenotrophomona
maltophilia
achromobact
xylosoxidan
microbiom
profil
identifi
pathogen
cultureposit
neg
sampl
respect
cultureposit
associ
significantli
greater
rel
abund
ra
genu
cultureposit
sampl
averag
ra
nearli
greater
cultureneg
sampl
cultureposit
mucoid
pseudomona
aeruginosa
associ
greater
pseudomona
rel
abund
sequenc
cultureposit
nonmucoid
pseudomona
aeruginosa
stenotrophomona
haemophilu
staphylococcu
pseudomona
highli
preval
even
cultureneg
sampl
support
canadian
institut
health
research
p
aeruginosa
common
pathogen
cystic
fibrosi
airway
colon
nearli
twothird
cf
popul
importantli
p
aeruginosa
associ
persist
chronic
infect
increasingli
difficult
treat
erad
due
bacteria
abil
form
biofilm
develop
antibiot
resist
p
aeruginosa
strain
clinic
isol
close
relat
phylogenet
clinic
isol
show
high
level
virul
compar
sever
well
studi
p
aeruginosa
strain
especi
strain
virul
phenotyp
link
endotoxin
profil
pili
structur
pathogen
island
composit
type
iii
secret
system
ttss
activ
cytotox
toward
mammalian
cell
strain
also
show
distinct
profil
antibiot
resist
respect
commonli
studi
strain
p
aeruginosa
analysi
character
strain
variabl
increas
understand
bacteri
process
ultim
inform
clinic
manag
pseudomona
aeruginosa
order
nonredund
transposon
insert
mutant
librari
set
construct
use
strain
dr
fred
ausubel
lab
liberati
n
et
al
pna
massachusett
gener
hospit
librari
recent
transfer
yonkerhurley
lab
curat
distribut
scientif
commun
set
compos
singl
mutant
per
nonessenti
open
read
frame
select
comprehens
librari
insert
mutant
version
set
consist
approxim
mutant
repres
approxim
gene
arrang
microtit
plate
present
studi
describ
method
use
replic
set
design
maxim
number
copi
produc
minim
crosscontamin
set
consist
microtit
plate
divid
set
microtit
plate
process
consecut
week
gener
total
copi
destin
librari
distribut
qualiti
control
done
test
random
set
mutant
confirm
gene
ident
use
arbitrari
pcr
subsequ
sequenc
use
p
aeruginosa
strain
order
nonredund
transposon
insert
mutant
librari
referenc
public
attest
import
use
insert
mutant
librari
tool
character
understand
bacteri
process
genet
screen
use
set
contribut
understand
mechan
involv
antibiot
resist
bacteri
metabol
growth
biofilm
stabil
hostpathogen
interact
set
becom
import
resourc
cf
commun
continu
avail
undoubtedli
import
implic
advanc
treatment
cf
airway
infect
gene
homolog
fixl
rhizobi
fixlfixj
twocompon
system
fixl
sensori
histidin
kinas
detect
oxygen
tension
phosphoryl
transcript
factor
fixj
low
oxygen
lead
activ
fixk
gene
previou
work
identifi
fixlj
system
involv
biofilm
format
motil
persist
murin
model
refer
strain
b
dolosa
isol
index
patient
sever
year
colon
contain
point
mutat
fixl
gene
compar
ancestr
isol
studi
sought
understand
implic
mutat
fixmedi
phenotyp
method
construct
fixlj
delet
mutant
b
dolosa
strain
use
allel
replac
well
isogen
strain
complement
delet
mutant
either
fixl
refer
sequenc
strain
fixl
ancestr
sequenc
contain
fixj
refer
sequenc
also
complement
delet
mutant
fixl
detect
period
fev
declin
b
dolosainfect
patient
measur
swim
motil
well
abil
construct
form
biofilm
pvc
plate
murin
model
pneumonia
intranas
inocul
assess
abil
b
dolosa
strain
persist
lung
dissemin
spleen
measur
fixregul
gene
express
use
rnaseq
result
b
dolosa
carri
ancestr
fixl
sequenc
produc
significantli
p
biofilm
isogen
bacteria
carri
refer
fixl
sequenc
interestingli
b
dolosa
carri
ancestr
fixl
nonmotil
b
dolosa
carri
refer
sequenc
motil
murin
pneumonia
model
b
dolosa
carri
ancestr
fixl
sequenc
lower
viabl
bacteria
lung
spleen
day
postinfect
compar
b
dolosa
carri
refer
fixl
sequenc
p
use
rnaseq
found
gene
downand
upregul
respect
rel
entir
flagellar
biosynthet
pathway
downregul
consist
nonmotil
phenotyp
biofilm
motil
phenotyp
similar
conclus
b
dolosa
strain
carri
one
sever
fixl
point
mutat
aris
later
human
infect
less
abl
form
biofilm
motil
better
abl
persist
vivo
murin
lung
spleen
compar
b
dolosa
carri
ancestr
genotyp
fund
cystic
fibrosi
foundat
introduct
two
mechan
druginduc
haemolysi
describ
usual
extravascular
intravascular
haemolysi
caus
drugdepend
antibodi
ddab
extravascular
haemolysi
present
mild
less
sever
clinic
symptom
anaemia
wherea
intravascular
haemolysi
usual
manifest
rapid
destruct
red
blood
cell
caus
antibodymedi
complement
activ
lead
acut
clinic
symptom
interestingli
piperacillininduc
immun
haemolyt
anaemia
piha
case
investig
refer
laboratori
germani
patient
cystic
fibrosi
cf
therefor
investig
hypothesi
studi
higher
preval
piha
patient
cf
gener
popul
method
includ
patient
cf
older
year
admit
hospit
antibiot
treatment
past
transplant
exclus
criterion
blood
sampl
obtain
begin
end
given
intraven
treatment
direct
antiglobulin
test
dat
indirect
antiglobulin
test
iat
perform
use
standard
techniqu
posit
sampl
antibodi
differenti
done
ddab
investig
use
gel
techniqu
thu
prepar
drug
solut
use
exvivo
antigen
respect
incub
minut
presenc
patient
plasma
group
rbc
individu
prior
exposur
piperacillin
inform
concern
atopi
microbiolog
document
result
current
ongo
trial
patient
develop
piha
high
preval
compar
gener
expect
approxim
ddab
complement
activ
typic
extravascular
haemolysi
clinic
symptom
haemolysi
mild
even
though
drop
haemoglobin
pseudomona
aeruginosa
gramneg
opportunist
pathogen
chronic
infect
approxim
cystic
fibrosi
cf
patient
earli
adulthood
account
major
morbid
mortal
patient
develop
chronic
p
aeruginosa
infect
cf
lung
involv
format
highli
recalcitr
biofilm
commun
clinic
observ
note
acquisit
chronic
p
aeruginosa
infect
cf
patient
often
occur
respiratori
viral
season
new
p
aeruginosa
colon
occur
within
week
follow
respiratori
viral
infect
johansen
hk
hoibi
n
thorax
collinson
j
et
al
thorax
although
mechan
underli
interact
cf
lung
well
understood
recent
shown
respiratori
syncyti
viru
rsv
coinfect
stimul
increas
biofilm
growth
p
aeruginosa
airway
epitheli
cell
aec
mechan
depend
apic
releas
host
ironbind
protein
transferrin
suggest
nutrit
immun
compromis
aec
rsv
coinfect
hendrick
mr
et
al
pna
howev
mechan
transferrin
releas
aec
respiratori
viral
infect
remain
undefin
transferrin
mrna
protein
level
alter
aec
rsv
infect
suggest
altern
mechan
secret
hypothes
respiratori
viral
infect
alter
transferrin
traffick
within
aec
allow
apic
secret
therebi
promot
p
aeruginosa
biofilm
biogenesi
show
studi
extracellular
vesicl
releas
apic
aec
rsv
coinfect
enhanc
p
aeruginosa
biofilm
growth
extracellular
vesicl
significantli
increas
level
iron
chelat
iron
extracellular
vesicl
reduc
abil
stimul
p
aeruginosa
biofilm
growth
interestingli
rsv
infect
enhanc
transcytosi
apic
secret
transferrin
origin
basolater
compart
cell
load
onto
extracellular
vesicl
togeth
result
suggest
rsv
infect
redirect
transferrin
traffick
aec
result
load
transferrin
onto
apic
releas
extracellular
vesicl
util
iron
sourc
p
aeruginosa
form
biofilm
current
investig
pathway
rsv
infect
induc
transferrin
packag
secret
extracellular
vesicl
stimul
p
aeruginosa
biofilm
growth
data
suggest
novel
mechan
host
respons
viral
infect
contribut
develop
chronic
pulmonari
p
aeruginosa
infect
provid
mechanist
insight
understand
nutrit
immun
lung
introduct
progress
airway
obstruct
chronic
inflamm
infect
continu
lead
caus
morbid
mortal
cystic
fibrosi
cf
patient
rise
multidrugresist
mdr
pseudomona
aeruginosa
spark
ongo
search
novel
antibiot
use
treatment
cfrelat
respiratori
infect
ceftazidimeavibactam
avycaz
antimicrobi
agent
combin
gener
cephalosporin
ceftazidim
inhibitor
avibactam
zhanel
g
et
al
drug
approv
use
unit
state
intraabdomin
infect
chalhoub
h
et
al
j
antimicrob
chemoth
studi
test
suscept
mdr
p
aeruginosa
sputum
isol
collect
cf
patient
ceftazidimeavibactam
vitro
method
sputum
cultur
collect
cf
patient
year
age
known
colon
mdr
p
aeruginosa
isol
ceftazidim
resist
demonstr
resist
antibiot
routin
use
treat
p
aeruginosa
respiratori
infect
patient
demograph
spirometri
coexist
organ
cultur
collect
p
aeruginosa
isol
cultur
sensit
test
antipseudomon
antimicrobi
includ
ceftazidimeavibactam
suscept
studi
irb
approv
univers
texa
southwestern
medic
center
dalla
tx
result
p
aeruginosa
isol
collect
sensit
ceftazidimeavibactam
averag
mean
inhibitori
concentr
mic
mean
age
patient
sensit
strain
year
versu
resist
strain
p
averag
patient
cohort
significantli
differ
isol
sensit
ceftazidimeavibactam
versu
isol
resist
p
nonmucoid
p
aeruginosa
isol
sensit
ceftazidimeavibactam
mucoid
p
aeruginosa
isol
sensit
ceftazidim
avibactam
suggest
benefit
may
independ
morphotyp
importantli
isol
collect
extens
mdr
resist
greater
commonli
use
antipseudomon
antibiot
sensit
ceftazidimeavibactam
conclus
ceftazidimeavibactam
novel
antimicrobi
agent
demonstr
signific
activ
vitro
highli
resist
p
aeruginosa
isol
collect
cf
patient
understand
p
aeruginosa
gene
express
may
predict
ceftazidimeavibactam
resist
impact
use
agent
cf
patient
mdr
p
aeruginosa
remain
determin
townsend
narayanaswami
v
baker
wiesmann
w
synedgen
inc
claremont
ca
usa
background
limit
therapeut
option
enhanc
virul
properti
phenotyp
adapt
biofilm
format
contribut
lack
effect
therapi
nontubercul
mycobacteria
ntm
lung
biofilm
infect
associ
cystic
fibrosi
cf
recent
determin
ntm
specif
mycobacterium
abscessu
complex
mabsc
strain
form
biofilm
cf
lung
chronic
infect
contribut
rapid
clinic
deterior
due
chronic
inflamm
tissu
damag
thick
mucu
biofilm
format
cf
lung
render
therapeut
less
effect
seri
nontox
derivat
polyglucosamin
shown
broadli
activ
dermal
mucos
interfac
encompass
newli
develop
class
molecul
design
poli
acetyl
arginyl
glucosamin
paag
specif
deriv
nontox
solubl
biopolym
shown
potenti
wide
rang
antibiot
gramneg
gramposit
bacteria
effect
dissolv
biofilm
includ
mabsc
minim
biofilm
erad
concentr
mbec
assay
stationari
tissu
cultur
plate
biofilm
assay
use
examin
remov
biofilm
form
sever
clinic
isol
mabsc
associ
cystic
fibrosi
respect
studi
demonstr
abil
disrupt
mabsc
biofilm
goal
support
effect
treatment
method
mbec
assay
parker
ae
et
al
j
microbi
method
stationari
biofilm
assay
perform
use
mabsc
strain
isol
sputum
cystic
fibrosi
patient
compar
biofilm
reduct
strain
obtain
atcc
cystic
fibrosi
research
center
birmingham
alabama
concentr
rang
significantli
reduc
ntm
biofilm
follow
oncedaili
treatment
p
treatment
significantli
reduc
preform
ntm
biofilm
dose
depend
manner
treatment
p
biofilm
less
bacteria
untreat
biofilm
conclus
effect
antibiofilm
agent
facilit
remov
biofilm
vitro
studi
show
ntm
biofilm
remov
dosedepend
manner
biofilm
dissolv
activ
may
result
posit
therapeut
outcom
particularli
cystic
fibrosisrel
ntm
infect
result
patient
identifi
median
age
present
rang
male
femal
pancreat
insuffici
pancreat
suffici
diabet
mabsc
isol
subspeci
abscessu
subspeci
massieliens
remain
unknown
patient
coinfect
mac
aspergillu
fumigatu
function
erm
gene
present
isol
patient
render
clarithromycin
resist
patient
receiv
combin
parenter
imipenemamikacincefoxitininh
amikacinor
zyvoxclarithromycin
averag
month
patient
die
advanc
cf
lung
diseas
receiv
lung
transplant
rest
aliv
well
therapi
microbiolog
respons
divid
group
neg
cultur
posit
cultur
group
transient
neg
posit
cultur
group
never
neg
countabl
coloni
group
persist
smear
cultur
posit
patient
distribut
within
subgroup
summar
tabl
conclus
know
subspeci
mabsc
presenc
function
erm
gene
critic
therapeut
algorithm
mabsc
infect
cf
factor
determin
true
morbid
mabsc
infect
cf
background
east
tennesse
children
hospit
patient
cystic
fibrosi
cf
routin
undergo
bronchoscopi
obtain
definit
endobronchi
cultur
guid
antibiot
therapi
howev
standard
practic
mani
cystic
fibrosi
center
use
less
invas
procedur
cf
foundat
assert
enough
evid
recommend
bronchoscopi
routin
cultur
therefor
recommend
routin
oropharyg
op
cultur
individu
cf
mogayzel
jr
p
et
al
annal
at
object
purpos
analysi
provid
evid
routin
use
bronchoscopi
obtain
definit
endobronchi
cultur
method
qualit
retrospect
data
analysi
use
cff
patient
registri
report
mechan
cultur
perform
cf
clinic
either
via
op
swab
sputum
compar
cultur
obtain
via
bronchoscopi
patient
defin
differ
discrep
report
cultur
collect
includ
multipl
differ
pathogen
found
one
incid
count
one
collect
differ
differ
found
would
merit
altern
cours
treatment
base
bronchoscop
cultur
versu
sputum
op
cultur
design
treatabl
differ
result
total
incid
analyz
incid
includ
cultur
collect
within
day
result
display
tabl
conclus
base
result
data
analysi
feel
continu
practic
routin
bronchoscopi
appropri
result
better
recoveri
pathogen
organ
see
high
percentag
discrep
cultur
obtain
cf
clinic
cultur
obtain
bronchoscopi
major
differ
also
consid
clinic
signific
ie
patient
would
treat
differ
antibiot
sever
limit
analysi
howev
exampl
unknown
patient
expos
new
pathogen
treat
oral
antibiot
time
clinic
visit
bronchoscopi
feel
prospect
studi
design
warrant
determin
valid
signific
find
addit
investig
differ
specif
pathogen
analysi
percentag
discrep
rel
consist
regardless
age
group
method
initi
cultur
pseudomona
aeruginosa
infect
cf
airway
associ
decreas
lung
function
increas
hospit
shorter
lifespan
p
aeruginosa
natur
antibiot
resist
make
difficult
treat
convent
therapi
furthermor
pathogen
regularli
augment
surviv
strategi
form
surfaceassoci
group
aggreg
known
biofilm
highli
toler
antibiot
anoth
strategi
involv
format
metabol
repress
cell
resist
antibiot
kill
known
persist
henc
complet
clearanc
p
aeruginosa
chronic
infect
via
antibiot
therapi
often
imposs
group
sought
overcom
p
aeruginosa
antibiot
resist
toler
develop
antivirul
compound
small
molecul
screen
identifi
inhibitor
mvfr
master
regul
quorumsens
pathway
affect
virul
factor
product
biofilm
persist
format
starkey
et
al
plo
pathog
inhibitor
fundament
differ
tradit
antimicrobi
therapi
specif
target
quorumsens
pathway
rather
basic
biolog
function
limit
select
pressur
resist
earli
studi
show
inhibitor
well
toler
enhanc
bacteri
clearanc
burn
model
infect
goal
project
test
whether
reduc
airway
damag
enhanc
clearanc
chronic
pulmonari
infect
date
test
effect
airway
cell
cfbe
found
signific
cytotox
therapeut
dose
airway
cell
cocultur
experi
demonstr
efficaci
limit
cytotox
p
aeruginosa
grown
plankton
dramat
decreas
cytotox
seen
p
aeruginosa
biofilm
biofilm
cfu
affect
system
cytokin
analys
biofilm
infect
show
strong
reduct
well
reduct
treatment
also
test
efficaci
drug
resistanttoler
pathogen
coexist
lung
p
aeruginosa
human
infect
similarli
form
persist
cell
escherichia
coli
staphylococcu
aureu
klebsiella
pneumonia
acinetobact
baumanii
burkholderia
addit
speci
test
inhibitor
monoand
polymicrobi
infect
set
airway
cell
expect
inhibitor
show
littl
effect
virul
speci
grown
either
plankton
biofilm
demonstr
specif
compound
importantli
inhibitor
efficaci
reduc
p
aeruginosa
virul
diminish
presenc
speci
suggest
polymicrobi
natur
cf
infect
obstacl
therapeut
studi
also
reveal
interest
interspeci
interact
p
aeruginosa
biofilm
infect
biofilm
polymicrobi
infect
preliminari
result
indic
may
serv
valuabl
therapeut
treatment
cf
lung
infect
effort
assess
inhibitor
efficaci
vivo
ongo
cystic
fibrosi
transmembran
conduct
regul
cftr
campactiv
chlorid
channel
play
critic
role
phagocyt
host
defens
howev
activ
neutrophil
regul
cftr
channel
distribut
subcellularli
well
defin
address
issu
multipl
antibodi
differ
cftr
domain
test
examin
cftr
express
human
peripher
blood
neutrophil
flow
cytometri
data
confirm
rest
neutrophil
pronounc
cftr
express
activ
neutrophil
vitro
solubl
particul
agonist
significantli
increas
cftr
express
level
induc
cftr
redistribut
cell
surfac
cftr
mobil
correl
cellsurfac
recruit
formyl
peptid
receptor
secretori
vesicl
exocytosi
intriguingli
neutrophil
patient
despit
express
mutant
cftr
show
littl
cellsurfac
mobil
upon
stimul
normal
neutrophil
effect
target
cftr
phagosom
neutrophil
impair
process
result
defici
hypochlor
acid
hocl
product
taken
togeth
activ
neutrophil
regul
cftr
distribut
target
chlorid
channel
subcellular
site
activ
neutrophil
fail
achiev
target
thu
undermin
host
defens
function
method
conduct
retrospect
chart
review
cf
patient
receiv
lung
transplant
institut
determin
preval
fungal
lung
isol
prior
transplant
impact
incid
invas
fungal
infect
first
month
transplant
fungemia
graft
fungal
infect
evalu
transplant
result
among
cf
patient
receiv
lung
transplant
least
one
fungal
isol
respiratori
sampl
sputum
tracheal
aspir
bal
prior
lung
transplant
fungi
isol
includ
mold
common
aspergillu
fumigatu
aspergillu
speci
scedosporium
apiospermum
fusarium
yeast
candida
albican
common
candida
speci
unspecifi
yeast
least
two
isol
organ
consid
persist
infect
among
posit
respiratori
cultur
within
month
prior
transplant
fungal
isol
blood
andor
lower
respiratori
tract
within
one
month
transplant
organ
isol
transplant
ident
pretranspl
isol
patient
specif
organ
includ
c
albican
c
glabrata
c
parapsilosi
trichosporon
penicillium
unspecifi
yeast
one
patient
grew
coccidiod
imiti
isol
recipi
prior
transplant
presum
donorderiv
intraop
donor
bronchial
cultur
eight
recipi
grew
c
albican
subsequ
growth
recipi
group
two
death
transplant
hospit
attribut
fungal
infect
three
patient
fungemia
immedi
postop
period
without
invas
fungal
diseas
treatment
protocol
chang
treat
everi
lung
transplant
recipi
extend
cours
oral
azol
treatment
inhal
amphotericin
b
first
one
two
week
surgeri
death
invas
fungal
diseas
patient
chronic
fungal
pulmonari
infect
recipi
coccidiomycosi
transplant
conclus
invas
fungal
infect
occur
cf
patient
within
one
month
bilater
lung
transplant
includ
two
death
recipi
donor
fungal
colonizationinfect
prior
transplant
associ
posttranspl
fungal
diseas
cf
patient
unabl
predict
risk
factor
pretranspl
cultur
fungal
cultur
collect
routin
respiratori
tract
help
assess
risk
posttranspl
infect
select
periand
postop
antifung
regimen
cf
lung
transplant
recipi
current
studi
util
molecular
signatur
present
outbreak
strain
name
two
singl
nucleotid
polymorph
snp
rpob
gene
identif
subtyp
among
nonoutbreak
clinic
mma
noncf
patient
wg
perform
explor
genet
divers
evolutionari
histori
isol
molecular
signatur
compar
prior
outbreak
strain
method
perform
wg
mma
isol
cohort
noncf
patient
repres
state
unit
state
us
includ
nonoutbreak
isol
contain
rpob
signatur
compar
genom
cfderiv
outbreak
mma
isol
uk
washington
epidem
soft
tissu
mma
isol
brazil
abscessu
us
europ
asia
use
bioinformat
phylogenom
estim
genet
divers
among
clinic
abscessu
popul
core
genom
ie
snp
accessori
genom
includ
mobil
genet
element
plasmid
result
conclus
base
core
genom
analys
major
nonoutbreak
mma
rpob
signatur
cluster
genet
similar
clade
includ
outbreak
cf
well
noncf
isol
howev
brazilian
epidem
isol
subgroup
us
noncf
isol
fell
distinct
lineag
outsid
cluster
examin
accessori
genom
variat
suggest
complex
evolutionari
histori
mma
subtyp
present
variou
region
world
among
dispar
patient
subpopul
key
differ
outbreak
nonoutbreak
mma
strain
remain
delin
discuss
support
ntm
center
excel
cfffund
colorado
cf
research
develop
program
nation
jewish
health
pott
foundat
owen
foundat
amon
g
carter
foundat
pugazhenthi
v
bhakta
zn
zobel
j
young
dc
citi
ut
usa
pharmaci
intermountain
primari
children
hospit
salt
lake
citi
ut
usa
introduct
stenotrophomona
maltophilia
emerg
opportunist
pathogen
affect
cystic
fibrosi
cf
patient
cystic
fibrosi
foundat
cff
patient
registri
report
averag
annual
increas
cf
sputum
isol
colon
maltophilia
cf
patient
independ
associ
declin
predict
forc
expiratori
volum
second
acut
pulmonari
exacerb
ape
hospit
lung
transplant
increas
mortal
mani
barrier
maltophilia
treatment
includ
multidrug
resist
requir
combin
multipl
antibiot
current
limit
publish
studi
treatment
guidelin
aid
clinician
select
antibiot
ape
due
maltophilia
infect
object
primari
purpos
studi
investig
current
antibiot
treatment
practic
maltophilia
infect
cf
patient
cffaccredit
care
center
unit
state
secondari
object
includ
describ
epidemiolog
maltophilia
cffaccredit
care
center
identifi
barrier
treatment
method
electron
survey
design
via
surveymonkey
distribut
cffaccredit
care
center
unit
state
complet
center
director
design
repres
period
survey
includ
question
regard
cf
center
demograph
incid
maltophilia
infect
antibiot
use
treatment
specif
respond
ask
select
commonli
use
antibiot
outpati
inpati
dose
strategi
monitor
paramet
result
survey
yield
respons
rate
particip
state
respons
pediatr
adult
patient
popul
pediatr
popul
cffaccredit
care
center
least
one
patient
colon
maltophilia
new
case
past
year
similarli
adult
popul
cffaccredit
care
center
least
one
patient
colon
maltophilia
new
case
past
year
commonli
use
antibiot
outpati
inpati
set
trimethoprimsulfamethoxazol
tetracyclin
levofloxacin
ceftazidim
high
variabl
medic
chosen
well
dose
strategi
monitor
individu
antibiot
frequent
report
barrier
treatment
maltophilia
includ
lack
research
antibiot
resist
antibiot
shortag
overal
respond
state
need
exist
clinic
practic
guidelin
aid
treatment
maltophilia
infect
conclus
treatment
practic
manag
maltophilia
infect
cf
patient
adult
pediatr
cffaccredit
care
center
highli
variabl
studi
highlight
need
clinic
research
clinic
practic
guidelin
cf
patient
infect
maltophilia
first
line
host
defens
airway
epithelium
compromis
absenc
cftr
function
howev
challeng
explain
loss
cftr
function
induc
excess
lung
inflamm
robust
inflammatori
respons
defend
cf
patient
bacteri
infect
cf
airway
epitheli
cell
clearli
contribut
proinflammatori
environ
cf
airway
adequ
explain
failur
cf
patient
innat
immun
respons
kill
clear
bacteria
identifi
understand
relev
compon
innat
host
defens
system
regul
cf
patient
benefici
design
implement
futur
therapeut
macrophag
one
kind
profession
phagocyt
play
import
role
innat
host
defens
absenc
cftr
myeloidderiv
cell
lead
impair
resolut
infect
elev
inflamm
mice
also
increas
cell
number
impair
bactericid
activ
cf
macrophag
report
murin
human
cf
lung
suggest
abnorm
macrophag
function
could
partial
contribut
impair
innat
immun
cf
patient
mous
bone
marrowderiv
macrophag
bmdm
matur
homogen
macrophag
propag
cultur
ex
vivo
model
studi
regard
macrophag
function
wt
cf
bone
marrow
isol
mous
leg
differenti
macrophag
treatment
mcsf
macrophag
coloni
stimul
factor
confirm
stain
tissu
alveolar
macrophag
secret
proinflammatori
cytokin
level
mediat
report
significantli
higher
cf
sourc
rel
noncf
tissu
examin
express
unstimul
cell
cell
expos
variou
stimuli
found
differ
wt
cf
bmdm
term
proinflammatori
cytokin
regardless
stimul
state
epigenet
chang
report
macrophag
chronic
lung
diseas
copd
perform
chipseq
antibodi
wt
cf
bone
marrowderiv
macrophag
preliminari
data
show
obviou
differ
epigenet
modif
antibodi
wt
cf
bmdm
data
compar
rnaseq
profil
fulli
determin
epigenet
profil
differ
cf
noncf
macrophag
baselin
stimul
profil
compar
current
data
impli
cf
macrophag
phenotyp
acquir
upon
migrat
lung
thu
similar
experi
perform
mous
alveolar
macrophag
provid
clue
regard
macrophag
affect
cftr
absenc
well
epigenom
respond
introduct
recent
emphasi
homebas
healthcar
us
present
uniqu
challeng
clinician
method
use
hospit
often
difficult
appli
home
set
exampl
therapeut
drug
level
monitor
tdm
iv
tobramycin
cystic
fibrosi
patient
current
exist
standard
home
set
hypothes
method
tobramycin
tdm
tailor
home
set
would
improv
patient
care
method
exist
tdm
method
home
iv
tobramycin
adult
cf
patient
assess
limit
new
method
aim
mitig
limit
devis
implement
inform
collect
period
month
implement
exist
tdm
method
first
month
entail
home
nurs
draw
true
trough
postdos
peak
pharmacist
would
appli
level
peaktrough
goal
latter
month
new
tdm
method
use
entail
home
nurs
draw
random
level
hour
postdos
pharmacist
would
appli
preferenti
inpati
kinet
data
altern
populationderiv
kinet
data
random
level
extrapol
peak
trough
would
appli
peaktrough
goal
dettli
equat
use
populationderiv
extrapol
inpati
halfliv
tabul
patient
group
staff
survey
observationsimpress
result
initi
assess
exist
tdm
method
reveal
two
primari
limit
frequent
skew
undetect
level
dose
draw
schedul
difficulti
retrospect
review
group
show
order
level
miss
drawn
patient
total
patientweek
trough
undetect
anoth
trough
peak
suspect
skew
valid
peak
trough
extrapol
time
retrospect
review
new
method
group
show
order
level
miss
drawn
patient
total
patientweek
level
detect
inpati
data
avail
patient
peak
trough
extrapol
time
dettlideriv
data
appli
peak
trough
often
consist
high
low
individu
patient
dettlideriv
halfliv
compar
inpati
halfliv
patient
equat
averag
accuraci
individu
accuraci
rang
averag
nurs
respons
entir
favor
chang
cite
increas
schedul
flexibl
greater
patient
freedom
primari
reason
pharmacist
respons
mix
cite
abil
achiev
peaktrough
favor
difficulti
interpret
result
primari
drawback
conclus
hometailor
method
tobramycin
tdm
implement
patient
care
improv
evidenc
fewer
miss
level
fewer
level
drawn
per
patientweek
increas
valid
peaktrough
extrapol
increas
dosedraw
schedul
flexibl
increas
patient
freedom
investig
need
develop
populationderiv
equat
greater
individu
patient
specif
introduct
ivacaftor
shown
clinic
effect
intervent
cf
patient
mutat
effect
second
host
system
name
colonisinginfect
bacteria
larg
unknown
howev
known
bacteria
also
possess
chlorid
ion
channel
remain
unclear
potenti
interfer
ivacaftor
bacteri
chlorid
channel
potenti
manifest
increaseddecreas
antibiot
suscept
aim
observ
studi
examin
sever
phenotyp
characterist
p
aeruginosa
pa
includ
antibiot
suscept
patient
commenc
ivacaftor
year
compar
microbiolog
twoyear
period
preced
ivacaftor
therapi
method
archiv
microbiologyrel
data
examin
adult
cf
patient
two
year
preand
post
commenc
ivacaftor
therapi
follow
microbiolog
characterist
examin
antibiot
treatment
oral
ivmonth
ii
rate
mucoidnonmucoid
pa
isol
iii
densiti
mucoidmonmucoid
pa
iv
antibiot
suscept
mucoidnonmucoid
pa
antibiot
class
aminoglycosid
gentamicin
tobramycin
amikacin
temocillin
ceftazidim
piperacillintazobactam
aztreonam
imipenem
meropenem
polymixin
colistin
fluoroquinolon
ciprofloxacin
resultsdiscuss
signific
differ
number
oral
antibiot
coursesmonth
ivacaf
therapi
coursesmonth
respect
howev
signific
reduct
relat
number
iv
treatmentsmonth
coursesmonth
respect
none
patient
neg
mucoid
pa
prior
ivacaftor
therapi
gain
mucoid
pa
approxim
onefifth
patient
lost
mucoid
pa
treatment
overal
signific
reduct
rate
densiti
mucoid
pa
isol
respect
signific
differ
rate
densiti
nonmucoid
pa
isol
therapi
respect
follow
ivacaftor
therapi
antibiot
suscept
total
pa
isol
significantli
increas
ceftazidim
piperacillin
tazobactam
aztreonam
meropenem
mucoid
pa
ceftazidim
antibiot
yield
increas
suscept
case
nomucoid
pa
ceftazidim
piperacillintazobactam
meropenem
antibiot
yield
increas
suscept
conclus
find
studi
indic
chang
microbiolog
pa
isol
patient
follow
ivacaftor
therapi
term
phenotyp
growth
antibiot
suscept
howev
clear
yet
pa
becom
suscept
agent
includ
cephalosporin
carbapenem
warrant
investig
bensman
jayn
jg
trinh
k
bering
p
univ
southern
california
lo
angel
ca
usa
background
airway
neutrophilia
promin
hallmark
cystic
fibrosi
cf
lung
diseas
posit
correl
diseas
sever
addit
neutrophil
associ
protein
ie
ne
instrument
perpetu
inflammatori
condit
mmp
inhibit
vitro
shown
reduc
mmpgener
matrikin
chemoattract
therefor
may
hold
therapeut
benefit
diseas
cf
object
evalu
therapeut
potenti
global
mmp
inhibit
murin
model
cf
airway
infect
inflamm
method
murin
respiratori
infect
model
mucoid
pa
impregn
agaros
bead
x
cfu
intratrach
instil
lung
mice
mice
receiv
daili
mgkg
intranas
intraperiton
ip
administ
normal
salin
group
lung
bacteri
burden
bacteria
bal
homogen
lung
tissu
quantifi
day
postinfect
inflamm
burden
bal
leukocyt
leukocyt
popul
bodi
weight
bal
cytokin
also
determin
result
inflamm
burden
ip
reduc
airway
leukocytosi
compar
control
p
bal
cell
differenti
reveal
reduct
neutrophil
ip
treat
mice
compar
control
p
differ
airway
leukocytosi
howev
increas
airway
neutrophil
treat
compar
salin
control
mice
p
weight
chang
baselin
significantli
differ
ip
compar
ip
control
mice
howev
mice
recov
slower
control
mice
start
day
p
persist
day
p
bal
tnf
kc
amphiregulin
differ
compar
control
lung
bacteri
burden
differ
cfuslung
ip
mice
compar
control
conclus
system
intrans
appear
benefici
reduc
airway
neutrophilia
potenti
metalloproteinas
inhibitor
antiinflammatori
agent
cf
warrant
investig
associ
cystic
fibrosi
cf
nontubercul
mycobacterium
ntm
becom
grow
concern
among
cf
popul
unlik
mycobacterium
tuberculosi
ntm
found
within
environ
histor
believ
transmiss
persontoperson
howev
research
gain
interest
investig
transmiss
cf
patient
mycobacteriolog
laboratori
nation
jewish
health
njh
nation
refer
laboratori
special
growth
detect
identif
antimicrobi
suscept
test
ntm
grant
cf
foundat
cff
bank
character
cf
ntm
isol
nationwid
biorepositori
made
possibl
furthermor
cf
ntm
isol
made
avail
qualifi
investig
method
cf
ntm
isol
variou
collect
date
either
clinic
research
accept
biorepositori
clinic
sampl
log
daili
technic
staff
upon
submiss
furthermor
outgo
cf
final
report
record
build
comprehens
record
cf
ntm
isol
submit
laboratori
cf
ntm
isol
record
check
puriti
prep
isol
intact
genom
dna
freezedown
pure
dna
extract
singl
isol
coloni
complet
use
zymo
research
genom
dna
clean
kit
design
analysi
via
next
gener
sequenc
flash
freez
methodolog
accomplish
use
dri
ice
ethanol
isol
frozen
aliquot
store
thermo
scientif
tsx
seri
freezer
vdrive
assur
maximum
preserv
avail
futur
research
endeavor
biorepositori
databas
construct
order
store
complet
document
cf
ntm
isol
includ
cultur
patient
inform
identif
antimicrobi
suscept
test
depend
submitt
clinic
request
geograph
locat
whole
genom
sequenc
result
databas
also
valuabl
catalog
frozen
aliquot
locat
subsequ
retriev
frozen
aliquot
process
allow
longitudin
data
store
among
patient
isol
well
geograph
locat
healthcar
facil
result
far
njh
mycobacteriolog
laboratori
obtain
approxim
cf
ntm
isol
biorepositori
coordin
start
facil
includ
new
york
texa
washington
new
jersey
organ
isol
transfer
concern
ntm
cluster
even
persontoperson
transmiss
relat
cf
patient
isol
inventori
expect
increas
least
cultur
per
month
without
addit
public
attent
colorado
cf
research
develop
program
project
gain
support
expans
cf
ntm
biorepositori
progress
goal
bank
cf
ntm
isol
nationwid
support
cfffund
colorado
cf
research
develop
program
nation
jewish
health
inform
visit
http
wwwnationaljewishorgcoloradocfresearchanddevelopmentprogramhom
much
research
focus
macrophag
less
known
cellular
signal
pathway
regul
macrophag
repar
properti
recent
studi
demonstr
inhibit
pathway
reduc
macrophag
proinflammatori
respons
lp
stimul
howev
whether
pathway
function
regul
repar
properti
macrophag
remain
unknown
object
determin
whether
inhibitor
meki
therapeut
administr
reduc
infectioninduc
lung
injuri
modul
macrophag
function
promot
resolut
inflamm
method
murin
bone
marrowderiv
bmdm
alveolar
macrophag
human
monocytederiv
macrophag
mdm
use
studi
effect
mekitreat
modul
macrophag
gene
express
efferocytosi
fluoresc
label
apoptot
cell
reveal
contribut
meki
acut
airway
injuri
vivo
meki
vehicl
administ
via
intraperiton
ip
inject
day
postintratrach
challeng
e
coli
lp
p
aeruginosa
strain
pak
weight
loss
monitor
track
diseas
immun
cell
popul
bal
character
flow
cytometri
cytospin
day
postchalleng
result
report
three
distinct
observ
support
hypothesi
meki
may
use
therapeut
promot
repar
properti
macrophag
reduc
acut
airway
inflamm
first
mekitreat
bmdm
either
wildtyp
cftrmice
increas
gene
express
part
increas
phosphoryl
treatment
second
mekitreat
increas
murin
bmdm
human
mdm
efferocytosi
apoptot
cell
mechan
independ
polar
coincid
increas
macrophag
surfac
express
protein
mediat
efferocytosi
mertk
third
meki
treatment
lp
challeng
significantli
reduc
airway
inflamm
increas
weightloss
recoveri
compar
vehicletr
mice
addit
mekitreat
follow
p
aeruginosa
infect
significantli
reduc
diseas
compar
vehicletr
control
mice
determin
weight
loss
lung
inflamm
bacteri
count
conclus
futur
studi
result
show
meki
promot
repar
properti
macrophag
reduc
lung
inflamm
murin
model
lung
injuri
pneumonia
futur
studi
evalu
vivo
role
meki
administr
cftrmice
lp
challeng
infect
model
determin
therapeut
strategi
reduc
detriment
airway
inflamm
view
cystic
fibrosi
cf
commun
optim
infect
control
practic
evolv
year
past
thought
patient
cf
rare
acquir
organ
cf
patient
recent
data
suggest
patienttopati
transmiss
possibl
increas
evid
implement
strict
infect
control
practic
cf
clinic
inpati
unit
decreas
spread
pathogen
bacteria
updat
infect
prevent
control
guidelin
cf
reflect
emerg
viewpoint
organ
transmiss
cf
guidelin
institut
cf
center
august
object
determin
effect
implement
new
infect
control
recommend
incid
preval
pathogen
organ
patient
one
cf
center
method
singl
center
prospect
studi
quarterli
data
obtain
incid
proport
patient
new
acquisit
preval
proport
patient
cultur
posit
organ
select
pathogen
bacteri
organ
commonli
found
patient
cf
four
quarter
implement
new
guidelin
compar
statist
signific
differ
result
respiratori
cultur
collect
patient
year
prior
implement
guidelin
center
patient
follow
year
annual
preval
rate
common
organ
year
guidelin
implement
shown
tabl
quarterli
preval
incid
rate
compar
organ
time
period
signific
chang
seen
institut
guidelin
conclus
signific
differ
incid
preval
nine
common
pathogen
first
year
implement
new
cf
foundat
infect
control
guidelin
ongo
data
collect
analysi
perform
determin
signific
decreas
occur
time
nation
data
analysi
need
determin
result
singl
center
studi
gener
progress
loss
lung
function
due
pseudomona
aeruginosa
infect
major
caus
morbid
mortal
cystic
fibrosi
p
aeruginosa
infect
typic
concurr
colon
oral
microbiota
follow
secondari
infect
bacteri
fungal
pathogen
burkholderia
aspergillu
speci
highdens
p
aeruginosa
popul
found
cf
airway
produc
signific
concentr
secret
metabolit
includ
least
quinolonebas
small
molecul
one
highli
abund
hqno
detect
micromolar
concentr
cf
sputum
show
physiolog
level
hqno
suppress
innat
immun
function
although
dysfunct
mechan
clearanc
cf
airway
well
character
cf
patient
also
seem
illdefin
defici
innat
immun
cell
function
difficulti
erad
pathogen
airway
despit
presenc
high
number
phagocyt
innat
immun
cell
kill
extracellular
bacteria
via
phagocytosi
subsequ
oxid
burst
phagosom
product
high
level
nitric
oxid
reactiv
oxygen
speci
ro
phagocytosi
oxid
burst
activ
tolllik
receptor
tlr
signal
respons
pathogen
activ
phagocyt
undergo
dramat
metabol
shift
order
gener
energi
reduc
potenti
requir
sustain
bactericid
oxid
burst
stimul
tlr
pathogen
induc
metabol
shift
requir
phagocyt
produc
ro
activ
kinas
mammalian
target
rapamycin
mtor
show
treat
macrophag
physiolog
level
hqno
inhibit
oxid
burst
prevent
phagocyt
kill
p
aeruginosa
burkholderia
multivoran
staphylococcu
aureu
data
show
treat
macrophag
hqno
prevent
activ
mtor
tlr
agonist
host
cell
mtor
neg
regul
ampactiv
kinas
ampk
central
sensor
cellular
energi
stress
increas
amp
atp
ratio
primari
sourc
atp
eukaryot
cell
oxid
phosphoryl
mitochondri
membran
hqno
previous
describ
inhibitor
mitochondri
respir
test
effect
physiolog
hqno
concentr
mitochondri
activ
data
show
hqno
potent
inhibitor
mitochondri
activ
caus
hyperpolar
mitochondri
membran
subsequ
product
reactiv
oxygen
speci
within
mitochondria
indic
loss
mitochondri
function
final
show
mtor
inhibit
hqno
depend
ampk
activ
summari
hqno
induc
ampk
activ
therebi
inhibit
mtor
activ
bactericid
activ
phagocyt
propos
hqno
produc
p
aeruginosa
signific
contributor
morbid
cf
patient
enhanc
immun
defect
cf
airway
lead
colon
p
aeruginosa
secondari
pathogen
background
infect
pseudomona
aeruginosa
opportunist
pathogen
frequent
occupi
cystic
fibrosi
cf
lung
associ
lung
inflamm
character
accumul
neutrophil
airspac
mucos
tissu
damag
neutrophil
migrat
across
lung
epithelium
amplifi
leukotrien
eicosanoid
produc
neutrophil
breach
infect
mucosa
deriv
arachidon
acid
produc
phospholipas
activ
bacteri
toxin
exou
exhibit
activ
well
conserv
patatin
domain
hypothes
exou
boost
product
neutrophil
therebi
amplifi
neutrophil
transepitheli
migrat
method
neutrophil
isol
blood
drawn
healthi
human
subject
epitheli
barrier
compris
lung
epitheli
cell
line
infect
apic
side
neutrophil
migrat
measur
across
epitheli
barrier
basolater
apic
side
via
myeloperoxidas
assay
level
apic
supernat
liquid
determin
via
elisa
multipl
assay
conduct
evalu
cytotox
effect
exou
epitheli
barrier
neutrophil
pretreat
variou
inhibitor
key
enzym
along
host
synthet
pathway
subject
migrat
across
barrier
infect
exou
exou
strain
result
greater
neutrophil
migrat
across
epitheli
barrier
observ
epithelium
infect
exou
strain
compar
genet
match
exou
strain
increas
neutrophil
migrat
associ
exou
correl
higher
level
epitheli
apic
supernat
epitheli
barrier
integr
cell
viabil
impact
presenc
exou
hour
infect
incub
treatment
neutrophil
inhibitor
multipl
enzym
along
host
synthet
pathway
impair
synthesi
neutrophil
migrat
epithelium
infect
pa
strain
lack
exou
infect
epithelium
pa
strain
express
exou
also
exhibit
inpair
neutrophil
synthesi
migrat
subject
inhibitor
synthet
enzym
howev
case
enzym
downstream
upstream
host
conclus
exou
augment
neutrophil
product
activ
potenti
exacerb
immun
respons
studi
further
understand
transepitheli
lung
neutrophil
traffick
aid
limit
inflammatori
pathophysiolog
futur
therapeut
approach
includ
mycobacterium
avium
complex
mac
rapidli
grow
abscessu
group
mabsc
divers
environment
organ
increasingli
recogn
pathogen
individu
underli
condit
includ
cystic
fibrosi
cf
treatment
ntm
lung
diseas
challeng
limit
number
activ
antibiot
requir
long
cours
potenti
toxic
drug
new
strategi
desper
need
improv
efficaci
treatment
regimen
recent
research
relat
mycobacteri
pathogen
tuberculosi
mtb
demonstr
express
bacteri
efflux
pump
mtb
within
macrophag
contribut
intracellular
surviv
antibiot
toler
furthermor
verapamil
ver
act
efflux
pump
inhibitor
ad
standard
regimen
mtb
mous
model
shorten
durat
treatment
reduc
risk
relaps
result
mtb
led
us
ask
whether
efflux
pump
serv
new
target
treatment
ntm
pathogen
object
work
area
seek
answer
follow
efflux
pump
contribut
intracellular
surviv
ntm
pathogen
ii
inhibit
efflux
pump
verapamil
ver
increas
effect
avail
antibiot
either
counteract
constitut
antibiot
resist
due
efflux
inhibit
macrophageinduc
toler
result
conclus
base
avail
refer
genom
mani
efflux
pump
conserv
mtb
ntm
mtb
macrophageinduc
efflux
pump
demonstr
ortholog
mac
mabsc
group
determin
whether
ver
inhibit
intramacrophag
growth
ntm
speci
infect
macrophag
treat
infect
cell
ver
ver
reduc
coloni
form
unit
cfu
refer
strain
cell
nearli
fold
log
effect
observ
multipl
cf
patient
mac
mabsc
strain
variabl
strain
show
effect
other
demonstr
subtl
decreas
cfu
also
use
broth
microdilut
determin
mic
multipl
antibiot
absenc
presenc
efflux
pump
inhibitor
see
signific
shift
mic
suggest
ver
counteract
intrins
resist
antibiot
current
use
infect
model
determin
whether
ntm
pathogen
develop
macrophageinduc
toler
whether
ver
inhibit
toler
preliminari
result
suggest
mabsc
develop
toler
amikacin
clarithromycin
ver
may
partial
counteract
toler
clarithromycin
amikacin
phan
j
whiteson
k
molecular
biolog
biochemistri
univers
california
irvin
irvin
ca
usa
cystic
fibrosi
cf
genet
diseas
caus
buildup
thick
mucu
lung
airway
patient
lead
prolong
infect
widespread
use
antibiot
later
centuri
patient
succumb
infect
staphylococcu
spp
streptococcu
spp
common
member
oral
microbiota
life
expect
grown
dramat
cf
patient
develop
persist
infect
slowgrow
antibioticresist
gramneg
bacteria
pseudomona
aeruginosa
burkholderia
spp
elucid
avail
nutrient
interact
bacteri
strain
within
polymicrobi
commun
airway
essenti
understand
persist
infect
patient
outlook
interest
studi
metabol
interact
nutrient
flow
clinic
isol
pseudomona
aeruginosa
rothia
mucilaginosa
domin
longterm
resid
cf
polymicrobi
commun
perform
ga
chromatographi
mass
spectrometri
gcm
monoand
cocultur
abl
character
molecul
present
interact
two
clinic
isol
r
mucilaginosa
produc
metabolit
consum
p
aeruginosa
may
provok
product
toxic
molecul
exampl
ferment
product
provok
p
aeruginosa
produc
phenazin
toxic
gener
reactiv
oxygen
speci
presenc
oxygen
may
also
act
altern
electron
acceptor
low
oxygen
environ
combin
metabolom
data
hypothesisdriven
experi
better
understand
interact
p
aeruginosa
r
mucilaginosa
present
ecolog
dynam
cf
lung
microbiota
play
critic
role
progress
airway
diseas
interact
canon
lung
pathogen
eg
pseudomona
aeruginosa
staphylococcu
aureu
describ
detail
ecolog
role
anaerob
microorgan
lower
airway
influenc
cf
diseas
progress
rel
unknown
object
determin
influenc
mucindegrad
mucinfer
anaerob
growth
pathogen
p
aeruginosa
vitro
vivo
method
purifi
mucin
use
sole
carbon
substrat
assess
abil
p
aeruginosa
util
respiratori
secret
carbon
sourc
presenc
absenc
mucindegrad
bacteria
rna
sequenc
use
monitor
vivo
bacteri
gene
express
proxi
mucin
util
final
epitheli
cell
line
model
use
determin
abil
p
aeruginosa
colon
airway
mucos
interfac
presenc
mucin
degrad
bacteria
eg
prevotella
veillonella
multiplex
immunoassay
also
use
test
whether
anaerob
stimul
p
aeruginosa
virul
factor
product
turn
elicit
heighten
host
immun
respons
result
clinic
isol
p
aeruginosa
unabl
grow
provid
mucin
lone
carbon
sourc
except
grown
cocultur
mucinfer
bacteria
suggest
anaerob
bacteria
critic
p
aeruginosa
growth
vivo
rnaseq
transcriptom
analysi
cocultur
anaerobesp
aeruginosa
also
reveal
similar
gene
express
profil
sputum
sampl
suggest
vitro
nutrit
interact
two
popul
also
occur
within
airway
addit
nutrit
interact
use
epitheli
cell
line
model
demonstr
anaerob
stimul
colon
lung
epithelium
p
aeruginosa
rel
p
aeruginosa
alon
result
mucin
degrad
final
multiplex
immunoassay
reveal
increas
inflammatori
activ
tnfa
p
cell
respons
p
aeruginosa
anaerob
bacteri
commun
rel
p
aeruginosa
monocultur
anaerob
bacteri
commun
alon
conclus
togeth
data
implic
central
ecolog
role
anaerob
mucindegrad
bacteria
colon
lower
airway
p
aeruginosa
influenc
host
result
motiv
futur
studi
target
bacteri
mucin
ferment
potenti
therapeut
strategi
help
delay
onset
p
aeruginosa
colon
allevi
progress
cf
lung
diseas
although
patient
b
contaminan
respiratori
tract
infect
transient
acquisit
typic
result
chronic
infect
gradual
declin
lung
function
recent
report
b
cenocepacia
belong
lineag
burholderia
cepacia
epidem
strain
marker
bcesm
genom
region
locat
genom
island
gi
contain
operon
possibl
involv
persist
quorum
sens
express
virul
aim
studi
possibl
relat
persist
establish
b
contaminan
chronic
infect
presenc
gene
associ
genom
island
report
speci
far
purpos
analyz
b
contaminan
isol
recov
patient
attend
period
differ
cf
refer
center
argentina
persist
cell
old
biofilm
expos
ciprofloxacin
concentr
mic
quantifi
bcesm
region
detect
pcr
use
b
cenocepacia
specif
primer
sequenc
percentag
persist
cell
b
contaminan
isol
recov
chronic
lung
infect
contrast
less
persistor
isol
obtain
transient
infect
interestingli
chronic
infect
patient
patient
patient
transient
infect
patient
harbor
bcesm
region
sequenc
analysi
show
amplif
product
region
ident
b
cenocepacia
respect
result
show
presenc
operon
contain
bcesm
region
might
respons
emerg
persistor
therefor
difficulti
erad
b
contaminan
chronic
infect
introduct
allerg
bronchopulmonari
aspergillosi
lung
diseas
caus
aspergillu
fumigatu
af
preval
peopl
cystic
fibrosi
role
respiratori
epitheli
cell
rec
clearanc
af
poorli
studi
present
studi
observ
rec
display
properti
inhibit
mycelium
develop
af
method
wildtyp
wt
bronchial
cell
line
cftrdelet
cell
line
cfbe
infect
af
hour
growth
fungu
estim
optic
microscopi
observ
measur
galactomannan
product
extracellular
media
role
kinas
evidenc
use
specif
inhibitor
result
observ
spore
incub
contact
wt
rec
germin
oppos
spore
incub
absenc
cell
fungal
growth
quantifi
measur
galactomannan
product
lower
presenc
cell
antiaspergillu
activ
inhibit
cell
incub
indic
involv
kinas
pathway
note
inhibitor
map
kinas
inact
also
observ
antifung
activ
releas
extracellular
medium
number
conidia
bind
rec
decreas
presenc
inhibitor
import
note
cfbe
cell
abl
inhibit
germin
conidia
observ
led
us
hypothes
receptor
express
could
involv
antifung
activ
valid
hypothesi
compar
transcriptom
analysi
incub
infect
af
h
compar
gene
express
time
point
infect
identifi
differenti
express
gene
h
postinfect
respect
focus
downregul
gene
commonli
express
time
point
infect
bioinformat
analysi
classif
gene
accord
protein
class
reveal
categori
among
defenseimmun
protein
categori
receptor
categori
focus
first
common
gene
belong
two
famili
identifi
gprotein
coupl
receptor
alreadi
valid
express
gene
next
step
look
express
cfbe
cell
gene
downregul
cfbe
cell
line
select
role
antifung
activ
search
af
infect
wt
rec
decreas
express
specif
sirna
conclus
unlik
cftrdelet
rec
wt
rec
play
role
morpholog
transit
af
conidia
filament
form
potenti
prevent
dissemin
result
could
explain
aspergillu
colon
airway
cystic
fibrosi
patient
fund
work
support
part
grant
vaincr
la
mucoviscidos
background
fev
insensit
earli
chang
lung
diseas
cf
hyperpolaris
ga
ventil
mri
hpmri
allow
direct
visualis
small
defect
sensit
fev
ct
lung
clearanc
index
lci
detect
earli
lung
diseas
cf
hypothesis
hpmri
would
abl
monitor
diseas
progress
time
hpmri
metric
would
sensit
longitudin
chang
lci
spirometri
aim
assess
chang
lung
diseas
use
hpmri
lci
spirometri
group
children
mild
cf
year
interv
method
origin
cohort
consist
cf
children
assess
hpmri
lci
full
lung
function
ct
date
assess
second
occas
year
children
follow
mild
cf
fev
zscore
baselin
result
fev
chang
significantli
year
mean
sd
baselin
vs
subject
abnorm
lci
baselin
year
lci
increas
significantli
subject
abnorm
lci
mean
sd
baselin
lci
vs
subject
ventil
defect
evid
hpmri
baselin
significantli
worsen
year
mean
sd
unventil
volum
significantli
increas
followup
vs
coeffici
varianc
intervoxel
ventil
heterogen
also
significantli
increas
vs
figur
demonstr
compar
hpmr
imag
baselin
year
singl
repres
subject
alongsid
correspond
lung
function
score
conclus
hp
ga
ventil
mri
capabl
detect
subclin
lung
diseas
well
children
cf
hpmri
sensit
detect
longitudin
lung
function
deterior
lci
fev
exampl
pair
hpmri
scan
lung
child
cf
baselin
year
correspond
lung
function
measur
shown
lung
imag
horsley
ar
background
lung
clearanc
index
lci
sensit
measur
earli
airway
chang
cf
deriv
multipl
breath
inert
ga
washout
order
clinic
use
howev
better
understand
requir
variabl
shortmedium
term
import
step
determin
minim
clinic
signific
differ
lci
lcisearch
longitudin
studi
lci
children
adult
lci
measur
clinic
review
use
portabl
closedcircuit
washin
system
wwwlcisearchcom
report
initi
lci
repeat
adult
cohort
repeat
measur
within
taken
time
clinic
stabil
method
lci
measur
perform
triplic
use
closedcircuit
washin
method
innocor
ga
analys
horsley
ar
et
al
erj
open
re
adult
patient
lcisearch
cohort
review
analysi
lci
measur
perform
triplic
visit
final
result
quot
mean
least
accept
repeat
recent
pair
lci
measur
includ
within
patient
deem
clinic
stabl
review
physician
score
respiratori
symptom
score
repeat
assess
blandaltman
analysi
result
subject
pair
data
fit
inclus
criteria
avail
subject
complet
assess
withdrawn
clinic
unstabl
subject
male
complet
median
lci
measur
rang
median
rang
day
apart
mean
age
mean
fev
predict
pancreat
suffici
never
pseudomona
infect
mean
sd
lci
visit
vs
visit
pn
median
coeffici
variat
lci
visit
visit
mean
chang
lci
visit
baselin
lci
limit
agreement
loa
baselin
lci
mild
cohort
patient
normal
lci
exclus
substanti
alter
loa
greater
variabl
frc
mean
bia
baselin
loa
conclus
even
mild
cohort
cf
adult
patient
frequent
unwel
symptomat
routin
review
withinvisit
repeat
good
similar
previou
report
clinic
stabl
lci
variabl
period
within
approxim
addit
adult
well
paediatr
data
assess
widen
applic
confid
interv
support
nihr
background
oral
antibiot
often
use
treat
pulmonari
exacerb
patient
cystic
fibrosi
cf
pulmonari
exacerb
treat
oral
antibiot
usual
lead
hospit
admiss
may
classifi
milder
may
affect
longterm
clinic
outcom
despit
extens
knowledg
regard
effect
pulmonari
exacerb
treat
intraven
iv
antibiot
clinic
outcom
cystic
fibrosi
cf
less
known
impact
pulmonari
exacerb
treat
oral
antibiot
opex
method
retrospect
cohort
studi
cf
patient
follow
hospit
sick
children
st
michael
hospit
pulmonari
exacerb
defin
clinic
event
treat
antibiot
respiratori
caus
patient
includ
studi
receiv
either
oral
antibiot
treatment
pulmonari
exacerb
opex
iv
antibiot
treatment
pulmonari
exacerb
ipex
patient
treat
consid
ivtreat
group
evalu
proport
opex
event
baselin
forc
expiratori
volum
second
fev
predict
recov
end
treatment
baselin
defin
best
measur
month
prior
event
provid
patient
receiv
treatment
time
measur
examin
associ
opex
fev
predict
declin
bodi
mass
index
bmi
zscore
declin
age
use
mix
effect
model
random
intercept
result
patient
follow
toronto
cf
databas
cf
popul
least
one
opex
studi
period
total
opex
event
subject
studi
period
overal
pulmonari
symptom
treat
oral
antibiot
nearli
time
often
iv
antibiot
half
opex
event
lung
function
alreadi
higher
baselin
fev
initi
oral
antibiot
therapi
major
recov
lung
function
followup
patient
return
higher
baselin
fev
adjust
known
risk
factor
lung
function
declin
increas
number
opex
event
independ
associ
fev
declin
group
event
tertil
opex
event
steeper
lung
function
declin
predictedyear
ci
compar
opex
event
year
ci
p
opex
event
independ
associ
chang
bmi
time
conclus
found
greater
number
opex
event
independ
ipex
event
associ
lung
function
declin
cf
patient
signific
proport
patient
treat
oral
antibiot
exacerb
recov
baselin
lung
function
rational
microbi
epidemiolog
cystic
fibrosi
cf
airway
becom
increasingli
complex
novel
pathogen
identifi
achromobact
speci
opportunist
bacteri
pathogen
clinic
outcom
remain
poorli
understood
object
determin
associ
achromobact
sp
infect
clinic
outcom
cohort
cf
patient
method
retrospect
longitudin
cohort
studi
pediatr
adult
patient
cf
follow
hospit
sick
children
st
michael
hospit
toronto
canada
conduct
achromobact
sp
infect
categor
timevari
manner
histori
infect
intermitt
infect
minimum
posit
cultur
chronic
infect
posit
cultur
preced
month
gener
estim
equat
model
use
assess
whether
time
rate
lung
function
declin
rate
pulmonari
exacerb
treat
intraven
iv
antibiot
differ
achromobact
sp
categori
cox
proport
hazard
model
use
estim
risk
death
transplant
covari
includ
age
sex
bodi
mass
index
pancreat
insuffici
forc
expiratori
volum
second
fev
predict
cfrelat
diabet
number
pex
airway
infect
p
aeruginosa
burkholderia
cepacia
complex
methicillinresist
staphylococcu
aureu
investig
use
stepwis
approach
result
patient
male
follow
studi
period
patient
least
one
posit
cultur
achromobact
speci
patient
achromobact
infect
greater
preval
coinfect
p
aeruginosa
vs
p
lower
proport
mild
mutat
vs
p
trend
lower
baselin
fev
predict
vs
p
total
cohort
infect
achromobact
sp
associ
either
rate
lung
function
declin
rate
pulmonari
exacerb
convers
chronic
achromobact
infect
associ
significantli
greater
risk
death
lung
transplant
compar
patient
histori
infect
unadjust
hr
ci
p
remain
signific
adjust
known
confound
adjust
hr
p
increas
risk
death
transplant
note
intermitt
achromobact
infect
adjust
hr
ci
p
conclus
chronic
achromobact
infect
associ
increas
risk
death
lung
transplant
acceler
lung
function
declin
pulmonari
exacerb
given
increas
mortal
risk
studi
optim
treatment
strategi
achromobact
sp
infect
cf
patient
need
r
somayaji
support
cf
canada
clinicalresearch
fellowship
although
classic
bacteri
pathogen
tradit
thought
major
caus
lung
diseas
progress
respiratori
viral
pathogen
increasingli
identifi
associ
pulmonari
exacerb
pex
wat
et
al
j
cyst
fibro
wang
ee
et
al
nejm
character
clinic
effect
respiratori
viral
pathogen
cf
pulmonari
diseas
need
object
determin
associ
influenza
respiratori
syncyti
viru
rsv
risk
pex
children
adult
cf
unit
state
method
conduct
cohort
studi
use
cf
foundat
cff
patient
registri
merg
cdc
viru
surveil
data
influenza
rsv
posit
children
adult
cf
use
monthli
influenza
rsv
surveil
data
us
censu
region
prior
studi
cf
use
data
set
link
individu
patient
region
viral
detect
data
adjust
individu
characterist
primari
outcom
relationship
influenza
rsv
posit
per
risk
pex
defin
respiratori
ill
requir
hospit
home
intraven
antibiot
fit
multivari
poisson
regress
model
estim
risk
pex
adjust
demograph
clinic
predictor
stratifi
adult
year
children
year
model
includ
covari
sex
age
race
genotyp
insur
pancreat
insuffici
bodi
mass
index
forc
expiratori
volum
second
predict
season
result
patient
male
cf
patient
cohort
compos
children
mean
age
adult
mean
age
review
test
data
indic
region
season
variabl
number
influenza
rsv
detect
associ
respiratori
ill
domin
influenza
strain
lesser
proport
influenza
b
virus
cohort
patient
experienc
least
one
pex
pex
requir
hospit
incid
rate
pex
per
personmonth
studi
period
children
proport
influenza
rr
ci
p
rsv
rr
ci
p
posit
region
surveil
adjust
confound
significantli
associ
pex
risk
convers
adult
influenza
posit
region
surveil
rr
ci
p
rsv
rr
adjust
confound
signific
associ
pex
risk
conclus
larg
cf
populationbas
cohort
studi
span
seven
year
demonstr
signific
associ
influenza
region
activ
children
adult
rsv
region
activ
children
prospect
studi
respiratori
viral
infect
necessari
understand
causal
impact
cf
lung
diseas
r
somayaji
support
cf
canada
fellowship
object
determin
median
surviv
us
cf
patient
fev
predict
identifi
predictor
surviv
among
patient
low
lung
function
method
conduct
retrospect
cohort
studi
use
cystic
fibrosi
foundat
patient
registri
data
avail
jan
dec
adult
patient
age
year
yet
undergon
lung
transplant
ltx
includ
fev
stabl
encount
mark
pulmonari
exacerb
hospit
patient
censor
time
ltx
document
loss
followup
end
avail
followup
kaplanmei
transplantfre
surviv
estim
multivari
cox
proport
hazard
ph
regress
includ
signific
covari
p
univari
regress
use
determin
predictor
surviv
schoenfeld
residu
use
confirm
ph
assumpt
result
subject
met
criteria
surviv
analysi
patient
die
without
ltx
patient
underw
ltx
median
surviv
year
ci
introduct
magnet
reson
imag
mri
multipl
breath
washout
mbw
may
sensit
method
monitor
cystic
fibrosi
cf
lung
diseas
studi
assess
treatment
respons
acut
pulmonari
exacerb
ape
shown
heterogen
respons
lung
clearanc
index
lci
main
outcom
measur
mbw
signific
proport
patient
show
worsen
lci
treatment
sonneveld
n
et
al
eur
respir
j
potenti
explain
recruit
poorli
ventil
area
lung
mbw
decreas
mucu
plug
treatment
ape
object
studi
evalu
mri
mbw
measur
cf
lung
diseas
treatment
ape
treat
intraven
iv
antibiot
children
cf
method
mri
chest
mbw
use
sulfur
hexafluorid
sf
spirometri
perform
day
iv
antibiot
lung
morphometri
bronchiectasi
airway
thicken
mucu
plug
parenchyma
trap
air
score
use
cfmri
score
adapt
version
brodi
score
mri
spirometri
measur
analyz
percent
predict
result
patient
male
mri
mean
age
rang
mean
fev
increas
ci
improv
also
seen
fvc
fev
fvc
fef
signific
chang
therapi
seen
mri
bronchiectasi
airway
thicken
parenchyma
total
lung
score
improv
seen
score
mucu
plug
ci
air
trap
ci
patient
underw
mri
researchqu
mbw
measur
mean
sd
lci
score
chang
treatment
ci
lci
posit
correl
total
mri
score
mucu
plug
bronchiectasi
score
correl
chang
mri
score
chang
spirometri
howev
signific
neg
correl
chang
lci
chang
mri
total
lung
score
p
signific
neg
correl
suggest
worsen
lci
improv
mucu
plug
air
trap
therapi
conclus
consist
previou
studi
mri
use
quantifi
lung
diseas
children
cf
pilot
studi
improv
mucu
plug
trap
air
cfmri
correl
worsen
lci
find
suggest
open
poorli
ventil
area
lung
treatment
affect
lci
measur
may
explain
previous
report
heterogen
respons
lci
treatment
ape
sensit
clinic
tool
assess
subtl
chang
lung
structur
function
essenti
assess
diseas
progress
therapeut
efficaci
earli
cf
lung
diseas
spirometri
clinic
goldstandard
measur
lung
function
known
somewhat
insensit
effortdepend
lung
clearanc
index
lci
via
multiplebreath
washout
emerg
sensit
biomark
ventil
heterogen
recent
demonstr
hyperpolar
xe
magnet
reson
imag
mri
sensit
ventil
deficit
cf
patient
clinicallynorm
spirometri
ie
fev
object
studi
investig
relationship
pft
lci
xe
mri
assess
ventil
heterogen
earli
cf
lung
diseas
method
hyperpolar
xe
mri
perform
pediatr
cf
patient
male
femal
age
fev
predict
use
xe
prepar
either
commerci
homebuilt
xe
polar
xe
ventil
imag
acquir
singl
breathhold
second
xe
function
residu
capac
ventil
deficit
identifi
use
signal
intens
threshold
mean
wholelung
xe
signal
quantifi
percentag
vdp
total
lung
volum
lobe
vdp
compar
clinicallyobtain
lci
fev
pearson
correl
result
xe
mri
breathhold
well
toler
subject
small
transient
decreas
blood
oxygen
spo
decreas
baselin
record
resolv
within
minut
normal
breath
ventil
deficit
visual
appar
cf
patient
even
subject
clinicallynorm
fev
vari
degre
lobar
distribut
mean
wholelung
xe
vdp
poorli
correl
fev
r
p
strongli
correl
lci
r
p
demonstr
sensit
xe
mri
earli
airway
obstruct
compar
spirometri
abil
xe
mri
quantifi
region
ventil
heterogen
conclus
xe
mri
sensit
techniqu
assess
ventil
heterogen
earli
cf
lung
diseas
correl
well
lci
xe
mri
also
provid
region
inform
use
guid
intervent
eg
bronchoscopi
evalu
region
ventil
chang
associ
diseas
progress
therapi
respons
method
studi
includ
subject
cystic
fibrosi
f
age
imag
baselin
use
ct
mri
subject
return
repeat
visit
week
later
ct
perform
use
lowdos
volumetr
protocol
includ
endinspir
endexpir
scan
mri
method
includ
convent
conv
newer
ultrashort
echo
time
ute
te
method
mr
imag
acquir
subject
receiv
mmolkg
gadoben
dimeglumin
two
cardiothorac
radiologist
score
imag
dataset
ct
precontrast
conv
postcontrast
conv
precontrast
ute
postcontrast
ute
random
blind
fashion
heidelberg
morpholog
score
system
modifi
ad
air
trap
score
increas
scale
none
lobe
affect
better
approxim
wellvalid
brodi
ct
score
score
compar
use
kruskalw
test
post
hoc
dunn
test
persubject
perlob
basi
correl
method
also
calcul
result
acquisit
data
complet
complet
analysi
complet
nacfc
meet
analysi
random
subset
subject
complet
submiss
date
perlob
analysi
reveal
differ
total
lobe
score
method
although
differ
bronchiectasi
score
amongst
mr
method
mr
method
underscor
bronchiectasi
rel
ct
p
consolid
pleural
categori
differ
method
respect
mr
score
differ
ct
air
trap
postcontrast
ute
persubject
basi
total
score
ct
differ
conv
mri
p
either
precontrast
postcontrast
ute
air
trap
ct
differ
conv
mri
p
either
precontrast
postcontrast
ute
iv
contrast
significantli
chang
either
total
score
air
trap
score
either
perlob
conv
ute
persubject
conv
ute
analysi
correl
ute
ct
total
air
trap
score
shown
tabl
conclus
ultrashort
echo
time
mri
significantli
outperform
convent
mri
show
excel
correl
ct
score
signific
differ
ct
ute
mri
either
total
score
air
trap
subscor
regardless
whether
contrast
given
rational
cystic
fibrosi
cf
lung
diseas
character
progress
bronchiectasi
lack
airway
taper
object
quantif
taper
patient
cf
control
defin
object
explor
taper
measur
novel
imag
biomark
cf
lung
diseas
establish
refer
taper
valu
method
spirometerguid
inspiratori
chest
ct
random
cf
patient
ageand
gendermatch
control
lung
evalu
normal
ct
year
old
retrospect
select
addit
subset
control
ct
normal
ct
dataset
intern
center
collect
clinic
indic
ct
normal
lung
evalu
ct
without
lung
volum
control
includ
stateoftheart
automat
imag
analysi
softwar
use
quantifi
intrabranch
taper
reduct
airway
diamet
along
branch
interbranch
taper
reduct
airway
diamet
bifurc
airway
arteri
aa
ratio
imag
biomark
obtain
individu
branch
report
median
valu
subject
biomark
stratifi
small
medium
larg
airway
base
equal
group
accompani
vessel
size
spirometerguid
control
within
mm
cfct
bronchiectasi
score
done
spirometerguid
ct
differ
test
use
mannwhitney
u
correl
spearman
correl
coeffici
result
one
patient
common
variabl
immun
defici
mislabel
cf
due
similar
structur
chang
remain
includ
cf
cf
patient
reduc
median
intrabranch
taper
outer
compar
control
outer
p
cf
patient
reduc
median
interbranch
taper
outer
compar
control
outer
p
differ
taper
cf
control
signific
airway
size
differ
aaratio
signific
small
airway
cfct
score
correl
intrabranch
taper
outer
p
interbranch
taper
outer
p
aaratio
outer
p
conclus
airway
taper
promis
novel
cf
biomark
correl
well
valid
ct
score
system
cf
patient
show
signific
reduct
airway
taper
across
airway
size
compar
control
wherea
signific
increas
aaratio
observ
small
airway
detect
taper
reduct
larger
airway
could
potenti
lead
earlier
diagnosi
bronchiectasi
ct
young
cf
patient
rel
low
ct
resolut
detect
chang
small
airway
thomen
rp
walkup
roach
dj
cleveland
z
fleck
r
clanci
jp
wood
jc
cincinnati
children
hospit
medic
center
cincinnati
oh
usa
introduct
ultrashort
echo
time
ute
mri
emerg
techniqu
quantifi
region
structur
abnorm
lung
sensit
similarli
ct
without
use
ioniz
radiat
hyperpolar
hp
xe
mri
gener
imag
region
pulmonari
ventil
obstruct
lung
diseas
provid
quantifi
map
region
ventil
defect
earli
cf
lung
diseas
defect
observ
even
without
clinic
signific
declin
pulmonari
function
hypothes
structurefunct
relationship
exhibit
patholog
associ
cf
lung
diseas
bronchiectasi
bronchial
wall
thicken
br
mucu
plug
mp
consolid
cn
ground
glass
opac
gg
air
trap
identifi
use
ute
hp
xe
mri
particular
use
ute
mr
imag
identifi
patholog
spatial
match
quantifi
correspond
ventil
defect
hp
xe
mri
method
adolesc
age
earli
cf
lung
diseas
imag
via
ute
mri
hp
xe
mri
region
defect
ventil
quantifi
hp
xe
imag
ute
imag
independ
examin
structur
abnorm
care
taken
locat
area
parenchyma
associ
abnorm
defect
percentag
associ
structur
abnorm
calcul
subject
result
wholelung
defect
percentag
averag
subject
mean
fev
across
subject
ventil
defect
volum
associ
clear
structur
abnorm
volum
br
respons
ventil
defect
mp
cn
gg
subject
lowest
fev
br
mp
respons
identifi
defect
volum
conclus
small
group
patient
identifi
associ
structur
abnorm
ute
mri
account
major
volumepercentag
ventil
defect
hp
xe
mri
subject
mp
br
respons
greatest
fraction
volum
ventil
defect
associ
region
ventil
region
structur
abnorm
may
particularli
use
longitudin
monitor
cf
diseas
progress
especi
evalu
individu
treatment
introduct
azithromycin
therapi
associ
qtc
prolong
cardiac
event
patient
without
cf
well
describ
patient
cf
april
outpati
ecg
protocol
develop
outlin
number
type
risk
factor
consid
obtain
ecg
pediatr
adult
popul
chronic
azithromycin
therapi
object
local
practic
obtain
ecg
patient
cf
risk
qtc
prolong
chronic
azithromycin
therapi
examin
identifi
number
type
qtc
prolong
risk
factor
percentag
patient
receiv
baselin
followup
ecg
classif
qtc
interv
method
retrospect
review
examin
medic
record
patient
age
clinic
visit
april
octob
patient
divid
initi
current
receiv
chronic
azithromycin
divid
number
type
qtcprolong
risk
factor
present
percentag
patient
initi
followup
ecg
determin
qtc
interv
classifi
normal
borderlin
prolong
result
sixtyf
patient
includ
half
examin
risk
factor
one
two
four
five
risk
factor
qtc
prolong
common
risk
factor
femal
gender
n
longact
beta
agonist
n
twentyfour
initi
ecg
obtain
azithromycin
patient
borderlin
qtc
interv
msec
four
followup
ecg
obtain
patient
prolong
qtc
interv
msec
patient
initi
borderlin
ecg
obtain
followup
ecg
qtc
interv
normal
conclus
cf
patient
may
multipl
risk
factor
qtc
prolong
system
implement
ensur
followup
ecg
initi
borderlin
prolong
qtc
interv
initi
azithromycin
qtc
interv
need
specif
request
order
ecg
import
studi
cardiac
risk
associ
medic
therapi
patient
cf
background
grow
interest
assess
lung
diseas
young
children
given
longterm
benefit
earli
intervent
preschool
children
cf
lung
clearanc
index
lci
sensit
spirometri
detect
abnorm
lung
function
predict
structur
lung
diseas
howev
lci
yet
standard
clinic
use
part
due
challeng
perform
test
hypothes
lci
reproduc
spirometri
detect
lung
diseas
preschool
children
posit
cf
newborn
screen
nb
object
compar
test
complet
ratio
lci
spirometri
fev
assess
reproduc
lci
fev
measur
explor
two
test
sensit
detect
earli
lung
diseas
cf
cftrrelat
metabol
syndrom
crm
subgroup
method
children
posit
nb
cf
cf
crm
year
age
recruit
cf
clinic
children
hospit
lo
angel
subject
acut
ill
exclud
agematch
healthi
control
hc
recruit
hospit
employe
day
care
persist
asthma
famili
histori
cf
exclud
elig
subject
schedul
visit
within
week
lci
spirometri
perform
day
subject
attempt
minut
per
test
satisfactori
complet
test
follow
at
criteria
statist
analysi
mean
differ
lci
fev
within
subject
group
hc
cf
crm
measur
anova
repeat
measur
adjust
gener
estim
equat
linear
regress
use
examin
differ
across
age
attempt
adjust
repeat
measur
result
studi
subject
cf
vs
crm
phenotyp
compar
follow
mean
sweat
chlorid
vs
pseudomona
aeruginosaev
vs
none
presenc
chronic
cough
vs
complet
rate
similar
lci
spirometri
ci
reproduc
lci
fev
measur
similar
variabl
cv
vs
respect
lci
fev
signific
differ
across
attempt
across
age
year
two
visit
sensit
signific
differ
mean
lci
group
mean
fev
conclus
conclud
lci
spirometri
reproduc
test
preschool
cf
crm
children
year
age
children
age
group
toler
attempt
per
test
perform
equal
across
attempt
also
perform
test
well
first
visit
second
visit
differ
lci
fev
group
valu
within
normal
limit
like
due
earli
therapeut
intervent
diagnosi
nb
support
webb
foundat
children
hospit
lo
angel
pediatr
pulmonari
background
trial
singlepati
clinic
trial
multipl
crossov
treatment
idea
studi
new
year
ago
feasibl
trial
servic
describ
offer
trial
recommend
patient
clinician
uncertain
valu
treatment
symptomat
chronic
diseas
agenc
healthcar
research
qualiti
releas
guid
design
implement
trial
improv
gener
understand
rais
level
evid
gener
trial
howev
trial
remain
rel
uncommon
area
may
benefici
pediatr
chronic
diseas
method
examin
trial
cystic
fibrosi
cf
identifi
trial
appropri
andor
effici
tradit
studi
design
discuss
design
consider
includ
random
blind
replic
washout
complex
statist
model
need
combin
trial
illustr
candid
trial
cf
identifi
trial
may
favor
tradit
studi
design
simul
compar
sampl
size
design
parallel
crossov
studi
present
pulmonari
function
sweat
chlorid
endpoint
studi
conduct
cf
therapeut
develop
network
use
select
simul
paramet
result
trial
requir
rigor
develop
tradit
clinic
trial
design
support
treatment
decis
make
individu
patient
well
potenti
combin
set
trial
provid
gener
treatment
recommend
patient
popul
set
complementari
trial
requir
smaller
sampl
size
abba
crossov
design
anticip
withinpati
correl
trial
feasibl
approach
treatment
decis
make
pediatr
chronic
diseas
conclus
trial
provid
opportun
practic
evidencebas
patientcent
care
primari
goal
trial
inform
treatment
decis
specif
patient
inform
gather
multipl
trial
leverag
metaanalysi
provid
generaliz
inform
compar
tradit
parallelarm
clinic
trial
trial
viabl
altern
tradit
design
hold
promis
evalu
new
therapi
rare
diseas
cf
scenario
assum
type
error
power
equal
introduct
fev
use
assess
global
cf
lung
function
function
imag
show
region
diseas
heterogen
although
hyperpolar
ga
ventil
imag
excel
tool
show
impair
ventil
cf
wide
avail
perfus
mri
howev
perform
site
mri
purpos
studi
compar
lung
function
assess
perfus
mri
ventil
mri
wide
rang
cf
lung
diseas
sever
method
spirometri
mri
perform
subject
f
age
ppfev
baselin
state
health
ventil
mri
breathhold
hyperpolar
dynam
contrastenhanc
perfus
mri
perform
use
previous
publish
method
imag
spirometri
repeat
subject
wk
later
ventil
defect
percent
vdp
quantifi
use
previous
publish
adapt
kmean
method
semiquantit
analysi
lung
perfus
use
time
cours
maximum
intens
project
manual
segment
defect
determin
perfus
defect
percent
pdp
blind
vdp
spirometri
result
vdp
pdp
measur
compar
use
blandaltman
analysi
linear
regress
determin
correl
pdp
vdp
fev
interday
repeat
pdp
vdp
fev
compar
use
intraclass
correl
coeffici
icc
blandaltman
plot
result
perfus
ventil
defect
gener
match
pdp
vdp
show
strong
correl
fev
pdp
higher
vdp
pdp
repeat
excel
differ
significantli
visit
vdp
also
show
strong
repeat
limit
agreement
loa
repeat
pdp
vdp
significantli
differ
fev
measur
show
strongest
repeat
least
variabl
conclus
perfus
mri
may
serv
rel
inexpens
easi
use
wide
avail
surrog
ventil
mri
depict
progress
function
defect
cf
lung
diseas
worlitzsch
et
al
j
clin
invest
howev
littl
followup
work
done
sinc
paper
measur
modifi
actual
oxygen
tension
cf
airway
use
fastrespons
sensor
introduc
noninvas
procedur
measur
abnorm
oxygen
content
airway
method
fraction
expir
airway
oxygen
measur
real
time
use
fast
laser
diod
oxygen
analyz
respons
time
ms
seri
pneumotachomet
co
analyz
oxigraf
mountain
view
ca
subject
breath
comfort
frc
lowresist
mouthpiec
exhal
expiratori
reserv
volum
flow
rate
ml
nadir
fraction
oxygen
nfo
record
fraction
exhal
co
cross
mmhg
measur
repeat
three
time
addit
measur
made
subject
breath
liter
per
minut
lpm
oxygen
nasal
cannula
nc
stabl
normox
cf
outpati
recruit
rainbow
babi
children
hospit
rbch
cf
clinic
healthi
volunt
recruit
faculti
staff
studi
review
approv
rbch
irb
result
procedur
welltoler
subject
mean
nfo
valu
adult
healthi
volunt
adult
cf
children
cf
n
respect
oneway
anova
adult
cf
nfo
valu
lower
adult
healthi
control
valu
tukey
pairwis
comparison
cf
patient
oxygen
content
increas
final
msec
exhal
presum
reflect
empti
popul
true
respiratori
bronchiol
alveoli
nfo
relat
arteri
oxygen
satur
measur
puls
oximetri
linear
regress
supplement
oxygen
nc
increas
healthi
adult
nfo
dosedepend
fashion
linear
regress
p
r
lpm
nfo
conclus
result
demonstr
gasphas
oxygen
level
termin
airway
low
cf
patient
phase
iv
valu
normal
arteri
oxygen
satur
howev
suggest
region
inhomogen
vq
match
higher
valu
cf
children
adult
suggest
decreas
airway
oxygen
level
may
aris
bronchiectasi
inflamm
andor
infect
though
also
evid
oxygen
consumpt
increas
cf
epitheli
cell
worlitzsch
et
al
data
rais
sever
question
physiolog
ontogeni
airway
ecolog
airway
oxygen
tension
cf
data
partial
consist
idea
oxygen
tension
may
favor
growth
mucoid
pseudomona
anaerob
bacteria
cf
airway
lowdos
oxygen
therapi
might
consid
antimicrobi
valu
object
cystic
fibrosi
cf
associ
high
rate
pulmonari
exacerb
pex
lead
acceler
declin
lung
function
impair
qualiti
life
increas
inpati
ip
admiss
prematur
mortal
clinic
trial
patient
cf
gate
mutat
ivacaftor
iva
treatment
associ
reduct
pex
object
analysi
multist
medicaid
data
compar
rate
pex
among
patient
cf
month
preandpost
initi
iva
treatment
medicaid
popul
method
retrospect
cohort
studi
use
administr
claim
data
us
patient
insur
medicaid
januari
novemb
patient
cf
year
age
claim
iva
initi
dateindex
date
month
continu
enrol
preand
postindex
includ
pex
defin
base
ip
stay
hospit
andor
intraven
iv
antibiot
use
ii
use
oral
antibiot
alon
acut
treatment
without
ip
stay
iv
use
rate
pex
compar
preand
postindex
period
result
studi
inclus
criteria
identifi
patient
initi
iva
truven
marketscan
medicaid
multist
databas
million
patient
studi
popul
femal
mean
age
sd
year
comparison
preand
postindex
period
show
statist
signific
declin
proport
patient
pex
requir
hospit
andor
iv
antibiot
use
patient
histori
pex
requir
hospit
andor
iv
antibiot
use
iva
initi
less
half
pex
event
requir
hospit
andor
iv
use
iva
initi
overal
proport
patient
without
pex
pulmonari
exacerb
free
tripl
preindex
period
iva
initi
conclus
find
retrospect
analysi
small
cohort
patient
cf
medicaid
popul
suggest
treatment
iva
associ
reduct
pex
rate
outcom
realworld
set
consist
result
clinic
trial
iva
among
patient
cf
gate
mutat
sponsor
vertex
pharmaceut
incorpor
result
eleven
femal
age
colon
bc
cbc
followup
cbc
year
nine
care
pediatr
cf
centr
patient
bc
segreg
cf
patient
mlst
identifi
four
differ
clone
evenli
infect
children
adult
best
fev
pred
year
prior
cbc
four
chronic
bronchial
infect
cbi
aureu
children
p
aeruginosa
adult
twelv
nebul
colistin
either
erad
therapi
cbi
p
aeruginosa
ten
includ
adult
chang
symptom
cbc
five
three
one
note
increas
symptom
week
month
symptom
subsid
follow
start
longterm
nebul
ceftazidim
bid
cft
children
absolut
increas
fev
pred
within
month
five
adult
develop
cbi
bc
first
year
cbc
still
eight
children
bcfree
two
children
intermitt
colon
signific
differ
annual
chang
best
fev
two
year
prior
cbc
vs
year
also
differ
annual
number
exacerb
requir
iv
antibiot
vs
remark
annual
total
number
exacerb
decreas
vs
p
fev
increas
significantli
within
month
patient
put
cft
vs
p
conclus
bc
emerg
multiresist
organ
infect
airway
cf
patient
associ
cbc
longterm
aerosol
colistin
found
bacteri
dna
studi
support
extens
crossinfect
third
progress
cbi
signific
differ
annual
chang
seen
along
two
year
cbc
annual
number
exacerb
even
decreas
nearli
put
cft
associ
shortterm
signific
improv
symptom
conclud
bcc
less
like
follow
cbi
associ
clinic
pulmonari
function
impair
compar
bm
bcpc
prospect
multicent
studi
need
evalu
clinic
impact
introduct
valu
lung
clearanc
index
lci
well
recognis
children
adult
also
sensit
measur
lung
diseas
infant
cystic
fibrosi
cf
potenti
role
clinic
practic
research
outcom
howev
measur
lci
infant
technic
challeng
due
need
accur
combin
flow
ga
measur
rapid
respiratori
rate
simpl
method
assess
lung
function
outsid
research
laboratori
popul
topic
increas
import
look
improv
longterm
outcom
infant
diagnos
newborn
screen
facilit
access
new
therapi
younger
patient
previous
describ
altern
method
perform
multipl
breath
washout
mbw
expir
ga
collect
analys
deriv
function
residu
capac
frc
lci
without
directli
measur
flow
elimin
one
major
technic
challeng
infant
mbw
whilst
also
reduc
dead
space
system
system
demonstr
highli
accur
vitro
mean
accuraci
frc
measur
within
frc
shawcross
et
al
pediatr
pulmonol
aim
assess
practic
applic
accuraci
method
vivo
method
healthi
control
infant
without
respiratori
diseas
alreadi
undergo
procedur
requir
sedat
infant
cystic
fibrosi
undergo
mbw
test
use
method
practic
applic
system
determin
number
success
lci
test
withinsubject
repeat
comparison
also
made
lci
measur
obtain
use
respiratori
mass
spectromet
current
consid
gold
standard
infant
lci
measur
result
date
healthi
control
mean
age
week
one
infant
cf
age
week
success
undergon
lci
measur
use
method
mean
lci
control
rang
mean
withinsubject
cv
infant
cf
lci
cv
conclus
preliminari
data
suggest
feasibl
reproduc
method
perform
lci
infant
result
fall
within
normal
rang
predict
mass
spectromet
lum
et
al
eur
respir
j
well
within
accuraci
limit
set
intern
guidelin
robinson
pd
et
al
eur
respir
j
could
provid
access
altern
previous
describ
system
avoid
pitfal
associ
direct
measur
flow
infant
pediatr
state
univ
new
york
buffalo
buffalo
ny
usa
biostatist
state
univ
new
york
buffalo
buffalo
ny
usa
background
lung
clearanc
index
lci
measur
ventil
inhomogen
base
tidal
breath
increas
peopl
cystic
fibrosi
cf
compar
normal
subject
subbarao
p
et
al
ann
thorac
soc
shown
improv
decreas
treatment
cf
pulmonari
exacerb
robinson
pd
et
al
pediatr
pulmonol
forc
maneuv
gener
fev
predict
usual
improv
increas
treatment
period
horsley
ar
et
al
thorax
howev
expect
invers
correl
fev
predict
lci
alway
seen
sonneveld
n
et
al
eur
respir
j
patient
satisfact
lci
previous
report
aim
compar
chang
lci
chang
fev
predict
treatment
cf
pulmonari
exacerb
compar
patient
satisfact
lci
compar
standard
pulmonari
function
test
pft
method
exploratori
studi
conveni
sampl
subject
age
consecut
admit
women
children
hospit
buffalo
perform
spirometri
plethysmographi
lci
order
begin
end
hospit
cf
pulmonari
exacerb
inform
consent
assent
indic
obtain
lung
function
test
perform
least
duplic
satisfact
test
assess
fiveitem
questionnair
test
begin
end
hospit
greatest
satisfact
least
satisfact
mean
score
gener
basic
demograph
inform
collect
pair
ttest
pearson
correl
coeffici
use
compar
data
result
patient
cf
enrol
august
octob
homozygot
heterozygot
grew
pseudomona
grew
mrsa
sputum
cultur
uniqu
subject
studi
consent
differ
hospit
complet
data
set
one
subject
withdrew
consent
test
one
withdrew
due
sinu
pain
one
lci
maneuv
two
subject
perform
lci
begin
end
hospit
satisfact
data
still
count
one
vomit
discharg
test
maneuv
one
want
particip
discharg
test
time
test
rang
averag
declin
lci
unit
p
increas
fev
predict
p
moder
invers
relationship
mean
chang
lci
mean
chang
fev
predict
r
p
better
satisfact
lci
vs
pft
averag
mean
score
vs
indic
greater
eas
perform
test
p
patient
report
less
cough
troubl
breath
perform
lci
compar
pft
conclus
lci
test
well
toler
children
young
adult
cf
found
moder
invers
correl
lci
fev
howev
satisfact
eas
test
higher
lci
standard
pft
huynh
hq
bhakta
zn
gurgel
r
young
dc
background
cystic
fibrosi
cf
genet
disord
lead
chronic
bacteri
colon
result
inflamm
destruct
respiratori
tract
cystic
fibrosi
patient
suffer
recurr
episod
deterior
call
acut
pulmonari
exacerb
ape
treatment
ape
includ
iv
antibiot
therapi
airway
clearanc
therapi
exercis
aminoglycosid
ag
frequent
use
treat
common
pathogen
associ
ape
eg
pseudomona
aeruginosa
known
caus
ototox
current
specif
guidelin
recommend
screen
aminoglycosideinduc
ototox
cystic
fibrosi
foundat
cff
guidelin
recommend
period
assess
ototox
provid
specif
recommend
type
frequenc
audiolog
screen
object
primari
object
studi
character
audiolog
screen
practic
cffaccredit
pediatr
adult
care
center
patient
receiv
ag
therapi
ape
studi
also
assess
need
standard
audiolog
screen
practic
guidelin
addit
develop
audiolog
screen
protocol
univers
utah
method
retrospect
case
seri
perform
univers
utah
assess
frequenc
audiolog
screen
perform
cf
patient
receiv
aminoglycosid
ape
order
character
audiolog
screen
practic
across
unit
state
survey
creat
via
email
cffaccredit
care
center
medic
director
design
repres
recipi
survey
period
complet
survey
remind
email
sent
everi
week
result
result
retrospect
case
seri
demonstr
rate
audiolog
screen
univers
utah
approxim
respons
rate
cffaccredit
care
center
survey
routin
audiolog
screen
perform
approxim
respond
care
center
center
protocol
frequenc
audiolog
screen
vari
annual
everi
cours
ag
use
everi
cours
ag
use
least
annual
patient
admit
ape
major
respond
care
center
perform
highfrequ
pureton
audiometri
approxim
respond
care
center
believ
need
standard
audiolog
screen
practic
guidelin
cf
patient
receiv
ag
survey
result
use
develop
protocol
audiolog
screen
univers
utah
implement
may
conclus
audiolog
screen
cffaccredit
care
center
cf
patient
receiv
aminoglycosid
therapi
ape
occur
low
rate
wide
variabl
type
frequenc
audiolog
test
perform
cffaccredit
care
center
high
percentag
respond
cffaccredit
care
center
believ
clinic
practic
guidelin
audiolog
screen
cf
patient
receiv
ag
ape
broder
ms
chang
e
reddi
sr
raimundo
k
holden
partnership
health
analyt
research
llc
beverli
hill
ca
usa
genentech
inc
south
san
francisco
ca
usa
introduct
dornas
alfa
shown
reduc
risk
respiratori
infect
improv
pulmonari
function
patient
cf
recommend
dosag
dornas
alfa
oncedaili
qd
although
certain
cf
patient
may
benefit
twicedaili
bid
regimen
littl
known
patient
treat
qd
bid
regimen
differ
method
retrospect
descript
analysi
deidentifi
commerci
insur
claim
data
examin
characterist
patient
cf
bid
vs
qd
dornas
alfa
regimen
identif
id
period
compar
patient
start
bid
use
continu
user
qd
dornas
alfa
first
fill
date
either
bid
qd
use
id
period
defin
index
date
patient
continu
enrol
month
baselin
followup
index
date
exclud
new
vs
continu
user
determin
base
baselin
medic
use
patient
demograph
comorbid
respiratori
exacerb
treatment
exposur
year
compar
studi
group
databas
clinic
variabl
exacerb
defin
cfrelat
hospit
emerg
depart
visit
use
ivor
antibiot
analysi
repeat
subset
patient
year
old
result
identifi
bid
qd
user
mean
sd
age
bid
user
year
vs
year
p
qd
regimen
imbal
gender
geograph
region
bid
qd
user
bid
user
charlson
comorbid
index
vs
qd
user
p
rate
comorbid
bid
vs
qd
diabet
vs
p
pancreat
insuffici
vs
p
pseudomona
infect
vs
p
gastroesophag
reflux
vs
chronic
sinus
vs
p
malnutrit
vs
osteoporosi
vs
allerg
bronchopulmonari
aspergillosi
vs
baselin
exacerb
rate
bid
qd
mean
number
exacerb
among
patient
exacerb
p
respect
threemonth
followup
exacerb
rate
bid
qd
respect
mean
number
exacerb
among
patient
exacerb
annual
mean
sd
day
suppli
fill
regimen
bid
vs
qd
p
result
patient
year
similar
conclus
averag
bid
dornas
alfa
user
older
qd
user
higher
rate
comorbid
includ
diabet
pseudomona
infect
chronic
sinus
lower
rate
pancreat
insuffici
overal
exposur
qd
treatment
twice
long
bid
treatment
betweengroup
differ
rate
respiratori
exacerb
statist
signific
baselin
followup
introduct
ventil
distribut
outcom
obtain
multipl
breath
washout
techniqu
mbw
sensit
structur
lung
damag
infect
inflamm
young
children
cystic
fibrosi
cf
impact
respiratori
symptom
ventil
distribut
outcom
includ
lung
clearanc
index
lci
unknown
assess
associ
recent
respiratori
symptom
hospit
admiss
ventil
distribut
outcom
young
children
cf
method
children
cf
age
year
recruit
within
arest
cf
clinic
trial
perth
melbourn
cf
clinic
riley
children
hospit
indianapoli
ventil
distribut
outcom
includ
lci
moment
ratio
measur
convectiondepend
inhomogen
convectioninteractiondepend
inhomogen
cond
acin
respect
measur
hospit
admiss
last
month
recent
last
month
current
respiratori
symptom
document
impact
presenc
binari
yesno
hospit
admiss
common
symptom
cough
cold
sputum
ventil
distribut
assess
chang
mbw
symptom
outcom
repeat
visit
assess
use
mix
effect
model
random
intercept
repeat
visit
result
pair
mbw
respiratori
symptom
data
avail
visit
children
male
cf
mean
rang
age
year
children
current
cough
visit
increas
lci
coeffici
ci
unchang
cond
acin
compar
children
without
cough
cough
last
month
associ
increas
lci
cond
compar
children
without
recent
cough
current
cold
symptom
associ
increas
acin
p
current
sputum
product
associ
wors
cond
hospit
admiss
past
month
associ
significantli
increas
lci
cond
acin
unchang
conclus
children
cf
present
cough
recent
hospit
admiss
significantli
wors
ventil
distribut
outcom
abil
ventil
distribut
outcom
predict
exacerb
monitor
treatment
need
assess
introduct
pulmonari
arteri
hypertens
pah
recogn
complic
advanc
lung
diseas
patient
cystic
fibrosi
cf
exact
preval
unknown
given
invas
natur
cardiac
catheter
gold
standard
method
diagnos
pah
earli
detect
manag
pah
could
improv
outcom
cf
patient
diamet
main
pulmonari
arteri
mpa
ascend
aorta
ao
readili
measur
chest
ct
scan
enlarg
mpa
increas
mpa
ao
ratio
associ
pah
adult
cutoff
mpa
ao
ratio
healthi
subject
found
ratio
exceed
indic
pah
recent
data
institut
suggest
upper
limit
normal
ratio
higher
children
adult
object
defin
preval
pah
pediatr
cf
patient
base
measur
mpa
ao
ratio
chest
ct
scan
use
ageappropri
refer
data
assess
relationship
mpa
ao
ratio
lung
function
cf
method
retrospect
studi
cf
patient
age
year
underw
chest
ct
scan
test
part
clinic
evalu
manag
cf
clinic
hospit
sick
children
toronto
januari
januari
clinic
characterist
pulmonari
function
test
chest
ct
scan
record
pulmonari
function
test
best
avail
valu
within
three
month
ct
scan
use
analysi
mpa
diamet
aortic
ao
diamet
measur
level
bifurc
chest
ct
scan
describ
measur
independ
perform
two
pediatr
radiologist
blind
pulmonari
function
result
result
total
patient
identifi
chest
ct
scan
perform
clinic
indic
time
period
mean
age
sd
patient
group
year
mean
group
predict
mean
sd
mpa
ao
ratio
cf
patient
rang
use
adult
cutoff
mpa
ao
ratio
patient
would
met
criteria
pah
howev
ageappropri
cutoff
ratio
use
patient
found
posit
use
linear
regress
analysi
associ
observ
mpa
ao
ratio
age
similarli
mpa
ao
ratio
show
signific
correl
percent
predict
conclus
knowledg
first
studi
assess
relationship
mpa
ao
ratio
surrog
pah
lung
function
pediatr
cf
patient
age
appropri
referenc
data
reduc
preval
increas
mpa
ao
ratio
whether
mpa
ao
ratio
predict
subsequ
clinic
outcom
requir
investig
refer
compton
gl
et
al
ajr
j
roentgenol
demonstr
increas
respiratori
rate
alter
breath
pattern
sleep
children
cf
compar
healthi
control
independ
age
bmi
lung
function
advanc
cf
lung
diseas
work
breath
contribut
significantli
pulmonari
cachexia
previous
assess
effect
high
flow
nasal
insuffl
hfni
respiratori
pattern
children
obstruct
sleep
apnea
osa
found
hfni
reduc
respiratori
rate
effort
sleep
purpos
studi
assess
effect
hfni
quiet
wake
sleep
individu
advanc
cf
lung
diseas
hypothesi
hypothes
individu
cf
sleep
impos
increas
cardiorespiratori
load
allevi
hfni
method
polysomnographi
psg
analyz
cardiorespiratori
load
ga
exchang
quiet
wake
nrem
sleep
brief
trial
hfni
turn
lmin
altern
minut
chang
respiratori
rate
f
tidal
volum
oxygen
satur
sao
transcutan
co
tcco
puls
rate
compar
hfni
case
seri
three
particip
underw
psg
altern
onoff
hfni
trial
mean
age
year
mean
fev
predict
mean
bmi
zscore
kgm
mean
percentag
nrem
sleep
time
mean
ahi
eventshr
indic
none
particip
osa
subject
show
moder
sever
tachypnea
quiet
wake
mean
breathsmin
increas
nrem
sleep
mean
breathsmin
consist
previous
publish
find
decreas
mean
tidal
volum
decreas
mean
sao
increas
tcco
quiet
wake
nrem
sleep
compar
quiet
wake
hfni
decreas
mean
f
reduc
mean
puls
rate
increas
tidal
volum
nearli
twofold
nrem
sleep
moreov
hfni
increas
sao
decreas
tcco
conclus
studi
consist
demonstr
increas
respiratori
rate
sleep
relev
diseas
biomark
individu
sever
cf
lung
diseas
exhibit
increas
cardiorespiratori
load
quiet
wake
nrem
sleep
allevi
hfni
sleep
furthermor
use
hfni
lessen
cardiorespiratori
load
sleep
may
associ
improv
respir
ga
exchang
also
signific
save
metabol
cost
breath
sleep
support
work
support
part
cff
smp
nih
hs
fischer
r
flume
pa
vandevant
dr
polu
k
pecoraro
bhatt
n
elborn
js
munich
germani
medic
univers
south
carolina
charleston
sc
usa
case
western
reserv
univers
school
medicin
cleveland
oh
usa
raptor
pharmaceut
novato
ca
usa
queen
univers
belfast
unit
kingdom
object
levofloxacin
inhal
solut
li
quinsair
recent
approv
ema
treatment
adult
cystic
fibrosi
p
aeruginosa
base
result
random
openlabel
three
onoff
cycl
noninferior
comparison
tobramycin
inhal
solut
ti
patient
year
age
stuart
ej
et
al
j
cyst
fibro
describ
efficaci
result
among
patient
year
basi
li
approv
method
data
patient
subgroup
studi
leastsquar
ls
mean
differ
absolut
chang
baselin
bl
forc
expiratori
volum
second
fev
percent
predict
end
ondrug
visit
determin
ancova
adjust
region
baselin
fev
predict
time
pulmonari
exacerb
pex
defin
either
antipseudomon
antibiot
abx
treatment
b
abx
treatment
presenc
wors
respiratori
symptom
compar
treatment
group
use
cox
proport
hazard
term
treatment
region
baselin
fev
predict
figur
conclus
mean
fev
chang
bl
end
treatment
greater
li
ti
patient
statist
signific
differ
second
third
treatment
cycl
adult
patient
receiv
li
lower
hazard
pex
studi
introduct
pseudomona
aeruginosa
pa
common
pathogen
patient
cf
frequent
target
antibiot
therapi
pulmonari
exacerb
pex
standard
care
clinician
monitor
sputum
cultur
drive
antibiot
choic
howev
poor
correl
drug
suscept
test
dst
result
clinic
outcom
treatment
pex
sinc
center
limit
dst
pa
annual
purpos
studi
assess
impact
chang
practic
clinic
outcom
patient
method
prior
pa
dst
perform
routin
everi
month
outpati
isol
first
isol
admiss
upon
request
clinician
sinc
dst
limit
first
isol
year
evalu
number
cultur
dst
pa
well
clinic
outcom
patient
year
chang
practic
includ
adult
pediatr
patient
analysi
result
object
assess
whether
children
cf
provid
accur
estim
lung
function
method
children
cf
seen
center
cf
provid
ask
qualit
estim
lung
function
comparison
prior
visit
bettersamewors
quantit
estim
current
fev
immedi
perform
spirometri
qualit
assess
compar
actual
fev
chang
better
fev
higher
prior
fev
within
wors
fev
lower
prior
quantit
assess
compar
current
fev
underestim
estim
lower
actual
fev
accur
estim
within
fev
overestim
estim
higher
fev
explor
factor
associ
categori
result
total
cf
patientprovid
encount
includ
mean
age
sd
year
male
patient
thought
lung
function
better
last
visit
time
wors
provid
number
agreement
qualit
estim
actual
categori
low
patient
moder
provid
patientsprovid
agreement
also
low
provid
year
experi
better
estim
none
covari
patient
age
sex
race
month
sinc
last
visit
year
best
fev
associ
patient
provid
accuraci
mean
actual
fev
patient
estim
provid
estim
mean
patient
error
mean
provid
error
patient
accur
estim
underestim
overestim
provid
number
patientprovid
agreement
moder
see
tabl
longer
visit
interv
associ
greater
error
patient
p
provid
p
experi
associ
slightli
lower
provid
error
case
patient
provid
underestim
fev
case
overestim
fev
high
risk
group
longer
interv
visit
show
nonsignific
trend
toward
higher
odd
high
risk
group
conclus
cf
patient
provid
percept
lung
function
low
moder
accur
best
reli
subject
impress
may
place
patient
risk
unnecessari
treatment
patient
high
risk
increas
morbid
longer
visit
interv
associ
higher
risk
overestim
lung
function
find
highlight
import
frequent
object
lung
function
assess
rather
reli
patient
provid
subject
impress
azithromycin
use
associ
electrocardiograph
abnorm
includ
qtc
prolong
particularli
taken
combin
qtc
prolong
drug
qtpd
albert
rk
et
al
j
respir
crit
care
med
kezerashvili
et
al
j
interv
card
electrophysiol
cf
patient
may
increas
risk
qtc
prolong
ventricular
arrhythmia
va
due
cat
without
administr
addit
qtpd
often
prescrib
treatment
cf
pulmonari
exacerb
method
perform
retrospect
review
telemetri
record
medic
use
cf
patient
admit
tertiari
care
medic
center
cf
patient
least
one
telemetri
record
hospit
includ
studi
longest
record
qtc
interv
valu
collect
patient
demograph
cat
admiss
inpati
qtpd
use
collect
electron
medic
record
primari
object
evalu
differ
qtc
interv
patient
cat
vs
cat
secondari
object
evalu
incid
va
patient
cat
vs
cat
influenc
addit
nonazithromycin
qtpd
qtc
result
identifi
telemetri
record
cf
patient
hospit
year
studi
cohort
male
mean
age
year
rang
year
mean
length
hospitalstay
day
averag
length
telemetri
day
patient
take
cat
admiss
hospit
encount
one
patient
cat
discontinu
admiss
qtpd
commonli
use
cohort
includ
ondansetron
azol
antifung
fluoroquinolon
signific
differ
longest
record
qtc
interv
patient
cat
vs
cat
vs
respect
gener
linear
model
glm
signific
associ
age
sex
cat
longest
qtc
respect
howev
glm
assess
total
number
qtpd
includ
cat
rang
adjust
age
sex
signific
associ
longest
qtc
interv
six
arrhythmia
note
patient
studi
period
includ
episod
nonsustain
ventricular
tachycardia
rang
beat
episod
atrial
fibril
signific
differ
incid
va
patient
cat
vs
cat
p
conclus
physician
routin
face
question
discontinu
cat
prescrib
qtpd
cf
patient
find
demonstr
signific
differ
qtc
base
cat
howev
cumul
number
qtpd
monitor
caution
futur
multicent
studi
consid
valid
find
object
cf
patient
expos
repeat
xray
comput
tomographi
ct
examin
may
problemat
due
cumul
radiat
dose
lung
magnet
reson
imag
mri
appear
promis
altern
ct
new
method
ultrashort
echo
time
ute
mri
improv
lung
imag
qualiti
avoid
motion
corrupt
imag
breath
hold
prospect
gate
acquisit
end
expir
usual
use
breath
hold
durat
limit
acquisit
durat
spatial
coverag
resolut
retrospect
gate
allow
reconstruct
imag
multipl
phase
respiratori
cycl
work
studi
new
method
retrospect
sort
data
acquir
free
breath
obtain
wholelung
coverag
high
isotrop
spatial
resolut
diagnost
perform
new
mri
techniqu
compar
ct
method
ute
mri
sequenc
use
acquir
data
free
breath
adult
cf
patient
ct
imag
avail
ct
acquir
year
mri
selfgat
method
use
reconstruct
motionsuppress
imag
mm
isotrop
spatial
resolut
endexpir
endinspir
subject
helbichbhalla
score
determin
use
endinspir
mri
data
ct
data
independ
spearman
intraclass
correl
consist
icc
mean
percentag
error
comput
result
averag
mri
data
acquisit
durat
min
sever
bronchiectasi
peribronchi
wall
thicken
could
well
assess
mri
imag
helbichbhalla
score
well
correl
modal
consist
method
moder
icc
may
link
fact
averag
score
lower
use
mri
compar
ct
preliminari
report
encourag
correl
ute
mri
ct
observ
assess
proxim
distal
airway
disord
without
requir
breath
hold
gate
hardwar
mri
examin
helbichbhalla
score
comput
use
mri
averag
lower
ct
comparison
delic
long
time
interv
examin
year
averag
colistimeth
sodium
coli
via
nebul
complex
time
consum
although
treatment
burden
nebul
therapi
document
clinic
studi
eas
use
inhal
antibiot
perform
date
studi
compar
eas
use
tobramycin
inhal
powder
tip
administ
via
inhal
ti
coli
administ
via
nebul
treat
chronic
pulmonari
pseudomona
aeruginosa
infect
patient
cystic
fibrosi
cf
openlabel
crossov
intervent
phase
iv
studi
approxim
durat
consist
screen
visit
visit
cycl
visit
cycl
visit
cf
patient
age
year
fev
normal
predict
valu
assign
treatment
arm
colitip
tistip
tip
tip
cycl
base
patient
usual
inhal
antibiot
treatment
patient
cross
receiv
tip
cycl
cycl
consist
ontreat
period
follow
offtreat
period
studi
primarili
compar
total
administr
time
time
requir
set
devic
administ
drug
clean
devic
tip
via
inhal
ti
coli
via
nebul
treatment
satisfact
evalu
treatment
satisfact
questionnair
medic
tsqm
chronic
treatment
accept
accept
questionnair
safeti
paramet
also
assess
result
total
patient
mean
sd
age
year
assign
treatment
arm
follow
tistip
colitip
tiptip
mean
total
administr
time
cycl
vs
cycl
tistip
colitip
tiptip
arm
min
vs
min
min
vs
min
min
vs
min
respect
differ
mean
total
administr
time
significantli
shorter
cycl
crossov
tip
cycl
tistip
min
colitip
min
arm
median
tsqm
score
conveni
domain
high
tistip
colitip
tiptip
cycl
either
improv
tistip
colitip
sustain
tiptip
cycl
score
accept
questionnair
follow
similar
pattern
treatmentrel
advers
event
cycl
report
patient
respect
major
mild
moder
intens
conclus
significantli
lower
administrationclean
time
improv
tsqmaccept
score
suggest
tip
easi
use
cf
patient
treat
pulmonari
p
aeruginosa
infect
safeti
result
observ
tip
studi
gener
consist
establish
safeti
profil
studi
sponsor
novarti
pharma
ag
background
restless
leg
syndrom
rl
sensorimotor
disord
clinic
diagnosi
character
urg
move
leg
bodi
part
begin
worsen
rest
inact
reliev
movement
occur
primarili
even
preval
gener
popul
higher
chronic
medic
condit
like
rheumatolog
disord
chronic
obstruct
pulmonari
diseas
copd
iron
defici
dysfunct
iron
metabol
dopamin
regul
hypothes
play
role
diseas
pathogenesi
cystic
fibrosi
cf
lead
multisystem
diseas
includ
chronic
inflammatori
lung
diseas
rl
wide
rang
sever
mere
annoy
sever
enough
disturb
sleep
qualiti
life
warrant
treatment
sleep
complaint
common
cf
patient
date
rl
symptom
preval
extens
investig
cf
popul
object
evalu
preval
sever
rl
patient
cf
investig
factor
associ
rl
among
adult
cf
method
total
adult
patient
cf
control
particip
without
cf
enrol
rl
survey
administ
singl
member
research
team
boardcertifi
sleep
physician
diagnosi
rl
made
accord
intern
rl
studi
group
irlssg
criteria
studi
subject
criteria
classifi
definit
rl
signific
rl
defin
symptom
occur
twice
per
week
least
moder
distress
epworth
sleepi
scale
ess
use
assess
excess
daytim
somnol
risk
factor
evalu
includ
lung
function
time
enrol
cftr
genotyp
age
sputum
microbiolog
antibiot
use
day
preced
year
presenc
cfrelat
diabet
cfrd
hemoglobin
serum
hemoglobin
vitamin
level
age
sex
bodi
mass
index
bmi
famili
histori
rl
result
rl
significantli
preval
cf
patient
control
vs
p
signific
maintain
control
bmi
age
sex
ess
score
rl
famili
histori
rl
signific
symptom
compar
none
control
group
trend
toward
increas
antibiot
use
day
lower
bmi
lung
function
signific
rl
reach
statist
signific
among
covari
analyz
sputum
microbiolog
cftr
mutat
type
cfrd
vitamin
level
hemoglobin
predict
develop
rl
multivari
logist
regress
subject
show
ess
score
factor
predict
rl
adjust
covari
cf
statu
conclus
rl
highli
preval
cf
patient
add
diseas
burden
specif
investig
part
overal
manag
improv
qualiti
life
data
singl
center
suggest
signific
rl
preval
cf
may
associ
advanc
diseas
larger
studi
multipl
cf
site
need
adequ
power
analysi
rl
signific
symptom
conrad
dj
medicin
uc
san
diego
san
diego
ca
usa
introduct
model
lung
function
time
cf
import
assess
sever
acut
ill
diseas
risk
spirometri
easi
obtain
reproduc
pose
minim
risk
patient
linear
model
lung
function
gener
lung
function
quantil
use
assess
genomicgenet
diseas
risk
howev
linear
model
less
use
studi
requir
shortterm
model
lung
function
metabolom
metagenom
investig
model
chang
median
quantil
spline
captur
variat
spline
use
variabl
creat
lung
function
dynam
phenotyp
method
subject
follow
adult
cf
clinic
sign
consent
spirometri
studi
calendar
year
includ
studi
median
quantil
spline
fit
patient
r
packag
qsreg
spline
period
first
recent
divid
interv
valu
median
spline
well
first
second
deriv
calcul
interv
patient
follow
variabl
calcul
effect
degre
freedom
spline
b
number
local
maxima
minima
spline
first
deriv
second
deriv
c
rang
percentil
valu
spline
first
deriv
second
deriv
median
valu
first
second
deriv
correl
variabl
clinic
paramet
class
dynam
lung
function
variabl
creat
correl
clinic
phenotyp
use
publish
protocol
conrad
dj
bailey
ba
plo
one
correl
physiolog
clinic
variabl
clinic
phenotyp
result
mani
subject
median
quantil
spline
identifi
shortterm
variat
lung
function
result
import
clinic
event
none
nine
individu
lung
function
dynam
variabl
correl
significantli
demograph
clinic
variabl
height
weight
bmi
age
gender
etc
dynam
class
gener
nine
variabl
form
group
classif
error
rate
strategi
identifi
stabl
intermedi
hypervari
dynam
phenotyp
stabl
dynam
phenotyp
seen
frequent
expect
cf
clinic
phenotyp
maledomin
phenotyp
excel
lung
function
nutrit
statu
intermedi
hypervari
phenotyp
seen
two
femaledomin
clinic
phenotyp
group
either
good
lung
function
clinic
phenotyp
c
wors
clinic
phenotyp
e
phenotyp
c
clinic
unstabl
patient
low
incid
pseudomona
higher
incid
combin
mssa
aspergillu
airway
infect
conclus
nonlinear
model
use
median
quantil
spline
use
pick
clinic
relev
shortterm
variat
lung
function
compar
standard
linear
model
furthermor
creat
class
lung
function
dynam
variabl
identifi
stabl
hypervari
phenotyp
use
character
publish
clinic
phenotyp
collin
n
steel
l
irv
carr
sb
davi
jc
physiotherapi
royal
brompton
hosp
london
unit
kingdom
paediatr
respiratori
medicin
royal
brompton
hosp
london
unit
kingdom
gene
therapi
imperi
colleg
london
unit
kingdom
background
earli
detect
organ
pseudomona
aeruginosa
pa
cf
essenti
success
erad
detect
howev
difficult
nonexpector
children
reli
larg
cough
swab
cs
suboptim
sensit
specif
uk
cystic
fibrosi
trust
antibiot
work
group
ed
cs
also
use
detect
nontubercul
mycobacteria
ntm
ahm
b
et
al
arch
di
child
sputum
induct
si
found
safe
feasibl
higher
rate
posit
bacteri
cultur
sameday
cs
jochmann
et
al
pediatr
pulmonol
increasingli
use
si
nonexpector
children
detect
infect
assess
respons
erad
intervent
object
compar
cultur
result
si
day
cs
assess
impact
treatment
decis
method
children
cf
refer
si
infect
suspect
despit
neg
cs
cultur
b
confirm
erad
treatment
success
cs
bronchodil
hyperton
salin
nebulis
via
ultrason
ultraneb
devilbiss
healthcar
min
spirometri
perform
pre
postand
interv
throughout
inhal
children
old
enough
perform
maneuv
satur
monitor
auscult
perform
sputum
collect
children
unabl
expector
receiv
oropharyng
op
suction
sampl
sent
microscopi
cultur
sensit
fungal
afb
analysi
result
patient
mean
age
rang
male
complet
si
old
enough
perform
spirometri
median
fev
z
score
rang
patient
manag
expector
sputum
si
receiv
op
suction
patient
refer
due
reason
refer
due
reason
b
patient
posit
bacteri
fungal
ntm
growth
si
pa
aureu
aspergillu
ntm
bacteria
patient
grew
organ
si
grew
organ
preced
cs
patient
posit
cs
neg
si
result
si
inform
clinic
manag
patient
patient
refer
si
check
erad
pa
grown
previou
cs
follow
treatment
clear
pa
si
remain
neg
determin
cs
month
clear
pa
si
regrew
within
month
grew
pa
si
situat
recomm
treatment
admit
iv
antibiot
therapi
conclus
si
higher
rate
posit
cultur
sameday
cs
identifi
ntm
obtain
cs
growth
si
good
predictor
success
erad
pa
follow
antibiot
therapi
month
si
thu
use
test
incorpor
clinic
manag
armori
deterior
patient
erad
therapi
inform
clinic
manag
almost
half
patient
refer
introduct
pulmonari
exacerb
common
children
cf
frequent
treat
outpati
set
oral
antibiot
limit
data
detail
characterist
exacerb
chang
occur
oral
antibiot
sought
prospect
determin
chang
lung
function
sputum
bacteri
coloni
count
cohort
children
cf
treat
oral
antibiot
outpati
set
pulmonari
exacerb
method
patient
age
year
prescrib
oral
antibiot
pulmonari
exacerb
enrol
subject
seen
first
visit
within
hour
start
antibiot
spirometri
preand
postbronchodil
perform
sputum
sampl
expector
induc
obtain
quantit
microbiolog
viral
test
subject
complet
two
week
oral
antibiot
second
visit
perform
within
one
week
complet
antibiot
spirometri
quantit
sputum
microbiolog
repeat
intend
captur
preand
postexacerb
data
subject
result
date
patient
median
age
rang
enrol
complet
preand
postantibiot
studi
visit
median
baselin
fev
base
highest
fev
month
prior
first
visit
predict
compar
median
fev
patient
year
age
cf
center
exacerb
onset
median
fev
cohort
predict
repres
median
decreas
fev
predict
prior
antibiot
therapi
rang
p
fev
improv
median
predict
rang
p
complet
treatment
fev
percent
predict
improv
greater
baselin
fev
valu
subject
ci
virus
identifi
subject
sampl
ci
primari
bacteria
identifi
sputum
cultur
methicillinsensit
staphylococcu
aureu
pseudomona
aeruginosa
methicillinresist
aureu
haemophilu
influenza
quantit
microbiolog
cultur
result
avail
fifteen
subject
two
time
point
subject
densiti
dominantdetect
bacteria
decreas
log
cfuml
log
log
conclus
treatment
pulmonari
exacerb
outpati
antibiot
associ
improv
fev
median
improv
similar
previous
report
studi
exacerb
treat
iv
antibiot
sander
db
et
al
pediatr
pulmonol
onethird
patient
improv
within
baselin
fev
similar
fail
return
baselin
fev
iv
antibiot
sander
db
et
al
trend
suggest
decreas
bacteri
densiti
howev
rang
larg
suggest
wide
variabl
antibiot
respons
lindblad
rosberg
gustafsson
p
dept
pediatr
sweden
clinic
physiolog
queen
silvia
children
hospit
gothenburg
sweden
dept
pediatr
queen
silvia
children
hospit
gothenburg
sweden
background
nitrogen
multipl
breath
washout
n
mbw
perform
commerci
equip
exhalyz
eco
medic
children
age
year
evalu
children
year
method
n
mbw
sf
mbw
use
massspectrometri
perform
children
age
year
cf
bronchopulmonari
dysplasia
oesophag
atresia
n
mbw
undertaken
without
prime
n
mbw
chlorat
hydrat
mgkg
use
sedat
mean
three
washout
aim
test
lung
clearanc
index
lci
use
assess
ventil
distribut
effici
equip
similar
prepostcapillari
dead
space
ds
filter
use
ml
respect
result
mean
sd
lci
sf
lci
n
p
frcsf
frcn
differ
significantli
differ
ml
vs
ml
tidal
volum
use
washout
ga
significantli
lower
compar
use
sf
tracer
ga
vs
ml
p
cev
sf
l
vs
cev
n
l
p
differ
chang
significantli
tidal
volum
prime
ml
lci
even
higher
conclus
n
mbw
produc
markedli
higher
lci
valu
sf
mbw
approxim
unit
similar
result
obtain
prime
child
suggest
prime
enough
normal
tidal
breath
possibl
explan
might
releas
tissu
n
due
rel
high
cardiac
output
young
children
smaller
tidal
volum
pure
oxygen
breath
decreas
alveolar
ventil
therebi
increas
number
breath
cev
combin
anderson
c
gao
donnola
kavran
drumm
ml
mcbennett
k
darrah
rm
flask
ca
biomed
engin
case
western
reserv
univ
cleveland
oh
usa
radiolog
case
western
reserv
univ
cleveland
oh
usa
genet
case
western
reserv
univ
cleveland
oh
usa
pediatr
case
western
reserv
univ
cleveland
oh
usa
rainbow
babi
children
hospit
cleveland
oh
usa
medicin
case
western
reserv
univ
cleveland
oh
usa
nurs
case
western
reserv
univ
cleveland
oh
usa
background
imag
potenti
power
tool
care
monitor
cf
patient
quantit
mri
hold
promis
safe
noninvas
method
perform
measur
lung
diseas
one
major
challeng
mri
lung
artifact
caus
respir
motion
manual
breathhold
typic
use
limit
motion
artifact
impract
patient
advanc
lung
diseas
infant
magnet
reson
fingerprint
mrf
novel
quantit
mri
method
demonstr
motion
insensit
clinic
preclin
applic
et
al
natur
gao
et
al
nmr
biom
studi
evalu
mrfbase
dictionari
match
process
respect
reduc
impact
respiratori
motion
artifact
mri
quantif
object
assess
impact
mrfbase
dictionari
match
respiratori
motion
artifact
relax
time
estim
method
numer
simul
use
model
convent
inversionrecoveri
looklock
irll
relax
time
mri
acquisit
use
numer
shepplogan
phantom
simul
irll
mri
data
corrupt
respiratori
motion
spike
stochast
nois
repres
real
lung
mri
data
quantit
relax
time
map
estim
use
dictionarybas
match
process
well
convent
leastsquar
error
fit
simul
data
simul
perform
respiratori
motion
artifact
alon
combin
stochast
nois
simul
experi
repeat
time
calcul
mean
standard
deviat
error
rang
valu
result
respiratori
motion
artifact
dictionari
match
result
significantli
reduc
error
ms
compar
standard
exponenti
fit
error
ms
p
combin
respiratori
motion
artifact
nois
result
larger
error
estim
method
howev
error
dictionarybas
match
process
remain
smaller
exponenti
fit
error
ms
vs
ms
p
conclus
initi
simul
studi
demonstr
dictionarybas
match
algorithm
employ
magnet
reson
fingerprint
result
significantli
reduc
error
respiratori
motion
artifact
comparison
convent
fit
techniqu
result
consist
prior
studi
qualit
describ
motion
insensit
mrf
importantli
result
suggest
opportun
use
dictionarybas
match
process
accur
quantif
freebreath
mri
studi
could
directli
limit
need
anesthesia
patient
background
li
improv
lung
function
reduc
exacerb
frequenc
patient
homozyg
howev
worsen
respiratori
symptom
report
individu
addit
lack
data
patient
sever
lung
diseas
predict
fev
purpos
studi
evalu
safeti
toler
li
includ
patient
sever
lung
diseas
method
retrospect
singl
center
descript
studi
patient
start
li
usckeck
cf
clinic
clinic
drug
challeng
monitor
perform
pharmacist
respiratori
therapist
peak
flow
pf
borg
score
perform
baselin
period
interv
challeng
dose
assess
toler
followup
visit
perform
assess
side
effect
result
total
patient
initi
li
center
initi
without
observ
median
age
year
old
male
median
bmi
kgm
seven
patient
pred
patient
start
observ
set
twelv
patient
subject
note
slight
increas
work
breath
chest
tight
follow
first
orkambi
dose
improv
albuterol
administr
observ
chang
median
peak
flow
borg
score
howev
five
patient
experienc
pf
reduct
rang
decreas
symptom
requir
albuterol
administr
increas
borg
score
note
patient
patient
went
home
full
dose
fdaapprov
dosag
adjust
base
ddi
hepat
impair
ten
patient
discontinu
li
initi
patient
start
orkambi
undergo
observ
dose
patient
discontinu
due
rash
swell
face
respiratori
intoler
vs
exacerb
complianc
lab
followup
appoint
increas
anxieti
persist
respiratori
intolerancetight
lumacaftorivacaftor
discontinu
li
greatest
patient
sever
lung
diseas
patient
fev
order
improv
toler
li
initi
slow
dose
titrat
one
patient
coadministr
prednison
anoth
patient
sinc
discontinu
li
due
respiratori
intolerancetight
conclus
subject
report
advers
respiratori
symptom
initi
lumacaftorivacaftor
common
chang
peak
flow
borg
score
uncommon
suggest
symptom
subject
natur
could
overcom
slower
dose
titrat
increas
bronchodil
usag
particulari
sever
lung
diseas
pediatr
children
hospit
richmond
virginia
commonwealth
univers
richmond
va
usa
chemic
life
scienc
engin
virginia
commonwealth
univers
richmond
va
usa
rational
despit
aggress
therapi
pulmonari
exacerb
overal
cours
cystic
fibrosi
cf
lung
diseas
relentless
progress
cf
lung
diseas
sever
directli
correl
airway
neutrophil
elastas
ne
activ
current
paradigm
sputum
ne
decreas
follow
treatment
pulmonari
exacerb
howev
publish
report
demonstr
inhal
dornas
increas
ne
activ
cf
sputum
therefor
increas
mucolyt
therapi
treatment
pulmonari
exacerb
may
paradox
increas
ne
activ
promot
cf
lung
diseas
progress
hypothesi
despit
clinic
improv
cf
patient
follow
treatment
pulmonari
exacerb
observ
increas
fev
decreas
sputum
viscoelast
sputum
ne
activ
may
increas
method
retrospect
studi
nine
cf
subject
ten
hospit
subject
provid
consent
particip
vcu
sputum
biorepositori
sputum
collect
spirometri
perform
hospit
home
intraven
antibiot
therapi
follow
remov
saliva
sputum
aliquot
store
frozen
sputum
thaw
divid
rheolog
biomark
analysi
rheolog
analysi
perform
stresscontrol
rheomet
ta
instrument
use
aluminum
parallel
plate
geometri
viscou
g
elast
g
moduli
strain
rad
report
ne
analysi
sputum
dilut
normal
salin
w
v
mix
incub
centrifug
ne
activ
quantifi
supernat
spectrophotometr
assay
use
ne
substrat
sucalaalaprovalpnitroanalid
test
whether
mucolyt
hyperosmolar
therapi
affect
ne
activ
addit
sputum
sampl
dilut
normal
salin
without
dornas
alfa
mgm
hyperton
salin
hs
nacl
mannitol
w
v
sputum
supernat
ne
activ
measur
knowledg
impact
hyperosmolar
therapi
includ
hs
mannitol
ne
activ
sputum
previous
report
result
signific
increas
fev
predict
signific
decreas
g
g
admiss
discharg
five
hospit
increas
ne
activ
chang
slight
decreas
ne
activ
patient
sampl
vitro
sputum
treatment
dornas
hs
mannitol
significantli
increas
ne
activ
conclus
result
suggest
therapi
pulmonari
exacerb
may
increas
airway
ne
activ
result
increas
inflammatori
load
despit
overal
clinic
improv
vitro
assay
demonstr
dornas
hs
increas
ne
activ
cf
sputum
therefor
attribut
increas
ne
activ
least
part
dornas
andor
hs
therapi
observ
support
develop
antiproteas
antiinflammatori
therapi
cf
patient
protect
lung
unoppos
ne
activ
support
cff
care
guidelin
children
year
age
evid
moder
lung
diseas
chronic
symptom
publish
guidelin
newborn
diagnos
cf
support
use
dornas
alfa
symptomat
infant
role
dornas
alfa
asymptomat
infant
cf
remain
unclear
provid
basi
retrospect
analysi
method
data
gather
chart
children
current
age
year
nemour
cf
center
includ
patient
group
accord
whether
dornas
alfa
initi
asymptomat
infant
month
vs
onset
symptom
month
group
dornas
alfa
compar
base
measur
lung
function
time
acquisit
p
aeruginosa
pa
aureusmethicillinsensit
mssa
methicillinresist
mrsa
strain
time
first
hospit
also
total
number
respiratori
hospit
data
avail
express
mean
sd
compar
ttest
result
children
earli
initi
dornas
alfa
similar
initi
month
age
time
first
acquisit
pa
similar
patient
earli
initi
dornas
alfa
mo
vs
initi
mo
month
time
first
acquisit
mrsa
similar
patient
earli
initi
dornas
alfa
month
vs
initi
month
month
time
first
acquisit
mssa
seen
earlier
patient
earli
initi
dornas
alfa
month
vs
initi
month
month
bmi
similar
earli
initi
vs
initi
month
time
first
hospit
slightli
increas
follow
earli
initi
dornas
alfa
month
vs
initi
month
month
number
total
hospit
similar
group
vs
safeti
concern
document
patient
receiv
dornas
alfa
conclus
earli
initi
dornas
alfa
center
improv
bmi
number
respiratori
hospit
prolong
time
acquisit
pa
mrsa
compar
children
dornas
alfa
start
symptom
aris
interestingli
acquisit
mssa
earlier
dornas
alfa
initi
month
trend
toward
increas
time
first
hospit
indetermin
extend
work
use
development
dataset
patient
randomli
select
cystic
fibrosi
foundat
patient
registri
guid
construct
algorithm
identifi
ip
individu
appli
larg
databas
object
develop
comput
algorithm
capabl
identifi
presenc
inflect
point
cours
fev
fvc
ratio
time
cf
patient
classifi
group
describ
method
iter
development
process
determin
yearli
best
yb
person
best
pb
fev
fvc
valu
best
confirm
pattern
propos
menendez
et
al
ip
defin
start
yb
fev
fvc
valu
normal
rang
b
consecut
yb
valu
observ
popul
standard
deviat
pb
c
yb
valu
observ
prior
consecut
point
ip
defin
last
prior
valu
develop
mathemat
definit
group
piecewis
linear
regress
model
discontinu
use
determin
preand
postip
rate
chang
fev
fvc
slope
individu
patient
result
group
mean
postip
slope
significantli
differ
zero
p
mean
preip
slope
p
tabl
preand
postip
period
group
separ
larg
discontinu
decreas
fev
fvc
singl
year
ip
first
postip
yb
averag
predict
conclus
result
support
concept
inflect
point
fev
fvc
distinctli
differ
behavior
preip
normal
rang
minim
chang
postip
steadili
declin
mean
oneyear
drop
predict
connect
period
futur
work
includ
valid
result
larger
confirm
dataset
result
may
valu
develop
better
clinic
trial
entranc
criteria
outcom
measur
design
epidemiolog
studi
inform
basic
translat
research
quantit
descript
lung
structur
function
follow
long
term
year
ivacaftor
therapi
could
help
elucid
underli
mechan
less
airflow
obstruct
cftr
restor
hypothes
year
ivacaftor
therapi
might
revers
aspect
cf
lung
diseas
method
seven
adult
cf
allel
particip
studi
spirometri
chestct
scan
endinspir
endexpir
obtain
baselin
approxim
year
ivacaftor
therapi
result
l
increas
significantli
baselin
year
ivacaftor
therapi
vs
l
p
quantit
analysi
chest
ct
scan
indic
littl
chang
inspiratori
lung
volum
vs
l
p
signific
decreas
expiratori
lung
volum
vs
l
p
volum
trap
air
lung
assess
expiratori
ct
scan
use
threshold
reduc
ivacaftor
therapi
vs
p
conclus
first
observ
improv
spirometri
air
trap
second
wthe
reduct
air
trap
associ
improv
residu
volum
final
addit
quantit
airway
measur
hope
gain
addit
insight
underli
mechan
ivacaftor
effect
cf
diseas
pathogenesi
major
cf
patient
us
receiv
care
cf
care
center
accredit
cf
foundat
strong
associ
establish
care
center
improv
patient
outcom
care
center
model
allow
standard
may
creat
travel
burden
patient
cf
travel
burden
impact
travel
distanc
health
care
studi
multipl
health
disciplin
associ
wors
outcom
howev
impact
travel
burden
studi
cf
object
primari
object
studi
assess
whether
increas
distanc
care
center
associ
decreas
lung
function
secondari
object
assess
whether
increas
distanc
associ
increas
odd
cfrelat
exacerb
decreas
number
clinic
visit
per
year
method
longitudin
cohort
studi
patient
cffpr
resid
subset
preselect
state
n
exclud
patient
histori
lung
transplant
younger
older
live
mile
care
center
distanc
measur
number
mile
individu
zip
code
zip
code
care
center
primari
analysi
use
multilinear
regress
gener
estim
equat
robust
varianc
estim
model
effect
distanc
percent
predict
fev
multivari
regress
model
effect
distanc
chang
fev
time
secondari
analysi
use
multivari
logist
regress
model
effect
distanc
odd
cfrelat
exacerb
separ
secondari
analysi
use
multivari
linear
regress
estim
effect
distanc
number
clinic
visit
per
year
model
adjust
age
cfrd
pancreat
insuffici
socioeconom
statu
presenc
pseudomona
aeruginosa
methicillinresist
staphylococcu
aureu
burkholderia
speci
respiratori
cultur
result
increas
distanc
care
center
statist
significantli
associ
lower
lung
function
everi
increas
distanc
fev
percent
predict
decreas
ci
p
howev
statist
signific
effect
chang
fev
percent
predict
coeffici
ci
p
odd
cfrelat
exacerb
rel
odd
ci
p
signific
decreas
number
outpati
visit
per
year
distanc
care
center
increas
everi
increas
distanc
number
visit
decreas
ci
p
conclus
associ
distanc
care
center
lung
function
although
clinic
signific
unclear
increas
distanc
care
center
associ
increas
rate
chang
lung
function
increas
odd
exacerb
associ
decreas
number
outpati
visit
research
need
investig
potenti
modifi
risk
factor
structur
health
care
deliveri
similarli
binari
outcom
model
low
oh
significantli
associ
least
one
cf
exacerb
conclus
oh
nutrient
concern
among
cf
patient
use
poisson
binari
outcom
model
found
correl
low
oh
level
increas
cf
exacerb
oh
associ
immun
function
inflamm
low
oh
level
associ
increas
cf
exacerb
annual
imper
monitor
oh
level
supplement
need
achiev
satisfactori
lab
valu
maintain
oh
level
within
accept
paramet
may
decreas
frequenc
cf
pulmonari
exacerb
research
associ
need
kim
stephenson
strug
lj
hospit
sick
children
toronto
canada
adult
cf
program
st
michael
hospit
toronto
canada
background
forc
expiratori
volum
per
second
play
key
role
manag
patient
cystic
fibrosi
cf
use
healthi
popul
norm
commonli
transform
predict
pp
ratio
patient
predict
healthi
individu
share
age
sex
height
healthi
cf
popul
known
differ
growth
characterist
critic
literatur
overcom
limit
cfspecif
refer
equat
use
us
cf
registri
data
gener
publicli
avail
contemporari
canadian
cfspecif
percentil
ile
current
avail
object
deriv
canadian
cfspecif
refer
equat
character
chang
ile
time
compar
us
canadian
cf
ile
method
longitudin
cohort
studi
use
canadian
cf
registri
data
subject
includ
least
one
measur
year
age
first
stabl
measur
per
person
per
year
use
postlung
transplant
measur
exclud
quantil
regress
use
model
ile
function
age
andor
height
stratifi
sex
lung
diseas
progress
compar
use
ile
vs
predict
pp
use
gli
refer
norm
canadian
ile
compar
us
ile
period
result
subject
femal
includ
studi
contribut
measur
taken
increas
exponenti
childhood
adolesc
declin
adulthood
figur
peak
reach
earlier
femal
male
improv
percentil
popul
whole
seen
recent
time
period
compar
improv
time
dramat
measur
percentil
well
male
figur
select
subject
pp
mask
chang
diseas
progress
evid
use
percentil
canadian
cf
patient
higher
ile
compar
us
patient
differ
ile
seen
earli
year
age
increas
lower
ile
male
conclus
canadian
cfspecif
ile
improv
time
provid
use
inform
chang
lung
health
may
mask
use
pp
appli
us
specif
refer
equat
canadian
patient
would
systemat
overestim
canadian
cfspecif
ile
chhatwani
l
mohabir
pk
divis
pulmonari
critic
care
medicin
stanford
univers
stanford
ca
usa
background
object
massiv
hemoptysi
challeng
clinic
problem
cystic
fibrosi
cf
review
center
experi
aim
evalu
risk
factor
clinic
outcom
cf
patient
sinc
clinic
present
signific
associ
morbid
mortal
yet
data
avail
guid
cf
pulmonologist
patient
face
present
method
studi
queri
adult
cf
center
clinic
databas
institut
identifi
patient
massiv
hemoptysi
requir
bronchial
arteri
embol
bae
present
hemoptysi
clinic
data
includ
risk
factor
manag
shortterm
longterm
outcom
review
result
twelv
patient
present
massiv
hemoptysi
patient
requir
bae
one
patient
requir
surgic
resect
higher
proport
male
patient
mean
age
present
year
present
predict
patient
predict
patient
review
microbiolog
respiratori
cultur
show
typic
cystic
fibrosi
organ
without
particular
pattern
identifi
regard
genet
mutat
patient
homozyg
patient
carri
one
copi
mutat
patient
patient
subsequ
present
massiv
hemoptysi
requir
multipl
repeat
bae
procedur
summari
massiv
hemoptysi
lifethreaten
complic
cystic
fibrosi
occur
patient
without
sever
obstruct
lung
diseas
includ
normal
lung
function
present
appear
associ
identifi
risk
factor
futur
manifest
cystic
fibrosi
lung
diseas
massiv
hemoptysi
despit
preserv
lung
function
studi
larg
multicent
cohort
aim
optim
manag
patient
harri
ce
dorkin
h
cataletto
katkin
j
laskosz
l
ruchross
h
mulvey
h
pediatr
lo
angel
ca
usa
pediatr
boston
children
hospit
boston
usa
pediatr
winthrop
mineola
ny
usa
pediatr
texa
children
hospit
houston
tx
usa
care
patient
cystic
fibrosi
past
year
improv
larg
educ
physician
special
expertis
condit
work
cf
foundat
pediatrician
took
task
lead
establish
center
network
promot
qualiti
research
time
pediatrician
becam
suffici
special
board
certif
pediatr
pulmonolog
offer
pediatrician
pass
certif
examin
american
academi
pediatr
survey
workforc
twice
recent
method
object
studi
survey
physician
career
demograph
practic
issu
internet
survey
design
help
aap
divis
workforc
medic
educ
polici
repres
onethird
pediatr
pulmonari
workforc
pediatrician
complet
survey
result
result
compar
possibl
prior
survey
done
averag
complet
medic
school
year
prior
give
averag
age
year
significantli
older
averag
age
year
clinician
spent
median
time
direct
patient
care
nearli
time
teach
research
activ
occupi
time
physician
survey
specialist
involv
basic
scienc
nearli
three
five
involv
clinic
investig
respond
clinic
time
spent
subspecialti
care
provid
primari
care
cf
common
diagnosi
seen
respond
report
part
accredit
cf
center
flexibl
bronchoscopi
lung
function
test
telephon
consult
home
care
common
procedur
activ
clinician
survey
confin
practic
pediatr
nearli
one
twenti
also
saw
adult
nearli
affili
medic
school
half
survey
would
like
add
colleagu
next
three
year
substanti
proport
respond
felt
would
job
avail
futur
insuffici
fund
new
posit
would
make
difficult
fill
nearli
pediatr
pulmonari
workforc
plan
retir
next
five
year
conclus
pediatr
pulmonologist
provid
much
cf
care
us
complex
patient
improv
outcom
seen
accredit
cf
center
although
success
transit
adult
intern
medicin
colleagu
cf
expertis
care
continu
time
consum
clear
pediatr
pulmonari
workforc
age
although
newborn
screen
help
identifi
cf
patient
lung
diseas
sever
number
cf
patient
care
decreas
despit
advanc
therapeut
unlik
cf
disappear
soon
clearli
attent
must
given
attract
traine
pediatr
pulmonolog
especi
major
debt
burden
background
cystic
fibrosi
cf
lead
progress
declin
lung
function
increas
incid
sleep
hypoxemia
patient
sever
lung
diseas
sleep
hypoxemia
cf
patient
propos
independ
paramet
evalu
cf
patient
signific
burden
diseas
laboratori
clinic
surrog
test
sleep
hypoxemia
howev
current
accept
guidelin
evalu
cf
patient
sleep
hypoxemia
polysomnographi
psg
object
aim
studi
determin
indic
cite
polysomnographi
studi
obtain
character
sever
sleep
disord
breath
determin
subgroup
patient
test
show
sleep
hypoxemia
larg
tertiari
pediatr
cystic
fibrosi
center
method
review
electron
medic
record
pediatr
cystic
fibrosi
patient
follow
center
januari
decemb
patient
underw
psg
birthday
includ
note
subject
forc
expiratori
volum
second
time
psg
well
year
highest
valu
psg
done
note
indic
paramet
oxygen
ventil
apnea
indic
defin
sleep
hypoxemia
hemoglobin
satur
averag
total
sleep
time
physician
pediatr
cystic
fibrosi
center
survey
practic
evalu
treatment
sleep
disord
breath
pediatr
cf
patient
written
multipl
choic
questionnair
result
patient
seen
pediatr
cystic
fibrosi
center
studi
period
met
inclus
criteria
total
psg
done
diagnost
studi
evalu
obstruct
sleep
apnea
due
sever
lung
diseas
studi
titrat
noninvas
ventil
cf
exacerb
total
patient
sleep
hypoxemia
age
rang
year
year
highest
valu
rang
predict
patient
obstruct
sleep
apnea
osa
patient
sleep
hypoxemia
frequent
sever
cf
exacerb
hospit
admiss
preced
year
studi
done
rule
osa
posit
physician
report
osa
symptom
subject
poor
sleep
qualiti
common
indic
psg
outpati
respect
wherea
poor
lung
function
least
common
inpati
psg
oxygen
desatur
note
continu
puls
oximetri
common
indic
treatment
choic
sleep
hypoxemia
cf
oxygen
via
nasal
cannula
conclus
pediatr
cf
patient
frequent
exacerb
sleep
hypoxemia
found
patient
high
irrespect
osa
object
novel
transnas
pulmonari
aerosol
deliveri
system
tpad
capabl
administ
nebul
medicin
overnight
sleep
deliv
aerosol
quietli
comfort
via
supplement
oxygenlik
nasal
cannula
develop
parion
scienc
tpad
evalu
adult
ideal
suit
deliveri
medic
pediatr
patient
aerosol
deliveri
particularli
challeng
primari
object
studi
quantit
determin
effici
pulmonari
bodi
deposit
hyperton
salin
hs
aerosol
label
salin
tcdiethylenetriaminepentaacet
acid
dtpa
deliv
via
tpad
children
cystic
fibrosi
well
character
pediatr
pari
lc
sprint
nebul
equip
oral
mouthpiec
instead
facemask
use
control
studi
method
singl
center
random
openlabel
crossov
studi
pulmonari
bodi
deposit
hs
aerosol
deliv
via
parion
tpad
versu
deliv
via
pari
lc
sprint
children
cystic
fibrosi
seven
children
cystic
fibrosi
parent
consent
particip
random
sequenc
complet
aerosol
deposit
nebul
subject
receiv
treatment
tcdtpa
label
nacl
via
tpad
pari
lc
sprint
devic
separ
studi
day
radioact
continu
monitor
dose
head
thorax
gamma
scintigraphi
correct
decay
soft
tissu
attenu
tracer
absorptionclear
primari
studi
endpoint
pulmonari
deposit
tcdtpa
express
percent
emit
dose
deposit
whole
lung
secondari
endpoint
studi
includ
percentag
tc
dtpa
deposit
central
lung
peripher
lung
nasooropharynx
stomach
esophagu
result
aerosol
deliveri
transnas
tpad
oral
lc
sprint
nebul
well
toler
five
seven
studi
particip
perform
deposit
studi
instruct
fulli
evalu
median
valu
subject
present
tabl
pulmonari
deposit
achiev
tpad
approxim
greater
achiev
via
pari
lc
sprint
greater
fraction
dose
deposit
nose
tpad
lc
sprint
lc
sprint
deposit
higher
fraction
stomach
tpad
conclus
observ
adult
tpad
effect
mean
deliv
aerosol
lung
children
tpad
deliv
aerosol
transnas
advantag
oral
nebul
handsfre
deliv
aerosol
extend
period
time
may
offer
therapeut
safeti
advantag
drug
administr
rapidli
via
oral
nebul
greater
longterm
surviv
mani
year
associ
regular
physic
exercis
increas
exercis
capac
cystic
fibrosi
cf
mani
patient
cf
find
achiev
regular
exercis
challeng
adher
daili
physic
activ
shown
mani
studi
cf
poor
object
establish
whether
increas
maxim
cardiopulmonari
exercis
test
cpet
associ
increas
well
adult
cf
across
age
lung
function
spectrum
method
patient
cf
unit
least
one
mutat
elig
treatment
ivacaftor
underw
cpet
use
maxim
increment
cycl
ergomet
use
godfrey
protocol
total
four
month
mo
treatment
ivacaftor
month
crossov
studi
month
openlabel
select
measur
cpet
lung
function
alfr
well
score
cf
awescorecf
measur
sputum
cough
energi
exercis
particip
appetit
weight
mood
anxieti
sleep
gener
health
total
score
present
result
present
mean
rang
adult
male
awescor
well
receiv
patient
took
minut
complet
valu
fact
measur
well
found
visual
pleas
compact
patient
perceiv
less
sputum
cough
treatment
ivacaftor
perceiv
led
improv
sleep
quantiti
qualiti
increas
energi
experienc
may
link
greater
exercis
particip
turn
may
led
improv
lung
function
paramet
exercis
capac
sens
well
conclus
total
month
treatment
ivacaftor
result
signific
improv
lung
function
exercis
time
along
total
well
score
adult
cf
across
age
spectrum
lung
function
studi
support
vertex
inc
background
cystic
fibrosi
cf
pediatr
patient
regular
evalu
includ
aerob
exercis
capac
cycl
ergometri
ce
puls
oximetri
godfrey
protocol
ce
complex
laboratori
test
requir
expens
equip
welltrain
special
personnel
altern
modifi
shuttl
walk
test
mswt
simpl
reliabl
field
test
minim
equip
requir
object
purpos
studi
compar
maximum
effort
calcul
heart
rate
hr
respons
ce
mswt
addit
examin
valid
mswt
promot
use
mswt
simpler
less
expens
method
ce
materi
method
decemb
decemb
stabl
cf
patient
includ
studi
mean
age
mean
bmi
kgm
mean
fev
frequent
mutat
heterozyg
pancreat
insuffici
pancreat
ce
test
perform
use
electron
brake
cycl
ergomet
hold
power
output
constant
independ
variat
cadenc
origin
godfrey
protocol
power
output
increment
w
individu
height
cm
w
cm
w
cm
tall
use
exercis
time
kept
within
min
mswt
carri
standard
fashion
use
cd
player
two
marker
place
apart
patient
pace
shuttl
walk
test
singh
et
al
adapt
valid
use
cf
subject
allow
run
increas
number
level
maximum
speed
km
patient
complet
test
day
second
test
sequenti
carri
interv
least
minut
return
rest
level
valu
paramet
measur
evalu
test
puls
oximet
hr
dyspnea
score
exercis
time
durat
record
distanc
peak
work
rate
measur
valu
express
mean
standard
deviat
ttest
correl
analysi
use
result
patient
abl
achiev
maximum
effort
test
signific
statist
differ
peak
puls
rate
mswt
ppm
ce
ppm
p
final
puls
oximetri
mswt
ce
p
dyspnea
score
averag
test
signific
correl
analysi
distanc
meter
power
watt
r
p
averag
time
durat
mswt
ce
conclus
studi
mswt
achiev
similar
peak
hr
respons
ce
show
strong
correl
power
distanc
statist
differ
final
puls
oximetri
mswt
simpler
less
expens
ce
cost
test
ce
mswt
respect
result
studi
suggest
mswt
lieu
ce
consid
use
institut
limit
resourc
manag
pediatr
cf
patient
mswt
provid
lowcost
effect
altern
exercis
toler
evalu
valid
inform
monitor
prescript
exercis
cf
patient
introduct
exercis
test
import
tool
evalu
care
patient
cystic
fibrosi
cf
robust
evid
surviv
cf
strongli
correl
exercis
test
result
laboratori
test
alway
freeli
avail
feasibl
result
field
exercis
test
often
perform
clinic
set
modifi
shuttl
test
mst
one
field
exercis
test
shown
strong
correl
vo
peak
respons
inpati
treatment
current
publish
norm
data
mst
either
healthi
individu
individu
cf
object
purpos
studi
audit
mst
result
children
cf
determin
factor
eg
age
height
fev
greatest
correl
distanc
factor
percentil
result
calcul
method
medic
record
cf
patient
cover
fouryear
period
retrospect
review
mst
result
note
best
result
year
age
patient
record
result
deem
two
reveiw
submaxim
exclud
correl
measur
distanc
calcul
use
pearson
productmo
coeffici
correl
box
plot
develop
outcom
strongest
correl
distanc
male
femal
show
percentil
result
test
found
subject
best
test
analys
deem
submaxim
leav
test
subject
age
year
subject
normal
mild
diseas
basi
fev
predict
outcom
strongest
correl
distanc
found
height
mean
distanc
cover
increas
increas
height
height
mean
distanc
male
femal
mean
distanc
male
femal
mean
distanc
male
femal
conclus
mst
distanc
strongli
correl
height
age
studi
develop
norm
data
cf
popul
allow
futur
test
compar
result
heightmatch
peer
rr
et
al
jama
pa
individu
cf
improv
exercis
capac
slow
declin
lung
function
increas
mucu
clearanc
improv
healthrel
qualiti
life
dwyer
tj
et
al
curr
opin
pulm
med
measur
ventil
inhomogen
provid
novel
approach
assess
effect
pa
lung
health
hypothesi
less
ventil
inhomogen
measur
lung
clearanc
index
lci
via
multipl
breath
washout
mbw
better
lung
function
via
spirometri
particip
cf
associ
greater
exercis
capac
measur
modifi
shuttl
walk
test
mswt
complet
mswt
spirometri
mbw
first
particip
enrol
bmore
live
fit
trial
random
control
trial
enrol
goal
particip
fit
train
program
design
optim
exercis
habit
yearold
cf
lung
function
measur
via
spirometri
mbw
use
exhalyz
ecomed
switzerland
lung
function
compar
number
mswt
shuttl
complet
enrol
result
particip
male
posit
pseudomona
aeruginosa
cultur
upon
enrol
mean
age
year
mean
bmi
sd
rang
genotyp
particip
includ
homozyg
heterozyg
heterozyg
mutat
mean
mswt
shuttl
complet
sd
rang
mean
sd
rang
mean
lci
sd
rang
mean
lci
sd
rang
mswt
shuttl
correl
better
lung
function
measur
r
p
also
associ
less
ventil
inhomogen
measur
lci
lci
r
p
r
p
respect
conclus
higher
number
mswt
shuttl
correl
better
lung
function
measur
ventil
inhomogen
measur
lci
lci
data
suggest
associ
lci
valu
better
exercis
capac
measur
mswt
base
correl
suggest
lci
similar
predictor
exercis
capac
continu
enrol
bmore
live
fit
trial
use
lci
reveal
improv
individu
mild
lung
diseas
relat
exercis
capac
may
elucid
notabl
one
first
trial
collect
mswt
data
adolesc
young
adult
cf
midst
pulmonari
exacerb
support
herbert
bearman
foundat
dwyer
tj
et
al
curr
opin
pulm
med
posit
effect
physic
condit
lung
function
report
howev
convent
measur
lung
function
may
lack
sensit
reveal
improv
individu
mild
lung
diseas
hypothesi
higher
selfreport
pa
individu
cf
associ
improv
lung
function
measur
lung
clearanc
index
lci
method
physic
activ
measur
selfreport
via
habitu
activ
estim
scale
hae
percentag
time
awak
particip
activ
assess
separ
weekday
versu
weekend
inact
defin
inact
somewhat
inact
categori
wherea
activ
includ
activ
somewhat
activ
categori
lung
function
measur
via
spirometri
multipl
breath
washout
mbw
use
exhalyz
ecomed
switzerland
first
particip
enrol
bmore
live
fit
trial
random
control
trial
enrol
goal
particip
fit
train
program
design
optim
exercis
habit
yearold
cf
result
particip
male
mean
age
year
sd
rang
year
mean
sd
rang
mean
percent
weekday
activ
time
sd
rang
wherea
mean
percent
weekend
activ
time
sd
rang
mean
percent
weekday
inact
time
sd
rang
mean
percent
weekend
inact
time
sd
rang
particip
activ
weekday
tend
activ
weekend
correl
r
p
weekday
weekend
inact
level
also
significantli
correl
r
p
hypothes
signific
neg
correl
lci
lci
r
p
r
p
respect
trend
correl
weekday
activ
level
lci
lci
r
p
r
p
respect
weekday
activ
correl
r
p
weekday
inact
weekend
activ
inact
level
associ
lci
conclus
signific
correl
selfreport
pa
level
ventil
inhomogen
appear
trend
weekday
activ
lci
data
suggest
lci
may
prove
sensit
indic
respons
pa
continu
enrol
bmore
live
fit
trial
trend
may
elucid
introduct
tai
chi
tc
ancient
chines
martial
art
use
control
movement
form
medit
techniqu
aid
postur
strength
wellb
due
risk
cross
infect
group
class
possibl
aim
investig
perceiv
physic
psycholog
benefit
tai
chi
tc
compar
facetofac
internet
base
ib
tc
teach
method
particip
randomis
lesson
home
group
ib
teach
group
cours
eight
tc
form
taught
three
month
eight
lesson
friend
famili
member
allow
learn
semistructur
interview
carri
end
tc
session
telephon
interview
end
studi
conduct
independ
member
research
team
result
fifti
particip
recruit
particip
complet
full
cours
group
age
rang
eleven
particip
withdrew
prior
start
lesson
logist
busi
ill
health
start
tc
group
child
could
see
teacher
ipad
home
comput
broke
miss
lesson
withdraw
ill
health
semistructur
interview
twentythre
report
improv
breath
group
group
eighteen
report
increas
sputum
product
tc
done
prior
airway
clearanc
group
group
eighteen
report
improv
postur
group
group
thirtysix
report
feel
calmer
less
stress
tc
group
group
telephon
interview
group
discuss
enjoy
method
teach
tc
reason
includ
conveni
famili
need
travel
reduc
risk
infect
reduc
embarrass
disrupt
class
cough
comment
includ
abl
take
bigger
breath
abl
breath
better
night
use
tc
relax
stress
conclus
shown
teach
tc
ib
home
environ
feasibl
particip
also
took
option
lesson
friend
famili
member
class
report
popular
achiev
patient
report
benefit
breath
sputum
expector
calmer
less
stress
extens
tc
teach
internet
form
group
class
next
logic
step
make
financi
achiev
therapi
black
kd
barfield
w
flume
pa
physic
therapi
medic
univers
south
carolina
john
island
sc
usa
respiratori
therapi
medic
univers
south
carolina
charleston
sc
usa
pulmonari
critic
care
divis
medic
univers
south
carolina
charleston
sc
usa
object
airway
clearanc
therapi
act
fundament
compon
treatment
cystic
fibrosi
cf
airway
diseas
exercis
recommend
import
adjunct
act
howev
adher
act
gener
report
poor
suspect
exercis
sought
measur
subject
adher
identifi
barrier
airway
clearanc
particip
exercis
patient
cystic
fibrosi
method
elevenitem
survey
consist
question
regard
perceiv
import
act
exercis
well
patient
abil
adher
barrier
act
exercis
administ
patient
clinic
januari
april
six
question
specif
act
question
specif
exercis
five
question
specif
adher
abil
import
measur
likert
scale
five
question
specif
mode
act
exercis
barrier
open
end
respons
one
question
close
end
result
median
age
patient
survey
year
femal
one
patient
complet
act
question
applic
patient
statu
postlung
transplant
adher
prescrib
act
report
overal
patient
rate
adher
act
one
patient
report
perform
act
least
daili
one
patient
report
util
vest
act
mode
includ
flutter
acapella
aerobika
manual
chest
pt
exercis
seventi
percent
patient
report
time
barrier
perform
act
half
patient
survey
report
exercis
regularli
sampl
age
predictor
report
particip
regular
exercis
howev
femal
like
report
regular
exercis
male
survey
femal
male
three
common
barrier
exercis
regularli
emerg
includ
lack
time
energi
motiv
averag
rate
abil
perform
prescrib
act
rate
great
difficulti
difficulti
averag
rate
import
perform
prescrib
act
import
import
averag
rate
abil
exercis
regularli
averag
rate
import
regular
exercis
conclus
major
adult
cf
patient
report
adher
prescrib
act
report
time
primari
barrier
treatment
fewer
patient
report
exercis
regularli
report
lack
time
energi
motiv
barrier
exercis
gener
patient
rate
abil
perform
act
exercis
highli
report
less
import
engag
regular
exercis
age
appear
factor
engag
exercis
femal
like
male
report
engag
exercis
futur
intervent
counsel
patient
aim
overcom
barrier
act
exercis
identifi
questionnair
richmond
lee
son
n
chilver
mcilwain
cf
clinic
bc
children
hospit
vancouv
bc
canada
introduct
peopl
cystic
fibrosi
cf
requir
perform
daili
airway
clearanc
techniqu
act
techniqu
may
take
anywher
minut
daili
monoton
result
report
adher
low
donoho
r
et
al
respir
care
report
adher
also
known
higher
actual
adher
modi
ac
et
al
j
cyst
fibro
prior
studi
object
way
measur
either
adher
qualiti
act
object
pilot
studi
assess
use
technolog
object
measur
adher
qualiti
act
perform
posit
expiratori
mask
pep
method
digit
manomet
use
bluetooth
technolog
develop
assist
softwar
compani
connect
pressur
port
pep
mask
digit
manomet
measur
record
pressur
inspiratori
expiratori
time
number
breath
set
pep
perform
time
day
session
perform
studi
enrol
patient
cf
bronchiectasi
year
age
routin
perform
pep
mask
therapi
daili
basi
home
patient
perform
two
treatment
b
use
pep
mask
random
order
treatment
perform
pep
manual
manomet
would
home
digit
manomet
record
session
without
feedback
patient
simultan
physic
therapist
train
use
pep
subject
score
patient
techniqu
treatment
b
perform
pep
use
digit
manomet
feedback
softwar
calcul
qualiti
treatment
base
achiev
inspiratori
pressur
cm
h
least
second
number
breath
taken
set
complet
result
patient
complet
pilot
studi
half
randomis
receiv
treatment
first
half
treatment
b
first
mean
percentag
qualiti
treatment
versu
treatment
b
physic
therapist
assess
qualiti
patient
perform
treatment
tabl
show
individu
rate
conclus
use
digit
manomet
onscreen
feedback
improv
qualiti
treatment
significantli
physic
therapist
overr
qualiti
treatment
session
second
part
studi
plan
patient
take
digit
manomet
home
blind
use
adher
qualiti
treatment
measur
month
aubriot
lebecqu
p
teresinha
l
liistro
g
reychler
g
pediatr
cf
center
belgium
louvain
centr
toxicolog
appli
pharmacolog
brussel
belgium
pneumonolog
dept
brussel
belgium
irec
brussel
belgium
physic
medicin
brussel
belgium
introduct
posit
airway
pressur
pep
frequent
use
patient
cystic
fibrosi
cf
combin
pep
nebul
could
reduc
treatment
time
perceiv
treatment
burden
patient
studi
object
compar
vivo
amikacin
lung
deliveri
classic
jet
nebul
lc
sprint
pari
de
use
alon
nebalon
coupl
pep
devic
nebpep
pari
pep
de
method
amikacin
bristolmy
nebul
configur
devic
lung
deliveri
assess
cf
patient
urinari
monitor
excret
amount
amikacin
studi
enrol
complet
nine
stabl
cf
patient
male
mean
age
patient
lung
dose
similar
compar
nebalon
nebpep
vs
initi
dose
well
halflif
vs
elimin
rate
constant
vs
conclus
data
suggest
combin
nebpep
modifi
efficaci
neb
alon
combin
neb
pep
allow
signific
time
save
daili
care
patient
without
modifi
lung
deliveri
could
improv
treatment
adher
introduct
patient
cystic
fibrosi
cf
impair
abil
clear
thicken
lower
airway
secret
often
lead
progress
loss
lung
function
pulmonari
exacerb
ultim
respiratori
failur
airway
clearanc
treatment
act
aim
improv
ventil
mucociliari
clearanc
remov
tenaci
obstruct
secret
howev
act
often
add
signific
treatment
burden
high
frequenc
chest
wall
oscil
hfcwo
common
method
act
us
cf
popul
oscillatori
posit
expiratori
pressur
opep
devic
approv
fda
may
becom
common
devic
within
us
cf
care
commun
despit
pauciti
publish
literatur
mani
cf
act
studi
compar
modal
publish
howev
studi
compar
simultan
use
act
modal
outpati
set
object
pilot
studi
provid
preliminari
evid
clinic
efficaci
augment
act
cf
patient
combin
simultan
use
hfcwo
provid
preliminari
data
relat
candid
primari
outcom
allow
futur
trial
search
possibl
effect
associ
help
inform
decis
larger
clinic
trial
patient
inclus
criteria
method
retrospect
chart
review
analyz
effect
fev
fef
bmi
need
addit
antibiot
frequenc
pulmonari
exacerb
six
cf
patient
select
patient
ad
routin
daili
hfcwo
patient
serv
control
month
preand
period
outcom
metric
measur
includ
rate
chang
fev
cumul
day
addit
antibiot
number
pulmonari
exacerb
pair
chang
valu
preto
posttreat
use
analysi
variabl
linear
regress
use
slope
preand
postiniti
data
compar
null
hypothesi
addit
calcul
index
individu
result
linear
regress
analysi
lung
function
measur
bmi
antibiot
usag
cf
exacerb
complet
show
patient
initi
fev
tend
show
largest
improv
notabl
reduc
rate
declin
fev
reduct
antibiot
usag
also
calcul
index
individu
fev
valu
compar
group
valu
find
refer
interv
support
compar
individu
rather
populationbas
comparison
conclus
data
support
need
research
augment
establish
act
strategi
cf
patient
moder
sever
lung
diseas
use
opep
devic
like
combin
hfcwo
coppolo
dp
suggett
ja
nagel
mw
mitchel
jp
jolyon
mitchel
inhal
consult
servic
inc
london
canada
monaghan
medic
corp
plattsburgh
ny
usa
trudel
medic
intern
london
canada
background
object
hyperton
salin
associ
increas
mucociliari
clearanc
secret
opep
therapi
help
mobil
secret
mechan
laboratori
investig
examin
perform
breathactu
nebul
ban
conjunct
opep
deliveri
hyperton
salin
see
opep
affect
emit
aerosol
size
distribut
method
ban
mmc
n
devic
tabletop
compressor
evalu
deliveri
hyperton
salin
ml
vw
nacl
aq
without
opep
devic
mmc
insert
mouthpiec
nebul
aerosol
ban
inhal
via
vacuum
sourc
oper
lmin
size
laser
diffractomet
malvern
spraytec
malvern
uk
compar
measur
also
made
wide
encount
breathenhanc
nebul
pari
respiratori
equip
midlothian
va
n
devic
oper
tabletop
compressor
boysx
result
measur
aerosol
size
distribut
volum
median
diamet
vmd
fine
droplet
fraction
defin
diamet
fdf
summar
tabl
conclus
addit
opep
devic
margin
reduc
droplet
size
pair
ttest
metric
p
effect
small
like
unimport
given
finer
droplet
like
penetr
airway
lung
especi
restrict
secret
compar
ben
devic
produc
similar
slightli
larger
droplet
size
result
use
tabletop
compressor
either
without
concurr
use
aerobika
opep
devic
would
appear
effect
method
deliv
hyperton
salin
lung
purpos
mucociliari
clearanc
introduct
mani
exercis
program
use
sixminut
walk
test
assess
chang
endur
patient
cystic
fibrosi
cf
howev
unclear
truli
captur
maximum
distanc
speed
patient
partial
due
lack
extern
motiv
apart
test
requir
standard
verbal
encourag
contrast
increment
shuttl
walk
test
iswt
provid
extern
motiv
test
particip
goal
reach
meter
distanc
prior
audibl
beep
purpos
retrospect
chart
review
determin
iswt
better
captur
endur
measur
distanc
speed
comparison
result
two
test
compar
preand
postcardiopulmonari
rehabilit
program
method
institut
review
board
irb
approv
obtain
demograph
clinic
data
gather
retrospect
chart
review
data
collect
chart
patient
cf
complet
week
outpati
cardiopulmonari
rehabilit
program
within
past
year
particip
complet
iswt
preand
postrehabilit
data
two
test
collect
analyz
variabl
interest
includ
distanc
speed
heart
rate
oxygen
satur
data
analyz
use
pair
ttest
separ
repeat
measur
analysi
varianc
anova
result
compar
iswt
seri
pair
ttest
reveal
signific
differ
endur
test
speed
distanc
preand
postrehabilit
p
examin
mean
score
indic
speed
distanc
greater
iswt
time
point
result
separ
anova
reveal
signific
improv
p
distanc
speed
preto
postrehabilit
regardless
endur
test
perform
conclus
particip
outpati
cardiopulmonari
rehabilit
program
cf
abl
ambul
greater
distanc
higher
speed
iswt
rehabilit
studi
suggest
extern
motiv
iswt
better
captur
endur
therefor
may
benefici
measur
outcom
exercis
prescript
particip
cardiopulmonari
rehabilit
program
griego
b
tataria
kirchner
k
children
healthcar
atlanta
atlanta
ga
usa
background
purpos
current
gold
standard
clinic
improv
patient
admit
hospit
cystic
fibrosi
cf
exacerb
fev
measur
standard
spirometri
howev
fev
may
accur
predict
patient
exercis
toler
great
variabl
exist
patient
compar
lung
function
radtk
et
al
pediatr
phi
ther
review
literatur
studi
found
measur
chang
physic
endur
pediatr
patient
acut
cf
exacerb
purpos
studi
examin
chang
physic
endur
measur
modifi
shuttl
walk
test
mswt
pulmonari
endur
measur
fev
pediatr
cf
patient
hospit
acut
exacerb
chang
differ
base
sever
patient
diseas
studi
design
studi
includ
pediatr
patient
year
age
hospit
acut
cf
exacerb
patient
receiv
cours
antibiot
therapi
airway
clearanc
nutrit
support
daili
physic
therapi
patient
divid
three
group
base
upon
sever
underli
lung
diseas
express
percent
predict
lung
function
admiss
mild
fev
moder
fev
sever
fev
percent
chang
perform
mswt
percent
chang
fev
admiss
discharg
record
patient
protect
health
inform
remov
record
link
exist
identifi
particip
patient
result
signific
improv
note
within
group
mswt
fev
despit
sever
diseas
howev
mswt
signific
differ
mean
percent
chang
identifi
mild
moder
sever
group
test
anova
fev
mild
group
demonstr
significantli
less
improv
airflow
compar
moder
sever
group
test
anova
use
fisher
lsd
test
signific
signific
differ
identifi
moder
sever
group
fev
percent
improv
fev
significantli
larger
percent
improv
mswt
moder
sever
group
differ
note
mild
group
conclus
studi
demonstr
moder
sever
group
pulmonari
endur
measur
fev
improv
significantli
physic
endur
limit
improv
mswt
studi
interv
may
occur
physic
endur
recoveri
requir
time
administr
mswt
outpati
set
conduct
annual
basi
would
provid
baselin
quantit
measur
trajectori
patient
physic
endur
way
fev
monitor
guid
treatment
mswt
may
prove
use
monitor
physic
endur
would
assist
clinician
tailor
continu
exercis
program
improv
patient
outcom
lifetim
cf
care
kay
robertimil
bhatia
r
pediatr
pulmonolog
akron
children
hospit
akron
oh
usa
pediatr
akron
children
hospit
akron
oh
usa
introduct
previous
show
util
multipl
outcom
measur
like
minut
walk
test
cfqr
cystic
fibrosi
questionnairerevis
pft
cf
pulmonari
exacerb
bhatia
r
et
al
pediatr
allergi
immunol
pulmonol
goal
studi
investig
cfqr
domain
pft
chang
time
includ
exacerb
baselin
health
cf
method
perform
mwt
pft
cfqr
moderatetosever
cf
subject
year
outpati
visit
well
weekli
hospit
first
four
encount
patient
chosen
baselin
encount
best
worst
score
fev
note
next
fev
rel
best
worst
score
calcul
encount
ex
fev
best
rel
score
encount
fev
best
fev
limit
bia
cfqr
domain
score
report
composit
score
domain
use
result
nine
cf
subject
complet
studi
far
usabl
data
point
rel
worst
score
fev
rel
worst
score
significantli
correl
p
rel
worst
score
cfqr
physic
domain
score
significantli
correl
correl
p
fev
rel
worst
score
cfqr
physic
domain
score
significantli
correl
suggest
fev
explain
differ
compon
physiolog
chang
visual
data
via
scatterplot
impos
linear
regress
line
reveal
line
small
posit
slope
fev
vs
rel
best
score
increas
faster
rate
fev
indic
two
clinic
measur
offer
differ
inform
figur
examin
cfqr
respiratori
domain
vs
fev
rel
score
reveal
posit
slope
rel
best
score
steeper
slope
fev
indic
two
measur
agreement
measur
respiratori
function
figur
conclus
preliminari
data
suggest
cfqr
fev
measur
differ
aspect
cf
patholog
multipl
outcom
measur
util
cf
care
get
complet
pictur
method
base
act
survey
airway
clearanc
survey
creat
bc
children
hospit
gather
inform
current
practic
act
use
cf
popul
survey
distribut
nacfc
variou
respiratori
therapi
rt
physic
therapi
pt
session
survey
ask
respond
identifi
act
use
cf
center
specif
age
treatment
time
length
healthcar
profession
taught
act
techniqu
initi
often
techniqu
review
result
survey
complet
respond
usa
respond
canada
result
indic
wide
varieti
act
use
individu
cf
pdp
still
predomin
act
report
year
group
canada
usa
howev
american
respond
canadian
respond
continu
use
tip
posit
act
depend
breath
pattern
ad
acbt
commonli
use
year
age
group
adult
group
appear
broadest
use
act
act
hfcwo
common
usa
canada
across
age
group
american
respond
report
use
hcfwo
center
depend
age
compar
canadian
respond
act
primarili
taught
rt
usa
pt
canada
rt
usa
pt
canada
american
respond
report
review
act
averag
time
per
year
compar
averag
time
per
year
canada
act
teach
initi
diagnosi
often
canada
canadian
respond
american
respond
conclus
wide
varieti
act
use
treat
individu
cf
north
america
compar
year
ago
differ
choic
act
use
individu
cf
may
influenc
age
countri
live
limit
studi
includ
low
number
canadian
respond
lack
standard
survey
respons
studi
requir
continu
look
act
use
cf
popul
bellini
r
cazzarolli
c
tridello
g
borruso
tartali
c
background
standard
exercis
test
part
regular
assess
subject
cystic
fibrosi
cf
higher
level
fit
associ
better
prognosi
surviv
cardiopulmonari
exercis
test
cpet
provid
detail
inform
abil
exercis
cf
palang
et
al
identifi
subject
vo
peak
predict
highest
level
fit
cpet
increment
shuttl
walk
test
iswt
repres
altern
cpet
identifi
possibl
caus
lower
exercis
capac
level
probst
et
al
develop
iswt
refer
equat
healthi
subject
determin
predict
iswt
distanc
iswd
date
threshold
valu
identifi
subject
higher
level
fit
basi
predict
iswd
aim
determin
best
cutoff
iswd
discrimin
cf
subject
highest
level
fit
method
retrospect
analysi
conduct
adult
subject
cf
mean
age
mean
fev
pred
perform
iswt
cpet
within
month
anthropometr
data
lung
function
collect
clinic
record
iswt
cpet
perform
accord
ersat
recommend
subject
await
lung
transplant
subject
need
oxygen
supplement
exclud
logist
model
perform
order
defin
relationship
iswt
distanc
predict
distanc
level
fit
high
vs
low
success
roc
curv
perform
order
detect
best
threshold
valu
identifi
subject
high
level
fit
best
cutoff
select
accord
maximum
youden
index
sensit
specif
order
obtain
higher
sensit
specif
valu
result
cutoff
meter
provid
higher
youden
index
sensit
specif
use
threshold
valu
iswt
patient
could
classifi
subject
high
level
fit
despit
patient
show
high
level
fit
vo
peak
pred
accord
gold
standard
cpet
among
subject
perform
meter
high
level
fit
compar
patient
cutoff
probst
refer
equat
applic
cohort
patient
due
differ
age
bmi
thu
predict
distanc
consid
conclus
iswt
cutoff
could
identifi
subject
lower
fit
level
result
relat
small
popul
show
poor
specif
develop
refer
equat
could
allow
better
interpret
walk
perform
gener
adopt
evalu
abil
respond
treatmentinduc
chang
exercis
capac
fri
lm
cahil
b
arora
thoma
r
frederick
ca
ubmd
intern
medicin
state
univ
ny
buffalo
buffalo
ny
usa
pediatr
state
univ
ny
buffalo
buffalo
ny
usa
radiolog
state
univ
ny
buffalo
buffalo
ny
usa
introduct
pulmonari
diseas
main
caus
morbid
mortal
patient
cystic
fibrosi
cf
erkkila
j
et
al
clin
orthop
relat
re
past
studi
children
cf
suggest
degre
thorac
kyphosi
posit
correl
sever
pulmonari
diseas
measur
fev
fvc
denton
j
et
al
clin
orthop
relat
re
bone
diseas
common
complic
adult
cf
result
low
bone
densiti
increas
risk
fractur
consider
may
given
increas
kyphosi
ad
risk
factor
compress
fractur
trunk
deform
elev
thorac
kyphosi
may
compromis
vital
capac
patient
popul
well
swisher
et
al
cf
phi
therapist
posit
correl
thorac
kyphosi
sever
lung
compromis
postur
correct
potenti
posit
intervent
may
warrant
primari
aim
analyz
correl
thorac
kyphosi
measur
cobb
angl
fev
fvc
measur
pulmonari
diseas
method
studi
evalu
subject
cf
age
elig
subject
pa
later
chest
xray
cxr
perform
sep
sep
least
two
spirometri
year
prior
subject
multipl
cxr
time
recent
cxr
select
best
fev
year
prior
cxr
use
analysi
altern
cobb
vertebrocentr
angl
measur
upright
later
cxr
angl
kyphosi
measur
three
time
one
reader
ensur
intern
valid
third
verifi
blind
second
reader
result
data
analyz
pearson
correl
coeffici
pcc
signific
correl
found
either
altern
cobb
vertebrocentr
angl
fev
respect
fvc
age
bmi
number
hospit
analyz
correl
degre
kyphosi
found
collect
pcc
variabl
relat
kyphosi
nearli
suggest
even
sampl
size
correl
would
unlik
clinic
statist
signific
conclus
physic
therapi
strengthen
condit
recogn
import
compon
cf
care
evalu
treatment
postur
dysfunct
includ
cf
guid
physic
therapi
swisher
et
al
cf
phi
therapist
despit
prior
studi
pediatr
adolesc
cf
popul
conclud
kyphosi
increas
sever
pulmonari
compromis
correl
found
adult
cf
popul
failur
find
correl
indic
correct
postur
dysfunct
without
benefit
unmeasur
benefit
decreas
pain
improv
function
statu
limit
progress
kyphosi
stabil
lung
function
time
may
exist
futur
research
need
help
target
rehabilit
effort
rodriguez
hortal
hedborg
nygrenbonni
hjelt
l
karolinska
univers
hospit
stockholm
sweden
karolinska
institutet
stockholm
sweden
introduct
noninvas
ventil
niv
bilevelpap
posit
airway
pressur
reduc
respiratori
muscl
work
prevent
respiratori
muscl
fatigu
could
thu
good
altern
ill
patient
need
extra
support
train
aim
studi
investig
niv
effect
oxygen
supplement
increment
test
lung
function
test
fev
fvc
transcutan
borg
rpe
scale
rate
perceiv
dyspnea
scale
oxygen
satur
respiratori
rate
heart
rate
measur
test
group
distanc
complet
record
wilcoxon
signedrank
test
use
statist
analysi
result
present
median
rang
result
decreas
niv
oxygen
supplement
differ
group
increas
niv
kpa
kpa
oxygen
supplement
kpa
kpa
ie
increas
less
niv
group
fev
fvc
chang
significantli
either
group
heart
rate
increas
niv
oxygen
supplement
signific
differ
group
borg
rpe
scale
increas
niv
oxygen
supplement
differ
group
rate
perceiv
dyspnea
scale
increas
niv
oxygen
supplement
differ
group
result
present
studi
show
niv
good
oxygen
supplement
increment
test
patient
cf
sever
ill
studi
niv
show
decreas
rise
maintain
level
within
normal
refer
valu
compar
oxygen
supplement
introduct
decreas
physic
activ
pa
poor
prognost
factor
variou
respiratori
diseas
yet
littl
data
exist
activ
level
adult
cystic
fibrosi
cf
examin
determin
objectivelymeasur
daili
pa
special
interest
extrapulmonari
factor
patient
sampl
method
crosssect
singlecent
studi
cf
patient
wore
multisensor
sensewear
armband
consecut
day
evalu
number
step
per
day
energi
expenditur
time
spent
differ
intens
mild
pa
metabol
equival
met
moder
pa
met
vigor
pa
met
addit
nutrit
biolog
paramet
data
bodi
composit
bone
miner
densiti
dual
xray
absorptiometri
bodi
plethysmographi
walk
test
collect
qualiti
life
anxieti
depress
assess
use
valid
questionnair
multivari
regress
model
use
identifi
demograph
behavior
clinic
biolog
factor
independ
associ
stepsday
time
spent
three
intens
pa
result
adult
cf
male
mean
age
year
bmi
kgm
predict
includ
februari
januari
pancreat
insuffici
diabet
patient
chronic
pulmonari
colon
pseudomona
aeruginosa
receiv
mean
antibiot
iv
cours
previou
year
mean
number
step
per
day
mean
daili
time
spent
mild
moder
vigor
activ
h
min
min
respect
univari
analysi
subject
step
countday
lower
fvc
lower
oxygen
satur
walk
test
p
antibiot
iv
cours
lower
lean
bodi
mass
trend
women
walk
less
men
correl
lower
bmi
higher
blood
fibrinogen
lower
step
count
per
day
time
spent
activ
met
lower
women
decreas
increas
bmi
fat
bodi
mass
tend
decreas
subject
walk
distanc
walk
test
correl
found
age
age
diagnosi
cftr
genotyp
diabet
bone
mass
densiti
multivari
analys
examin
determin
time
spent
moder
vigor
activ
multivari
analys
present
meet
conclus
determin
pa
level
adult
cf
includ
marker
respiratori
diseas
fvc
oxygen
satur
walk
test
iv
antibiot
importantli
nutrit
characterist
appear
also
strongli
correl
pa
increas
lean
bodi
mass
time
spent
activ
neg
correl
bmi
fat
bodi
mass
final
time
activ
higher
men
women
hilton
n
craig
ledson
nazareth
walshaw
liverpool
heart
chest
hospit
liverpool
unit
kingdom
object
given
forc
expiratori
volum
one
second
fev
frequent
use
marker
diseas
sever
cf
fail
detect
structur
airway
damag
beyond
conduct
zone
furthermor
grow
concern
fev
lack
sensit
earlystag
chang
small
airway
peak
aerob
capac
vo
peak
larg
affect
structur
chang
lung
use
determin
prognosi
assess
lung
transplant
elig
although
evid
suggest
vo
peak
signific
determin
cf
healthrel
qualiti
life
yet
establish
surrog
marker
diseas
sever
aim
studi
determin
impact
vo
peak
fev
number
day
spent
receiv
intraven
antibiot
iva
method
sixteen
adult
cf
male
femal
year
mean
sd
age
perform
vo
peak
assess
follow
modifi
bruce
protocol
accord
european
guidelin
spirometri
conduct
within
day
exercis
assess
inclus
criteria
requir
patient
deem
least
week
clear
pulmonari
exacerb
day
test
number
iva
day
determin
month
postexercis
assess
data
analys
use
pearson
correl
coeffici
oneway
betweensubject
analysi
varianc
post
hoc
test
alpha
level
signific
set
p
result
signific
neg
correl
vo
peak
iva
day
r
p
vo
peak
account
variat
iva
day
signific
neg
correl
fev
iva
day
r
p
fev
account
variat
iva
day
mean
number
iva
day
excel
vo
peak
group
day
lower
mean
good
day
averag
day
poor
day
poor
day
group
signific
effect
vo
peak
iva
day
f
p
poor
group
mean
iva
day
significantli
higher
mean
iva
day
excel
group
ci
mean
differ
poor
excel
group
iva
day
signific
differ
mean
iva
day
poor
averag
good
group
main
find
studi
vo
peak
determin
number
iva
day
greater
extent
fev
structur
lung
damag
diminish
arterioven
oxygen
differ
larg
govern
vo
peak
therefor
may
sensit
marker
diseas
sever
fev
futur
vo
peak
test
regard
prefer
indic
diseas
sever
fev
research
includ
larg
cohort
requir
identifi
whether
improv
vo
peak
exercis
train
lead
signific
reduct
hospit
admiss
paediatr
respiratori
royal
brompton
hospit
london
unit
kingdom
south
bank
univers
london
unit
kingdom
royal
brompton
hospit
london
unit
kingdom
introduct
emerg
evid
tai
chi
tc
ancient
chines
martial
art
benefici
effect
respiratori
condit
previou
pilot
studi
adult
cf
suggest
benefit
qualiti
life
score
cfqr
sleep
qualiti
aim
assess
impact
learn
tc
physic
outcom
qualiti
life
sleep
qualiti
gener
wellb
compar
outcom
deliveri
train
via
individu
facetofac
teach
home
group
individu
internetbas
ib
teach
via
group
method
children
adult
recruit
cf
clinic
royal
brompton
hospit
randomis
control
trial
particip
randomis
receiv
tc
teach
via
ib
deliv
eight
session
month
ib
group
runin
period
continu
usual
activ
tc
group
given
dvd
handbook
aid
learn
ask
practic
minut
day
measur
record
baselin
three
month
lesson
includ
cfqr
pittsburgh
sleep
qualiti
index
five
facet
mind
questionnair
height
weight
lung
function
fev
fvc
record
time
point
result
particip
group
male
median
age
rang
median
height
rang
median
weight
rang
median
fev
rang
median
fvc
rang
comparison
tc
versu
usual
activ
fev
fvc
bmi
signific
comparison
group
start
end
lesson
bmi
fev
fvc
nonsignific
comparison
group
start
end
lesson
bmi
fev
fvc
nonsignific
comparison
group
group
end
lesson
show
signific
fvc
p
chang
questionnair
score
group
start
end
lesson
signific
conclus
first
randomis
control
trial
tai
chi
cf
slight
clinic
improv
fvc
found
group
particip
complet
tc
train
maintain
lung
function
slight
improv
bmi
statist
signific
studi
show
internetbas
teach
accept
age
safe
method
teach
complex
instruct
patient
join
group
lesson
mewa
elarabi
griffin
k
mahendira
l
syke
j
norri
e
stephenson
tulli
e
rubin
l
rheumatolog
st
michael
hospit
toronto
canada
adult
cf
program
st
michael
hospit
toronto
canada
background
increas
life
expect
adult
cf
patient
led
complic
previous
recogn
arthralgia
arthriti
fractur
osteoporosi
preval
inflammatori
arthriti
musculoskelet
msk
manifest
cf
well
character
furthermor
use
marker
bone
turnov
evalu
cf
patient
unclear
object
assess
msk
burden
preval
serolog
biochem
marker
bone
turnov
assess
relationship
chronic
infect
bodi
mass
index
bmi
pancreat
statu
cf
pulmonari
diseas
measur
fev
msk
system
method
prospect
cohort
studi
adult
cf
patient
follow
st
michael
hospit
smh
adult
cf
clinic
conduct
subject
complet
valid
mskspecif
questionnair
mdhaq
womac
osteoporosi
fractur
histori
examin
tender
swollen
joint
serum
rheumatoid
factor
rf
antinuclear
antibodi
ana
anticycl
citrullin
peptid
anticcp
antibodi
erythrocyt
sediment
rate
esr
creactiv
protein
crp
ctermin
telopeptid
ctx
measur
data
link
toronto
cf
databas
captur
longitudin
measur
fev
bmi
diabet
microbiolog
pancreat
statu
bone
densiti
vitamin
level
spearman
correl
calcul
investig
correl
two
continu
variabl
mannwhitney
test
fisher
exact
test
use
categor
variabl
result
total
subject
femal
includ
median
age
year
rang
fev
predict
rang
pred
bmi
kgm
rang
kgm
mean
mdhaq
score
patient
womac
score
four
subject
least
swollen
joint
least
tender
joint
eight
subject
rf
anticcp
ana
two
subject
swollen
joint
posit
antibodi
rf
andor
anticcp
median
ctx
ngl
rang
ngl
patient
abnorm
elev
ctx
suggest
increas
bone
loss
statist
signific
associ
fev
antibodi
statu
found
maltophilia
burkholderia
cepacia
complex
bcc
associ
significantli
higher
anticcp
titr
respect
patient
infect
bcc
borderlin
signific
rf
titr
signific
correl
found
ctx
bmd
clinic
factor
vitamin
level
conclus
adult
cf
small
proport
patient
abnorm
rheumatolog
serolog
andor
evid
inflammatori
arthriti
preval
confirm
seroposit
inflammatori
arthriti
studi
similar
gener
popul
relationship
maltophilia
bcc
serolog
warrant
investig
ctx
seem
associ
import
cf
clinic
measur
background
lung
transplant
wide
accept
treatment
cystic
fibrosi
cf
endstag
lung
diseas
us
lung
alloc
score
la
system
priorit
transplant
candid
base
calcul
risk
mortal
despit
rel
youth
cf
candid
second
highest
rate
waitlist
mortal
suggest
la
may
accur
reflect
risk
waitlist
mortal
cf
candid
optim
time
list
lung
transplant
establish
scientif
registri
transplant
recipi
srtr
includ
variabl
time
waitlist
posttranspl
period
us
transplant
candid
recipi
cf
foundat
patient
registri
cffpr
includ
nearli
us
cf
popul
cffpr
includ
diseasespecif
variabl
ie
microbiolog
captur
srtr
longitudin
inform
year
waitlist
object
link
srtr
cffpr
creat
novel
databas
describ
characterist
cf
patient
transplant
studi
design
srtr
candid
cffpr
includ
encompass
srtr
candid
use
determinist
match
algorithm
includ
name
birthdat
sex
race
death
date
state
resid
zip
code
cffpr
candid
match
srtr
candid
recipi
report
result
transplant
recipi
postla
implement
era
result
srtr
recipi
match
recipi
cffpr
cf
transplant
recipi
femal
age
year
cf
diagnos
age
cohort
age
homozyg
found
class
ivv
mutat
fiftythre
percent
underw
transplant
median
bmi
recipi
age
year
year
transplant
median
fev
predict
median
number
pulmonari
exacerb
number
day
receiv
iv
antibiot
noninvas
ventil
use
cohort
cfrelat
complic
includ
cfrelat
diabet
impair
glucos
toler
cirrhosi
osteoporosi
gerd
depress
sinu
diseas
follow
microorgan
detect
respiratori
tract
p
aeruginosa
mucoid
p
aeruginosa
mrsa
maltophilia
xylosoxidan
ntm
b
cepacia
complex
summari
strength
novel
databas
abil
fulli
character
cf
patient
undergo
transplant
data
databas
may
help
optim
time
referr
transplant
identifi
addit
variabl
may
better
predict
risk
waitlist
posttranspl
morbid
mortal
cf
popul
fund
introduct
lung
transplant
lifesav
procedur
cf
extend
surviv
postlung
transplant
median
surviv
report
year
canada
year
us
studi
compar
clinic
demograph
characterist
patient
prior
lung
transplant
canada
us
determin
pretranspl
factor
differ
two
countri
may
provid
insight
report
differ
posttranspl
surviv
method
canadian
us
cf
registri
data
use
studi
patient
prior
nonlung
organ
transplant
exclud
gli
refer
equat
use
calcul
fev
percent
predict
cdc
growth
chart
use
calcul
bmi
percentil
children
age
adult
bmi
calcul
use
kgm
patient
classifi
underweight
bmi
percentil
less
children
age
year
bmi
less
kgm
adult
recent
lung
function
bmi
prior
transplant
record
sputum
microbiolog
base
ever
vs
never
growth
prior
transplant
patient
classifi
receiv
bipap
home
feed
tube
use
support
three
year
transplant
differ
two
countri
assess
use
mannwhitneywilcoxon
test
chisquar
test
appropri
result
studi
period
canadian
american
cf
underw
lung
transplant
cf
patient
undergo
lung
transplant
canada
slightli
older
year
vs
year
p
lower
proport
receiv
transplant
age
year
vs
p
compar
us
median
fev
predict
similar
two
countri
greater
proport
recipi
us
prescrib
home
oxygen
vs
p
bipap
vs
p
compar
canada
patient
us
underweight
vs
p
despit
greater
use
feed
tube
us
vs
p
compar
canada
infect
b
cepacia
complex
common
among
canadian
recipi
vs
p
mrsa
higher
among
us
recipi
vs
p
conclus
prior
lung
transplant
american
cf
like
undernourish
advanc
lung
diseas
base
higher
rate
home
oxygen
bipap
use
futur
studi
plan
compar
postlung
transplant
surviv
two
countri
determin
impact
pretranspl
factor
posttranspl
surviv
support
cff
rational
signific
number
pediatr
patient
cystic
fibrosi
cf
die
waitlist
transplant
surviv
benefit
procedur
controversi
liou
tg
et
al
n
engl
j
med
modif
select
criteria
transplant
pediatr
patient
cf
could
improv
preand
posttranspl
mortal
previou
research
demonstr
cystic
fibrosi
questionniarerevis
cfqr
abl
predict
preand
posttranspl
mortal
adult
quittner
al
et
al
ped
pulmonol
et
al
j
heart
lung
transplant
posttranspl
mortal
children
bernstein
r
et
al
pediatr
pulmonol
studi
aim
expand
previou
research
evalu
abil
cfqr
predict
waitlist
mortal
determin
abil
parentproxi
version
cfqr
given
pretranspl
predict
preand
posttranspl
mortal
evalu
separ
addit
sensit
specif
cfqr
waitlist
transplant
assess
method
pretranspl
cfqr
score
collect
part
larger
studi
evalu
impact
transplant
qualiti
life
transplant
particip
waitlist
particip
recruit
intern
pediatr
lung
transplant
collabor
transplant
center
follow
five
year
cox
regress
use
determin
cfqr
scale
ie
physic
function
respiratori
symptom
predict
length
surviv
list
pretranspl
parentproxi
cfqr
scale
ie
vital
health
percept
roleschool
function
predict
length
surviv
posttranspl
receiv
oper
characterist
roc
curv
use
evalu
sensit
specif
signific
cfqr
domain
group
result
parentproxi
cfqr
health
percept
scale
signific
predictor
death
individu
waitlist
examin
separ
parentproxi
cfqr
health
percept
scale
roleschool
function
scale
signific
predictor
surviv
year
posttranspl
roc
curv
parentproxi
cfqr
health
percept
scale
demonstr
good
sensitivityspecif
individu
waitlist
similarli
good
sensit
specif
found
cfqr
respiratori
symptom
scale
posttranspl
also
demonstr
good
sensit
specif
individu
posttranspl
conclus
two
cfqr
scale
ie
respiratori
symptom
health
percept
signific
predictor
mortalitysurviv
individu
waitlist
posttranspl
abl
balanc
accur
classif
minim
fals
posit
fals
neg
futur
direct
includ
determin
specif
cutscor
scale
relat
mortal
waitlist
posttranspl
use
multicent
prospect
design
introduct
lung
transplant
ltx
center
volum
accept
measur
expertis
report
predictor
outcom
ltx
lung
transplant
cystic
fibrosi
cf
frequent
perform
smaller
program
experienc
cf
patient
lack
high
overal
ltx
volum
sought
determin
whether
higher
center
cf
noncf
ltx
volum
equal
associ
improv
outcom
ltx
cf
unit
network
organ
share
data
queri
cf
patient
year
age
receiv
ltx
may
march
center
ltx
volum
period
calcul
separ
noncf
cf
ltx
perform
patient
age
multivari
cox
proport
hazard
model
patient
surviv
fit
case
complet
data
model
includ
cf
noncf
ltx
volum
continu
variabl
wald
test
use
compar
associ
surviv
result
total
patient
met
inclus
criteria
die
followup
complet
data
covari
sixtyeight
center
repres
analysi
perform
mean
cf
ltx
noncf
ltx
multivari
adjust
cox
regress
demonstr
greater
cf
ltx
volum
ci
greater
noncf
ltx
volum
ci
associ
improv
surviv
ltx
recipi
cf
wald
test
confirm
cf
ltx
volum
strongli
associ
improv
surviv
noncf
ltx
volum
conclus
cfspecif
expertis
transplant
center
associ
improv
outcom
ltx
cf
wherea
gener
ltx
expertis
associ
cf
patient
surviv
multivari
analysi
referr
cf
ltx
candid
transplant
program
specif
expertis
popul
consid
gray
palmer
finlen
copeland
medicin
duke
univers
durham
nc
usa
introduct
despit
advanc
care
improv
median
surviv
respiratori
failur
account
death
individu
cystic
fibrosi
lung
transplant
viabl
treatment
strategi
care
select
patient
advanc
lung
diseas
due
cf
potenti
extend
life
howev
question
persist
benefit
transplant
particularli
patient
sever
diseas
sought
determin
cystic
fibrosi
patient
urgent
transplant
indic
high
risk
death
defin
high
lung
alloc
score
la
associ
wors
overal
posttranspl
surviv
center
method
conduct
singlecent
retrospect
analysi
cf
patient
underw
singl
organ
first
lung
transplant
duke
univers
medic
center
postla
era
exclud
cf
patient
recipi
multiorgan
transplant
retranspl
patient
includ
research
databas
patient
transplant
may
decemb
includ
provid
minimum
month
followup
result
cohort
consist
cf
patient
predomin
white
femal
median
age
transplant
iqr
rang
cf
patient
underw
bilater
lung
transplant
median
la
marker
diseas
sever
repres
estim
risk
die
wait
transplant
estim
odd
surviv
first
year
transplant
iqr
oneand
fiveyear
kaplanmei
overal
post
transplant
surviv
estim
respect
median
observ
followup
day
iqr
use
cox
proport
hazard
model
examin
impact
la
overal
posttranspl
surviv
la
consid
continu
variabl
associ
wors
surviv
p
hr
ci
high
la
marker
sever
advanc
diseas
defin
approxim
percentil
la
score
patient
also
associ
wors
posttranspl
surviv
ci
oneand
fiveyear
kaplanmei
overal
posttranspl
surviv
estim
high
la
group
vs
low
la
vs
respect
conclus
individu
cystic
fibrosi
experi
sever
acut
flare
diseas
put
immin
risk
death
role
lung
transplant
set
debat
due
concern
patient
may
sick
surviv
transplant
result
demonstr
advanc
endstag
cf
patient
highli
like
die
without
transplant
compar
overal
surviv
rate
stabl
endstag
cf
patient
fact
fiveyear
surviv
rate
ident
group
better
median
surviv
lung
transplant
recipi
noncf
diseas
uno
registri
suggest
lung
transplant
appropri
judici
use
resourc
care
select
individu
advanc
lung
failur
due
cystic
fibrosi
highvolum
experienc
lung
transplant
center
furthermor
cftr
express
ventricular
myocyt
reduc
cftr
activ
could
potenti
predispos
lv
dysfunct
object
determin
preval
cad
lv
systol
dysfunct
cf
patient
advanc
lung
diseas
method
review
adult
cf
larg
academ
cf
program
vancouv
bc
underw
lung
transplant
evalu
sinc
echocardiogram
coronari
angiogram
noninvas
cardiac
stress
test
includ
coronari
angiogram
perform
centr
pretranspl
subject
age
year
regardless
risk
factor
record
demograph
data
presenc
cad
risk
factor
histori
ac
cardiac
test
result
preval
cad
lv
systol
dysfunct
defin
eject
fraction
ef
less
echocardiogram
andor
coronari
angiogram
associ
risk
factor
report
statist
test
perform
determin
differ
clinic
characterist
vs
without
cad
well
normal
vs
low
ef
result
adult
cf
lung
transplant
record
avail
review
echocardiogram
coronari
angiogram
coronari
angiogram
mean
age
year
rang
male
mean
predict
fev
sd
atherosclerosi
observ
coronari
angiogram
patient
despit
signific
cad
risk
factor
cfrd
dyslipidemia
lv
systol
dysfunct
present
mild
lv
dysfunct
ef
moder
dysfunct
global
hypokinesi
signific
differ
age
sex
pancreat
statu
concurr
pulmonari
exacerb
fev
hypertens
cfrd
dyslipidemia
normal
vs
reduc
ef
conclus
coronari
atherosclerosi
evid
cohort
cf
adult
advanc
lung
diseas
undergo
lung
transplant
evalu
despit
presenc
multipl
risk
factor
lv
systol
dysfunct
observ
onequart
case
mechan
elucid
futur
studi
ocallaghan
l
moloni
j
peng
suthoff
e
snyder
j
waltz
vertex
pharmaceut
incorpor
boston
usa
chronic
diseas
research
group
minneapoli
mn
usa
object
character
burden
diseas
lung
transplant
ltx
wait
list
wl
candid
recipi
cf
quantifi
outcom
wl
candid
method
retrospect
cohort
studi
use
data
scientif
registri
transplant
recipi
standard
analyt
file
candid
analysi
includ
patient
pt
unit
state
cf
ad
wl
record
previou
ltx
recipi
analysi
includ
subset
candid
whose
list
end
ltx
agestratifi
demograph
clinic
characterist
candid
recipi
summar
wl
outcom
analysi
follow
ltx
candid
list
date
earliest
either
remov
wl
reason
date
year
list
wl
outcom
ltx
death
improv
health
ltx
need
sick
ltx
evalu
month
postlist
stratifi
age
group
diabet
statu
primari
payment
sourc
privat
public
result
identifi
wl
candid
median
age
year
iqr
age
age
age
age
median
percent
predict
pp
fev
iqr
mean
bmi
sd
quarter
ppfev
diabet
receiv
life
support
ltx
recipi
includ
wait
month
characterist
similar
wl
candid
cohort
within
month
list
wl
pt
receiv
ltx
tabl
median
time
ltx
month
iqr
candid
remov
wl
within
month
includ
receiv
ltx
surviv
becam
inelig
due
diseas
progress
still
wait
month
receiv
ltx
within
month
wait
month
pt
age
year
vs
year
time
list
receiv
ltx
within
month
vs
respect
pt
whose
primari
payment
sourc
privat
vs
public
like
receiv
ltx
earlier
vs
receiv
ltx
within
month
respect
conclus
major
pt
wl
receiv
ltx
month
approxim
still
wait
surviv
inelig
due
diseas
progress
nearli
third
wait
month
ltx
addit
diseas
burden
pt
cf
list
first
ltx
sever
highlight
import
maintain
health
delay
diseas
progress
sponsor
vertex
pharmaceut
incorpor
vari
season
health
trend
may
depend
time
visit
strategi
need
adjust
us
data
mimic
data
collect
uk
object
creat
combin
longitudin
data
set
comparison
us
uk
cf
patient
registri
minim
differ
season
time
interv
patient
encount
record
method
data
uk
us
registri
use
uk
data
analyz
identifi
proport
visit
per
calendar
month
well
interv
patient
record
annual
visit
distribut
season
compar
us
registri
preliminari
strategi
employ
select
annual
visit
us
data
use
iter
random
select
algorithm
invers
proport
number
avail
visit
mimic
distribut
month
visit
time
visit
uk
data
select
match
us
encount
result
season
time
interv
select
record
compar
uk
data
analysi
explor
addit
approach
result
patient
follow
us
uk
registri
respect
match
substanti
differ
us
uk
popul
visit
us
evenli
distribut
throughout
year
percent
quarter
visit
uk
occur
frequent
later
year
percent
quarter
uk
median
time
visit
month
interquartil
rang
month
result
match
strategi
regard
abil
balanc
distribut
season
time
visit
present
conclus
creat
longitudin
dataset
merg
data
two
intern
patient
registri
necessari
minim
potenti
bias
due
differ
data
collect
procedur
us
uk
cf
registri
challeng
reduc
differ
season
time
visit
method
develop
lesson
learn
may
applic
effort
combin
data
nation
registri
stephenson
st
michael
hospit
toronto
canada
univ
british
columbia
vancouv
bc
canada
hospit
sick
children
toronto
canada
cystic
fibrosi
foundat
bethesda
md
usa
univ
washington
seattl
wa
usa
background
standard
comparison
median
age
surviv
canada
us
found
canadian
patient
cf
live
averag
year
longer
us
sinc
nutrit
lung
function
import
predictor
surviv
individu
patient
longitudin
trend
nutrit
lung
function
may
help
elucid
reason
behind
observ
differ
surviv
object
compar
longitudin
chang
lung
function
nutrit
statu
canada
us
method
canadian
us
cf
registri
data
use
registri
contain
demograph
clinic
data
patient
follow
cf
center
forc
expiratori
volum
second
fev
express
percent
predict
use
gli
equat
bodi
mass
index
bmi
percentil
calcul
children
year
age
use
center
diseas
control
growth
chart
bmi
kgm
use
age
year
clinic
measur
postlung
transplant
exclud
median
fev
predict
bmi
percentil
bmi
calcul
year
countri
analys
stratifi
three
age
group
year
year
year
result
total
canadian
subject
canada
american
subject
contribut
analys
median
fev
bmi
higher
canada
three
age
group
outcom
improv
faster
rate
us
compar
canada
age
group
p
gap
lung
function
greatest
year
age
canada
vs
us
p
remain
higher
canada
compar
us
end
studi
period
contrast
year
group
pediatr
age
group
gap
canada
us
close
respect
figur
similar
trend
seen
nutrit
except
signific
differ
bmi
year
children
us
surpass
canada
bmi
percentil
recent
studi
period
conclus
canadian
adult
cf
higher
lung
function
bmi
measur
compar
us
howev
rate
improv
popul
level
faster
us
observ
catchup
nutrit
may
reflect
delay
introduct
improv
nutrit
support
cf
patient
began
canada
introduc
us
late
fund
us
cf
foundat
introduct
ivacaftor
iva
first
cftr
modul
demonstr
improv
cftr
function
clinic
benefit
patient
cf
intend
chronic
lifelong
use
ongo
observ
postapprov
safeti
studi
use
data
uk
us
cf
registri
evalu
longterm
clinic
outcom
patient
treat
iva
realworld
set
result
data
analysi
present
method
patient
treat
iva
match
age
sex
cftr
genotyp
sever
compar
patient
comp
never
receiv
iva
key
clinic
outcom
includ
death
organ
transplant
hospit
pulmonari
exacerb
pex
annual
risk
key
outcom
calcul
proport
patient
cohort
outcom
interest
time
analysi
year
unadjust
rel
risk
compar
cohort
correspond
confid
interv
calcul
preval
complic
cf
ie
cfrelat
diabet
hepatobiliari
pulmonari
gastrointestin
bonejoint
complic
select
pulmonari
microorgan
also
estim
result
analysi
includ
iva
comp
patient
us
registri
iva
comp
patient
uk
registri
iva
comp
patient
well
match
regard
age
sex
averag
durat
iva
exposur
year
us
year
uk
among
treat
patient
annual
risk
death
transplant
hospit
pex
significantli
lower
us
iva
cohort
us
comp
cohort
trend
similar
uk
tabl
find
consist
analys
stratifi
age
percent
predict
fev
addit
preval
complic
cf
p
aeruginosa
select
microorgan
tend
lower
iva
cohort
comp
cohort
registri
conclus
annual
analysi
us
uk
cf
registri
data
found
new
safeti
concern
reveal
favor
find
respect
clinic
import
outcom
patient
treat
iva
realworld
set
result
indic
potenti
iva
cf
diseas
modif
realworld
set
sponsor
vertex
pharmaceut
incorpor
introduct
ivacaftor
iva
first
cftr
modul
demonstr
clinic
benefit
patient
cf
intend
chronic
lifelong
use
present
result
diseas
progress
analys
use
uk
cf
registri
data
ongo
longterm
postapprov
observ
safeti
studi
evalu
outcom
patient
treat
iva
realworld
set
method
patient
record
iva
use
first
year
commerci
avail
uk
continu
treatment
receiv
organ
transplant
match
baselin
characterist
age
sex
genotyp
sever
compar
comp
patient
record
iva
use
baselin
characterist
ascertain
use
patient
data
prior
iva
commerci
avail
uk
outcom
interest
includ
percent
predict
pp
fev
pulmonari
exacerb
pex
hospit
pex
bmi
cfrelat
diabet
cfrd
distal
intestin
obstruct
syndrom
dio
result
iva
comp
patient
similar
respect
age
sex
lung
function
medic
use
baselin
mean
ppfev
chang
baselin
percentag
point
iva
vs
percentag
point
comp
patient
mean
bmi
increas
kgm
iva
vs
kgm
comp
patient
mean
ppfev
annual
risk
pex
hospit
pex
preval
cfrd
dio
present
tabl
conclus
uk
patient
cf
receiv
iva
first
year
commerci
avail
improv
lung
function
nutrit
statu
decreas
risk
pex
hospit
pex
rel
baselin
comp
patient
iva
patient
also
lower
cfrd
dio
preval
comp
patient
observ
clinic
benefit
iva
diseas
progress
among
patient
cf
real
world
sponsor
vertex
pharmaceut
incorpor
sawicki
gs
background
cftr
modul
novel
therapi
direct
improv
function
cftr
first
cftr
modul
approv
clinic
use
ivacaftor
iva
rapid
uptak
among
elig
patient
cftr
mutat
elig
us
patient
receiv
therapi
within
month
us
fda
approv
lumacaftorivacaftor
lumiva
approv
fda
juli
treatment
cf
patient
age
year
homozyg
cftr
mutat
object
examin
uptak
document
lumiva
therapi
among
patient
cf
us
evalu
demograph
clinic
differ
elig
patient
without
document
lumiva
therapi
method
use
data
cf
foundat
patient
registri
cffpr
identifi
patient
homozyg
genotyp
least
one
clinic
encount
uptak
lumiva
use
defin
least
clinic
encount
lumiva
document
chronic
therapi
comparison
elig
patient
age
without
document
lumiva
use
made
use
ttest
continu
variabl
chi
squar
test
categor
variabl
variabl
interest
includ
age
state
resid
insur
statu
clinic
characterist
predict
exacerb
rate
result
cf
patient
homozyg
mutat
age
follow
cffpr
end
lumiva
use
document
elig
patient
age
year
homozyg
genotyp
lumiva
use
document
patient
younger
age
patient
cftr
mutat
respect
popul
two
hundr
thirtyf
patient
document
lumiva
use
prior
juli
patient
document
lumiva
therapi
first
document
use
julyseptemb
elig
patient
document
lumiva
use
like
age
vs
p
fewer
clinic
encount
mean
vs
p
document
lumiva
therapi
like
privat
health
insur
vs
p
without
document
use
lumiva
higher
mean
vs
fewer
cours
iv
antibiot
mean
vs
p
wide
variat
uptak
lumiva
patient
state
resid
rang
across
state
state
elig
patient
document
use
lumiva
end
conclus
minor
homozyg
cf
patient
us
document
use
lumiva
within
month
fda
approv
uptak
lumiva
therapi
much
lower
rate
uptak
iva
among
cf
patient
follow
approv
suggest
clinician
may
slower
recommend
lumiva
therapi
compar
histor
preced
iva
monotherapi
differ
group
patient
differ
lumiva
uptak
appear
base
lung
function
age
insur
statu
geograph
variat
szczesniak
rd
li
clanci
jp
biostatist
epidemiolog
cincinnati
children
hospit
cincinnati
oh
usa
depart
mathemat
scienc
univers
cincinnati
cincinnati
oh
usa
pulmonari
medicin
cincinnati
children
hospit
medic
center
cincinnati
oh
usa
object
identifi
phenotyp
rapid
declin
use
longitudin
lung
function
measur
determin
extent
phenotyp
relat
clinic
characterist
studi
design
particip
longitudin
cohort
studi
patient
year
age
data
avail
us
cf
foundat
patient
registri
postlung
transplant
data
patient
less
two
year
observ
time
exclud
analys
primari
outcom
mean
quarterli
predict
characterist
interest
includ
birth
cohort
sex
first
record
predict
cfrelat
diabet
crfd
posit
cultur
methicillinresist
staphylococcu
aerueu
mrsa
pseudomona
aeruginosa
pa
burkholderia
cepacia
bc
socioeconom
statu
se
method
patient
classifi
distinct
phenotyp
evalu
trajectori
rapid
lung
function
declin
use
score
spars
function
princip
compon
analysi
statist
approach
cluster
longitudin
profil
patient
account
miss
spars
data
phenotyp
identifi
use
approach
compar
respect
baselin
mortal
characterist
result
three
distinct
phenotyp
rapid
lung
function
declin
correspond
high
moder
low
degre
predict
loss
overal
cohort
major
variat
first
function
princip
compon
among
patient
profil
character
differ
mean
predict
time
averag
degre
rapid
declin
similar
among
three
phenotyp
roughli
predictedyear
howev
averag
time
differ
mild
moder
sever
phenotyp
experienc
rapid
declin
year
age
respect
individu
mild
phenotyp
rapid
declin
highest
initi
predict
experi
greatest
loss
lung
function
individu
sever
phenotyp
rapid
declin
like
infect
mrsa
pa
bc
baselin
develop
subsequ
compar
mild
moder
phenotyp
rapid
declin
p
conclus
distinct
phenotyp
rapid
cf
lung
diseas
progress
identifi
risk
factor
phenotyp
intervent
may
precis
target
subgroup
highest
risk
lung
function
loss
support
li
clanci
jp
szczesniak
rd
biostatist
epidemiolog
cincinnati
children
hospit
cincinnati
oh
usa
depart
mathemat
scienc
univers
cincinnati
cincinnati
oh
usa
pulmonari
medicin
cincinnati
children
hospit
medic
center
cincinnati
oh
usa
object
understand
link
fev
forc
expiratori
volum
second
percentag
predict
declin
risk
onset
pulmonari
exacerb
pex
cystic
fibrosi
cf
allow
accur
infer
regard
longitudin
fev
respons
improv
predict
pex
prognosi
method
develop
flexibl
semiparametr
joint
model
consist
semiparametr
mix
effect
submodel
repeat
fev
measur
surviv
submodel
possibl
censor
pex
time
event
data
associ
two
submodel
aris
subjectspecif
random
effect
propos
joint
model
contrast
tradit
separ
model
analyz
longitudin
surviv
data
separ
model
appli
clinic
encount
data
unit
state
cf
foundat
patient
registri
individu
year
age
fev
clinic
encount
includ
data
includ
time
first
pex
potenti
predictor
includ
age
birth
cohort
gender
first
record
fev
socioeconom
statu
baselin
se
timevari
predictor
cfrelat
diabet
crfd
posit
cultur
methicillinresist
staphylococcu
aerueu
mrsa
burkholderia
cepacia
bc
pseudomona
aeruginosa
pa
comput
implement
via
markov
chain
mont
carlo
mcmc
method
result
report
posterior
mean
highest
posterior
densiti
hpd
interv
model
comparison
select
base
dic
criteria
result
overal
cohort
individu
pex
median
time
first
pex
year
longitudin
submodel
initi
fev
recent
birth
cohort
associ
less
declin
lower
se
cfrd
mrsa
bc
pa
associ
declin
within
event
submodel
male
lower
initi
fev
associ
lower
risk
pex
peopl
lower
se
associ
higher
risk
pex
posterior
estim
random
intercept
slope
coeffici
measur
strength
associ
two
submodel
neg
significantli
differ
zero
provid
strong
evid
associ
two
submodel
indic
initi
level
slope
fev
neg
associ
hazard
onset
pex
less
bias
effici
statist
infer
obtain
via
propos
joint
model
conclus
pex
associ
lung
function
declin
cf
subject
like
diagnos
pex
experienc
loss
fev
preced
period
pediatr
indiana
univ
indianapoli
usa
cf
foundat
bethesda
md
usa
pediatr
univ
washington
seattl
wa
usa
pediatr
virginia
commonwealth
univ
richmond
va
usa
pediatr
boston
children
hospit
boston
usa
medicin
pediatr
medic
univ
south
carolina
charleston
sc
usa
pediatr
univ
arizona
tucson
az
usa
background
outcom
pulmonari
exacerb
pex
vari
base
sever
factor
includ
treatment
choic
begin
cf
foundat
patient
registri
cffpr
includ
data
presenc
absenc
pex
treatment
prescrib
clinic
encount
object
describ
treatment
pex
document
clinic
visit
time
iv
antibiot
follow
initi
pex
treatment
method
elig
studi
popul
made
individu
cffpr
pex
clinic
visit
one
cf
center
complet
pex
assess
clinic
visit
analysi
select
first
index
pex
document
clinic
visit
follow
clinic
visit
without
document
pex
period
exclud
individu
receiv
iv
antibiot
baselin
index
clinic
visit
describ
initi
treatment
prescrib
index
visit
account
iv
antibiot
may
schedul
index
visit
includ
iv
antibiot
start
day
index
visit
initi
treatment
compar
proport
individu
receiv
iv
antibiot
day
later
accord
initi
treatment
choic
result
cohort
includ
peopl
mean
age
year
femal
cultur
posit
p
aeruginosa
prior
year
median
time
baselin
index
visit
day
signific
differ
mean
fev
predict
baselin
index
visit
respect
p
overal
individu
initi
treat
antibiot
oral
antibiot
alon
iv
antibiot
oral
inhal
antibiot
inhal
antibiot
alon
percentag
treatment
includ
oral
antibiot
higher
among
individu
year
old
higher
baselin
fev
andor
infect
p
aeruginosa
individu
initi
receiv
antibiot
decreas
fev
predict
baselin
index
visit
day
index
visit
individu
treat
oral
antibiot
treat
inhal
antibiot
treat
oral
inhal
antibiot
without
document
antibiot
subsequ
treat
iv
antibiot
conclus
oral
antibiot
prescrib
first
treatment
major
individu
pex
document
clinic
howev
onethird
individu
document
antibiot
treatment
within
day
index
visit
data
receipt
oral
antibiot
may
incomplet
cffpr
find
concern
given
neg
outcom
associ
pex
fund
cfft
mcmahon
vr
nelson
burgess
ca
schellenberg
background
due
larg
geograph
spread
british
columbia
bc
irtdnairt
algorithm
use
decreas
number
newborn
requir
travel
sweat
test
newborn
identifi
carrier
one
cf
mutat
normal
repeat
irt
consid
low
risk
cf
parent
newborn
receiv
telephon
counsel
clinic
reproduct
risk
cfnb
nurs
cfnbsn
addit
famili
option
attend
sweat
test
exclud
possibl
cf
residu
anxieti
remain
report
suggest
famili
healthi
cf
carrier
undertak
parent
carrier
test
given
uniqu
natur
bc
cfnb
program
aim
evalu
uptak
genet
test
low
risk
group
aim
review
uptak
parent
carrier
test
famili
newborn
identifi
unaffect
cf
carrier
cfnb
examin
potenti
factor
associ
parent
decisionmak
around
genet
followup
method
retrospect
chart
review
conduct
newborn
identifi
low
risk
cf
carrier
cfnb
exclud
infant
lost
followup
deceas
demograph
collect
number
contact
cfnbsn
birth
order
attend
option
sweat
test
parent
underw
carrier
test
identifi
provinci
genet
laboratori
data
analys
use
logist
regress
chisquar
test
result
carrier
infant
identifi
famili
pursu
parent
carrier
test
famili
test
parent
infant
seen
option
sweat
test
attend
option
sweat
test
like
undergo
genet
test
famili
test
parent
one
parent
test
parent
telephon
contact
cfnbsn
like
carrier
test
shown
tabl
uptak
test
increas
number
contact
nbsn
birth
order
known
famili
parent
whose
cf
carrier
infant
first
child
like
pursu
carrier
test
famili
firstborn
obtain
carrier
test
compar
famili
children
centr
awar
two
cf
diagnos
made
famili
subsequ
child
identifi
cfnb
unaffect
carrier
one
famili
test
one
parent
pursu
carrier
test
conclus
uptak
parent
carrier
test
low
centr
inperson
counsel
increas
contact
cfnbsn
lower
birth
order
affect
rate
parent
carrier
test
two
cf
diagnos
follow
carrier
identif
older
sibl
highlight
need
appropri
counsel
followup
prospect
studi
done
studi
factor
affect
parent
decisionmak
around
genet
followup
saunder
w
ruban
c
public
health
scienc
unc
charlott
charlott
nc
usa
background
cystic
fibrosi
cf
condit
character
inherit
diseas
mucu
sweat
gland
affect
variou
area
bodi
includ
lung
pancrea
liver
intestin
sinus
sex
organ
current
minim
research
cf
object
character
cf
patient
healthcar
util
associ
hospit
cost
given
increas
preval
rare
diseas
import
understand
better
cf
condit
better
diagnos
control
method
util
one
year
nationwid
inpati
sampl
ni
ni
repres
inpati
stay
random
sampl
hospit
unit
state
group
cf
individu
primari
secondari
discharg
diagnosi
compar
cf
other
regard
length
stay
lo
total
cost
final
look
factor
predict
increas
lo
result
estim
us
preval
cfrelat
inpati
admiss
case
cf
patient
younger
averag
age
versu
year
noncf
peer
hospit
associ
cf
increas
lo
compar
noncf
patient
versu
day
averag
cost
per
stay
greater
differ
seen
loss
function
lof
cf
patient
mostli
major
lof
categori
wherea
noncf
patient
spread
minor
moder
major
lof
respect
signific
posit
predictor
increas
lo
among
cf
patient
includ
either
minor
moder
odd
ratio
lof
selfpay
primari
payer
depress
comorbid
conclus
character
cf
seen
associ
increas
length
stay
increas
cost
sever
loss
function
patient
compar
without
cf
edmondson
c
grime
c
prasad
walli
c
cowlard
j
nwokoro
c
ruiz
g
balfourlynn
royal
brompton
hospit
london
unit
kingdom
great
ormond
street
hospit
children
london
unit
kingdom
bart
london
nh
trust
london
unit
kingdom
king
colleg
london
london
unit
kingdom
introduct
sinc
juli
cystic
fibrosi
cf
newborn
screen
carri
south
east
england
english
protocol
base
irtdnairt
suspect
cf
refer
cf
centr
sweat
test
new
genet
mutat
continu
discov
look
outcom
children
normal
sweat
chlorid
ensur
diagnosi
cf
miss
previous
present
result
tertiari
referr
centr
south
east
england
grime
c
et
al
pediatr
pulmonol
present
extens
project
includ
four
main
tertiari
centr
south
east
england
method
retrospect
review
referr
document
comput
record
larg
paediatr
specialist
cf
centr
london
follow
telephon
contact
fax
questionnair
children
regist
gener
practition
gp
result
juli
august
children
screen
posit
cf
normal
sweat
chlorid
diagnos
cf
due
diseasecaus
mutat
initi
extend
genet
screen
fulfil
criteria
group
cystic
fibrosi
screen
posit
inconclus
diagnosi
cfspid
ie
cftr
mutat
least
one
unclear
phenotyp
consequ
crm
usa
remain
followup
tertiari
centr
one
patient
genotyp
subsequ
diagnos
cf
sweat
chlorid
increas
within
first
year
life
develop
respiratori
symptom
one
diseasecaus
mutat
identifi
initi
screen
remain
children
consid
carrier
remain
children
could
trace
await
confirm
gp
detail
gp
declin
complet
questionnair
could
infer
regist
gp
return
questionnair
respiratori
symptom
unknown
local
tertiari
respiratori
servic
questionnair
outcom
avail
children
confirm
featur
cf
howev
signific
health
problem
child
die
gastric
bleed
die
unknown
caus
cardiac
diagnos
global
development
delay
speech
delay
diagnos
mccune
albright
suspect
chromosom
abnorm
confirm
diagnosi
diagnosi
asthma
conclus
total
children
refer
normal
sweat
chlorid
went
given
diagnosi
cf
cfspid
base
genet
result
knowledg
none
remain
children
far
reref
concern
regard
possibl
diagnosi
cf
extend
studi
howev
substanti
proport
children
without
cf
posit
cf
newborn
screen
found
signific
health
problem
subsequ
french
newborn
screen
nb
program
combin
immunoreact
trypsinogen
irt
kit
mutat
written
inform
consent
wic
safeti
net
case
wic
detect
mutat
plu
ultrahigh
infant
mutat
mutat
rais
refer
nearest
cf
center
cfc
sweat
test
st
object
evalu
track
process
set
nation
nb
structur
charg
nb
program
afdph
method
infant
screen
posit
need
refer
cfc
prefil
document
complet
cf
physician
includ
outcom
data
complianc
algorithm
st
valu
genotyp
infant
statu
cf
cf
screen
posit
inconclus
diagnosi
cfspid
meconium
ileu
mi
antenat
diagnosi
noncf
process
lost
followup
includ
death
symptom
histori
cf
time
initi
visit
cf
center
filledout
form
sent
region
associ
forward
quarterli
partial
deidentif
afdph
refer
cf
physician
data
manag
charg
monitor
collect
cfcfspid
case
miss
nb
yearli
questionnair
practic
aspect
nb
program
discuss
monthli
board
meet
quarterli
technic
committe
thu
lead
chang
algorithm
munck
et
al
j
pediatr
nation
databas
afdph
link
french
cf
registri
result
screen
includ
babi
two
period
screen
posit
sp
decreas
improv
ppv
stabl
sensit
cf
similar
ratio
cfcfspid
among
sp
track
process
identifi
decreas
rate
miss
wic
infant
lost
followup
report
st
valu
nonmi
case
reach
diagnos
cfcfspid
mutat
found
allel
exhaust
genet
test
requir
conclus
concern
pend
cfcfspid
initi
visit
cfc
exclud
mi
day
respect
p
day
p
infant
symptomat
p
time
initi
visit
diagnos
cf
wo
mi
day
increas
day
technic
committe
analyz
case
seen
day
four
main
step
screen
protocol
identifi
measur
improv
year
median
delay
initi
visit
return
baselin
conclus
french
program
perform
agreement
european
standard
strength
lie
high
rate
definit
st
valu
mutat
identif
efficaci
collect
cf
case
miss
nb
acknowledg
weak
delay
initi
visit
object
twotier
strategi
wide
use
populationbas
cf
screen
use
algorithm
base
elev
irt
follow
dna
mutat
panel
limit
strategi
includ
high
rate
fals
posit
identif
carrier
cftr
allel
variant
express
diseas
herein
untarget
metabolit
profil
retrospect
dri
blood
spot
db
cutout
perform
order
discov
novel
metabol
signatur
affect
cf
infant
way
improv
posit
predict
valu
newborn
screen
nb
also
amen
low
cost
msm
analysi
method
retrospect
analysi
db
extract
normal
birth
weight
newborn
infant
newborn
screen
ontario
confirm
cf
case
screenneg
control
select
train
set
biomark
discoveri
multiseg
injectioncapillari
electrophoresismass
spectrometri
msicem
use
untarget
yet
highthroughput
screen
polarion
metabolit
qualiti
assur
random
analysi
aqueou
methanol
db
extract
use
msicem
conjunct
univari
multivari
statist
method
allow
rank
molecular
featur
differenti
express
affect
cf
infant
unknown
yet
biolog
relev
metabolit
identifi
spike
authent
standard
andor
chemic
structur
elucid
high
resolut
msm
result
cation
metabolit
consist
detect
db
extract
accept
reproduc
use
msicem
posit
ion
mode
detect
good
discrimin
affect
cf
infant
rel
healthi
control
subset
eight
statist
signific
metabolit
measur
db
extract
bonferroni
correct
p
includ
three
novel
metabolit
adduct
elev
blood
cf
infant
valid
cohort
current
underway
evalu
screen
perform
lead
metabolit
earli
detect
cf
improv
specif
conclus
untarget
metabolit
profil
db
extract
reveal
signific
differ
metabol
phenotyp
cf
infant
improv
overal
posit
predict
valu
cost
effect
nb
screen
program
provid
new
insight
underli
diseas
pathophysiolog
cf
ooi
cy
sutherland
keenan
k
castellani
c
van
wylick
r
price
boland
reisman
j
zuberbuhl
p
bjornson
c
chilver
bruski
j
mateoscorr
hugh
morgan
l
duri
pr
ratjen
f
gonska
univ
new
south
wale
sydney
nsw
australia
azienda
ospedaliera
univ
integ
verona
itali
queen
univ
kingston
canada
children
hosp
london
canada
cheo
ottawa
canada
stolleri
children
hosp
edmonton
ab
canada
bc
children
hosp
vancouv
bc
canada
royal
univ
hosp
saskatoon
sk
canada
iwk
health
centr
halifax
ns
canada
windsor
reg
hosp
windsor
canada
alberta
children
hosp
calgari
ab
canada
hosp
sick
children
toronto
canada
univ
toronto
toronto
canada
introduct
infant
cf
screen
posit
inconclus
diagnosi
cfspid
cftrrelat
metabol
syndrom
crm
may
turn
cf
littl
known
individu
includ
predictor
later
cf
diagnosi
role
laboratori
test
typic
perform
patient
establish
cf
among
children
cfspid
remain
establish
base
multicent
studi
cf
centr
canada
verona
itali
establish
prospect
evalu
children
cfspid
ooi
cy
et
al
pediatr
studi
aim
compar
laboratorytest
outcom
subject
cfspid
cf
method
cfspid
cf
subject
enrol
june
cfspid
subject
fulfil
diagnost
criteria
cf
diagnosi
remain
uncertain
cfspid
serial
serum
electrolyt
liver
biochemistri
fatsolubl
vitamin
hematolog
inflammatori
marker
measur
studi
period
compar
cf
cfspid
use
gener
linear
mix
model
factor
repeat
measur
time
model
result
blood
analys
perform
subject
median
iqr
age
time
measur
year
comparison
summar
tabl
vari
proport
subject
cfspid
found
abnorm
measur
howev
signific
differ
laboratori
outcom
cf
subject
significantli
abnorm
liver
biochemistri
bicarbon
vitamin
level
cfspid
conclus
routin
perform
laboratori
paramet
cf
predict
help
differenti
although
test
may
reveal
abnorm
result
subset
children
cfspid
clinic
relev
remain
determin
butcher
jl
filbrun
merrick
e
ayyash
nasr
background
prior
research
clearli
demonstr
cystic
fibrosi
cf
newborn
screen
period
highli
stress
famili
retrospect
research
interview
parent
regard
experi
suggest
famili
differ
educ
need
diagnosi
prefer
factual
inform
other
desir
emot
support
initi
educ
period
import
time
build
relationship
medic
provid
set
stage
longterm
famili
adjust
method
tailor
educ
diagnosi
base
individu
famili
need
would
highli
benefici
object
object
studi
determin
whether
measur
parent
cope
famili
psychosoci
risk
could
use
predict
famili
educ
prefer
cf
newborn
screen
diagnosi
method
parent
retrospect
contact
mail
within
five
year
child
cf
diagnosi
newborn
screen
enrol
parent
complet
cope
strategi
inventori
csi
psychosoci
assess
tool
pat
also
complet
semistructur
interview
regard
perspect
type
use
satisfact
time
educ
materi
provid
diagnosi
data
analyz
use
onesampl
independentsampl
ttest
continu
variabl
chi
squar
dichotom
variabl
result
date
famili
enrol
complet
questionnair
enrol
ongo
interview
complet
famili
particip
mother
boy
girl
age
month
children
caucasian
live
home
two
parent
onethird
mother
endors
elev
famili
psychosoci
risk
pat
compar
norm
sampl
mother
report
engag
less
emotionfocus
cope
express
emot
seek
social
support
diagnosi
preliminari
data
analys
suggest
trend
p
mother
engag
problemfocus
cope
higher
rate
mean
spend
hour
use
educ
materi
first
month
report
greater
satisfact
educ
materi
provid
mother
prefer
educ
materi
focu
first
year
life
significantli
mother
lower
averag
rate
problemfocus
cope
p
mother
engag
emotionfocus
cope
greater
rate
mean
trend
spend
less
time
use
educ
materi
first
month
p
mother
prefer
receiv
educ
time
rather
first
appoint
p
discuss
preliminari
result
suggest
screen
mother
prefer
cope
strategi
may
way
tailor
time
amount
educ
provid
also
note
mother
report
famili
psychosoci
risk
elev
compar
norm
group
famili
children
chronic
ill
suggest
famili
educ
psychosoci
support
import
follow
cf
diagnosi
newborn
screen
support
cystic
fibrosi
foundat
newborn
screen
qualiti
improv
program
object
newborn
screen
nb
cystic
fibrosi
cf
enabl
earlier
proactiv
treatment
improv
prognosi
ecf
neonat
screen
work
group
nswg
establish
track
current
practic
nb
support
implement
nb
establish
consensu
strategi
improv
public
health
intervent
nswg
last
conduct
survey
nb
europ
aim
provid
updat
nb
europ
discuss
differ
protocol
identifi
barrier
establish
nb
programm
method
three
questionnair
sent
key
worker
european
countri
key
worker
complet
appropri
questionnair
depend
situat
countri
nb
undertaken
might
nation
programm
region
implement
nb
undertaken
enquir
plan
barrier
implement
result
compar
survey
nation
nb
programm
europ
increas
includ
russia
turkey
countri
itali
spain
germani
serbia
region
programm
spain
complet
coverag
popul
region
programm
germani
start
nation
nb
countri
nb
cf
countri
nb
programm
consider
nation
nb
programm
follow
protocol
use
irtdnairt
irtirt
irtdna
irtpapdna
irtpapirt
use
fix
cutoff
irt
big
variabl
irt
cutoff
age
test
second
tier
strategi
protocol
includ
dna
test
better
ppv
mean
rang
compar
without
mean
rang
cost
recognis
infant
inconclus
diagnosi
carrier
lack
financi
support
cut
back
health
care
budget
main
barrier
implement
nb
report
howev
report
expect
start
nb
programm
within
year
conclus
nb
programm
cover
major
popul
western
europ
numer
protocol
degre
reflect
differ
econom
health
system
well
genet
divers
european
popul
howev
degre
variabl
optim
urgent
need
provid
robust
framework
evalu
impact
nb
cf
provid
clearer
inform
consensu
best
practic
keogh
rh
szczesniak
rd
medic
statist
london
school
hygien
tropic
medicin
london
unit
kingdom
div
biostatist
epidemiolog
univ
cincinnati
cincinnati
oh
usa
object
investig
differ
measur
predict
surviv
cf
whether
incorpor
variabilityin
addit
level
rate
declineimprov
predict
studi
design
particip
use
longitudin
clinic
encount
data
us
cf
foundat
patient
registri
among
individu
age
older
alongsid
correspond
surviv
data
period
method
aim
predict
surviv
among
individu
live
seri
clinic
relev
age
rang
year
refer
landmark
age
use
landmark
approach
van
houwelingen
h
scand
j
stat
cox
proport
hazard
model
fit
landmark
age
fit
restrict
individu
aliv
uncensor
landmark
age
use
predictor
deriv
avail
longitudin
measur
began
use
usual
level
slope
chang
landmark
age
predictor
obtain
fit
linear
mix
model
measur
period
prior
landmark
age
interest
four
measur
variabl
base
interv
landmark
age
consid
addit
predictor
standard
deviat
sd
measur
ii
residu
sd
obtain
mix
model
iii
rang
iv
median
deviat
best
measur
interv
follow
morgan
wj
et
al
j
pediatr
show
result
use
interv
prior
landmark
age
model
includ
differ
predictor
compar
use
cindex
measur
strength
associ
predictor
outcom
predict
error
use
brier
score
compar
predict
probabl
observ
data
model
calibr
result
usual
level
select
landmark
age
strongli
predict
surviv
ad
slope
addit
predictor
improv
predict
abil
addit
includ
variabl
predictor
give
improv
albeit
quit
small
variabl
measur
iv
appear
least
use
addit
predictor
difficult
distinguish
three
variabl
measur
measur
highli
predict
surviv
cindex
goe
across
landmark
age
indic
measur
better
predictor
surviv
younger
age
predict
surviv
age
cindex
approxim
respect
predict
surviv
age
cindex
approxim
respect
calibr
investig
show
predict
probabl
obtain
model
close
true
probabl
conclus
usual
level
strongli
predict
surviv
howev
improv
predict
abil
made
includ
slope
measur
variabl
addit
predictor
work
need
investig
whether
includ
addit
predictor
improv
predict
especi
older
age
posit
result
report
primari
care
provid
instruct
refer
infant
one
institut
sweat
test
genet
counsel
initi
sweat
test
often
confirm
exclud
diagnosi
cf
howev
intermedi
sweat
test
result
extend
period
diagnost
uncertainti
famili
provid
alik
limit
data
diagnost
outcom
infant
retrospect
studi
examin
diagnost
outcom
intermedi
sweat
test
ethnic
divers
group
infant
refer
ann
robert
h
luri
children
hospit
chicago
period
method
databas
establish
onset
cf
nb
track
outcom
infant
seen
followup
posit
cf
nb
screen
retrospect
chart
review
done
infant
initi
intermedi
sweat
test
diagnost
outcom
followup
present
studi
result
illinoi
approxim
posit
cf
newborn
screen
result
annual
twenti
percent
infant
refer
ann
robert
h
luri
children
hospit
followup
initi
sweat
test
normal
posit
infant
ten
percent
infant
intermedi
test
result
initi
categor
possibl
cftrrelat
metabol
syndrom
crm
cf
addit
one
cftr
mutat
variant
nb
prenat
genet
variabl
unknown
signific
vu
sweat
test
also
categor
possibl
crmscf
month
age
nearli
infant
initi
intermedi
sweat
test
normal
repeat
sweat
test
discharg
care
two
infant
posit
repeat
sweat
test
confirm
cf
week
month
age
respect
twentyf
infant
given
diagnosi
crm
month
age
base
persist
intermedi
sweat
test
andor
genet
vu
two
infant
initi
posit
sweat
test
repeat
sweat
test
prompt
genet
vu
persist
intermedi
diagnos
chang
crm
adher
consensu
guidelin
crm
follow
variabl
nearli
infant
famli
declin
follow
follow
annual
reassur
lack
symptom
reflect
inadequ
cftr
function
conclus
use
illinoi
algorithm
infant
posit
nb
result
intermedi
sweat
test
follow
resolut
outcom
possibl
includ
diagnosi
cf
adher
guidelin
crm
care
month
age
inconsist
repres
area
qualiti
improv
addit
studi
need
outcom
infant
long
term
background
fecal
elastas
fe
measur
becom
routin
reli
upon
evalu
pancreat
function
statu
low
fe
consist
pancreat
insuffici
pi
use
newborn
screen
program
part
diagnost
process
howev
cff
diagnosi
consensu
committe
question
valu
fe
especi
followup
newborn
screen
object
assess
variabl
fe
measur
first
year
life
util
secondari
indic
cf
newborn
screen
algorithm
method
studi
popul
includ
infant
enrol
first
feed
infant
start
prospect
observ
studi
initi
enrol
infant
cf
center
madison
milwauke
boston
indianapoli
salt
lake
citi
chicago
identifi
optim
feed
infant
enrol
mo
fe
measur
enrol
mo
consecut
valu
mgg
analyz
fe
measur
infant
reach
mo
age
result
infant
initi
fe
measur
mo
one
infant
homozyg
genotyp
initi
fe
ugg
wherea
infant
heterozyg
one
infant
mutat
initi
fe
ugg
infant
initi
fe
mgg
subsequ
fe
valu
alway
infant
howev
one
infant
subsequ
fe
valu
fluctuat
infant
subsequ
fe
declin
one
declin
two
declin
latter
infant
one
homozygot
three
compound
heterozygot
one
mutat
three
compound
heterozygot
one
infant
nondiseas
caus
mutat
accord
databas
anoth
infant
second
mutat
found
databas
infant
second
mutat
yet
identifi
conclus
cohort
infant
cf
initi
fe
mo
age
among
declin
month
age
appar
fals
neg
rate
appear
high
consid
make
decis
adopt
fe
secondari
criterion
cf
newborn
screen
algorithm
introduct
newborn
screen
ns
implement
hospit
year
ago
ns
cystic
fibrosi
cf
provid
opportun
cascad
carrier
test
rel
posit
case
discov
routin
parent
diagnos
patient
test
confirm
carrier
diagnosi
object
describ
experi
diagnosi
cf
parent
rel
children
cf
discov
ns
method
examin
clinic
retrospect
data
parentsrel
children
diagnos
cf
ns
result
total
cf
children
detect
ns
center
last
year
parent
identifi
heterozyg
carrier
correspond
mutat
except
three
parent
grandmoth
addit
correspond
mutat
present
cftr
mutat
tran
two
parent
clinic
symptom
rhinosinus
bronchiti
concept
cf
babi
vitro
fertil
ivf
made
suspicion
cf
diagnosi
late
confirm
genet
test
famili
case
index
nb
mmoll
genotyp
genet
test
mother
identifi
mutat
affect
son
transmit
mutat
transmit
father
st
mmoll
histori
recurr
rhinosinus
present
famili
case
index
nb
st
mmoll
genotyp
mother
carrier
studi
two
sibl
mother
show
one
carri
genet
test
grandmoth
index
case
identifi
mutat
st
mmoll
histori
asthma
bronchiectasi
final
diagnos
cf
age
year
age
sever
year
follow
respiratori
diseas
conclus
carrier
test
cf
diagnosi
ns
mandatori
order
identifi
true
carrier
cftrrd
mild
cf
case
better
followup
famili
genet
counsel
hinojosaamaya
ab
torr
r
ga
arredondovazquez
p
villarrealperez
jz
bustamant
ae
martinez
de
villarr
le
hospit
universitario
uanl
monterrey
nuevo
leon
mexico
servicio
de
salud
de
nuevo
leon
monterrey
mexico
ceprep
hospit
universitario
uanl
monterrey
mexico
introduct
cystic
fibrosi
cf
hereditari
autosom
recess
disord
whose
earli
detect
may
decreas
morbid
mortal
vandevant
dr
et
al
j
cyst
fibro
newborn
screen
ns
cf
includ
sever
program
worldwid
mexico
detect
cf
includ
yokoyama
e
et
al
rev
invest
clin
nevertheless
nuevo
leon
state
locat
northeast
mexico
neonat
quantif
irt
start
object
present
result
ns
cf
nuevo
leon
mexico
method
crosssect
observ
descript
retrospect
studi
newborn
eight
public
hospit
belong
health
servic
state
nuevo
univers
hospit
dr
jose
e
gonzalez
uanl
sampl
septemb
octob
birth
hospit
around
birth
per
year
capillari
blood
sampl
taken
direct
heel
punctur
hour
birth
place
filter
paper
transport
genet
depart
medic
school
uanl
immunoreact
trypsinogen
quantifi
fluoroimmunoassay
techniqu
irt
perkin
elmer
cutoff
valu
obtain
diagnost
algorithm
follow
infant
result
sd
mean
second
sampl
request
newborn
valu
sent
urgent
evalu
pediatr
pulmonologist
cystic
fibrosi
clinic
second
sampl
taken
result
second
sampl
normal
patient
sent
evalu
confirmatori
sweat
chlorid
test
made
use
iontophoresi
techniqu
patient
alter
sampl
neg
confirmatori
test
follow
within
year
detect
clinic
featur
result
cutoff
valu
establish
ngml
ngml
adjust
accord
sampl
size
total
sampl
analyz
posit
first
sampl
second
sampl
obtain
total
second
sampl
report
abnorm
diagnosi
confirm
case
six
case
diagnosi
confirm
due
four
patient
lost
followup
one
die
ichthyosi
sweat
test
could
done
seven
sweat
chlorid
neg
follow
three
newborn
normal
tir
two
develop
meconium
ileu
anoth
develop
clinic
symptom
cf
classifi
falseneg
case
total
confirm
patient
cf
current
patient
surveil
good
health
two
patient
die
one
lost
incid
birth
calcul
conclus
ns
cf
nuevo
leon
show
incid
similar
report
literatur
indic
diseas
present
mexican
popul
includ
ns
earli
detect
contribut
prompt
manag
lead
good
health
major
case
introduct
manag
cystic
fibrosi
cf
requir
ongo
monitor
patient
mani
marker
relat
evolut
diseas
collect
analysi
marker
allow
us
describ
progress
diseas
anticip
occurr
clinic
event
case
cystic
fibrosi
one
import
marker
fev
use
assess
diseas
sever
detect
patient
elig
lung
transplant
marker
dynam
chang
time
import
take
account
repeat
measur
fev
rather
valu
baselin
better
assess
relationship
marker
surviv
better
predict
risk
event
patient
cf
object
aim
studi
first
examin
relationship
evolut
fev
occurr
death
transplant
adult
patient
cf
second
provid
dynam
predict
risk
death
transplant
use
develop
model
develop
joint
model
share
random
effect
assess
relationship
repeat
fev
measur
timetodeath
transplant
patient
cf
model
combin
two
process
longitudin
process
describ
repeat
measur
fev
surviv
process
describ
event
defin
death
transplant
analyz
data
french
cystic
fibrosi
registri
patient
age
older
decemb
nontranspl
studi
period
vital
statu
known
decemb
includ
studi
perform
forward
stepwis
select
identifi
baselin
variabl
relat
process
surviv
process
depend
current
level
slope
fev
use
retain
joint
model
provid
dynam
predict
result
total
patient
includ
studi
among
die
transplant
studi
period
younger
patient
femal
gender
higher
bodi
mass
index
bmi
lower
number
day
intraven
treatment
highli
associ
increas
fev
factor
associ
lower
fev
includ
burkholderia
cepacia
infect
pseudomona
aeruginosa
infect
long
term
oxygen
therapi
factor
associ
death
transplant
includ
burkholderia
cepacia
use
oral
corticosteroid
high
number
intraven
treatment
day
lower
bmi
risk
death
transplant
significantli
depend
current
valu
slope
fev
lower
fev
specif
time
point
favor
increas
death
transplant
adult
patient
cf
model
gave
good
predict
perform
conclus
joint
model
provid
accur
individu
predict
updat
addit
fev
valu
may
use
clinician
identifi
patient
elig
transplant
support
vaincr
la
mucoviscidos
introduct
newborn
screen
program
begin
measur
immunoreact
trypsinogen
irt
dri
blood
spot
taken
earli
life
howev
univers
portion
cf
case
miss
level
irt
program
cut
point
lower
cut
point
improv
program
sensit
reason
cut
point
found
screen
sensit
sought
enrol
us
program
survey
determin
preval
cf
case
miss
due
irt
level
program
cutoff
b
characterist
newborn
popul
screen
program
hospit
laboratori
specimen
transit
associ
risk
miss
cf
newborn
screen
low
irt
valu
method
studi
popul
includ
live
birth
occur
introduct
cf
newborn
screen
prior
allow
followup
period
identifi
miss
case
program
ask
provid
cf
newborn
screen
programspecif
data
individuallevel
data
lowirt
fals
neg
lfn
cf
case
summari
data
screenposit
confirm
cf
case
summari
data
screen
newborn
survey
question
design
identifi
possibl
mechan
irt
degrad
risk
factor
includ
hospit
set
transit
screen
laboratori
laboratori
analysi
child
demograph
genotyp
diagnosi
risk
factor
distribut
lfn
case
compar
screenposit
cf
case
cf
screen
newborn
result
date
state
collect
compris
us
birth
screen
newborn
complet
survey
total
cf
case
identifi
screen
addit
lfn
case
report
yield
overal
low
irt
miss
cf
case
rate
irt
valu
higher
lfn
case
median
respect
lfn
case
irt
valu
within
state
cut
point
lfn
cf
case
group
similar
regard
sex
median
infant
age
blood
collect
hour
longer
cf
case
hour
longer
similarli
median
age
irt
test
day
longer
cf
case
respect
excess
lfn
birth
found
birth
month
august
novemb
birth
day
saturday
compar
cf
case
conclus
preliminari
find
suggest
vast
major
lfn
miss
case
would
detect
small
adjust
screen
irt
cut
point
older
age
specimen
collect
irt
test
distribut
month
weekday
may
point
aspect
hospit
andor
laboratori
import
determin
lfn
case
support
legaci
angel
foundat
health
resourc
servic
administr
introduct
germani
feder
joint
committe
decid
implement
nationwid
cf
newborn
screen
evid
recent
european
studi
suggest
protocol
use
immunoreact
trypsinogen
irt
pancreatitisassoci
protein
pap
cystic
fibrosi
cf
newborn
screen
nb
may
success
use
pure
biochem
nb
strategi
pure
irtpap
protocol
reach
accept
sensit
specif
come
expens
rel
low
posit
predict
valu
ppv
dutch
chopin
studi
vernooijvan
langen
amm
et
al
thorax
report
use
threetier
strategi
irtpap
extend
gene
analysi
result
better
ppv
german
author
decid
also
irtpapdna
protocol
due
strict
german
gene
diagnost
act
extend
gene
analysi
desir
tier
object
assess
perform
differ
irtpapdna
cf
newborn
screen
protocol
use
differ
mutat
panel
dna
analysi
reach
allel
coverag
german
popul
method
raw
data
heidelberg
cf
newborn
screen
cohort
approxim
newborn
use
post
hoc
analysi
data
obtain
previou
studi
evalu
pure
biochem
irtpap
protocol
one
irtindepend
papcutoff
safeti
net
strategi
cfnb
posit
irt
irt
percentil
accord
sommerburg
et
al
j
inherit
metab
di
suppl
studi
result
irtpap
protocol
compar
intern
standard
irtdna
protocol
run
parallel
assess
efficaci
perform
step
irtpap
dna
protocol
mutat
panel
cftr
mutat
cover
cftr
mutat
cover
cftr
mutat
cover
allel
found
german
popul
evalu
find
threetier
strategi
irtpapdna
keep
main
advantag
irtpap
detect
consider
fewer
carrier
fewer
newborn
cfspid
compar
current
irtdna
screen
strategi
show
gener
higher
specif
higher
ppv
howev
combin
protocol
achiev
sensit
similar
twotier
irtpap
protocol
cftr
mutat
panel
least
allel
coverag
use
conclus
result
obtain
cohort
newborn
support
use
irtpapdna
protocol
mutat
panel
cftr
mutat
achiev
suffici
sensit
compar
twotier
irtpap
protocol
zirb
jm
yacob
milla
c
pediatr
stanford
univers
palo
alto
ca
usa
lung
diseas
continu
domin
featur
cf
contribut
significantli
morbid
mortal
cf
newborn
screen
cfnb
provid
opportun
earli
diseas
identif
intervent
avert
progress
lung
diseas
california
cfnb
start
juli
screen
algorithm
implement
detect
previous
known
well
novel
mutat
variant
unknown
signific
correspond
vari
degre
cftr
dysfunct
present
diagnost
dilemma
mani
remain
asymptomat
earli
childhood
condit
categor
cftrrelat
metabol
syndrom
crm
systemat
detail
longitudin
studi
infant
crm
understand
associ
risk
lung
diseas
better
establish
hypothes
biomark
reflect
inflammatori
activ
lung
diseas
differ
cf
crm
infant
evalu
panel
inflammatori
biomark
cohort
infant
identifi
cfnb
plasma
sampl
obtain
part
longitudin
prospect
studi
period
good
health
freedom
exacerb
human
cytokin
luminex
antibodi
bead
kit
custombuilt
ebiosci
san
diego
ca
use
accord
manufactur
recommend
particular
interest
inflammatori
cytokin
typic
report
cf
lung
diseas
significantli
differ
group
found
low
level
perhap
reflect
stabl
health
earli
stage
diseas
process
howev
notic
differ
cytokin
associ
immun
modul
respons
infect
innat
immun
statist
signific
differ
note
infant
cf
crm
boxplot
distribut
studi
group
figur
comparison
p
cf
infant
demonstr
increas
level
pgml
proinflammatori
cytokin
mig
vegf
resistin
lower
level
immunemodulatori
conclud
system
inflammatori
profil
cf
nb
infant
demonstr
signific
differ
benign
profil
infant
crm
suggest
lack
signific
lung
diseas
earli
life
group
ongo
observ
studi
track
longitudin
demograph
clinic
treatment
outcom
peopl
cystic
fibrosi
cf
receiv
care
cf
care
center
unit
state
cffpr
captur
patient
death
date
along
six
option
specifi
primari
caus
death
howev
peopl
cf
particip
cffpr
death
peopl
cf
record
registri
therefor
true
number
death
caus
cf
year
remain
unknown
object
object
analysi
compar
number
death
age
death
report
cffpr
multipl
caus
death
file
mcod
base
death
certif
us
resid
secondari
object
compar
caus
death
report
cffpr
mcod
method
cffpr
team
annual
valid
death
data
care
center
cffpr
captur
one
primari
caus
death
wherea
mcod
contain
singl
underli
caus
death
twenti
addit
multipl
caus
analysi
includ
death
data
peopl
cf
cffpr
includ
death
peopl
cf
mcod
includ
peopl
whose
death
certif
list
cf
caus
death
identifi
one
diagnost
code
cystic
fibrosi
cffpr
mcod
data
stratifi
compar
age
death
result
cf
death
report
cffpr
mcod
cf
death
report
cffpr
compar
cf
death
mcod
report
age
death
vari
dataset
report
death
year
age
cffpr
data
correl
mcod
data
howev
youngest
oldest
case
less
overlap
report
death
year
fewer
five
case
cffpr
wherea
mcod
case
differ
cohort
month
age
cffpr
fewer
five
case
wherea
mcod
case
differ
nearli
cohort
caus
death
list
mcod
cf
includ
respiratori
failur
unspecifi
acut
pneumonia
cardiac
arrest
lung
disord
diabetesrel
complic
organ
transplant
pneumonia
cirrhosi
liver
kidney
failur
diseas
pancrea
unspecifi
data
cffpr
show
transplantrel
death
mcod
conclus
best
correl
mcod
cffpr
data
achiev
individu
age
year
possibl
age
year
mcod
higher
probabl
incorrect
death
certif
code
cf
differ
death
count
first
year
life
may
suggest
die
receiv
care
cf
center
therefor
could
particip
cffpr
granular
analysi
mcod
data
need
may
indic
import
trend
caus
death
peopl
cf
background
cystic
fibrosi
canada
cfc
invest
futur
cf
care
fund
research
support
live
cf
today
healthcar
program
augment
work
cfc
introduc
structur
qualiti
improv
qi
program
cf
clinic
method
follow
nation
qi
confer
may
canadian
cf
clinic
invit
particip
new
cfc
qi
program
launch
octob
endors
board
director
leadership
assist
guidanc
cfc
director
healthcar
program
twelv
clinic
team
particip
first
three
oneyear
cohort
program
time
met
regularli
learn
conduct
improv
work
qi
expert
program
develop
collabor
dartmouth
institut
microsystem
academi
given
expertis
qi
initi
specif
cf
tool
concept
method
taught
address
clinic
activ
outcom
team
work
close
assign
qi
coach
assist
curriculum
learn
motiv
guid
team
qi
effort
marker
measur
identifi
track
order
quantifi
chang
demonstr
improv
result
introduct
qi
program
subsequ
awar
among
clinic
nation
landscap
distinct
focu
qi
refresh
mindset
clinic
deliv
care
identifi
way
improv
largest
clinic
countri
earli
particip
smaller
clinic
includ
one
smallest
countri
also
eager
involv
particip
provinc
includ
cf
clinic
bc
new
improv
capac
cf
clinic
identifi
address
theme
improv
includ
increas
knowledg
adher
airway
clearanc
techniqu
frequenc
treatment
improv
fev
measur
better
nutrit
increas
bmi
measur
deliveri
care
sick
patient
present
outsid
standard
outpati
clinic
time
reduct
wait
time
clinic
visit
increas
access
medic
nurs
support
better
followthrough
monitor
ancillari
clinic
test
process
screen
depress
anxieti
earli
result
suggest
improv
clinic
outcom
work
theme
underway
common
concern
express
particip
time
commit
consider
howev
deter
involv
anticip
effici
gain
save
time
vast
differ
clinic
popul
size
fewer
program
adapt
particip
team
especi
respect
measur
conclus
near
end
initi
threeyear
launch
program
uptak
among
clinic
good
quarter
cf
clinic
canada
particip
program
wellreceiv
although
still
earli
encourag
progress
observ
patient
outcom
continu
improv
anticip
commit
clinic
requir
particip
initi
howev
benefit
consider
potenti
longterm
nation
improv
great
investig
way
overcom
clinic
time
constraint
conflict
agenda
interfer
success
implement
program
method
increas
enrol
particip
program
follow
step
taken
social
worker
cf
rise
champion
swc
patient
sign
cf
rise
patient
portal
clinic
ensur
particip
help
troubleshoot
problem
registr
sent
individu
remind
patient
day
prior
clinic
visit
complet
portion
program
remind
sent
via
email
textfromcomput
patient
agre
enrol
hospit
admiss
swc
met
patient
introduc
program
bedsid
encourag
particip
orient
inpati
team
includ
nurs
staff
inpati
sw
program
help
remind
encourag
patient
particip
coordin
inpati
nurs
coordin
involv
get
well
network
gwn
inpati
bedsid
comput
system
gwn
creat
link
gain
easier
access
cf
rise
websit
well
allow
messag
system
individu
patient
room
swc
coordin
remind
appropri
new
popup
messag
abl
sent
individu
bedsid
tvcomput
result
enrol
improv
patient
sign
patient
portal
clinic
admiss
particip
also
improv
use
remind
prior
clinic
visit
well
remind
patient
complet
portion
hospit
admiss
date
patient
total
age
success
enrol
program
patient
express
sens
accomplish
increas
cf
knowledg
base
parent
also
respond
favor
prepar
effort
express
relief
someth
tangibl
focu
anticip
lead
reduct
anxieti
stress
relat
transit
process
allow
meaning
discuss
success
goal
complet
discuss
program
well
receiv
patient
parent
addit
program
welcom
addit
transit
program
pediatr
adult
team
excit
result
program
better
patient
knowledg
independ
find
creativ
way
remind
help
patient
particip
program
well
receiv
patient
reward
medic
team
capit
use
clinic
inpati
time
get
patient
particip
help
next
step
incorpor
direct
quot
age
rang
share
whole
center
hope
encourag
particip
patient
may
less
motiv
aim
valid
portcf
icf
site
assess
current
portcf
inform
consentenrol
process
identifi
qualiti
issuesbarri
complianc
method
first
step
creat
list
patient
current
enrol
portcf
identifi
valid
icf
origin
icf
file
chronolog
year
consent
alphabet
origin
icf
scan
electron
archiv
icf
activ
patient
upload
portcf
origin
icf
refil
alphabet
next
method
obtain
record
file
icf
review
previous
consent
process
complet
clinician
research
staff
list
kept
enrol
includ
icf
date
sever
barrier
icf
process
identifi
includ
multipl
individu
involv
set
process
inconsist
commun
staff
consent
staff
enrol
patient
portcf
ineffici
file
system
inadequ
track
icf
result
intern
icf
audit
identifi
one
activ
patient
enrol
origin
consent
could
locat
consent
next
clinic
visit
two
patient
identifi
recons
pursuant
protocol
amend
due
legal
guardianship
issu
note
amend
affect
particip
portcf
longer
seen
center
event
report
children
hospit
wisconsin
irb
improv
process
consist
effici
prevent
futur
error
occur
new
process
icf
obtain
research
team
member
includ
cf
registri
coordin
cfrc
research
coordin
lead
research
coordin
research
manag
icf
sign
cfrc
updat
track
spreadsheet
b
send
copi
icf
medic
record
c
scan
icf
electron
archiv
file
origin
icf
alphabet
e
enrol
patient
portcf
f
upload
icf
portcf
new
list
creat
track
patient
declin
consent
enrol
approach
initi
consent
requir
recons
due
age
list
access
care
team
issu
portcf
icf
conclus
intern
audit
reveal
overal
high
complianc
portcf
icf
document
patient
icf
file
patient
sign
current
irbapprov
icf
prevent
futur
error
standard
workflow
process
improv
implement
remov
barrier
improv
effici
portcf
inform
consent
enrol
process
next
step
assess
icf
processdocument
studi
nasr
univ
michigan
ann
arbor
mi
usa
introduct
tremend
advanc
cf
care
result
vast
improv
health
lifespan
qualiti
life
individu
cf
unfortun
optim
medic
care
time
consum
complex
involv
medic
treatment
administr
multipl
modal
day
maintain
daili
medic
regimen
difficult
mani
peopl
cf
famili
previou
research
demonstr
rate
medic
regimen
adher
peopl
cf
around
patient
famili
cite
number
barrier
adher
includ
educ
defici
famili
stressor
schedul
difficulti
defianc
qualiti
improv
qi
initi
crucial
help
overcom
barrier
success
manag
daili
therapi
object
review
develop
cultiv
qi
cultur
cf
center
univers
michigan
u
method
member
cf
center
team
includ
pediatr
pulmonologist
pediatr
pulmonari
fellow
respiratori
therapist
nurs
social
worker
dietician
psychologist
clinic
coordin
medic
assist
physic
therapist
pharmacist
activ
famili
advisor
board
fab
qi
process
includ
center
particip
cff
ellc
provid
formal
qi
teach
group
led
coach
assign
group
qi
discuss
qi
work
involv
cf
team
member
qi
project
select
review
center
cf
registri
data
identifi
opportun
improv
center
align
qi
effort
result
measur
improv
clinic
outcom
process
improv
tie
clinic
outcom
key
driver
center
consist
involv
patient
famili
identifi
design
implement
improv
effort
fab
famili
educ
night
discuss
clinic
result
formal
teach
team
member
help
creat
cultur
qi
center
includ
peopl
cf
famili
integr
member
care
team
help
support
buyin
partnership
help
improv
priorit
individu
treatment
plan
improv
qualiti
life
qi
project
intervent
includ
bmi
improv
b
assess
barrier
adher
c
use
prescript
refil
data
improv
adher
medic
improv
annual
lab
work
test
patient
ogtt
test
year
old
e
use
home
spirometri
spiro
pd
monitor
improv
adher
f
improv
adher
cff
guidelin
clinic
visit
attend
g
fab
creat
inpati
high
calori
menu
discuss
cultiv
qi
cultur
center
possibl
formal
qi
teach
whole
team
empow
whole
team
particip
qi
work
also
led
member
team
come
qi
idea
involv
parent
patient
qi
work
abl
come
qi
idea
involv
stakehold
qi
process
ensur
sustain
qi
work
center
prior
research
shown
malnutrit
associ
reduc
lung
function
increas
mortal
adult
cystic
fibrosi
cf
patient
maintain
optim
nutrit
essenti
part
cf
care
adult
cf
patient
goal
bmi
therefor
undertook
qualiti
improv
qi
project
improv
nutrit
statu
adult
cf
popul
method
first
secur
financi
support
via
geising
qi
grant
provid
protect
time
cf
dietitian
also
benefit
cf
foundationsupport
qi
coach
help
launch
project
multidisciplinari
team
includ
adult
cf
patient
assembl
june
perform
microsystem
assess
patient
knowledg
assess
ka
global
aim
statement
improv
percentag
adult
cf
patient
goal
bodi
mass
index
bmi
june
incorpor
result
ka
action
plan
result
reveal
clinic
bmi
data
accur
height
weight
measur
precis
first
intervent
reeduc
nurs
staff
accur
anthropometr
measur
techniqu
digit
stadiomet
instal
cf
clinic
height
measur
monitor
next
month
variabl
clinic
visit
record
averag
differ
visit
per
patient
reduc
cm
ka
reveal
linear
relationship
bmi
cf
nutrit
knowledg
patient
comment
identifi
nutrit
barrier
time
cost
food
andor
supplement
notabl
inconsist
provid
nutrit
recommend
includ
use
oral
supplement
discuss
feed
tube
base
find
design
multifacet
cf
nutrit
algorithm
incorpor
patient
educ
standard
nutrit
intervent
base
sever
malnutrit
patient
cf
dietitian
track
educ
receiv
nutrit
goal
intervent
recommend
stage
algorithm
nutrit
statu
patient
discuss
preclin
multidisciplinari
meet
incorpor
nutrit
inform
algorithm
intervent
goal
next
appoint
cf
clinic
note
templat
educ
materi
describ
nutrit
supplement
financi
resourc
develop
first
month
nutrit
initi
averag
bmi
adult
patient
increas
median
median
conclus
nutrit
essenti
compon
adult
cf
care
target
measur
process
knowledg
issu
cf
clinic
improv
nutrit
statu
cf
patient
collect
reliabl
bmi
data
nutrit
protocol
start
address
gap
patient
educ
ensur
consist
applic
nutrit
intervent
patient
bmi
improv
work
achiev
goal
patient
reach
target
bmi
june
support
geising
health
plan
qualiti
pilot
fund
cf
foundat
approxim
patient
cf
admit
year
inpati
respirolog
unit
accommod
inpati
cf
time
year
prior
program
saw
increas
number
patient
yet
staf
physiotherapist
pt
remain
steadi
two
fulltim
equival
fte
pt
cf
team
respons
pulmonari
inpati
outpati
well
crosscov
pt
absenc
clinic
unit
improv
qualiti
care
patient
develop
model
forecast
number
fte
pt
requir
clinic
size
also
appli
model
obtain
addit
fte
pt
valid
accuraci
method
data
record
daili
number
propos
observ
treatment
session
separ
inpati
cf
noncf
base
prioriti
matrix
high
vs
moder
number
outpati
cf
noncf
saw
time
spent
coverag
clinic
unit
patientcar
round
administrativeteachingresearch
activ
overtim
use
data
estim
total
time
pt
avail
patient
care
time
spent
inpati
use
total
number
propos
treatment
session
inpati
cf
noncf
total
time
need
patient
care
well
duti
forecast
requir
number
fte
pt
data
adjust
time
spent
cover
clinic
unit
time
pt
cover
inpati
respirolog
unit
data
weekday
includ
public
holiday
day
insuffici
data
exclud
calcul
median
percentil
tabul
result
data
collect
two
pt
week
data
day
avail
calcul
number
fte
pt
requir
clinic
size
time
forecast
percentag
treatment
session
actual
done
inpati
cf
propos
session
high
prioriti
categori
propos
session
moder
prioriti
categori
inform
use
advoc
increas
fund
pt
staf
one
extra
fte
pt
ad
data
collect
three
pt
period
data
day
avail
calcul
model
inform
us
need
fte
pt
current
clinic
size
percentag
treatment
session
perform
inpati
cf
propos
session
high
prioriti
categori
propos
session
moder
prioriti
categori
conclus
model
effect
estim
number
fte
pt
need
increas
size
larg
cf
clinic
increas
fte
pt
abl
complet
larger
percentag
propos
treatment
session
model
use
clinic
accur
forecast
staf
need
univers
kansa
hospit
cffaccredit
care
center
provid
care
adult
cf
patient
inpati
unit
due
averag
preval
multidrugresist
pseudomona
aeruginosa
infect
adult
cf
popul
studi
realtim
infect
control
practic
rel
cff
cdc
guidelin
develop
intervent
improv
staff
infectioncontrol
complianc
object
assess
improv
multidisciplinari
staff
adher
current
guidelin
proper
use
person
protect
equip
ppe
use
safe
zone
foot
area
within
patient
room
door
care
cf
inpati
method
qualiti
improv
initi
develop
use
plandostudyact
pdsa
cycl
assess
ppe
safe
zone
complianc
seventi
onehour
audit
conduct
day
night
shift
one
week
cf
inpati
unit
audit
conduct
preand
postintervent
staff
member
inform
audit
conduct
data
preintervent
audit
inform
develop
intervent
procedur
intervent
consist
educ
materi
ie
infect
control
brochur
patient
cf
patient
educ
board
door
sign
relat
infect
control
infect
control
inservic
video
unit
staff
addit
safe
zone
decal
appli
floor
room
accord
institut
standard
infect
control
unit
staff
member
mandat
complet
educ
program
sign
complianc
contract
postintervent
audit
perform
week
follow
intervent
determin
ppe
safe
zone
complianc
improv
result
preintervent
audit
includ
observ
incid
improp
ppe
safe
zone
use
hospit
staff
complianc
one
hundr
percent
unit
staff
complet
educ
compon
intervent
postintervent
audit
includ
observ
instanc
improp
ppe
safe
zone
use
complianc
analyz
profession
disciplin
nurs
complianc
improv
dietari
staff
improv
nondietarynonnurs
staff
improv
complianc
chisquar
test
differ
proport
show
statist
signific
improv
within
group
note
p
p
p
respect
conclus
studi
provid
baselin
knowledg
infect
control
complianc
inpati
cf
care
center
implement
safe
zone
decal
patient
educ
hospit
staff
educ
improv
ppe
safe
zone
use
adher
greater
disciplinari
group
studi
intervent
feasibl
care
facil
implement
improv
adher
infect
control
measur
wide
carden
j
antoni
v
pulmonari
critic
care
uab
birmingham
al
usa
background
uab
adult
cystic
fibrosi
cf
program
start
juli
adult
cf
program
reorgan
improv
adher
cystic
fibrosi
foundat
cff
guidelin
sinc
care
team
annual
review
cff
year
end
center
report
gener
port
cf
databas
identifi
area
improv
summer
team
review
year
end
report
found
patient
year
older
receiv
hyperton
salin
compar
patient
top
care
center
daili
use
inhal
hyperton
salin
recommend
cff
guidelin
initi
qualiti
improv
qi
studi
increas
hyperton
salin
use
rate
compar
top
care
center
purpos
purpos
qualiti
improv
project
threefold
first
increas
awar
cff
care
guidelin
relat
hyperton
salin
usag
second
determin
usag
rate
port
cf
accur
reflect
patient
popul
third
evalu
patient
current
hyperton
salin
determin
therapi
ad
clinic
coordin
initi
chart
review
patient
schedul
clinic
visit
fall
quarter
flag
patient
without
hyperton
salin
medic
list
cf
care
confer
cf
care
team
evalu
flag
patient
hyperton
salin
indic
patient
good
candid
test
dose
hyperton
salin
administ
clinic
toler
prescript
gener
toler
patient
given
test
dose
patient
toler
refus
therapi
note
made
chart
result
chart
review
patient
perform
fall
quarter
intervent
patient
hyperton
salin
patient
demonstr
data
port
cf
reflect
patient
popul
port
cf
show
patient
hyperton
salin
patient
hyperton
salin
evalu
clinic
eight
start
hyperton
salin
start
hyperton
salin
report
toler
hyperton
salin
seven
refus
therapi
intervent
patient
hyperton
salin
conclus
futur
direct
qibas
intervent
increas
number
patient
hyperton
salin
three
month
center
within
five
point
top
care
center
countri
metric
improv
maintain
longterm
standard
practic
adult
cf
team
review
medic
list
clinic
visit
determin
appropri
therapi
includ
hyperton
salin
prescrib
children
alabamaunivers
alabama
birmingham
coauab
pediatr
cf
center
util
equip
review
assess
patient
famili
compet
inform
use
direct
teach
equip
chang
patient
famili
improv
high
frequenc
chest
wall
oscil
hfcwo
devic
part
cf
popul
lung
health
routin
hfcwo
devic
histor
discuss
review
convers
without
actual
devic
clinic
set
howev
proper
function
fit
machin
actual
vest
garment
crucial
effect
treatment
period
pilot
group
patientspar
ask
bring
home
hfcwo
devic
clinic
troubleshoot
adjust
made
custom
improv
hfcwo
patient
home
use
object
measur
satisfact
handson
review
improv
proper
home
use
hfcwo
devic
method
respiratori
therapist
rt
made
contact
patientspar
via
phone
ask
bring
hfcwo
devic
clinic
review
adjust
request
made
hour
day
appoint
total
patient
involv
pilot
clinic
visit
size
garment
assess
set
chang
made
overal
equip
review
complet
satisfact
survey
given
parentspati
complet
day
equip
review
result
total
patient
involv
pilot
brought
devic
receiv
adjust
hfcwo
set
person
therapi
need
new
equip
due
damag
tube
inoper
devic
improp
garment
size
adjust
need
satisfact
survey
complet
time
hfcwo
assess
among
respons
answer
hfcwo
devic
review
help
would
like
bring
devic
clinic
yearli
review
conclus
signific
number
patientspar
agre
bring
hfcwo
devic
clinic
review
evalu
devic
assess
need
chang
adjust
devic
assess
clinic
found
benefici
parentspati
also
cf
team
provid
better
standard
care
base
success
project
center
implement
annual
hfcwo
devic
review
along
physic
assess
respiratori
equip
use
home
set
activ
qualiti
improv
initi
develop
transit
program
base
best
practic
goal
identifi
barrier
effect
transit
improv
patient
outcom
experi
method
anonym
survey
administ
electron
member
pediatr
adult
cf
care
team
survey
evalu
caregiv
attitud
toward
best
practic
transit
care
patient
transfer
care
pediatr
adult
cf
program
indiana
univers
also
survey
regard
compon
transit
program
well
impress
preand
posttransf
adult
team
rate
done
likert
scale
strongli
disagre
strongli
agre
spss
version
chicago
spss
inc
use
analyz
data
result
patient
respons
rate
pediatr
provid
adult
provid
overal
patient
least
like
feel
though
provid
discuss
transit
prior
age
although
agre
pediatr
team
discuss
transit
age
transit
reach
question
pediatr
team
provid
educ
regard
transit
process
famili
statist
signific
varianc
p
base
age
transit
sever
area
statist
signific
compar
feel
adult
health
care
team
transfer
care
see
figur
pediatr
provid
felt
least
strongli
use
chart
flow
sheet
readi
assess
patient
encount
respect
feel
howev
initi
meet
introduct
adult
team
help
adult
care
team
agre
use
readi
assess
address
need
goal
selfcar
less
like
complet
conclus
data
highlight
area
improv
program
includ
address
transit
prior
age
provid
consist
educ
transit
process
appear
young
adult
concern
adult
program
improv
transfer
generaliz
singlecent
data
limit
small
sampl
size
inform
provid
start
point
implement
chang
improv
introduct
cystic
fibrosisrel
diabet
cfrd
common
comorbid
patient
cf
surviv
increas
incid
cfrd
like
correspondingli
increas
associ
ad
mortal
howev
sever
small
studi
demonstr
improv
lung
function
bmi
insulin
therapi
oral
glucos
toler
test
ogtt
standard
care
screen
howev
associ
histor
low
rate
patient
complianc
emerg
literatur
suggest
detect
treatment
postprandi
hyperglycemia
diagnos
glucos
challeng
test
gct
may
benefici
howev
overal
research
limit
object
center
ogtt
complet
rate
adult
well
nation
averag
root
caus
analysi
suggest
low
rate
relat
patient
forget
fast
inconveni
test
lack
patient
understand
import
test
recent
systemat
review
suggest
gct
may
sensit
screen
test
cfrd
waugh
n
et
al
health
technol
assess
object
qualiti
improv
initi
implement
algorithm
compris
patient
educ
remind
system
well
compress
ogtt
gct
shorter
fast
period
improv
complianc
rate
adult
cf
would
also
benefit
detect
postprandi
hyperglycemia
possibl
precursor
state
cfrd
method
univers
massachusett
center
cystic
fibrosi
patient
age
greater
cf
without
cfrd
quarterli
visit
assess
need
cfrd
screen
educ
physician
import
test
contact
night
prior
next
visit
pulmonari
fellow
screen
acut
ill
would
preclud
test
remind
test
remain
noth
mouth
npo
four
hour
prior
addit
given
option
come
gct
morn
prior
visit
separ
test
facil
conveni
fast
patient
present
clinic
fingerstick
glucos
measur
valu
mgdl
patient
refer
formal
ogtt
otherwis
patient
consum
oral
glucos
solut
onehour
post
valu
obtain
valu
test
perform
valu
mgdl
patient
ask
return
full
ogtt
npo
period
result
complet
rate
increas
qualiti
improv
intervent
two
gct
suggest
previous
unrecogn
cfrd
patient
refer
endocrinolog
test
treatment
conclus
combin
patient
educ
compress
test
gct
referr
ogtt
result
abnorm
institut
patient
remind
system
moder
increas
screen
complianc
remain
room
signific
improv
root
caus
analysi
ongo
increas
screen
optim
level
introduct
cystic
fibrosisrel
diabet
cfrd
common
comorbid
cystic
fibrosi
cf
preval
exce
cf
adult
neg
impact
nutrit
statu
lung
function
mortal
cf
foundat
care
guidelin
recommend
annual
screen
oral
glucos
toler
test
ogtt
ogtt
screen
rate
nation
averag
adult
cf
patient
process
place
allow
time
endocrin
evalu
cfrd
patient
initi
qualiti
improv
qi
project
improv
diagnosi
manag
cfrd
center
method
develop
formal
multidisciplinari
cfrd
qi
program
earli
includ
adult
cf
endocrin
clinician
adult
cf
patient
cfrd
goal
improv
screen
rate
ogtt
facilit
time
referr
endocrin
provid
cfrd
manag
systemat
monitor
screen
microvascular
complic
cfrd
target
goal
least
yearli
endocrin
visit
cfrd
patient
order
increas
adher
annual
screen
ogtt
arrang
patient
test
done
facil
typic
coordin
cf
clinic
visit
educ
patient
cfrd
screen
advanc
place
remind
call
patient
prior
schedul
visit
cfrd
diagnos
enhanc
process
time
endocrin
referr
followup
visit
send
electron
messag
endocrin
clinic
schedul
coordin
cf
endocrin
physician
appoint
date
possibl
furthermor
endocrin
clinic
diabet
educ
often
day
avail
meet
patient
need
optim
cfrd
manag
teach
improv
microvascular
screen
incorpor
assess
cfrd
complic
cf
clinic
templat
note
review
preclin
multidisciplinari
meet
result
baselin
ogtt
screen
rate
implement
qi
project
ogtt
screen
rate
increas
remain
past
year
adult
cfrd
patient
evalu
endocrin
clinician
median
hemoglobin
improv
estim
median
bmi
increas
kgm
kgm
remain
stabl
adult
cf
clinic
note
templat
includ
microvascular
screen
prompt
provid
order
lab
referr
defici
note
visit
conclus
adult
cf
center
ogtt
screen
rate
improv
dramat
patient
increas
access
endocrin
clinician
diabet
educ
reflect
decreas
measur
improv
nutrit
statu
adult
cfrd
patient
seen
endocrin
provid
least
past
year
anticip
success
continu
collabor
effort
standard
approach
monitor
cfrd
complic
come
year
strive
maintain
ogtt
screen
rate
background
children
al
coa
cf
center
partner
univers
al
birmingham
uab
adult
pulmonari
team
start
adult
center
transit
program
program
evolv
includ
workgroup
wg
meet
adult
pediatr
ped
team
patient
tour
adult
facil
transit
clinic
uabcoa
cf
center
follow
patient
age
year
median
median
bmi
method
team
revisit
transit
effort
goal
becom
unifi
cf
center
start
retreat
fall
focus
collabor
qi
work
retreat
jointli
plan
well
attend
disciplin
follow
retreat
wg
expand
began
meet
monthli
order
rapidli
implement
chang
idea
share
drive
establish
hous
improv
work
patient
staff
satisfact
survey
administ
transit
outcom
track
time
result
retreat
team
establish
purpos
statement
coproduc
list
transit
expect
patient
caregiv
patient
satisfact
survey
result
indic
satisfact
prepar
transit
care
receiv
adult
center
concern
includ
infect
control
stay
healthi
transit
treat
respect
establish
trust
relationship
adult
team
staff
knowledg
satisfact
survey
show
adequ
knowledg
transit
agreement
process
better
month
ago
overarch
theme
staff
recommend
includ
continu
collabor
adult
ped
team
sinc
young
adult
transit
mean
time
last
ped
visit
first
adult
visit
day
rang
mean
group
last
ped
visit
mean
bmi
group
receiv
tour
adult
facil
prior
transit
improv
standard
practic
includ
annual
joint
retreat
educ
day
monthli
transit
wg
meet
annual
inservic
ped
inpati
staff
visit
adult
team
member
ped
clinic
hospit
stay
transit
track
transit
outcom
develop
educ
tool
flyer
highlight
similar
differ
two
center
conclus
joint
retreat
adult
ped
team
facilit
collabor
approach
gener
qi
goal
monthli
wg
meet
help
team
maintain
momentum
qi
work
receiv
feedback
patient
caregiv
staff
transit
process
help
ensur
focu
qi
work
includ
thing
import
consum
next
step
includ
develop
transit
checklist
administr
satisfact
survey
patient
month
transit
provis
inform
packet
patient
state
titl
v
program
outlin
benefit
chang
occur
transit
agreement
provid
patient
found
regard
use
patient
provid
work
togeth
make
decis
patient
provid
provid
like
agreestrongli
agre
dashboard
help
discuss
matter
patient
provid
patient
patient
comment
dashboard
empow
previsit
plan
develop
agenda
driven
goalsconcern
allow
deeper
evalu
question
clinic
abil
trend
health
metric
sidebysid
coupl
ongo
track
goal
remind
aftervisit
summari
also
posit
area
improv
patientspar
includ
confus
word
potenti
disrupt
authent
convers
provid
posit
includ
strength
prepar
visit
ad
structur
focus
patient
concern
use
share
graph
bmi
streamlin
clinic
flow
concern
provid
perspect
includ
ad
clinician
agenda
time
explan
duplic
emr
cff
patient
registri
report
graph
includ
simpl
trend
refin
goal
settingact
plan
word
desir
alertsnotif
assist
futur
plan
conclus
frequent
test
identifi
feasibl
util
dashboard
enabl
coproduct
area
improv
address
rapid
pdsa
cycl
method
pilot
test
prepar
dashboard
enabl
prepar
site
test
hightech
version
acknowledg
support
robert
wood
johnson
foundat
grant
cff
grant
object
character
patient
knowledg
attitud
belief
around
ic
practic
associ
cf
care
tertiari
care
medic
center
kumc
method
conduct
voluntari
semistructur
interview
conveni
sampl
patient
cf
sampl
includ
adult
patient
cf
admit
kumc
cf
inpati
unit
oneweek
studi
period
survey
contain
qualit
quantit
question
administ
survey
question
focus
knowledg
sourc
knowledg
provid
selfreport
patientadher
ic
guidelin
demograph
data
patient
interview
collect
medic
record
qualit
data
transcrib
code
common
theme
result
elig
patient
particip
yield
respons
rate
subject
state
receiv
understood
educ
cf
ic
practic
primarili
healthcar
provid
import
aspect
ic
perceiv
patient
hand
hygien
avoid
contact
patient
cf
use
person
protect
equip
staff
patient
felt
healthcar
provid
staff
primarili
respons
ic
identifi
respons
particip
report
signific
differ
hospit
staff
adher
guidelin
measur
role
staff
member
eg
nurs
vs
dietari
staff
complementari
investig
ic
practic
show
support
object
evid
observ
unpublish
data
assess
patient
adher
ic
guidelin
reveal
patient
selfreport
alway
adher
infect
control
guidelin
hospit
cf
clinic
medic
set
patient
report
adher
home
report
adher
public
place
facetofac
contact
person
cf
avoid
particip
report
rare
contact
inpati
outpati
set
patient
cite
live
person
cf
remain
report
volit
occasion
contact
other
cf
conclus
gener
patient
cf
receiv
understood
educ
regard
ic
practic
identifi
agre
import
aspect
ic
report
good
adher
ic
practic
hospit
cf
outpati
clinic
patient
receiv
ic
educ
healthcar
staff
although
mani
unawar
inform
provid
obtain
specif
cff
guidelin
find
underscor
import
engag
patient
famili
regular
discuss
ic
reason
volit
contact
other
cf
may
relat
psychosoci
need
studi
studi
limit
conveni
sampl
futur
investig
valid
cohort
consid
univers
tennesse
medic
center
utmc
becam
one
eight
team
onecf
learn
leadership
collabor
llc
onecf
team
evalu
current
process
throughout
lifespan
cf
patient
east
tennesse
identifi
opportun
improv
transit
pediatr
adult
care
first
action
hold
graduat
patient
account
make
appoint
adult
clinic
patient
last
pediatr
appoint
ask
make
first
adult
appoint
provid
date
time
discharg
solv
two
problem
decreas
amount
time
patient
go
without
cf
care
provid
definit
end
date
pediatr
care
next
onecf
team
began
concentr
commun
pediatr
adult
team
although
two
team
met
semiannu
medic
record
fax
patient
discuss
among
team
member
aim
improv
consist
qualiti
commun
pediatr
adult
cf
team
provid
seamless
transfer
care
method
llc
team
systemat
address
commun
issu
specif
time
transfer
pediatr
adult
program
first
step
addit
patient
report
agenda
center
meet
pediatr
coordin
team
provid
summari
graduat
patient
adult
coordin
provid
updat
patient
transfer
year
prior
handoff
tool
develop
use
plan
studi
act
qualiti
improv
method
plan
templat
creat
includ
inform
valuabl
disciplin
care
new
patient
onepag
document
includ
six
box
inform
nurs
respiratori
care
physic
therapi
social
work
nutrit
serv
summari
page
sent
patient
medic
record
studi
data
collect
plan
worksheet
use
develop
survey
evalu
effect
fall
adult
team
answer
scale
help
extrem
help
help
inform
provid
newli
transit
etch
patient
feel
fulli
prepar
care
patient
addit
inform
would
help
act
tool
continu
modifi
base
upon
survey
result
multidisciplinari
patient
summari
expect
element
transfer
record
result
multidisciplinari
handoff
tool
accompani
medic
record
patient
transfer
etch
utmc
primari
goal
provid
essenti
inform
adult
team
care
patient
patient
transit
adult
team
total
survey
adult
team
return
evalu
inform
provid
tool
survey
rate
inform
extrem
help
help
total
score
suggest
improv
tool
includ
addit
age
height
weight
clinic
trial
particip
thoma
rg
chmiel
j
pediatr
pulmonolog
rainbow
babi
children
hospit
cleveland
oh
usa
introduct
airway
infect
remain
import
contributor
cystic
fibrosi
cf
lung
diseas
antibiot
therapi
contribut
significantli
increas
surviv
cf
howev
cf
patient
gener
requir
higher
dose
without
cf
differ
organ
minimum
inhibitori
concentr
antibiot
airway
penetr
alter
medic
pharmacokinet
secondari
cf
make
dose
antibiot
difficult
time
consum
creat
cf
antibiot
dose
calcul
cfadc
goal
make
dose
faster
easier
patient
popul
method
cfadc
excel
file
save
share
comput
drive
pediatr
pulmonari
depart
calcul
contain
four
page
iv
oral
dose
adult
children
respect
children
calcul
function
input
weight
calcul
recommend
dose
dose
rang
base
publish
recommend
cf
antibiot
dose
maximum
dose
cap
maximum
daili
dose
maximum
weight
enter
cap
eas
oral
dose
cfadc
addit
recommend
round
dose
tablet
oral
solut
within
calcul
dose
rang
iv
dose
calcul
round
dose
nearest
vial
size
minim
wast
medic
cfadc
put
use
month
anonym
survey
given
pulmonari
physician
cf
center
staff
provid
ask
estim
time
took
dose
antibiot
without
calcul
also
ask
rank
eas
decid
dose
confid
dose
scale
one
ten
ten
repres
easiest
confid
without
calcul
respons
collect
analyz
use
twotail
ttest
result
survey
complet
provid
one
provid
fail
answer
question
regard
eas
use
confid
dose
time
calcul
dose
decreas
minut
also
show
trend
toward
increas
eas
confid
dose
one
provid
felt
eas
dose
confid
decreas
tabl
conclus
cfadc
decreas
time
dose
antibiot
children
cf
also
show
trend
toward
improv
eas
dose
medic
provid
confid
dose
calcul
could
addit
benefit
decreas
dose
error
improv
adher
recommend
dose
creat
uniform
dose
among
provid
center
howev
studi
time
improv
could
made
eas
dose
creat
applic
provid
could
download
phone
cfadc
potenti
creat
easier
safer
consist
dose
patient
cf
provid
mean
dose
time
minut
provid
mean
dose
confid
eas
dose
scale
repres
easiest
confid
vital
clinic
visit
serv
marker
qualiti
care
deliv
also
highlight
area
care
need
improv
order
better
serv
patient
cystic
fibrosi
pediatr
center
children
health
distribut
clinicspecif
patient
satisfact
survey
march
may
result
survey
analyz
area
suboptim
abil
easili
schedul
quarterli
appoint
cf
foundat
cff
clinic
care
guidelin
recommend
peopl
age
older
visit
care
center
least
four
time
year
order
compli
cff
recommend
increas
patient
satisfact
area
imper
implement
proactiv
schedul
could
done
minim
patient
caregiv
burden
method
qualiti
improv
qi
project
focus
obtain
emrgener
report
januari
juli
juli
januari
report
track
number
cf
patient
seen
clinic
time
period
number
without
schedul
followup
appoint
report
util
schedul
call
schedul
patient
quarterli
visit
base
report
concurr
patient
satisfact
survey
conduct
children
health
determin
schedul
enter
patient
room
clinic
visit
schedul
appoint
prior
discharg
assur
followup
could
made
time
fashion
result
initi
januari
report
demonstr
differ
patient
seen
schedul
followup
appoint
second
report
run
juli
show
differ
patient
seen
left
without
followup
appoint
even
though
second
quarter
percentag
increas
posit
chang
note
patient
satisfact
result
quarter
children
health
score
patient
satisfact
regard
obtain
appoint
report
quarter
satisfact
increas
patient
satisfact
increas
due
appoint
made
prior
clinic
discharg
schedul
proactiv
call
famili
situat
appoint
promptli
schedul
patient
satisfact
still
improv
famili
given
explan
assur
quick
resolut
reason
delay
often
unopen
physician
templat
attempt
coordin
care
provid
differ
disciplin
conclus
qi
project
identifi
need
clinic
reduc
number
famili
leav
clinic
without
schedul
appoint
attempt
reduc
burden
schedul
room
prior
discharg
need
schedul
call
soon
visit
move
forward
monthli
monitor
unschedul
appoint
complet
decreas
number
patient
seen
quarterli
basi
current
state
screen
cystic
fibrosi
newborn
screen
texa
cf
screen
ad
panel
high
level
immunoreact
trypsinogen
irt
protein
blood
may
marker
cystic
fibrosi
texa
use
irtdna
algorithm
initi
screen
use
irt
second
screen
requir
screen
common
mutat
case
understand
possibl
outcom
newborn
screen
obtain
sweat
chlorid
test
newborn
challeng
confus
lead
delay
diagnosi
cystic
fibrosi
delay
initi
treatment
cystic
fibrosi
foundat
award
pediatr
center
univers
texassouthwestern
medic
center
children
health
screen
improv
program
sip
grant
order
optim
diagnosi
earli
treatment
newborn
qualiti
improv
project
involv
educ
pediatrician
famili
medicin
practic
nicu
catchment
area
enhanc
understand
cf
newborn
screen
refer
patient
sweat
test
diseasespecif
care
method
initi
step
creation
algorithm
cf
flier
detail
obtain
sweat
test
refer
patient
cf
clinic
secondli
creat
hotlin
via
children
health
page
system
well
cfspecif
email
account
provid
util
question
cf
flier
algorithm
given
children
health
physician
liaison
group
dissemin
pediatrician
offic
catchment
area
nurs
practition
assist
physician
outreach
program
variou
primari
care
provid
pcp
offic
answer
question
review
cf
inform
algorithm
also
ad
children
health
polici
tracker
quick
refer
guid
result
sinc
initi
distribut
educ
materi
newborn
refer
clinic
histor
greatest
delay
get
nicu
babi
test
seen
time
fashion
initi
earlier
commun
nicu
commun
abl
send
cf
provid
privileg
outsid
nicu
provid
consult
allow
better
parent
understand
diagnosi
assist
improv
transit
nicu
cf
clinic
newborn
refer
earlier
due
visit
pcp
offic
abl
offer
patient
expedit
sweat
test
clinic
appoint
within
hour
confirm
neither
email
hotlin
util
much
direct
contact
clinic
conclus
goal
come
year
continu
collabor
children
health
provid
ongo
educ
strengthen
relationship
commun
physician
also
work
dilig
screen
team
austin
help
identifi
newborn
cf
get
expedit
clinic
referr
visit
object
cystic
fibrosi
center
undertook
process
improv
project
enhanc
immun
statu
patient
streptococcu
pneumonia
administr
ppv
pneumovax
recommend
certain
high
risk
patient
advisori
committe
immun
practic
acip
american
academi
pediatr
aap
chronic
lung
diseas
one
high
risk
categori
uk
cf
trust
canadian
cff
includ
pneumococc
vaccin
recommend
cf
patient
howev
part
standard
cf
guidelin
given
center
us
twelvemonth
period
time
abl
move
popul
fulli
immun
per
guidelin
fulli
immun
albeit
specif
aim
popul
immun
vaccin
mors
mr
et
al
pediatr
pulmonol
second
year
project
sought
standard
process
would
lose
gain
made
potenti
improv
result
even
method
varieti
plandostudyact
cycl
conduct
algorithm
devis
previou
year
improv
electron
medic
record
system
instal
data
base
previou
year
continu
run
chart
made
report
data
dissemin
quarterli
oppos
monthli
first
year
addit
compar
data
caregiv
ad
present
period
stakehold
result
end
patient
receiv
compar
begin
receiv
compar
begin
lost
ground
year
end
year
return
level
previou
gain
patient
fulli
immun
ie
receiv
vaccin
influx
patient
previous
receiv
pcv
rate
year
end
conclus
difficulti
sustain
gain
made
year
follow
project
immun
cf
patient
invas
pneumococc
diseas
ipd
continu
meet
hurdl
ingrain
longstand
hospit
cultur
could
overcom
without
project
leader
return
champion
project
without
recommend
immun
ipd
per
acip
aap
guidelin
us
cff
countri
measur
requir
compet
attent
receiv
prioriti
without
champion
rowbotham
nj
elliot
z
morley
r
smyth
divis
child
health
obstetr
gynaecolog
univers
nottingham
nottingham
unit
kingdom
parent
children
cf
nottingham
unit
kingdom
cochran
york
unit
kingdom
introduct
alway
evid
support
treatment
decis
cf
present
cohes
strategi
fill
evid
gap
research
driven
financi
interest
investig
tradit
patient
view
consid
set
research
agenda
object
partnership
cf
commun
collect
prioritis
uncertainti
futur
research
question
method
undertak
jame
lind
allianc
jla
prioriti
set
partnership
psp
http
wwwjlanihracuk
free
text
survey
avail
global
interest
cf
collect
research
question
parallel
conduct
systemat
review
identifi
known
known
known
unknown
cf
treatment
decis
allow
us
exclud
suggest
research
question
alreadi
answer
use
framework
approach
true
treatment
uncertainti
collat
utilis
delphi
method
second
onlin
survey
final
workshop
particip
prioritis
collat
uncertainti
top
ten
question
clinic
research
cf
agre
unlik
psp
condit
onlin
conferenc
method
utilis
avoid
crossinfect
believ
widen
particip
timelin
show
cf
jla
psp
process
result
month
first
survey
go
live
respons
question
submit
advertis
via
social
media
gain
submiss
world
top
two
countri
respons
england
usa
respond
peopl
cf
famili
friend
clinician
varieti
theme
identifi
includ
nutrit
physiotherapi
medic
manag
exacerb
lifestyl
health
care
system
even
role
polit
present
shortlist
top
question
vote
cf
commun
conclus
exercis
engag
cf
commun
around
globe
give
uniqu
opportun
help
set
futur
research
agenda
psp
diseas
area
led
major
research
fund
mani
top
ten
question
jla
cf
psp
support
cf
trust
univ
nottingham
nottingham
hospit
chariti
njr
support
nihr
academ
clinic
fellowship
author
present
behalf
jla
cf
psp
steer
group
timelin
outlin
jla
cf
psp
process
background
adult
cf
express
desir
program
could
use
reallif
knowledg
compass
mentor
peer
share
clinic
inform
facilit
share
experi
live
cf
impact
life
mileston
transit
colleg
date
job
experi
etc
associ
cff
adult
advisori
committe
mentor
develop
committe
pilot
program
develop
follow
aim
offer
access
sustain
mentor
program
meet
need
cf
commun
achiev
high
level
satisfact
mentor
peer
cffaccredit
care
center
method
survey
conduct
among
cf
care
center
identifi
exist
mentor
program
assess
needdesir
nation
effort
next
scan
noncf
organ
peer
mentor
conduct
plan
made
recruit
adult
cf
program
time
zone
standard
oper
procedur
document
develop
train
materi
creat
onlin
platform
allow
selfpac
cours
content
quizz
commun
instructor
content
includ
confidenti
boundari
mentor
resourc
effect
listen
posit
commun
strategi
mentorp
match
base
mentor
topic
consid
peer
prefer
follow
domain
health
statu
adult
vs
earli
diagnosi
age
gender
time
zone
employ
statu
interest
central
coordin
arrang
match
content
discuss
respons
mentorp
dyad
mentor
advisori
group
conven
respond
program
feedback
issu
program
design
scalabl
success
result
exist
cf
mentor
arrang
inform
respond
enthusiast
develop
formal
program
mentor
program
usc
cf
stanford
gener
imerman
angel
cancer
christoph
dana
reev
foundat
spinal
cord
injuri
kidney
foundat
pa
chronic
renal
diseas
ms
societi
alzheim
associ
review
common
thread
content
effect
empathet
listen
share
experi
nonauthoritarian
way
twelv
adult
care
program
includ
pilot
phase
baylor
colleg
columbia
univers
intermountain
medic
univers
south
carolina
nation
jewish
northwestern
oregon
health
scienc
univers
st
luke
stanford
univers
univers
iowa
univers
pennsylvania
usckeck
preliminari
result
present
nacfc
includ
number
mentor
train
site
satisfact
process
site
assess
program
burden
number
peer
access
program
number
match
made
averag
rang
durat
mentorship
varieti
satisfact
score
conclus
listen
voic
adult
commun
work
cooper
cff
resourc
use
creat
program
leverag
power
person
experi
cf
provid
peertop
support
preliminari
result
indic
program
feasibl
creat
minimum
work
care
center
importantli
lead
high
degre
mentorp
dyad
satisfact
thoma
lk
kimberli
b
rodger
tf
lauderdal
mim
c
pediatr
pulmonari
children
alabama
univers
alabama
birmingham
birmingham
al
usa
inpati
cystic
fibrosi
cf
children
alabamaunivers
alabama
birmingham
coauab
pediatr
cf
center
care
either
medic
resid
nurs
practition
np
team
led
attend
physician
outpati
cf
team
identifi
issu
continu
care
caregiv
pharmacist
call
cf
center
discharg
problem
lack
prior
author
pa
unwritten
prescript
lack
knowledg
get
medic
prescript
sent
incorrect
pharmaci
issu
caus
delay
long
week
recept
discharg
medic
therefor
inpati
outpati
cf
team
along
titl
v
program
children
rehabilit
servic
cr
provid
insur
supplement
qualifi
patient
develop
plan
improv
discharg
plan
medic
prescript
method
inpati
np
pharmacist
outpati
nurs
coordin
cr
social
worker
met
understand
role
team
member
determin
process
cr
involv
discharg
plan
determin
process
specialti
pharmaci
prescript
identifi
medic
requir
pa
respons
develop
commun
plan
discharg
medic
among
three
group
result
meet
excel
file
document
new
medic
refil
need
pa
statu
discharg
date
place
secur
share
drive
daili
updat
review
cr
also
develop
new
role
hospit
liaison
coordin
updat
patient
need
commun
among
cr
inpati
outpati
team
becom
standard
process
patientspar
survey
regard
knowledg
discharg
home
plan
abil
recit
plan
well
difficulti
prescript
fill
overwhelmingli
agre
knew
home
plan
half
report
ask
recit
plan
discharg
although
report
difficulti
receiv
discharg
medic
outpati
nurs
phone
note
use
measur
delay
januari
discharg
plan
meet
occur
patient
record
reveal
delay
discharg
medic
follow
facetofac
meet
implement
share
discharg
document
delay
rapidli
decreas
month
current
averag
month
without
record
delay
discuss
facetofac
meet
result
improv
awar
role
process
also
daili
commun
plan
improv
motiv
knowledg
plan
avoid
delay
discharg
medic
importantli
delay
discharg
medic
greatli
decreas
particularli
impress
given
rapid
chang
polici
parti
payor
specialti
pharmaci
coauab
pediatr
cf
program
establish
practic
discharg
goal
set
primari
pulmonologist
recogn
program
leadership
increas
isol
inpati
team
outpati
team
due
physic
expans
facil
may
result
patient
discharg
prior
meet
specif
nutrit
respiratori
health
goal
expect
primari
pulmonologist
discharg
goal
institut
improv
commun
defin
patientspecif
goal
determin
resolut
pulmonari
exacerb
pe
nutrit
endpoint
set
primari
pulmonologist
method
discharg
goal
initi
set
primari
pulmonologist
howev
practic
becam
standard
longterm
goal
develop
patient
parent
team
outpati
rt
admiss
discharg
followup
predict
collect
patient
admit
pe
abl
reproduc
reliabl
lung
function
test
result
goal
also
establish
patient
unabl
perform
spirometri
includ
weight
gain
symptom
control
patient
also
given
survey
relat
satisfact
hospit
result
uniqu
patient
admit
hospit
inpati
day
averag
stay
day
uniqu
patient
admit
hospit
inpati
day
averag
stay
day
patient
reach
discharg
goal
common
reason
unmet
goal
includ
patient
goal
align
primari
pulmonologist
special
event
patient
averag
chang
admiss
discharg
discharg
clinic
followup
averag
day
compar
improv
hospit
chang
discharg
fu
statist
analysi
process
time
write
hospit
survey
complet
encount
major
patient
report
likert
scale
hospit
experi
improv
last
hospit
experi
discharg
goal
discuss
conclus
establish
discharg
goal
improv
commun
inpati
outpati
team
least
admiss
goal
share
primari
pulmonologist
inpati
team
predetermin
discharg
goal
seem
neg
impact
patient
satisfact
hospit
experi
sinc
goal
establish
discharg
past
potenti
improv
commun
patient
although
improv
averag
admiss
discharg
lower
compar
decreas
followup
less
number
uniqu
patient
requir
admiss
discharg
goal
standard
care
goal
increas
jointli
establish
goal
popul
patient
abl
reliabl
perform
pulmonari
function
test
background
patient
staff
satisfact
survey
show
patient
felt
wait
long
clinic
quarterli
visit
staff
view
clinic
stress
place
work
upon
closer
review
cycl
time
note
averag
cycl
time
minut
contact
time
provid
give
patient
impress
lot
wast
time
aim
improv
patient
knowledg
adher
prescrib
pulmonari
therapi
found
global
knowledg
deficit
among
patient
well
patient
staff
dissatisfact
method
assembl
multidisciplinari
team
includ
cf
center
director
associ
director
coordin
dietician
social
worker
respiratori
therapist
rt
nurs
practition
portcf
data
coordin
cf
patient
mother
team
conduct
assess
clinic
function
review
patient
staff
satisfact
anonym
survey
collect
cycl
time
data
set
global
specif
aim
improv
examin
clinic
function
satisfact
costrel
measur
use
clinic
valu
compass
complet
driver
diagram
better
understand
factor
affect
patient
adher
began
rapidli
test
idea
chang
use
plandostudyact
pdsa
model
intervent
use
pdsa
approach
test
follow
idea
track
signin
signout
time
patient
provid
multidisciplinari
clinic
util
one
team
member
flow
master
keep
provid
move
trial
three
differ
cf
patient
action
plan
clinic
better
commun
treatment
plan
famili
base
test
handwritten
treatment
plan
ad
burden
care
lengthen
clinic
visit
without
ad
signific
valu
patient
develop
electron
version
model
prefer
handwritten
version
cycl
time
highli
variabl
differ
patient
depend
arriv
time
test
new
clinic
templat
improv
flow
bring
sick
patient
clinic
date
time
outsid
multidisciplinari
clinic
lighten
clinic
burden
ad
cf
rise
program
clinic
help
measur
knowledg
deficit
improv
screen
patient
parent
anxieti
depress
via
social
worker
team
psychologist
institut
specif
rt
educ
review
airway
clearanc
protocol
clean
order
therapi
famili
quarterli
visit
reeduc
staff
area
infect
control
respiratori
therapi
guidelin
preschool
treatment
guidelin
improv
staff
satisfact
note
result
note
signific
improv
cycl
time
contact
time
provid
patient
satisfact
score
lung
function
measur
also
see
effort
recogn
outsid
microsystem
recent
request
particip
qi
initi
regard
inpati
care
patient
cf
project
support
cff
fundament
learn
leadership
collabor
schechter
ms
schmidt
hj
william
r
norton
r
taylor
pediatr
children
hospit
richmond
virginia
commonwealth
univers
chor
vcu
richmond
va
usa
respiratori
therapi
chor
vcu
richmond
va
usa
background
much
variat
pulmonari
outcom
exist
among
patient
due
individu
characterist
signific
compon
appear
depend
upon
cf
center
care
previou
investig
includ
cf
benchmark
program
sever
observ
data
base
analys
suggest
cf
center
success
attain
better
fev
higher
expect
outcom
achiev
systemat
approach
ensur
consist
proactiv
respons
pulmonari
exacerb
recogn
opportun
improv
pulmonari
manag
chor
vcu
attempt
incorpor
philosophi
multifacet
program
improv
cf
outcom
could
bundl
share
interest
cf
center
method
reorgan
cf
pulmonari
care
chor
vcu
began
includ
follow
compon
use
cf
foundat
patient
registri
smart
report
track
fev
time
preclin
meet
develop
pulmonari
algorithm
defin
therapeut
respons
chang
fev
creation
spreadsheet
tool
calcul
chang
fev
baselin
everi
visit
complet
respiratori
therapist
use
run
chart
track
adher
algorithm
use
run
chart
demonstr
effect
intervent
averag
fev
popul
outcom
measur
use
roll
averag
best
fev
previou
patient
follow
pediatr
program
roll
month
averag
calcul
use
center
data
download
portcf
enter
program
stata
commonli
use
statist
softwar
packag
output
illustr
run
chart
gener
excel
result
run
chart
chang
period
shown
mean
best
fev
children
year
age
rose
predict
p
januari
p
march
children
rose
p
children
rose
p
p
discuss
improv
pulmonari
outcom
accomplish
rel
rapidli
use
basic
qualiti
improv
principl
includ
interdisciplinari
team
goal
set
standard
proactiv
approach
ensur
consist
recognit
treatment
pulmonari
exacerb
use
data
follow
effect
process
believ
step
involv
would
easi
cf
center
adopt
adapt
set
support
cff
mean
patient
best
fev
previou
month
background
differ
cf
center
care
account
much
variat
nutrit
outcom
exist
among
cf
patient
find
cff
benchmark
program
suggest
cf
center
success
attain
better
growth
higher
expect
achiev
outcom
systemat
approach
ensur
consist
respons
small
falloff
bmi
percentil
attempt
incorpor
philosophi
multifacet
program
improv
cf
outcom
could
bundl
share
interest
cf
center
method
reorgan
cf
nutrit
care
chor
vcu
began
includ
follow
compon
use
cff
patient
registri
smart
report
track
nutriton
measur
time
preclin
meet
develop
nutrit
algorithm
defin
therapeut
respons
children
less
satisfactori
bmi
weightforlength
wfl
percentil
use
run
chart
track
adher
algorithm
use
run
chart
demonstr
effect
intervent
nutrit
measur
popul
outcom
measur
use
roll
averag
best
bmi
wfl
children
year
previou
month
patient
follow
pediatr
program
roll
averag
calcul
use
center
data
download
portcf
enter
program
stata
commonli
use
statist
softwar
packag
output
illustr
run
chart
gener
excel
result
mean
best
wfl
rose
januari
march
bmi
percentil
bmip
children
year
old
rose
year
rose
importantli
us
percentag
patient
best
wfl
th
ile
previou
month
drop
percentag
best
bmip
drop
percentag
best
bmip
drop
percentag
best
bmip
drop
shown
figur
discuss
improv
nutrit
outcom
accomplish
rel
rapidli
use
basic
qi
principl
includ
interdisciplinari
team
goal
set
standard
proactiv
approach
ensur
consist
recognit
earli
treatment
children
less
satisfactori
nutrit
statu
use
data
follow
effect
process
believ
step
involv
would
easi
cf
center
adopt
adapt
set
support
cff
introduct
clear
associ
bmi
lung
function
adult
patient
cystic
fibrosi
cf
cf
foundat
recommend
bmi
kgm
adult
women
kgm
adult
men
cf
higher
bmi
correl
higher
lung
function
also
associ
lower
bmi
poor
clinic
outcom
includ
lower
lung
function
reason
uab
adult
cf
center
defin
urgent
nutrit
need
statu
bmi
kgm
women
kgm
men
object
improv
nutrit
statu
measur
bmi
sever
malnourish
urgent
need
categori
patient
cf
adult
cf
center
method
multidisciplinari
nutrit
algorithm
implement
patient
classifi
urgent
nutrit
need
statu
algorithm
focus
improv
bmi
nutritionfocus
clinic
visit
regist
dietitian
social
worker
physician
nurs
practition
shorter
clinic
followup
interv
week
nutrit
intervent
includ
dietari
counsel
increas
calori
use
commerci
beverag
optim
enzym
referr
specialist
appetit
stimul
initi
optim
supplement
tube
feed
patient
met
social
worker
assess
financi
statu
depressionanxieti
screen
patient
receiv
written
nutrit
action
plan
end
visit
summar
nutrit
recommend
intervent
medic
chang
provid
specif
calor
weight
gain
goal
result
least
two
visit
algorithm
complet
patient
femal
male
identifi
urgent
nutrit
need
statu
three
visit
complet
patient
femal
male
patient
complet
second
visit
patient
complet
third
visit
return
clinic
recommend
week
follow
interv
averag
weight
gain
follow
initi
intervent
algorithm
initi
visit
visit
kg
averag
net
weight
gain
initi
visit
visit
kg
averag
bmi
femal
initi
visit
kgm
averag
bmi
male
initi
visit
kgm
visit
averag
bmi
femal
improv
kgm
averag
bmi
male
improv
kgm
visit
averag
bmi
femal
improv
kgm
averag
bmi
male
improv
slightli
kg
onethird
patient
complet
least
two
visit
algorithm
move
urgent
nutrit
need
categori
conclus
implement
multidisciplinari
urgent
nutrit
need
algorithm
use
written
nutrit
action
plan
unifi
team
messag
improv
nutrit
led
improv
nutrit
statu
malnourish
subset
patient
adult
cf
center
despit
limit
adher
recommend
closer
followup
interv
improv
weight
gain
bmi
statu
achiev
futur
work
continu
use
pathway
focu
sustain
weight
gain
optim
nutrit
statu
subsequ
visit
sadeghi
h
keat
c
dimango
e
altman
k
tsang
sewel
w
robinson
v
pincu
columbia
univers
medic
center
new
york
ny
usa
introduct
life
expect
increas
individu
cystic
fibrosi
cf
adult
children
diseas
formal
transit
program
transfer
care
pediatr
cf
center
adult
cf
center
previous
exist
center
creat
obstacl
patient
famili
anxieti
apprehens
transfer
care
miss
delay
appoint
new
center
lack
adequ
commun
among
healthcar
provid
newli
develop
transit
program
aim
share
respons
pediatr
adult
cf
team
secur
smooth
transit
care
improv
prepared
transit
patient
cf
famili
posit
impact
patient
outcom
object
survey
conduct
focu
patient
opinion
regard
percept
transfer
process
time
transfer
adult
care
educ
need
within
transit
process
method
part
one
cf
learn
leadership
collabor
grant
transit
team
columbia
univers
medic
center
organ
consist
provid
pediatr
adult
cystic
fibrosi
care
center
adult
cf
parent
child
cf
coach
patient
transfer
columbia
pediatr
cf
center
adult
cf
center
previou
four
year
patient
year
older
survey
onemonth
period
survey
look
opinion
percept
transfer
process
time
transfer
educ
within
current
transit
process
result
seventeen
patient
particip
five
year
age
eleven
year
one
document
age
none
respond
felt
transfer
occur
high
school
graduat
accord
particip
mean
ideal
age
transfer
year
prepar
selfcar
prepar
independ
felt
comfort
commun
adult
provid
knew
locat
adult
clinic
prepar
relationship
sexual
discuss
felt
prepar
insur
issu
comfort
make
appoint
adult
clinic
conclus
cf
patient
felt
transfer
adult
center
best
high
school
graduat
major
patient
report
confid
selfcar
independ
base
survey
result
pediatr
program
need
better
prepar
adolesc
medic
insur
issu
topic
relat
relationship
sexual
transit
process
success
transit
provid
need
assess
development
need
knowledg
gap
individu
time
transfer
base
prepared
futur
hope
also
evalu
outcom
transit
adult
care
acknowledg
support
cff
one
cf
learn
leadership
collabor
grant
johnson
pulmonari
nationwid
children
hospit
columbu
oh
usa
background
cystic
fibrosi
cf
care
complex
requir
skill
almost
life
realm
well
mani
teen
continu
reli
adult
caregiv
manag
care
peopl
cf
surviv
adulthood
requir
certain
skill
maintain
good
health
satisfi
live
pediatr
adult
cf
team
nationwid
children
hospit
recogn
need
develop
trial
multidisciplinari
approach
success
transit
cf
pediatr
adult
care
object
object
establish
smooth
transit
pediatr
adult
care
patient
cf
without
decreas
healthcar
statu
defin
cohort
patient
age
year
goal
complet
transit
remain
patient
transit
end
cycl
age
method
multidisciplinari
team
includ
parent
member
identifi
skill
inform
crucial
selfcar
team
member
identifi
process
within
hisher
area
expertis
assess
teach
patient
cohort
identifi
cf
foundat
registri
patient
complet
sawicki
readi
questionnair
enrol
identifi
order
prefer
transit
topic
allow
particip
input
process
patient
track
weekli
team
member
respons
individu
topic
met
patient
clinic
visit
disciplinespecif
quiz
administ
followup
teach
quiz
readminist
addit
teach
need
score
obtain
topic
complet
handoff
visit
patient
caregiv
pediatr
adult
program
provid
perform
patient
elig
seen
adult
clinic
complet
second
sawicki
questionnair
satisfact
survey
bmi
visit
schedul
call
initi
patient
track
year
bmi
data
compar
patient
year
age
complet
formal
transit
process
result
present
patient
complet
process
move
adult
clinic
averag
time
graduat
month
rang
month
averag
chang
sawicki
score
point
rang
area
greatest
chang
track
health
issu
follow
manag
medic
appoint
keep
patient
satisfact
process
high
item
satisfact
survey
answer
conclus
develop
program
time
consum
standard
incorpor
visit
identif
specif
cf
team
member
track
patient
progress
imper
assess
teach
done
within
exist
clinic
visit
structur
twoyear
timefram
adequ
complet
process
major
patient
process
occur
pediatr
cf
clinic
requir
excel
commun
adult
pediatr
team
patient
famili
satisfact
high
readi
selfcar
improv
transit
process
pociask
jj
jame
j
occup
therapi
depart
cystic
fibrosi
care
center
children
hospit
lo
angel
lo
angel
ca
usa
background
may
cystic
fibrosi
care
center
identifi
decreas
habitu
physic
activ
inpati
popul
recruit
expertis
ot
team
address
deficit
adolesc
transit
time
life
requir
need
develop
habit
role
routin
support
emerg
independ
adolesc
cf
face
addit
challeng
barrier
particip
healthi
lifestyl
relat
area
occup
occup
therapi
practic
framework
domain
process
aota
ot
occup
therapist
specif
skill
set
uniqu
foster
increas
independ
particip
meaning
activ
inpati
ot
program
base
goalset
creat
implement
address
need
hypothesi
hypothes
particip
inpati
goalset
ot
intervent
adolesc
cf
promot
independ
increas
particip
meaning
activ
method
ot
evalu
patient
age
cf
inpati
stay
evalu
includ
motiv
interview
administr
children
assess
particip
enjoy
cape
complet
cystic
fibrosi
questionnairerevis
cfqr
creation
written
daili
schedul
particip
ask
engag
selfreflect
creat
shortand
longterm
goal
ot
collabor
patient
goal
set
activ
facilit
engag
meaning
activ
hospit
discharg
ot
provid
therapeut
use
self
tailor
treatment
session
tap
individu
intrins
motiv
facilit
selfawar
need
make
lifestyl
chang
result
may
patient
particip
ot
program
patient
requir
level
verbal
cue
creat
goal
patient
success
complet
task
set
shortand
longterm
goal
patient
abl
identifi
factor
relat
cf
creat
barrier
independ
particip
typic
prefer
adolesc
activ
goal
categor
base
area
occup
otpf
categor
goal
reveal
theme
relat
emerg
independ
highest
frequenc
goal
desir
independ
relat
health
manag
follow
work
leisur
educ
household
establish
manag
health
manag
goal
includ
independ
treatment
manag
home
make
one
doctor
appoint
increas
physic
activ
conclus
conclud
inpati
goalset
ot
intervent
promot
independ
goal
set
adolesc
cf
howev
need
support
area
health
manag
specul
ot
play
import
role
promot
independ
particip
meaning
activ
adolesc
cf
support
transit
adulthood
ot
use
combin
psychosoci
emot
physic
intervent
promot
independ
selfefficaci
requir
manag
one
life
chronic
ill
chemtob
ch
layish
calimano
f
summo
k
serr
cf
center
central
florida
pulmonari
group
winter
park
fl
usa
object
improv
screen
process
cystic
fibrosisrel
diabet
cfrd
process
begin
identifi
patient
without
cfrd
need
yearli
screen
end
ogtt
result
obtain
address
set
central
florida
pulmonari
group
adult
cystic
fibrosi
center
serv
patient
within
privat
practic
set
background
inform
incid
cfrd
report
high
data
rate
cfrd
patient
popul
significantli
higher
nation
averag
rate
despit
high
incid
cfrd
averag
annual
rate
screen
nationwid
clinic
screen
rate
significantli
lower
nation
averag
screen
nondiabet
patient
requir
test
method
specif
goal
project
increas
number
patient
screen
cfrd
one
year
initi
step
studi
clinic
process
gener
first
increas
number
cf
clinic
initi
appoint
remind
call
allow
cf
coordin
instruct
patient
get
laboratori
test
includ
ogtt
done
prior
visit
track
lab
result
real
time
document
port
cf
within
one
day
clinic
visit
make
improv
clinic
process
gener
began
take
step
specif
address
cfrd
screen
explor
ogtt
test
offic
decid
feasibl
action
plan
develop
improv
cfrd
screen
process
first
cf
annual
lab
order
sheet
revis
make
easier
staff
order
lab
ogtt
test
staff
educ
cfrd
import
ogtt
screen
patient
educ
cfrd
ogtt
test
complet
md
regist
dietitian
patient
educ
materi
provid
financi
insur
resourc
test
provid
social
worker
addit
list
endocrinologist
insur
accept
develop
serv
resourc
referr
diagnosi
result
compar
center
report
data
port
cf
center
report
avail
ran
report
port
cf
analyz
result
data
show
dramat
increas
cfrd
screen
result
improv
screen
process
patient
diagnos
cfrd
rate
cfrd
patient
popul
conclus
chang
clinic
process
address
problem
identifi
clinic
gener
specif
cfrd
screen
abl
dramat
improv
cfrd
screen
improv
patient
care
diagnos
new
case
cfrd
aim
cfrd
screen
rate
would
like
thank
cff
allow
us
particip
fun
llc
qi
program
grate
guidanc
encourag
coach
dr
zanni
provid
st
ong
corrigan
coat
fletcher
c
manchest
n
abbott
tyrrel
wyatt
c
cairn
barbara
bush
children
hospit
main
medic
center
portland
usa
object
improv
inpati
pediatr
cf
care
outcom
patient
experi
improv
commun
coordin
care
specif
aim
increas
famili
satisfact
commun
among
cf
team
improv
patient
experi
increas
adher
improv
respiratori
therapi
rt
physic
therapi
pt
servic
method
prospect
observ
time
seri
conduct
small
academ
children
hospit
sept
support
institut
senior
manag
seri
parallel
intervent
plan
implement
improv
team
includ
hospit
vice
presid
project
manag
resid
attend
physician
nurs
therapist
dietician
social
worker
child
life
parent
improv
commun
interdisciplinari
round
initi
five
day
per
week
person
schedul
board
updat
round
daili
afternoon
huddl
team
introduc
improv
patient
experi
cf
famili
advisori
board
creat
inform
brochur
discuss
expect
hospit
dietician
develop
highcalori
cf
menu
increas
adher
reward
program
offer
patient
use
electron
medic
record
epic
clinic
scorecard
establish
track
outcom
increas
weight
gain
track
measur
clinic
improv
improv
rt
servic
need
assess
complet
compar
total
number
pediatr
inhal
therapi
current
rt
staf
improv
pt
servic
cf
bootcamp
expand
exercis
option
establish
fitbit
given
patient
age
monitor
exercis
data
track
use
epic
redcap
softwar
pediatr
hcahp
famili
survey
discharg
result
studi
period
patient
admit
cf
pulmonari
exacerb
interdisciplinari
round
success
complet
day
per
week
averag
time
hcahp
survey
patient
rate
hospit
experi
highli
nation
hcahp
averag
admiss
increas
averag
goal
amount
weight
gain
admiss
patient
percentil
goal
sinc
start
adher
program
june
satisfact
data
show
famili
complet
survey
felt
child
compliant
nurs
survey
felt
patient
adher
fewer
barrier
care
success
demonstr
need
full
time
rt
pediatr
unit
posit
approv
fitbit
distribut
patient
part
cf
bootcamp
program
conclus
success
improv
cf
inpati
care
measur
improv
weight
gain
famili
satisfact
enhanc
pt
rt
servic
key
success
includ
famili
advisori
board
involv
plan
project
multidisciplinari
bedsid
round
improv
commun
use
reward
system
adher
next
step
expans
inpati
exercis
program
ong
cassidi
j
mcnamara
davi
c
gibson
r
lion
k
pediatr
divis
pulmonari
sleep
medicin
univers
washington
seattl
wa
usa
seattl
children
hospit
seattl
wa
usa
pediatr
univers
washington
seattl
wa
usa
background
clinic
practic
manag
cystic
fibrosi
cf
shift
evolut
cftr
modul
kalydeco
ivacaftor
first
approv
medic
class
shown
persist
benefit
lung
function
diseas
marker
concurr
rapid
adopt
cf
commun
recent
approv
orkambi
lumacaftor
ivacaftor
expand
avail
patient
common
mutat
cftr
safe
medic
use
challeng
navig
concern
associ
advers
effect
object
implement
standard
cftr
modul
assess
tool
clinic
determin
modul
use
assess
knowledg
routin
monitor
captur
side
effect
method
qualiti
improv
tool
monitor
medic
safeti
cystic
fibrosi
momscf
develop
clinic
team
momscf
tool
assess
patient
knowledg
cftr
modul
elig
monitor
review
adher
side
effect
associ
modul
use
medic
reconcili
healthrel
qualiti
life
cfqr
also
assess
patient
elig
modul
therapi
screen
prior
clinic
clinic
packet
popul
momscf
tool
provid
review
tool
patient
clinic
visit
result
nineteen
patient
elig
cftr
modul
center
assess
momscf
tool
sinc
initi
march
seventeen
patient
elig
orkambi
two
patient
know
elig
therapi
two
patient
knew
elig
declin
prescript
patient
prescrib
therapi
receiv
medic
four
patient
cataract
screen
monitor
lab
medic
report
daili
adher
report
take
medic
day
week
eight
patient
deni
stop
therapi
take
orkambi
kalydeco
one
patient
report
use
airway
clearanc
less
often
five
patient
report
symptom
sinc
start
modul
therapi
includ
increas
cough
chest
pain
chest
tight
troubl
breath
stomach
pain
four
patient
felt
symptom
relat
start
medic
continu
therapi
one
patient
increas
cough
discontinu
medic
restart
median
cfqr
respiratori
domain
score
patient
modul
therapi
conclus
success
develop
implement
tool
standard
assess
cftr
modul
use
real
world
practic
momscf
tool
provid
detail
ascertain
modifi
patient
level
factor
may
impact
cftr
modul
use
object
evalu
measur
fit
core
strength
cf
patient
particip
exercis
program
visit
method
elig
patient
year
age
baselin
health
statu
visit
program
design
fit
cardiopulmonari
evalu
certifi
athlet
trainer
everi
month
prior
cf
clinic
appoint
fit
educ
exercis
recommend
goal
set
also
occur
visit
among
metric
collect
bruce
protocol
stage
time
minut
max
mlkgmin
static
hold
core
strength
test
superman
vsit
planktim
second
sec
rest
activ
vital
heart
rate
respiratori
rate
cfqr
hae
score
mean
standard
deviat
calcul
continu
demograph
variabl
frequenc
percentag
calcul
categor
variabl
linear
mix
model
gener
pair
ttest
use
assess
patient
metric
time
particip
program
result
januari
patient
fit
cardiopulmonari
evalu
done
visit
subset
patient
complet
visit
characterist
subset
patient
gener
similar
total
cohort
patient
includ
mean
age
year
sd
mean
fev
predict
sd
femal
overal
cohort
femal
patient
complet
exercis
visit
patient
visit
patient
visit
patient
visit
patient
visit
patient
visit
mean
time
visit
day
rang
day
slight
improv
vsit
secyear
p
increas
seci
superman
although
statist
signific
p
bruce
protocol
improv
includ
stage
increas
averag
stagesi
p
time
increas
averag
mini
p
max
increas
averag
mlkgmin
per
year
p
discuss
improv
bruce
protocol
stage
time
max
suggest
patient
visit
increas
endur
program
one
measur
improv
core
strength
vsit
reach
statist
signific
other
superman
plank
limit
includ
variabl
time
visit
small
sampl
size
patient
nonadher
exercis
recommend
anoth
potenti
limit
assess
time
variabl
visit
primarili
relat
system
schedul
issu
futur
focu
program
includ
assess
adher
exercis
recommend
reduc
standard
time
visit
decreas
variabl
increas
sampl
size
determin
improv
fit
sustain
time
sawicki
gs
boston
children
hosp
boston
usa
riley
children
hosp
indianapoli
usa
background
individu
cf
often
unprepar
transit
care
adult
provid
may
poor
understand
routin
cf
care
medic
regimen
health
insur
collegecar
develop
option
meet
ongo
health
challeng
young
adult
cf
transit
prepar
start
adolesc
essenti
object
use
multidisciplinari
qualiti
improv
qi
approach
establish
program
facilit
transit
patient
pediatr
adult
care
within
larg
pediatr
adult
cf
care
program
method
qi
project
initi
conjunct
cff
fund
onecf
team
includ
multidisciplinari
clinician
well
old
cf
parent
young
adult
cf
need
assess
survey
sent
young
adult
recent
transfer
adult
cf
team
parent
adolesc
pediatr
program
health
care
provid
process
map
transit
establish
onecf
center
transit
polici
develop
fifti
patient
age
year
old
follow
pediatr
team
identifi
initi
transit
cohort
letter
sent
famili
commun
goal
transit
program
cf
patient
assign
transit
coordin
within
team
exist
transit
tool
includ
cf
rise
implement
quarterli
transit
meet
involv
pediatr
adult
team
initi
systemat
discuss
transit
cohort
patient
identifi
potenti
obstacl
transit
establish
mutual
agre
upon
plan
time
frame
transfer
result
transit
need
assess
survey
complet
parent
clinician
young
adult
adult
respond
program
would
made
chang
pediatr
adult
care
easier
parent
survey
felt
import
child
understand
manag
therapi
commun
cf
health
care
team
transit
adult
care
parent
felt
import
patient
receiv
ageappropri
care
care
adult
provid
time
right
provid
felt
develop
formal
transit
program
would
make
transfer
easier
felt
import
formal
transit
program
patient
identifi
initi
cf
rise
webbas
knowledg
transit
care
skill
assess
forti
percent
cohort
present
joint
team
meet
transfer
care
success
adult
team
conclus
use
multidisciplinari
approach
involv
clinic
care
team
patientfamili
input
establish
formal
transit
program
prepar
individu
follow
pediatr
cf
program
transit
adult
program
patient
satisfact
survey
plan
year
transfer
establish
care
adult
program
anticip
program
improv
transit
prepar
care
coordin
commun
within
onecf
center
program
stalker
hj
jonasson
hopfer
moffett
ks
schuler
p
collin
zori
r
delgado
hart
kj
pediatr
univ
florida
gainesvil
fl
usa
univ
connecticut
farmington
ct
usa
pediatr
west
virginia
univ
morgantown
wv
usa
utah
dept
health
salt
lake
citi
ut
usa
introduct
notif
posit
newborn
screen
nb
result
tremend
anxieti
uncertainti
parent
first
contact
nb
program
resolut
screen
much
anxieti
relat
fear
unknown
unrealist
expect
risk
child
might
cf
nb
program
mandat
genet
counsel
servic
quit
variabl
depend
center
genet
counsel
frequent
provid
genet
counselor
gc
due
fund
constraint
avail
genet
counselor
within
cf
treatment
center
gc
routin
part
pulmonari
clinic
must
brought
anoth
program
smaller
rural
center
access
gc
might
possibl
use
telemedicin
allow
access
genet
counsel
servic
mani
region
would
otherwis
access
servic
either
geograph
financi
two
major
issu
signific
provis
better
gc
servic
famili
identifi
cf
nb
program
reduc
inappropri
anxieti
ensur
famili
appropri
inform
screen
risk
cf
process
involv
come
diagnost
resolut
child
ensur
famili
better
understand
genet
implic
child
identifi
carrier
cf
possibl
futur
child
cf
screen
famili
member
appropri
given
specif
structur
famili
specif
mutat
identifi
method
provid
gc
via
telemedicin
patient
identifi
abnorm
newborn
screen
cf
four
dispar
locat
across
countri
uf
uconn
wvu
state
utah
follow
provis
gc
famili
complet
satisfact
survey
regard
qualiti
inform
provid
comfort
use
telemedicin
modal
provis
inform
evalu
knowledg
cf
base
cisk
index
interview
analyz
content
theme
result
analysi
satisfact
survey
reveal
enthusiasm
comfort
process
gc
provis
via
telemedicin
overal
comfort
rate
across
question
relat
satisfact
analysi
cisk
data
reveal
knowledg
genet
issu
relat
cf
gener
quit
good
conclus
provis
gc
via
telemedicin
well
toler
appreci
famili
face
abnorm
nb
cf
differ
note
center
involv
studi
famili
report
increas
understand
process
nb
decreas
anxieti
process
analysi
cisk
knowledg
acquisit
tool
reveal
good
understand
implic
cf
gene
famili
abil
one
gc
provid
servic
throughout
countri
make
financi
viabl
approach
provis
muchneed
servic
lehman
sakon
c
kane
c
pharmaci
univers
hospit
indiana
univers
health
indianapoli
usa
purdu
univers
west
lafayett
usa
background
presenc
pain
well
document
adult
cystic
fibrosi
cf
popul
optim
pain
manag
patient
cf
yet
studi
howev
sever
disadvantag
opioid
medic
exist
includ
toler
possibl
overdos
potenti
abus
addit
opioid
known
side
effect
respiratori
depress
constip
nausea
sedat
especi
problemat
cf
patient
final
opioid
may
suppress
cough
may
hinder
full
effect
airway
clearanc
purposeobject
may
respons
grow
concern
opioid
abus
patient
popul
nonsurg
pain
treatment
algorithm
approv
iu
health
adult
cystic
fibrosi
center
inpati
pulmonari
physician
algorithm
emphas
multimod
approach
regimen
includ
nonopioid
pharmacolog
nonpharmacolog
treatment
option
object
studi
evalu
impact
algorithm
reduc
opioid
prescrib
method
conduct
retrospect
chart
review
patient
cystic
fibrosi
admit
hospit
one
year
preand
postalgorithm
initi
respect
june
may
june
may
opioid
name
dose
rout
frequenc
collect
electron
medic
administr
record
opioid
dose
convert
singl
daili
oral
morphin
equival
dose
comparison
purpos
patient
pain
score
durat
hospit
stay
also
collect
result
one
hundr
eightyfour
admiss
includ
studi
prealgorithm
postalgorithm
period
follow
algorithm
initi
averag
daili
morphin
dose
decreas
versu
number
dose
given
intraven
decreas
versu
dose
administ
daili
averag
pain
score
similar
preand
postalgorithm
versu
respect
averag
length
stay
similar
preand
postalgorithm
day
versu
day
respect
conclus
center
implement
nonsurg
pain
treatment
algorithm
along
prescrib
support
reduc
opioid
prescrib
without
neg
impact
pain
score
background
low
vitamin
store
common
cystic
fibrosi
cf
patient
due
decreas
absorpt
insuffici
intak
cf
center
serum
vitamin
routin
check
part
annual
lab
sinc
qualiti
improv
qi
goal
center
improv
patient
vitamin
store
supplement
protocol
correct
low
level
patient
least
one
vitamin
level
obtain
part
annual
lab
sinc
qi
initi
began
level
obtain
increas
use
evidencebas
guidelin
manag
vitamin
recommend
cf
foundat
supplement
protocol
use
protocol
monitor
supplement
vitamin
patient
low
level
implement
patient
suffici
vitamin
level
object
purpos
studi
evalu
current
protocol
effect
provid
adequ
vitamin
supplement
dose
effect
maintain
suffici
serum
level
method
irbapprov
qi
studi
patient
treat
cf
center
children
healthcar
atlanta
scottish
rite
januari
decemb
vitamin
level
drawn
assess
patient
suffici
serum
vitamin
level
recommend
supplement
vitamin
dose
record
averag
daili
dose
supplement
vitamin
defin
amount
vitamin
taken
addit
cfspecif
vitamin
multivitamin
data
exclud
patient
selfreport
poor
adher
patient
take
cfspecif
vitamin
supplement
vitamin
result
vitamin
level
elig
patient
obtain
elig
patient
suffici
implement
exclusionari
criteria
patient
take
supplement
vitamin
includ
analysi
supplement
vitamin
dose
rang
intern
unit
iu
iu
daili
averag
supplement
daili
dose
iu
iu
discuss
sinc
initi
goal
qi
project
improv
routin
vitamin
monitor
serum
vitamin
level
patient
patient
suffici
serum
vitamin
increas
respect
suggest
current
protocol
meet
vitamin
requir
major
patient
prompt
us
examin
supplement
vitamin
dose
patient
popul
found
patient
maintain
suffici
serum
level
supplement
averag
iu
vitamin
addit
cfspecif
vitamin
multivitamin
adher
vitamin
formul
degre
malabsorpt
may
explain
wide
rang
supplement
vitamin
dose
requir
iu
daili
goal
educ
patient
import
vitamin
thu
improv
adher
recommend
regimen
final
util
result
plan
investig
implement
standard
mainten
dose
protocol
approxim
iu
daili
patient
parkinson
hf
reilli
cc
channon
k
elston
c
cystic
fibrosi
team
king
colleg
hospit
london
unit
kingdom
physiotherapi
king
colleg
hospit
london
unit
kingdom
introduct
advanc
medic
manag
mean
life
expect
cf
continu
improv
number
patient
live
complex
endstag
diseas
increas
king
colleg
hospit
specialist
cf
centr
care
adult
addit
standard
care
cf
team
provid
multidisciplinari
home
care
servic
offer
patient
across
full
spectrum
diseas
sever
aim
provid
addit
conveni
support
patient
manag
diseas
patient
seen
home
number
reason
last
month
increas
referr
support
patient
live
endstag
diseas
studi
aim
explor
role
physiotherapi
support
patient
home
method
retrospect
review
physiotherapi
provis
within
cf
home
care
servic
april
patient
endstag
support
primari
reason
visit
descript
data
includ
number
patient
seen
total
time
spent
patient
whether
visit
avoid
addit
hospit
attend
intervent
perform
code
summaris
use
descript
statist
result
visit
complet
patient
visit
patient
predict
requir
supplement
oxygen
niv
endstag
support
mean
rang
number
visit
per
patient
durat
visit
minut
half
visit
prevent
addit
hospit
attend
context
overal
servic
visit
endstag
support
howev
account
total
home
care
servic
time
intervent
identifi
code
categori
figur
major
intervent
focus
complex
symptom
support
requir
manag
unpredict
natur
endstag
diseas
includ
practic
live
oxygen
niv
home
conclus
review
endstag
patient
home
facilit
deliveri
complex
respiratori
intervent
would
otherwis
requir
attend
hospit
thu
reduc
patient
burden
time
spent
deliv
visit
must
acknowledg
howev
time
allow
deliveri
personalis
care
contextspecif
intervent
focus
address
daytoday
challeng
patient
endstag
cf
face
home
replic
outpati
clinic
seffrood
e
albe
k
becker
c
harmelink
j
iannacchino
k
pfeil
rock
mj
pediatr
pulmonologycf
center
american
famili
children
hospit
madison
wi
usa
dartmouth
institut
lebanon
nh
usa
introduct
pediatr
cf
center
american
famili
children
hospit
madison
wi
award
learn
leadership
qi
grant
fun
llc
cff
june
focu
nutrit
pulmonari
qi
project
first
task
examin
patient
registri
data
review
show
downward
trend
nutrit
outcom
year
old
mean
weight
length
wl
close
ile
wherea
mean
wl
th
ile
downward
trend
continu
wl
fall
cff
goal
wl
ile
cdc
growth
chart
aim
improv
process
achiev
optim
nutrit
year
old
cf
work
process
improv
wl
eventu
posit
relationship
weight
lung
function
well
known
mani
studi
show
earlier
goal
wl
achiev
healthier
peopl
long
run
subject
includ
patient
diagnos
cf
age
year
june
includ
patient
crm
nicu
total
patient
male
femal
pi
ps
wl
ile
mean
wl
entir
group
method
complet
sever
plandostudyact
cycl
pdsa
focus
differ
aspect
clinic
care
cycl
includ
ad
preclin
huddl
standard
length
measur
clinic
infant
hard
measur
get
fals
high
length
send
caregiv
practition
wrong
inform
growth
call
patient
wl
ile
week
clinic
visit
review
patient
specif
goal
requir
patient
complet
day
food
record
determin
calori
intak
make
target
recommend
reach
goal
recommend
dietari
allow
rda
improv
timeli
room
patient
improv
organ
account
stock
room
increas
effici
provid
written
materi
wl
bmi
posit
correl
lung
function
provid
earlier
better
inform
tube
feed
familytofamili
letter
result
although
still
progress
date
mean
wl
increas
averag
variabl
length
measur
cm
mandatori
take
averag
measur
patient
wl
ile
averag
calori
intak
went
rda
patient
receiv
feed
tube
addit
result
chang
pend
conclus
standard
length
measur
call
patient
follow
goal
evalu
food
record
hold
preclin
huddl
increas
commun
famili
becom
routin
part
clinic
care
improv
wl
year
old
dedic
time
meet
work
qi
project
help
coach
enabl
us
bring
sever
idea
realiti
overal
benefit
nutrit
statu
long
run
lung
function
patient
cf
support
cff
fun
llc
grant
background
good
nutrit
infant
cystic
fibrosi
imper
posit
impact
lung
function
qualiti
life
center
identifi
underon
age
group
specif
target
improv
nutrit
outcom
larg
center
mani
physician
dietitian
manag
cf
patient
note
providerdietitian
team
nonstandard
approach
manag
infant
center
develop
specif
algorithm
patient
one
year
age
standard
care
within
center
goal
improv
nutrit
statu
younger
patient
object
primari
aim
increas
weightforlength
percentil
infant
popul
recommend
cf
goal
percentil
secondari
aim
measur
complianc
use
nutrit
algorithm
method
multidisciplinari
qualiti
improv
committe
specif
focus
creat
algorithm
use
new
patient
diagnos
newborn
screen
first
year
life
committe
specif
chose
focu
maintain
infant
enzym
dose
unit
lipas
per
kilogram
per
meal
well
use
rapid
stepup
higher
calor
concentr
infant
milk
express
breast
milk
formula
two
compon
measur
adher
algorithm
enzym
dose
formulaexpress
breast
milk
concentr
outcom
measur
weightforlength
percentil
compar
infant
diagnos
via
newborn
screen
two
year
prior
implement
one
year
life
mark
compar
one
year
life
mark
patient
treat
sinc
implement
algorithm
result
team
patient
reach
first
birthday
sinc
implement
new
nutrit
algorithm
averag
weightforlength
patient
first
birthday
prior
start
algorithm
implement
algorithm
averag
weightforlength
percentil
complianc
increas
enzym
dose
month
age
one
year
age
complianc
higher
calori
formula
month
month
conclus
limit
sampl
size
abl
success
increas
averag
weightforlength
percentil
infant
one
year
age
committe
also
shown
larg
center
mani
differ
personnel
take
care
patient
specif
centerbas
algorithm
benefici
standard
care
futur
plan
center
plan
continu
follow
nutrit
algorithm
patient
one
year
old
follow
outcom
see
provid
higher
enzym
dose
malabsorpt
symptom
occur
increas
calor
concentr
infant
diet
improv
nutrit
statu
sustain
benefit
without
advers
event
parad
r
murphi
k
langner
e
newborn
medicin
brigham
women
hospit
boston
usa
background
nb
process
test
blood
collect
filter
paper
birth
identifi
babi
risk
lifethreaten
disord
complex
public
health
process
place
us
year
effect
collect
transport
sampl
lab
test
result
report
must
time
diagnost
treatment
delay
impact
neonat
outcom
secretari
advisori
committe
herit
disord
newborn
children
achdnc
recommend
nb
result
timecrit
disord
report
day
life
accomplish
nb
must
collect
transport
newborn
screen
lab
multistep
intrahospit
process
also
known
preanalyt
phase
nb
newborn
hour
age
aim
develop
hospitalbas
qi
process
toolkit
minim
risk
miss
delay
collect
transport
nb
sampl
brigham
women
hospit
bwh
boston
dissemin
toolkit
birth
center
use
analyz
optim
perform
timeli
nb
sampl
collect
transport
reduc
statewid
risk
delay
miss
sampl
method
use
standard
qi
approach
develop
preanalyt
process
chart
redcap
databas
track
data
nb
sampl
draw
bwh
birth
use
time
sampl
collect
transport
calcul
preintervent
baselin
metric
sampl
sent
appropri
day
ad
hour
birth
respons
metric
intervent
plandostudyact
pdsa
cycl
assess
impact
graph
use
spc
pchart
decreas
number
nb
sampl
sent
state
nb
lab
outsid
ad
window
pdsa
cycl
improv
translat
decreas
time
birth
nb
sampl
arriv
state
lab
day
day
allow
rapid
gener
nb
result
report
discuss
improv
preanalyt
perform
within
hospit
develop
nb
qi
toolkit
identifi
problem
facilit
intervent
address
problem
provid
data
assess
effect
intervent
time
toolkit
dissemin
birth
hospit
neoqic
statewid
nicu
qi
network
adopt
hospit
map
detail
process
determin
baselin
identifi
problem
point
track
progress
measur
effect
toolkit
compar
metric
preand
postdissemin
minim
preanalyt
time
metric
sampl
collect
transport
nb
sampl
accomplish
propos
process
potenti
cut
day
time
birth
result
report
minim
delay
diagnosi
treatment
cf
lifethreaten
disord
support
cf
foundat
newborn
screen
qualiti
improv
grant
studi
data
collect
manag
use
redcap
electron
data
captur
tool
host
bwh
j
biom
inform
apr
background
wide
agre
upon
nutrit
statu
import
independ
determin
lung
function
surviv
individu
live
cf
cystic
fibrosi
foundat
cff
establish
goal
bodi
mass
index
bmi
men
minimum
women
minimum
howev
nutrit
knowledg
understand
basic
dietari
concept
low
lack
awar
link
diet
diseas
problem
attribut
poor
educ
inadequ
adultcent
educ
materi
misconcept
care
team
method
review
cff
patient
registri
data
show
cf
patient
popul
adult
cf
program
colorado
bmi
less
assess
nutrit
knowledg
attitud
patient
questionnair
develop
valid
questionnair
cfqr
cfqol
valid
questionnair
administ
june
novemb
patient
present
clinic
bmi
less
result
period
administr
questionnair
complet
subject
bmi
less
femal
male
equal
overal
return
rate
possibl
patient
result
identifi
key
area
improv
subject
knowledg
cffrecommend
bmi
low
femal
male
correct
knowledg
bmi
rang
higher
femal
male
calori
content
food
incorrectli
identifi
femal
male
twentyseven
percent
male
also
incorrectli
identifi
high
calori
beverag
bodi
imag
issu
report
femal
male
feed
tube
use
femal
male
though
femal
male
know
take
enzym
symptom
enough
enzym
incorrectli
identifi
femal
male
conclus
educ
effort
focus
adult
nutrit
need
exist
materi
written
young
children
adolesc
mind
cf
popul
get
older
ageappropri
materi
discuss
dietari
requir
need
develop
teach
moment
bmi
food
choic
incorpor
care
visit
multidisciplinari
team
addit
care
team
need
awar
patient
manag
nutritionrel
behavior
psychosoci
physic
collabor
pediatr
center
crucial
ensur
relationship
nutrit
pulmonari
function
commun
parent
patient
prior
transit
dunn
km
hovat
c
georg
c
polineni
riekert
ka
sawicki
gs
stark
lj
cystic
fibrosi
foundat
bethesda
md
usa
univers
kansa
school
medicin
kansa
citi
ks
usa
john
hopkin
univers
baltimor
md
usa
boston
children
hospit
boston
usa
cincinnati
children
hospit
cincinnati
oh
usa
cfft
strc
steer
committe
bethesda
md
usa
background
success
therapi
research
consortium
strc
creat
studi
help
peopl
cf
famili
better
balanc
complet
cf
treatment
live
life
strc
studi
involv
differ
level
daili
effort
risk
reward
tradit
clinic
drug
devic
trial
object
gather
stakehold
feedback
appropri
compens
level
strc
studi
method
adult
cf
caregiv
strc
research
team
member
rtm
eg
princip
investig
research
coordin
complet
onlin
survey
hourli
compens
reimburs
expens
compens
ongo
consult
survey
peopl
cf
famili
sent
cf
foundat
adult
famili
advisor
network
respons
repres
differ
cf
care
center
survey
result
rtm
repres
strc
site
result
major
adultscaregiv
rtm
agre
appropri
compens
rate
strc
studi
simpl
studi
eg
tenminut
survey
adultscaregiv
rtm
agre
appropri
minimum
compens
howev
sever
adultscaregiv
prefer
cite
exist
time
burden
valu
input
organ
compens
standard
long
complex
studi
respond
adult
caregiv
rtm
agre
addit
pay
consid
divid
complet
bonu
adultscaregiv
rtm
escal
pay
structur
adultscaregiv
rtm
comment
note
escal
pay
might
effect
without
penal
particip
withdraw
studi
due
unforeseen
ill
respond
agre
particip
reimburs
mileag
park
meal
even
visit
coincid
clinic
visit
respond
agre
rate
appropri
research
consult
includ
serv
patient
famili
advisori
board
regardless
whether
consult
person
cf
caregiv
rtm
throughout
survey
comment
emphas
time
financi
burden
cf
gener
studi
particip
specif
compens
research
particip
consult
servic
seen
necessari
encourag
broader
divers
engag
research
conclus
overal
adultscaregiv
rtm
agre
studi
compens
paramet
adultscaregiv
stress
time
financi
burden
cf
factor
consid
compens
studi
particip
stakehold
feedback
shape
strc
compens
guidelin
fund
sourc
cystic
fibrosi
foundat
therapeut
inc
object
cystic
fibrosi
cf
patient
often
requir
intraven
antibiot
treatment
lower
respiratori
tract
infect
use
total
implant
venou
access
devic
tivad
peripher
insert
central
venou
cathet
picc
complic
may
associ
substanti
morbid
specif
patient
characterist
care
practic
relat
complic
clearli
establish
vascular
infecti
complic
tivad
picc
cf
patient
describ
primarili
singlecent
studi
studi
examin
variat
complic
rate
within
region
cf
consortium
method
conduct
retrospect
review
picc
tivad
adult
children
eightyear
period
three
cf
center
northern
new
england
demograph
factor
includ
genotyp
comorbid
condit
pulmonari
nutrit
statu
line
place
microbiolog
result
collect
linespecif
inform
includ
line
type
lumen
size
number
lumen
use
anticoagul
vascular
complic
defin
line
occlus
venou
thrombosi
infecti
complic
includ
blood
stream
infect
local
cellul
survey
administ
attend
physician
site
assess
practic
variat
picc
complic
model
use
multilevel
logist
regress
line
nest
within
patient
time
complic
model
use
cox
proport
hazard
regress
patient
first
tivad
record
studi
period
result
patient
pediatr
adult
line
place
studi
period
evalu
total
line
picc
tivad
overal
rate
vascular
infecti
complic
picc
catheterday
tcd
eventstcd
respect
overal
rate
complic
tivad
lower
picc
eventstcd
eventstcd
vascular
infecti
complic
respect
median
surviv
tivad
day
vari
significantli
center
interestingli
observ
rang
overal
picc
complic
rate
per
tcd
across
center
vari
found
probabl
line
complic
treat
patient
vari
across
center
physician
survey
show
inconsist
amongst
three
center
anticoagul
treatment
thrombosi
prophylaxi
recurr
thrombosi
conclus
use
central
venou
cathet
cf
patient
associ
vascular
infecti
complic
rate
complic
per
cathet
day
higher
picc
tivad
observ
signific
center
effect
complic
rate
picc
line
tivad
inconsist
practic
pattern
center
manag
thrombot
complic
track
complic
cf
foundat
patient
registri
may
identifi
center
excel
line
manag
caregiv
primarili
respons
carri
complex
daili
treatment
patient
cystic
fibrosi
cf
along
ensur
treatment
regimen
appoint
prescript
refil
make
sick
call
transfer
adult
clinic
patient
expect
manag
diseas
discuss
key
selfmanag
skill
occur
caregiv
healthcar
provid
patient
object
project
compar
pediatr
versu
adult
patient
rate
key
selfcar
skill
transfer
method
self
care
skill
worksheet
adapt
exist
tool
wood
et
al
acad
pediatr
reiss
jg
et
al
pediatr
sawicki
gs
et
al
j
pediatr
psychol
worksheet
identifi
key
selfcar
skill
transfer
readi
includ
contact
cf
clinic
call
provid
unusualunexpect
chang
health
call
provid
get
prescrib
medic
reorder
medic
prescript
run
call
provid
get
equipmentsuppli
call
equipmentsuppli
compani
problem
notifi
provid
offic
insur
chang
ask
providerstaff
clarifi
understand
inform
providerstaff
uncomfort
respons
rank
likert
scale
alway
learn
nt
know
want
learn
nt
know
nt
need
worksheet
administ
juneaugust
patient
age
median
interquartil
rang
score
skill
compar
patient
pediatr
vs
adult
care
pvalu
util
determin
signific
hypothes
adult
patient
would
endors
higher
rate
pediatr
patient
total
patient
complet
worksheet
four
key
skill
significantli
differ
p
pediatr
adult
patient
call
provid
unusualunexpect
chang
health
vs
call
provid
get
prescrib
medic
vs
reorder
medic
prescript
run
vs
call
provid
get
equipmentsuppli
vs
score
remain
item
differ
pediatr
adult
patient
conclus
pediatr
patient
selfrat
lower
four
key
skill
area
notabl
area
requir
commun
health
care
provid
highlight
need
transit
educ
focu
selfmanag
treatment
also
teach
effect
medic
commun
skill
futur
direct
includ
util
selfcar
skill
worksheet
identifi
area
educ
need
transit
retrospect
skill
build
recent
transit
adult
lindsay
kl
revilla
e
tangpricha
v
stecenko
egleston
children
healthcar
atlanta
atlanta
ga
usa
med
emori
univ
atlanta
ga
usa
ped
emori
univ
atlanta
ga
usa
background
cystic
fibrosi
foundat
cff
recommend
use
oral
vitamin
individu
cf
maintain
serum
ngml
although
daili
weekli
dose
suggest
specif
dose
given
daili
base
age
group
year
year
year
agebas
dose
pediatr
popul
may
effect
weightbas
dose
child
may
tripl
weight
year
year
adulthood
also
weekli
dose
could
result
increas
complianc
reduc
pill
burden
therefor
base
effect
weekli
dose
iu
adult
khazai
nb
et
al
j
clin
endocrinol
metab
calcul
weekli
dose
protocol
pediatr
patient
base
weight
object
determin
efficaci
weekli
weightbas
dose
maintain
cf
pediatr
patient
method
dose
oral
weekli
per
protocol
shown
tabl
measur
least
annual
patient
regardless
season
ngml
first
determin
patient
compliant
mainten
dose
regimen
noncompli
daili
dose
given
dose
mainten
dose
mainten
dose
resum
patient
compliant
mainten
dose
increas
iu
daili
dose
new
mainten
dose
given
new
mainten
dose
given
weekli
use
maximum
independ
verifi
show
contain
amount
label
tangpricha
unpublish
data
result
patient
elig
elig
weight
kg
patient
level
done
patient
patient
classifi
suffici
ngml
patient
insuffici
ngml
patient
defici
ngml
mean
patient
ngml
rang
ngml
patient
insuffici
defici
level
repeat
level
done
achiev
mean
patient
increas
ngml
conclus
weightbas
weekli
dose
vitamin
safe
effect
strategi
maintain
optim
pediatr
patient
cf
evidenc
data
pediatr
patient
vitamin
dsuffici
use
weekli
dose
regimen
threequart
insuffici
defici
becam
suffici
use
daili
replet
dose
none
patient
level
greater
recommend
maximum
ngml
schwab
l
zobel
j
collingridg
gregersen
russel
h
intermountain
specialti
pharmaci
midval
ut
usa
intermountain
cystic
fibrosi
pediatr
center
salt
lake
citi
ut
usa
intermountain
healthcar
salt
lake
citi
ut
usa
selecthealth
salt
lake
citi
ut
usa
intermountain
primari
children
salt
lake
citi
ut
usa
background
intermountain
specialti
pharmaci
isp
work
conjunct
intermountain
cystic
fibrosi
pediatr
center
streamlin
counsel
deliveri
process
patient
improv
adher
barrier
medic
adher
cystic
fibrosi
cf
patient
includ
cost
access
polypharmaci
primari
purpos
studi
compar
medic
possess
ratio
mpr
preand
postimplement
integr
pharmaci
team
design
cf
start
januari
second
purpos
compar
hospit
rate
mpr
isp
nonisp
pharmaci
dornas
alfa
evalu
due
evid
increas
lung
function
patient
flume
p
et
al
j
respir
crit
care
med
method
retrospect
claim
analysi
perform
patient
fill
isp
order
calcul
mpr
preand
postjanuari
includ
patient
pediatr
cf
patient
year
insur
must
least
one
pharmaci
claim
dornas
alfa
patient
must
admit
hospit
due
pulmonari
exacerb
includ
hospit
analysi
descript
statist
util
describ
characterist
cf
popul
analys
perform
data
updat
result
includ
result
isp
patient
identifi
mpr
evalu
mean
monthli
mpr
calcul
compar
comparison
mean
monthli
mpr
nonisp
patient
compar
gener
estim
equat
gee
analysi
calcul
statist
signific
differ
adher
isp
vs
nonisp
patient
p
total
patient
identifi
least
one
dornas
alfa
claim
repres
roughli
onefifth
cf
center
popul
patient
patient
fill
isp
patient
fill
isp
total
isp
patient
hospit
comparison
nonisp
patient
averag
mpr
isp
patient
hospit
versu
patient
hospit
nonisp
patient
averag
mpr
respect
spearman
rho
test
calcul
correl
averag
mpr
hospit
isp
patient
conclus
term
adher
studi
demonstr
isp
patient
time
like
take
medic
direct
comparison
nonisp
patient
although
correl
mpr
hospit
isp
patient
statist
signific
trend
note
mpr
increas
hospit
note
decreas
expect
dedic
integr
pharmaci
team
specif
manag
cf
increas
medic
adher
appear
result
decreas
hospit
compar
patient
fill
nonspecialti
pharmaci
dubos
l
peac
r
clark
c
gaffney
c
snodgrass
sm
pediatr
pulmonolog
greenvil
health
system
greenvil
sc
usa
background
cystic
fibrosi
foundat
guidelin
recommend
quarterli
cf
clinic
visit
ongo
multidisciplinari
evalu
close
surveil
earli
intervent
exacerb
complic
center
serv
upstat
sc
portion
nc
ga
believ
distanc
center
cost
ga
appoint
avail
show
excess
appoint
durat
commun
barrier
low
socioeconom
statu
contribut
declin
quarterli
visit
note
previou
year
also
advers
affect
collect
annual
lab
pft
surveil
cultur
trend
identifi
area
improv
part
ongo
center
qi
assess
review
centerspecif
registri
data
specif
patient
age
year
believ
one
factor
inhibit
abil
deliv
time
high
qualiti
cf
care
object
establish
qi
project
test
hypothesi
offer
ga
card
quarterli
visit
complet
would
increas
appoint
complianc
improv
result
collect
cultur
pft
center
data
set
method
qi
project
develop
includ
cleric
staff
involv
clinic
cf
team
member
patient
alreadi
receiv
care
januari
continu
receiv
care
decemb
includ
util
websit
quarterli
newslett
clinic
staff
educ
famili
clinic
visit
earli
intervent
import
occur
regularli
increas
emphasi
place
systemat
review
process
put
place
regular
cf
team
meet
punch
card
also
use
track
visit
includ
review
patient
famili
social
worker
cleric
staff
work
close
schedul
reschedul
patient
meet
quarterli
visit
goal
case
manag
high
risk
famili
began
occur
much
higher
rate
appoint
complianc
becam
part
team
meet
discuss
also
place
greater
emphasi
schedul
patient
frequent
account
miss
visit
schedul
also
occur
flexibl
cf
clinic
slot
result
center
specif
data
patient
age
year
visit
cultur
pft
improv
follow
conclus
qi
project
focus
improv
regular
visit
complianc
includ
financi
incent
effect
improv
centerspecif
registri
outcom
reflect
cf
team
behavior
discuss
chang
markedli
qi
project
way
believ
highli
impact
like
addit
offer
financi
incent
also
anticip
posit
sustain
cultur
chang
within
center
unanticip
effect
includ
increas
budget
hour
sw
regular
structur
weekli
cf
team
meet
know
anecdot
monetari
reward
factor
chang
futur
use
guarante
may
target
need
high
risk
wesson
sj
smith
e
egen
n
nation
jewish
health
saint
joseph
hospit
denver
co
usa
background
patient
cystic
fibrosi
cf
receiv
mani
antibiot
throughout
lifetim
treat
pulmonari
infect
time
develop
allergi
antibiot
may
consid
optim
effect
treatment
patient
histori
typei
hypersensit
reaction
antibiot
desensit
drug
clinic
necessari
desensit
induc
temporari
immunetoler
state
allow
safe
administr
allergen
medic
schedul
dose
stop
accomplish
administ
increas
dose
therapeut
dose
reach
toler
due
risk
allerg
reaction
process
nurs
care
necessari
howev
sever
reaction
rare
leger
h
et
al
j
cyst
fibro
cf
patient
tradit
transfer
intens
care
unit
icu
procedur
complet
move
back
pulmonari
unit
pu
process
note
caus
delay
patient
care
decreas
patient
staff
satisfact
increas
risk
handoff
error
misus
icu
resourc
purpos
purpos
project
allow
cf
patient
remain
pu
desensit
clinic
appropri
process
chang
aim
expand
nurs
skill
improv
patient
staff
satisfact
maintain
patient
safeti
retain
success
outcom
method
collabor
pu
hospitalist
nonicu
protocol
antibiot
desensit
develop
includ
order
call
rapid
respons
sever
reaction
patient
must
prior
success
desensit
drug
desensit
pu
staff
nurs
train
shadow
desensit
icu
complet
skill
check
compet
nurs
postimplement
survey
util
evalu
effect
chang
staff
patient
satisfact
result
staff
satisfact
survey
issu
prior
process
chang
util
comparison
particip
patient
interview
outcom
icu
vs
pu
desensit
review
potenti
outcom
differ
outcom
process
chang
took
effect
march
end
april
four
patient
desensit
pu
one
patient
desensit
icu
per
develop
criteria
five
success
moder
sever
reaction
four
patient
desensit
pu
desensit
icu
prior
admiss
particip
patient
posit
respons
ask
opinion
process
chang
seven
pu
nurs
complet
train
report
feel
nurs
skill
elev
staff
felt
posit
chang
process
desensit
nurs
satisfact
survey
respons
question
job
make
good
use
skill
abil
went
favor
favor
postimplement
conclus
project
resolv
mani
delay
issu
due
bed
staff
limit
patient
care
transfer
handoff
overal
chang
success
demonstr
consist
patient
outcom
posit
patient
respons
increas
staff
satisfact
loveless
mo
allada
g
satcher
v
block
r
gold
ja
public
health
oregon
health
scienc
univ
portland
usa
medicin
oregon
health
scienc
univ
portland
usa
mnr
analyt
portland
usa
background
qualiti
care
adult
cf
depend
effect
special
interdisciplinari
team
understand
structur
function
individu
team
affect
interfac
cf
patient
may
explain
varianc
patient
outcom
appli
network
analyt
provid
tool
qualit
quantit
assess
cf
team
patientteam
interfac
singlesit
cf
program
fieldtest
novel
network
map
tool
assess
process
measur
workflow
analysi
patient
interfac
method
studi
site
univers
teach
hospit
region
outpati
cf
clinic
hospitalistl
inpati
care
team
model
support
consult
pulmonari
faculti
fellow
without
cf
specialist
outcom
data
cf
registri
unitspecif
qualiti
improv
project
review
patient
valu
stream
graphic
inpati
outpati
creat
critic
workflow
relat
specif
qualiti
measur
analyz
medic
team
survey
complet
hospit
personnel
involv
inpati
cf
care
cf
outpati
clinic
personnel
network
graphic
network
descript
analyt
creat
use
gephi
patientteam
interact
evalu
supplement
survey
patient
op
clinic
result
survey
healthcar
team
high
respons
rate
est
inpati
outpati
network
map
demonstr
interrel
outpati
team
inpati
servic
sever
critic
role
identifi
pulmonari
fellow
resid
cf
nurs
practition
patient
survey
reveal
patient
depend
key
personnel
especi
cf
care
coordin
standard
descript
network
statist
densiti
central
gener
clinic
microsystem
network
map
approach
evalu
function
structur
individu
cf
team
feasibl
potenti
scalabl
may
help
cf
team
wish
better
align
resourc
improv
commun
map
made
complex
cf
care
explicit
especi
risk
commun
error
could
benefit
program
oper
two
medic
team
inpati
outpati
depend
personnel
variabl
expertis
cf
patient
care
support
ncff
grant
object
give
updat
nation
deploy
report
survey
find
januari
april
method
total
cf
program
pediatr
adult
affili
invit
join
nation
deploy
version
survey
pediatr
parent
caregiv
child
cf
adult
person
cf
year
older
interv
follow
clinic
care
encount
accredit
program
letter
email
sent
parent
adult
cf
invit
himher
complet
survey
data
analyz
use
top
box
approach
respond
select
posit
respons
choic
choic
compar
program
result
done
use
varianc
compon
analysi
establish
program
standard
deviat
survey
question
comparison
made
percentil
compar
valu
result
program
cf
program
total
deploy
survey
januari
program
start
collect
survey
april
program
collect
data
program
agre
total
across
particip
program
peopl
cf
invit
compet
survey
respond
respons
rate
result
similar
pediatr
adult
respond
mani
survey
question
three
question
domain
experi
care
team
best
result
courtesi
respect
easi
understand
explan
spent
enough
time
lowest
report
experi
ask
mental
health
abl
maintain
bodi
weight
know
whether
feet
anoth
person
cf
area
signific
differ
pediatr
adult
respond
includ
pediatr
report
visit
cf
center
visit
per
year
vs
act
treatment
work
vs
abl
manag
cf
vs
conclus
result
nation
cf
patient
famili
experi
care
survey
show
cf
program
strength
well
improv
opportun
program
deploy
survey
track
result
number
strategi
improv
experi
care
promot
nation
patient
experi
institut
cultiv
respect
partnership
establish
infrastructur
support
engag
stakehold
encourag
stakeholderspati
provid
institut
leadersto
review
result
leverag
social
media
network
build
cultur
improv
particip
benchmark
program
excel
experi
care
peopl
cf
famili
member
bring
pointofview
expertis
clinic
encount
also
provid
valuabl
reflect
insight
work
relationship
healthcar
team
fresh
eye
process
care
deliveri
knowledg
manag
diseas
measur
patient
famili
experi
care
reveal
care
process
cf
clinic
work
well
improv
januari
accredit
cf
care
center
pediatr
adult
affili
program
invit
particip
nation
deploy
cf
patient
famili
experi
care
survey
survey
design
continu
data
collect
enabl
program
measur
monitor
experi
care
time
compar
result
cf
program
feedback
system
implement
enabl
team
review
result
plan
futur
improv
work
evalu
impact
work
object
share
rollout
feedback
system
januari
april
method
collabor
vendor
partner
qualiti
data
manag
onlin
report
tool
develop
use
establish
tool
qualiti
desktop
tm
qd
qd
provid
type
data
display
thermomet
result
comparison
other
bar
chart
distribut
question
respons
statist
process
control
chart
addit
comment
openend
question
review
januari
juli
program
collect
pediatr
parent
caregiv
child
cf
adult
peopl
cf
year
older
questionnair
creat
benchmark
cohort
percentil
compar
valu
calcul
survey
question
varianc
compon
analysi
establish
program
standard
deviat
use
program
comparison
qd
avail
program
septemb
attend
qd
train
session
result
benchmark
dataset
updat
februari
pediatr
adult
respond
april
peopl
program
receiv
qd
train
need
least
respond
peopl
access
qd
averag
time
qd
access
anytim
although
user
feedback
indic
took
much
time
review
inform
respons
push
report
lowtech
paper
version
result
draft
februari
sent
cf
program
version
sent
cf
program
request
program
latest
push
report
includ
program
variat
chart
data
time
verbatim
comment
patient
famili
april
program
respond
email
program
push
report
conclus
feedback
cf
program
crucial
develop
meaning
push
report
patient
famili
experi
care
survey
data
much
unknown
cf
program
use
qd
push
report
celebr
posit
program
attribut
strateg
improv
process
care
patient
report
less
ideal
gregoirebottex
hollenbeck
p
anjorin
n
bonnema
pediatr
adolesc
medicin
western
michigan
univers
school
medicin
kalamazoo
mi
usa
nutrit
bronson
methodist
hospit
kalamazoo
mi
usa
background
vitamin
defici
preval
patient
cystic
fibrosi
cf
due
malabsorpt
decreas
uv
light
exposur
poor
intak
defici
caus
poor
bone
health
reduc
lung
function
increas
pulmonari
exacerb
cf
foundat
adopt
new
guidelin
follow
evid
prior
recommend
insuffici
maintain
normal
serum
oh
level
tangpricha
v
et
al
j
clin
endocrinol
metab
object
cf
patient
center
normal
oh
first
quarter
therefor
june
began
process
improv
enhanc
monitor
assess
treatment
inadequ
vitamin
level
patient
cf
aim
cf
patient
consist
maintain
normal
oh
method
cf
team
review
literatur
guidelin
attend
session
motiv
interview
focus
adher
administr
medic
visit
schedul
ahead
time
pharmacist
provid
prepackag
medic
medpack
oh
result
dose
adjust
mail
patientspar
data
oh
level
abstract
patient
record
sa
use
analys
graphic
gener
result
conclus
ongo
monitor
data
collect
teach
process
evalu
import
continu
improv
due
mani
factor
affect
oh
vitamin
level
patient
cf
import
factor
improv
reduc
staff
turnov
followup
assign
cf
dietician
stricter
monitor
use
higher
vitamin
dose
address
adher
medpack
remind
kubiak
stitt
g
jone
wong
berger
r
abdulrazak
n
roboff
j
uluer
az
boston
children
hosp
boston
usa
brigham
women
hosp
boston
usa
introduct
oncedaili
tobramycin
odt
often
use
acut
pulmonari
exacerb
ape
gramneg
organ
cf
due
odt
narrow
therapeut
index
institut
practic
monitor
peak
trough
serum
concentr
marker
efficaci
toxic
data
suggest
current
target
serum
trough
concentr
may
excess
area
concentrationtim
curv
auc
monitor
may
predict
odt
exposur
begg
e
et
al
br
j
clin
pharmac
data
found
auc
valu
frequent
elev
despit
trough
level
coulthard
k
et
al
j
cyst
fibro
initi
qualiti
improv
pilot
evalu
precis
report
valu
vs
calcul
pharmacokinet
pk
paramet
hr
peak
auc
assess
accuraci
odt
monitor
cf
institut
object
primari
object
evalu
accuraci
tradit
peak
trough
monitor
odt
institut
compar
report
valu
calcul
pk
valu
second
object
determin
peak
trough
measur
within
goal
rang
correl
goal
auc
method
report
peak
trough
level
compar
patientspecif
pk
calcul
peak
auc
measur
adult
patient
cf
initi
odt
part
antibiot
regimen
treatment
ape
trough
obtain
immedi
prior
dose
peak
schedul
min
infus
dose
random
level
schedul
hour
dose
peak
auc
valu
calcul
use
level
goal
serum
concentr
peak
trough
auc
mg
hr
l
result
evalu
discret
cours
odt
patient
base
calcul
pk
paramet
auc
mg
hr
l
peak
l
therapeut
case
appear
therapeut
base
report
peak
trough
cours
supratherapeut
base
calcul
pk
paramet
peak
andor
auc
mg
hr
l
report
peak
indic
supratherapeut
dose
base
calcul
pk
paramet
cours
subtherapeut
peak
andor
auc
mg
hr
l
report
peak
reflect
subtherapeut
dose
cours
patient
cours
maintain
trough
evalu
cours
odt
case
appear
within
goal
rang
base
report
peak
trough
measur
within
goal
rang
pk
paramet
peak
auc
calcul
trend
toward
potenti
nephrotox
scr
increas
baselin
seen
patient
trough
auc
mg
hr
l
conclus
compar
calcul
pk
valu
report
peak
trough
patient
receiv
odt
accur
monitor
paramet
drug
exposur
clearanc
order
ensur
accur
assess
efficaci
toxic
use
patientspecif
pk
calcul
standard
care
monitor
patient
odt
studi
coordin
multifacet
job
vital
clinic
research
industri
yet
across
institut
lack
standard
educ
train
prepar
invalu
studi
team
member
role
success
effort
close
gap
adequ
prepar
disproportion
expect
rc
john
hopkin
jh
studi
coordin
apprenticeship
mentor
program
hallmark
work
toward
standard
rc
educ
train
cff
provid
similar
mentor
program
train
resourc
cf
studi
team
assess
rc
train
experi
need
shape
program
object
method
qualit
studi
evalu
jhmi
research
team
train
experi
percept
electron
survey
survey
email
deliv
via
qualtric
onlin
survey
softwar
survey
question
explor
area
train
job
descript
length
employ
percept
prepar
rc
role
studi
approv
jh
institut
review
board
data
analysi
aid
qualtric
survey
distribut
cff
network
result
survey
complet
jhmi
research
team
staff
jhmi
respond
felt
need
addit
train
perform
role
identifi
barrier
lack
specif
train
avail
protect
time
allot
complet
train
although
major
respond
prefer
inperson
interact
workshop
train
minim
varianc
among
report
receiv
inperson
train
earli
stage
employ
jhmi
rc
train
program
rctp
serv
train
educ
research
team
inperson
interact
workshop
yet
respond
complet
rctp
addit
offici
job
titl
perform
rc
respons
major
respond
research
staff
jh
year
lack
standard
among
job
titl
barrier
staff
receiv
appropri
train
job
titl
reflect
rc
respons
collect
analysi
survey
rc
cff
network
ongo
result
avail
juli
expect
identifi
common
discord
theme
among
train
percept
jhmi
rc
cff
rc
conclus
result
jhmi
rc
group
survey
piqu
interest
jhmi
leadership
determin
correl
staff
obtain
certif
whether
certif
selfmotiv
seek
obtain
addit
train
educ
understand
rc
train
experi
percept
inform
direct
jh
studi
coordin
apprenticeship
mentor
program
cff
rc
train
initi
institut
attempt
standard
rc
educ
trainingultim
close
gap
prepared
respons
patient
led
import
pediatr
provid
center
begin
prime
patient
young
age
learn
care
prepar
transit
adult
health
care
system
success
transit
requir
patient
learn
skill
necessari
selfmanag
selfadvocaci
health
care
decis
make
way
skill
typic
assess
transitionreadi
assess
tra
cf
center
one
biggest
dispar
knowledg
clean
steril
airway
clearanc
equip
csace
qualiti
improv
qi
approach
util
focu
selfmanag
skill
gradual
develop
appropri
goal
respiratori
therapist
rt
patient
caregiv
collabor
team
method
key
diagram
driver
kdd
process
flowchart
develop
organ
implement
qi
project
patient
age
year
caregiv
survey
creat
obtain
baselin
inform
famili
barrier
csace
primarili
respons
often
patient
involv
process
assess
checklist
creat
method
continu
evalu
knowledg
techniqu
use
household
properli
csac
equip
handout
proper
clean
steril
step
produc
famili
easi
refer
use
home
practic
demonstr
video
record
patient
cf
center
way
illustr
ageappropri
patient
abil
learn
selfmanag
skill
success
trial
elig
patient
follow
process
implement
visit
baselin
survey
assess
educ
visit
reassess
reeduc
demonstr
video
visit
reassess
reeduc
patient
demonstr
video
review
rt
inaccuraci
visit
annual
reassess
result
baselin
data
collect
patient
expect
addit
patient
data
obtain
along
patient
visit
prior
octob
propos
outcom
includ
rank
list
barrier
baselin
survey
increas
assess
score
knowledg
skill
set
maintain
annual
improv
effect
partnership
engag
rt
patient
caregiv
decreas
csace
dispar
tra
conclus
increas
attent
awar
properli
csace
systemat
teach
patient
caregiv
encourag
greater
independ
knowledg
immedi
handson
feedback
help
reinforc
learn
promot
behavior
chang
well
encourag
effect
partnership
patient
caregiv
improv
knowledg
skill
begun
seen
patient
complet
visit
indic
possibl
impact
patient
score
tra
brozik
e
webb
b
pediatr
west
virginia
univers
medicin
morgantown
wv
usa
introduct
earli
diagnosi
cystic
fibrosi
crucial
improv
outcom
implement
newborn
screen
nb
prospect
earli
diagnosi
becom
realiti
corollari
nb
perform
sweat
chlorid
test
earli
possibl
cf
center
averag
delay
notif
nb
result
appoint
sweat
chlorid
test
background
west
virginia
primari
care
physician
pcp
histor
respons
notifi
cf
center
receiv
abnorm
nb
result
center
notifi
sweat
chlorid
test
coordin
lab
patient
famili
closer
look
process
reveal
sever
barrier
time
sweat
chlorid
test
object
decreas
time
interv
posit
nb
result
sweat
chlorid
test
averag
age
patient
time
test
fall
within
cystic
fibrosi
foundat
guidelin
within
week
birth
method
work
west
virginia
state
lab
notifi
center
abnorm
nb
result
time
pcp
notifi
plan
nurs
coordin
would
contact
pcp
famili
directli
discuss
result
schedul
sweat
chlorid
test
genet
counsel
followup
cf
attend
physician
also
incorpor
six
reserv
sweattest
slot
physician
followup
week
track
follow
data
demograph
date
nb
result
date
nb
receiv
lab
date
result
discuss
pcp
date
result
discuss
famili
date
patient
schedul
sweat
chlorid
result
averag
delay
posit
nb
sweat
chlorid
test
decreas
day
day
averag
time
birth
sweat
test
decreas
day
day
conclus
state
lab
notif
cf
center
posit
nb
result
contribut
decreas
interv
time
posit
nb
sweat
chlorid
test
state
recent
increas
number
nurs
handl
nb
may
decreas
interv
time
test
result
time
notifi
improv
may
attain
increas
avail
sweat
chlorid
testprovid
appoint
current
oncal
physician
staff
patient
howev
addit
advanc
practic
provid
center
allow
increas
avail
final
barrier
continu
access
care
transport
famili
coordin
travel
despit
best
effort
issu
continu
ongo
effort
work
diagnosi
patient
quickli
possibl
homa
k
sabadosa
k
loma
ph
ashar
dowd
cg
marshal
b
dartmouth
institut
lebanon
nh
usa
consult
cff
orford
nh
usa
cystic
fibrosi
foundat
bethesda
md
usa
dartmouth
hitchcock
medic
center
lebanon
nh
usa
background
intern
committe
mental
health
cf
publish
clinic
practic
guidelin
screen
treat
depress
anxieti
behalf
us
cf
foundat
cff
european
cf
societi
quittner
al
et
al
thorax
jumpstart
implement
guidelin
cff
award
fund
accredit
program
support
role
mental
health
mh
coordin
mhc
januari
nation
cf
patient
famili
experi
care
survey
data
collect
program
question
mh
includ
survey
recent
visit
heath
care
team
ask
mental
emot
health
survey
invit
sent
everi
six
month
patient
famili
object
detect
initi
mh
process
improv
use
data
cf
patient
famili
experi
care
survey
method
nation
deploy
cf
patient
famili
experi
care
survey
began
januari
accredit
program
particip
april
averag
respond
sd
per
week
total
respond
total
respond
answer
mh
survey
question
respons
choic
includ
ye
definit
ye
somewhat
percentag
respond
select
ye
definit
examin
statist
process
control
spc
chart
group
program
program
receiv
mhc
fund
program
particip
mhc
intervent
chisquar
test
use
determin
whether
program
result
significantli
increas
program
signific
improv
ask
initi
implement
strategi
result
spc
chart
program
mhc
fund
show
signific
improv
respond
report
ask
mh
coincid
start
fund
begin
year
spc
chart
program
without
fund
mhc
show
random
variat
respond
ask
mh
although
program
respond
reliabl
chisquar
test
program
mhc
fund
signific
increas
p
strategi
report
gener
increas
attent
mh
dilig
ask
patient
famili
complet
mh
screen
conclus
cf
patient
famili
experi
care
survey
provid
data
track
earli
progress
accredit
program
implement
mh
care
guidelin
patient
famili
report
attent
address
mh
clinic
encount
role
mhc
develop
within
context
cf
care
deliveri
continu
monitor
result
cf
patient
famili
experi
care
survey
may
signal
improv
mh
care
mh
data
becom
avail
supplement
survey
data
screen
rate
mh
question
captur
report
cff
patient
registri
frederick
ca
fri
lm
roach
cm
cogswel
smith
ba
pulmonari
women
children
hospit
buffalo
lung
cystic
fibrosi
center
buffalo
ny
usa
pulmonari
univers
pediatr
associ
buffalo
ny
usa
pediatr
suni
buffalo
buffalo
ny
usa
psychiatri
suni
buffalo
buffalo
ny
usa
introduct
depress
cf
associ
advers
health
outcom
lower
fev
fidika
ploessl
lower
bmi
snell
vitamin
defici
smith
reason
intern
committe
mental
health
cystic
fibrosi
publish
consensu
statement
includ
recommend
routin
depress
screen
quittner
cf
center
women
children
hospit
buffalo
began
routin
depress
screen
previous
evalu
health
outcom
relat
incid
depress
hypothes
rate
declin
health
outcom
sinc
screen
initi
would
wors
depress
individu
evalu
effect
depress
patient
health
outcom
includ
fev
predict
bmi
level
hospit
method
individu
cf
year
old
assess
annual
symptom
depress
use
patient
health
score
use
screen
addit
symptom
depress
sever
suicid
patient
screen
posit
depress
receiv
assess
intervent
base
sever
health
outcom
measur
fev
predict
bmi
time
annual
screen
incid
hospit
year
prior
record
result
data
screen
show
adult
teen
screen
posit
depress
differ
fev
predict
adult
screen
posit
depress
vs
vs
mean
fev
predict
lower
teen
screen
posit
depress
vs
vs
p
signific
differ
mean
bmi
adult
vs
kgm
bmi
percentil
teen
vs
screen
posit
depress
vs
lower
vitamin
measur
individu
screen
posit
depress
vs
vs
p
increas
incid
hospit
note
screenposit
teen
vs
howev
find
present
adult
longitudin
combin
data
analyz
predict
fev
declin
significantli
greater
individu
screen
posit
depress
vs
mean
fev
vs
signific
chang
bmi
measur
time
lower
vitamin
level
remain
present
screenposit
individu
chang
time
conclus
depress
screen
cf
relev
import
health
outcom
year
lower
fev
predict
consist
found
depress
teen
time
strikingli
steeper
declin
fev
seen
adult
teen
screen
posit
depress
find
support
recommend
screen
treat
depress
cf
educ
treatment
may
potenti
imped
lung
function
declin
improv
health
outcom
fund
cfft
grant
method
intervent
begin
adult
cystic
fibrosi
cf
team
began
qualiti
improv
project
focus
standard
deliveri
inpati
care
first
outpati
cf
team
work
inpati
colleagu
implement
standard
care
nutrit
adult
ideal
bodi
weight
equat
adjust
includ
diseasesever
factor
airway
clearanc
therapi
act
cf
center
respiratori
therapist
rt
provid
retrain
hospit
rt
act
modal
inhal
medic
recent
includ
ipv
pulmonari
exacerb
inpati
act
goal
becam
hday
hospit
implement
epic
electron
medic
record
emr
allow
standard
order
set
cfspecif
teach
provid
hospitalist
admiss
central
specif
respiratoryfocus
floor
cf
team
provid
educ
nurs
staff
pharmaci
physic
therapi
diabet
educ
assign
floor
final
infect
control
practic
review
standard
result
averag
length
stay
lo
adult
cf
inpati
admiss
day
institut
intervent
lo
decreas
day
implement
patient
admiss
singl
floor
lo
decreas
day
subsequ
lo
consist
day
portcf
data
show
antibiot
durat
chang
current
literatur
lack
addit
metric
determin
effect
hospit
propos
evalu
chang
crp
level
hospit
chang
lung
function
eg
return
within
baselin
hospit
improv
lung
function
hospit
pulmonari
exacerb
admiss
treat
distal
intestin
obstruct
syndrom
dio
time
next
episod
dio
evalu
overal
portcf
data
show
continu
improv
lung
function
bmi
adult
patient
anecdot
patient
comment
continu
casemanag
social
work
servic
improv
admiss
central
specif
floor
conclus
hospit
admiss
requir
coordin
multipl
care
provid
deliveri
sever
intervent
present
multidisciplinari
approach
improv
consist
care
appear
cohort
patient
one
locat
allow
standard
care
decreas
lo
analysi
provid
inform
evalu
whether
result
translat
improv
metric
care
piccorelli
stanek
j
nick
ja
statist
univers
wyom
larami
wy
usa
nationwid
children
hospit
columbu
oh
usa
nation
jewish
health
denver
co
usa
introduct
accur
predict
model
call
nomogram
would
valuabl
clinic
care
research
trial
design
predict
surviv
cystic
fibrosi
cf
patient
although
sever
model
develop
predict
surviv
cf
patient
none
allow
physician
graphic
demonstr
probabl
patient
outcom
appoint
motiv
nomogram
abil
allow
graphic
present
predict
model
integr
patient
measur
label
predictor
predictor
model
scale
possibl
valuecategori
predictor
correspond
specif
number
point
base
prognost
signific
valuecategori
model
repres
graphic
scale
predictor
combin
calcul
continu
probabl
particular
outcom
illustr
enabl
physician
research
make
educ
accur
patientspecif
determin
prognosi
therapi
decis
allow
commun
prognosi
patient
effect
manner
method
dataset
analyz
pediatr
adult
cf
patient
akron
children
hospit
cox
regress
model
develop
predict
surviv
base
characterist
cf
patient
age
use
event
time
model
age
patient
defin
either
age
last
appoint
patient
aliv
time
studi
age
death
patient
aliv
time
studi
consid
censor
surviv
time
indic
variabl
death
statu
use
differenti
censor
surviv
time
age
death
base
previou
surviv
model
cf
patient
follow
predictor
includ
gender
bmi
race
baselin
fev
cystic
fibrosisrel
diabet
cfrd
statu
pseudomona
aeruginosa
statu
methicillinresist
staphylococcu
aureu
mrsa
statu
length
diagnosi
year
number
hospit
sinc
diagnosi
burkholderia
cepacia
statu
predictor
wald
test
signific
level
less
p
includ
final
model
result
cox
regress
model
develop
identifi
follow
variabl
signific
predictor
p
surviv
baselin
fev
length
diagnosi
number
hospit
cfrd
statu
includ
final
model
along
gender
known
predictor
surviv
cf
patient
final
model
concord
index
mean
order
predict
surviv
time
concord
order
observ
surviv
time
model
use
construct
nomogram
predict
probabl
surviv
base
cf
patient
characterist
inform
predictor
conclus
cox
regress
model
use
construct
nomogram
predict
surviv
cf
patient
sinc
death
among
patient
use
studi
larger
sampl
size
enabl
us
develop
model
predict
surviv
signific
predictor
current
studi
expand
includ
entir
cff
patient
registri
result
avail
fall
tm
call
patient
shown
educ
slide
individu
lung
statist
highlight
sputum
cultur
result
chest
xray
report
lung
function
trend
past
year
educ
tool
present
purpos
educ
patient
improv
outcom
potenti
increas
patient
satisfact
method
patient
identifi
preclin
meet
patient
outstand
annual
assess
identifi
respiratori
assess
requir
element
annual
visit
involv
cf
rt
observ
patient
perform
act
patient
elect
tm
assess
sent
invit
particip
previous
agre
upon
time
date
track
percent
predict
prior
tm
call
follow
tm
educ
session
addit
particip
ask
complet
preand
postsatisfact
survey
patient
provid
url
link
onlin
questionnair
ask
describ
understand
act
necessari
tool
necessari
perform
prescrib
therapi
whether
felt
therapi
oner
burden
answer
presurvey
follow
tm
encount
patient
ask
particip
postsurvey
question
includ
encount
improv
understand
act
tm
compar
facetofac
visit
would
particip
anoth
tm
educ
session
complet
postsurvey
result
patient
show
improv
percent
predict
n
averag
improv
increas
decreas
percent
predict
reveal
decreas
two
patient
preand
postencount
stay
patient
yet
complet
posttm
pft
test
preencount
satisfact
survey
report
full
understand
act
report
understand
report
necessari
tool
perform
act
ask
act
took
much
time
day
report
took
much
time
postencount
satisfact
survey
report
telemedicin
session
improv
understand
act
report
tm
encount
good
faceto
face
visit
ask
would
particip
anoth
tm
educ
session
said
absolut
interest
discuss
saw
improv
percent
predict
prior
tm
call
may
health
benefit
track
patient
report
satisfi
type
educ
option
would
particip
tm
educ
opportun
center
network
develop
rapidli
includ
core
center
affili
program
recent
improv
effort
focus
role
affili
program
within
network
strategi
strengthen
program
object
analyz
data
cystic
fibrosi
foundat
patient
registri
cffpr
explor
whether
clinic
outcom
differ
affili
versu
core
program
within
care
center
network
method
elig
popul
individu
data
cffpr
least
one
year
outcom
interest
percent
predict
elig
individu
age
older
bodi
mass
index
bmi
percentil
individu
age
bmi
individu
age
older
individu
younger
classifi
pediatr
individu
age
older
classifi
adult
year
studi
individu
assign
program
base
program
provid
care
calendar
year
data
analyz
program
level
patient
level
assess
differ
patient
outcom
affili
program
core
center
program
includ
pediatr
adult
program
within
core
center
result
patient
pediatr
adult
seen
affili
program
compar
patient
pediatr
adult
seen
core
center
overal
mean
outcom
valu
affili
program
tend
cluster
among
lowest
valu
care
center
network
especi
evid
pediatr
lung
function
elig
affili
program
fall
lowest
quartil
repres
affili
program
patient
lung
function
measur
patient
level
data
show
substanti
improv
pulmonari
nutrit
outcom
past
year
patient
regardless
receiv
care
despit
gain
mean
predict
significantli
lower
among
pediatr
patient
receiv
care
affili
program
compar
core
center
program
tabl
conclus
opportun
improv
clinic
outcom
affili
program
within
cff
care
center
network
pulmonari
function
among
pediatr
patient
present
greatest
opportun
continu
show
significantli
lower
valu
patient
seen
core
center
program
analysi
differ
within
affili
program
need
identifi
target
area
qualiti
improv
initi
largest
impact
improv
clinic
outcom
gastroenterolog
hepatolog
nutrit
children
hospit
philadelphia
philadelphia
pa
usa
univers
pennsylvania
philadelphia
pa
usa
rome
itali
pediatr
perelman
school
medicin
univers
pennsylvania
philadelphia
pa
usa
background
treatment
ivacaftor
cftr
gate
mutat
result
improv
weight
pulmonari
function
growth
statu
outcom
respons
ivacaftor
pancreat
insuffici
pi
compar
pancreat
suffici
ps
unknown
aim
determin
respons
ivacaftor
treatment
subject
cftr
gate
mutat
differ
pancreat
statu
method
subject
year
old
one
cftr
gate
mutat
recruit
usa
canada
itali
pancreat
statu
ls
mean
se
p
p
resp
signific
chang
time
daili
intak
control
percent
calori
protein
decreas
time
signific
differ
declin
group
chang
percent
calori
protein
signific
predictor
haz
chang
f
p
waz
chang
although
trend
toward
signific
f
percent
calori
fat
significantli
increas
bl
month
signific
impact
treatment
group
time
fat
intak
chang
fat
intak
predict
chang
growth
carbohydr
intak
signific
associ
growth
conclus
bn
group
significantli
increas
daili
energi
intak
protein
intak
macronutri
significantli
associ
chang
haz
trend
observ
associ
waz
percent
intak
protein
intak
decreas
posttreat
children
concomit
decreas
haz
futur
research
need
examin
interrelationship
macronutri
intak
impact
protein
intak
growth
preschool
support
nih
grant
pi
scott
w
power
pohl
j
robson
j
pediatr
gastroenterolog
nutrit
univers
utah
salt
lake
citi
ut
usa
primari
children
hospit
salt
lake
citi
ut
usa
pediatr
gastroenterolog
nutrit
ucsf
benioff
children
hospit
san
francisco
ca
usa
pediatr
pulmonari
univers
utah
salt
lake
citi
ut
usa
object
determin
whether
earli
childhood
growth
measur
use
cdc
versu
scale
associ
differ
longterm
cystic
fibrosi
cf
outcom
current
cystic
fibrosi
foundat
cff
recommend
children
diagnos
cf
prior
age
year
strive
weightforlength
th
percentil
base
cdc
growth
curv
stall
va
et
al
j
diet
assoc
recommend
appli
use
growth
curv
standard
measur
children
year
unit
state
method
cohort
studi
use
cff
patient
registri
particip
born
follow
cf
center
age
age
year
patient
categor
age
weightforlength
wfl
th
percentil
cdc
measur
th
percentil
cdc
th
percentil
cdc
primari
outcom
fev
percent
predict
fev
age
secondari
outcom
includ
bmi
total
hospit
day
lungtransplantfre
surviv
result
age
th
percentil
cdc
chart
th
cdc
th
percentil
multivari
linear
regress
analysi
show
stepwis
increas
fev
age
across
three
wfl
categori
lowest
wfl
th
percentil
cdc
measur
highest
wfl
th
percentil
measur
ci
posit
linear
test
trend
p
surviv
analysi
demonstr
highest
wfl
categori
also
greater
chanc
lungtransplantfre
surviv
p
adulthood
figur
conclus
children
cf
reach
wfl
th
percentil
cdc
measur
age
improv
pulmonari
growth
surviv
outcom
adulthood
compar
lower
earli
growth
categori
seek
maxim
longterm
pulmonari
surviv
outcom
cf
care
team
continu
util
cdc
growth
curv
patient
support
cystic
fibrosi
fellowship
train
grant
du
jr
nih
fellowship
train
grant
du
jr
depart
pediatr
univ
mn
mason
children
hospit
minneapoli
mn
usa
cincinnati
children
hospit
medic
center
cincinnati
oh
usa
univ
michigan
ann
arbor
mi
usa
luri
children
hospit
chicago
chicago
il
usa
univ
children
hospit
colorado
aurora
co
usa
background
spectrum
liver
diseas
cystic
fibrosi
cf
wide
rang
mild
transaminas
elev
mani
multilobar
cirrhosi
portal
hypertens
progress
liver
injuri
may
associ
decrement
patient
report
outcom
liver
diseas
clinic
appar
analysi
examin
serial
health
relat
qualiti
life
hrqol
measur
children
without
evid
newli
diagnos
cfrelat
liver
diseas
method
children
age
cf
without
previous
identifi
cirrhosi
portal
hypertens
enrol
prospect
multicent
studi
ultrasound
us
predict
hepat
fibrosi
consensu
us
pattern
assign
radiologist
normal
nl
heterogen
htg
homogen
hmg
nodular
cir
parent
inform
result
assess
parentand
childreport
hrqol
pedsql
tm
gener
core
scale
cf
questionnairerevis
cfqr
obtain
baselin
prior
knowledg
us
pattern
annual
patient
abnorm
pattern
match
control
hrqol
scale
score
compar
us
pattern
baselin
baselin
postenrol
result
us
find
baselin
subject
male
mean
age
nl
htg
hmg
cir
baselin
patient
cir
group
lower
mean
parentreport
pedsql
tm
physic
summari
score
cir
vs
nl
social
scale
score
cir
vs
nl
pedsql
tm
selfreport
remain
parentreport
score
vari
us
pattern
parentreport
cfqr
score
differ
bodi
scale
cir
vs
nl
eat
scale
hmg
vs
nl
weight
scale
hmg
vs
nl
p
selfreport
cfqr
scale
differ
us
pattern
comparison
baselin
parentreport
pedsql
tm
score
demonstr
declin
score
patient
hmg
us
pattern
selfreport
score
less
signific
parentreport
cfqr
score
stabl
interv
selfreport
emot
scale
score
improv
nl
group
tabl
conclus
differ
note
gener
diseasespecif
hrqol
score
us
pattern
baselin
subject
cir
lower
qol
score
clinic
liver
diseas
score
stabl
period
cir
group
score
hmg
group
declin
parent
selfreport
suggest
silent
liver
involv
cf
effect
qol
method
thirtyf
children
year
cf
ageand
sexmatch
children
without
cf
recruit
sydney
children
hospit
australia
consent
complet
australian
child
adolesc
eat
survey
aca
aca
valid
semiquantit
food
frequenc
questionnair
ffq
report
usual
dietari
consumpt
previou
six
month
addit
socioeconom
data
collect
includ
net
household
incom
level
parent
educ
postcod
result
age
gender
distribut
household
incom
matern
level
educ
compar
cf
control
group
p
children
cf
consum
averag
estim
energi
need
compar
control
p
noncor
food
contribut
significantli
total
energi
intak
compar
control
vs
convers
consum
significantli
less
energi
corefood
vs
p
howev
clear
gender
effect
male
cf
account
much
differ
compar
male
without
cf
consum
significantli
energi
noncor
food
significantli
less
core
food
p
differ
seen
femal
neither
children
cf
control
met
current
australian
dietari
guidelin
core
food
intak
howev
children
cf
significantli
like
meet
requir
meat
sociodemograph
factor
relat
intak
core
noncor
food
conclus
children
cf
especi
male
nearli
half
habitu
daili
energi
intak
provid
nutrient
poor
noncor
food
fell
short
meet
requir
nutrient
dens
core
food
establish
role
prevent
chronic
diseas
care
need
taken
ensur
cf
diet
becom
junk
food
diet
behavior
health
nutrit
univers
delawar
newark
de
usa
depart
surgeri
beth
israel
deaco
medic
center
boston
usa
cincinnati
children
hosp
med
ctr
cincinnati
oh
usa
object
examin
macronutri
intak
among
children
age
year
diagnos
cf
target
macronutri
may
mani
health
growth
benefit
includ
offset
catabol
associ
chronic
ill
acut
infect
method
seventyeight
children
age
year
cf
pancreat
insuffici
particip
random
clinic
trial
conduct
cf
center
compar
behavior
nutrit
treatment
bn
educ
attent
control
treatment
aim
improv
energi
intak
ei
growth
dietari
intak
assess
baselin
posttreat
month
use
weigh
food
diet
record
record
parent
dietari
data
analyz
use
nutrit
data
system
research
softwar
given
daili
total
ei
statist
differ
baselin
condit
group
collaps
examin
daili
total
averag
ei
percent
ei
macronutri
baselin
secondari
data
analysi
result
mean
total
ei
kcalday
averag
estim
energi
requir
eer
children
meet
eer
baselin
meet
daili
ei
fat
minimum
recommend
term
macronutri
intak
averag
ei
deriv
fat
protein
carbohydr
averag
protein
intak
per
day
children
achiev
recommend
benchmark
neg
relationship
baselin
carbohydr
fat
intak
r
p
dinner
meal
highest
percent
calori
protein
consum
fat
snack
highest
percent
calori
carbohydr
consum
conclus
preschool
achiev
similar
percent
eer
document
previou
studi
mani
children
meet
cf
foundat
nutrit
guidelin
benchmark
least
daili
ei
deriv
fat
children
met
cf
foundat
preschool
recommend
daili
protein
intak
g
promot
optim
growth
health
preschool
within
cf
nutrit
care
data
suggest
highlight
import
develop
famili
dinner
routin
preschool
year
may
boost
opportun
fat
protein
intak
partner
famili
identifi
substitut
high
carbohydr
food
beverag
particularli
snack
may
also
creat
opportun
children
consum
optim
protein
fat
support
nih
grant
pi
scott
w
power
mccrori
harper
h
mcphail
gl
cincinnati
children
hospit
medic
center
cincinnati
oh
usa
background
patient
cystic
fibrosi
cf
commonli
prescrib
proton
pump
inhibitor
ppi
despit
studi
link
ppi
potenti
sever
advers
effect
studi
shown
larg
portion
cf
patient
gastroesophag
reflux
ger
treat
chronic
ppi
therapi
patient
cf
may
also
take
ppi
adjuv
therapi
pancreat
enzym
improv
nutrit
statu
project
design
evalu
incid
advers
effect
associ
chronic
ppi
use
well
evalu
dose
indic
durat
use
ppi
cf
patient
center
method
retrospect
chart
review
ppi
use
incid
advers
effect
cf
popul
cincinnati
children
hospit
medic
center
cchmc
patient
identifi
either
current
receiv
ppi
therapi
least
month
durat
ppi
group
never
receiv
ppi
therapi
control
group
june
may
data
collect
retrospect
identifi
studi
patient
june
end
inclus
time
period
date
first
ppi
prescript
end
inclus
time
period
whichev
shortest
durat
data
collect
includ
serum
magnesium
serum
calcium
correspond
albumin
level
number
pulmonari
exacerb
c
difficil
toxin
test
result
serum
vitamin
serum
ferritin
dxa
scan
result
result
patient
ppi
group
patient
control
group
baselin
characterist
similar
group
except
age
sex
mean
baselin
valu
percent
predict
ppi
group
compar
control
group
pn
indic
dose
durat
ppi
therapi
collect
see
tabl
ppi
group
patient
incid
hypomagnesemia
compar
patient
control
group
number
need
harm
nnh
ppi
group
patient
least
one
pulmonari
exacerb
compar
patient
placebo
group
p
nnh
signific
differ
incid
hypocalcemia
low
bone
miner
densiti
posit
c
difficil
toxin
two
group
vitamin
ferritin
level
could
evalu
due
lack
data
conclus
ppi
therapi
predomin
prescrib
indic
ger
enzym
enhanc
cf
popul
chronic
ppi
therapi
use
cautious
patient
cf
could
increas
risk
seriou
advers
effect
cf
popul
particular
concern
increas
risk
pulmonari
exacerb
potenti
hypomagnesemia
valu
express
mean
sd
minimum
maximum
unless
otherwis
state
group
patient
year
bmi
wtlength
group
method
irb
approv
implement
hv
famili
met
criteria
consent
group
initi
followup
hv
year
age
group
hv
prior
hv
famili
complet
follow
survey
cf
knowledg
cf
nutrit
knowledg
cope
health
inventori
parent
chip
behavior
pediatr
feed
assess
scale
group
cf
team
sw
rd
rrt
andor
counselor
attend
hv
review
survey
result
patientsfamili
hv
famili
provid
scale
track
weekli
weight
clinic
visit
follow
hv
survey
repeat
famili
cf
team
member
involv
visit
also
complet
satisfact
survey
result
decemb
infant
diagnos
nb
enrol
group
survey
result
show
overal
correct
respons
cf
nutrit
knowledg
posit
satisfact
hv
report
famili
cf
team
famili
cope
survey
chip
provid
inform
allow
cf
team
tailor
convers
famili
cope
style
chip
result
reveal
parent
priorit
care
cope
behavior
parent
report
develop
earli
strong
close
relationship
medic
team
help
cope
chronic
ill
child
differ
nutrit
paramet
note
enrol
nonenrol
patient
enrol
infant
overal
higher
number
hospit
admiss
came
clinic
frequent
signific
impact
shown
regard
nutrit
statu
lung
function
frequenc
clinic
visit
hospit
admiss
phone
contact
complet
hv
five
patient
enrol
group
signific
barrier
carri
enrol
group
conclus
overal
goal
increas
patientcar
provid
interact
cf
clinic
visit
achiev
howev
impact
clinic
outcom
note
may
attribut
small
sampl
size
increas
hospit
admiss
clinic
visit
group
may
relat
increas
earli
ill
recognit
chip
result
allow
cf
team
focu
import
parent
selfcar
often
neglect
failur
enrol
group
patient
hv
caus
cf
team
consid
differ
intervent
group
earli
stage
develop
introduct
underweight
individu
cystic
fibrosi
cf
commonli
one
barrier
contribut
low
weight
factor
fall
sever
categori
includ
medic
nonmed
issu
correctli
identifi
specif
barrier
essenti
find
appropri
intervent
promot
weight
gain
bodi
mass
index
bmi
often
use
marker
nutrit
statu
optim
bmi
cf
patient
kgm
femal
kgm
male
context
cqi
initi
improv
nutrit
statu
survey
patient
identifi
barrier
optim
nutrit
object
identifi
barrier
interf
optim
bmi
statu
adult
patient
cystic
fibrosi
method
patient
enrol
cf
center
listserv
invit
email
complet
question
survey
use
onlin
survey
websit
particip
allow
day
complet
survey
given
two
email
remind
survey
question
develop
cqi
team
topic
includ
demograph
medic
problem
mental
health
financi
statu
enjoy
eat
collect
respons
filter
bmi
group
respons
summari
within
group
analyz
data
trend
ensur
sampl
obtain
repres
center
popul
incid
diabet
entir
sampl
compar
port
cf
data
found
similar
result
given
aim
improv
nutrit
statu
focus
data
trend
within
bmi
group
compar
bmi
group
group
found
increas
incid
diabet
gi
symptom
decreas
appetit
financi
barrier
state
need
encourag
idea
surround
eat
incid
medic
nonmed
issu
similar
among
three
bmi
group
conclus
result
suggest
underweight
individu
center
experi
greater
incid
diabet
gi
symptom
decreas
appetit
financi
hardship
would
like
encourag
idea
surround
eat
focus
specif
problem
associ
low
bmi
statu
may
best
way
promot
weight
gain
overal
nutrit
improv
within
group
notabl
risk
identif
may
also
help
identifi
patient
risk
weight
loss
base
comorbid
diagnos
symptomolog
financi
statu
report
barrier
eat
next
step
cqi
initi
onepag
inform
sheet
outlin
financi
resourc
avail
cf
patient
develop
financi
hardship
identifi
one
preval
barrier
optim
nutrit
cf
team
member
distribut
onepag
inform
sheet
review
financi
resourc
patient
bmi
clinic
object
kid
cystic
fibrosi
cf
problem
maintain
healthi
weight
relat
diseas
statu
could
increas
parent
stress
neg
sway
percept
mealtim
behavior
evidencebas
cfspecif
treatment
shown
reduc
parent
percept
mealtim
problem
involv
high
degre
famili
burden
eg
travel
extra
clinic
visit
clinic
eg
staff
time
commit
purpos
pilot
new
intervent
address
parent
stress
parent
neg
mealtim
percept
use
videobas
telemedicin
reduc
trip
clinic
individu
problemfocus
curriculum
promot
effici
method
far
recruit
famili
kid
cf
year
old
struggl
gain
weight
famili
receiv
clinicprovid
ipad
particip
monthli
videobas
telemedicin
session
last
minut
two
provid
field
session
base
famili
need
eg
behavior
versu
nutrit
problem
avail
determin
need
famili
complet
brief
assess
prior
telemedicin
session
complet
pediatr
inventori
parent
pip
behavior
pediatr
feed
assess
scale
bpfa
baselin
month
month
data
pend
descript
statist
present
along
effect
size
cohen
morri
deshon
depend
correct
ttest
perform
small
sampl
size
result
baselin
mean
age
children
year
mean
bmi
zscore
kgm
half
girl
parent
mean
pipfrequ
score
baselin
month
show
slight
decreas
frequenc
stress
event
contrast
parent
mean
pipdifficulti
score
virtual
unchang
baselin
month
respect
respect
mealtim
parent
mean
bpfa
parentfrequ
score
baselin
month
mean
bpfa
childfrequ
score
baselin
month
suggest
slight
decreas
perceiv
frequenc
mealtim
problem
respect
addit
decreas
number
child
problem
report
baselin
month
respect
number
parent
problem
report
baselin
month
respect
overal
qualit
analys
indic
parent
endors
behavior
challeng
nutrit
concern
session
kappa
conclus
initi
data
suggest
problemfocus
videobas
telemedicin
intervent
may
help
reduc
parent
stress
parentperceiv
mealtim
problem
sixmonth
followup
complet
june
final
result
includ
comparison
parent
questionnair
score
baselin
month
result
use
inform
intervent
manual
could
test
larger
clinic
trial
regalado
lam
chew
tun
r
porhownik
nr
taback
oleschuk
c
dept
nutrit
health
scienc
centr
winnipeg
mb
canada
dept
pediatr
child
health
univers
manitoba
winnipeg
mb
canada
diagnost
servic
manitoba
winnipeg
mb
canada
dept
respirolog
health
scienc
centr
winnipeg
mb
canada
background
effect
high
dose
oral
cholecalciferol
replet
strategi
vitamin
insuffici
adult
cf
still
unknown
therefor
assess
effect
current
approach
give
oral
vitamin
supplement
dose
iu
monday
friday
total
iu
weekli
vitamin
insuffici
adult
cf
method
perform
retrospect
chart
review
adult
cf
patient
age
year
routin
follow
cf
adult
program
winnipeg
health
scienc
centr
winnipeg
cf
clinic
locat
latitud
n
w
patient
diagnos
cf
basi
sweat
chlorid
test
genotyp
adult
cf
undergon
lung
transplant
n
known
cirrhot
liver
diseas
n
weekli
dose
vitamin
iu
n
weekli
dose
iu
n
repeat
vitamin
test
n
exclud
studi
approv
univers
manitoba
health
research
ethic
board
consult
endocrinologist
clinic
vitamin
replet
protocol
treat
cf
adult
patient
serum
nmoll
ngml
prescrib
vitamin
iu
oral
monday
friday
weekli
equival
iu
week
addit
regular
cf
vitamin
suppli
iu
vitamin
daili
cholecalciferol
conveni
administ
oral
either
one
capsul
iu
one
tablet
iu
patient
instruct
obtain
followup
serum
level
postcomplet
treatment
serum
concentr
measur
semiautom
liquid
chromatographi
tandem
mass
spectrometri
lcmsm
analysi
result
adult
patient
cf
clinic
patient
optim
serum
level
patient
identifi
patient
insuffici
serum
level
nmoll
ngml
fulfil
inclus
criteria
signific
increas
serum
level
observ
p
mean
valu
nmoll
ngml
baselin
nmoll
ngml
month
post
intervent
current
treatment
approach
success
treat
vitamin
insuffici
patient
low
level
conclus
result
studi
demonstr
larg
number
adult
attend
winnipeg
health
scienc
centr
cf
clinic
serum
level
nmoll
support
need
dedic
individu
approach
manag
condit
high
dose
therapi
vitamin
although
aggress
treatment
approach
may
result
achiev
optim
level
serum
adult
cf
reilli
mg
dempsey
c
morgan
slatteri
nutrit
dietet
children
univers
hospit
dublin
dublin
ireland
respiratori
children
univers
hospit
dublin
dublin
ireland
introduct
ree
repres
calori
requir
period
bodi
inact
period
ree
greater
cf
patient
healthi
control
vaisman
n
et
al
j
pediatr
buchdahl
rm
et
al
j
app
phi
reason
poorli
understood
object
studi
evalu
factor
may
influenc
ree
cf
method
ree
measur
use
quark
rmr
indirect
calorimet
patient
year
age
femal
respiratori
baselin
routin
review
paramet
collect
time
point
includ
lung
function
weight
height
bmi
genotyp
presenc
gastrostomi
tube
result
mean
ree
predict
increas
greater
femal
male
statist
signific
signific
differ
ree
pubert
group
versu
nonpubert
group
small
posit
correl
ree
increas
weight
associ
higher
ree
homozyg
lower
ree
genotyp
vs
result
statist
signific
peg
tube
lower
ree
without
vs
also
lower
vs
conclus
overal
ree
elev
studi
lower
seen
studi
suggest
good
overal
health
group
higher
ree
femal
well
document
studi
significantli
higher
group
suggest
narrow
gap
gender
puberti
would
seem
exert
obviou
impact
requir
group
higher
ree
seen
better
nonhomozyg
genotyp
novel
would
use
futur
interpret
alongsid
bodi
composit
physic
activ
level
perhap
health
encourag
improv
exercis
level
higher
muscl
mass
thu
higher
ree
possibl
peg
lower
ree
due
reduc
physic
effortmuscl
mass
result
decreas
lung
function
futur
studi
investig
muscl
fat
mass
activ
level
tandem
ree
background
object
univers
alabama
birminghamchildren
alabama
uabcoa
pediatr
cf
program
implement
cf
foundat
cff
guidelin
bone
health
algorithm
adapt
program
order
test
effect
guidelin
within
program
examin
associ
vitamin
supplement
serum
bone
miner
densiti
bmd
method
use
retrospect
chart
review
evalu
patient
prescrib
high
dose
vitamin
supplement
bmd
assess
baselin
year
postsupplement
sampl
includ
particip
compos
femal
male
mean
age
year
baselin
two
group
group
group
mean
statu
group
baselin
ngml
two
year
mean
increas
ngml
group
baselin
two
year
mean
increas
descript
statist
gener
well
correl
analys
multipl
linear
regress
examin
potenti
relationship
concentr
bmd
lumbar
spine
total
bodi
year
maximum
dose
supplement
independ
test
run
compar
differ
group
regard
supplement
dose
result
baselin
serum
level
found
significantli
associ
bmd
baselin
lumbar
spine
p
total
bodi
howev
associ
seen
follow
two
year
supplement
signific
differ
note
group
receiv
iu
group
receiv
iu
lean
bodi
mass
lbm
found
significantli
associ
bmd
baselin
lumbar
spine
total
bodi
p
signific
associ
bmd
lbm
remain
year
supplement
lumbar
spine
total
bodi
conclus
baselin
associ
show
link
low
bmd
although
supplement
patient
defici
level
could
result
improv
bmd
popul
never
reach
suggest
least
surprisingli
differ
note
group
receiv
either
iu
conclud
increas
supplement
effect
patient
group
adher
prescrib
regimen
alway
question
address
signific
associ
lbm
bmd
show
import
bodi
composit
maintain
bone
health
nt
emphas
enough
cf
find
strengthen
previou
recommend
weight
bear
exercis
highli
emphas
patient
futur
research
area
focu
intervent
prevent
care
achiev
adequ
attain
optim
bone
health
background
children
cf
predispos
essenti
fatti
acid
efa
abnorm
character
low
level
linol
acid
la
docosahexaeno
acid
dha
alter
arachidon
acid
level
aa
well
elev
patholog
trien
level
trien
tetraen
tt
ratio
littl
known
whether
dietari
efa
intak
adequ
young
children
cf
current
cff
infant
care
guidelin
report
insuffici
evid
recommend
la
dha
supplement
object
evalu
efa
statu
first
year
life
associ
dietari
intak
method
studi
popul
consist
infant
enrol
first
feed
infant
start
multicent
prospect
observ
studi
initi
cf
center
madison
milwauke
indianapoli
salt
lake
citi
boston
identifi
optim
feed
infant
cf
total
erythrocyt
specimen
infant
reach
year
age
analyz
fa
composit
type
feed
food
record
obtain
express
percentag
weight
total
fa
efa
abnorm
defin
efa
defici
efad
tt
ratio
efa
insuffici
efai
tt
ratio
elev
trien
trien
total
fa
result
subject
meconium
ileu
mi
mi
pancreat
insuffici
pi
pancreat
suffici
ps
defin
fecal
elastas
consist
preval
efadefai
elev
trien
increas
age
p
subject
fa
composit
analyz
age
efa
suffici
throughout
efadefai
least
first
year
life
mean
erythrocyt
la
level
increas
age
wherea
mean
dha
p
aa
level
decreas
age
mean
dha
mean
aa
within
pi
group
breastf
infant
tend
efa
suffici
compar
formula
fed
infant
infant
feed
type
la
intak
total
calori
posit
correl
erythrocyt
la
mean
la
intak
factor
fat
malabsorpt
mean
la
intak
equat
well
ai
subject
la
intak
ai
efad
preval
efad
among
la
intak
mean
alpha
linolen
acid
intak
ai
conclus
preliminari
analysi
show
efa
abnorm
common
young
children
cf
age
efa
insuffici
preval
even
though
efa
intak
meet
ai
routin
test
earli
intervent
detect
potenti
correct
efa
abnorm
object
previou
studi
pediatr
cf
patient
done
chu
stejustin
cf
clinic
show
patient
serum
oh
defici
low
level
optim
level
result
studi
led
new
vitamin
supplement
protocol
clinic
part
new
protocol
patient
year
receiv
addit
iu
vitamin
total
iu
daili
reach
optim
level
supplement
receiv
addit
iu
vitamin
week
object
studi
document
chang
serum
vitamin
level
cf
pediatr
popul
follow
new
protocol
establish
may
method
retrospect
chart
review
vitamin
supplement
oh
level
patient
pancreaticinsuffici
pi
pancreaticsuffici
ps
one
year
protocol
implement
result
background
rest
metabol
rate
rmr
increas
peopl
cystic
fibrosi
pwcf
howev
reason
poorli
understood
result
increas
rmr
malnutrit
cf
associ
reduc
lung
function
prognosi
pwcf
improv
year
due
part
aggress
symptomat
treatment
introduct
new
drug
ivacaftor
object
assess
paramet
influenc
rmr
lung
function
nutrit
statu
pwcf
key
prognost
indic
patient
examin
impact
ivacaftor
outcom
pwcf
mutat
design
studi
popul
consist
pwcf
age
year
rmr
measur
prospect
indirect
calorimetri
patient
routin
review
patient
rmr
measur
retrospect
paramet
collect
includ
lung
function
anthropometr
measur
genotyp
bacteri
colonis
physic
activ
level
comorbid
fat
solubl
vitamin
statu
presenc
peg
tube
statist
analysi
carri
use
spss
window
version
outcom
mean
rmr
predict
mean
bmi
centil
mean
statist
signific
associ
paramet
assess
rmr
signific
posit
associ
found
bmi
r
p
peg
insert
found
significantli
lower
bmi
centil
vs
p
vs
without
peg
differ
persist
control
bmi
homozyg
significantli
lower
heterozyg
mutat
vs
patient
colonis
mrsa
significantli
lower
colonis
staphylococcu
aureu
vs
addit
diabet
patient
significantli
lower
without
diabet
vs
five
patient
take
ivacaftor
significantli
higher
take
drug
vs
trend
toward
improv
observ
paramet
assess
relat
ivacaftor
except
height
centil
interestingli
patient
activ
patient
suffici
vitamin
level
demonstr
improv
health
paramet
howev
result
statist
signific
conclus
studi
group
appear
maintain
rel
good
growth
lung
function
introduct
ivacaftor
appear
signific
benefit
mutat
increas
rmr
observ
expect
howev
paramet
affect
rmr
remain
poorli
understood
aitken
ml
ramo
kj
kapnadak
sg
loprior
univers
washington
seattl
wa
usa
background
maintain
optim
nutrit
healthi
weight
import
patient
cf
despit
limit
inform
adult
cf
patient
perspect
regard
nutrit
exercis
need
wish
systemat
gather
patient
percept
dietaryphys
activ
need
goal
creat
patientcent
data
allow
improv
qualiti
care
method
survey
design
regard
nutrit
physic
wellb
adult
year
cf
patient
survey
pilot
cf
patient
univers
washington
feasibl
clariti
respond
found
survey
took
fewer
minut
complet
patient
seen
regist
dietician
rd
clinic
ask
complet
survey
includ
question
address
patient
nutrit
concern
use
felt
dietician
support
time
spent
food
prepar
exercis
frequenc
choic
healthimprov
program
would
find
valuabl
result
patient
men
women
complet
survey
age
rang
year
pancreat
insuffici
averag
rang
women
averag
bmi
kgm
rang
kgm
cff
guidelin
overweight
men
averag
bmi
kgm
rang
kgm
cff
guidelin
overweight
cfrd
five
use
insulin
oral
nutrit
supplement
use
aid
maintain
healthi
weight
patient
took
probiot
daili
basi
major
patient
found
rd
visit
help
patient
time
spent
daili
food
prepar
vari
spend
minut
spend
minut
spend
greater
minut
less
minut
daili
patient
report
routin
exercis
exercis
minut
daili
walk
strength
train
popular
form
exercis
patient
primari
nutrit
concern
relat
maintain
healthi
weight
choos
weight
gain
choos
weight
loss
primari
concern
nutrit
concern
blood
glucos
control
nutrit
educ
digest
healthenzym
use
term
nutrit
fit
program
chose
increas
access
onlin
nutrit
educ
fit
inform
would
like
cf
cookbook
emphas
healthi
food
conclus
preliminari
data
patientcent
nutrit
exercis
need
show
patient
bmi
meet
cff
guidelin
interestingli
overweight
wish
weight
loss
patient
regularli
exercis
would
like
improv
onlin
access
cfspecif
nutrit
educ
well
increas
fit
knowledg
specif
patient
respiratori
diseas
lamer
cr
van
der
feen
c
van
der
doef
hp
van
der
ent
ck
houwen
rh
pediatr
gastroenterolog
univers
medic
center
utrecht
utrecht
netherland
pediatr
gastroenterolog
univers
medic
center
groningen
groningen
netherland
pediatr
pulmonolog
univers
medic
center
utrecht
utrecht
netherland
background
aim
ursodeoxychol
acid
might
prevent
progress
cystic
fibrosisrel
liver
diseas
object
paramet
effect
lack
method
observ
studi
pediatr
cystic
fibrosi
patient
perform
patient
least
two
measur
liver
stiff
transient
elastographi
least
one
year
apart
januari
april
patient
differ
first
last
measur
avail
calcul
express
stiff
kpa
per
year
evalu
effect
ursodeoxychol
acid
result
pair
measur
liver
stiff
median
interv
month
done
patient
patient
ursodeoxychol
acid
given
initi
liver
stiff
iqr
kpa
patient
ursodeoxychol
acid
liver
stiff
iqr
kpa
group
patient
cirrhosi
initi
liver
stiff
kpa
patient
ursodeoxychol
acid
start
heterogen
liver
ultrasound
combin
either
hepatomegali
andor
increas
liver
enzym
colombo
criteria
initi
liver
stiff
iqr
kpa
patient
ursodeoxychol
acid
start
reason
gener
isol
rais
transaminas
initi
liver
stiff
kpa
group
without
ursodeoxychol
acid
liver
stiff
increas
iqr
kpayear
liver
stiff
also
increas
group
cirrhosi
iqr
kpayear
howev
patient
ursodeoxychol
acid
start
colombo
criteria
met
decreas
liver
stiff
iqr
kpayear
observ
significantli
differ
increas
liver
stiff
group
without
ursodeoxychol
acid
patient
ursodeoxychol
acid
reason
liver
stiff
increas
iqr
kpayear
conclus
data
suggest
ursodeoxychol
acid
might
abl
reduc
liver
stiff
use
patient
well
defin
mild
liver
diseas
perez
drumm
ml
pediatr
cwru
cleveland
oh
usa
cfrd
incid
increas
cf
patient
longev
risen
even
strike
cf
patient
exhibit
form
glucos
intoler
readili
explain
cf
mous
exhibit
pancreat
insuffici
therefor
repres
good
model
studi
insulin
regul
tissu
cf
context
without
pancreat
atrophi
found
mice
fast
hour
lower
basal
glucos
valu
wt
litterm
investig
glucos
toler
test
gtt
perform
male
femal
wt
mice
background
hour
overnight
fast
tabl
indic
basal
glucos
valu
significantli
lower
cf
mice
area
curv
auc
also
lower
indic
cf
mice
dispos
glucos
rapidli
wt
lower
basal
glucos
valu
cf
mice
correl
higher
keton
valu
indic
oxid
fat
wt
glucos
keton
valu
measur
mice
fed
condit
one
week
later
return
preexperiment
level
still
lower
higher
respect
cf
mice
lower
fast
glucos
cf
mice
could
due
smaller
glycogen
pool
sinc
cf
mice
smaller
less
fat
muscl
mass
wt
femal
mice
test
week
age
sacrif
either
fed
fast
hour
hour
total
glycogen
measur
liver
mice
g
glucos
whole
liverkg
bodi
weight
wt
fed
n
hour
fast
n
hour
fast
n
fed
n
hour
fast
n
hour
fast
n
fed
n
hour
fast
n
hour
fast
n
p
liver
cf
femal
mice
glycogen
wt
either
fed
state
fast
yet
blood
glucos
level
lower
indic
cf
mice
may
problem
releas
glucos
store
glycogen
calorimetri
use
measur
respiratori
quotient
rq
wt
male
mice
week
old
hour
last
hour
without
food
rq
indic
presenc
food
cf
mice
preferenti
burn
carbohydr
night
fat
day
wt
food
withdrawn
night
cf
mice
switch
fat
store
sooner
wt
data
indic
pancreat
suffici
young
cf
mice
abl
use
readili
avail
carbohydr
energi
substrat
sensit
util
presum
peripheri
indic
enhanc
insulin
sensit
age
howev
less
effect
access
store
glycogen
deplet
dietari
carbohydr
faster
wt
metabol
scenario
could
contribut
glucos
intoler
seen
cf
patient
even
absenc
cfrd
support
nih
grant
backgroundobject
adequ
nutrit
crucial
health
wellb
cystic
fibrosi
cf
patient
gener
two
way
cf
patient
use
calcul
pancreat
enzym
replac
therapi
pert
meal
far
popular
base
weight
lipasekg
patientm
typic
rang
lipas
unitkg
patientm
may
howev
best
way
assess
requir
enzym
dose
best
optim
nutrit
statu
altern
strategi
calcul
gram
fat
meal
base
pill
strength
known
lipas
unit
per
gram
fat
per
meal
commonli
undertaken
although
altern
endors
cf
foundat
studi
purpos
assess
potenti
benefit
cystic
fibrosi
patient
exocrin
pancreat
insuffici
epi
use
smartphon
app
manag
dose
pancreat
enzym
order
optim
health
nutrit
statu
method
cohort
studi
evalu
benefit
use
pancreat
enzym
manag
smartphon
app
inclus
criteria
includ
year
age
older
diagnosi
pancreat
insuffici
current
use
pert
smartphon
smartphon
app
develop
use
fat
lipas
ratio
regul
number
enzym
taken
meal
snack
determin
number
fat
gram
use
intern
food
catalog
patient
epi
smartphon
devic
provid
verbal
consent
clinic
hour
particip
ask
complet
initi
gastrointestin
stool
questionnair
follow
fiveday
food
pancreat
enzym
diari
use
inform
particip
provid
fat
lipas
ratio
instruct
use
smartphon
app
seven
day
end
period
particip
complet
followup
gastrointestin
stool
questionnair
assess
chang
report
symptom
result
enrol
five
particip
date
initi
stool
questionnair
particip
report
approxim
stool
daili
averag
gastrointestin
complaint
daili
one
particip
complet
studi
initi
questionnair
patient
report
approxim
stool
averag
gi
complaint
daili
final
assess
patient
report
reduct
gi
complaint
fewer
bowel
movement
improv
weight
gain
week
use
smartphon
app
inform
need
remain
particip
order
assess
potenti
benefit
pancreat
manag
smartphon
app
discuss
studi
still
ongo
initi
result
show
promis
resolv
gastrointestin
complaint
weight
gain
hypothes
result
continu
prove
efficaci
smartphon
app
manag
pancreat
enzym
replac
therapi
optim
nutrit
statu
pancreat
insuffici
cystic
fibrosi
patient
method
studi
elig
children
enrol
ongo
multicent
prospect
studi
investig
util
earli
abdomin
ultrasonographi
us
predict
later
cirrhosi
push
studi
children
pancreat
insuffici
cf
age
heterogen
liver
us
htg
match
children
cf
normal
us
nl
also
includ
children
nodular
liver
nod
bright
homogen
liver
hmg
baselin
use
baselin
blood
work
us
data
express
us
spleen
size
ageadjust
zscore
ssaz
calcul
ast
platelet
ratio
index
apri
fibrosi
index
base
factor
undertook
univari
analysi
multivari
model
result
univari
analysi
show
signific
differ
us
group
platelet
count
alt
ast
ggt
apri
ssaz
tabl
multivari
regress
model
develop
nod
vs
nl
auroc
final
model
includ
ggt
ssaz
final
model
ggt
model
test
distinguish
htg
vs
nl
ggt
remain
final
model
auroc
best
model
distinguish
nod
vs
htg
includ
alkalin
phosphatas
auroc
hmg
vs
nl
distinguish
model
age
us
ethnic
hispan
vs
bodi
mass
index
zscore
alt
auroc
conclus
liver
us
appear
children
cf
correl
chang
simpl
biomark
liver
diseas
valu
htg
intermedi
nl
nod
multivari
model
simpl
biomark
excel
discrimin
abil
nl
vs
nod
find
support
us
grade
may
correl
develop
liver
diseas
caus
chang
blood
work
spleen
size
variabl
futur
studi
explor
longitudin
chang
simpl
biomark
children
transit
us
grade
time
nl
htg
htg
nod
increas
risk
earli
death
rodman
et
al
medicin
baltimor
object
baylor
colleg
medicin
bcm
adult
cystic
fibrosi
center
larg
adult
center
houston
texa
activ
patient
registri
data
set
diagnos
either
impair
glucos
toler
cfrd
light
signific
impact
cfrd
morbid
adult
cf
preval
clinic
popul
determin
organ
multidisciplinari
approach
diagnosi
manag
cohort
essenti
improv
clinic
outcom
hypothes
format
cfrd
multidisciplinari
clinic
committe
lead
time
diagnosi
improv
manag
cfrd
method
form
multidisciplinari
committe
novemb
compos
member
cf
center
team
adult
endocrin
section
includ
physician
nurs
dietitian
administr
diabet
educ
multidisciplinari
committe
met
monthli
agenda
includ
develop
algorithm
time
diagnosi
monitor
oper
chang
streamlin
care
patient
cfrd
case
manag
discuss
complic
cfrd
patient
result
result
committe
effort
creat
endocrin
referr
protocol
cfrd
care
algorithm
well
form
comprehens
cfrd
clinic
includ
cf
endocrin
care
provid
diabet
educ
cfrd
clinic
offer
monthli
allow
patient
see
pulmonologist
routin
cf
care
endocrinologist
diabet
mainten
receiv
diabet
educ
nutrit
evalu
consecut
appoint
provid
abl
discuss
care
patient
person
real
time
lead
maxim
commun
care
team
improv
effici
patient
care
conclus
hypothes
format
cfrd
committe
multidisciplinari
clinic
lead
time
diagnosi
improv
manag
cfrd
plan
present
data
preand
month
postclin
creation
evalu
number
patient
complet
yearli
ogtt
number
patient
igt
cfrd
complet
outpati
endocrin
appoint
quarter
percent
patient
use
insulin
pump
control
diabet
also
trend
clinic
outcom
lung
function
nutrit
statu
hemoglobin
marker
diabet
control
shoff
sm
lai
hj
first
studi
group
nutrit
scienc
univers
wisconsin
madison
wi
usa
background
fatti
acid
fa
composit
breast
milk
bm
influenc
matern
diet
variabl
rais
concern
whether
exclus
breastfeed
provid
adequ
amount
essenti
fa
efa
infant
cf
accord
dietari
refer
intak
adequ
intak
ai
principl
efa
linol
acid
la
infant
mo
gday
ai
estim
base
averag
daili
bm
intak
ml
contain
g
total
fat
calori
fat
factor
fat
malabsorpt
cf
infant
exclus
breastf
would
adequ
la
intak
unless
bm
intak
increas
mlday
la
content
bm
enrich
ml
object
determin
fa
profil
bm
associ
matern
dietari
fa
intak
method
first
feed
infant
start
multicent
prospect
observ
studi
initi
cf
center
madison
milwauke
boston
indianapoli
salt
lake
citi
identifi
optim
feed
infant
cf
bm
substudi
initi
mother
age
enrol
bm
sampl
collect
mo
postpartum
analyz
matern
dietari
intak
also
obtain
food
frequenc
questionnair
six
women
exclus
breast
fed
mo
mo
mo
respect
result
calor
densiti
averag
kcaloz
vari
greatli
among
bm
sampl
kcaloz
protein
averag
goz
calori
rang
goz
calori
total
fat
averag
goz
calori
rang
goz
calori
averag
calor
densiti
protein
content
similar
fat
content
lower
valu
use
establish
ai
healthi
infant
efa
content
also
vari
greatli
la
averag
goz
rang
repres
total
fat
rang
linolen
acid
lna
docosahexaeno
acid
dha
averag
goz
rang
goz
rang
respect
base
composit
data
ml
bm
sampl
would
provid
averag
g
la
meet
ai
sampl
would
contain
less
lowest
provid
g
la
ml
bm
take
account
fat
malabsorpt
bm
sampl
would
abl
provid
suffici
la
infant
cf
matern
la
intak
averag
gday
mother
la
intak
ai
lactat
women
gday
ratio
dietari
la
lna
indic
typic
american
diet
la
content
bm
total
fat
posit
correl
matern
la
total
polyunsatur
fa
total
fat
conclus
preliminari
analysi
indic
breast
milk
sampl
appear
contain
insuffici
linol
acid
cf
infant
futur
analysi
assess
associ
breast
milk
efa
infant
efa
statu
may
help
explain
efa
defici
infant
cf
la
content
breast
milk
matern
diet
significantli
correl
thu
increas
supplement
matern
diet
fund
background
anemia
complic
chronic
diseas
preval
clinic
implic
defin
adult
cf
normal
rang
hemoglobin
use
clinic
laboratori
account
demograph
clinic
attribut
cf
patient
could
influenc
hemoglobin
level
object
studi
determin
preval
cfrelat
anemia
use
data
us
cf
foundat
patient
registri
cffpr
elucid
associ
anemia
comorbid
identifi
variat
mean
hemoglobin
concentr
report
us
cf
care
program
method
defin
cfrelat
anemia
race
gender
cffpr
registr
year
age
hemoglobin
valu
fifth
percentil
mean
valu
adult
scrippskais
nation
health
nutrit
examin
survey
nhane
databas
model
likelihood
anem
adult
cf
specif
clinic
attribut
compar
anem
character
programspecif
variat
mean
hemoglobin
read
result
adult
registr
hemoglobin
measur
least
white
male
white
femal
black
male
black
femal
hispan
male
hispan
femal
anem
lower
hemoglobin
valu
associ
lower
fev
mean
hemoglobin
concentr
across
cf
care
program
gmdl
figur
white
male
anemia
least
twice
like
white
male
without
anemia
cirrhosi
fev
predict
hospit
treat
prednison
compar
white
male
without
anemia
anemia
time
like
bmi
kgm
time
like
massiv
hemoptysi
time
like
pulmonari
exacerb
pex
time
like
cfrelat
diabet
cfrd
white
cf
femal
anemia
least
twice
like
white
cf
femal
without
anemia
use
prednison
cirrhosi
clinic
correl
appar
black
hispan
without
anemia
conclus
anemia
preval
complic
adult
cf
associ
specif
patient
attribut
variat
hemoglobin
concentr
among
us
cf
care
program
requir
explan
secondari
uneth
natur
withhold
necessari
treatment
data
deriv
pediatr
popul
demonstr
posit
impact
bodi
mass
index
bmi
potenti
pulmonari
function
test
studi
examin
demograph
age
adult
popul
need
longterm
enter
tube
placement
indic
invas
placement
gastrostomytub
gtube
jejunostomytub
jtube
gastrojejunostomytub
gjtube
standard
variabl
outcom
purpos
assess
incid
gtube
jtube
gjtube
placement
adult
cf
patient
assess
patient
demograph
outcom
mortal
data
specif
cohort
materi
method
retrospect
observ
singl
adult
cf
center
experi
inclus
criteria
conclus
signific
proport
patient
requir
perman
enter
feed
tube
cohort
major
mild
increas
bmi
month
placement
patient
sever
obstruct
defect
prior
placement
minim
improv
month
insert
limit
includ
small
sampl
size
minim
longitudin
data
background
studi
report
decreas
cystic
fibrosi
cf
pulmonari
exacerb
hospit
rate
decreas
gastrointestin
gi
symptom
inflammatori
marker
improv
qualiti
life
probiot
use
howev
littl
publish
clinic
use
probiot
cf
prescript
track
nation
registri
note
anecdot
patient
take
probiot
without
supervis
much
known
patient
belief
around
efficaci
side
effect
agent
object
aim
explor
rational
probiot
usenonus
look
associ
probiot
use
patient
characterist
care
pattern
health
statu
within
northern
new
england
cf
consortium
nnecfc
method
survey
popul
cf
patient
center
within
nnecfc
survey
complet
regularli
schedul
outpati
visit
inpati
stay
via
email
use
webbas
questionnair
redcap
assess
probiot
use
rational
use
probiot
selfreport
gi
symptom
queri
cf
registri
demograph
socioeconom
gi
pulmonari
statu
particip
along
responderspecif
medic
therapi
microbiolog
exacerb
frequenc
differ
subgroup
analyz
ttest
mannwhitney
u
chisquar
test
appropri
studi
approv
institut
irb
result
subject
complet
survey
frequenc
report
probiot
use
vari
significantli
center
p
among
take
probiot
report
daili
use
remaind
report
use
antibiot
among
patient
use
probiot
note
lack
knowledg
product
report
cf
team
recommend
differ
socioeconom
statu
pulmonari
function
microbiolog
colon
antibiot
use
exacerb
rate
probiot
use
group
patient
diarrhea
antibiot
sought
urgent
care
gi
issu
take
supplement
tube
feed
significantli
like
report
probiot
use
p
respect
conclus
cf
popul
lack
knowledg
probiot
receiv
recommend
use
cf
care
team
major
reason
take
take
probiot
significantli
like
report
gi
symptom
associ
medic
care
due
crosssect
design
studi
impli
causal
unlik
prior
smaller
studi
detect
differ
pulmonari
function
rate
exacerb
nutrit
statu
probiot
use
subgroup
likewis
relationship
probiot
use
socioeconom
statu
studi
need
confirm
evalu
relationship
compar
practic
center
background
cystic
fibrosi
cf
common
autosom
recess
diseas
caucasian
recent
consensu
statement
cystic
fibrosi
foundat
emphas
adequ
nutrit
vital
element
preserv
lung
function
surviv
patient
cf
malnutrit
common
problem
patient
cf
result
inabl
meet
nutrit
demand
improv
nutrit
statu
patient
cf
shown
posit
effect
pulmonari
function
respiratori
statu
bodi
composit
surviv
studi
investig
outcom
efficaci
nutrit
supplement
via
percutan
endoscop
gastrostomi
peg
tube
feed
method
obtain
irb
approv
perform
retrospect
chart
review
electron
medic
record
john
hopkin
children
hospit
cf
center
studi
extens
ongo
qualiti
improv
project
start
improv
maintain
bmi
patient
cf
percentil
follow
cf
foundat
guidelin
recommend
reveal
malnourish
patient
cf
age
year
younger
receiv
dietari
supplement
via
peg
tube
nutrit
failur
data
analyz
see
improv
percent
predict
compar
year
prior
year
result
patient
cystic
fibrosi
receiv
supplement
peg
tube
nutrit
failur
male
caucasian
observ
signific
chang
percent
predict
compar
prior
peg
tube
placement
oneyear
followup
howev
data
obtain
immedi
prior
peg
tube
placement
one
year
postop
show
signific
rise
bmi
percentil
conclus
data
suggest
peg
placement
nutrit
rehabilit
significantli
improv
bmi
oneyear
followup
p
percent
predict
p
show
chang
percent
predict
may
affect
confound
factor
includ
advanc
lung
diseas
longer
followup
may
need
observ
signific
chang
lung
function
background
aim
fecal
loss
bile
acid
ba
compens
de
novo
synthesi
regul
fine
tune
homeostat
control
mechan
maintain
near
constant
bodi
ba
pool
one
key
element
direct
activ
nuclear
receptor
fxr
ileal
epitheli
cell
reclaim
ba
activ
ba
uptak
asbt
apic
sodiumdepend
ba
transport
trigger
product
releas
hormon
mice
repress
hepat
express
ratelimit
enzym
cholic
acid
ca
synthesi
cystic
fibrosi
cf
associ
enhanc
fecal
ba
excret
concomit
increas
de
novo
synthesi
hypothes
fxr
signal
attenu
cf
intestin
method
intestin
hepat
express
fxrregul
gene
assess
cftr
null
mice
control
litterm
absenc
presenc
ca
result
cf
ileum
found
strongli
reduc
express
despit
normal
ileal
ba
content
normal
asbt
protein
transcript
level
ex
vivo
cadepend
induct
similar
cf
control
ileum
vivo
dietari
ca
supplement
fail
restor
induct
cf
mice
attenu
intestin
signal
associ
blunt
hepat
trophic
respons
impair
repress
hepat
express
antibiot
treatment
previous
shown
reduc
fecal
ba
excret
cf
mice
wouthuyzenbakk
et
al
pediatr
re
fulli
restor
express
cf
ileum
conclus
cf
mice
quantit
andor
qualit
chang
gut
microbiom
lead
loss
fxrdepend
feedback
control
hepat
ba
synthesi
acknowledg
support
dutch
cf
foundat
ncf
part
hitcf
program
well
establish
cf
mice
exhibit
reduc
weight
reduc
fat
accumul
compar
wildtyp
wt
control
previous
demonstr
cf
epitheli
cell
tissu
exhibit
reduc
microtubul
acetyl
correct
inhibit
cytosol
histon
deactylas
famili
member
gener
mice
lack
express
determin
cf
phenotyp
could
attribut
microtubul
alter
vivo
one
phenotyp
correct
cftr
mice
ablat
restor
fat
accumul
associ
increas
weight
gain
hypothesi
studi
cftr
dysfunct
adipocyt
impair
adipocyt
differenti
modul
microtubul
stabil
test
hypothesi
util
cf
preadipocyt
develop
drumm
laboratori
cftr
gene
disrupt
system
along
wt
control
consist
epitheli
cell
cf
cell
exhibit
fold
reduct
acetyl
tubulin
level
compar
control
also
determin
preadipocyt
marker
factor
express
fold
greater
cf
cell
compar
wt
cell
increas
express
like
signific
sinc
demonstr
elev
express
prevent
preadipocyt
differenti
adipocyt
quantit
rtpcr
also
show
mrna
level
increas
cf
cell
fold
wt
level
sinc
mice
abl
store
fat
examin
whether
inhibit
could
impact
express
inhibit
tubastatin
inhibit
express
cf
cell
dosedepend
manner
convers
destabil
microtubul
nocodazol
wt
cell
result
dosedepend
increas
express
data
suggest
microtubul
stabil
via
inhibit
improv
preadipocyt
differenti
allow
fat
deposit
vivo
verifi
find
primari
tissu
epididym
fat
wt
mice
examin
express
consist
cell
model
express
significantli
increas
mice
fat
compar
wt
mice
restor
wt
level
mice
data
show
inhibit
restor
level
wt
level
primari
cf
fat
tissu
cf
preadipocyt
cell
model
remain
determin
elev
express
cf
respons
reduc
fat
accumul
cf
mice
simpli
marker
differenti
signal
sensit
inhibit
introduct
liver
diseas
second
lead
caus
mortal
cf
contribut
signific
morbid
mani
patient
due
associ
liver
fibrosi
cirrhosi
current
cf
foundat
guidelin
cf
liver
diseas
cfld
screen
includ
annual
serum
lab
lft
ggt
cbc
coag
workup
indic
astalt
normal
evid
nutritionindepend
coagulopathi
thrombocytopenia
transaminas
good
indic
noncf
liver
diseas
correl
well
cfld
thu
current
screen
primarili
identifi
endstag
liver
cirrhosi
synthet
function
compromis
portal
hypertens
develop
suspect
current
guidelin
ineffect
detect
cfld
earli
stage
fibrosi
identifi
earli
liver
fibrosi
great
import
develop
intervent
aim
halt
cfld
progress
endstag
liver
diseas
aim
assembl
multimod
practic
screen
protocol
implement
cf
center
identifi
earli
cfld
method
literatur
review
perform
identifi
biomark
serum
lab
imag
modal
shown
accuraci
identifi
liver
fibrosi
cf
result
chang
pediatr
cf
center
cfld
screen
protocol
elev
astalt
ggt
ul
two
separ
occas
result
referr
pediatr
gastroenterolog
hepatolog
detail
evalu
liver
function
perform
apri
serum
indic
liver
fibrosi
portal
hypertens
respect
calcul
interpret
base
cfspecif
cutoff
ultrasound
us
doppler
acoust
radiat
forc
impuls
arfi
ad
patient
yearsold
pancreat
insuffici
patient
persist
lab
abnorm
fibrosi
us
magnet
reson
elastographi
imag
mri
perform
determin
fibrosi
stage
result
modifi
screen
protocol
wellaccept
famili
cf
center
staff
prompt
increas
discuss
cfld
increas
consult
gi
increas
scrutini
lab
help
identifi
individu
precirrhot
cfld
mani
would
miss
current
cf
foundat
guidelin
us
arfi
provid
valuabl
inform
contour
liver
potenti
presenc
regen
nodul
fibrosi
went
mri
new
diagnosi
cfld
elastographi
consist
fibrosi
conclus
cfld
major
caus
morbid
mortal
cf
part
inabl
detect
liver
dysfunct
prior
endstag
liver
diseas
preliminari
experi
demonstr
util
valid
hepatolog
tool
help
advanc
abil
detect
earli
stage
liver
fibrosi
becom
import
optim
nutrit
correctli
dose
test
efficaci
correctorspotenti
prevent
potenti
lethal
impact
endstag
liver
diseas
object
elimin
summer
declin
nutrit
statu
children
cf
intervent
spring
share
anticipatori
guidanc
problem
show
patientspecif
bmi
graph
help
facilit
discuss
famili
regard
barrier
adequ
summer
weight
gain
spring
ad
intervent
includ
onlin
track
orchestra
app
frequent
phone
call
increas
frequenc
clinic
visit
patient
meet
cf
nutrit
goal
measur
primari
outcom
measur
percentag
patient
cf
center
age
year
bmi
percentil
th
year
compar
aprilmay
data
augustseptemb
data
captur
center
level
chang
summer
month
result
percentag
patient
age
year
bmi
percentil
th
declin
averag
rel
declin
aprilmay
augustseptemb
averag
n
patient
year
averag
patient
summer
bmi
declin
percentil
cff
goal
nutrit
statu
aprilmay
augustseptemb
trend
chang
percentag
patient
bmi
percentil
declin
rel
declin
aprilmay
augustseptemb
bundl
intervent
percentag
patient
age
year
bmi
percentil
improv
chang
discuss
cf
center
bmi
statu
declin
summer
month
year
trend
improv
anticipatori
guidanc
qualiti
improv
bundl
track
frequent
phone
contact
frequent
clinic
visit
result
signific
improv
summer
bmi
outcom
mcdonald
cm
dietitian
primari
children
hospit
salt
lake
citi
ut
usa
enter
feed
often
employ
supplement
oral
intak
improv
nutrit
statu
child
adult
cf
howev
scarc
data
exist
inform
manag
feed
gastrostomi
placement
current
practic
initi
enter
feed
cf
patient
age
year
older
describ
two
onlin
survey
conduct
octob
anonym
respond
provid
conveni
sampl
cf
health
care
profession
particip
cfnutrit
listserv
dartmouthedu
first
survey
receiv
respons
subsequ
survey
repres
pediatr
adult
combin
cf
center
respond
follow
inpati
outpati
work
cf
center
within
usa
respond
work
larg
cf
center
patient
medium
center
patient
cf
center
fewer
patient
report
percentag
enter
fed
patient
individu
cf
center
vari
wide
rang
mean
median
respond
indic
standard
polymer
ageappropri
formula
commonli
use
initi
enter
feed
semielement
ageappropri
product
introduc
less
often
homeprepar
blender
formula
rare
use
initi
feed
gastrostomi
placement
major
respond
report
initi
enter
feed
concentr
formula
calori
ml
enter
feed
cf
patient
gener
provid
total
estim
calori
nutrient
need
overnight
continu
drip
feed
daytim
high
calori
high
nutrient
densiti
oral
diet
report
cf
patient
receiv
enter
feed
regardless
formula
type
respond
recommend
use
pancreat
enzym
replac
therapi
pert
either
bolu
continu
drip
feed
use
pert
semielement
formula
use
pert
continu
fed
formula
pert
dose
calcul
either
meal
dose
per
gram
fat
formula
administ
pert
enter
feed
respond
recommend
dose
pert
prior
begin
enter
infus
report
dose
pert
conclus
feed
approxim
half
respond
recommend
pert
continu
enter
feed
suggest
pert
administr
feed
mix
formula
recommend
pert
dose
patient
wake
night
crush
nonentericco
enzym
dissolvingcrush
enter
coat
pancreat
enzym
addit
formula
report
mani
respond
report
combin
pert
dose
method
percentag
could
calcul
gener
individu
patient
medicalsurg
histori
anticip
toler
primari
consider
select
enter
standard
port
cf
data
collect
form
use
determin
exposur
specif
pert
patient
suspect
fc
ask
give
inform
consent
collect
addit
data
independ
adjud
committe
confirm
diagnosi
result
end
enrol
period
juli
patient
cf
compris
base
studi
popul
total
time
studi
personyear
py
mean
sd
age
studi
entri
year
median
year
rang
year
patient
male
white
total
patient
base
popul
receiv
pert
sometim
studi
entri
first
year
trial
py
mean
daili
dose
pert
lipas
unit
median
lipas
unit
percentil
lipas
unit
eight
patient
expos
pert
suspect
fc
case
fc
confirm
adjud
committe
confirm
indetermin
incid
rate
confirm
fc
py
ci
patient
cf
current
receiv
pert
incid
rate
confirm
indetermin
fc
py
ci
popul
suspect
confirm
case
fc
among
patient
expos
pert
first
year
studi
conclus
rigor
prospect
studi
larg
welldefin
popul
includ
patient
cf
unit
state
demonstr
low
incid
confirm
fc
patient
cf
receiv
pert
dose
observ
interim
analysi
subsequ
interim
analys
everi
year
continu
defin
incid
fc
assess
potenti
risk
factor
occurr
acknowledg
allergan
janssen
abbvi
fund
research
allergan
abbvi
contribut
design
involv
collect
analysi
interpret
data
write
review
approv
public
author
contribut
maintain
control
final
content
recogn
daniel
fife
gerhard
leitz
janssen
valuabl
input
studi
design
interpret
michael
j
theisen
phd
natalia
zhukovskaya
phd
complet
public
solut
llc
provid
medic
write
support
fund
abbvi
manifest
cf
gastrointestin
tract
diseas
frequent
begin
infanc
pancreat
exocrin
insuffici
pi
result
profound
nutrient
malabsorpt
malnutrit
lead
growth
failur
even
intestin
obstruct
despit
aggress
earli
nutrit
intervent
pancreat
enzym
replac
therapi
earli
growth
failur
remain
common
among
infant
cf
suggest
pi
sole
contributor
growth
nutrit
failur
identif
growth
nutrit
determin
children
cf
therefor
remain
key
research
goal
cf
care
grow
bodi
evid
support
role
gut
microbiota
nutrient
harvest
metabol
microbiota
often
alter
varieti
diseas
state
therefor
infant
gi
tract
microb
may
import
determin
cf
nutrit
outcom
recent
show
infant
children
cf
gi
microbiota
differ
markedli
children
without
cf
dysbiosi
correl
fecal
measur
fat
malabsorpt
inflamm
support
role
earli
cf
growth
gi
function
method
hypothes
intestin
microbiom
among
children
cf
correl
sever
malabsorpt
intestin
inflamm
gastrointestin
sign
symptom
vitamin
miner
defici
growth
test
hypothes
defin
fecal
microbiom
infant
cf
particip
multicent
studi
infant
nutrit
babi
observ
nutrit
studi
bonu
use
highthroughput
metagenom
sequenc
resourc
defin
fecal
microbiom
compos
microbiota
speci
microb
present
metagenom
microbi
gene
present
reflect
metabol
capac
microbiota
four
stool
sampl
per
subject
first
year
life
determin
relationship
fecal
microbiom
evolut
year
studi
nutrit
biochem
clinic
paramet
includ
weight
height
age
zscore
rate
growth
among
subject
serum
vitamin
level
fecal
nutrient
metabolit
content
gi
symptom
measur
intestin
inflamm
microbiom
analysi
use
illumina
hiseq
dna
sequenc
platform
coupl
combin
bioinformat
analyt
method
statist
analysi
identifi
correl
metabolom
clinic
measur
result
data
studi
gener
nacfc
later
octob
conclus
goal
defin
impact
eventu
role
infant
cf
gi
microbiom
growth
nutrit
hope
identifi
intervent
improv
earli
growth
thu
longterm
outcom
cf
fund
nih
object
pauciti
research
exist
longitudin
trend
bone
miner
densiti
bmd
adult
cf
patient
current
standard
care
guidelin
canada
recommend
dualenergi
xray
absorptiometri
dxa
scan
perform
everi
five
year
averag
adult
cf
patient
frequent
scan
recommend
indic
osteopenia
osteoporosi
tradit
method
analyz
longitudin
data
mix
model
oper
assumpt
singl
overal
popul
trajectori
presenc
absenc
certain
variabl
may
add
subtract
minor
differ
either
popul
baselin
slope
time
studi
aim
use
novel
statist
approach
cluster
patient
distinct
group
base
trend
bone
densiti
time
method
femor
neck
bmd
bmdfn
gcm
demograph
clinic
data
collect
patient
least
one
dxa
scan
toronto
adult
cf
clinic
st
michael
hospit
data
restrict
prelung
transplant
dxa
scan
age
peak
bone
mass
reach
prior
menopaus
latent
class
mix
model
approach
use
classifi
patient
distinct
class
base
common
trend
bone
densiti
life
cours
optim
number
class
function
form
chosen
minim
bayesian
inform
criterion
bic
result
patient
met
criteria
median
age
dxa
scan
year
rang
patient
classifi
two
distinct
class
base
declin
bmdfn
time
class
consist
patient
indic
major
patient
show
slight
declin
bmdfn
life
cours
decreas
gcm
per
year
second
class
compris
patient
made
patient
whose
bmdfn
declin
much
faster
rate
gcm
per
year
decreas
much
dramat
found
use
standard
mix
model
approach
suggest
steepest
declin
gcm
per
year
six
patient
class
either
went
develop
osteoporosi
femor
neck
compar
class
analysi
perform
determin
clinic
demograph
characterist
defin
group
membership
conclus
convent
statist
techniqu
longitudin
trend
may
mask
fact
patient
follow
trajectori
identifi
two
distinct
group
patient
one
show
slow
declin
bone
loss
time
stringent
screen
like
benefici
techniqu
potenti
identifi
differ
trend
longitudin
outcom
background
gut
microbiota
refer
trillion
microorgan
human
gi
tract
play
central
role
health
includ
energi
macronutri
metabol
nutrient
captur
immun
function
emerg
research
suggest
gut
microbiota
may
disrupt
individu
cf
cftrknockout
mice
display
significantli
less
bacteri
rich
divers
paramet
usual
associ
healthi
gut
microbiota
compar
wt
anim
vitamin
defici
common
comorbid
cf
patient
may
influenc
composit
gut
microbiota
vitamin
defici
increas
sever
intestin
inflamm
mous
colon
revers
vitamin
supplement
similarli
human
high
dose
vitamin
supplement
result
mark
reduct
typic
opportunist
pathogen
increas
gut
microbiota
rich
whether
vitamin
affect
gut
microbiota
cf
known
object
assess
effect
highdos
vitamin
bolu
regimen
composit
gut
microbiota
adult
patient
stabl
cf
lung
diseas
vitamin
insuffici
plasma
oh
ngml
studi
design
doubleblind
random
placebocontrol
intervent
pilot
studi
adult
cf
patient
cf
year
age
toler
oral
medic
without
contraind
high
dose
vitamin
meet
inclus
criteria
major
exclus
criteria
hypercalcem
disord
use
system
antibiot
last
week
use
immunosuppress
recruit
patient
classifi
two
group
plasma
oh
level
ngml
plasma
level
ngml
subject
vitamin
insuffici
block
random
either
receiv
placebo
oral
vitamin
weekli
month
baselin
stool
sampl
obtain
subject
dna
isol
gut
microbiota
analyz
use
primer
hypervari
region
rrna
repeat
oh
level
along
stool
sampl
collect
month
initi
intervent
entir
cohort
endpoint
primari
outcom
measur
microbiota
composit
rich
supplement
high
dose
vitamin
use
unifrac
metric
ecolog
divers
measur
shannon
index
secondari
outcom
measur
lung
function
measur
number
pulmonari
exacerb
baselin
month
supplement
summari
determin
first
time
cf
patient
whether
highdos
vitamin
administr
favor
modul
gut
microbiota
treatment
period
also
relat
chang
gut
microbiota
chang
lung
function
time
betacel
dysfunct
cystic
fibrosi
cf
wide
accept
caus
cystic
fibrosisrel
diabet
hypothes
cftr
express
betacel
play
intrins
role
insulin
secret
support
hypothesi
larg
base
find
cftr
inhibitor
impair
insulin
secret
chlorid
transport
betacel
andor
isol
islet
also
shown
isol
islet
newborn
cf
ferret
impair
glucosestimul
insulin
secret
gsi
find
could
taken
support
intrins
role
cftr
islet
insulin
secret
sought
investig
mechan
alter
insulin
secret
cf
ferret
islet
defin
cell
type
within
pancrea
islet
express
cftr
use
singl
molecul
fluoresc
situ
hybrid
smfish
local
cftr
rna
express
ferret
human
pancrea
andor
isol
islet
found
evid
cftr
express
endocrin
cell
rather
high
level
cftr
rna
express
within
pancreat
ductal
cell
isol
islet
intact
pancrea
islet
neonat
cf
ferret
demonstr
significantli
blunt
first
p
second
p
phase
insulin
secret
compar
noncf
control
similarli
knockdown
cftr
mrna
wildtyp
adult
ferret
human
islet
use
recombin
adenoviru
express
cftrshrna
demonstr
impair
gsi
compar
control
shrna
importantli
other
observ
reduc
insulin
secret
islet
find
compound
also
significantli
reduc
insulin
secret
glucosestimul
ca
flux
cftrko
ferret
islet
question
specif
inhibitorbas
approach
investig
mechan
alter
insulin
respons
cf
islet
evalu
transcript
involv
betacel
function
matur
quantitativerna
analysi
demonstr
significantli
lower
insulin
glucagon
transcript
cftrko
islet
unchang
level
glucosesens
rna
gck
similarli
cftr
knockdown
wt
ferret
islet
reduc
insulin
rna
express
rna
involv
transcript
regul
betacel
matur
prolifer
increas
cftrko
islet
mafb
express
remain
unchang
interestingli
express
exocrin
duct
marker
marker
stellat
cell
activ
inflamm
alphasma
significantli
increas
cftrko
islet
consist
observ
newborn
cf
pancreata
demonstr
higher
level
activ
stellat
cell
desminalphasma
posit
compar
noncf
result
suggest
cftr
impact
betacel
function
via
paracrin
mechan
isletassoci
duct
andor
stellat
cell
elucid
signal
pathway
cftr
mutant
ductal
cell
affect
islet
function
requir
investig
introduct
cystic
fibrosisrel
diabet
cfrd
common
complic
cf
major
risk
factor
cfassoci
morbid
earli
mortal
tradit
hypothesi
cfrd
caus
progress
destruct
exocrin
pancrea
lead
collater
damag
pancreat
islet
howev
littl
direct
evid
collater
damag
hypothesi
recent
studi
show
cf
patient
pancreassuffici
enhanc
acut
insulin
respons
arginin
stimul
suggest
insulin
secretori
capac
pancreassuffici
patient
enhanc
rather
impair
data
support
altern
hypothesi
cftr
may
intrins
role
regul
insulin
secret
explor
mechan
dysregul
insulin
secret
cf
creat
induc
specif
cftr
knockout
mous
transfect
system
overexpress
cftr
method
pancreat
islet
isol
control
cftr
knockout
mice
evalu
respons
glucos
stimul
islet
cytosol
calcium
ca
respons
cftr
express
determin
singlecel
rna
sequenc
dispers
islet
cell
cftr
function
investig
overexpress
cftr
dispers
islet
cell
use
lentivir
transfect
vector
result
use
singl
rna
sequenc
analys
found
cftr
express
approxim
detect
remaind
function
cftrposit
cell
examin
measur
singl
islet
cell
ca
sensit
cftr
inh
elev
basal
ca
inhibit
cftr
cell
delay
respons
glucos
stimul
fail
return
baselin
remov
glucos
mice
knockout
cftr
normal
mass
islet
isol
mice
exhibit
elev
ca
presenc
mm
glucos
suggest
increas
sensit
glucos
stimul
islet
perifus
show
cftrislet
increas
sensit
glucosestimul
insulin
secret
delay
turnoff
insulin
secret
glucos
withdraw
contrast
wildtyp
mous
islet
cftrislet
fail
show
normal
transient
increas
ca
respons
thapsigargin
suggest
alter
er
calcium
handl
overexpress
wildtyp
cftr
show
impair
respons
glucos
stimul
inhibit
overexpress
cftr
cftr
inh
restor
glucos
respons
summari
cftr
express
subpopul
knockout
cftr
result
elev
basal
ca
show
increas
sensit
glucos
stimul
delay
turnoff
insulin
secret
data
strongli
suggest
cftr
function
cell
autonom
regul
function
like
process
repolar
studi
support
cff
background
cystic
fibrosisrel
diabet
cfrd
associ
wors
cystic
fibrosi
cf
outcom
impact
cftr
potenti
ivacaftor
upon
insulin
secret
receiv
limit
attent
improv
glucos
toler
appreci
object
pilot
studi
aim
understand
impact
ivacaftor
therapi
upon
insulin
secret
incretin
secret
glucos
toler
pancreat
exocrin
suffici
ps
insuffici
pi
individu
cf
designmethod
oral
glucos
toler
test
ogtt
mix
meal
toler
test
mmtt
glucosepotenti
arginineinduc
insulin
secret
test
gpa
perform
prior
week
initi
ivacaftor
treatment
compar
cf
particip
age
usual
state
health
least
one
cftr
gate
conduct
mutat
first
phase
insulin
secret
quantit
acut
cpeptid
respons
arginin
iv
min
acr
arg
cpeptid
mean
min
mean
min
prior
glucos
clamp
glucosepotenti
secret
acr
pot
defin
acut
cpeptid
respons
mgdl
plasma
glucos
pg
secretori
capac
acr
max
defin
respons
mgdl
glucos
sensit
glucos
character
glucos
concentr
halfmaxim
insulin
secret
achiev
max
air
pot
air
arg
pg
pg
fast
insulin
sensit
mi
determin
divid
mean
glucos
infus
rate
requir
mgdl
glucos
clamp
mean
prestimulu
insulin
level
min
glucos
infus
area
curv
auc
first
min
mmtt
calcul
glucos
cpeptid
glucagon
like
glp
gastric
inhibitori
peptid
gip
result
preliminari
data
avail
subject
impair
glucos
toler
median
minmax
age
bmiz
predict
glucos
toler
normal
igt
subject
follow
ivacaftor
therapi
first
phase
insulin
secret
acr
arg
median
minmax
conclus
insulin
secret
improv
follow
four
month
ivacaftor
therapi
rel
young
group
pi
ps
particip
larg
normal
glucos
toler
incretin
secret
remain
unchang
improv
secretori
capac
suggest
ivacaftor
either
directli
affect
function
augment
insulin
secret
indirectli
improv
cf
outcom
addit
studi
need
delin
direct
indirect
role
cftr
function
support
grant
cfft
method
perform
retrospect
chart
review
patient
age
year
underw
lung
transplant
bch
jan
jan
part
routin
clinic
care
patient
undergo
dxa
scan
time
transplant
evalu
annual
transplant
result
dxa
scan
includ
recent
obtain
patient
along
clinic
data
time
scan
includ
anthropometr
measur
diagnos
medic
pertin
lab
result
fractur
confirm
xray
linear
regress
use
identifi
predictor
low
bmd
time
transplant
evalu
repeat
measur
analys
use
compar
bmd
zscore
chang
time
result
fiftyon
patient
studi
age
transplant
femal
cf
time
lung
transplant
evalu
bmd
zscore
patient
zscore
bmd
zscore
time
transplant
evalu
correl
height
sd
p
nine
patient
sustain
fractur
prior
transplant
spine
hip
extrem
bmd
zscore
declin
first
year
treatment
gradual
return
nearbaselin
third
posttranspl
year
zscore
normal
figur
pattern
signific
total
hip
margin
signific
spine
height
zscore
oh
number
reject
episod
significantli
affect
bmd
zscore
chang
multivari
adjust
covari
strengthen
pattern
hip
spine
fifteen
patient
suffer
fractur
posttranspl
period
spine
hip
rib
extrem
occur
transplant
conclus
pediatr
patient
high
preval
low
bmd
fractur
time
lung
transplant
evalu
bmd
zscore
declin
even
year
transplant
gradual
return
pretranspl
level
third
posttranspl
year
bmd
normal
transplant
fractur
year
transplant
common
occur
site
associ
signific
morbid
find
support
increas
effort
optim
bone
health
pediatr
lung
transplant
patient
mean
bmd
se
lung
transplant
canada
univ
toronto
toronto
canada
pediatr
case
western
reserv
univ
cleveland
oh
usa
pediatr
genet
john
hopkin
univ
baltimor
md
usa
pediatr
endocrinolog
john
hopkin
univ
baltimor
md
usa
background
cfrelat
diabet
cfrd
affect
adolesc
adult
year
old
sever
cftr
mutat
confer
earli
onset
pancreat
insuffici
pi
howev
risk
cfrd
variabl
depend
mani
factor
includ
cfrd
risk
gene
blackman
sm
et
al
diabet
cfrd
occur
frequent
individu
evid
liver
dysfunct
affect
peopl
cf
also
progress
cirrhosi
portal
hypertens
earli
life
median
age
sever
cfliver
diseas
cfld
sometim
requir
liver
transplant
object
compar
rate
risk
factor
cfrd
two
largest
cohort
date
cf
individu
sever
cfld
vs
liver
diseas
cfnold
design
individu
sever
cfld
recruit
genet
modifi
studi
sever
cf
liver
diseas
cfnold
individu
recruit
north
american
cf
gene
modifi
consortium
cftr
genotyp
confer
sever
exocrin
pi
cfrd
risk
genotyp
obtain
consortium
outcom
defin
use
clinic
record
censor
organ
transplant
except
note
result
sever
cfld
group
younger
mean
age
vs
like
male
vs
like
cfrd
vs
earlier
age
median
diagnosi
age
vs
compar
cfnold
use
cox
proport
hazard
regress
account
age
differ
cfld
strong
risk
factor
cfrd
hazard
ratio
ci
cfld
greater
risk
factor
earli
onset
cfrd
diagnos
age
especi
cfrd
occur
liver
transplant
exclud
cfld
cohort
cfrd
independ
correl
femal
sex
earlier
diagnosi
cfld
per
year
risk
score
top
variant
publish
cfrd
modifi
loci
associ
cfrd
genotyp
cohort
cfnold
per
allel
cfld
per
allel
interact
cfld
cfld
associ
snp
cfrd
genet
risk
score
conclus
diabet
occur
earlier
greater
proport
peopl
cfld
especi
cfrd
risk
gene
variant
data
consist
model
sever
cfld
predispos
cfrd
via
pathway
involv
cfrd
risk
gene
includ
analysi
cf
foundat
recommend
annual
diabet
screen
start
age
recommend
screen
start
cfld
diagnosi
age
support
cff
nih
cystic
fibrosi
transmembran
conduct
regul
cftr
anion
channel
ductal
epithelium
pancrea
play
critic
role
transport
bicarbon
lumen
duct
bicarbon
anion
alkalin
ductal
lumen
turn
inactiv
pancreat
digest
enzym
secret
pancreat
acinar
cell
loss
function
cftr
cystic
fibrosi
cf
caus
ph
imbal
lumen
persist
acid
environ
thought
prematur
activ
digest
enzym
lead
inflamm
fibrosi
loss
betacel
function
develop
cftrko
ferret
model
develop
similar
pancreat
patholog
seen
human
cf
patient
use
cf
ferret
model
sought
understand
earliest
phase
cf
pancreat
exocrin
dysfunct
lead
endocrin
pancrea
abnorm
influenc
insulin
secret
hypothes
neuroendocrin
regul
phase
abnorm
due
inflamm
alter
product
certain
neuropeptid
neg
impact
pancreat
endocrin
function
previous
shown
newborn
cf
ferret
impair
glucos
toler
poorli
regul
insulin
secret
impair
first
phase
insulin
accentu
second
phase
insulin
secret
despit
normal
islet
cell
mass
j
clin
invest
isol
islet
cf
newborn
ferret
similarli
dysregul
insulin
secret
hypothes
proinflammatori
environ
cf
pancrea
impair
function
islet
screen
plasma
urin
pancrea
neuropeptid
associ
inflamm
found
calcitonin
generel
peptid
cgrp
bradykinin
bk
present
elev
level
newborn
cf
ferret
therefor
sought
determin
cgrp
bk
impair
islet
hormon
regul
mechan
action
studi
action
bk
islet
first
local
bradykinin
receptor
endocrin
hormon
secret
cell
islet
found
local
alphacel
human
ferret
mice
rat
local
betacel
interestingli
older
cf
ferret
local
betacel
alphacel
sinc
cf
rat
mice
lack
pancreat
exocrin
endocrin
diseas
observ
cf
human
ferret
sought
understand
bk
might
differenti
affect
insulin
glucagon
secret
ferret
mice
low
glucos
condit
bk
treatment
reduc
glucagon
secret
ferret
islet
p
decreas
insulin
secret
mous
islet
p
contrast
high
glucos
condit
bk
enhanc
secretori
index
glucagon
p
reduc
secretori
index
insulin
p
ferret
islet
studi
dissect
effect
cgrp
islet
hormon
secret
underway
preliminari
studi
suggest
cgrp
enhanc
insulin
secret
ferret
islet
low
glucos
condit
hypothes
neuropeptid
influenc
glucos
sensit
islet
may
contribut
poorli
regul
insulin
respons
observ
earli
cf
pancreat
diseas
introduct
cystic
fibrosi
cf
patient
risk
kidney
injuri
even
undergo
lung
transplant
prolong
exposur
aminoglycosid
complic
diabet
mellitu
usual
equat
estim
glomerular
filtrat
rate
gfr
cockroft
mdrd
formula
adapt
cf
popul
due
patient
low
bodi
weight
bering
pm
et
al
j
cyst
fibro
aim
studi
measur
precis
gfr
cf
adult
patient
lung
transplant
method
iohexol
inulin
clearanc
realiz
adult
cf
patient
enter
lung
transplant
wait
list
patient
consid
clinician
high
risk
renal
diseas
patient
treat
aminoglycosid
time
gfr
measur
bmi
histori
diabet
mellitu
high
blood
pressur
record
exposur
intraven
aminoglycosid
within
year
gfr
measur
calcul
urin
sampl
collect
check
proteinuria
albuminuria
result
popul
predominantli
male
mean
age
gfr
measur
year
old
rang
mean
bmi
rang
one
patient
histori
high
blood
pressur
patient
diabet
patient
albuminuria
none
proteinuria
mean
day
exposur
iv
aminoglycosid
therapi
within
year
gfr
evalu
day
rang
day
tobramycin
mostus
aminoglycosid
mean
dose
gfr
measur
use
iohexol
patient
inulin
use
remain
patient
mean
measur
gfr
patient
measur
gfr
two
patient
gfr
estim
use
ckd
epi
unabl
detect
moder
declin
kidney
function
estim
gfr
conclus
despit
prolong
exposur
high
dose
aminoglycosid
associ
high
preval
diabet
mellitu
major
declin
gfr
observ
cohort
data
necessari
determin
ckd
epi
equat
adequ
estim
gfr
adult
cf
patient
repeat
gfr
measur
use
iohexol
inulin
lung
transplant
could
allow
evalu
degrad
renal
function
transplant
determin
risk
factor
poorer
renal
outcom
secret
insulin
glucagon
gip
pp
inject
differenti
inhibit
glucagon
p
enhanc
gip
secret
p
cf
anim
use
second
approach
creat
recombin
adenoassoci
viru
express
ferret
pp
perform
intramuscular
inject
wildtyp
ferret
week
age
dnaas
resist
particlesgram
bodi
weight
infect
ferret
demonstr
plasma
pp
level
fold
p
higher
uninfect
control
week
age
mmtt
studi
anim
week
postinfect
demonstr
improv
glucos
toler
p
ongo
studi
evalu
whether
recombin
pp
express
enhanc
glucos
toler
cf
ferret
also
delin
mechan
improv
glucos
toler
noncf
anim
use
euglycem
hyperinsulinem
glucos
clamp
tracer
evalu
glucos
metabol
liver
peripher
organ
studi
may
provid
new
insight
mechan
pp
action
glucos
metabol
cfrd
pathogenesi
work
fund
nation
institut
health
grant
niddk
jfe
introduct
absolut
insulin
defici
caus
growth
failur
nutrit
decay
cystic
fibrosi
insulin
secretori
defect
common
also
normotoler
patient
evalu
whether
prepubert
insulin
secretori
defect
predict
reduc
adult
height
method
perform
ogtt
prepubert
patient
femal
without
previous
known
diabet
recruit
patient
yr
old
age
pancreat
insuffici
enzym
replac
insulin
secretori
beta
cell
respons
glucos
insulin
sensit
paramet
deriv
model
glucos
insulin
cpeptid
profil
evalu
interv
evalu
accord
refer
valu
sex
age
recent
develop
cf
center
milan
battezzati
et
al
j
clin
endocrinol
metab
year
followup
adult
height
record
age
year
result
regress
model
adjust
sex
ogtt
glucos
concentr
unrel
adult
height
contrast
insulin
concentr
predictor
adult
height
bmi
p
similar
result
obtain
bmi
zscore
ad
model
among
predictor
take
account
nutrit
statu
time
ogtt
adjust
sex
beta
cell
function
tendenti
predictor
final
height
well
p
femal
beta
cell
function
centil
sex
age
lower
final
height
vs
cm
p
conclus
result
confirm
anabol
role
insulin
promot
linear
growth
indipend
glucos
toler
statu
insulin
secretori
defect
evalu
ogtt
associ
reduc
final
height
even
preclud
normotoler
detect
warrant
intervent
ensur
full
growth
potenti
achiev
among
insulin
therapi
could
consid
support
grant
ffc
italian
cystic
fibrosi
research
foundat
stalvey
ms
havasi
v
tuggl
k
wang
birket
row
sm
pediatr
univ
alabama
birmingham
al
usa
uab
gregori
fleme
jame
cystic
fibrosi
research
center
birmingham
al
usa
cystic
fibrosi
foundat
bethesda
md
usa
medicin
univ
alabama
birmingham
al
usa
patholog
univ
alabama
birmingham
al
usa
despit
improv
lung
health
nutrit
reduc
growth
osteopenia
common
cf
caus
seriou
morbid
data
suggest
cf
caus
inher
defect
bone
metabol
etiolog
may
resid
express
cftr
osteoblast
reduc
linear
growth
occur
cf
despit
normal
lung
health
potenti
cftr
ivacaftor
cf
children
result
improv
growth
mechan
intrins
defect
propos
util
cftrrat
wildtyp
wt
litterm
studi
differ
growth
bone
metabolismin
absenc
signific
pulmonari
pancreat
diseaselongitudin
wean
adulthood
determin
mechan
evalu
differ
cartilagin
growth
plate
secondari
cftrdefici
cftr
wt
male
rat
underw
vivo
dxa
imag
everi
week
week
week
age
anim
weight
femur
tibia
length
well
bone
miner
densiti
bmd
compar
time
via
linear
regress
analysi
igfi
urin
ntelopeptid
type
collagen
collect
compar
histolog
differ
cartilagin
growth
plate
femur
cftr
wt
male
rat
week
age
week
age
wt
rat
gain
weight
greater
rate
cftrrat
p
tibia
femur
length
reduc
cftrrat
week
tibia
vs
femur
vs
mm
p
persist
week
p
tibia
femur
bmd
reduc
cftrrat
compar
wt
week
tibia
vs
femur
vs
gcm
p
week
p
histolog
comparison
growth
plate
reveal
reduct
femur
growth
plate
thick
cftrrat
p
suggest
underli
caus
observ
differ
prolif
zone
thick
averag
number
prolifer
cellscolumn
howev
hypertroph
zone
thick
mean
volum
hypertroph
cell
mean
hypertroph
cell
volum
standard
deviat
reduc
cftrrat
p
analys
marker
anabol
function
bone
turnov
progress
growth
bone
densiti
impair
cftrdefici
rat
despit
lack
pancreat
overt
pulmonari
diseas
prior
data
suggest
defect
bone
metabol
provid
mechan
differ
growth
howev
alter
cartilag
differenti
function
growth
platefrom
prolif
zone
hypertroph
zoneprovid
novel
mechan
growth
restrict
seen
cf
combin
recent
clinic
data
indic
improv
growth
children
cftr
upon
initi
ivacaftor
find
implic
mechan
direct
influenc
cftr
bone
length
provid
improv
understand
impair
growth
author
acknowledg
uab
cf
anim
model
core
histomorphometri
molecular
analysi
core
small
anim
phenotyp
core
well
fund
support
nih
object
compar
continu
glucos
monitor
cgm
measur
cf
youth
initi
ivacaftorlumacaftor
method
cf
patient
without
cystic
fibrosisrel
diabet
cfrd
underw
cgm
part
research
protocol
within
month
prior
start
ivacaftorlumacaftor
recruit
undergo
repeat
cgm
within
month
postiniti
ivacaftorlumacaftor
data
also
collect
time
cgm
wear
exclus
criteria
includ
chang
dose
medic
affect
glucos
metabol
eg
insulin
atyp
antipsychot
etc
within
month
prior
cgm
hospit
system
steroid
within
prior
week
cgm
data
analyz
nightday
period
intraindividu
pre
post
cgm
measur
compar
use
wilcoxon
signedrank
test
pvalu
consid
signific
result
cgm
data
pre
postiniti
ivacaftorlumacaftor
avail
particip
median
rang
age
male
cfrd
median
rang
time
cgm
wear
prior
cftr
modul
initi
month
postmodul
initi
month
median
prior
modul
initi
postmodul
initi
pn
two
particip
cfrd
basal
insulin
glargin
ukgd
preand
postivacaftorlumacaftor
mean
glucos
peak
glucos
time
spent
mgdl
glycem
variabl
measur
standard
deviat
significantli
differ
ivacaftorlumacaftor
although
trend
toward
less
hyperglycemia
posttreat
particularli
mean
overnight
glucos
tabl
conclus
cgm
chang
small
pilot
studi
statist
differ
prepost
ivacaftorlumacaftor
although
trend
toward
decreas
hyperglycemia
note
recruit
studi
ongo
introduct
cystic
fibrosisrel
diabet
cfrd
frequent
comorbid
produc
impact
pulmonari
function
pf
nutrit
statu
ns
detect
year
previou
diagnosi
impair
glucos
toler
igt
defin
fast
glycemia
fg
mgdl
mgdl
hour
administr
glucos
oral
glucos
toler
test
ogtt
correl
lower
pf
poorer
ns
although
clear
whether
track
retrospect
glucos
toler
alter
indetermin
indet
categori
normal
fg
hour
valu
mgdl
test
detect
complet
ogtt
hypothes
patient
igt
indet
wors
pf
ns
present
previous
detect
alter
object
assess
glucos
toler
group
children
adolesc
cystic
fibrosi
cf
follow
cf
center
retrospect
associ
pf
ns
data
method
patient
year
old
refer
complet
ogtt
divid
group
accord
glycem
statu
normal
cfrd
igt
indet
retrospect
data
pf
fev
percent
predict
fev
absolut
fev
valu
ns
zscore
bmi
moment
test
one
two
three
year
previou
collect
record
well
sex
age
cf
mutat
bacteriolog
shapirowilk
test
use
evalu
normal
variabl
parametr
nonparametr
test
compar
mean
result
patient
recruit
may
april
male
mean
age
homozyg
heterozyg
three
patient
pancreat
suffici
ps
four
patient
diagnos
cfrd
normal
igt
indet
signific
differ
sex
age
bacteriolog
cf
mutat
group
signific
differ
found
fev
normal
igt
fev
valu
significantli
differ
signific
differ
zscore
bmi
found
normal
igt
persist
ps
patient
exclud
almost
reach
signific
differ
comparison
within
group
signific
differ
found
fev
vs
vs
zscore
bmi
vs
vs
igt
group
conclus
igt
subject
deterior
pf
ns
year
previou
diagnosi
wors
ns
compar
normal
group
differ
pf
group
inconsist
probabl
due
small
sampl
size
complet
ogtt
allow
us
detect
indet
subject
follow
prospect
previous
report
increas
cfrd
screen
well
increas
diagnos
cfrd
center
object
determin
chang
bmi
zscore
fvc
patient
diagnos
cfrd
diagnosi
insulin
start
method
data
extract
local
cf
databas
determin
number
youth
diagnos
cfrd
time
frame
patient
diagnos
cfrd
oral
glucos
toler
test
fpg
mgdl
glucos
mgdl
persist
hyperglycemia
mgdl
hospit
data
analyz
determin
slope
bmi
fvc
month
inflect
point
defin
date
insulin
start
cfrd
diagnosi
subgroup
patient
never
start
insulin
vari
reason
mix
model
fit
bmi
zscore
predict
fvc
predict
evalu
chang
slope
start
insulin
cfrd
diagnosi
insulin
age
diagnosi
sex
ivacaftorlumacaftor
therapi
includ
covari
random
coeffici
includ
subject
specif
intercept
slope
prepost
inflect
point
result
diagnosi
cfrd
made
youth
male
bmi
zscore
fvc
start
insulin
compar
insulin
differ
demograph
insulin
vs
insulin
model
estim
slope
bmi
zscore
differ
start
vs
start
insulin
prior
vs
inflect
vs
slope
predict
prior
inflect
differ
start
vs
start
insulin
vs
inflect
insulin
less
steep
declin
compar
insulin
vs
covari
ivacaftorlumacaftor
significantli
shift
averag
bmi
zscore
gender
age
diagnosi
associ
conclus
youth
diagnos
cfrd
continu
exhibit
declin
bmi
zscore
fvc
insulin
treatment
howev
associ
trend
slower
declin
dept
clinic
physiolog
nuclear
medicin
rigshospitalet
copenhagen
denmark
cf
centr
rigshospitalet
copenhagen
denmark
dept
clinic
biochemistri
rigshospitalet
copenhagen
denmark
dept
endocrinolog
koeg
hospit
koeg
denmark
background
cf
patient
increas
risk
osteoporosi
despit
daili
cholecalciferol
supplement
iu
vitamin
level
often
inadequ
nmoll
vitamin
import
bone
health
gener
popul
increas
bone
strength
reduc
fractur
risk
object
determin
preval
osteopenia
osteoporosi
bone
metabol
statu
bmd
copenhagen
cystic
fibrosi
popul
evalu
calcium
metabol
preval
decreas
level
import
bone
health
method
retrospect
crosssect
studi
cf
patient
attend
copenhagen
cystic
fibrosi
centr
inclus
criteria
adult
nonlung
transplant
patient
year
age
least
one
dxa
scan
perform
rigshospitalet
latest
dxa
scan
result
spine
femor
bmd
tand
zscore
collect
anthropometr
biochemistri
clinic
data
year
dxa
scan
extract
danish
cf
registri
correl
analys
perform
use
pearson
r
stepwis
multivari
linear
regress
mlr
perform
identifi
factor
associ
bmd
zscore
result
patient
women
includ
studi
median
iqr
age
bmi
z
bmi
median
percent
predict
patient
homozyg
mutat
pancreat
insuffici
defin
take
pert
bmd
normal
patient
criteria
patient
osteopenia
patient
osteoporosi
median
level
nmoll
median
serum
pth
phosphat
calcium
magnesium
within
normal
rang
univari
correl
analysi
z
bmi
correl
spine
bmd
p
p
respect
femor
bone
bmd
p
p
respect
pth
correl
neg
weakli
femor
bone
bmd
p
correl
significantli
bone
site
zscore
spine
femor
bone
correl
posit
z
bmi
pth
age
correl
neg
femor
bone
zscore
stepwis
mlr
analysi
contain
variabl
z
bmi
calcium
pth
cfrd
gender
z
bmi
cfrd
independ
associ
femor
bone
bmd
adjust
r
z
bmi
remain
significantli
associ
spine
bmd
adjust
r
spinal
zscore
independ
associ
male
gender
howev
adjust
r
cfrd
male
gender
independ
predict
femor
bone
zscore
adjust
r
conclus
osteopenia
osteoporosi
common
present
nearli
adult
cf
popul
median
level
recommend
valu
clinic
paramet
associ
wors
health
outcom
cf
low
low
z
bmi
cfrd
associ
decreas
bmd
z
score
moonnumak
sp
georg
c
pool
al
pediatricspulmonari
baylor
colleg
medicin
houston
tx
usa
background
cystic
fibrosisrel
diabet
cfrd
common
complic
cystic
fibrosi
cf
cfrd
differ
type
type
diabet
pathophysiolog
diagnosi
treatment
likelihood
cfrd
diagnosi
increas
age
affect
adolesc
adult
patient
cfrd
like
poor
nutrit
outcom
decreas
lung
function
decreas
surviv
present
clinic
care
guidelin
outlin
diagnost
criteria
manag
cfrd
howev
remain
pauciti
data
character
popul
time
diagnosi
particularli
sinc
advent
aggress
screen
guidelin
object
studi
provid
indepth
descript
analysi
pediatr
cf
patient
time
diagnosi
method
perform
retrospect
chart
review
current
pediatr
cf
patient
diagnos
cfrd
baylor
colleg
medicin
cf
center
houston
tx
exclus
criteria
patient
without
diagnost
inform
avail
prior
lung
transplant
screen
patient
occur
accord
current
guidelin
patient
diagnos
impair
glucos
toler
consid
studi
demograph
clinic
data
obtain
time
diagnosi
descript
statist
method
use
analyz
data
result
pediatr
patient
center
pediatr
patient
diagnosi
cfrd
four
patient
exclud
due
lack
clinic
data
time
diagnosi
thu
patient
analyz
studi
mean
age
diagnosi
year
diagnos
year
age
malefemal
ratio
racial
breakdown
caucasian
hispan
africanamerican
socioeconom
statu
categor
insur
type
privat
medicaidchip
least
one
mutat
present
patient
homozyg
time
diagnosi
mean
bmi
ile
mean
predict
diagnosi
occur
outpati
set
annual
screen
lab
time
wherea
diagnos
inpati
hospit
twohour
oral
glucos
toler
test
ogtt
diagnost
patient
fast
plasma
glucos
fpg
mgdl
ogtt
glucos
mg
dl
mean
fpg
mgdl
mean
ogtt
glucos
mgdl
casual
blood
sugar
mgdl
diagnost
patient
mean
diagnost
glucos
mgdl
singl
patient
unabl
perform
ogtt
diagnos
screen
mean
time
diagnosi
patient
insulin
requir
time
cfrd
diagnosi
patient
conclus
pediatr
patient
cfrd
uniqu
characterist
patient
diagnos
year
old
recommend
age
screen
patient
diagnos
cfrd
high
percentag
either
one
two
mutat
patient
diagnos
inpati
set
outpati
set
via
annual
screen
lab
elev
casual
blood
sugar
diagnost
almost
often
ogtt
patient
requir
insulin
time
diagnosi
object
preval
cfrelat
diabet
cfrd
estim
adolesc
adult
often
cfrd
first
seen
acut
pulmonari
exacerb
steroid
therapi
enter
feed
commenc
onset
cfrd
often
asymptomat
howev
clinic
marker
frequent
note
weight
loss
declin
lung
function
oral
glucos
toler
test
ogtt
gold
standard
diagnosi
cfrd
patient
year
uk
local
polici
start
screen
cfrd
age
year
use
ogtt
continu
glucos
monitor
cgm
measur
subcutan
interstiti
glucos
level
continu
test
recent
introduc
center
clinic
concern
regard
unexplain
deterior
weight
lung
function
rais
aim
studi
review
incid
cfrd
use
cgm
diagnos
cfrd
comparison
ogtt
method
review
cgm
ogtt
data
patient
test
part
annual
review
last
month
center
cgm
excurs
ogtt
result
compar
world
health
organis
classif
normal
impair
cfrd
result
children
cf
male
age
year
includ
also
cgm
due
clinic
concern
children
complet
cgm
last
year
patient
diagnos
cfrd
cgm
impair
glucos
toler
child
diagnos
cfrd
cgm
would
identifi
ogtt
patient
identifi
impair
glucos
toler
cgm
would
diagnos
use
ogtt
level
borderlin
children
ogtt
normal
furthermor
patient
asymptomat
hypoglycaemia
diagnos
oneoff
low
valu
cgm
low
ogtt
read
conclus
cgm
well
toler
children
result
show
cgm
diagnos
glycaem
abnorm
frequent
patient
identifi
clinic
concern
compar
ogtt
earlier
screen
cfrd
use
cgm
may
identifi
glycaem
abnorm
earlier
may
prevent
clinic
declin
patient
cfrd
occur
hyperglycemia
associ
increas
morbid
mortal
effect
blood
sugar
control
improv
lung
function
weight
mainten
overal
health
individu
cf
insulin
defici
due
pancreat
destruct
wellknown
contributor
cfrd
role
glucagon
produc
pancreat
well
character
dysregul
glucagon
secret
may
contribut
overal
glucos
intoler
cf
type
diabet
therefor
present
studi
seek
character
glucagon
respons
standard
mix
meal
challeng
subject
cf
data
critic
understand
basic
pathophysiolog
cfrd
develop
novel
therapeut
option
manag
cfrd
method
crosssect
studi
stimul
glucagon
respons
conveni
sampl
individu
cf
across
spectrum
glucos
toler
normal
impair
consist
cfrd
perform
individu
cf
age
year
underw
oral
glucos
toler
test
ogtt
mix
meal
toler
test
mmtt
data
compar
histor
data
glucagon
respons
mmtt
healthi
control
subject
result
mmtt
perform
subject
cf
date
mean
age
year
mean
subject
meet
criteria
cfrd
glucos
cpeptid
glucagon
respons
mmtt
shown
figur
mean
peak
rise
cpeptid
ng
ml
mean
peak
rise
glucagon
level
pgml
posit
correl
peak
rise
cpeptid
peak
rise
glucagon
level
two
subject
demonstr
rise
glucagon
respons
incident
hypoglycemia
occur
mmtt
conclus
preliminari
find
demonstr
preserv
glucagon
secret
mix
meal
individu
cf
thu
far
identifi
hypoglucagonemia
would
expect
indiscrimin
destruct
pancreat
cell
although
correl
peak
cpeptid
glucagon
suggest
loss
glucagon
reserv
may
parallel
cpeptid
loss
hyperglucagonemia
respons
mix
meal
seen
subject
present
subject
addit
subject
need
verifi
preliminari
find
onset
cystic
fibrosisrel
diabet
cfrd
associ
acceler
declin
lung
function
ultim
increas
mortal
despit
effect
health
outcom
rel
littl
known
underli
mechan
involv
develop
cfrd
howev
known
onset
cfrd
abrupt
rather
preced
period
prediabet
cfpred
last
sever
year
found
teen
young
adult
cfpred
cfrd
system
redox
imbal
oxid
state
glucos
administr
significantli
worsen
imbal
therefor
set
determin
whether
young
children
cf
demonstr
evid
abnorm
glucos
homeostasi
similar
derang
redox
imbal
could
implic
develop
cfrd
method
clinic
stabl
cf
children
age
year
old
class
iiii
cftr
mutat
healthi
control
ctrl
age
recruit
undergo
oral
glucos
toler
test
ogtt
follow
overnight
fast
subject
ingest
gkg
oral
glucos
solut
plasma
level
glucos
glu
cystein
cy
cystin
cyss
reduc
oxid
glutathion
gsh
gssg
measur
hour
glu
ingest
redox
measur
done
use
highperform
liquid
chromatographi
redox
potenti
ehci
ehgsh
determin
util
nernst
equat
data
express
mean
sd
result
total
subject
cf
ctrl
recruit
cf
patient
normal
fast
glu
level
cfngt
prediabet
cfpred
cfpred
normal
fast
glu
elev
glu
level
mgdl
ctrl
normal
ogtt
result
thu
cfpred
patient
higher
glu
hour
cfpred
mgdl
cfngt
mgdl
ctrl
mg
dl
p
differ
cfngt
cfpred
term
sex
age
bmi
pancreat
insuffici
pseudomona
colon
plasma
ehci
potenti
impress
oxid
baselin
cfpred
patient
mv
two
hour
follow
ogtt
control
cfngt
also
demonstr
oxid
plasma
ehci
group
demonstr
trend
toward
reduc
total
cy
follow
ogtt
cfngt
cfpred
demonstr
trend
toward
oxid
ehgsh
baselin
well
conclus
studi
show
common
impair
glucos
metabol
among
clinic
stabl
cf
children
younger
age
recommend
routin
screen
cfrd
also
demonstr
impress
system
oxid
occur
cfpred
patient
baselin
surprisingli
ctrl
cfngt
becam
oxid
respons
glucos
challeng
taken
togeth
data
cf
teen
young
adult
preliminari
data
lead
us
concept
toddler
young
children
acut
system
redox
imbal
oxid
state
ingest
simpl
sugar
glucos
furthermor
loss
cftr
function
acut
imbal
may
becom
chronic
push
patient
along
continuum
cf
prediabet
ultim
cfrd
support
cff
grant
background
cystic
fibrosisrel
diabet
cfrd
known
comorbid
patient
cystic
fibrosi
research
shown
earli
intervent
cfrd
patient
insulin
therapi
improv
clinic
outcom
includ
lung
function
nutrit
statu
intermitt
insulin
therapi
use
treat
patient
posit
screen
cfrd
intermitt
elev
blood
glucos
level
howev
littl
known
whether
practic
produc
posit
outcom
patient
center
sought
evalu
clinic
differ
nutrit
statu
lung
function
demograph
inform
patient
treat
chronic
insulin
therapi
pump
intens
insulin
manag
compar
treat
intermitt
insulin
therapi
method
crosssect
retrospect
review
institut
patient
identifi
diagnos
cfrd
patient
exclud
undergon
lung
liver
transplant
incomplet
data
past
year
patient
divid
group
group
consist
patient
chronic
insulin
regimen
continu
infus
insulin
insulin
pump
group
consist
patient
intermitt
insulin
baselin
variabl
includ
gender
age
diagnosi
patient
abpa
patient
previous
steroid
comparison
made
two
group
regard
bmi
zscore
mean
past
year
best
patient
preced
year
statist
analysi
done
use
unpair
ttest
correl
evalu
use
linear
regress
analysi
result
differ
seen
two
group
regard
gender
age
diagnosi
cfrd
abpa
statu
patient
intermitt
insulin
regimen
like
privat
insur
lower
mean
score
patient
chronic
insulin
regimen
continu
infus
insulin
note
higher
bmi
z
score
vs
see
tabl
expect
direct
correl
bmi
statu
patient
correl
seen
bmi
conclus
intermitt
insulin
sometim
use
treatment
patient
cfrd
intermitt
high
glucos
data
demonstr
significantli
higher
bmi
patient
chronic
insulin
therapi
compar
intermitt
regimen
although
intermitt
insulin
regimen
consid
studi
suggest
use
may
benefici
use
chronic
insulin
maintain
nutrit
statu
sheikh
kelli
rubenstein
rc
children
hospit
philadelphia
philadelphia
pa
usa
object
cystic
fibrosisrel
diabet
cfrd
associ
wors
cystic
fibrosi
cf
outcom
includ
lower
bodi
mass
index
bmi
lean
bodi
mass
lbm
deficit
aris
hypoinsulinemia
suspect
least
partial
mediat
worsen
pulmonari
function
recent
demonstr
lbm
even
strongli
associ
pulmonari
function
bmi
howev
chang
bodi
composit
cfrd
receiv
limit
attent
hypothesi
worsen
glucos
toler
reflect
oral
glucos
toler
test
ogtt
associ
lbm
deficit
method
pilot
studi
dualenergi
xray
absorptiometri
dxa
scan
perform
children
young
adult
pancreaticinsuffici
pi
pancreaticsuffici
ps
cf
undergo
routin
ogtt
screen
usual
state
health
subject
enrol
across
spectrum
glucos
toler
normal
glucos
toler
ngt
defin
plasma
glucos
mgdl
pg
indetermin
indet
impair
igt
cfrd
sexand
ageadjust
lbm
index
fat
mass
index
z
score
lbmiz
fmiz
respect
gener
use
contemporari
refer
data
result
data
avail
subject
cfrd
manag
clinic
diet
modif
alon
median
minmax
age
bmiz
predict
lbmiz
fmiz
lbmiz
neg
associ
ci
strength
associ
lessen
adjust
age
lbmiz
associ
neg
associ
reach
signific
ci
two
dietcontrol
cfrd
particip
lower
lbmiz
compar
group
partial
ci
appear
higher
fmiz
although
reach
signific
partial
ci
conclus
preliminari
data
suggest
bodi
composit
differ
associ
abnorm
glucos
toler
cfrd
specif
lbmiz
jeopard
individu
cfrd
extent
insulin
therapi
prevent
revers
lbm
deficit
need
explor
histor
individu
live
cystic
fibrosi
cf
would
gather
strength
support
attend
summer
camp
commun
event
support
group
howev
medic
guidelin
recommend
stringent
separ
individu
cf
reduc
risk
crossinfect
studi
seek
examin
impact
recommend
social
experi
young
adult
cf
qualit
exploratori
ground
theori
approach
employ
understand
experi
young
adult
live
cf
specif
emphasi
impact
social
isol
live
semistructur
individu
interview
conduct
ten
young
adult
age
diagnos
cf
interview
guid
use
elicit
inform
individu
cf
understand
experi
perceiv
social
isol
other
cf
way
experi
isol
impact
isol
medic
psychosoci
develop
interview
digit
record
transcrib
verbatim
code
use
ground
theori
constant
compar
method
analysi
identifi
import
social
connect
isol
common
theme
support
particip
level
connect
other
particip
struggl
defin
normal
daili
live
increas
practition
awar
way
support
young
adult
chronic
ill
engag
cf
commun
may
improv
health
mental
health
outcom
group
exist
within
reason
distanc
decid
explor
develop
group
abstract
describ
develop
implement
evalu
group
method
input
interdisciplinari
focu
group
collect
survey
sent
parent
email
address
paper
survey
went
household
email
file
total
gaug
interest
prefer
daystim
topicsformat
total
respons
collect
respond
indic
would
interest
support
group
indic
would
prefer
group
held
weekday
even
weekend
day
indic
frequenc
meet
bimonthli
quarterli
survey
also
explor
topic
interest
respond
financi
support
pulmonari
div
secur
invit
sent
famili
via
postal
servic
evit
date
group
meet
occur
meal
share
meet
virtual
attend
use
gotomeet
also
offer
use
particip
first
meet
attend
rang
particip
topic
meet
follow
life
diagnosisstag
grief
school
cf
childcar
cf
stress
relax
base
group
feedback
locat
time
adjust
accommod
prefer
group
friday
even
bimonthli
result
particip
ask
complet
evalu
group
respond
use
likert
scale
statement
particip
group
benefici
feel
connect
parent
children
cf
group
feel
emot
support
group
learn
someth
group
help
everyday
life
particip
also
ask
respond
openend
question
found
help
group
might
chang
idea
futur
meet
evalu
result
averag
group
evalu
reveal
particip
strongli
agreeagre
particip
group
benefici
strongli
agreeagre
feel
connect
parent
children
cf
strongli
agreeagre
feel
emot
support
group
strongli
agreeagre
learn
someth
group
help
everyday
life
particip
respons
found
help
group
center
major
theme
feel
alon
gain
hope
futur
act
connect
parent
practic
inform
conclus
caregiv
particip
group
found
benefici
particip
left
group
feel
connect
peer
emot
support
inform
could
use
everyday
life
particip
group
somewhat
low
idea
reach
famili
via
close
facebook
group
social
worker
administr
explor
bridg
gap
connect
cystic
fibrosi
caregiv
wortham
l
guthri
c
taskar
v
rodger
cystic
fibrosi
ut
health
northeast
tyler
tyler
tx
usa
object
demand
care
patient
cystic
fibrosi
cf
need
often
impact
emot
caregiv
social
isol
among
famili
cf
patient
describ
result
neg
impact
famili
dynam
ultim
adher
cf
patient
observ
behavior
pattern
patient
popul
perceiv
need
caregiv
group
logist
establish
group
achiev
challeng
present
method
cf
center
uthsct
combin
pediatr
adult
program
compris
pediatr
adult
patient
cf
semirur
center
patient
travel
averag
hour
target
popul
broadli
chosen
includ
famili
friend
parent
newli
diagnos
patient
parent
patient
newli
transit
pediatr
adult
individu
play
import
support
role
cf
patient
life
social
worker
sent
survey
determin
mani
caregiv
would
interest
particip
support
group
obtain
respons
venu
select
content
structur
frequenc
meet
evolv
last
year
result
total
survey
distribut
cf
patient
caregiv
respond
posit
becom
involv
caregiv
group
averag
particip
caregiv
group
rang
particip
group
dynam
caregiv
support
group
consist
mothersfath
pediatr
adult
patient
spous
adult
patient
friend
cystic
fibrosi
patient
coordin
local
chapter
cystic
fibrosi
foundat
fund
sourc
came
volunt
servic
educ
day
venu
chosen
neutral
ground
away
cf
clinic
bimonthli
correspond
particip
sent
via
email
flyer
clinic
flyer
mail
cf
famili
text
messag
facebook
meet
last
hour
poll
member
idea
meet
survey
member
prefer
unstructur
versu
structur
meet
caregiv
group
unstructur
mean
caregiv
abl
come
social
vent
frustrat
worri
caregiv
meet
structur
mean
invit
guest
come
speak
caregiv
meet
cope
method
tri
true
techniqu
caregiv
develop
invalu
relationship
caregiv
feel
less
isol
discuss
confidenti
issu
concern
care
social
worker
encourag
direct
commun
care
team
conclus
conclus
cf
patient
often
depend
caregiv
caregiv
devot
entir
live
patient
caregiv
wealth
knowledg
resourc
share
other
especi
child
may
grown
pass
away
need
share
everyday
trial
tribul
caregiv
cf
patient
overal
caregiv
support
group
member
laugh
cri
provid
invalu
support
one
anoth
less
formal
forum
patientfamili
advisori
board
valu
landon
c
turner
r
pediatr
diagnost
center
ventura
counti
medic
center
ventura
ca
usa
purpos
realworld
adher
inhal
oral
therapi
cystic
fibrosi
cf
patient
remain
discouragingli
low
rang
inhal
antibiot
program
enhanc
adher
includ
comprehens
behavior
intervent
adolesc
met
mix
success
bluetoothen
technolog
allow
advanc
patient
medic
adher
monitor
intervent
method
proofofconcept
openlabel
studi
initi
evalu
systemat
approach
link
treatment
feedback
compon
util
nebul
system
pari
bluetoothen
medic
deliveri
devic
equip
ebas
control
monitor
function
altera
nebul
handset
devic
util
qualcomm
hub
pari
server
amazon
cloud
redcap
data
collect
cf
clinic
patient
screen
multidisciplinari
team
moriskey
adher
questionnair
maq
risk
poor
adher
devic
demonstr
dispens
clinic
follow
baselin
assess
pulmonari
exacerb
score
pulmonari
function
mental
health
assess
result
pilot
studi
fourteen
subject
age
popul
deliber
nonadher
crosscultur
commun
initi
complex
regimen
use
complex
medic
devic
devic
enabl
team
util
technolog
clinic
hospit
discharg
kit
initi
medic
provid
rapid
feedback
util
use
part
depress
intervent
reward
adher
adher
bring
complianc
line
prior
initi
orkambi
use
adher
booster
patient
regress
test
dispens
medic
deliveri
anoth
languag
cultur
conclus
devic
allow
activ
engag
discuss
patient
provid
treatment
regimen
dateand
timestamp
data
allow
share
decis
make
individu
therapi
patient
schedul
creat
pathway
toward
cognit
behavior
therapi
intervent
weekli
review
adher
studi
process
oppos
quarterli
team
review
patient
recal
medic
possess
refil
data
addit
commun
patient
famili
cf
team
address
challeng
adher
cf
treatment
collabor
avoid
miscommun
misunderstand
treatment
regimen
selfreport
measur
adher
supplement
realtim
data
conjunct
addit
measur
tool
clinic
implic
largescal
studi
devic
potenti
replac
pharmaci
refil
histori
feasibl
measur
adher
devic
potenti
replac
daili
phone
diari
ema
strategi
pda
assess
devic
provid
highli
accur
inform
use
conjunct
measur
pilot
studi
demonstr
electron
monitor
becom
gold
standard
integr
deliveri
system
current
place
patientcent
develop
cystic
fibrosi
caremessag
landon
c
papador
j
turner
r
ventura
counti
medic
center
ventura
ca
usa
purpos
cystic
fibrosi
cf
requir
treatment
complex
medic
regimen
special
diet
adher
treatment
plan
remain
discouragingli
low
rate
rang
inhal
antibiot
educ
program
develop
increas
knowledg
attitud
practic
patient
provid
caregiv
patient
ultim
user
healthcar
research
find
import
stakehold
engag
patient
research
step
prepar
research
agenda
formul
fund
procur
execut
research
studi
conduct
data
analys
translat
result
action
method
caremessag
cm
text
messag
servic
util
databas
question
statement
send
messag
design
popul
send
prewritten
feedback
base
respons
given
cfcm
databas
uniqu
modifi
creat
program
target
given
group
individu
particip
messag
sent
irb
review
assent
consent
issu
focu
group
consist
patient
parent
cf
team
use
identifi
greatest
learn
need
target
popul
consult
clinic
cf
team
visit
clinic
use
surveymonkey
cf
team
consult
postclin
meet
cm
program
copd
diabet
review
messag
crossov
cf
health
result
base
data
collect
patient
popul
cfrelat
topic
import
need
patient
includ
nutrit
exercis
diseas
inform
adher
along
educ
portion
cm
patient
request
appoint
remind
visit
cf
team
medic
refil
daili
medic
remind
adher
issu
emerg
patient
agre
intervent
notic
educ
event
enrol
program
request
visit
cf
team
messag
cfcm
databas
cater
enhanc
educ
topic
cf
team
interview
reveal
reluct
provid
particip
smartphon
educ
program
via
text
messag
question
copd
diabet
program
identifi
integr
cf
databas
conclus
base
need
increas
adher
cf
treatment
feedback
receiv
patient
program
begin
messag
relat
adher
adher
messag
taken
moriski
adher
questionnair
implement
cm
system
sent
patient
give
anoth
measur
patient
adher
goal
particip
includ
patient
provid
caregiv
set
cfcm
program
clinic
implic
cfcm
program
potenti
increas
knowledg
attitud
practic
cf
health
patientcent
process
allow
better
understand
patient
educ
need
cm
also
use
clinic
send
appoint
remind
receiv
confirm
patient
visit
patient
engag
process
potenti
enhanc
qualiti
research
project
improv
enrol
rate
studi
make
studi
consist
patient
valu
goal
prefer
rational
hospit
inpati
stay
acut
pulmonari
exacerb
day
year
old
infect
control
polici
design
protect
patient
effect
confin
patient
room
stay
sever
limit
physic
activ
hospit
stay
associ
depress
anxiou
mood
children
adolesc
systemat
review
found
improv
lung
function
shortterm
inhospit
exercis
exercis
particip
link
improv
mood
youth
primari
aim
current
studi
pilot
test
selfadminist
exergam
program
hospit
microsoft
xboxkinect
game
system
use
wholebodi
limb
movement
hypothes
program
would
feasibl
indic
patient
complianc
studi
procedur
secondari
aim
compar
youth
complet
exergam
protocol
inpati
monitor
group
chang
physic
activ
level
psycholog
distress
across
hospit
stay
method
particip
youth
acut
exacerb
age
parent
consent
upon
admiss
exclus
criteria
baselin
nonenglish
speak
development
delay
youth
complet
exergam
intervent
monitor
procedur
hospit
stay
youth
exergam
condit
instruct
complet
hour
exergam
per
day
room
youth
underw
actigraph
monitor
via
wristmount
actigraphi
devic
object
measur
moder
vigor
level
physic
activ
complet
activ
diari
well
rate
posit
neg
affect
result
complianc
exergam
program
high
base
selfreport
via
activ
diari
review
actigraphi
data
complianc
wear
actigraph
monitor
high
wear
time
across
group
mean
hrsday
complianc
activ
diari
complet
moder
high
youth
complet
least
one
entri
day
preliminari
result
show
exergam
group
report
lower
neg
affect
higher
posit
affect
discharg
well
time
spent
moder
vigor
level
physic
activ
measur
actigraphi
chang
significantli
differ
group
though
observ
effect
size
moder
cohen
parent
youth
also
provid
posit
qualit
feedback
exergam
protocol
exergam
protocol
appear
feasibl
use
pediatr
inpati
set
exergam
program
view
posit
particip
larger
trial
need
initi
result
promis
suggest
selfguid
exergam
intervent
might
use
way
provid
inpati
exercis
improv
hospit
stay
background
identifi
highperform
cf
centr
drive
learn
inform
qualiti
improv
outcom
exacerb
insensit
chang
centr
level
randomis
control
trial
adequ
sampl
size
shown
mainten
inhal
therapi
result
variou
import
outcom
improv
decreas
exacerb
allow
adher
rate
inhal
therapi
process
measur
use
qualiti
indic
identifi
highli
perform
centr
object
monitor
adher
inhal
therapi
use
chip
nebulis
suggest
median
adher
adult
daniel
et
al
chest
howev
data
base
nebulis
brought
clinic
import
understand
adher
rate
nebulis
never
brought
clinic
aim
explor
effect
miss
data
nebulis
adher
rate
adult
cf
centr
method
retrospect
analysi
adher
data
measur
ineb
nebulis
sheffield
adult
cf
centr
adher
calcul
norm
adher
hoo
zh
et
al
patient
prefer
adher
take
account
patient
characterist
defin
minimum
requir
treatment
regim
peopl
nonchip
devic
inhal
therapi
ivacaftor
previou
lung
transplant
exclud
everi
person
least
month
worth
adher
data
two
potenti
caus
miss
data
consid
ineb
difficult
obtain
download
defin
peopl
data
download
month
particular
year
whose
ineb
download
subsequ
year
peopl
use
form
inhal
therapi
accord
clinic
characterist
base
definit
hoo
zh
et
al
result
adult
adult
use
ineb
measur
adher
ineb
easili
obtain
overestim
overal
centr
adher
adher
rate
fell
peopl
inhal
therapi
clinic
characterist
suggest
inhal
therapi
includ
overal
estim
centr
adher
conclus
nebulis
data
miss
random
adher
level
fell
includ
difficulttoobtain
nebulis
analysi
account
popul
inhal
therapi
qualiti
indic
cf
base
nebulis
adher
need
consid
data
complet
compar
adher
rate
differ
centr
background
intervent
support
prevent
inhal
therapi
adher
import
effect
selfmanag
treatment
rationalis
reduc
burden
potenti
improv
adher
may
lead
suboptim
treatment
regim
defin
minimum
treatment
regim
given
person
characterist
norm
regim
provid
help
metric
understand
adher
rate
time
may
well
differ
measur
unadjust
adher
provid
less
precis
estim
qualiti
care
aim
explor
impact
differ
adher
definit
unadjust
vs
norm
adher
chang
adult
cf
centr
method
retrospect
analysi
object
nebulis
adher
data
measur
chip
ineb
nebulis
sheffield
adult
cf
centr
peopl
nonchip
devic
inhal
therapi
ivacaftor
previou
lung
transplant
exclud
unadjust
adher
calcul
percent
agre
regimen
clinician
patient
norm
adher
take
account
person
characterist
defin
minimum
requir
treatment
regim
calcul
previous
describ
method
exampl
denomin
person
chronic
pseudomona
requir
mucolyt
antibiot
agre
use
nebulis
dornas
alfa
daili
nebday
calcul
agre
adher
denomin
nebday
calcul
norm
adher
result
adult
ineb
increas
gener
improv
across
adher
metric
adult
ineb
year
among
cohort
regim
rationalis
regim
augment
regim
rationalis
lower
norm
adher
compar
regim
augment
median
iqr
vs
median
iqr
regim
rationalis
associ
improv
unadjust
adher
median
chang
iqr
reduct
norm
adher
median
chang
iqr
total
nebulis
usedweek
median
chang
iqr
regim
augment
opposit
effect
median
chang
unadjust
adher
iqr
median
chang
norm
adher
iqr
median
chang
total
nebulis
usedweek
iqr
conclus
genuin
improv
use
prevent
nebulis
among
adult
cf
sheffield
howev
crucial
consid
metric
use
measur
adher
purpos
qualiti
improv
regim
rationalis
commonli
institut
adher
low
appear
improv
unadjust
adher
without
actual
improv
overal
nebulis
use
life
expect
peopl
cystic
fibrosi
cf
steadili
increas
need
transit
care
pediatr
adult
specialist
transfer
done
appropri
patient
futur
health
continu
care
adher
medic
may
disrupt
time
transit
complic
development
psychosoci
challeng
common
adolesc
young
adult
object
review
univers
michigan
u
transit
program
progress
qualiti
improv
qi
initi
method
u
cf
center
transit
program
establish
transit
process
usual
introduc
patient
famili
first
visit
center
pediatr
team
reintroduc
transit
program
patient
reach
earli
teen
time
gain
independ
readi
usual
year
age
adult
pulmonologist
meet
patient
famili
pediatr
pulmonologist
pediatr
clinic
patient
famili
readi
joint
clinic
session
session
repeat
time
addit
tour
adult
inpati
outpati
facil
offer
prior
transfer
adult
care
program
evalu
qi
project
follow
evalu
transit
process
modifi
meet
patient
expect
improv
patient
satisfact
also
area
weak
strength
within
program
identifi
result
time
transit
complic
development
psychosoci
challeng
common
adolesc
young
adult
although
structur
transit
program
appear
decreas
patient
anxieti
stress
period
appear
improv
patient
satisfact
perceiv
health
statu
independ
transit
program
optim
patient
health
continu
care
discuss
evalu
program
reveal
patient
proceed
formal
transit
program
report
higher
level
satisfact
care
transfer
pediatr
adult
care
patient
opinion
regard
transfer
care
consid
patient
report
significantli
higher
perceiv
health
statu
transit
patient
report
use
experi
meet
adult
physician
pediatr
clinic
follow
close
social
worker
help
transit
process
formal
transit
process
crucial
optim
patient
health
continu
care
reduc
loss
followup
recent
cf
rise
transit
readi
program
adopt
center
help
improv
cf
patient
knowledg
foster
independ
move
adult
program
abstract
canada
paediatr
cf
patient
requir
transit
adult
cf
clinic
age
regardless
readi
desir
transit
told
caus
anxieti
stress
patient
famili
among
myriad
chang
encount
includ
entir
new
team
new
clinic
locat
space
new
inpati
set
shift
selfcar
model
current
transit
program
start
age
initi
privat
discuss
time
paediatr
health
care
team
questionnair
track
develop
cf
knowledg
selfmanag
skill
process
provid
level
prepared
term
knowledg
skill
patient
famili
still
voic
anxieti
actual
physic
experi
transit
transit
night
creat
provid
opportun
transit
youth
famili
meet
interact
adult
team
introduc
new
clinic
space
routin
meet
parent
abl
present
question
concern
parent
invit
present
due
infect
control
guidelin
youth
abl
attend
person
therefor
connect
via
live
webinar
feed
gave
opportun
view
present
meet
adult
clinic
team
anonym
send
question
even
session
record
post
cf
clinic
websit
avail
teach
tool
method
transit
even
event
held
local
hotel
recept
room
easi
access
highway
outoftown
particip
target
popul
identifi
transit
within
next
year
person
invit
poster
event
sent
email
regular
post
even
support
fund
pharmaceut
compani
provid
technolog
support
equip
event
film
record
air
via
confidenti
live
interact
webinar
home
disciplin
adult
paediatr
team
present
powerpoint
slide
inform
variou
aspect
transit
adult
clinic
highlight
chang
patient
might
expect
encount
refresh
meet
greet
session
occur
present
display
tabl
cfrelat
inform
item
equip
display
evalu
form
avail
complet
session
result
eight
famili
possibl
famili
approach
transit
attend
patient
log
remot
particip
includ
log
activ
engag
ask
question
staff
overal
evalu
prove
extrem
posit
evalu
complet
attende
found
present
met
learn
need
high
degre
true
clariti
organ
understand
speaker
particip
found
event
valuabl
help
host
event
everi
year
take
pictur
event
welcom
object
studi
evalu
role
medic
social
complex
health
outcom
cystic
fibrosi
cf
transit
adult
care
hypothes
individu
high
diseas
complex
poor
social
support
system
gap
care
experi
rapid
declin
lung
function
increas
health
care
util
transit
method
use
retrospect
cohort
design
cf
patient
transit
adult
care
indiana
univers
pediatr
center
januari
decemb
includ
along
demograph
comorbid
variabl
includ
age
transit
gap
care
day
pediatr
adult
cf
center
visit
treatment
complex
score
tc
sawicki
gs
et
al
j
cyst
fibro
diagnosi
depress
anxieti
object
score
measur
social
complex
bob
level
social
support
blss
relationship
fev
predict
tc
blss
assess
use
bivari
linear
regress
relationship
gap
care
predict
well
gap
care
tc
blss
assess
use
analysi
varianc
anova
tc
blss
tertil
compar
hospit
outpati
visit
rate
use
anova
lastli
bivari
linear
regress
use
correl
tc
blss
hospit
rate
preand
posttransit
outpati
visit
rate
result
averag
age
patient
n
time
transit
year
averag
fev
transit
predict
half
patient
male
white
sixtythre
percent
high
school
diploma
medicaid
insur
correl
tc
r
p
blss
r
p
declin
fev
group
gap
care
signific
differ
declin
fev
p
higher
tc
blss
correl
increas
hospit
rate
r
p
prior
transit
higher
tc
predict
outpati
visit
howev
higher
blss
associ
lower
number
outpati
visit
signific
drop
transit
see
tabl
conclus
greater
treatment
complex
social
complex
relat
increas
health
care
util
patient
higher
treatment
complex
frequent
outpati
followup
visit
well
hospit
patient
psychosoci
issu
tend
increas
hospit
fewer
outpati
visit
screen
young
adult
social
complex
provid
support
may
reduc
avoid
health
care
use
introduct
cftr
express
sever
brain
area
patient
pt
show
varieti
symptom
includ
mood
cognit
respiratori
autonom
issu
abnorm
symptom
suggest
possibl
brain
injuri
examin
noninvas
mri
procedur
method
cf
pt
homozyg
age
bmi
kgm
control
age
bmi
kgm
vital
sign
demograph
collect
baselin
good
health
complet
mood
cognit
sleep
survey
beck
depress
inventori
ii
bdiii
beck
anxieti
inventori
bai
epworth
sleepi
scale
ess
montreal
neurocognit
assess
moca
trail
make
test
tmt
pittsburgh
sleep
qualiti
index
psqi
diffus
tensor
imag
dti
procedur
dti
seriessubject
perform
use
mri
scanner
use
diffus
nondiffus
imag
mean
diffus
md
valu
indic
averag
motion
water
molecul
within
tissu
show
microstructur
chang
decreas
valu
acut
increas
chronic
patholog
condit
calcul
voxel
dti
seri
md
map
deriv
dti
seri
realign
averag
normal
common
space
smooth
compar
group
use
ancova
covari
age
gender
p
extend
threshold
voxel
result
signific
differ
age
gender
bmi
cf
control
initi
spo
rang
room
air
drop
rang
cf
subject
supin
mri
scanner
cf
subject
one
bdiii
bai
psqi
moca
abnorm
score
variou
brain
area
show
significantli
reduc
md
valu
cf
indic
predomin
acut
tissu
chang
control
site
reduc
md
valu
includ
bilater
prefront
frontal
pariet
occipit
cortic
bilater
corona
radiat
anterior
mid
posterior
cingul
cortic
insula
cerebellar
vermi
middl
cerebellar
peduncl
cerebellar
cortic
deep
nuclei
ventral
medulla
area
includ
basalforebrain
right
occipit
cortex
show
increas
md
valu
cf
suggest
chronic
tissu
damag
control
conclus
adult
cf
pt
homozyg
poor
sleep
unsuspect
low
oxygen
satur
rest
cf
subject
show
mood
cognit
issu
cf
subject
show
predomin
acut
tissu
chang
area
control
mood
cognit
respiratori
autonom
function
howev
current
mood
cognit
screen
test
appear
less
sensit
show
limit
issu
specul
alter
brain
structur
may
due
cftr
protein
dysfunct
malnutrit
hypoxemia
studi
need
determin
brain
structur
chang
present
cftr
mutat
cf
age
group
background
cystic
fibrosi
cf
heterogen
diseas
even
among
patient
share
genotyp
socioeconom
statu
se
home
environ
contribut
variabl
previous
observ
socioeconom
influenc
patern
educ
famili
incom
manifest
clinic
detect
cf
diseas
infanc
better
understand
link
se
infant
outcom
interview
cf
caregiv
regard
level
social
support
hypothesi
impair
caregiv
support
mechan
link
low
se
overt
cf
diseas
progress
infanc
method
caregiv
cf
infant
provid
modifi
valid
questionnair
analyz
se
support
wellb
factor
compar
composit
clinic
score
nutrit
microbiolog
cough
pulmonari
exacerb
hospit
cf
infant
ttest
analyz
continu
data
fisher
exact
test
analyz
categor
data
signific
assign
p
result
lead
caregiv
cf
infant
particip
annual
incom
less
high
school
educ
singl
parent
infant
gener
healthi
averag
clinic
score
averag
fev
caregiv
report
well
support
howev
perceiv
support
decreas
famili
lower
annual
incom
lower
patern
educ
school
colleg
singl
parent
home
sph
sph
two
parent
home
tph
p
caregiv
sph
diminish
annual
household
incom
sph
earn
versu
tph
patern
educ
similarli
lower
environ
p
relationship
support
se
evid
sph
sph
report
excel
support
contrast
tph
report
low
level
support
likelihood
ratio
lr
posit
predict
valu
ppv
specif
p
low
level
perceiv
support
associ
diminish
clinic
score
lr
ppv
specif
particular
infant
sph
overtli
lower
clinic
score
sp
home
vs
tp
home
p
conclus
cf
caregiv
gener
report
good
health
adequ
support
howev
caregiv
percept
support
significantli
diminish
associ
low
incom
low
patern
educ
singl
parent
home
infant
caregiv
report
low
perceiv
support
risk
develop
increas
diseas
singl
parent
home
significantli
associ
low
support
low
clinic
score
assess
caregiv
perceiv
support
household
type
may
enabl
target
intervent
enhanc
care
environ
infanc
optim
cf
outcom
support
uab
cunningham
memori
summer
research
program
cff
seay
ad
whitak
b
menendez
pediatr
univers
arkansa
medic
scienc
lowel
ar
usa
arkansa
children
hospit
littl
rock
ar
usa
introduct
assess
emot
behavior
function
facilit
patient
caregiv
commun
behavior
health
need
facilit
appropri
referr
treatment
behavior
health
problem
better
identifi
patient
may
benefit
psycholog
evalu
abbrevi
screen
tool
address
uniqu
demand
clinic
time
constraint
develop
routin
use
arkansa
children
hospit
two
cf
center
site
pediatr
behavior
health
questionnair
pbhq
questionnair
briefli
assess
behavior
health
across
follow
domain
anxieti
depress
behavior
academ
social
treatment
famili
adjustmentstressor
develop
increas
commun
behavior
health
inform
purpos
identifi
patient
caregiv
servic
need
standard
referr
rout
appropri
psychosoci
treatment
servic
increas
access
care
studi
aim
includ
establish
intern
reliabl
extern
valid
pbhq
crossvalid
pbhq
valid
psycholog
questionnair
method
project
crosssect
survey
studi
design
inform
approach
refer
patient
famili
psychosoci
servic
pediatr
cf
popul
parent
schoolag
cf
patient
consent
clinic
complet
pediatr
symptom
checklist
pbhq
brief
satisfact
survey
medic
inform
extract
medic
record
includ
statist
analys
descript
statist
chisquar
analys
correl
conduct
result
sampl
femal
caucasian
mean
age
survey
year
sd
year
known
mental
health
diagnosi
gtube
multipl
hospit
period
preliminari
result
show
good
intern
consist
pbhq
cronbach
alpha
posit
correl
psc
r
known
mental
health
diagnos
r
conclus
preliminari
data
indic
pbhq
good
intern
consist
extern
valid
parent
rate
child
high
pbhq
also
rate
child
high
psc
like
report
child
known
mental
health
diagnosi
evid
util
brief
screener
suffici
identifi
patient
need
addit
assess
propos
work
signific
routin
screen
psychosoci
difficulti
improv
access
servic
impact
current
healthrel
qualiti
life
adher
physic
health
outcom
quittner
al
et
al
thorax
find
led
develop
intern
guidelin
mental
health
cf
recommend
annual
screen
depress
anxieti
individu
cf
age
older
parent
children
cf
birth
quittner
al
et
al
thorax
studi
aim
determin
feasibl
implement
guidelin
cf
clinic
south
florida
elicit
patient
parent
rate
satisfact
screen
experi
method
train
cf
team
member
use
ipad
administ
patient
health
gener
anxieti
disord
scale
patient
age
older
parent
caregiv
complet
screen
measur
stabl
visit
elev
mild
rang
given
support
psychoeduc
mental
health
elev
moder
sever
rang
provid
psychoeduc
referr
commun
psychologist
patient
complet
month
followup
survey
via
mail
email
patient
medic
data
extract
electron
record
institut
review
board
approv
gain
part
studi
result
adult
adolesc
parent
complet
screen
satisfact
survey
sixti
percent
adult
age
fev
pred
minor
rate
screen
process
help
somewhat
help
help
larg
major
adult
report
mental
health
issu
import
adult
also
report
comfort
ask
complet
screen
satisfi
length
screen
fiftyf
percent
patient
satisfi
feedback
receiv
screen
satisfi
fifti
percent
patient
report
concern
address
effect
somewhat
effect
parent
adolesc
report
similar
result
conclus
patient
highli
satisfi
screen
process
gener
found
help
howev
result
also
indic
area
improv
includ
feedback
result
given
concern
address
eg
get
feedback
get
feedback
front
companion
result
reflect
limit
mental
health
train
initi
implement
clinic
studi
howev
grant
fund
cff
enabl
us
place
psycholog
traine
pediatr
adult
clinic
supervis
provid
licens
psychologist
continu
annual
screen
patient
parent
util
feedback
skill
clinic
psychologist
readminist
survey
determin
whether
process
improv
fund
vertex
cf
circl
care
grant
background
person
cystic
fibrosi
cf
median
age
death
year
often
receiv
aggress
lifesustain
treatment
within
hour
death
consider
burden
physic
emot
symptom
well
reduc
qualiti
life
cf
progress
yet
surprisingli
littl
known
palli
care
advanc
care
plan
acp
need
peopl
cf
famili
object
identifi
assess
palli
care
acp
need
patient
singl
cf
center
identifi
assess
famili
member
clinician
role
meet
patient
palli
care
acp
need
method
qualit
studi
adult
patient
age
older
moder
advanc
cf
famili
member
involv
care
particip
recruit
univers
washington
adult
cf
clinic
semistructur
interview
minut
conduct
inperson
phone
questionnair
complet
time
interview
includ
question
palli
care
need
demograph
groundedtheori
constantcomparison
method
use
analyz
transcript
coreview
ensur
trustworthi
result
fortyseven
cf
patient
famili
member
particip
patient
age
rang
year
median
rang
famili
member
age
rang
year
identifi
follow
theme
regard
patient
unmet
palli
care
need
discuss
qualiti
life
includ
impact
manag
current
symptom
complic
treatment
routin
provis
inform
futur
cours
ill
commun
futur
function
practic
assist
financ
health
insur
legal
issu
support
emot
concern
includ
referr
counsel
opportun
engag
advanc
care
plan
famili
identifi
similar
concern
futur
qualiti
life
love
one
given
current
level
independ
guidanc
support
love
one
address
hisher
practic
need
connected
love
one
cf
care
health
statu
patient
famili
member
time
locat
address
acp
need
import
patient
vari
willing
discuss
acp
agre
acp
convers
experienc
exacerb
howev
patient
often
difficulti
describ
time
would
actual
best
famili
member
endors
need
desir
acp
similarli
unsur
point
discuss
patient
famili
member
thought
need
support
rather
palli
would
choos
discuss
unmet
need
cf
practition
rather
anoth
provid
believ
discuss
might
best
done
regularli
schedul
cf
appoint
discuss
patient
famili
member
experi
palli
care
need
span
number
domain
see
role
cf
provid
meet
need
discuss
care
time
occur
exacerb
help
plan
ill
trajectori
futur
studi
evalu
intervent
address
palli
care
need
patient
cf
famili
member
beachi
baker
quittner
al
riekert
ka
pulmonari
critic
care
medicin
john
hopkin
univers
baltimor
md
usa
psycholog
univers
miami
miami
fl
usa
background
treatment
regimen
cystic
fibrosi
cf
complex
challeng
peopl
cf
take
half
prescrib
treatment
healthcar
provid
uniqu
posit
assist
patient
famili
overcom
adher
barrier
howev
provid
must
first
recogn
full
spectrum
adher
barrier
object
identifi
patient
famili
adher
barrier
report
cf
provid
method
overal
pediatr
adult
provid
cf
center
unit
state
particip
semistructur
interview
includ
provid
follow
disciplin
dietitian
nurs
nurs
practition
pharmacist
physic
therapist
physician
psychologistpsychiatrist
respiratori
therapist
social
worker
interview
record
transcrib
respons
qualit
code
theme
result
overal
theme
identifi
costaccess
pediatr
adult
provid
eg
copay
pharmaci
difficulti
timeschedul
eg
work
school
activ
attitud
belief
eg
buy
motiv
lack
perceiv
efficaci
commonli
endors
barrier
patient
adher
barrier
endors
provid
includ
mental
health
eg
depress
anxieti
center
resourc
eg
space
staff
turnov
famili
eg
famili
conflict
parent
monitor
knowledg
skill
eg
understand
prevent
understand
devic
daili
habitsroutin
eg
organ
sleep
social
eg
social
stigma
isol
other
care
team
eg
trust
care
team
experi
energi
eg
burnout
fatigu
treatment
eg
tast
nausea
food
eg
picki
ca
nt
enjoy
food
intervent
eg
accept
counsel
lack
outcom
data
adher
development
eg
transit
matur
clinic
visit
eg
visit
long
miss
clinic
appoint
disclos
nonadher
eg
lack
honesti
nt
want
disappointang
behavior
eg
behavior
issu
rebellion
patient
ca
nt
articul
barrier
total
pediatr
adult
provid
indic
interest
checklist
facilit
identif
adher
barrier
provid
identifi
mani
way
checklist
could
inform
includ
support
collabor
commun
tailor
intervent
determin
intervent
reduc
barrier
effect
conclus
cf
provid
recogn
patient
famili
experi
wide
rang
adher
barrier
major
felt
develop
barrier
checklist
would
help
care
team
quickli
identifi
barrier
promot
collabor
patient
famili
overcom
barrier
support
background
improv
surviv
increas
number
adult
cf
receiv
care
dedic
adult
cf
program
adolesc
cf
assess
transit
readi
import
compon
prepar
transfer
pediatricto
adultfocus
cf
care
object
identifi
clinic
demograph
factor
associ
improv
transit
readi
among
adolesc
young
adult
cf
method
transit
readi
assess
crosssect
survey
studi
adolesc
young
adult
cf
receiv
care
larg
pediatr
cf
center
use
transit
readi
assess
questionnair
traq
valid
selfreport
measur
diseas
selfmanag
skill
score
rang
measur
includ
prescrib
cf
treatment
complex
score
score
rang
qualiti
life
measur
cfqr
selfreport
question
transit
counsel
receiv
health
care
provid
differ
traq
score
clinic
demograph
factor
evalu
via
multivari
linear
regress
model
includ
covari
signific
bivari
associ
result
among
particip
mean
age
year
femal
mean
mean
traq
score
mean
cf
treatment
complex
score
fifti
respond
report
provid
talk
health
care
need
becom
adult
report
plan
address
need
develop
thirtynin
report
talk
transfer
provid
treat
adult
sixtyf
report
provid
usual
alway
encourag
take
respons
health
care
need
report
discuss
maintain
health
insur
adult
bivari
analys
higher
traq
score
significantli
associ
older
age
lower
higher
treatment
complex
score
posit
respons
transit
counsel
question
correl
traq
score
cfqr
qualiti
life
domain
multivari
regress
model
older
age
higher
treatment
complex
remain
significantli
associ
higher
traq
score
addit
report
provid
encourag
take
respons
health
discuss
health
insur
also
remain
associ
higher
traq
score
conclus
among
cohort
adolesc
young
adult
cf
transit
readi
associ
older
age
higher
prescrib
treatment
complex
addit
adjust
age
diseas
sever
specif
counsel
transit
prepar
topic
health
insur
also
associ
improv
transit
readi
skill
transit
program
within
pediatr
cf
program
encourag
counsel
order
optim
transitionrel
outcom
introduct
transit
paediatr
adult
care
involv
take
respons
becom
independ
mani
parent
feel
becom
exclud
manag
child
care
follow
transit
ten
year
ago
clinic
nurs
specialist
team
cnst
present
data
collect
four
month
estim
level
parent
involv
adult
child
diseas
manag
follow
transit
aim
reevalu
level
parent
involv
compar
method
tri
match
method
review
howev
although
audit
carri
time
year
contact
increas
despit
stabl
patient
popul
email
use
addit
telephon
call
therefor
contact
telephon
email
made
cnst
review
twomonth
period
novemb
decemb
includ
number
callsemail
ident
caller
age
gender
patient
reason
call
result
comparison
contact
tabl
reason
contact
includ
patient
unwel
result
appointmentsadmiss
letterswelfar
issu
conclus
signific
increas
number
contact
last
ten
year
mani
patient
taken
respons
cf
manag
fall
number
call
made
behalf
contact
made
behalf
patient
mother
note
mother
call
small
group
seven
mother
call
repeatedli
appear
last
ten
year
prepar
transit
support
follow
transit
process
succeed
empow
mani
young
patient
take
respons
care
although
small
number
mother
continu
activ
involv
mani
year
profession
work
adult
cf
team
need
awar
follow
transit
paediatr
adult
care
young
adult
need
encourag
support
becom
independ
howev
mother
particularli
continu
play
activ
role
number
year
posttransit
littl
known
effect
social
support
mental
physic
health
adult
cystic
fibrosi
cf
adult
cf
may
face
uniqu
set
clinic
psychosoci
barrier
affect
attain
mainten
social
support
includ
frequent
hospit
transit
pediatr
care
chang
primari
support
person
social
isol
due
infect
control
polici
studi
examin
role
perceiv
social
support
selfreport
mental
physic
health
adult
cf
method
examin
respons
adult
cf
interperson
support
evalu
list
isel
scale
memori
symptom
assess
scale
msa
scale
part
singl
survey
wave
project
adult
care
cystic
fibrosi
paccf
longitudin
multicent
panel
studi
cf
adult
unit
state
msa
address
selfreport
mental
physic
health
higher
score
repres
increas
symptom
burden
linear
regress
analys
conduct
social
support
predictor
mental
health
physic
health
control
follow
covari
diseas
sever
number
pulmonari
exacerb
fev
age
gender
educ
weight
percentil
diabet
pancreat
suffici
colon
staphylococcu
aureu
pseudomona
aeruginosa
andor
burkholderia
cepacia
result
particip
mean
age
year
femal
posthigh
school
degre
report
social
support
rang
mean
physic
health
symptom
score
rang
mean
mental
health
symptom
score
rang
mean
greater
level
social
support
associ
fewer
neg
mental
health
symptom
p
r
fewer
physic
health
symptom
p
r
covari
includ
analys
femal
gender
predict
poorer
mental
physic
health
conclus
perceiv
social
support
significantli
predict
selfreport
mental
physic
health
adult
cf
independ
clinic
indic
diseas
sever
previou
qualit
research
indic
social
support
seen
valuabl
resourc
children
adolesc
cf
howev
studi
examin
role
social
support
health
outcom
quantit
design
implement
social
support
program
may
prove
benefici
care
individu
live
cf
introduct
patient
cystic
fibrosi
cf
mental
ill
increas
morbid
burden
diseas
noncompli
treatment
worsen
qualiti
life
recent
guidelin
recommend
screen
depress
anxieti
patient
health
questionnair
gener
anxieti
disord
scale
standard
compon
comprehens
cf
care
object
object
evalu
consist
mental
health
address
cf
clinic
visit
without
use
formal
screen
questionnair
routin
care
compar
use
term
detect
symptom
suggest
anxieti
depress
method
review
chart
patient
cf
seen
saskatoon
adult
cf
clinic
patient
previous
undergon
lung
transplant
exclud
fortyf
patient
met
inclus
criteria
physician
note
review
mention
plan
regard
mental
health
addit
data
collect
spirometri
sputum
cultur
pulmonari
exacerb
antibiot
use
januari
saskatoon
adult
cf
clinic
initi
screen
score
questionnair
administ
sixmonth
period
compar
detect
depress
anxieti
without
formal
tool
preced
year
result
without
use
screen
tool
mental
health
address
patient
patient
screen
score
five
least
one
questionnair
suggest
minimum
mild
depress
anxieti
screen
tool
identifi
subject
potenti
mental
health
concern
miss
routin
assess
overal
screen
tool
identifi
mental
health
issu
often
standard
patient
interview
vs
p
conclus
result
demonstr
mental
health
assess
minor
patient
routin
care
use
result
improv
consist
assess
mental
health
well
identif
patient
potenti
mental
health
disord
introduct
young
women
cf
face
uniqu
sexual
reproduct
health
srh
concern
prior
research
shown
prefer
receiv
cfspecif
srh
inform
cf
care
provid
purpos
studi
investig
preval
cfspecif
srh
problem
care
provis
cf
team
young
women
cf
method
femal
cf
age
year
recruit
five
us
cf
center
particip
anonym
electron
survey
investig
srh
behavior
experi
srh
care
util
prefer
relat
srh
care
cf
set
descript
statist
use
summar
cfspecif
srh
problem
rate
discuss
cf
care
team
result
respond
thu
far
includ
women
cf
mean
age
year
thirtyseven
percent
rate
cf
sever
mild
moder
sever
selfreport
baselin
predict
respond
thirtytwo
percent
cfrelat
diabet
report
age
adrenarch
year
age
menarch
year
onethird
perceiv
pubert
delay
compar
healthi
peer
discuss
puberti
cf
team
eighteen
percent
report
histori
urinari
incontin
ui
mean
age
onset
year
respond
discuss
ui
cf
team
fifti
percent
report
histori
vulvovagin
candidiasi
two
episodesyear
respond
discuss
topic
cf
team
fortytwo
percent
alway
disclos
cf
diagnosi
sexual
partner
disclos
commit
relationship
respond
report
vagin
sex
past
four
week
n
report
pain
vagin
penetr
half
time
cough
sex
hemoptysi
respond
report
discuss
sexual
activ
cf
team
report
discuss
sexual
function
concern
cf
provid
twentyseven
percent
report
discuss
fertil
cf
team
one
respond
told
infertil
due
cf
healthcar
provid
fortyon
percent
discuss
contracept
cf
team
sixtynin
percent
concern
futur
children
would
cf
would
elect
genet
test
cf
futur
child
fortyon
percent
discuss
contracept
cf
team
discuss
pregnanc
plan
conclus
young
women
cf
face
mani
diseasespecif
srh
issu
despit
desir
discuss
topic
cf
provid
minor
report
ever
discuss
srh
concern
cf
team
improv
patient
educ
counsel
care
provis
around
srh
need
popul
support
cff
year
clinic
fellowship
grant
introduct
surviv
cf
improv
patient
need
prevent
servic
care
relev
adolesc
young
adulthood
includ
sexual
reproduct
health
srh
howev
srh
experi
young
women
cf
studi
studi
compar
srh
behavior
young
women
cf
gener
us
popul
method
femal
cf
age
year
five
us
cf
center
particip
anonym
electron
survey
explor
sexual
histori
contracept
use
sexual
transmit
infect
sti
pregnanc
result
compar
data
nation
survey
famili
growth
nsfg
larg
nation
repres
survey
conduct
cdc
understand
male
femal
srh
behavior
trend
us
via
chisquar
linear
regress
test
result
date
women
cf
mean
age
year
complet
survey
nsfg
comparison
data
avail
subject
age
year
mean
age
year
eightynin
percent
women
cf
identifi
heterosexu
homosexu
bisexu
similar
gener
us
popul
sixti
percent
women
cf
report
vagin
sex
male
partner
compar
us
women
women
cf
older
age
first
vagin
sex
p
fewer
lifetim
male
partner
p
gener
us
popul
fiftyseven
percent
women
cf
survey
report
histori
contracept
use
compar
us
women
p
fourteen
percent
women
cf
current
use
longact
revers
contracept
larc
method
compar
gener
us
popul
p
oral
contracept
use
women
cf
us
women
women
cf
less
like
ever
use
emerg
contracept
vs
p
test
sti
past
year
vs
p
compar
gener
us
popul
two
percent
women
cf
report
ever
pregnant
compar
gener
us
popul
p
conclus
young
women
cf
less
sexual
experienc
compar
gener
us
popul
much
less
like
ever
pregnant
howev
women
cf
report
lower
rate
contracept
use
sti
test
suggest
gap
srh
educ
differ
consid
futur
develop
srh
educ
materi
care
provis
young
women
cf
investig
dispar
rate
pregnanc
contracept
use
sti
test
warrant
introduct
cystic
fibrosi
challeng
timeconsum
expens
diseas
mani
peopl
cf
famili
face
issu
get
afford
care
need
recent
studi
cf
foundat
show
percent
adult
cf
worri
financi
support
need
live
diseas
nearli
percent
worri
get
keep
health
insur
patient
famili
even
choos
pay
medic
necess
food
rent
cf
foundat
compass
launch
tool
peopl
cf
famili
health
care
provid
help
complex
insur
financi
legal
issu
team
knowledg
case
manag
mani
year
experi
help
peopl
cf
offer
assist
phone
email
method
compass
case
record
comprehens
databas
collect
inform
issu
peopl
face
well
propos
solut
analyz
data
march
septemb
identifi
common
topic
address
trend
result
averag
compass
receiv
call
per
day
health
insur
issu
common
call
issu
help
choos
insur
option
benefit
verif
understand
particular
plan
cover
help
coordin
benefit
number
call
requir
help
financi
assist
care
treatment
exampl
call
often
result
referr
nonprofit
foundat
provid
fund
peopl
cf
well
manufactur
patient
assist
program
fewer
call
legal
issu
relat
insur
employ
educ
govern
benefit
well
need
assist
social
secur
applic
mani
caller
experi
issu
impact
abil
get
care
treatment
top
issu
assist
pay
medic
bill
help
live
expens
find
cf
care
center
find
afford
hous
lodg
pay
assist
issu
relat
medic
devic
averag
month
compass
refer
peopl
cfffund
cf
legal
inform
hotlin
tm
run
law
firm
sufian
passamano
llp
fund
peopl
law
firm
sufian
passamano
llp
assist
social
secur
disabl
insur
social
secur
incom
applic
review
appeal
fund
genotyp
peopl
conclus
peopl
cf
face
mani
barrier
access
care
treatment
although
mani
barrier
directli
relat
access
financi
need
mani
barrier
impact
access
qualiti
life
cf
foundat
compass
help
mani
barrier
provid
glimps
prioriti
area
mani
vulner
peopl
cf
famili
care
children
cystic
fibrosi
cf
increas
rate
parent
depress
intern
depress
epidemiolog
studi
tide
cf
found
elev
symptom
depress
center
epidemiolog
studi
depress
scale
cesd
mother
father
time
rate
commun
sampl
quittner
al
et
al
thorax
turn
parent
depress
increas
risk
depress
youth
cf
quittner
al
et
al
neg
affect
child
adher
health
outcom
barker
dh
quittner
al
pediatr
result
cf
foundat
european
cf
societi
consensu
statement
screen
treat
depress
recommend
annual
screen
depress
parent
caregiv
patient
cf
age
patient
health
shorter
base
staf
resourc
quittner
al
et
al
thorax
method
cf
center
women
children
hospit
buffalo
cfc
screen
patient
cf
year
depress
began
annual
screen
expand
parentscaregiv
use
streamlin
process
clinic
due
low
rate
caregiv
depress
observ
compar
tide
data
caregiv
patient
year
age
random
screen
half
parent
last
name
al
half
mz
object
examin
differ
measur
also
compar
region
differ
use
data
compar
data
pediatr
cf
center
ann
robert
h
luri
children
hospit
chicago
screen
caregiv
start
result
cfc
caregiv
complet
elig
famili
refus
miss
two
posit
cfc
caregiv
random
screen
parent
refus
miss
three
posit
caregiv
random
screen
refus
eight
screen
posit
one
answer
posit
suicid
question
score
score
conclus
found
lower
rate
caregiv
depress
report
larg
intern
studi
though
differ
screen
measur
use
greater
rate
caregiv
depress
detect
compar
screen
although
small
sampl
suggest
may
sensit
caregiv
depress
screen
prefer
data
compar
caregiv
screen
ann
robert
h
luri
children
hospit
chicago
data
avail
octob
reason
lower
rate
caregiv
depress
could
includ
underreportingfailur
report
team
smaller
center
differ
screen
measur
season
variat
object
cystic
fibrosi
cf
affect
estim
peopl
unit
state
pancreat
insuffici
preval
result
malnutrit
nutrit
statu
directli
correl
lung
function
cf
gastrostomi
tube
gt
place
assist
meet
nutrit
goal
research
show
treatment
benefici
safe
yet
impact
decis
weigh
heavili
caregiv
studi
aim
examin
knowledg
attitud
regard
gt
placement
among
caregiv
children
cf
explor
relationship
healthrel
qualiti
life
method
caregiv
child
pair
recruit
regular
pediatr
cf
clinic
visit
pair
exclud
child
gt
remov
multidisciplinari
team
design
parallel
survey
one
caregiv
children
gt
one
caregiv
children
without
gt
establish
intern
consist
cronbach
alpha
calcul
whole
sampl
studi
subject
complet
appropri
cystic
fibrosi
questionnairerevis
cfqr
survey
demograph
clinic
data
collect
electron
medic
record
result
sampl
femal
gt
caucasian
result
show
moder
intern
consist
knowledg
cronbach
attitud
cronbach
decis
make
cronbach
alpha
withgt
group
addit
scale
measur
current
health
cronbach
alpha
group
differ
decisionmak
scale
chi
squar
p
cfqr
two
selfreport
version
age
group
sampl
complet
teen
version
complet
child
version
caregiv
n
complet
cfqr
correspond
child
version
n
spearman
correl
teenadult
cfqr
knowledg
attitud
decisionmak
questionnair
reveal
strong
neg
correl
teen
role
knowledg
r
p
teen
eat
attitud
toward
gt
r
p
correl
child
cfqr
knowledg
attitud
decisionmak
questionnair
reveal
moder
correl
cfqr
scale
eat
bodi
imag
digest
r
p
r
p
r
p
respect
caregiv
cfqr
knowledg
attitud
decisionmak
questionnair
correl
reveal
moder
neg
correl
bodi
imag
gt
attitud
r
p
conclus
compar
group
reveal
differ
withgt
withoutgt
group
decis
make
import
differ
note
healthrel
qualiti
life
patient
gt
identifi
troubl
eat
bodi
imag
better
understand
relationship
attitud
toward
gt
bodi
imag
eat
may
import
role
decis
make
process
patient
caregiv
cohen
la
walker
sd
kempker
j
howard
pulmonari
critic
care
emori
univers
atlanta
ga
usa
intern
medicin
emori
univers
atlanta
ga
usa
background
cystic
fibrosi
cf
foundat
current
recommend
patient
cf
attend
clinic
quarterli
routin
nutrit
respiratori
care
studi
specul
increas
clinic
attend
lead
improv
adher
medic
therefor
improv
paramet
fev
hypothes
patient
percent
predict
fev
fev
baselin
frequent
clinic
visit
would
demonstr
slower
declin
pulmonari
function
fev
method
queri
center
registri
databas
identifi
patient
baselin
fev
review
clinic
visit
routin
sick
visit
total
togeth
determin
total
number
clinic
encount
patient
within
last
three
year
routin
visit
defin
visit
occur
within
clinic
set
patient
show
sign
acut
pulmonari
exacerb
ape
sick
visit
defin
sign
ape
clinic
set
chang
slope
fev
calcul
subtract
fev
baselin
year
prior
current
baselin
fev
divid
data
analysi
perform
use
spearman
correl
coeffici
result
total
patient
baselin
fev
averag
age
patient
femal
median
number
clinic
encount
median
number
routin
visit
last
three
year
median
chang
fev
slope
baselin
signific
correl
frequent
routin
clinic
visit
fev
slope
r
p
howev
invers
correl
number
total
clinic
visit
per
patient
chang
fev
baselin
r
p
discuss
studi
suggest
correl
frequenc
routin
clinic
visit
outcom
cf
patient
might
expect
pronounc
patient
sever
lung
diseas
closer
monitor
could
lead
stabl
diseas
howev
seen
popul
may
due
small
number
patient
sever
lung
diseas
baselin
might
due
instabl
often
seen
advanc
cf
lung
diseas
addit
patient
unstabl
diseas
may
schedul
shorter
interv
worsen
declin
lung
function
associ
increas
total
clinic
visit
suggest
patient
acut
ill
attend
cf
clinic
frequent
conclus
increas
number
routin
clinic
visit
cf
patient
sever
lung
diseas
associ
slower
declin
fev
background
cf
care
center
strive
provid
best
care
patient
famili
alway
abl
adequ
address
mental
health
need
recent
intern
studi
found
rate
anxieti
depress
patient
cf
parent
two
three
time
individu
commun
quittner
et
al
thorax
respons
cf
foundat
develop
guidelin
encourag
center
annual
least
screen
patient
caregiv
anxieti
depress
last
month
design
implement
mental
health
screen
program
larg
pediatr
cf
center
systemat
evalu
barrier
benefit
outcom
method
prior
screen
develop
suicid
algorithm
larger
children
hospit
includ
safeti
plan
alreadi
use
two
patient
cf
endors
suicid
ideat
also
develop
referr
network
across
state
partner
state
manag
care
organ
mco
area
educ
center
ahec
develop
didact
modul
present
throughout
state
local
mental
health
primari
care
provid
cf
appropri
evidencebas
intervent
patient
age
year
caregiv
approach
outpati
clinic
visit
occasion
hospit
member
cf
mental
health
team
social
worker
psychologist
ask
complet
pediatr
cf
center
serv
around
patient
yearsold
result
date
two
mco
sever
ahec
agre
host
continu
educ
session
summer
fall
data
collect
ongo
mental
health
screen
began
april
thu
far
screen
patient
caregiv
around
patient
screen
posit
anxieti
depress
mild
moder
sever
caregiv
provid
psychoeduc
referr
barrier
implement
includ
clinic
time
parent
refus
child
particip
parent
declin
child
particip
sever
reason
includ
patient
alreadi
treatment
concern
impact
poor
medic
health
score
sever
benefit
howev
also
identifi
mani
parent
express
sentiment
time
reflect
grate
cff
center
priorit
mental
health
mani
individu
without
previou
diagnos
also
identifi
conclus
overal
impact
mental
health
initi
seem
posit
center
despit
barrier
implement
feedback
also
posit
within
children
hospit
gener
provid
across
state
futur
direct
includ
develop
telehealth
group
adolesc
cf
score
mildtomoder
rang
anxieti
depress
addit
continu
work
upcom
educ
intervent
provid
throughout
nc
support
grant
cystic
fibrosi
foundat
background
new
mental
health
guidelin
cf
foundat
encourag
routin
screen
patient
caregiv
depress
anxieti
mani
cf
center
begun
process
improv
awar
treatment
patient
mental
health
need
center
receiv
grant
mental
health
coordin
mhc
partial
fulli
fill
psychologist
site
help
implement
develop
mental
health
screen
referr
procedur
method
adult
patient
age
year
old
pediatr
patient
age
year
year
caregiv
pediatr
patient
ask
complet
outpati
clinic
visit
inpati
admiss
four
divers
cf
center
unc
pediatr
cf
center
serv
pediatr
patient
across
nc
boston
children
serv
pediatr
patient
northeast
children
hospit
orang
counti
serv
pediatr
patient
southern
ca
rush
univ
medic
center
serv
around
pediatr
adult
patient
chicago
patient
popul
highli
divers
regard
raceethn
primari
languag
incom
resid
eg
urbanrur
domesticintern
psychologist
particip
variou
aspect
screen
process
hospit
provid
uniqu
perspect
key
barrier
facilit
result
four
center
screen
pediatr
andor
adult
patient
least
one
month
rang
mo
total
screen
elig
patient
thu
far
rang
possibl
caregiv
thu
far
theme
facilit
barrier
similar
although
uniqu
situat
arisen
across
clinic
key
facilit
includ
establish
referr
network
safeti
plan
role
definit
mhc
within
team
collabor
amongst
center
provid
social
worker
assist
screen
process
buyin
patient
caregiv
cf
team
one
uniqu
facilit
identifi
abil
selfref
due
protect
time
rush
bch
acrossclin
barrier
includ
clinic
time
space
staff
avail
addit
complex
barrier
emerg
regard
screen
caregiv
includ
concern
regard
document
result
privaci
issu
uniqu
barrier
includ
underreport
among
spanishspeak
caregiv
choc
occasion
patient
caregiv
refus
unc
conclus
appear
mani
factor
aid
implement
cff
new
mental
health
guidelin
overal
feedback
famili
staff
posit
similar
implement
factor
identifi
across
divers
clinic
suggest
clinic
prepar
implement
screen
maxim
facilit
prepar
report
barrier
futur
direct
includ
continu
collabor
center
network
addit
support
role
identif
delin
within
center
identif
strategi
improv
accept
patient
caregiv
support
grant
cystic
fibrosi
foundat
background
cf
chronic
diseas
affect
peopl
us
qualiti
improv
effort
improv
outcom
healthcar
util
popul
effort
necessari
increas
qualiti
care
promot
adher
assist
cost
contain
cff
patient
registri
sourc
aggreg
data
cf
patient
lack
healthcar
util
data
readili
access
outsid
clinic
care
resourc
within
healthcar
system
may
benefit
algorithm
identifi
classic
cf
patient
would
allow
focu
healthcar
promot
adher
monitor
enrol
care
coordin
goal
improv
care
patient
satisfact
lower
healthcar
cost
claim
data
intern
classif
diseas
icd
code
readili
avail
dataset
howev
algorithm
identifi
cf
patient
base
claim
data
exist
devolp
algorithm
util
claim
data
pediatr
account
care
organ
aco
identifi
patient
cf
method
aco
databas
queri
patient
claim
prescript
claim
cf
medic
valid
standard
patient
list
gener
cff
patient
registri
electron
health
record
sensit
specif
posit
neg
predict
valu
calcul
sa
enterpris
guid
irb
exempt
grant
result
claim
method
produc
patient
standard
cf
list
includ
patient
compar
list
confirm
claim
method
produc
fals
posit
eight
fals
neg
follow
valu
claim
method
calcul
sensit
specif
posit
predict
valu
neg
predict
valu
high
valu
sensit
specif
posit
predict
valu
demonstr
excel
reliabl
valid
identifi
cf
patient
use
claim
data
discuss
mani
potenti
applic
exist
data
deriv
medic
claim
howev
first
step
must
reliabl
identifi
patient
popul
identifi
claimsbas
data
fill
exist
gap
current
knowledg
exampl
current
data
collect
includ
medic
prescrib
claimsbas
data
accur
regard
prescript
dispens
may
reveal
pattern
nonadher
may
address
improv
health
outcom
claim
data
facilit
track
healthcar
util
new
therapi
practic
guidelin
introduc
payor
ask
justif
costli
therapi
may
essenti
data
come
year
addit
valid
method
identifi
patient
base
claim
paid
allow
identif
patient
across
multipl
cf
center
allow
assess
healthcar
util
prescrib
pattern
patient
adher
across
center
within
cf
center
addit
allow
first
time
captur
aggreg
data
patient
attend
cf
center
chosen
particip
registri
miami
coral
gabl
fl
usa
rush
univers
medic
center
chicago
il
usa
children
hospit
philadelphia
philadelphia
pa
usa
john
hopkin
univers
baltimor
md
usa
introduct
evidencebas
adher
intervent
must
dissemin
clinic
patient
benefit
requir
train
provid
rang
experi
deliv
behavior
intervent
compet
degre
provid
deliv
intervent
compon
skill
import
mediat
patient
outcom
examin
predictor
multidisciplinari
healthcar
provid
compet
deliv
problemsolv
ps
intervent
icar
nation
rct
cf
center
across
us
adolesc
method
provid
social
worker
nurs
physician
receiv
inperson
train
conduct
videotap
ps
session
receiv
ongo
clinic
supervis
tailor
feedback
train
coder
rate
compet
tape
use
pscomp
observ
scale
technic
item
eg
defin
problem
explain
brainstorm
relat
item
eg
rapport
activ
listen
teen
activ
particip
item
enthusiasm
ontask
behavior
score
likerttyp
scale
poor
excel
icc
interrat
agreement
technic
compet
relat
compet
teen
activ
particip
multilevel
model
examin
longitudin
predictor
technic
relat
compet
includ
practic
session
conduct
supervis
teen
activ
particip
mental
health
provid
mhp
statu
result
practic
supervis
significantli
predict
technic
compet
time
respect
p
mhp
perform
significantli
better
baselin
nonmhp
p
differ
rate
improv
found
mhp
nonmhp
ns
neither
practic
supervis
predict
improv
relat
compet
time
ns
differ
baselin
perform
rate
improv
mhp
nonmhp
teen
activ
particip
significantli
associ
technic
relat
compet
p
strongest
predictor
ad
prior
model
account
teen
activ
particip
amplifi
relationship
supervis
technic
compet
p
reveal
previous
nonsignific
relationship
supervis
relat
compet
p
conclus
multidisciplinari
team
implement
adher
intervent
onetim
train
suffici
compet
implement
intens
train
ongo
supervis
indicatedespeci
provid
lack
formal
mental
health
trainingand
includ
rapportenhanc
strategi
patient
activ
particip
provid
compet
like
reciproc
relat
intervent
easier
deliv
patient
engag
compet
deliveri
facilit
patient
engag
support
cff
genentech
novarti
pharmaceut
univers
miami
summer
dean
fellowship
harri
cf
care
center
nyulmc
new
york
ny
usa
problem
longitudin
research
indic
adolesc
cystic
fibrosi
cf
increas
risk
depress
depress
cf
patient
link
lower
qualiti
life
wors
respiratori
symptom
wors
medic
treatment
adher
burden
treatment
may
also
contribut
depress
identifi
cf
patient
affect
depress
anxieti
connect
appropri
mental
health
care
prioriti
project
goal
align
nation
guidelin
mental
health
care
cf
patient
aim
increas
rate
depress
screen
cf
patient
age
current
level
juli
team
member
dr
robert
guisti
christin
mavaro
cf
coordin
mari
ann
harri
lcsw
intervent
collabor
adapt
refin
depress
suicid
screen
algorithm
fit
fink
cf
workflow
base
cf
foundat
nation
guidelin
universti
buffalo
screen
program
depress
screen
use
patient
health
questionnair
suicid
risk
screen
use
columbia
suicid
risk
sever
scale
csrss
case
manag
psychiatr
evalu
treatment
referr
offer
appropri
progress
date
screen
intiat
januari
date
elig
adolec
screen
lesson
learn
depress
screen
adolesc
cf
patient
feasibl
nyulmc
cf
care
center
referr
network
must
avail
offer
access
care
patient
differ
se
geograph
area
differ
insur
provid
next
step
expand
depress
screen
includ
young
adult
cf
caregiv
initi
screen
clinic
signific
anxieti
garner
support
feedback
cf
parent
advisori
council
extend
behavior
health
treatment
referr
network
collabor
ny
region
cf
care
center
cf
foundat
background
access
mental
health
assess
treatment
often
barrier
individu
cf
would
benefit
treatment
annual
mental
health
screen
cf
patient
age
indic
effort
identifi
level
therapi
need
bridg
continuum
mental
physic
health
limit
access
licens
qualifi
profession
provid
therapi
serv
barrier
especi
cf
clinic
abl
psychologist
part
primari
cf
team
creat
integr
approach
primari
cf
team
therapist
special
treat
patient
chronic
ill
may
improv
patient
access
need
assess
therapi
method
period
cf
social
worker
use
patient
health
questionnair
gener
anxieti
disord
screen
tool
provid
score
indic
patient
level
treatment
psycholog
servic
need
cf
social
worker
collabor
cf
institut
psycholog
depart
collabor
result
establish
access
therapist
special
chronic
ill
abl
provid
servic
slide
monetari
scale
patient
offer
consult
special
therapist
regardless
screen
score
score
guid
level
followup
treatment
indic
screen
tool
complet
week
therapi
therapi
includ
accept
commit
therapi
act
proven
effect
treatment
adult
anxieti
depress
symptom
well
cognit
behavior
therapi
cbt
proven
effect
intervent
individu
depress
chronic
ill
result
screen
period
cf
social
worker
screen
pediatr
adult
cf
patient
use
screen
tool
patient
screen
four
patient
access
servic
offer
special
therapist
patient
report
anxieti
decreas
accept
cf
diagnosi
improv
abil
manag
neg
emot
improv
patientreport
feel
consist
correl
posttreat
screen
score
conclus
provid
access
therapist
special
chronic
ill
may
improv
patient
abil
manag
live
cf
diagnosi
treatment
util
servic
avail
academ
largehealth
institut
set
may
allow
financiallyand
logisticallyaccess
servic
decreas
patient
barrier
seek
treatment
vecchiet
novak
kj
mccoy
ks
kaczor
c
pharmaci
nationwid
children
hospit
columbu
oh
usa
pulmonolog
nationwid
children
hospit
columbu
oh
usa
background
lifelong
durat
complex
cf
medic
regimen
common
deterr
adher
cf
patient
popul
mani
medic
consid
specialti
medic
health
system
increasingli
start
inhous
sp
improv
transit
care
leverag
interdisciplinari
team
improv
patient
outcom
medic
adher
commonli
use
adher
measur
medic
possess
ratio
mpr
newer
measur
proport
day
cover
pdc
accur
repres
adher
combin
therapi
regimen
purpos
studi
measur
medic
adher
cf
patient
popul
implement
sp
associ
accredit
pediatr
adult
cf
center
method
retrospect
analysi
refil
histori
complet
two
phase
phase
preimplement
data
januari
decemb
patient
year
age
phase
postimplement
sp
conduct
juli
februari
patient
age
patient
inhous
sp
includ
patient
fill
one
follow
specialti
medic
intend
chronic
use
defin
greater
one
month
dornas
alfa
tobramycin
ivacaftor
colistin
aztreonam
lumacaftorivacaftor
chart
review
conduct
assess
intend
medic
regimen
collect
baselin
characterist
bmi
bmi
percentil
fev
medic
adher
calcul
patient
studi
period
phase
mpr
calcul
number
prescript
fill
period
divid
number
prescript
fill
pdc
calcul
combin
medic
regimen
number
month
patient
medic
avail
divid
total
number
month
patient
medic
statist
analysi
group
comparison
assess
use
kruskalw
wilcoxon
rank
sum
test
continu
variabl
chisquar
test
categor
variabl
unpair
differ
exclud
patient
phase
assess
use
wilcoxon
rank
sum
test
result
phase
patient
includ
median
age
year
phase
patient
includ
median
age
year
p
signific
differ
adher
score
age
group
phase
patient
present
phase
exclud
adher
calcul
leav
patient
phase
patient
phase
median
mpr
score
iqr
phase
patient
singl
medic
phase
median
mpr
score
iqr
significantli
increas
p
patient
combin
therapi
regimen
phase
median
pdc
score
iqr
phase
median
pdc
iqr
significantli
increas
p
patient
combin
therapi
regimen
conclus
mpr
pdc
adher
score
increas
significantli
postimplement
inhous
sp
adher
score
associ
age
denver
co
usa
cornel
univ
ithaca
ny
usa
harvard
medic
school
boston
usa
introduct
increas
number
patient
cf
achiev
development
appropri
adult
mileston
higher
educ
employ
object
understand
whether
employ
associ
higher
level
healthrel
qualiti
life
hrqol
adult
cf
method
data
obtain
baselin
survey
project
adult
care
cystic
fibrosi
paccf
longitudin
studi
adult
cf
n
particip
complet
cystic
fibrosi
questionnairerevis
cfqr
valid
hrqol
instrument
scale
report
employ
statu
employ
fullor
parttim
diseas
sever
assess
forc
expiratori
volum
second
fev
number
pulmonari
exacerb
hospit
home
iv
treatment
preced
month
demograph
clinic
covari
may
relat
hrqol
includ
age
gender
educ
weight
percentil
diabet
pancreat
suffici
colon
staphylococcu
aureu
pseudomona
aeruginosa
burkholderia
cepacia
twelv
stepwis
hierarch
linear
regress
model
creat
one
cfqr
domain
clinic
demograph
covari
enter
first
diseas
sever
second
employ
statu
third
due
multipl
test
bonferroni
correct
use
evalu
signific
p
level
unstandard
regress
coeffici
b
show
increas
cfqr
domain
score
employ
individu
uniqu
varianc
account
employ
statu
indic
r
result
particip
mean
age
year
femal
posthigh
school
degre
report
employ
employ
significantli
associ
higher
hrqol
sever
cfqr
domain
emot
function
social
function
role
function
physic
function
vital
health
percept
treatment
burden
control
covari
diseas
sever
employ
strongli
relat
role
function
r
health
percept
r
social
function
r
physic
function
r
emot
function
r
predictor
enter
third
model
step
employ
strongli
associ
cfqr
domain
diseas
sever
except
physic
function
domain
employ
statu
associ
remain
predominantli
symptombas
cfqr
domain
bodi
imag
digest
symptom
eat
disturb
weight
respiratori
symptom
conclus
cohort
adult
cf
employ
stronger
predictor
mani
aspect
hrqol
measur
diseas
sever
highlight
rel
import
employ
adult
cf
particularli
area
emot
social
role
function
find
suggest
encourag
support
employ
among
adult
cf
potenti
help
patient
focu
less
physic
symptom
aspect
life
lead
overal
improv
hrqol
graziano
lucidi
v
gentil
tabarini
p
unit
clinic
psycholog
bambino
pediatr
hospit
ircc
rome
itali
itali
cystic
fibrosi
unit
bambino
pediatr
hospit
ircc
rome
itali
introduct
cystic
fibrosi
cf
lifethreaten
genet
diseas
caus
persist
lung
infect
progress
limit
abil
breath
individu
cf
parent
caregiv
increas
risk
depress
anxieti
gener
popul
quittner
al
et
al
thorax
psycholog
symptom
associ
wors
health
outcom
goldbeck
et
al
cochran
databas
syst
rev
cf
foundat
european
cf
societi
set
consensu
statement
screen
treat
depress
anxieti
individu
cf
parent
caregiv
intervent
design
base
level
sever
depress
anxieti
identifi
annual
screen
quittner
al
et
al
thorax
aim
studi
investig
anxieti
depress
symptom
italian
patient
cf
parent
caregiv
use
new
intern
guidelin
method
patient
recruit
ongo
select
consecut
patient
age
year
diagnos
cf
adolescentsf
mean
age
sd
adult
mean
age
sd
consecut
parent
caregiv
mean
age
sd
includ
patient
cf
age
year
older
caregiv
children
cf
birth
year
age
exclud
patient
chronic
diseas
mental
health
sever
diseas
wait
list
organ
transplant
patient
parent
complet
two
selfreport
measur
patient
health
gener
anxieti
disord
recommend
intern
committe
mental
health
cf
result
preliminari
data
analysi
shown
high
percentag
patient
parent
caregiv
report
score
cutoff
level
depress
symptom
anxieti
symptom
elev
symptom
depress
found
adolesc
adult
mother
father
elev
symptom
anxieti
report
adolesc
adult
mother
father
consid
rang
sever
mild
moder
sever
found
mild
rang
predomin
depress
anxieti
found
moder
rang
depress
adolesc
adult
mother
father
moder
rang
anxieti
adolesc
adult
mother
father
low
percentag
subject
shown
symptom
sever
rang
conclus
symptom
depress
anxieti
preval
patient
cf
parent
caregiv
adolesc
report
symptom
adult
mother
report
symptom
father
depress
anxieti
symptom
mild
rang
seem
predomin
patient
cf
parent
caregiv
preliminari
data
confirm
import
annual
screen
depress
anxieti
use
program
design
address
issu
pertain
selfcar
among
inpati
cystic
fibrosi
cf
popul
texa
children
hospit
note
cf
patient
develop
depend
nurs
ancillari
staff
thing
wake
breath
treatment
take
medic
maintain
good
person
hygien
goal
studi
gain
better
understand
cf
patient
feel
toward
selfcar
admiss
requir
particip
studi
admiss
hospit
age
six
year
particip
studi
earn
point
day
activ
particip
three
breath
treatment
physic
therapi
take
prescrib
nutrit
supplement
good
hygien
good
behavior
throughout
admiss
particip
earn
point
reward
coupon
either
mcdonald
texa
children
hospit
food
court
particip
ask
complet
presurvey
start
program
postsurvey
prior
discharg
addit
postsurvey
clinic
followup
approxim
week
discharg
survey
rate
system
design
obtain
inform
import
patient
feel
certain
aspect
health
care
hope
studi
help
find
motiv
factor
inpati
cf
patient
take
charg
care
key
compon
overal
outcom
hospit
studi
current
take
place
thu
far
particip
repeat
admiss
goal
complet
studi
end
may
enough
inform
determin
inpati
reward
program
posit
effect
patient
overal
wellb
selfmotiv
smoke
excess
alcohol
consumpt
illicit
drug
use
preval
within
cf
popul
behaviour
advers
health
effect
upon
patient
regardless
treatment
adher
attempt
prevent
initi
aid
cessat
riski
behaviour
within
cf
popul
factor
associ
behaviour
firstli
need
identifi
therefor
investig
belief
associ
behaviour
within
adult
cf
patient
method
twentyfour
adult
particip
recruit
male
age
rang
year
two
uk
region
cf
centr
median
fev
predict
qualit
semistructur
interview
provid
interpret
perspect
investig
patient
belief
toward
cf
impact
cf
upon
life
explor
rational
patient
engag
riski
behaviour
result
themat
analysi
identifi
five
theme
within
data
set
ident
realiti
live
cf
impact
cf
upon
individu
live
within
social
world
patient
attitud
belief
cope
mechan
respons
live
cf
support
other
accept
awar
find
illustr
factor
associ
riski
behaviour
within
cf
popul
multifactori
desir
normalci
seen
import
mani
literatur
acknowledg
desir
normalci
accompani
engag
normalis
riski
behaviour
retali
ill
ident
evid
life
orient
perspect
also
preval
particip
report
engag
riski
behaviour
fun
overal
report
lack
knowledg
concern
consequ
riski
behaviour
mani
particip
state
inform
clinician
line
transit
evalu
conduct
research
indic
mani
uk
cf
unit
integr
discuss
riski
behaviour
patient
transit
adult
care
howev
result
current
research
highlight
import
awar
patient
good
awar
consequ
riski
behaviour
often
accept
engag
behaviour
conclus
research
highlight
need
effect
health
promot
measur
reduc
prevent
riski
behaviour
within
cf
popul
conduct
semistructur
interview
paediatr
cf
patient
investig
awar
belief
toward
riski
behaviour
age
commonli
associ
initi
behaviour
result
also
discuss
nacfc
overal
research
highlight
cf
patient
engag
riski
behaviour
inform
intervent
prevent
initi
aid
cessat
riski
behaviour
increas
patient
awar
consequ
behaviour
specif
cf
cf
legal
inform
provid
accur
inform
legal
issu
affect
peopl
cf
data
show
cf
hotlin
continu
meet
cf
commun
need
inform
legal
right
peopl
cf
discuss
conclus
adult
cf
continu
need
accur
resourc
inform
legal
issu
nearli
twothird
call
relat
adult
also
cf
hotlin
remain
import
resourc
cf
care
center
staff
inform
right
patient
call
member
cf
center
team
number
call
relat
health
insur
coverag
decreas
afford
care
act
made
obtain
maintain
health
coverag
easier
inform
maintain
social
secur
benefit
understand
complex
benefit
elig
criteria
critic
mani
cf
reli
benefit
monthli
incom
support
access
health
insur
coverag
caller
repeatedli
report
difficulti
access
correct
inform
social
secur
benefit
spoke
cf
hotlin
nearli
half
caller
question
social
secur
benefit
elig
nearli
half
call
health
benefit
inquir
medicar
medicaid
benefit
base
report
caller
clear
without
access
cf
hotlin
vulner
member
cf
commun
would
risk
becom
homeless
access
crucial
healthcar
need
fight
cf
object
excit
advanc
medic
care
cystic
fibrosi
led
extens
lifespan
patient
cf
therefor
optim
earli
ongo
success
engag
educ
critic
order
prepar
individu
learn
essenti
skill
promot
selfsupport
fulfil
live
spite
awar
great
need
support
success
academ
set
school
intervent
coordin
model
current
exist
cf
center
provid
systemat
prevent
educ
resourc
patient
famili
school
promot
engag
collabor
academ
success
abstract
describ
rational
develop
academ
success
program
primari
outcom
measur
method
plan
pilot
project
inform
thorough
need
assess
necessari
determin
develop
key
tool
process
rightsiz
program
emb
program
innov
cf
care
spread
learn
cf
center
develop
program
assist
patient
famili
effect
interfac
school
creat
learn
environ
student
cf
achiev
academ
outcom
align
aptitud
develop
optim
socialemot
function
program
develop
inform
key
stakehold
includ
parent
student
cf
hospit
school
intervent
staff
institut
leadership
cf
multidisciplinari
team
member
specif
goal
includ
ensur
school
receiv
educ
cf
impact
health
learn
social
systemat
help
famili
school
develop
iep
plan
appropri
accommod
ensur
success
execut
plan
coordin
time
academ
achievementcognit
test
need
result
propos
outcom
includ
increas
percentag
patient
plan
appropri
accomod
decreas
academicschool
stress
parent
student
improv
academ
perform
increas
school
attend
improv
child
qol
improv
treatment
adher
conclus
increas
attent
promot
academ
success
greatli
need
comprehens
cf
care
given
proxim
distal
cognit
socioemot
behavior
outcom
associ
academ
success
much
attent
academ
issu
within
cf
care
manag
social
work
member
team
like
anxieti
depress
pressacupunctur
needl
size
x
insert
bilater
shenmen
point
found
triangular
fossa
ear
one
week
patient
instruct
stimul
touch
feel
symptom
anxieti
depress
patient
return
follow
week
remov
pressneedl
repeat
questionnair
result
score
questionnair
show
patient
score
reduc
point
questionnair
patient
reduc
lower
categori
symptom
sever
result
questionnair
show
patient
score
reduc
point
found
patient
reduc
lower
categori
symptom
sever
advers
effect
experienc
pressneedl
stay
durat
week
conclus
despit
small
sampl
size
evid
patient
complet
studi
reduc
anxieti
depress
score
least
one
questionnair
significantli
patient
drop
two
categori
sever
moder
sever
mild
moder
normal
patient
score
higher
initi
questionnair
appear
respond
better
treatment
mind
consid
auricular
acupunctur
adjunct
treatment
cf
patient
high
anxieti
depress
score
could
valuabl
adjunct
physiotherapi
treatment
take
holist
approach
could
help
reduc
amount
medic
requir
patient
techniqu
patient
respons
press
acupunctur
needl
littl
often
requiredw
thu
give
patient
control
care
lead
improv
adher
improv
qualiti
life
background
current
guidelin
recommend
patient
cystic
fibrosi
cf
attend
special
clinic
time
per
year
base
find
frequent
clinic
visit
posit
associ
higher
lung
function
howev
histor
adher
guidelin
variabl
rang
pediatr
clinic
patient
attend
princ
charl
hospit
tpch
cf
clinic
spread
larg
geograph
area
travel
seen
undoubtedli
place
addit
burden
patient
somewhat
offset
outreach
telehealth
clinic
object
studi
identifi
proport
adult
patient
attend
tpch
cf
clinic
recommend
time
per
year
determin
adher
guidelin
associ
clinic
characterist
higher
lung
function
andor
increas
hospit
method
patient
regist
cf
clinic
tpch
attend
clinic
includ
retrospect
studi
patient
transplant
transfer
center
lost
followup
die
exclud
patient
divid
adher
attend
clinic
time
nonadher
attend
clinic
time
group
continu
variabl
two
group
compar
use
independ
ttest
categor
variabl
chisquar
analysi
result
patient
includ
analysi
attend
clinic
occas
differ
mean
sd
age
bmi
fev
adher
nonadher
patient
age
vs
year
bmi
vs
kgm
fev
vs
predict
addit
differ
proport
male
patient
vs
patient
homozyg
vs
preval
cfrelat
diabet
vs
pancreat
insuffici
vs
adher
nonadher
patient
howev
signific
differ
group
number
hospit
p
number
day
hospit
p
preval
chronic
p
aeruginosa
pa
infect
p
patient
adher
group
admit
averag
time
day
vs
nonadher
group
mean
admiss
day
adher
patient
chronic
infect
pa
vs
nonadher
patient
associ
live
remot
clinic
road
clinic
failur
attend
p
conclus
despit
univers
guidelin
recommend
patient
cf
attend
clinic
occas
per
year
patient
tpch
reach
goal
associ
recommend
clinic
attend
frequent
hospit
day
hospit
chronic
pa
infect
factor
associ
nonattend
distanc
clinic
melani
chin
support
ontario
lung
associ
cystic
fibrosi
canada
cooney
k
pediatr
rhode
island
hospitalhasbro
children
hospit
provid
ri
usa
introduct
rhode
island
hospit
cf
center
establish
separ
adult
program
casebas
transit
process
due
staf
chang
patient
age
year
old
transit
abruptli
adult
provid
result
care
team
set
identifi
process
support
time
transfer
adult
care
object
design
implement
patientand
familycent
process
improv
patient
famili
experi
transit
pediatr
adult
care
method
cf
care
team
determin
need
clear
transfer
protocol
system
commun
document
team
establish
target
age
year
old
transfer
adult
care
process
requir
patientfamili
involv
suffici
support
given
intens
patientprovid
relationship
pediatr
year
transit
coordin
tc
identifi
team
review
case
preclin
meet
facilit
commun
track
progress
inform
feedback
obtain
patient
famili
result
commun
track
document
challeng
requir
identifi
tc
particip
team
modif
made
protocol
allow
introductori
visit
adult
provid
prior
final
pediatr
visit
clarifi
visit
replac
routin
care
patient
parent
feedback
identifi
key
compon
impact
success
transfer
includ
continu
parent
involv
throughout
process
adult
consult
pediatr
inpati
admiss
final
protocol
transit
pediatr
adult
provid
implement
routin
care
pediatr
patient
includ
ageappropri
assess
transit
readi
transit
readi
transfer
plan
patient
year
age
discuss
pediatr
preclin
meet
tc
document
notifi
adult
provid
patient
approach
transfer
clinic
visit
follow
birthday
transfer
adult
care
discuss
patientfamili
date
initi
visit
adult
provid
establish
patient
initi
visit
adult
provid
review
histori
plan
care
initi
visit
follow
inpati
admiss
concern
transfer
initi
visit
discuss
pediatr
provid
written
plan
establish
tc
inform
adult
provid
plan
pediatr
provid
remain
primari
provid
final
visit
patient
pediatr
provid
document
transfer
care
emr
inform
tc
adult
provid
pediatr
provid
email
transit
coordin
adult
provid
patient
complet
final
visit
patient
elig
transfer
orient
adult
inpati
care
hospit
preced
year
inpati
pediatr
admiss
age
includ
consult
adult
cf
provid
initi
inpati
admiss
adult
servic
may
includ
consult
pediatr
provid
need
conclus
patientand
familycent
transfer
protocol
track
system
necessari
ensur
success
time
transit
adult
care
process
best
facilit
identifi
transit
coordin
background
object
deficit
cognit
function
report
peopl
diabet
type
chang
cognit
perform
observ
posttransplant
aim
studi
investig
cognit
peopl
cystic
fibrosi
cf
assess
impact
cfrelat
diabet
cfrd
transplant
variou
measur
cognit
function
method
cognit
function
assess
use
cambridg
neuropsycholog
test
autom
batteri
cantab
pancreaticinsuffici
patient
recruit
leed
adult
cf
unit
healthi
control
recruit
gener
popul
studi
peopl
insulintr
cfrd
nondiabet
peopl
cf
receiv
normal
oral
glucos
toler
test
past
month
healthi
control
studi
peopl
cfrd
posttranspl
peopl
cfrd
nt
undergon
transplant
healthi
control
studi
date
peopl
cfrd
nt
undergon
transplant
posttranspl
recipi
retest
use
cognit
batteri
parallel
version
test
administ
studi
group
match
age
gender
educ
level
result
studi
found
peopl
cf
show
degre
cognit
impair
test
visual
memori
new
learn
verbal
memori
sustain
attent
execut
function
compar
healthi
control
cfrd
gener
show
greater
impair
nondiabet
studi
found
peopl
cfrd
posttranspl
show
impair
test
sustain
attent
work
memori
compar
healthi
control
perform
similar
undergon
transplant
preliminari
find
studi
show
cognit
perform
stabl
month
period
except
improv
verbal
memori
conclus
cognit
function
impair
peopl
cf
without
cfrd
rel
healthi
control
transplant
seem
result
improv
perform
cfrd
compar
nondiabet
peopl
cf
cfrd
show
greater
deficit
test
verbal
memori
sustain
attent
work
memori
process
speed
palli
care
interdisciplinari
model
care
coordin
array
intervent
intent
mitig
suffer
ill
burden
experienc
patient
seriou
lifethreaten
ill
famili
time
diagnosi
forward
ill
burden
experienc
patient
cystic
fibrosi
cf
caregiv
character
problem
mani
domain
eg
physic
symptom
psycholog
distress
caregiv
burden
burden
fluctuat
year
gradual
worsen
context
advanc
ill
cf
repres
type
chronic
condit
best
manag
integr
palli
plan
care
routin
care
throughout
diseas
trajectoryan
approach
known
concurr
care
approach
intervent
address
unmet
need
defin
domain
palli
care
undertaken
throughout
cours
ill
cf
profession
support
palli
care
specialist
referr
specialist
palli
care
team
consid
ill
advanc
death
perceiv
soon
problem
multipl
complex
present
time
exist
model
concurr
palli
primari
cf
care
unit
state
propos
studi
describ
implement
midproject
evalu
innov
model
jointli
develop
cystic
fibrosi
center
cfc
beth
israel
medic
center
bimc
mjh
institut
innov
palli
care
recruit
conclud
januari
patient
caregiv
screen
elig
approach
studi
patient
caregiv
consent
studi
declin
sinc
implement
screen
symptom
burden
patient
complet
monthli
screen
total
screen
patient
trigger
triag
evalu
social
worker
one
follow
domain
global
distress
sever
distress
pain
sever
distress
dyspnea
psycholog
distress
andor
request
advanc
care
plan
patient
trigger
reachabl
phone
complet
triag
evalu
miss
due
patient
unreach
telephon
seen
subsequ
clinic
visit
miss
triag
occur
prior
may
point
staf
model
chang
improv
followup
sinc
time
miss
patient
patient
complet
triag
requir
followup
cf
center
clinician
receiv
followup
continu
screen
patient
monthli
symptom
burden
unmet
palli
care
need
collect
quarterli
data
outcom
determin
effect
intervent
may
implement
music
therapi
program
special
design
cystic
fibrosi
patient
assess
patient
satisfact
webbas
survey
system
present
case
cystic
fibrosi
patient
perish
result
complic
diseas
coupl
refus
treatment
patient
diagnos
month
life
older
brother
diagnos
cf
throughout
cours
life
sever
admiss
pediatr
intens
care
unit
result
intub
diagnos
aspergillu
pneumonia
mssa
mrsa
pneumonia
eventu
multidrugresist
stenotrophomona
pneumonia
time
death
diagnos
includ
acuteonchron
respiratori
failur
insulindepend
cfrelat
diabet
mellitu
pulmonari
hypertens
steroid
depend
secondari
immunocompromis
last
admiss
directli
pulmonologist
offic
develop
increas
secret
sputum
product
also
describ
chest
pain
well
increas
oxygen
need
liter
per
minut
lpm
continu
oxygen
lpm
continu
oxygen
day
chang
nightli
bipap
set
patient
respiratori
pathogen
panel
posit
rsv
rhinoviru
adenoviru
place
support
care
sputum
cultur
posit
multidrugresist
stenotrophomona
maltophilia
place
intraven
colistin
nebul
colistin
vancomycin
base
sensit
chang
polymixin
b
howev
react
advers
symptom
chang
back
iv
colistin
pertin
neg
includ
fungal
cultur
aspergillosi
titer
patient
posit
aspergillosi
past
respiratori
statu
stabl
first
three
week
admiss
point
worsen
respiratori
distress
note
air
hunger
bipap
set
adjust
blood
gase
worsen
began
increas
co
level
baselin
clinic
statu
introduct
annual
ohsu
pediatr
cf
center
retreat
brainstorm
issu
relat
clinic
flow
long
patient
wait
time
ineffici
time
manag
staff
commun
need
valu
contribut
care
provid
identifi
issu
address
qualiti
improv
qi
team
object
global
aim
improv
clinic
flow
pediatr
cf
center
ohsu
specif
aim
clinic
flow
qi
process
reduc
time
clinic
arriv
patient
room
reduc
wait
time
multidisciplinari
care
provid
reduc
wait
time
hope
improv
patient
staff
satisfact
clinic
flow
anoth
object
improv
staff
commun
work
relationship
profession
appreci
disciplin
method
tool
use
includ
definit
worksheet
plandostudyact
pdsa
worksheet
data
collect
plan
worksheet
brainstorm
util
process
map
develop
high
level
flow
chart
clinic
process
action
plan
develop
task
would
requir
revis
clinic
flow
base
flow
chart
task
includ
measur
patient
per
clinic
patient
requir
pulmonari
function
test
pft
number
late
patient
per
clinic
time
stamp
done
measur
patient
wait
time
provid
averag
time
room
multidisciplinari
provid
swim
lane
also
use
visual
time
stamp
data
addit
pdsa
focus
staff
commun
develop
late
arriv
patient
algorithm
survey
use
determin
famili
want
hear
cf
care
team
clinic
visit
result
clinic
flow
map
demonstr
sever
team
member
need
see
patient
without
consensu
order
addit
epic
templat
reflect
actual
time
spent
clinic
patient
measur
current
state
reveal
averag
lobbi
wait
time
min
averag
total
wait
time
provid
min
time
stamp
measur
util
develop
level
load
clinic
flow
specif
provid
order
qi
team
also
work
epic
programm
revis
cf
clinic
templat
implement
chang
averag
lobbi
wait
time
decreas
min
averag
overal
clinic
wait
time
reduc
min
staff
commun
handoff
script
develop
measur
late
patient
algorithm
design
use
clinic
survey
staff
patient
satisfact
regard
new
clinic
flow
process
distribut
time
analyz
prior
present
conclus
success
measur
clinic
flow
process
use
sever
pdsa
implement
chang
cf
clinic
flow
measur
allow
build
specif
clinic
flow
process
reduc
clinic
wait
time
patient
anticip
improv
patient
satisfact
survey
result
analyz
base
preliminari
feedback
addit
adjust
clinic
flow
process
still
like
requir
enhanc
team
member
commun
appreci
disciplin
input
improv
cff
recommend
cf
clinic
visit
quarterli
basi
design
diagnosticlaboratori
test
monitor
potenti
complicationsdiseas
progress
fall
part
cf
fundament
learn
leadership
collabor
cf
fun
llc
univers
arizona
cf
qi
team
develop
comprehens
outpati
project
address
shortcom
achiev
follow
specif
aim
june
improv
patient
attend
quarterli
clinic
visit
pediatr
adult
center
method
achiev
project
aim
sought
improv
patientscaregiv
clinic
experi
use
team
develop
implement
tool
help
redesign
clinic
workflow
includ
preproject
assess
patientcaregiv
clinic
survey
assess
perceiv
time
spent
overal
disciplin
comfort
understand
current
medic
labimag
test
reason
miss
clinic
approach
schedul
appoint
commun
staff
commun
eg
letter
newslett
patientscaregiv
import
reason
quarterli
visit
laboratorydiagnost
test
increas
clinic
capac
ad
adult
hospit
followupacut
clinic
clinic
visit
map
commun
expect
disciplin
care
visit
patient
commun
specif
area
concernquest
outcom
track
use
design
spreadsheet
run
chart
held
weekli
ongo
qi
team
meet
review
progress
adjust
tool
assess
outcom
ongo
pdsa
plan
studi
act
cycl
use
intraprofession
preclin
round
meet
help
implement
tool
chang
workflow
result
analyz
survey
data
track
project
specif
aim
first
quarter
amongst
pediatr
patient
caregiv
felt
appropri
clinic
durat
min
vs
min
amongst
adult
patient
primari
reason
miss
clinic
lack
appoint
fit
schedul
group
pediatr
patient
caregiv
adult
patient
felt
clinic
visit
somewhat
long
pediatr
patient
caregiv
would
like
know
disciplin
expect
given
clinic
visit
compar
adult
patient
time
spent
disciplin
perceiv
appropri
similar
group
rang
percent
clinic
attend
data
tabular
form
compar
progress
current
avail
cff
center
report
avail
local
portcf
data
conclus
use
team
develop
implement
tool
redesign
clinic
workflow
order
improv
pediatr
adult
cf
clinic
attend
continu
adapt
tool
clinic
workflow
provid
optim
patient
caregiv
cf
clinic
experi
encourag
ongo
outpati
cf
care
background
insight
cf
commun
reveal
find
right
approach
discuss
challeng
daili
cf
care
difficult
patient
famili
care
team
patientprovid
commun
cite
healthcar
literatur
haskard
zolnierek
kb
et
al
influenti
treatment
therapi
adher
recogn
cf
foundat
cff
conduct
pilot
help
patient
care
team
open
nonjudgment
problemsolv
care
convers
pilot
part
larger
initi
address
adher
behavior
research
promot
improv
health
outcom
help
individu
cf
live
full
product
live
object
test
languag
materi
convers
starter
adult
cf
care
team
member
open
commun
sustain
daili
care
identifi
potenti
barrier
solut
method
six
adult
care
program
took
part
pilot
nov
jan
patient
care
team
repres
site
form
work
group
design
convers
starter
materi
poster
tent
card
magnet
sticki
note
id
badg
materi
includ
three
question
spirit
would
help
today
balanc
life
care
plan
care
team
put
materi
practic
accord
clinic
flow
feedback
collect
patient
clinician
feasibl
util
materi
qualit
survey
inperson
videoconfer
interview
result
survey
complet
patient
care
team
member
interview
conduct
patient
care
team
member
care
team
perceiv
materi
engag
patient
new
way
open
convers
sustain
daili
care
barrier
adher
care
team
report
materi
help
remind
ask
patient
practic
person
question
use
verbatim
line
question
materi
felt
forc
train
implement
materi
verbatim
question
materi
felt
inadequ
care
team
member
found
use
word
weav
theme
natur
convers
work
best
patient
report
word
materi
innov
engag
said
materi
inspir
compassion
eyecatch
clinic
visit
impact
effect
patient
felt
question
ask
start
everi
visit
patient
indic
would
use
continu
remind
encourag
feel
abl
open
person
practic
way
convers
care
team
conclus
pilot
project
demonstr
materi
trigger
convers
use
care
team
patient
creat
open
judgmentfre
convers
may
help
build
success
partnership
lead
improv
adher
health
outcom
qualiti
life
individu
care
team
train
may
help
hone
commun
skill
maxim
convers
patient
famili
educ
effect
convers
care
team
regard
barrier
adher
may
also
use
gore
w
leyva
c
mors
k
children
hospit
lo
angel
lo
angel
ca
usa
background
signific
cystic
fibrosi
longer
diseas
confin
pediatr
popul
life
expect
cf
continu
rise
import
prepar
pediatr
patient
live
independ
adult
transit
transfer
wide
discuss
within
cf
commun
time
transfer
adult
cf
care
often
coincid
dynam
period
adolesc
young
adulthood
lung
function
may
declin
treatment
burden
complic
multisystem
diseas
increas
tuchman
e
et
al
pediatr
question
adher
complic
transit
transfer
adolesc
struggl
adher
relat
increas
care
respons
treatment
burden
perceiv
treatment
benefit
lack
educ
literatur
relat
transit
transfer
agre
need
standard
program
within
center
howev
much
literatur
discuss
transit
descript
measur
outcom
relat
satisfact
percept
littl
done
measur
quantit
health
outcom
transit
program
consensu
best
program
improv
transit
tuchman
e
et
al
pediatr
method
chla
cf
care
center
creat
program
help
motiv
patient
encourag
becom
involv
care
patient
age
given
cf
care
notebook
help
organ
cfrelat
health
care
materi
section
notebook
includ
cf
center
medic
therapi
nutrit
clinic
visit
transit
school
inform
infect
control
patient
ask
complet
ageappropri
task
prior
come
quarterli
appoint
task
base
transit
stage
introduc
univers
wisconsin
includ
complet
medic
list
maintain
log
fev
bmi
patient
earn
total
point
per
clinic
complet
medic
list
ad
bmi
fev
previou
visit
result
log
brought
binder
quarterli
appoint
point
could
earn
quarterli
visit
patient
abl
receiv
incent
reach
point
reach
point
result
fourth
quarter
cf
care
notebook
distribut
cf
patient
age
notebook
end
first
quarter
patient
particip
program
particip
earn
mileston
incent
earn
mileston
incent
addit
quarterli
appoint
adher
patient
age
improv
conclus
conclud
standard
transit
incent
program
quarterli
goal
encourag
patient
particip
improv
quarterli
visit
adher
specul
increas
level
particip
transitionrel
goal
lead
increas
knowledg
independ
cf
care
life
expect
patient
cystic
fibrosi
cf
continu
rise
cf
remain
lifelimit
ill
despit
fact
advanc
care
plan
acp
discuss
low
rate
health
care
set
could
leav
patient
without
endoflif
care
plan
uphold
valu
role
cope
mechan
acp
assess
cf
patient
maladapt
cope
avoid
suggest
potenti
barrier
commun
acp
patient
whose
end
life
may
progress
unexpect
rate
studi
evalu
whether
cope
style
relat
comfort
discuss
actual
complet
acp
independ
ill
sever
method
particip
individu
project
adult
care
cystic
fibrosi
longitudin
cohort
survey
studi
scale
comfort
comfort
particip
report
comfort
discuss
acp
famili
cf
provid
appoint
medic
decis
maker
acp
complet
yesno
particip
report
complet
n
health
care
proxi
live
author
organ
donat
cope
style
measur
cf
cope
scale
measur
four
cope
style
optimist
accept
avoid
distract
hope
pearson
correl
assess
relationship
acp
variabl
comfort
complet
hierarch
regress
evalu
associ
comfort
acp
cope
style
logist
regress
evalu
relationship
acp
complet
cope
style
covari
analys
includ
ill
sever
number
pulmonari
exacerb
fev
age
gender
educ
weight
percentil
diabet
pancreat
suffici
colon
staphylococcu
aureu
pseudomona
aeruginosa
andor
burkholderia
cepacia
result
particip
mean
age
year
particip
report
follow
comfort
level
acp
discuss
comfort
somewhat
comfort
comfort
comfort
particip
complet
variou
type
acp
comfort
level
significantli
correl
complet
health
care
proxi
live
author
organ
donat
greater
optimist
cope
significantli
relat
comfort
discuss
acp
greater
avoid
cope
significantli
relat
less
comfort
discuss
acp
cope
style
significantli
relat
comfort
level
complet
acp
significantli
relat
cope
style
conclus
adult
cf
optimist
cope
may
increas
comfort
wherea
avoid
cope
may
interfer
discuss
acp
independ
age
cf
ill
sever
complet
acp
significantli
correl
comfort
level
cope
style
suggest
increas
comfort
level
may
indirect
path
toward
acp
complet
cf
patient
current
analysi
suggest
target
cope
style
may
increas
cf
patient
recognit
advantag
import
acp
background
even
promis
new
therapi
cf
emerg
peopl
cf
famili
face
challeng
manag
seriou
chronic
ill
cope
expect
shorten
life
expect
palli
care
approach
care
focus
enhanc
qualiti
life
consid
standard
care
peopl
seriou
chronic
ill
consensu
incorpor
palli
care
principl
practic
cf
care
object
aim
determin
knowledg
percept
palli
care
among
adult
cf
parent
adolesc
cf
cf
care
provid
elicit
opinion
incorpor
palli
care
cf
care
elicit
recommend
cfspecif
educ
palli
care
method
conduct
semistructur
interview
adult
cf
parent
adolesc
cf
cf
care
provid
follow
initi
question
prior
knowledg
experi
percept
palli
care
particip
provid
standard
definit
palli
care
meant
frame
discuss
regard
incorpor
palli
care
cf
care
well
creation
palli
care
educ
interview
transcript
review
recur
theme
result
ten
adult
men
median
age
median
fev
predict
parent
adolesc
patient
patient
median
age
median
fev
predict
provid
physician
nurs
pediatr
provid
interview
half
patient
parent
never
heard
palli
care
major
particip
group
associ
palli
care
hospic
end
life
relief
suffer
patient
parent
felt
palli
care
could
help
plan
futur
provid
emot
support
facilit
patientprovid
commun
hear
definit
palli
care
patient
parent
felt
palli
care
could
help
peopl
cf
half
cf
provid
could
envis
refer
patient
palli
care
consult
note
associ
end
life
may
barrier
recommend
educ
patient
famili
palli
care
includ
cf
care
team
member
introduc
concept
includ
definit
exampl
resourc
initi
convers
share
written
onlin
materi
conclus
despit
high
burden
symptom
diseaserel
care
limit
life
expect
cf
mani
patient
parent
unfamiliar
palli
care
could
help
peopl
cf
famili
educ
cf
provid
palli
care
would
allow
initi
convers
patient
famili
would
help
identifi
need
improv
knowledg
access
palli
care
potenti
improv
patient
familycent
outcom
develop
current
test
cfspecif
standard
educ
palli
care
support
cystic
fibrosi
foundat
method
conduct
focu
group
caregiv
followup
phone
interview
focu
group
particip
caregiv
inpati
interview
sought
inform
particip
prior
convers
clinician
advanc
care
plan
b
exist
knowledg
treatment
lung
transplant
mechan
ventilationintub
c
import
inform
need
decis
make
focu
group
interview
audio
record
transcrib
themat
analysi
result
earli
qualit
analysi
show
major
particip
convers
clinician
lung
transplant
discuss
intub
sever
peopl
felt
want
discuss
intub
unless
knew
certainti
would
need
particip
knew
lung
transplant
involv
experienc
intub
knew
anyth
possibl
intub
upon
learn
intub
cf
particip
state
would
want
perman
particip
view
lung
transplant
favor
would
consid
small
number
particip
state
want
due
risk
one
cf
inpati
mention
support
network
place
recoveri
still
think
lung
transplant
mostli
describ
isthey
told
must
famili
member
nobodi
work
ask
inform
peopl
need
order
feel
make
inform
decis
regard
advanc
care
felt
prognost
estim
necessari
other
felt
bad
idea
ask
surviv
ask
question
live
basic
say
may
die
worst
thing
could
patient
felt
would
help
hear
cf
peopl
experi
lung
transplant
intub
sever
particip
state
follow
blog
lung
transplant
survivor
conclus
clinician
discuss
lung
transplant
intub
cf
patient
may
due
prognost
uncertainti
part
clinician
patient
regard
patient
may
end
need
intub
may
also
mean
clinician
avoid
convers
intub
associ
die
fact
great
deal
variat
peopl
desir
hear
prognost
estim
suggest
care
taken
assess
whether
convey
inform
patient
decis
aid
use
facilit
share
decis
make
elicit
patient
valu
prefer
outcom
also
live
experi
preconceiv
notion
treatment
fear
may
impact
peopl
understand
medic
inform
convey
clinician
may
critic
understand
data
inform
decis
make
tallarico
e
thaxton
merlo
c
school
medicin
john
hopkin
univers
baltimor
md
usa
introduct
although
novel
therapi
increas
averag
lifespan
patient
cystic
fibrosi
cf
year
mani
individu
cf
still
develop
endstag
lung
diseas
lung
transplant
remain
effect
intervent
improv
surviv
transit
lung
transplant
complex
process
involv
share
decis
provid
patient
take
account
diseas
sever
social
factor
mental
health
physiolog
criteria
well
social
mental
health
requir
multidisciplinari
coordin
despit
advanc
transit
process
cf
pediatr
care
adult
care
littl
known
transit
process
lung
transplant
patient
cf
endstag
lung
diseas
aim
studi
therefor
evalu
cf
center
transit
patient
transplant
understand
interact
cf
transplant
team
cf
center
method
qualit
pilot
studi
evalu
current
practic
transit
transplant
cf
center
use
electron
survey
survey
deliv
via
email
cff
network
regist
nurs
use
qualtric
qualtric
provo
ut
version
june
onlin
survey
softwar
survey
question
explor
cff
network
rn
experi
transplant
discuss
evalu
referr
center
studi
approv
john
hopkin
institut
review
board
result
data
analysi
ongo
result
avail
juli
expect
identifi
common
discord
theme
among
differ
cf
center
practic
transit
patient
transplant
conclus
understand
current
practic
transit
individu
cf
transplant
help
aid
format
decreas
ineffici
deliveri
commun
method
provid
opportun
educ
patient
andor
famili
lador
sl
raju
bray
l
school
nurs
univers
alabama
birmingham
hoover
al
usa
background
advanc
research
genet
test
therapeut
comprehens
care
peopl
cf
live
adulthood
engag
development
mileston
includ
parenthood
cf
foundat
patient
registri
indic
number
cf
women
becam
pregnant
doubl
last
year
new
cftrmodul
drug
approv
number
pregnanc
like
continu
increas
specif
combin
drug
ivacaftorlumacaftor
target
underli
caus
cf
peopl
homozyg
mutat
doubl
shown
improv
patient
sweat
chlorid
concentr
howev
impact
fertil
studi
studi
aim
explor
percept
women
childbear
age
doubl
fertil
chang
secondari
drug
method
semistructur
audiotap
interview
conduct
ten
women
age
doubl
profici
english
interview
transcript
review
code
analyz
use
braun
clark
approach
themat
analysi
result
three
main
theme
emerg
describ
particip
percept
fertil
reproduct
health
potenti
impact
ivacaftorlumacaftor
posit
neg
unknown
effect
ivacaftorlumacaftor
need
comprehens
reproduct
sexual
health
educ
counsel
cf
care
team
want
child
despit
know
suspect
impair
fertil
half
particip
ivacaftorlumacaftor
describ
posit
effect
ie
lung
clearanc
increas
energi
improv
qualiti
life
sever
identifi
neg
effect
ie
loos
stool
chest
tight
major
share
concern
drug
unknown
fetal
effect
particip
believ
drug
potenti
affect
fertil
mainli
make
cervic
mucu
less
viscou
thu
allow
easier
sperm
transport
one
particip
directli
link
pregnanc
drug
take
two
week
secondli
particip
describ
uniform
reproduct
sexual
health
inform
dissemin
report
desir
collabor
cf
care
team
discuss
pregnanc
plan
lastli
particip
wish
least
one
child
despit
know
suspect
may
problem
conceiv
secondari
cf
two
particip
share
ivacaftorlumacaftor
made
possibl
make
plan
futur
includ
mother
conclus
studi
illustr
women
childbear
age
doubl
want
becom
mother
even
potenti
impair
fertil
current
clear
evid
show
ivacaftor
lumacaftor
improv
fertil
women
hope
target
therapeut
make
dream
motherhood
realiti
also
awar
drug
effect
concern
unknown
effect
fetu
desir
comprehens
clinic
care
includ
discuss
fertil
reproduct
health
cf
care
team
sever
implic
practic
educ
research
glean
studi
enoch
c
kleweno
c
filbrun
nasr
pediatr
pulmonolog
univers
michigan
ann
arbor
mi
usa
introduct
cystic
fibrosi
cf
lifeshorten
genet
diseas
requir
frequent
use
intraven
antibiot
ivabx
use
aminoglycosid
antibiot
increas
risk
acut
kidney
injuri
chronic
kidney
diseas
requir
close
monitor
drug
level
renal
function
cf
center
patient
often
initi
treatment
hospit
discharg
home
complet
ivabx
cours
identifi
transit
point
time
receipt
andor
review
laboratori
result
may
delay
miss
determin
whether
structur
commun
plan
inpati
nurs
rn
case
manag
ambulatori
care
clinic
rn
would
provid
consist
time
monitor
antibiot
level
renal
function
cf
patient
home
iv
therapi
method
current
commun
method
evalu
consist
notif
outpati
team
patient
discharg
occur
consist
notif
process
inpati
outpati
team
structur
process
electron
medic
record
emr
develop
collabor
inpati
rn
case
manag
ambulatori
care
clinic
rn
case
manag
began
send
notif
ambulatori
care
rn
inbasket
emr
patient
discharg
home
ivabx
new
process
implement
octob
cff
patient
registri
use
identifi
patient
cours
home
ivabx
one
year
implement
structur
process
retrospect
chart
review
patient
use
identifi
number
miss
delay
lab
receiv
cf
clinic
one
year
prior
one
year
follow
implement
miss
laboratori
result
defin
document
review
emr
delay
laboratori
result
defin
document
receipt
review
busi
day
draw
lab
test
except
amikacin
trough
delay
amikacin
trough
result
defin
busi
day
draw
result
prior
intervent
octob
septemb
patient
requir
monitor
drug
level
andor
renal
function
nine
instanc
miss
initi
result
identifi
seven
patient
two
patient
lab
result
receiv
two
consecut
week
delay
result
identifi
patient
intervent
octob
septemb
patient
requir
monitor
drug
level
andor
renal
function
one
patient
identifi
miss
initi
laboratori
result
seven
patient
delay
result
followup
conclus
implement
structur
commun
process
transit
care
cf
patient
receiv
home
ivabx
therapi
inpati
ambulatori
care
decreas
miss
laboratori
result
year
follow
intervent
rntorn
commun
increas
clinic
awar
patient
need
laboratori
monitor
action
taken
result
receiv
anticip
delay
laboratori
followup
identifi
area
need
investig
caus
possibl
intervent
lucia
rj
green
nelson
children
hospit
illinoi
peoria
il
usa
background
adult
cystic
fibrosi
special
healthcar
need
requir
coordin
complex
health
care
servic
particularli
relat
hospit
inpati
stay
attend
resid
physician
rotat
unit
inpati
staff
may
becom
familiar
patient
frequent
readmit
howev
often
limit
indepth
knowledg
recommend
cystic
fibrosi
care
guidelin
result
care
provid
patient
cystic
fibrosi
fragment
ineffici
result
readmiss
within
day
state
illinoi
medicaid
reimburs
hospit
readmiss
occur
within
day
discharg
therefor
appropri
manag
patient
complex
health
need
import
patient
longterm
health
also
financi
stabil
institut
assess
hospit
day
day
admit
hospit
patient
cystic
fibrosi
day
relat
readmiss
one
patient
account
hospit
day
averag
cost
per
day
adult
cystic
fibrosi
admiss
institut
first
month
rate
readmiss
within
day
escal
without
intervent
estim
day
readmiss
calendar
year
cost
admiss
would
amount
loss
method
admiss
statist
financi
data
analyz
present
hospit
administr
job
descript
develop
primari
respons
includ
daili
inpati
round
includ
expand
nurs
assess
ensur
need
met
daili
commun
supervis
attend
physician
discuss
plan
care
educ
hospit
staff
physician
resid
bedsid
nurs
ancillari
staff
regard
cystic
fibrosi
regist
nurs
hire
inpati
clinic
coordin
posit
patient
provid
poll
person
regard
satisfact
new
inpati
clinic
coordin
result
within
first
month
establish
inpati
clinic
coordin
decreas
averag
readmiss
within
day
daysmonth
daysmonth
result
cost
save
approxim
per
month
hospit
averag
salari
benefit
packag
rn
posit
paid
first
two
month
program
also
increas
collabor
outpati
inpati
physician
staff
patient
satisfact
increas
due
coordin
servic
satisfact
also
increas
attend
staff
resid
conclus
establish
rn
inpati
clinic
coordin
posit
increas
patient
profession
staff
satisfact
decreas
financi
burden
hospit
result
readmiss
within
day
discharg
object
analys
compar
pulmonari
function
test
result
cohort
cystic
fibrosi
mother
pregnanc
method
retrospect
cohort
analysi
conduct
examin
data
women
success
complet
pregnanc
evalu
lung
function
paramet
use
forc
expiratori
volum
one
second
best
percent
predict
normal
pred
determin
year
preand
postdeliveri
mother
exclud
comparison
less
two
data
point
avail
lung
function
perform
posttranspl
includ
diagnosi
diabet
cf
mutat
statu
time
subsequ
lung
transplant
also
note
result
analysi
reveal
mother
deliv
children
least
two
pred
result
avail
mother
total
children
mean
age
mother
time
birth
year
either
gestat
diabet
preexist
cfrelat
diabet
cfrd
seen
women
women
diabet
multipl
pregnanc
nine
women
went
undergo
lung
transplant
mean
time
last
deliveri
transplant
year
four
mother
went
lung
transplant
diabet
women
mean
time
transplant
deliveri
year
year
comparison
lung
function
data
sever
subgroup
reveal
statist
signific
differ
predict
time
compar
lung
function
variat
women
homozyg
mean
age
year
nonhomozygot
mean
age
year
differ
averag
rate
declin
per
year
year
vs
respect
p
signific
differ
lung
function
trend
seen
diabet
nondiabet
group
mean
age
group
year
differ
averag
rate
declin
per
year
year
vs
respect
p
conclus
analysi
cohort
illustr
women
diabet
lower
prepregn
predict
diabet
group
also
appear
acceler
rate
declin
postdeliveri
addit
homozyg
acceler
rate
declin
pred
preand
postdeliveri
compar
homozyg
data
set
suggest
mother
cfrd
andor
homozyg
higher
risk
acceler
lung
function
declin
pregnanc
erdo
j
falardeau
motgi
feng
l
public
polici
cystic
fibrosi
foundat
bethesda
md
usa
background
rise
cost
health
care
coupl
trend
toward
increas
patient
cost
share
signific
concern
cystic
fibrosi
cf
commun
commonwealth
fund
studi
found
nearli
one
four
privat
insur
adult
deduct
annual
incom
skip
need
care
rose
individu
high
deduct
specialti
medic
care
form
core
cf
treatment
regimen
higher
cost
cf
patient
could
impact
access
care
object
determin
impact
health
care
coverag
outofpocket
oop
cost
access
care
treatment
cf
patient
method
studi
use
mix
method
design
onlin
survey
complet
cf
patient
caregiv
respond
survey
cost
share
respons
impact
careseek
behavior
insur
coverag
use
supplement
coverag
financi
support
subset
respond
particip
guid
phone
interview
result
ninetynin
percent
patient
report
health
insur
two
form
coverag
third
patient
report
coverag
medicar
medicaid
chip
state
program
due
cost
concern
patient
report
delay
seek
get
medic
care
report
take
smaller
fewer
dose
prescrib
medic
patient
higher
oop
respons
lower
household
incom
report
delay
care
reduc
medic
often
lower
oop
expens
highest
incom
bracket
patient
cover
medicaid
medicar
report
reduc
dose
frequenc
prescrib
medic
significantli
often
insur
type
respect
find
guid
interview
follow
theme
onlin
survey
mani
respond
discuss
delay
care
skip
medic
due
cost
concern
despit
insur
interviewe
also
note
administr
barrier
eg
prior
author
caus
miss
dose
prescrib
medic
financi
stress
discuss
everi
interview
mani
caregiv
patient
elabor
burden
indirect
expens
adult
patient
note
stress
exacerb
difficulti
maintain
fulltim
work
conclus
studi
inform
payor
financi
burden
influenc
access
care
patient
cf
individu
cover
public
program
higher
oop
expens
lower
household
incom
sensit
elev
oop
spend
like
reduc
dose
prescrib
medic
delay
care
result
addit
cost
relat
directli
health
care
patient
burden
indirect
expens
includ
transport
cost
attend
clinic
visit
food
cost
oop
payment
noncov
product
patient
cf
reduct
care
treatment
could
result
seriou
advers
health
consequ
research
address
impact
costshar
social
determin
health
clinic
outcom
sponsorship
survey
conduct
shugol
research
inc
partnership
fund
cystic
fibrosi
foundat
rise
cost
health
care
coupl
trend
toward
increas
patient
cost
share
signific
concern
cystic
fibrosi
cf
commun
commonwealth
fund
studi
found
nearli
one
four
privat
insur
adult
deduct
annual
incom
skip
need
care
rose
individu
deduct
account
incom
specialti
medic
care
form
core
cf
treatment
regimen
higher
cost
cf
patient
could
impact
access
time
lifesav
care
object
determin
impact
outofpocket
cost
access
care
treatment
patient
cystic
fibrosi
resurvey
complet
elig
children
adolesc
parent
percent
correct
subject
area
talli
age
group
tabl
compar
initi
survey
result
overal
averag
score
similarli
improv
postintervent
across
group
group
score
well
gener
cf
knowledg
children
demonstr
greatest
improv
respiratori
health
adolesc
continu
score
well
respiratori
health
similar
parent
parent
continu
score
lowest
nutrit
prompt
second
review
survey
question
twentyfour
parent
survey
match
preand
postsurvey
comparison
two
question
deem
ambiguousunclear
answer
incorrectli
parent
preand
postsurvey
respect
two
question
remov
data
set
signific
differ
preand
postpar
survey
perform
note
conclus
quarterli
educ
session
effect
method
deliv
specif
educ
topic
address
knowledg
deficit
enhanc
overal
cf
knowledg
base
prior
exposur
inform
like
factor
children
signific
improv
score
across
topic
neglig
improv
nutrit
content
score
parent
may
due
unclear
test
question
answer
choic
either
similar
lack
person
relev
educ
deliveri
method
adequ
meet
adult
learner
need
children
may
benefit
individu
age
appropri
educ
earlier
age
given
score
improv
within
child
group
palli
care
enhanc
qualiti
life
peopl
seriou
chronic
ill
opportun
numer
introduc
palli
care
patient
cf
develop
advanc
diseas
standard
approach
incorpor
palli
care
routin
cf
care
object
aim
test
feasibl
incorpor
standard
palli
care
educ
routin
cf
care
assess
knowledg
percept
palli
care
provid
palli
care
educ
method
design
interact
palli
care
educ
session
util
exist
palli
care
resourc
data
qualit
interview
key
stakehold
patient
age
year
design
famili
caregiv
elig
particip
ongo
studi
particip
complet
survey
assess
knowledg
percept
palli
care
educ
session
routin
clinic
visit
session
includ
definit
palli
care
descript
compon
palli
care
illustr
case
exampl
chang
knowledg
percept
measur
use
nonparametr
mannwhitney
u
test
result
twentyseven
particip
complet
educ
session
date
includ
adult
patient
adolesc
patient
caregiv
median
age
adult
patient
year
median
fev
predict
median
age
pediatr
patient
year
median
fev
predict
particip
report
low
baselin
knowledg
palli
care
median
composit
knowledg
score
maximum
mani
report
emot
uncertainti
concern
relat
subject
matter
educ
session
particip
felt
help
easi
understand
contain
appropri
amount
inform
knowledg
score
increas
significantli
postsess
median
knowledg
score
p
particip
understood
definit
palli
care
may
appropri
peopl
cf
could
benefit
peopl
cf
particip
describ
less
fear
uncertainti
learn
palli
care
endors
feel
reliev
hope
recruit
ongo
cf
care
center
followup
survey
conduct
month
assess
knowledg
retent
percept
time
medic
record
patient
particip
examin
subsequ
document
discuss
palli
care
andor
referr
palli
care
consult
conclus
particip
willing
engag
palli
care
educ
suggest
open
discuss
cf
provid
palli
care
preliminari
data
indic
standard
relev
palli
care
educ
provid
within
reason
amount
time
outpati
set
wellreceiv
adolesc
adult
cf
caregiv
futur
direct
includ
dissemin
educ
session
cf
care
center
support
cystic
fibrosi
foundat
background
ivacaftorlumacaftor
orkambi
fda
approv
use
cystic
fibrosi
cf
patient
juli
due
number
drug
interact
lab
monitor
requir
administr
direct
ivacaftorlumacaftor
protocol
educ
program
develop
singl
pediatr
cf
center
pharmacistdriven
medic
educ
program
includ
medic
historydrug
interact
screen
perform
pharmacist
ivacaftorlumacaftor
educ
pharmacist
followup
educ
next
clinic
appoint
facilit
educ
ivacaftorlumacaftor
educ
sheet
develop
pediatr
cf
center
pharmacist
collabor
adult
cf
center
pharmacist
method
patient
includ
result
elig
ivacaftorlumacaftor
treatment
educ
complet
pharmacist
patient
parent
given
sevenquest
preeduc
knowledg
survey
pharmacist
medic
histori
session
patient
parent
given
followup
sevenquest
knowledg
survey
next
clinic
appoint
assess
effect
educ
provid
discuss
point
reeduc
pharmacist
visit
result
thirti
patient
parent
educ
pharmacist
complet
followup
visit
timefram
median
age
year
iqr
median
time
visit
visit
day
twentyf
drug
interact
differ
patient
identifi
pharmacist
discuss
patient
parent
pulmonologist
mean
baselin
score
patient
preeduc
survey
sd
sd
parent
second
visit
survey
score
increas
sd
patient
sd
parent
p
conclus
pharmacistdriven
ivacaftorlumacaftor
educ
program
increas
medic
knowledg
patient
parent
meet
pharmacist
also
identifi
address
drug
interact
prior
start
medic
use
knowledg
survey
help
guid
educ
target
knowledg
gap
second
educ
session
longterm
knowledg
retent
method
educ
subject
investig
result
demonstr
role
educ
program
ivacaftorlumacaftor
valu
pharmacist
cf
team
event
via
mail
email
flyer
clinic
remind
clinic
visit
summari
new
guidelin
use
novel
format
topic
help
sustain
attend
interest
cf
educ
event
financi
support
pharmaceut
compani
particip
vendor
fair
event
result
continu
organ
host
averag
event
per
year
sinc
event
sinc
infect
control
guidelin
see
expect
decreas
attend
effort
use
maintain
attend
includ
offer
differ
format
roundtabl
discuss
b
interact
learn
activ
c
cook
class
weekend
event
e
lectur
ad
livestream
capabl
includ
peopl
unabl
attend
person
addit
divers
rang
topic
keep
interest
engag
use
includ
highprofil
speaker
panel
discuss
theme
event
research
evalu
attende
show
overal
rate
program
good
excel
new
guidelin
attend
rang
peopl
mean
implement
attend
rang
mean
peopl
conclus
educ
cystic
fibrosi
continu
expand
beyond
clinic
visit
even
chang
infect
control
guidelin
continu
includ
peopl
cf
famili
quarterli
educ
program
also
work
maintain
cultur
excit
around
program
util
patient
famili
feedback
ad
option
livestream
offer
varieti
format
continu
success
futur
want
enhanc
livestream
better
captur
attend
home
make
userfriendli
background
pediatr
resid
limit
opportun
gain
experi
longitudin
care
cf
patient
resid
care
cf
patient
either
hospit
briefli
pulmonari
elect
recent
year
concept
individu
curriculum
develop
pediatr
resid
allow
transit
continu
clinic
experi
thirdyear
resid
gener
pediatr
desir
subspecialti
method
patient
seen
weekli
clinic
thirdyear
resid
physician
goal
follow
cf
patient
util
visit
introduc
depress
screen
patient
chosen
base
age
avail
schedul
initi
target
patient
popul
includ
adolesc
age
first
resid
util
children
depress
inventori
selfand
parentreport
nacfc
plenari
session
anxieti
depress
screen
tool
modifi
includ
recommend
resid
staf
patient
attend
clinic
full
cf
followup
visit
complet
patient
also
seen
child
life
staff
review
psychosoci
concern
increas
continu
inpati
child
life
patient
complet
evalu
provid
feedback
ongo
concern
seen
followup
visit
result
total
cf
patient
clinic
adolesc
identifi
seen
resid
well
provid
mental
health
screen
within
period
two
refus
particip
screen
screen
two
refer
psychiatri
evalu
one
patient
screen
alreadi
follow
psychiatri
medic
patient
feedback
posit
observ
time
avail
discuss
issu
oneonon
even
topic
directli
relat
cf
resid
report
experi
allow
better
understand
challeng
face
patient
cf
well
addit
educ
ongo
care
patient
group
discuss
thirdyear
resid
increas
exposur
cf
care
provid
addit
valuabl
servic
cf
popul
center
addit
patient
feedback
overwhelmingli
posit
mani
patient
note
improv
time
discuss
question
also
provid
opportun
resid
experi
multidisciplinari
care
coordin
includ
use
nurs
staff
child
life
servic
mental
health
referr
conclus
util
cf
clinic
avenu
continu
pediatr
resid
potenti
provid
new
approach
resid
educ
within
field
resid
particip
vital
aspect
patient
care
use
opportun
enhanc
commun
skill
hone
knowledg
cf
clinic
concept
could
provid
springboard
qualiti
improv
project
well
coordin
resid
pulmonari
servic
allow
relationship
mutual
benefici
enhanc
educ
resid
care
patient
nacfc
meet
one
emphas
introduct
discuss
newli
updat
cf
infect
prevent
control
ip
c
guidelin
publish
import
new
recommend
share
experi
other
patienttopati
transmit
outbreak
cf
center
clinic
hospit
profoundli
impact
team
decis
made
aggress
quickli
work
implement
systemwid
approach
would
bring
ip
c
practic
line
latest
recommend
children
hospit
locat
sever
mile
outpati
practic
cf
clinic
also
hous
lab
radiolog
depart
health
system
also
process
acquir
multipl
facil
area
thu
prior
implement
challeng
design
ip
c
session
nacfc
provid
strategi
guid
implement
updat
recommend
cf
team
work
close
multidisciplinari
fashion
close
collabor
infecti
diseas
colleagu
infect
control
staff
facilit
necessari
chang
inpati
outpati
ip
c
polici
updat
reflect
new
chang
educ
start
staff
inpati
infect
control
notifi
everi
new
cf
patient
center
chart
may
contain
alert
allow
prompt
initi
contact
droplet
precaut
indic
patient
famili
educ
also
initi
regular
newslett
mailer
outpati
depart
visit
packet
given
children
hospit
cf
fastpass
uniqu
system
mask
letter
outlin
new
polici
children
hospit
sent
mass
email
pediatrician
famili
practic
provid
servic
area
make
awar
chang
instruct
occur
person
laboratori
radiolog
er
surgeri
busi
offic
manag
even
inform
staff
build
entranc
result
implement
new
ip
c
guidelin
success
health
system
endors
fulli
support
guidelin
within
month
implement
occur
novemb
conclus
although
face
continu
barrier
success
well
advanc
expect
institut
rigor
new
guidelin
prove
feasibl
continu
educ
famili
staff
variou
depart
care
cf
popul
schedul
review
polici
institut
cf
outpati
team
inpati
team
provid
care
patient
also
request
depart
would
like
develop
fastpass
patient
popul
immunocompromis
gener
fastpass
well
receiv
patient
famili
healthcar
system
whole
prove
feasibl
greatli
reduc
elimin
wait
time
common
area
patient
famili
demonstr
accept
new
polici
given
posit
feedback
system
whole
make
ip
c
high
prioriti
